<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27068280</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>673</StartPage><EndPage>684</EndPage><MedlinePgn>673-684</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(16)00070-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(16)00070-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease biomarkers are important for early diagnosis in routine clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's disease (A&#x3b2;42, T-tau, and P-tau) have been assessed in numerous studies, and several other Alzheimer's disease markers are emerging in the literature. However, there have been no comprehensive meta-analyses of their diagnostic performance. We systematically reviewed the literature for 15 biomarkers in both CSF and blood to assess which of these were most altered in Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this systematic review and meta-analysis, we screened PubMed and Web of Science for articles published between July 1, 1984, and June 30, 2014, about CSF and blood biomarkers reflecting neurodegeneration (T-tau, NFL, NSE, VLP-1, and HFABP), APP metabolism (A&#x3b2;42, A&#x3b2;40, A&#x3b2;38, sAPP&#x3b1;, and sAPP&#x3b2;), tangle pathology (P-tau), blood-brain-barrier function (albumin ratio), and glial activation (YKL-40, MCP-1, and GFAP). Data were taken from cross-sectional cohort studies as well as from baseline measurements in longitudinal studies with clinical follow-up. Articles were excluded if they did not contain a cohort with Alzheimer's disease and a control cohort, or a cohort with mild cognitive impairment due to Alzheimer's disease and a stable mild cognitive impairment cohort. Data were extracted by ten authors and checked by two for accuracy. For quality assessment, modified QUADAS criteria were used. Biomarker performance was rated by random-effects meta-analysis based on the ratio between biomarker concentration in patients with Alzheimer's disease and controls (fold change) or the ratio between biomarker concentration in those with mild cognitive impariment due to Alzheimer's disease and those with stable mild cognitive impairment who had a follow-up time of at least 2 years and no further cognitive decline.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of 4521 records identified from PubMed and 624 from Web of Science, 231 articles comprising 15&#x2008;699 patients with Alzheimer's disease and 13&#x2008;018 controls were included in this analysis. The core biomarkers differentiated Alzheimer's disease from controls with good performance: CSF T-tau (average ratio 2&#xb7;54, 95% CI 2&#xb7;44-2&#xb7;64, p&lt;0&#xb7;0001), P-tau (1&#xb7;88, 1&#xb7;79-1&#xb7;97, p&lt;0&#xb7;0001), and A&#x3b2;42 (0&#xb7;56, 0&#xb7;55-0&#xb7;58, p&lt;0&#xb7;0001). Differentiation between cohorts with mild cognitive impairment due to Alzheimer's disease and those with stable mild cognitive impairment was also strong (average ratio 0&#xb7;67 for CSF A&#x3b2;42, 1&#xb7;72 for P-tau, and 1&#xb7;76 for T-tau). Furthermore, CSF NFL (2&#xb7;35, 1&#xb7;90-2&#xb7;91, p&lt;0&#xb7;0001) and plasma T-tau (1&#xb7;95, 1&#xb7;12-3&#xb7;38, p=0&#xb7;02) had large effect sizes when differentiating between controls and patients with Alzheimer's disease, whereas those of CSF NSE, VLP-1, HFABP, and YKL-40 were moderate (average ratios 1&#xb7;28-1&#xb7;47). Other assessed biomarkers had only marginal effect sizes or did not differentiate between control and patient samples.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The core CSF biomarkers of neurodegeneration (T-tau, P-tau, and A&#x3b2;42), CSF NFL, and plasma T-tau were strongly associated with Alzheimer's disease and the core biomarkers were strongly associated with mild cognitive impairment due to Alzheimer's disease. Emerging CSF biomarkers NSE, VLP-1, HFABP, and YKL-40 were moderately associated with Alzheimer's disease, whereas plasma A&#x3b2;42 and A&#x3b2;40 were not. Due to their consistency, T-tau, P-tau, A&#x3b2;42, and NFL in CSF should be used in clinical practice and clinical research.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Swedish Research Council, Swedish State Support for Clinical Research, Alzheimer's Association, Knut and Alice Wallenberg Foundation, Torsten S&#xf6;derberg Foundation, Alzheimer Foundation (Sweden), European Research Council, and Biomedical Research Forum.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Bob</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. Electronic address: bob.olsson@neuro.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautner</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;hrfelt</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjerke</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Department of Biomedical Sciences, University of Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;ltt&#xe4;</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ros&#xe9;n</LastName><ForeName>Christoffer</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Physics, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strobel</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Alzforum, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzforum, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Alzforum, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petzold</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit for Health Metrics, Department of Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2016 Jun;15(7):650-651. doi: 10.1016/S1474-4422(16)30040-0.</RefSource><PMID Version="1">27302222</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2016 Nov;15(12):1204. doi: 10.1016/S1474-4422(16)30238-1.</RefSource><PMID Version="1">27751543</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2016 Nov;15(12):1204-1205. doi: 10.1016/S1474-4422(16)30247-2.</RefSource><PMID Version="1">27751544</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pii">S1474-4422(16)00070-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27064267</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.</ArticleTitle><Pagination><StartPage>698</StartPage><EndPage>705</EndPage><MedlinePgn>698-705</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.0194</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Clinical trials testing treatments for Alzheimer disease (AD) are increasingly focused on cognitively normal individuals in the preclinical phase of the disease. To optimize observing a treatment effect, such trials need to enroll cognitively normal individuals likely to show cognitive decline over the duration of the trial.</AbstractText><AbstractText Label="OBJECTIVE">To identify which group of cognitively normal individuals shows the greatest cognitive decline over time based on their cerebrospinal fluid biomarker profile.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this cohort study, cognitively normal participants were classified into 1 of the following 4 hypothetical preclinical AD groups using baseline cerebrospinal fluid levels of A&#x3b2; and tau or A&#x3b2; and phosphorylated tau (p-tau): stage 0 (high A&#x3b2; and low tau), stage 1 (low A&#x3b2; and low tau), stage 2 (low A&#x3b2; and high tau), and suspected non-AD pathology (SNAP) (high A&#x3b2; and high tau). The data presented herein were collected between August 1995 and August 2014.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">An a priori cognitive composite score based on the following 4 tests previously shown to predict progression from normal cognition to symptom onset of mild cognitive impairment or dementia: Paired Associates immediate recall, Logical Memory delayed recall, Boston Naming, and Digit-Symbol Substitution. Linear mixed-effects models were used to compare the cognitive composite scores across the 4 groups over time, adjusting for baseline age, sex, education, and their interactions with time.</AbstractText><AbstractText Label="RESULTS">Two hundred twenty-two cognitively normal participants were included in the analyses (mean follow-up, 11.0 years [range, 0-18.3 years] and mean baseline age, 56.9 years [range, 22.1-85.8 years]). Of these, 102 were stage 0, 46 were stage 1, 28 were stage 2, and 46 were SNAP. Individuals in stage 2 (low A&#x3b2; and high tau [or p-tau]) had lower baseline cognitive scores and a greater decline in the cognitive composite score relative to the other 3 groups (&#x3b2;&#x2009;&#x2264;&#x2009;-0.06 for all and P&#x2009;&#x2264;&#x2009;.001 for the rate of decline for all). Individuals in stage 0, stage 1, and SNAP did not differ from one another in cognitive performance at baseline or over time (11.0 years) and showed practice-related improvement in performance. The APOE &#x3b5;4 genotype was not associated with baseline cognitive composite score or the rate of change in the cognitive composite score.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">These results suggest that, to optimize observing a treatment effect, clinical trials enrolling cognitively normal individuals should selectively recruit participants with abnormal levels of both amyloid and tau (ie, stage 2) because this group would be expected to show the greatest cognitive decline over time if untreated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soldan</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettigrew</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mei-Cheng</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghekar</LastName><ForeName>Abhay R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selnes</LastName><ForeName>Ola A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>BIOCARD Research Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG033655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Jun 1;73(6):640-2. doi: 10.1001/jamaneurol.2016.0281.</RefSource><PMID Version="1">27064971</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: Dr. Soldan reports no disclosures. Dr. Pettigrew reports no disclosures. Ms. Cai reports no disclosures. Dr. Wang reports no disclosures. Dr. Moghekar reports no disclosures. Dr. O&#x2019;Brien reports no disclosures. Dr. Albert is an advisor to Eli Lilly.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27064267</ArticleId><ArticleId IdType="mid">NIHMS833648</ArticleId><ArticleId IdType="pmc">PMC5173327</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.0194</ArticleId><ArticleId IdType="pii">2511291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain : a journal of neurology. 2009;132:2048&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714061</ArticleId><ArticleId IdType="pubmed">19460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Heinsen H, Amaro E, Jr, Grinberg LT, Teipel SJ. Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. Cereb Cortex. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869802</ArticleId><ArticleId IdType="pubmed">25840425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, De Carli F, Morbelli S, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage Clinical. 2015;7:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299956</ArticleId><ArticleId IdType="pubmed">25610765</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of neurology. 2012;71:765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiology of aging. 2011;32(Suppl 1):S4&#x2013;S9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233690</ArticleId><ArticleId IdType="pubmed">22078172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Archives of neurology. 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. The Lancet Neurology. 2013;12:957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA neurology. 2014;71:1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293023</ArticleId><ArticleId IdType="pubmed">25222039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ. The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement. 2013;9:687&#x2013;698. e681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823816</ArticleId><ArticleId IdType="pubmed">23474040</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Johnson K, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Molecular psychiatry. 2014;19:1044&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4195975</ArticleId><ArticleId IdType="pubmed">24614494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA neurology. 2014;71:961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain : a journal of neurology. 2015;138:761&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339775</ArticleId><ArticleId IdType="pubmed">25595145</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784&#x2013;1791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC. CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. Neurology. 2013;81:2028&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3854826</ArticleId><ArticleId IdType="pubmed">24212387</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Millard SP, Peskind ER, et al. Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA neurology. 2014;71:742&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4051849</ArticleId><ArticleId IdType="pubmed">24756381</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodzik L, de Santi S, Tsui WH, et al. Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. Neurobiology of aging. 2011;32:2131&#x2013;2141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179835</ArticleId><ArticleId IdType="pubmed">20133017</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner AJ, Balota DA, Fagan AM, Duchek JM, Benzinger TL, Morris JC. Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. Journal of the International Neuropsychological Society : JINS. 2015;21:573&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4610253</ArticleId><ArticleId IdType="pubmed">26416094</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel PS, Mattsson N, Mackin RS, et al. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of clinical and translational neurology. 2015;2:534&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435707</ArticleId><ArticleId IdType="pubmed">26000325</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Soldan A, Gottesman R, et al. Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Current Alzheimer research. 2014;11:773&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163954</ArticleId><ArticleId IdType="pubmed">25212916</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort. Archives of neurology. 2012;69:246&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310240</ArticleId><ArticleId IdType="pubmed">22332192</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of neurology. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. Journal of neuropathology and experimental neurology. 1998;57:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. Journal of neuropathology and experimental neurology. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Science translational medicine. 2014;6:228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Annals of neurology. 2013;73:472&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660408</ArticleId><ArticleId IdType="pubmed">23424032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2013;33:5553&#x2013;5563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687777</ArticleId><ArticleId IdType="pubmed">23536070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Archives of neurology. 2011;68:1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482918</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Bilgel M, Moghekar A, et al. Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiology of aging. 2015;36:2333&#x2013;2339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084914</ArticleId><ArticleId IdType="pubmed">26004017</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Archives of general psychiatry. 2004;61:518&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123497</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Archives of neurology. 2011;68:1145&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203689</ArticleId><ArticleId IdType="pubmed">21911695</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan A, Pettigrew C, Li S, et al. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiology of aging. 2013;34:2827&#x2013;2834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3823238</ArticleId><ArticleId IdType="pubmed">23916061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27065010</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>538</EndPage><MedlinePgn>531-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nbt.3514</ELocationID><Abstract><AbstractText>Genetic studies of human disease have traditionally focused on the detection of disease-causing mutations in afflicted individuals. Here we describe a complementary approach that seeks to identify healthy individuals resilient to highly penetrant forms of genetic childhood disorders. A comprehensive screen of 874 genes in 589,306 genomes led to the identification of 13 adults harboring mutations for 8 severe Mendelian conditions, with no reported clinical manifestation of the indicated disease. Our findings demonstrate the promise of broadening genetic studies to systematically search for well individuals who are buffering the effects of rare, highly penetrant, deleterious mutations. They also indicate that incomplete penetrance for Mendelian diseases is likely more common than previously believed. The identification of resilient individuals may provide a first step toward uncovering protective genetic variants that could help elucidate the mechanisms of Mendelian diseases and new therapeutic strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rong</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6322-0340</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Lisong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakenberg</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naughton</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>23andMe, Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>BGI-Shenzhen, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hanlin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>BGI-Shenzhen, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Lifeng</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1880-5811</Identifier><AffiliationInfo><Affiliation>Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Om</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Diabetes &amp;Endocrinology, Lund University Diabetes Center, Sk&#xe5;ne University Hospital, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemire</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ontario Institute for Cancer Research, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleiman</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Wei-Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wanting</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>BGI-Shenzhen, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Hardik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yulan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2866-4146</Identifier><AffiliationInfo><Affiliation>BGI-Shenzhen, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fromer</LastName><ForeName>Menachem</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3749-4342</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute and Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omberg</LastName><ForeName>Larsson</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deardorff</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zackai</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobe</LastName><ForeName>Jason R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Elissa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-1376-4849</Identifier><AffiliationInfo><Affiliation>Ontario Institute for Cancer Research, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groop</LastName><ForeName>Leif</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Diabetes &amp;Endocrinology, Lund University Diabetes Center, Sk&#xe5;ne University Hospital, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>iCarbonX, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojcicki</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>23andMe, Mountain View, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>George A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edelmann</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadt</LastName><ForeName>Eric E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friend</LastName><ForeName>Stephen H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-0830-7600</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2016 May;34(5):512-3. doi: 10.1038/nbt.3555.</RefSource><PMID Version="1">27065009</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Genet. 2016 Jun;17(6):316. doi: 10.1038/nrg.2016.54.</RefSource><PMID Version="1">27109919</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060467" MajorTopicYN="N">Disease Resistance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030342" MajorTopicYN="N">Genetic Diseases, Inborn</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27065010</ArticleId><ArticleId IdType="doi">10.1038/nbt.3514</ArticleId><ArticleId IdType="pii">nbt.3514</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2001 Feb 9;291(5506):1001-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11232561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2003 Jan;40(1):65-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12525546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Genet. 1991;34(3-4):233-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1809232</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1997 Dec;17(4):393-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9398839</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Feb 17;335(6070):823-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22344438</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Nov 1;491(7422):56-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1994 Dec 16;79(6):1111-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8001137</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Jul 6;337(6090):64-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22604720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genet. 2014 Jan;133(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24077912</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1991 May 2;324(18):1232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2014036</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Bioinformatics. 2016 Jan 08;17:24</Citation><ArticleIdList><ArticleId IdType="pubmed">26746786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Vis. 2009 May 22;15:1050-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19471582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1997 Jan;6(1):91-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9002675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2015 Jun;14(6):1488-94</Citation><ArticleIdList><ArticleId IdType="pubmed">25852059</ArticleId></ArticleIdList></Reference><Reference><Citation>Genet Med. 2013 Mar;15(3):178-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22975760</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 2009 Jun;50(6):1223-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19181627</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2004;5(7):R49</Citation><ArticleIdList><ArticleId IdType="pubmed">15239834</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2007 Apr;80(4):588-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17357067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2014 Apr;46(4):357-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24584071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2014 Mar 27;157(1):241-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24679539</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Oncol. 2015 Jul;1(4):466-74</Citation><ArticleIdList><ArticleId IdType="pubmed">26181256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Biol. 2005 Oct;77(5):705-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16596947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Hum Genet. 2001 May;65(Pt 3):229-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11427181</ArticleId></ArticleIdList></Reference><Reference><Citation>J Invest Dermatol. 2010 Oct;130(10):2407-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20574443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1994 Nov;8(3):269-74</Citation><ArticleIdList><ArticleId IdType="pubmed">7874169</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">7682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 1992 Sep;86(3):748-55</Citation><ArticleIdList><ArticleId IdType="pubmed">1516186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2003 May 15;63(10):2688-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12750298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2004 May;23(5):447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15108276</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2014 Sep;22(9):1100-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24424120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2016 Aug 17;536(7616):285-91</Citation><ArticleIdList><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2001 Jul;38(7):443-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11432962</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2001 Sep 15;103(1):75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11562938</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11700-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17606896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2015 Nov 19;163(5):1204-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26582133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Jun 16;369(9578):1980-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17574079</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2010 Dec;42(12):1049-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21057501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2016 Jan 1;32(1):151-3</Citation><ArticleIdList><ArticleId IdType="pubmed">26363178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Oct;45(10):1160-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23974870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology. 2010 Apr;117(4):825-30.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">20079539</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2014 May 30;344(6187):970-2</Citation><ArticleIdList><ArticleId IdType="pubmed">24876479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2003 May;21(5):466-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12673788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Diagn. 2014 May;16(3):350-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24517888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2011 May;32(5):557-63</Citation><ArticleIdList><ArticleId IdType="pubmed">21520333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2005 Feb;37(2):161-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15654334</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2011 Jan 12;3(65):65ra4</Citation><ArticleIdList><ArticleId IdType="pubmed">21228398</ArticleId></ArticleIdList></Reference><Reference><Citation>Fly (Austin). 2012 Apr-Jun;6(2):80-92</Citation><ArticleIdList><ArticleId IdType="pubmed">22728672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2012 May;33(5):803-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22422702</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2014 Nov 12;312(18):1880-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25326637</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Feb 13;506(7487):185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">24463508</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2004 Dec;75(6):1136-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15486829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2011 Mar 1;27(5):718-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21208982</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Aug 26;363(9):852-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20818846</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Med. 2012 Dec 27;4(12):103</Citation><ArticleIdList><ArticleId IdType="pubmed">23270647</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 1999 Jul 1;21(3):189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10421241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27076423</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>15</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-&#x3b2; Alterations in a Monkey Model of Type 1 Diabetes.</ArticleTitle><Pagination><StartPage>4248</StartPage><EndPage>4258</EndPage><MedlinePgn>4248-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4640-14.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">Epidemiological findings suggest that diabetic individuals are at a greater risk for developing Alzheimer's disease (AD). To examine the mechanisms by which diabetes mellitus (DM) may contribute to AD pathology in humans, we examined brain tissue from streptozotocin-treated type 1 diabetic adult male vervet monkeys receiving twice-daily exogenous insulin injections for 8-20 weeks. We found greater inhibitory phosphorylation of insulin receptor substrate 1 in each brain region examined of the diabetic monkeys when compared with controls, consistent with a pattern of brain insulin resistance that is similar to that reported in the human AD brain. Additionally, a widespread increase in phosphorylated tau was seen, including brain areas vulnerable in AD, as well as relatively spared structures, such as the cerebellum. An increase in active ERK1/2 was also detected, consistent with DM leading to changes in tau-kinase activity broadly within the brain. In contrast to these widespread changes, we found an increase in soluble amyloid-&#x3b2; (A&#x3b2;) levels that was restricted to the temporal lobe, with the greatest increase seen in the hippocampus. Consistent with this localized A&#x3b2; increase, a hippocampus-restricted decrease in the protein and mRNA for the A&#x3b2;-degrading enzyme neprilysin (NEP) was found, whereas various A&#x3b2;-clearing and -degrading proteins were unchanged. Thus, we document multiple biochemical changes in the insulin-controlled DM monkey brain that can link DM with the risk of developing AD, including dysregulation of the insulin-signaling pathway, changes in tau phosphorylation, and a decrease in NEP expression in the hippocampus that is coupled with a localized increase in A&#x3b2;.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT" NlmCategory="CONCLUSIONS">Given that diabetes mellitus (DM) appears to increase the risk of developing Alzheimer's disease (AD), understanding the mechanisms by which DM promotes AD is important. We report that DM in a nonhuman primate brain leads to changes in the levels or posttranslational processing of proteins central to AD pathobiology, including tau, amyloid-&#x3b2; (A&#x3b2;), and the A&#x3b2;-degrading protease neprilysin. Additional evidence from this model suggests that alterations in brain insulin signaling occurred that are reminiscent of insulin signaling pathway changes seen in human AD. Thus, in an in vivo model highly relevant to humans, we show multiple alterations in the brain resulting from DM that are mechanistically linked to AD risk.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 the authors 0270-6474/16/364248-11$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales-Corraliza</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, Departments of Psychiatry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Harrison</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzella</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Che</LastName><ForeName>Shaoli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, Departments of Psychiatry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang Han</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petkova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, Child and Adolescent Psychiatry, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Janice D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemby</LastName><ForeName>Scott E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-6987-1133</Identifier><AffiliationInfo><Affiliation>Fred Wilson School of Pharmacy, High Point University, High Point, North Carolina 27268.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-1797-4288</Identifier><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, Departments of Psychiatry, Neuroscience and Physiology, New York University Langone Medical Center, New York, New York 10016.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962, Departments of Psychiatry, mathews@nki.rfmh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OD010965</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 OD010965</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 RR019963</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG052524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR019963</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043375</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007333" MajorTopicYN="Y">Insulin Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alzheimer's disease</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">neprilysin</Keyword><Keyword MajorTopicYN="N">nonhuman primate</Keyword><Keyword MajorTopicYN="N">streptozotocin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27076423</ArticleId><ArticleId IdType="pmc">PMC4829649</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4640-14.2016</ArticleId><ArticleId IdType="pii">36/15/4248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agresti A. An introduction to categorical data analysis. Ed 2. New York: Wiley; 2007.</Citation></Reference><Reference><Citation>Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006;63:1551&#x2013;1555. doi: 10.1001/archneur.63.11.1551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.11.1551</ArticleId><ArticleId IdType="pubmed">17101823</ArticleId></ArticleIdList></Reference><Reference><Citation>Alldred MJ, Che S, Ginsberg SD. Terminal continuation (TC) RNA amplification without second strand synthesis. J Neurosci Methods. 2009;177:381&#x2013;385. doi: 10.1016/j.jneumeth.2008.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2008.10.027</ArticleId><ArticleId IdType="pmc">PMC2659495</ArticleId><ArticleId IdType="pubmed">19026688</ArticleId></ArticleIdList></Reference><Reference><Citation>Alldred MJ, Duff KE, Ginsberg SD. Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis. 2012;45:751&#x2013;762. doi: 10.1016/j.nbd.2011.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.10.022</ArticleId><ArticleId IdType="pmc">PMC3259262</ArticleId><ArticleId IdType="pubmed">22079237</ArticleId></ArticleIdList></Reference><Reference><Citation>Biessels GJ, Reagan LP. Hippocampal insulin resistance and cognitive dysfunction. Nat Rev Neurosci. 2015;16:660&#x2013;671. doi: 10.1038/nrn4019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn4019</ArticleId><ArticleId IdType="pubmed">26462756</ArticleId></ArticleIdList></Reference><Reference><Citation>Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64&#x2013;74. doi: 10.1016/S1474-4422(05)70284-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70284-2</ArticleId><ArticleId IdType="pubmed">16361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;278. discussion 278&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223&#x2013;234. doi: 10.1146/annurev.med.46.1.223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.med.46.1.223</ArticleId><ArticleId IdType="pubmed">7598459</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Bussi&#xe8;re T, Bu&#xe9;e-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95&#x2013;130. doi: 10.1016/S0165-0173(00)00019-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(00)00019-9</ArticleId><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in A&#x3b2;-degrading enzymes: implications for A&#x3b2;-induced disorders. Neurobiol Aging. 2005;26:645&#x2013;654. doi: 10.1016/j.neurobiolaging.2004.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.06.013</ArticleId><ArticleId IdType="pubmed">15708439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AY, Schneider DI. Hepatic enzyme activities in streptozotocin-diabetic rats before and after insulin treatment. Diabetes. 1971;20:71&#x2013;77. doi: 10.2337/diab.20.2.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.20.2.71</ArticleId><ArticleId IdType="pubmed">5543194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, Liu F, Gong CX. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces A&#x3b2; level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol. 2014a;261:610&#x2013;619. doi: 10.1016/j.expneurol.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.06.004</ArticleId><ArticleId IdType="pubmed">24918340</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Run X, Liang Z, Zhao Y, Dai CL, Iqbal K, Liu F, Gong CX. Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. Front Aging Neurosci. 2014b;6:100. doi: 10.3389/fnagi.2014.00100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2014.00100</ArticleId><ArticleId IdType="pmc">PMC4038959</ArticleId><ArticleId IdType="pubmed">24910612</ArticleId></ArticleIdList></Reference><Reference><Citation>Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis. 2015;44:897&#x2013;906. doi: 10.3233/JAD-141791. [Erratum (2015) 45:1269&#x2013;1270]</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-141791</ArticleId><ArticleId IdType="pubmed">25374101</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69:29&#x2013;38. doi: 10.1001/archneurol.2011.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.233</ArticleId><ArticleId IdType="pmc">PMC3260944</ArticleId><ArticleId IdType="pubmed">21911655</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol. 2014;88:548&#x2013;559. doi: 10.1016/j.bcp.2013.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2013.12.012</ArticleId><ArticleId IdType="pmc">PMC4550323</ArticleId><ArticleId IdType="pubmed">24380887</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. RAGE mediates &#x3b2;-amyloid peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907&#x2013;913. doi: 10.1038/nm890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm890</ArticleId><ArticleId IdType="pubmed">12808450</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of &#x3b2;-amyloid peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2009;8:16&#x2013;30. doi: 10.2174/187152709787601867.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152709787601867</ArticleId><ArticleId IdType="pmc">PMC2872930</ArticleId><ArticleId IdType="pubmed">19275634</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, Lourenco MV. Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease. Front Aging Neurosci. 2015;7:94. doi: 10.3389/fnagi.2015.00094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00094</ArticleId><ArticleId IdType="pmc">PMC4436878</ArticleId><ArticleId IdType="pubmed">26042036</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787&#x2013;835. ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308380</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of &#x3b2;-amyloidosis in a mouse model of Alzheimer's disease. PLoS One. 2012;7:e32792. doi: 10.1371/journal.pone.0032792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032792</ArticleId><ArticleId IdType="pmc">PMC3293895</ArticleId><ArticleId IdType="pubmed">22403710</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G, Lichtenberg-Kraag B, D&#xf6;ring F, Mandelkow EM, Biernat J, Goris J, Dor&#xe9;e M, Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 1992;11:2131&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556680</ArticleId><ArticleId IdType="pubmed">1376245</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer's &#x3b2;-amyloid peptide by endothelin- converting enzyme. J Biol Chem. 2001;276:24540&#x2013;24548. doi: 10.1074/jbc.M007579200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M007579200</ArticleId><ArticleId IdType="pubmed">11337485</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury NB, Gratuze M, Papon MA, Bretteville A, Planel E. Insulin dysfunction and Tau pathology. Front Cell Neurosci. 2014;8:22. doi: 10.3389/fncel.2014.00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00022</ArticleId><ArticleId IdType="pmc">PMC3920186</ArticleId><ArticleId IdType="pubmed">24574966</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, &#x3b2;-amyloid protein, and the &#x3b2;-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100:4162&#x2013;4167. doi: 10.1073/pnas.0230450100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0230450100</ArticleId><ArticleId IdType="pmc">PMC153065</ArticleId><ArticleId IdType="pubmed">12634421</ArticleId></ArticleIdList></Reference><Reference><Citation>Farris W, Sch&#xfc;tz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007;171:241&#x2013;251. doi: 10.2353/ajpath.2007.070105.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070105</ArticleId><ArticleId IdType="pmc">PMC1941603</ArticleId><ArticleId IdType="pubmed">17591969</ArticleId></ArticleIdList></Reference><Reference><Citation>Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation. 2006;113:1753&#x2013;1759. doi: 10.1161/CIRCULATIONAHA.106.616177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.616177</ArticleId><ArticleId IdType="pubmed">16585388</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;ia-Casares N, Jorge RE, Garc&#xed;a-Arn&#xe9;s JA, Acion L, Berthier ML, Gonzalez-Alegre P, Nabrozidis A, Guti&#xe9;rrez A, Ariza MJ, Rioja J, Gonz&#xe1;lez-Santos P. Cognitive dysfunctions in middle-aged type 2 diabetic patients and neuroimaging correlations: a cross-sectional study. J Alzheimers Dis. 2014;42:1337&#x2013;1346. doi: 10.3233/JAD-140702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140702</ArticleId><ArticleId IdType="pubmed">25024335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B. Systemic catabolism of Alzheimer's A&#x3b2;40 and A&#x3b2;42. J Biol Chem. 2004;279:45897&#x2013;45908. doi: 10.1074/jbc.M407668200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407668200</ArticleId><ArticleId IdType="pubmed">15322125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, Che S. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol Psychiatry. 2010;68:885&#x2013;893. doi: 10.1016/j.biopsych.2010.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2010.05.030</ArticleId><ArticleId IdType="pmc">PMC2965820</ArticleId><ArticleId IdType="pubmed">20655510</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A&#x3b2;42 fibrils. Science. 2001;293:1491&#x2013;1495. doi: 10.1126/science.1062097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062097</ArticleId><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev. 2002;18:192&#x2013;200. doi: 10.1002/dmrr.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.291</ArticleId><ArticleId IdType="pubmed">12112937</ArticleId></ArticleIdList></Reference><Reference><Citation>Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87:99&#x2013;109. doi: 10.1016/j.biochi.2004.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2004.10.019</ArticleId><ArticleId IdType="pubmed">15733744</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Halabisky B, Thwin MT, Kim D, Hamto P, Lo I, Yu GQ, Palop JJ, Masliah E, Mucke L. Transsynaptic progression of &#x3b2;-amyloid-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441. doi: 10.1016/j.neuron.2010.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.10.020</ArticleId><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstr&#xf6;m-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A&#x3b2; levels. Neurobiol Aging. 2008;29:210&#x2013;221. doi: 10.1016/j.neurobiolaging.2006.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.10.010</ArticleId><ArticleId IdType="pubmed">17098332</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. Alzheimers Dement. 2014;10:S33&#x2013;S37. doi: 10.1016/j.jalz.2013.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.12.006</ArticleId><ArticleId IdType="pubmed">24529523</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major A&#x3b2;1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143&#x2013;150. doi: 10.1038/72237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/72237</ArticleId><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain A&#x3b2; by neprilysin. Science. 2001;292:1550&#x2013;1552. doi: 10.1126/science.1059946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1059946</ArticleId><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson GD, Stevenson T, Ahn K. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. J Biol Chem. 1999;274:4053&#x2013;4058. doi: 10.1074/jbc.274.7.4053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.7.4053</ArticleId><ArticleId IdType="pubmed">9933597</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol. 2010;223:422&#x2013;431. doi: 10.1016/j.expneurol.2009.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.11.005</ArticleId><ArticleId IdType="pmc">PMC2864332</ArticleId><ArticleId IdType="pubmed">19931251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung HJ, Kim YJ, Eggert S, Chung KC, Choi KS, Park SA. Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. Exp Neurol. 2013;248:441&#x2013;450. doi: 10.1016/j.expneurol.2013.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.07.013</ArticleId><ArticleId IdType="pubmed">23906983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavanagh K, Flynn DM, Nelson C, Zhang L, Wagner JD. Characterization and validation of a streptozotocin-induced diabetes model in the vervet monkey. J Pharmacol Toxicol Methods. 2011;63:296&#x2013;303. doi: 10.1016/j.vascn.2011.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vascn.2011.02.003</ArticleId><ArticleId IdType="pmc">PMC3085883</ArticleId><ArticleId IdType="pubmed">21356321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke YD, Delerue F, Gladbach A, G&#xf6;tz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One. 2009;4:e7917. doi: 10.1371/journal.pone.0007917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007917</ArticleId><ArticleId IdType="pmc">PMC2775636</ArticleId><ArticleId IdType="pubmed">19936237</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia. 1996;7:177&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491. doi: 10.1126/science.1058189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1058189</ArticleId><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav. 2012;101:564&#x2013;574. doi: 10.1016/j.pbb.2012.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2012.03.002</ArticleId><ArticleId IdType="pmc">PMC3327803</ArticleId><ArticleId IdType="pubmed">22425595</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem. 2009;111:242&#x2013;249. doi: 10.1111/j.1471-4159.2009.06320.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06320.x</ArticleId><ArticleId IdType="pmc">PMC2760012</ArticleId><ArticleId IdType="pubmed">19659459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of &#x3b2;-cleaved C-terminal APP fragments. J Biol Chem. 2002;277:36415&#x2013;36424. doi: 10.1074/jbc.M205208200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205208200</ArticleId><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. Diabetes. 2010;59:2333&#x2013;2339. doi: 10.2337/db10-0103.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db10-0103</ArticleId><ArticleId IdType="pmc">PMC3279554</ArticleId><ArticleId IdType="pubmed">20876723</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012;379:2291&#x2013;2299. doi: 10.1016/S0140-6736(12)60360-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60360-2</ArticleId><ArticleId IdType="pubmed">22683129</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31:224&#x2013;243. doi: 10.1016/j.neurobiolaging.2008.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.04.002</ArticleId><ArticleId IdType="pubmed">18479783</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, Matsuoka Y, Planel E, Mathews PM. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the &#x3b2;-amyloid depositing mice. PLoS One. 2009;4:e7134. doi: 10.1371/journal.pone.0007134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007134</ArticleId><ArticleId IdType="pmc">PMC2741602</ArticleId><ArticleId IdType="pubmed">19771166</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Corraliza J, Schmidt SD, Mazzella MJ, Berger JD, Wilson DA, Wesson DW, Jucker M, Levy E, Nixon RA, Mathews PM. Immunization targeting a minor plaque constituent clears &#x3b2;-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. Neurobiol Aging. 2013;34:137&#x2013;145. doi: 10.1016/j.neurobiolaging.2012.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.04.007</ArticleId><ArticleId IdType="pmc">PMC3426627</ArticleId><ArticleId IdType="pubmed">22608241</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham BE, Wlodek ME, Ciccotosto GD, Fam BC, Masters CL, Proietto J, Andrikopoulos S, Cappai R. Identification of the Alzheimer's disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J Pathol. 2008;215:155&#x2013;163. doi: 10.1002/path.2343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2343</ArticleId><ArticleId IdType="pubmed">18393365</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y. BACE1 inhibition reduces endogenous A&#x3b2; and alters APP processing in wild-type mice. J Neurochem. 2006;99:1555&#x2013;1563. doi: 10.1111/j.1471-4159.2006.04178.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04178.x</ArticleId><ArticleId IdType="pubmed">17083447</ArticleId></ArticleIdList></Reference><Reference><Citation>No&#xeb;l A, Poitras I, Julien J, Petry FR, Morin F, Charron J, Planel E. ERK (MAPK) does not phosphorylate tau under physiological conditions in vivo or in vitro. Neurobiol Aging. 2015;36:901&#x2013;902. doi: 10.1016/j.neurobiolaging.2014.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.11.005</ArticleId><ArticleId IdType="pubmed">25491074</ArticleId></ArticleIdList></Reference><Reference><Citation>Papon MA, El Khoury NB, Marcouiller F, Julien C, Morin F, Bretteville A, Petry FR, Gaudreau S, Amrani A, Mathews PM, H&#xe9;bert SS, Planel E. Deregulation of protein phosphatase 2A and hyperphosphorylation of tau protein following onset of diabetes in NOD mice. Diabetes. 2013;62:609&#x2013;617. doi: 10.2337/db12-0187.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db12-0187</ArticleId><ArticleId IdType="pmc">PMC3554372</ArticleId><ArticleId IdType="pubmed">22961084</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 2007;27:13635&#x2013;13648. doi: 10.1523/JNEUROSCI.3949-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3949-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673606</ArticleId><ArticleId IdType="pubmed">18077675</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. Insulin-degrading enzyme regulates extracellular levels of &#x3b2;-amyloid protein by degradation. J Biol Chem. 1998;273:32730&#x2013;32738. doi: 10.1074/jbc.273.49.32730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.49.32730</ArticleId><ArticleId IdType="pubmed">9830016</ArticleId></ArticleIdList></Reference><Reference><Citation>Rdzak GM, Abdelghany O. Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease? Pharmacotherapy. 2014;34:1317&#x2013;1323. doi: 10.1002/phar.1494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1494</ArticleId><ArticleId IdType="pubmed">25280207</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3&#x3b2;. J Neurochem. 2000;74:1587&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737616</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerri&#xe8;re A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26. doi: 10.1038/ng1718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1718</ArticleId><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of &#x3b2;-amyloid by circulating lipoprotein receptors. Nat Med. 2007;13:1029&#x2013;1031. doi: 10.1038/nm1635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1635</ArticleId><ArticleId IdType="pmc">PMC2936449</ArticleId><ArticleId IdType="pubmed">17694066</ArticleId></ArticleIdList></Reference><Reference><Citation>Saisho Y, Manesso E, Butler AE, Galasso R, Kavanagh K, Flynn M, Zhang L, Clark P, Gurlo T, Toffolo GM, Cobelli C, Wagner JD, Butler PC. Ongoing &#x3b2;-cell turnover in adult nonhuman primates is not adaptively increased in streptozotocin-induced diabetes. Diabetes. 2011;60:848&#x2013;856. doi: 10.2337/db09-1368.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db09-1368</ArticleId><ArticleId IdType="pmc">PMC3046845</ArticleId><ArticleId IdType="pubmed">21270238</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Nixon RA, Mathews PM. Tissue processing prior to analysis of Alzheimer's disease associated proteins and metabolites, including A&#x3b2;. Methods Mol Biol. 2012a;849:493&#x2013;506. doi: 10.1007/978-1-61779-551-0_33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-551-0_33</ArticleId><ArticleId IdType="pubmed">22528111</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Mazzella MJ, Nixon RA, Mathews PM. A&#x3b2; measurement by enzyme-linked immunosorbent assay. Methods Mol Biol. 2012b;849:507&#x2013;527. doi: 10.1007/978-1-61779-551-0_34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-551-0_34</ArticleId><ArticleId IdType="pubmed">22528112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6:551&#x2013;559. doi: 10.1038/nrneurol.2010.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.130</ArticleId><ArticleId IdType="pmc">PMC3199576</ArticleId><ArticleId IdType="pubmed">20842183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006;129:2977&#x2013;2983. doi: 10.1093/brain/awl203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl203</ArticleId><ArticleId IdType="pubmed">16921174</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleilhac JM, Lafuma C, Porcher JM, Auburtin G, Roques BP. Characterization of a soluble form of neutral endopeptidase-24.11 (EC 3.4.24.11) in human serum: enhancement of its activity in serum of underground miners exposed to coal dust particles. Eur J Clin Invest. 1996;26:1011&#x2013;1017. doi: 10.1046/j.1365-2362.1996.2420580.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2362.1996.2420580.x</ArticleId><ArticleId IdType="pubmed">8957208</ArticleId></ArticleIdList></Reference><Reference><Citation>Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM, Grant PJ. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 2011;35:1031&#x2013;1040. doi: 10.1038/ijo.2010.227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijo.2010.227</ArticleId><ArticleId IdType="pmc">PMC3040694</ArticleId><ArticleId IdType="pubmed">21042321</ArticleId></ArticleIdList></Reference><Reference><Citation>Szendrei GI, Lee VM, Otvos L., Jr Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J Neurosci Res. 1993;34:243&#x2013;249. doi: 10.1002/jnr.490340212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490340212</ArticleId><ArticleId IdType="pubmed">7680727</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, Kurinami H, Shinohara M, Rakugi H, Morishita R. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A&#x3b2; deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010;107:7036&#x2013;7041. doi: 10.1073/pnas.1000645107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1000645107</ArticleId><ArticleId IdType="pmc">PMC2872449</ArticleId><ArticleId IdType="pubmed">20231468</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316&#x2013;1338. doi: 10.1172/JCI59903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI59903</ArticleId><ArticleId IdType="pmc">PMC3314463</ArticleId><ArticleId IdType="pubmed">22476197</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, Peters EC, Urbina HD, Welzel G, Althage A, Liu B, Tuntland T, Jacobson LH, Harris JL, Schumacher AM. Enhanced proteolytic clearance of plasma A&#x3b2; by peripherally administered neprilysin does not result in reduced levels of brain A&#x3b2; in mice. J Neurosci. 2013;33:2457&#x2013;2464. doi: 10.1523/JNEUROSCI.3407-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3407-12.2013</ArticleId><ArticleId IdType="pmc">PMC6619149</ArticleId><ArticleId IdType="pubmed">23392674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhou Y, Wang X, Evers BM. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene. 2006;25:43&#x2013;50. doi: 10.1038/sj.onc.1209004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1209004</ArticleId><ArticleId IdType="pmc">PMC1413679</ArticleId><ArticleId IdType="pubmed">16278684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem. 2010;115:47&#x2013;57. doi: 10.1111/j.1471-4159.2010.06899.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06899.x</ArticleId><ArticleId IdType="pmc">PMC2939954</ArticleId><ArticleId IdType="pubmed">20663017</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol Aging. 2000;21:719&#x2013;727. doi: 10.1016/S0197-4580(00)00157-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00157-3</ArticleId><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>White MF. Regulating insulin signaling and &#x3b2;-cell function through IRS proteins. Can J Physiol Pharmacol. 2006;84:725&#x2013;737. doi: 10.1139/y06-008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y06-008</ArticleId><ArticleId IdType="pubmed">16998536</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med. 2000;6:643&#x2013;651. doi: 10.1038/76216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/76216</ArticleId><ArticleId IdType="pubmed">10835680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014;63:2253&#x2013;2261. doi: 10.2337/db14-0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-0287</ArticleId><ArticleId IdType="pmc">PMC4066335</ArticleId><ArticleId IdType="pubmed">24931035</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of &#x3b2;-amyloid peptide. Neurosci Lett. 2001;297:97&#x2013;100. doi: 10.1016/S0304-3940(00)01675-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01675-X</ArticleId><ArticleId IdType="pubmed">11121879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27080313</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia.</ArticleTitle><Pagination><StartPage>11253</StartPage><MedlinePgn>11253</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11253</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms11253</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping, fatal neurodegenerative disorders in which the molecular and pathogenic basis remains poorly understood. Ubiquitinated protein aggregates, of which TDP-43 is a major component, are a characteristic pathological feature of most ALS and FTD patients. Here we use genome-wide linkage analysis in a large ALS/FTD kindred to identify a novel disease locus on chromosome 16p13.3. Whole-exome sequencing identified a CCNF missense mutation at this locus. Interrogation of international cohorts identified additional novel CCNF variants in familial and sporadic ALS and FTD. Enrichment of rare protein-altering CCNF variants was evident in a large sporadic ALS replication cohort. CCNF encodes cyclin F, a component of an E3 ubiquitin-protein ligase complex (SCF(Cyclin F)). Expression of mutant CCNF in neuronal cells caused abnormal ubiquitination and accumulation of ubiquitinated proteins, including TDP-43 and a SCF(Cyclin F) substrate. This implicates common mechanisms, linked to protein homeostasis, underlying neuronal degeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0001-6319-9473</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales 2139, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topp</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5200-3284</Identifier><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales 2139, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fifita</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales 2139, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warraich</LastName><ForeName>Sadaf T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Katharine Y</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrawell</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, New South Wales 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblond</LastName><ForeName>Claire S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Qu&#xe9;bec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology and Cellular Biology Department, Montreal University, Montreal, QC H3T 1J4 Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5156-0567</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Proteome Analysis Facility, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rayner</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundaramoorthy</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, La Trobe University, Melbourne, Victoria 3086, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson-Stone</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, Sydney, New South Wales 2031, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Kensington, Sydney, New South Wales 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molloy</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Proteome Analysis Facility, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Blitterswijk</LastName><ForeName>Marka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Rochester, Rochester, Minneapolis 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic Rochester, Rochester, Minneapolis 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-7379-2545</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pottier</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Don</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winnick</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCann</LastName><ForeName>Emily P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daoud</LastName><ForeName>Hussein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Qu&#xe9;bec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology and Cellular Biology Department, Montreal University, Montreal, QC H3T 1J4 Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levert</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Qu&#xe9;bec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology and Cellular Biology Department, Montreal University, Montreal, QC H3T 1J4 Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dion</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Qu&#xe9;bec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology and Cellular Biology Department, Montreal University, Montreal, QC H3T 1J4 Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsui</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishiura</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kost</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Worcester Polytechnic Institute, Worcester, Massachusetts 01609, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gellera</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkazi</LastName><ForeName>Athina Soragia</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stockton</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, Sydney, New South Wales 2031, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boundy</LastName><ForeName>Karyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Queen Elizabeth Hospital, Woodville South, South Australia 5011, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Meraida</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Blanco</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Unidad de ELA, Instituto de Investigaci&#xf3;n Hospital Gregorio Mara&#xf1;&#xf3;n de Madrid, Sermas 28007, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteban-P&#xe9;rez</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unidad de ELA, Instituto de Investigaci&#xf3;n Hospital 12 de Octubre de Madrid, Sermas 28041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER U-723), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;bano</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Banco de Tejidos, Centro Alzheimer-Fundaci&#xf3;n Reina Sofia, Fundaci&#xf3;n CIEN, Madrid 28071, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20149 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center-Universit&#xe0; degli Studi di Milano, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20149 Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center-Universit&#xe0; degli Studi di Milano, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Belleroche</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurogenetics Group, Division of Brain Sciences, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>John B J</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Neuroscience Research Australia, Randwick, Sydney, New South Wales 2031, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Kensington, Sydney, New South Wales 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemin</LastName><ForeName>Gilles J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-8105-4470</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Shoji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Genome Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Redondo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de ELA, Instituto de Investigaci&#xf3;n Hospital 12 de Octubre de Madrid, Sermas 28041, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Raras (CIBERER U-723), Madrid 28029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0001-8603-1526</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Qu&#xe9;bec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathology and Cellular Biology Department, Montreal University, Montreal, QC H3T 1J4 Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerbury</LastName><ForeName>Justin J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-2528-7039</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, New South Wales 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkin</LastName><ForeName>Julie D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, La Trobe University, Melbourne, Victoria 3086, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Medical Research Council Centre for Neurodegeneration Research, Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Garth A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales 2139, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Medicine Laboratory, Concord Hospital, New South Wales 2139, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian P</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales 2139, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1DP2OD0044171</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS72187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 NS070342</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076471</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>208973</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065317</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MRF-060-0003-RG-SMITH</GrantID><Acronym>MRF_</Acronym><Agency>MRF_</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SMITH/APR16/847-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RC2-NS070-342</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS050557</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026251</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050557</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C503669">CCNF protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016213">Cyclins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002885" MajorTopicYN="N">Chromosomes, Human, Pair 16</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016213" MajorTopicYN="N">Cyclins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27080313</ArticleId><ArticleId IdType="pmc">PMC4835537</ArticleId><ArticleId IdType="doi">10.1038/ncomms11253</ArticleId><ArticleId IdType="pii">ncomms11253</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen D. R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59&#x2013;62 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668&#x2013;1672 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208&#x2013;1211 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H. X. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211&#x2013;215 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C. H. et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488, 499&#x2013;503 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223&#x2013;226 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J. O. et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron 68, 857&#x2013;864 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J. O. et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat.Neurosci. 17, 664&#x2013;666 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B. N. et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 84, 324&#x2013;331 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;133 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W. &amp; Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 14, 248&#x2013;264 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angiolella V. et al. SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 466, 138&#x2013;142 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946399</ArticleId><ArticleId IdType="pubmed">20596027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai C. et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86, 263&#x2013;274 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8706131</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Angiolella V., Esencay M. &amp; Pagano M. A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends Cell Biol. 23, 135&#x2013;140 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597434</ArticleId><ArticleId IdType="pubmed">23182110</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S. C., Polymenidou M. &amp; Cleveland D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence N. F., Sampat R. M. &amp; Kopito R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552&#x2013;1555 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Duennwald M. L. &amp; Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev. 22, 3308&#x2013;3319 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600758</ArticleId><ArticleId IdType="pubmed">19015277</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams K. L. et al. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol. Aging 33, 2527 e2523&#x2013;2527 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22717235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F. et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 68, 1440&#x2013;1446 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl C. C. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. Curr. Alzheimer Res. 8, 252&#x2013;260 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246398</ArticleId><ArticleId IdType="pubmed">21222596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T. et al. Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS ONE 6, e16983 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037939</ArticleId><ArticleId IdType="pubmed">21347293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandopadhyay R. &amp; de Belleroche J. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. Trends Mol. Med. 16, 27&#x2013;36 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20036196</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y. R. et al. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201, 361&#x2013;372 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Heck M. V. et al. Dysregulated expression of lipid storage and membrane dynamics factors in Tia1 knockout mouse nervous tissue. Neurogenetics 15, 135&#x2013;144 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994287</ArticleId><ArticleId IdType="pubmed">24659297</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B. R., Miller R. G., Swash M. &amp; Munsat T. L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord 1, 293&#x2013;299 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathrop G. M. &amp; Lalouel J. M. Easy calculations of lod scores and genetic risks on small computers. Am. J. Hum. Genet. 36, 460&#x2013;465 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1684427</ArticleId><ArticleId IdType="pubmed">6585139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner T. H. &amp; Hoffmann K. easyLINKAGE: a PERL script for easy and automated two-/multi-point linkage analyses. Bioinformatics 21, 405&#x2013;407 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15347576</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. &amp; Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754&#x2013;1760 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078&#x2013;2079 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Li M. &amp; Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2014).</Citation></Reference><Reference><Citation>McKenna A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297&#x2013;1303 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491&#x2013;498 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083463</ArticleId><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1&#x2013;11.10.33 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243306</ArticleId><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence N. F., Bennett E. J. &amp; Kopito R. R. Application and analysis of the GFPu family of ubiquitin-proteasome system reporters. Methods Enzymol. 399, 481&#x2013;490 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16338377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27088965</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.</ArticleTitle><Pagination><StartPage>721</StartPage><EndPage>732</EndPage><MedlinePgn>721-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.0580</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The use of anticholinergic (AC) medication is linked to cognitive impairment and an increased risk of dementia. To our knowledge, this is the first study to investigate the association between AC medication use and neuroimaging biomarkers of brain metabolism and atrophy as a proxy for understanding the underlying biology of the clinical effects of AC medications.</AbstractText><AbstractText Label="OBJECTIVE">To assess the association between AC medication use and cognition, glucose metabolism, and brain atrophy in cognitively normal older adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Indiana Memory and Aging Study (IMAS).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The ADNI and IMAS are longitudinal studies with cognitive, neuroimaging, and other data collected at regular intervals in clinical and academic research settings. For the participants in the ADNI, visits are repeated 3, 6, and 12 months after the baseline visit and then annually. For the participants in the IMAS, visits are repeated every 18 months after the baseline visit (402 cognitively normal older adults in the ADNI and 49 cognitively normal older adults in the IMAS were included in the present analysis). Participants were either taking (hereafter referred to as the AC+ participants [52 from the ADNI and 8 from the IMAS]) or not taking (hereafter referred to as the AC- participants [350 from the ADNI and 41 from the IMAS]) at least 1 medication with medium or high AC activity. Data analysis for this study was performed in November 2015.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Cognitive scores, mean fludeoxyglucose F 18 standardized uptake value ratio (participants from the ADNI only), and brain atrophy measures from structural magnetic resonance imaging were compared between AC+ participants and AC- participants after adjusting for potential confounders. The total AC burden score was calculated and was related to target measures. The association of AC use and longitudinal clinical decline (mean [SD] follow-up period, 32.1 [24.7] months [range, 6-108 months]) was examined using Cox regression.</AbstractText><AbstractText Label="RESULTS">The 52 AC+ participants (mean [SD] age, 73.3 [6.6] years) from the ADNI showed lower mean scores on Weschler Memory Scale-Revised Logical Memory Immediate Recall (raw mean scores: 13.27 for AC+ participants and 14.16 for AC- participants; P&#x2009;=&#x2009;.04) and the Trail Making Test Part B (raw mean scores: 97.85 seconds for AC+ participants and 82.61 seconds for AC- participants; P&#x2009;=&#x2009;.04) and a lower executive function composite score (raw mean scores: 0.58 for AC+ participants and 0.78 for AC- participants; P&#x2009;=&#x2009;.04) than the 350 AC- participants (mean [SD] age, 73.3 [5.8] years) from the ADNI. Reduced total cortical volume and temporal lobe cortical thickness and greater lateral ventricle and inferior lateral ventricle volumes were seen in the AC+ participants relative to the AC- participants.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The use of AC medication was associated with increased brain atrophy and dysfunction and clinical decline. Thus, use of AC medication among older adults should likely be discouraged if alternative therapies are available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Risacher</LastName><ForeName>Shannon L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indiana University Health Neuroscience Center, Indianapolis2Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Brenna C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indiana University Health Neuroscience Center, Indianapolis2Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tallman</LastName><ForeName>Eileen F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indiana University Health Neuroscience Center, Indianapolis2Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indiana University Health Neuroscience Center, Indianapolis2Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis3Department of Neurology, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Fredrick W</ForeName><Initials>FW</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis4Department of Psychiatry, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Sujuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis5Department of Biostatistics, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boustani</LastName><ForeName>Malaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis6Indiana University Center for Aging Research, Indianapolis7Regenstrief Institute Inc, Indianapolis, Indiana8Eskenzai Health, Indianapolis, Indiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California-Berkeley, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Departments of Radiology, Medicine, and Psychiatry, University of California-San Francisco, San Francisco15Department of Veterans Affairs Medical Center, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indiana University Health Neuroscience Center, Indianapolis2Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG031563</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016381</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044292</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036535</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011360</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021028</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA101318</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049050</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031563</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030048</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018680">Cholinergic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2016 Apr 18;353:i2220. doi: 10.1136/bmj.i2220.</RefSource><PMID Version="1">27095803</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2016 Nov;196(5):1500. doi: 10.1016/j.juro.2016.08.070.</RefSource><PMID Version="1">27751466</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2016 Dec;21(6):235. doi: 10.1136/ebmed-2016-110555.</RefSource><PMID Version="1">27815304</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="Y">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018680" MajorTopicYN="N">Cholinergic Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: Dr Farlow reports grant research support from Accera, Biogen, Eisai, Eli Lilly, Genentech, Roche, Lundbeck, Chase Pharmaceuticals, and Boehringer-Ingelheim and being a consultant for or on the advisory or data and safety monitoring boards of Accera, Alltech, Avanir, Biogen, Eisai Medical Research Inc, FORUM Pharmaceuticals, Genentech Inc, Grifols, Helicon Inc Research, Lundbeck, Medavante, Medivation Inc, Merck and Company Inc, Medtronic, Neurotrope Biosciences, Novartis, Pfizer, QR Pharma, Axovant Sciences Inc, Roche, Sanofi-Aventis, Schering-Plough, Takeda, Toyama Pharmaceutical, Pharm, Eli Lilly and Company, and UCB Pharma. Dr Petersen serves on the advisory boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is a consultant for Roche Incorporated, Merck, Genentech, and Biogen. He receives support from the National Institute on Aging (grants U01-AG006786, P50-AGG016574, R01-AG011378, and U01-AG024904) and publishing royalties from Oxford University Press. Dr Jack serves as a consultant for Eli Lilly and Company and receives research support from the National Institute on Aging (grants R01 AG11378 and R01 AG041851) and the Alexander Family Alzheimer&#x2019;s Disease Research Professorship of the Mayo Foundation. Dr Jagust serves on the scientific advisory boards of Genentech and Banner/ Genentech and was a consultant for Synarc, Siemens Medical, Genentech, F. Hoffman&#x2013;La Roche, and Novartis. He receives research support from Avid Radiopharmaceuticals, the Rainwater Foundation, and the National Institutes of Health (NIH) (grants AG034570, AG025303, AG044292, AG012345, AG021028, AG031563, AG019724, AG030048, AG032306, and AG024904). Dr Aisen serves on the scientific advisory boards of Novartis and Biogen and has been a consultant for Elan Corporation, Wyeth, Eisai Inc, Schering-Plough Corp, Bristol-Myers Squibb, Eli Lilly and Company, Roche, Amgen, Genentech Inc, Abbott, Pfizer Inc, Novartis, Bayer, Medivation Inc, Daiichi Sankyo, Astellas, Bainippon, Biomarin, Solvay, Ostuka, AstraZeneca, and Janssen. He receives research support from Baxter, Pfizer, Janssen, and Eli Lilly and Company, as well as from the National Institute on Aging (grants U01-AG10483, U01 AG024904, R01 AG030048, and R01 AG16381). Dr Weiner serves on the scientific advisory boards for Pfizer, BOLT International, Neurotrope Bioscience, Eli Lilly and Company, the University of Pennsylvania&#x2019;s Neuroscience of Behavior Initiative, the National Brain Research Centre, India, and the ADNI and is a consultant for Synarc, Pfizer, Janssen, KLJ Associates, Easton Associates, Harvard University, the University of California, Los Angeles (UCLA), the Alzheimer&#x2019;s Drug Discovery Foundation, Avid Radiopharmaceuticals, Clearview Healthcare Partners, Perceptive Informatics, Smartfish AS, Decision Resources Inc, Neurotrope Bioscience, Araclon, Merck, Defined Health, and Genentech. He receives research support from Avid Radiopharmceuticals, Eli Lilly and Company, the NIH, the US Department of Defense, and the Veterans Administration. He also has received travel funding or speaker honoraria from Pfizer, Paul Sabatier University, the MCI Group France, eDreams, the Neuroscience School of Advanced Studies, Danone Trading, BV, CTAD ANT Congr&#xe8;s, Kenes International, the Aging and Disability Resource Center, UCLA, the University of California, San Diego, the Sanofi-Aventis Group, University Center Hospital, Toulouse, Araclon, AC Immune, Eli Lilly and Company, the New York Academy of Sciences, the National Brain Research Center, Indiana for Johns Hopkins Medicine, the Consortium for Multiple Sclerosis Centers, Northwestern University, and the University of Pennsylvania. Dr Saykin serves on scientific advisory boards of Siemens Healthcare and Eli Lilly and Company and was a consultant for Baxter Bioscience, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer Inc, Siemens Healthcare, Dartmouth Medical School, the University of Michigan, the University of Vermont, Vanderbilt University, and Brigham and Women&#x2019;s Hospital/ Massachusetts General Hospital. He has received research support from Siemens Medical Solutions, Welch Allyn Inc, the Foundation for the NIH, and the NIH (grants R01 AG19771, R01 CA101318, R01 LM011360, RC2 AG036535, P30 AG10133, and U01 AG032984). He has also received travel support and/or speaker honoraria from Siemens Healthcare. No other disclosures are reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27088965</ArticleId><ArticleId IdType="mid">NIHMS816867</ArticleId><ArticleId IdType="pmc">PMC5029278</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.0580</ArticleId><ArticleId IdType="pii">2514553</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382539</ArticleId><ArticleId IdType="pubmed">16452102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14(11):980&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">17068321</ArticleId></ArticleIdList></Reference><Reference><Citation>Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311&#x2013;320.</Citation></Reference><Reference><Citation>Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9(4):377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674201</ArticleId><ArticleId IdType="pubmed">23183138</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697587</ArticleId><ArticleId IdType="pubmed">19554093</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75(2):152&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905930</ArticleId><ArticleId IdType="pubmed">20625168</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri&#xe8;re I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933398</ArticleId><ArticleId IdType="pubmed">19636034</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477&#x2013;1483.</Citation><ArticleIdList><ArticleId IdType="pubmed">21707557</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashyap M, Belleville S, Mulsant BH, et al. Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc. 2014;62(2):336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4233958</ArticleId><ArticleId IdType="pubmed">24417438</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi K, Hori K, Uchida H, et al. Adverse effects of anticholinergic activity on cognitive functions in Alzheimer&#x2019;s disease. Psychogeriatrics. 2010;10(1):34&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">20594285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampela P, Lavikainen P, Garcia-Horsman JA, Bell JS, Huupponen R, Hartikainen S. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging. 2013;30(5):321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">23475596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-R&#xe9;glat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 2005;59(2):143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1884748</ArticleId><ArticleId IdType="pubmed">15676035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah RC, Janos AL, Kline JE, et al. Cognitive decline in older persons initiating anticholinergic medications. PLoS One. 2013;8(5):e64111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669362</ArticleId><ArticleId IdType="pubmed">23741303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sittironnarit G, Ames D, Bush AI, et al. AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord. 2011;31(3):173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">21389718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29(8):639&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">22812538</ArticleId></ArticleIdList></Reference><Reference><Citation>Uusvaara J, Pitkala KH, Kautiainen H, Tilvis RS, Strandberg TE. Detailed cognitive function and use of drugs with anticholinergic properties in older people: a community-based cross-sectional study. Drugs Aging. 2013;30(3):177&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">23361527</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox C, Livingston G, Maidment ID, et al. The impact of anticholinergic burden in Alzheimer&#x2019;s dementia-the LASER-AD study. Age Ageing. 2011;40(6):730&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">21926432</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358759</ArticleId><ArticleId IdType="pubmed">25621434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Kaduszkiewicz H, Daerr M, et al. Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur Arch Psychiatry Clin Neurosci. 2010;260(suppl 2):S111&#x2013;S115.</Citation><ArticleIdList><ArticleId IdType="pubmed">20960005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashyap M, Mulsant BH, Tannenbaum C. Small longitudinal study of serum anticholinergic activity and cognitive change in community-dwelling older adults. Am J Geriatr Psychiatry. 2015;23(3):326&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">25450763</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl) 1992;107(2&#x2013;3):437&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">1615141</ArticleId></ArticleIdList></Reference><Reference><Citation>Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev. 1992;17(3):215&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">1467811</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Bruno D, Grothe MJ, Nierenberg J, Pomara N. Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults. Alzheimers Dement. 2015;1(2):216&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4876898</ArticleId><ArticleId IdType="pubmed">27239506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Borowski BJ, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Update on the magnetic resonance imaging core of the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2010;6(3):212&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886577</ArticleId><ArticleId IdType="pubmed">20451869</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6(3):221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Vandeerstichele H, Korecka M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Update on the biomarker core of the Alzheimer&#x2019;s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6(3):230&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867838</ArticleId><ArticleId IdType="pubmed">20451871</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Foroud TM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimer&#x2019;s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010;6(3):265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR, Jr, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: progress report and future plans. Alzheimers Dement. 2010;6(3):202&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Aging Brain Care.  [Accessed March 24, 2016];Anticholinergic Cognitive Burden scale: 2012 update.   http://www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf.</Citation></Reference><Reference><Citation>Drugs on the Anitcholinergic Burden (ACB) scale.  [Accessed March 24, 2016];  http://www.bmedreport.com/wp-content/uploads/2011/06/Drugs-on-the-Anticholinergic-Burden-ACB-scale.jpg.</Citation></Reference><Reference><Citation>Anticholinergics and the elderly.  [Accessed March 24, 2016];Pharmacist&#x2019;s Letter website.   http://pharmacistsletter.therapeuticresearch.com/pl/ArticleDD.aspx?nidchk=1&amp;cs=&amp;s=PL&amp;pt=5&amp;fpt=2&amp;dd=271223&amp;pb=PRL.</Citation></Reference><Reference><Citation>Risacher SL, Kim S, Nho K, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI). APOE effect on Alzheimer&#x2019;s disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015;11(12):1417&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4637003</ArticleId><ArticleId IdType="pubmed">25960448</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL, Kim S, Shen L, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI)&#x2020;. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) Front Aging Neurosci. 2013;5:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612590</ArticleId><ArticleId IdType="pubmed">23554593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. A composite score for executive functioning, validated in Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Development and assessment of a composite score for memory in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav. 2012;6(4):502&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3488276</ArticleId><ArticleId IdType="pubmed">16966547</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM toolbox [abstract]. Presented at: Eighth International Conference on Functional Mapping of the Human Brain; June 2&#x2013;6, 2002; Sendai, Japan.</Citation></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol. 1997;48:649&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">9046571</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Pino J, Zeballos G, Anad&#xf3;n MJ, et al. Cadmium-induced cell death of basal forebrain cholinergic neurons mediated by muscarinic M1 receptor blockade, increase in GSK-3&#x3b2; enzyme, &#x3b2;-amyloid and tau protein levels [published online May 31, 2015] Arch Toxicol</Citation><ArticleIdList><ArticleId IdType="pubmed">26026611</ArticleId></ArticleIdList></Reference><Reference><Citation>Capsoni S, Giannotta S, Stebel M, et al. Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. Am J Alzheimers Dis Other Demen. 2004;19(3):153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10833932</ArticleId><ArticleId IdType="pubmed">15214201</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C. Abnormalities of neural circuitry in Alzheimer&#x2019;s disease: hippocampus and cortical cholinergic innervation. Neurology. 1998;51(1)(suppl 1):S18&#x2013;S29. discussion S65-S67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674759</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau PH, Cosquer B, Jeltsch H, Cassel JC, Mathis C. Neuroanatomical and behavioral effects of a novel version of the cholinergic immunotoxin mu p75-saporin in mice. Hippocampus. 2008;18(6):610&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">18306300</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Jeon WK, Bizon JL, Han JS. Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment. Front Aging Neurosci. 2015;7:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382969</ArticleId><ArticleId IdType="pubmed">25883567</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll JC, Iba M, Bangasser DA, et al. Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy. J Neurosci. 2011;31(40):14436&#x2013;14449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230070</ArticleId><ArticleId IdType="pubmed">21976528</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci. 2003;23(8):3295&#x2013;3301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742337</ArticleId><ArticleId IdType="pubmed">12716936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27088644</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.</ArticleTitle><Pagination><StartPage>691</StartPage><EndPage>697</EndPage><MedlinePgn>691-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.0150</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Late-onset Alzheimer disease (AD), the most common form of dementia, places a large burden on families and society. Although epidemiological and clinical evidence suggests a relationship between inflammation and AD, their relationship is not well understood and could have implications for treatment and prevention strategies.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether a subset of genes involved with increased risk of inflammation are also associated with increased risk for AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In a genetic epidemiology study conducted in July 2015, we systematically investigated genetic overlap between AD (International Genomics of Alzheimer's Project stage 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, and psoriasis using summary data from genome-wide association studies at multiple academic clinical research centers. P values and odds ratios from genome-wide association studies of more than 100&#x202f;000 individuals were from previous comparisons of patients vs respective control cohorts. Diagnosis for each disorder was previously established for the parent study using consensus criteria.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was the pleiotropic (conjunction) false discovery rate P value. Follow-up for candidate variants included neuritic plaque and neurofibrillary tangle pathology; longitudinal Alzheimer's Disease Assessment Scale cognitive subscale scores as a measure of cognitive dysfunction (Alzheimer's Disease Neuroimaging Initiative); and gene expression in AD vs control brains (Gene Expression Omnibus data).</AbstractText><AbstractText Label="RESULTS">Eight single-nucleotide polymorphisms (false discovery rate P&#x2009;&lt;&#x2009;.05) were associated with both AD and immune-mediated diseases. Of these, rs2516049 (closest gene HLA-DRB5; conjunction false discovery rate P&#x2009;=&#x2009;.04 for AD and psoriasis, 5.37&#x2009;&#xd7;&#x2009;10-5 for AD, and 6.03&#x2009;&#xd7;&#x2009;10-15 for psoriasis) and rs12570088 (closest gene IPMK; conjunction false discovery rate P&#x2009;=&#x2009;.009 for AD and Crohn disease, P&#x2009;=&#x2009;5.73&#x2009;&#xd7;&#x2009;10-6 for AD, and 6.57&#x2009;&#xd7;&#x2009;10-5 for Crohn disease) demonstrated the same direction of allelic effect between AD and the immune-mediated diseases. Both rs2516049 and rs12570088 were significantly associated with neurofibrillary tangle pathology (P&#x2009;=&#x2009;.01352 and .03151, respectively); rs2516049 additionally correlated with longitudinal decline on Alzheimer's Disease Assessment Scale cognitive subscale scores (&#x3b2; [SE], 0.405 [0.190]; P&#x2009;=&#x2009;.03). Regarding gene expression, HLA-DRA and IPMK transcript expression was significantly altered in AD brains compared with control brains (HLA-DRA: &#x3b2; [SE], 0.155 [0.024]; P&#x2009;=&#x2009;1.97&#x2009;&#xd7;&#x2009;10-10; IPMK: &#x3b2; [SE], -0.096 [0.013]; P&#x2009;=&#x2009;7.57&#x2009;&#xd7;&#x2009;10-13).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Our findings demonstrate genetic overlap between AD and immune-mediated diseases and suggest that immune system processes influence AD pathogenesis and progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yunpeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St Louis, Missouri3Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schork</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Cognitive Sciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Wesley K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witoelar</LastName><ForeName>Aree</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Norwegian Centre for Mental Disorders Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway8Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chi-Hua</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla6Department of Radiology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franke</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillon</LastName><ForeName>William P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Pratik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>Luke W</ForeName><Initials>LW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsen</LastName><ForeName>Tom H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Norwegian PSC Research Center and KG Jebsen Inflammation Research Centre, Research Institute of Internal Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway14Division of Gastroenterolog.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Norwegian Centre for Mental Disorders Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway8Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla4Department of Cognitive Sciences, University of California, San Diego, La Jolla5Department of Psychiatry, University of California, San Diego, La Jolla6Department of Radiology, Uni.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>Rahul S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 AG036528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG049152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104400</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG041689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG046374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD061414</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 DA029475</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059847">HLA-DRB5 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D017853">Phosphotransferases (Alcohol Group Acceptor)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C434257">inositol polyphosphate multikinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Jun 1;73(6):638-40. doi: 10.1001/jamaneurol.2016.0407.</RefSource><PMID Version="1">27088554</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Oct 1;73(10):1255. doi: 10.1001/jamaneurol.2016.2799.</RefSource><PMID Version="1">27532297</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Oct 1;73(10):1255. doi: 10.1001/jamaneurol.2016.2796.</RefSource><PMID Version="1">27533876</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059847" MajorTopicYN="N">HLA-DRB5 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017853" MajorTopicYN="N">Phosphotransferases (Alcohol Group Acceptor)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27088644</ArticleId><ArticleId IdType="mid">NIHMS785588</ArticleId><ArticleId IdType="pmc">PMC4905783</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.0150</ArticleId><ArticleId IdType="pii">2514054</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3(3):186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van Gool WA. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2012;4(3):15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506930</ArticleId><ArticleId IdType="pubmed">22647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52(2):168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210786</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A, O&#x2019;Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer&#x2019;s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693673</ArticleId><ArticleId IdType="pubmed">22982688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, Chibnik LB, Keenan BT, et al. Alzheimer Disease Neuroimaging Initiative CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16(7):848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, et al. Inflammation Working Group and International Genomics of Alzheimer&#x2019;s Disease Project (IGAP) and DemGene Investigators Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation. 2015;131(23):2061&#x2013;2069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Cruchaga C, Goate AM. Alzheimer&#x2019;s disease genetics: from the bench to the clinic. Neuron. 2014;83(1):11&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120741</ArticleId><ArticleId IdType="pubmed">24991952</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Djurovic S, Thompson WK, et al. International Consortium for Blood Pressure GWAS. Diabetes Genetics Replication and Meta-analysis Consortium. Psychiatric Genomics Consortium Schizophrenia Working Group Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92(2):197&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3567279</ArticleId><ArticleId IdType="pubmed">23375658</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Thompson WK, Schork AJ, et al. Psychiatric Genomics Consortium. Bipolar Disorder and Schizophrenia Working Groups Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet. 2013;9(4):e1003455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636100</ArticleId><ArticleId IdType="pubmed">23637625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer&#x2019;s Disease Initiative. Genetic and Environmental Risk in Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Disease Genetic Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet. 2013;45(12):1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn&#x2019;s disease susceptibility loci. Nat Genet. 2010;42(12):1118&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299551</ArticleId><ArticleId IdType="pubmed">21102463</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl EA, Raychaudhuri S, Remmers EF, et al. BIRAC Consortium. YEAR Consortium Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42(6):508&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243840</ArticleId><ArticleId IdType="pubmed">20453842</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JC, Clayton DG, Concannon P, et al. Type 1 Diabetes Genetics Consortium Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41(6):703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889014</ArticleId><ArticleId IdType="pubmed">19430480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois PCA, Trynka G, Franke L, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet. 2010;42(4):295&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847618</ArticleId><ArticleId IdType="pubmed">20190752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90(4):636&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322238</ArticleId><ArticleId IdType="pubmed">22482804</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084597</ArticleId><ArticleId IdType="pubmed">21297633</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea L-G, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153(3):707&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, et al. Alzheimer&#x2019;s Disease Genetics Consortium Genome-wide association meta-analysis of neuropathologic features of Alzheimer&#x2019;s disease and related dementias. PLoS Genet. 2014;10(9):e1004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Zuber V, Thompson WK, et al. PRACTICAL Consortium. CRUK GWAS Shared common variants in prostate cancer and blood lipids. Int J Epidemiol. 2014;43(4):1205&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121563</ArticleId><ArticleId IdType="pubmed">24786909</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, McEvoy LK, Thompson WK, et al. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic Factors for Osteoporosis Consortium Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes. Hypertension. 2014;63(4):819&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984909</ArticleId><ArticleId IdType="pubmed">24396023</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen OA, Desikan RS, Wang Y, et al. Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One. 2015;10(4):e0123057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4390360</ArticleId><ArticleId IdType="pubmed">25853426</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols T, Brett M, Andersson J, Wager T, Poline JB. Valid conjunction inference with the minimum statistic. Neuroimage. 2005;25(3):653&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">15808966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Kim SF, Maag D, et al. Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab. 2011;13(2):215&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042716</ArticleId><ArticleId IdType="pubmed">21284988</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Paul BD, Smith DR, et al. Inositol polyphosphate multikinase is a transcriptional coactivator required for immediate early gene induction. Proc Natl Acad Sci U S A. 2013;110(40):16181&#x2013;16186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791727</ArticleId><ArticleId IdType="pubmed">24043835</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Sen N, Paul BD, et al. Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death. Sci Signal. 2013;6(269):ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108196</ArticleId><ArticleId IdType="pubmed">23550211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickramasinghe VO, Savill JM, Chavali S, et al. Human inositol polyphosphate multikinase regulates transcript-selective nuclear mRNA export to preserve genome integrity. Mol Cell. 2013;51(6):737&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">24074953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed I, Sbodio JI, Harraz MM, et al. Huntington&#x2019;s disease: neural dysfunction linked to inositol polyphosphate multikinase. Proc Natl Acad Sci U S A. 2015;112(31):9751&#x2013;9756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4534278</ArticleId><ArticleId IdType="pubmed">26195796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolles J, Bothmer J, Markerink M, Ravid R. Phosphatidylinositol kinase is reduced in Alzheimer&#x2019;s disease. J Neurochem. 1992;58(6):2326&#x2013;2329.</Citation><ArticleIdList><ArticleId IdType="pubmed">1315381</ArticleId></ArticleIdList></Reference><Reference><Citation>Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27091843</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques.</ArticleTitle><Pagination><StartPage>667</StartPage><EndPage>675</EndPage><MedlinePgn>667-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20151948</ELocationID><Abstract><AbstractText>Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid &#x3b2; (A&#x3b2;) accumulation and neuronal degeneration in Alzheimer's disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around A&#x3b2; deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on A&#x3b2; accumulation are a matter of debate. Using parabiosis, we found that amyloid-associated myeloid cells derive from brain-resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on A&#x3b2; accumulation, we examined A&#x3b2; plaques in the 5XFAD model of AD at the onset of A&#x3b2;-related pathology. At this early time point, A&#x3b2; accumulation was similar in TREM2-deficient and -sufficient 5XFAD mice. However, in the absence of TREM2, A&#x3b2; plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter A&#x3b2; plaque structure, thereby limiting neuritic damage.</AbstractText><CopyrightInformation>&#xa9; 2016 Wang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulland</LastName><ForeName>Tyler K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110 Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110 Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wilbur</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzaferis</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hole</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT 06520.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110 Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110 Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110 Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110 Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT 06520.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMattos</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110 Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110 Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110 Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110 Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110 mcolonna@pathology.wustl.edu holtzman@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009547</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27091843</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pii">jem.20151948</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brendza R.P., O&#x2019;Brien C., Simmons K., McKeel D.W., Bales K.R., Paul S.M., Olney J.W., Sanes J.R., and Holtzman D.M.. 2003. PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J. Comp. Neurol. 456:375&#x2013;383. 10.1002/cne.10536</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.10536</ArticleId><ArticleId IdType="pubmed">12532409</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Jedrychowski M.P., Moore C.S., Cialic R., Lanser A.J., Gabriely G., Koeglsperger T., Dake B., Wu P.M., Doykan C.E., et al. . 2014. Identification of a unique TGF-&#x3b2;-dependent molecular and functional signature in microglia. Nat. Neurosci. 17:131&#x2013;143. 10.1038/nn.3599</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon J.P., O&#x2019;Driscoll M., and Litman G.W.. 2012. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics. 64:39&#x2013;47. 10.1007/s00251-011-0562-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-011-0562-4</ArticleId><ArticleId IdType="pubmed">21800138</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Yuan P., Schain A., and Grutzendler J.. 2015. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun. 6:6176 10.1038/ncomms7176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7176</ArticleId><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Daws M.R., Sullam P.M., Niemi E.C., Chen T.T., Tchao N.K., and Seaman W.E.. 2003. Pattern recognition by TREM-2: binding of anionic ligands. J. Immunol. 171:594&#x2013;599. 10.4049/jimmunol.171.2.594</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.2.594</ArticleId><ArticleId IdType="pubmed">12847223</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., O&#x2019;dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., Paul S.M., Aronow B.J., and Holtzman D.M.. 2002. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 99:10843&#x2013;10848. 10.1073/pnas.162228299</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.162228299</ArticleId><ArticleId IdType="pmc">PMC125060</ArticleId><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R.B., Lu J., Tang Y., Racke M.M., Delong C.A., Tzaferis J.A., Hole J.T., Forster B.M., McDonnell P.C., Liu F., et al. . 2012. A plaque-specific antibody clears existing &#x3b2;-amyloid plaques in Alzheimer&#x2019;s disease mice. Neuron. 76:908&#x2013;920. 10.1016/j.neuron.2012.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Perdiguero E., Schulz C., and Geissmann F.. 2013. Development and homeostasis of &#x201c;resident&#x201d; myeloid cells: the case of the microglia. Glia. 61:112&#x2013;120. 10.1002/glia.22393</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22393</ArticleId><ArticleId IdType="pubmed">22847963</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M., and Merad M.. 2013. Regulation of microglia development and homeostasis. Glia. 61:121&#x2013;127. 10.1002/glia.22408</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22408</ArticleId><ArticleId IdType="pubmed">22927325</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., and Hardy J.. 2014. Genetics of Alzheimer&#x2019;s disease. Neurotherapeutics. 11:732&#x2013;737. 10.1007/s13311-014-0295-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0295-9</ArticleId><ArticleId IdType="pmc">PMC4362699</ArticleId><ArticleId IdType="pubmed">25113539</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y., Saido T.C., Eckman C.B., Prada C.M., Shoji M., and Younkin S.G.. 2000. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer&#x2019;s disease brain. Biochem. Biophys. Res. Commun. 276:422&#x2013;427. 10.1006/bbrc.2000.3490</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2000.3490</ArticleId><ArticleId IdType="pubmed">11027491</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T.C., et al. . 2013. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 493:674&#x2013;678. 10.1038/nature11729</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., Morris J.C., and Goate A.M.. 2011. Alzheimer&#x2019;s disease: the challenge of the second century. Sci. Transl. Med. 3:77sr1 10.1126/scitranslmed.3002369</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T.R., Miller C.M., Cheng P.J., Graham L.C., Bemiller S., Broihier M.L., Xu G., Margevicius D., Karlo J.C., Sousa G.L., et al. . 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 212:287&#x2013;295. 10.1084/jem.20142322</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., and Goate A.M.. 2015. Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry. 77:43&#x2013;51. 10.1016/j.biopsych.2014.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2014.05.006</ArticleId><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummer M.P., and Heneka M.T.. 2014. Truncated and modified amyloid-beta species. Alzheimers Res. Ther. 6:28 10.1186/alzrt258</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt258</ArticleId><ArticleId IdType="pmc">PMC4055046</ArticleId><ArticleId IdType="pubmed">25031638</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., and Games D.. 1996. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer&#x2019;s disease. J. Neurosci. 16:5795&#x2013;5811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578961</ArticleId><ArticleId IdType="pubmed">8795633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A., Schlevogt B., Kierdorf K., B&#xf6;ttcher C., Erny D., Kummer M.P., Quinn M., Br&#xfc;ck W., Bechmann I., Heneka M.T., et al. . 2011. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer&#x2019;s disease. J. Neurosci. 31:11159&#x2013;11171. 10.1523/JNEUROSCI.6209-10.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6209-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., et al. . 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26:10129&#x2013;10140. 10.1523/JNEUROSCI.1202-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K., Turnbull I.R., Poliani P.L., Vermi W., Cerutti E., Aoshi T., Tassi I., Takai T., Stanley S.L., Miller M., et al. . 2009. Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat. Immunol. 10:734&#x2013;743. 10.1038/ni.1744</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1744</ArticleId><ArticleId IdType="pmc">PMC4004764</ArticleId><ArticleId IdType="pubmed">19503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J., Manninen T., Christman G., Hovanes K., Mandelin J., Adolfsson R., Bianchin M., Bird T., Miranda R., Salmaggi A., et al. . 2002. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71:656&#x2013;662. 10.1086/342259</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342259</ArticleId><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M., and Priller J.. 2014. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15:300&#x2013;312. 10.1038/nrn3722</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3722</ArticleId><ArticleId IdType="pubmed">24713688</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokop S., Miller K.R., Drost N., Handrick S., Mathur V., Luo J., Wegner A., Wyss-Coray T., and Heppner F.L.. 2015. Impact of peripheral myeloid cells on amyloid-&#x3b2; pathology in Alzheimer&#x2019;s disease-like mice. J. Exp. Med. 212:1811&#x2013;1818. 10.1084/jem.20150479</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150479</ArticleId><ArticleId IdType="pmc">PMC4612091</ArticleId><ArticleId IdType="pubmed">26458768</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Rochford C.D., and Neumann H.. 2005. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201:647&#x2013;657. 10.1084/jem.20041611</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R.E. 2012. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:10 10.1101/cshperspect.a006296</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006296</ArticleId><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R.E. 2015. TREM2 and Risk of Alzheimer&#x2019;s Disease--Friend or Foe? N. Engl. J. Med. 372:2564&#x2013;2565. 10.1056/NEJMcibr1503954</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr1503954</ArticleId><ArticleId IdType="pubmed">26107057</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull I.R., Gilfillan S., Cella M., Aoshi T., Miller M., Piccio L., Hernandez M., and Colonna M.. 2006. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177:3520&#x2013;3524. 10.4049/jimmunol.177.6.3520</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J.D., Finn M.B., Wang Y., Shen A., Mahan T.E., Jiang H., Stewart F.R., Piccio L., Colonna M., and Holtzman D.M.. 2014. Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9:20 10.1186/1750-1326-9-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel N.H., Grathwohl S.A., Degenhardt K., Resch C., Bosch A., Jucker M., and Neher J.J.. 2015. Replacement of brain-resident myeloid cells does not alter cerebral amyloid-&#x3b2; deposition in mouse models of Alzheimer&#x2019;s disease. J. Exp. Med. 212:1803&#x2013;1809. 10.1084/jem.20150478</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150478</ArticleId><ArticleId IdType="pmc">PMC4612086</ArticleId><ArticleId IdType="pubmed">26458770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H., et al. . 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 160:1061&#x2013;1071. 10.1016/j.cell.2015.01.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27092707</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II.</ArticleTitle><Pagination><StartPage>11398</StartPage><MedlinePgn>11398</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms11398</ELocationID><Abstract><AbstractText>Dramatic global increases in future numbers of people with dementia have been predicted. No multicentre population-based study powered to detect changes over time has reported dementia incidence. MRC Cognitive Function and Ageing Study (CFAS) undertook baseline interviews in populations aged 65+ years in England and Wales (1989-1994). Three areas (CFAS I) were selected for new sampling two decades later (2008-2011) with same geographical boundaries, sampling and approach methods (CFAS II). At 2&#x2009;years CFAS I interviewed 5,156 (76% response) with 5,288 interviewed in CFAS II (74% response). Here we report a 20% drop in incidence (95% CI: 0-40%), driven by a reduction in men across all ages above 65. In the UK we estimate 209,600 new dementia cases per year. This study was uniquely designed to test for differences across geography and time. A reduction of age-specific incidence means that the numbers of people estimated to develop dementia in any year has remained relatively stable.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>F E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>MRC Biostatistics Unit, Institute of Public Health, Cambridge CB2 0SR, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health and Society, Faculty of Medicine, Newcastle University, Newcastle NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>B C M</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Institute of Health and Society, Faculty of Medicine, Newcastle University, Newcastle NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Health and Society, Faculty of Medicine, Newcastle University, Newcastle NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagger</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Health and Society, Faculty of Medicine, Newcastle University, Newcastle NE4 5PL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>L E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Cambridge Institute of Public Health, Cambridge University, Cambridge CB2 0SR, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arthur</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Health Sciences, University of East Anglia, Norwich NR4 7TJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Cambridge Institute of Public Health, Cambridge University, Cambridge CB2 0SR, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Cognitive Function and Ageing Studies (CFAS) Collaboration</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0900582</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J004308/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0300126</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U105292687</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G06010220</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0601022</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U105292687</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2016 Apr 19;353:i2258. doi: 10.1136/bmj.i2258.</RefSource><PMID Version="1">27094819</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014852" MajorTopicYN="N" Type="Geographic">Wales</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Comas-Herrera</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wittenberg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dening</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCracken</LastName><ForeName>C F M</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moody</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parry</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnes</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warwick</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gao</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mattison</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrison</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woods</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKeith</LastName><ForeName>I G</ForeName><Initials>IG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ince</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wharton</LastName><ForeName>S B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forster</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27092707</ArticleId><ArticleId IdType="pmc">PMC4838896</ArticleId><ArticleId IdType="doi">10.1038/ncomms11398</ArticleId><ArticleId IdType="pii">ncomms11398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prince M.
et al.. World Alzheimer Report 2015: The Gobal Impact of Dementia ana analysis of prevalence, incidence, cost and trends http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf (2015).</Citation></Reference><Reference><Citation>Prince M.
et al.. Dementia UK: Update Second Edition. http://www.alzheimers.org.uk/site/scripts/download_info.php?fileID=2323 (2014).</Citation></Reference><Reference><Citation>Lewis F. Estimation of future cases of dementia from those born in 2015 http://cdn.dementiablog.org/wp-content/uploads/2015/09/OHE_Consulting_ARUK_FINAL.pdf (2015).</Citation></Reference><Reference><Citation>Prince M. et al.. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9, 63 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Akushevich I., Kravchenko J., Ukraintseva S., Arbeev K. &amp; Yashin A. I. Time trends of incidence of age-associated diseases in the US elderly population: Medicare-based analysis. Age Ageing 42, 494 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684110</ArticleId><ArticleId IdType="pubmed">23482353</ArticleId></ArticleIdList></Reference><Reference><Citation>Langa K. M. et al.. Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? Alzheimers Dement. 4, 134 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390845</ArticleId><ArticleId IdType="pubmed">18631957</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers E. M. et al.. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 78, 1456 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22551732</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C., von S. E., Backman L., Winblad B. &amp; Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 80, 1888 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23596063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca W. A. et al.. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 7, 80 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026476</ArticleId><ArticleId IdType="pubmed">21255746</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B. et al.. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet. Neurol. 13, 614 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews F. E. et al.. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 382, 1405 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906607</ArticleId><ArticleId IdType="pubmed">23871492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo A. et al.. Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP Project. Acta. Psychiatr. Scand. 116, 299 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17803760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y. T. et al.. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet. Neurol. 15, 116&#x2013;124 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26300044</ArticleId></ArticleIdList></Reference><Reference><Citation>Capewell S. Cardio &amp; Vascular Coalition Modelling the UK Burden of Cardiovascular Disease to 2020 (Cardio &amp; Vascular Coalition and the British Heart Foundation, London, UK, 2008).</Citation></Reference><Reference><Citation>Norton S., Matthews F. E., Barnes D. E., Yaffe K. &amp; Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet. Neurol. 13, 788 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela M., Brayne C., Sachdev P., Wilcock G. &amp; Matthews F. Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort. Am. J. Epidemiol. 173, 1004 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21378129</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela M. J. et al.. Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol. Psychiatry. 71, 783 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22055015</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni R. E. et al.. Active cognitive lifestyle associates with cognitive recovery and a reduced risk of cognitive decline. J. Alzheimer's Dis. 28, 223&#x2013;230 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21971400</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaie K. W., Willis S. L. &amp; Pennak S. An historical framework for Cohort differences in intelligence. Res. Hum. Dev. 2, 43 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513180</ArticleId><ArticleId IdType="pubmed">16858496</ArticleId></ArticleIdList></Reference><Reference><Citation>Llewellyn D. J. &amp; Matthews F. E. Increasing levels of semantic verbal fluency in elderly English adults. Neuropsychol. Dev. Cogn. B. Aging. Neuropsychol. Cogn. 16, 433 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19319746</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse T. Book review (K Warner Schaie, Developmental Influences on adult intelligence: The Seattle Longitudinal Study, New York.). Intelligence 33, 551&#x2013;554 (2005).</Citation></Reference><Reference><Citation>CFAS M. R. C. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. Pyschol. Med. 28, 319 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9572090</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D. S. et al.. Incidence of dementia among participants and nonparticipants in a longitudinal study of cognitive aging. Am. J. Epidemiol. 180, 414 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4128768</ArticleId><ArticleId IdType="pubmed">24859276</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 5th edn ((2013).</Citation></Reference><Reference><Citation>Matthews F. &amp; Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. PLoS. Med. 2, e193 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1188245</ArticleId><ArticleId IdType="pubmed">16111436</ArticleId></ArticleIdList></Reference><Reference><Citation>Prime ministers challenge on dementia, a. u. o. p. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/200030/9535-TSO-2900951-PM_Challenge_Dementia_ACCESSIBLE.PDF (2013).</Citation></Reference><Reference><Citation>Brayne C. The elephant in the room&#x2014;healthy brains in later life, epidemiology and public health. Nat. Rev. Neurosci. 8, 233 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17299455</ArticleId></ArticleIdList></Reference><Reference><Citation>Claudia L. et al.. Incidence of Dementia over Three Decades in the Framingham Heart Study. The New England Journal of Medicine 374, 523 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943081</ArticleId><ArticleId IdType="pubmed">26863354</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C., Gao L., Dewey M. &amp; Matthews F. E. Dementia before death in ageing societies--the promise of prevention and the reality. PLoS Med. 3, e397 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1626550</ArticleId><ArticleId IdType="pubmed">17076551</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland J. R. et al.. The Geriatric Mental State (GMS) used in the community: replication studies of the computerized diagnosis AGECAT. Psychol. Med. 18, 219 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3283808</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland J. R., Dewey M. E. &amp; Griffiths-Jones H. M. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol. Med. 16, 89 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3515380</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M. F., Folstein S. E. &amp; McHugh P. R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr. Res. 313, 1419 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland J. R., Dewey M. E. &amp; Griffiths-Jones H. M. Dementia and depression in elderly persons: AGECAT compared with DSM III and pervasive illness. Int. J. Geriatr. Psychiatry 5, 47 (1990).</Citation></Reference><Reference><Citation>Clayton D., Spiegelhalter D., Dunn G. &amp; Pickles A. Analysis of longitudinal binary data from multiphase sampling. Stat. Med. 60, 71 (2002).</Citation></Reference><Reference><Citation>Spiegelhalter D., Thomas A., Best N. &amp; Lunn D. WinBUGS. Stat. Comput. 10, 325&#x2013;337 (2007).</Citation></Reference><Reference><Citation>Statacorp Stata Statistical Software. Release 12.1 (College Station, Texas, (2014).</Citation></Reference><Reference><Citation>Matthews F. E. Doctor of Philosophy, University of Cambridge (2005).</Citation></Reference><Reference><Citation>Matthews F. E. et al.. Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation. BMC Public Health 4, 12 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419705</ArticleId><ArticleId IdType="pubmed">15113437</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatfield M. D., Brayne C. E. &amp; Matthews F. E. A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies. J. Clin. Epidemiol. 58, 13 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15649666</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks S. P. &amp; Gelman A. Alternative methods for monitoring convergence of iterative simulations. J. Comput. Graph. Stat. 7, 434 (1998).</Citation></Reference><Reference><Citation>Rubin D. B. Multiple imputation after 18+ years (with discussion). J. Am. Stat. Assoc. 91, 473 (1996).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29067290</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-8737</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia (New York, N. Y.)</Title><ISOAbbreviation>Alzheimers Dement (N Y)</ISOAbbreviation></Journal><ArticleTitle>Design of a Bayesian adaptive phase 2 proof-of-concept trial for&#xa0;BAN2401, a putative disease-modifying monoclonal antibody for&#xa0;the&#xa0;treatment of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>12</EndPage><MedlinePgn>1-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.trci.2016.01.001</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Recent failures in phase 3 clinical trials in Alzheimer's disease (AD) suggest that novel approaches to drug development are urgently needed. Phase 3 risk can be mitigated by ensuring that clinical efficacy is established before initiating confirmatory trials, but traditional phase 2 trials in AD can be lengthy and costly.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We designed a Bayesian adaptive phase 2, proof-of-concept trial with a clinical endpoint to evaluate BAN2401, a monoclonal antibody targeting amyloid protofibrils. The study design used dose response and longitudinal modeling. Simulations were used to refine study design features to achieve optimal operating characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study design includes five active treatment arms plus placebo, a clinical outcome, 12-month primary endpoint, and a maximum sample size of 800. The average overall probability of success is &#x2265;80% when at least one dose shows a treatment effect that would be considered clinically meaningful. Using frequent interim analyses, the randomization ratios are adapted based on the clinical endpoint, and the trial can be stopped for success or futility before full enrollment.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Bayesian statistics can enhance the efficiency of analyzing the study data. The adaptive randomization generates more data on doses that appear to be more efficacious, which can improve dose selection for phase 3. The interim analyses permit stopping as soon as a predefined signal is detected, which can accelerate decision making. Both features can reduce the size and duration of the trial. This study design can mitigate some of the risks associated with advancing to phase 3 in the absence of data demonstrating clinical efficacy. Limitations to the approach are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satlin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience &amp; General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroscience &amp; General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logovinsky</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neuroscience &amp; General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Berry Consultants, LLC, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swanson</LastName><ForeName>Chad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuroscience &amp; General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhadda</LastName><ForeName>Shobha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience &amp; General Medicine, Eisai Inc., Woodcliff Lake, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Donald A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Berry Consultants, LLC, Austin, TX, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement (N Y)</MedlineTA><NlmUniqueID>101650118</NlmUniqueID><ISSNLinking>2352-8737</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive trial</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Bayesian analysis</Keyword><Keyword MajorTopicYN="N">Clinical trial simulation</Keyword><Keyword MajorTopicYN="N">Interim analysis</Keyword><Keyword MajorTopicYN="N">Monoclonal antibody</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>4</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29067290</ArticleId><ArticleId IdType="pmc">PMC5644271</ArticleId><ArticleId IdType="doi">10.1016/j.trci.2016.01.001</ArticleId><ArticleId IdType="pii">S2352-8737(16)00003-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2015;6:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883262</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., LEADe Investigators Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74:956&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">20200346</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Bapineuzumab 201 Clinical Trial Investigators A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061&#x2013;2070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., Bapineuzumab 301 and 302 Clinical Trial Investigators Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong D., Jansen R., Hoefnagels W., Jellesma-Eggenkamp M., Verbeek M., Borm G. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One. 2008;3:e1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194921</ArticleId><ArticleId IdType="pubmed">18213383</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin N. Intravenous immunoglobulin for Alzheimer's disease. Clin Exp Immunol. 2014;178(Suppl 1):27&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285480</ArticleId><ArticleId IdType="pubmed">25546751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., F&#xf6;rster S. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a Phase 2, randomised, double-blind, placebo-controlled, dose finding trial. Lancet Neurol. 2013;12:233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986921</ArticleId><ArticleId IdType="pubmed">23375965</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol. 2014;34(Suppl 1):S74&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">24760112</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody R.S.I., Gavrilova S.I., Sano M., Thomas R.G., Aisen P.S., Bachurin S.O. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect. 2010;23:518&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922928</ArticleId><ArticleId IdType="pubmed">21031168</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pubmed">12783912</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group. Martin B.K., Szekely C., Brandt J., Piantadosi S., Breitner J.C., Craft S. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65:896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A., Andreasen N., Almkvist O., Wall A., Forsberg A., Engler H. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol. 2008;63:621&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300284</ArticleId></ArticleIdList></Reference><Reference><Citation>Axonyx. Axonyx announces that phenserine did not achieve significant efficacy in phase 3 Alzheimer's disease trial. Available at: http://www.businesswire.com/news/home/20050206005019/en/Axonyx-Announces-Phenserine-Achieve-Significant-Efficacy-Phase#.VLADX_R0xZQ. Accessed January 9,&#xa0;2015.</Citation></Reference><Reference><Citation>Sabbagh M.N. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother. 2009;7:167&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948028</ArticleId><ArticleId IdType="pubmed">19616185</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase 3 study. Dement Geriatr Cogn Disord. 2010;30:131&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214882</ArticleId><ArticleId IdType="pubmed">20733306</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682361</ArticleId><ArticleId IdType="pubmed">18695053</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody R.S., Raman R., Farlow M., Iwatsubo T., Vellas B., Joffe S., Alzheimer's Disease Cooperative Study Steering Committee. Semagacestat Study Group A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369:341&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M., Bell K.L., Galasko D., Galvin J.E., Thomas R.G., van Dyck C.H. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77:556&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149154</ArticleId><ArticleId IdType="pubmed">21795660</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;8:261&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672770</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock G.K., Black S.W., Hendrix S.B., Zavitz K.H., Swabb E.A., Laughlin M.A., Tarenflurbil Phase 2 Study investigators Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase 2 trial. Lancet Neurol. 2008;7:483&#x2013;493. Errata in Lancet Neurol 2008;7:575; Lancet Neurol 2011;10:297.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450517</ArticleId></ArticleIdList></Reference><Reference><Citation>Green R.C., Schneider L.S., Amato D.A., Beelen A.P., Wilcock G., Swabb E.A., Tarenflurbil Phase 3 Study Group Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902875</ArticleId><ArticleId IdType="pubmed">20009055</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen P.S., Gauthier S., Vellas B., Briand R., Saumier D., Laurin J. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007;4:473&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">17908052</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen P.S., Gauthier S., Ferris S.H., Saumier D., Haine D., Garceau D. Tramiprosate in mild-to-moderate Alzheimer's disease &#x2013; a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch Med Sci. 2011;7:102&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258678</ArticleId><ArticleId IdType="pubmed">22291741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot P.N., Loy R., Ryan J.M., Porsteinsson A., Ismail S. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev. 2002;54:1567&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot P.N., Schneider L.S., Cummings J., Thomas R.G., Raman R., Jakimovich L.J., Alzheimer's Disease Cooperative Study Group Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68:853&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7003728</ArticleId><ArticleId IdType="pubmed">21810649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen R.L., Perry G., Xiong C., Smith M.A., Atwood C.S. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015;44:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">25310993</ArticleId></ArticleIdList></Reference><Reference><Citation>APM Health Europe  . 2007. Sanofi's Alzheimer's drug xaliproden fails in phase 3. Available at:  http://www.apmhealtheurope.com/story.php?mots=UPDATE&amp;searchScope=1&amp;searchType=0&amp;numero=L8198. Accessed December 11, 2015.</Citation></Reference><Reference><Citation>Schneider L.S., Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009;5:388&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321732</ArticleId><ArticleId IdType="pubmed">19751918</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomone S., Caraci F., Leggio G.M., Fedotova J., Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2012;73:504&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3376428</ArticleId><ArticleId IdType="pubmed">22035455</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider L.S., Mangialasche F., Andreasen N., Feldman H., Giacobini E., Jones R. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3956752</ArticleId><ArticleId IdType="pubmed">24605808</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg B.D., Carrillo M.C., Ryan J.M., Gold M., Gallagher K., Grundman M. Improving Alzheimer's disease phase 2 clinical trials. Alzheimers Dement. 2013;9:39&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23164548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray J.A., Fleet D., Winblad B. The need for thorough phase 2 studies in medicines development for Alzheimer's disease. Alzheimers Res Ther. 2015;7:67&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620743</ArticleId><ArticleId IdType="pubmed">26503107</ArticleId></ArticleIdList></Reference><Reference><Citation>Riepe M.W., Wilkinson D., F&#xf6;rstl H., Brieden A. Additive scales in degenerative disease &#x2013; calculation of effect sizes and clinical judgment. BMC Med Res Methodol. 2011;11:169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268737</ArticleId><ArticleId IdType="pubmed">22176535</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo P., Chuang-Stein C., Dragalin V., Gaydos B., Krams M., Pinheiro J., PhRMA Working Group Adaptive designs in clinical drug development &#x2013; an Executive Summary of the PhRMA Working Group. J Biopharm Stat. 2006;16:275&#x2013;283. discussion 285&#x2013;91, 293&#x2013;8, 311&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16724485</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo P., Anderson K., Chuang-Stein C., Dragalin V., Gaydos B., Krams M. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J Biopharm Stat. 2010;20:1115&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">21058107</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin G., Chen N., Lee J.J. Phase 2 trial design with Bayesian adaptive randomization and predictive probability. J R Stat Soc Ser C Appl Stat. 2012;61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832255</ArticleId><ArticleId IdType="pubmed">24259753</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry S.M., Spinelli W., Littman G.S., Liang J.Z., Fardipour P., Berry D.A. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials. 2010;7:121&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">20338905</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry D.A. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011;9:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">22064459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrix S, Logovinsky V, Perdomo C, Wang J, Satlin A. Optimizing responsiveness to decline in early AD. Presented at AAIC, July 14&#x2013;19, 2012; Vancouver, Canada. Abstract #P4-305.</Citation></Reference><Reference><Citation>Lai R, Logovinsky V, Kaplow JM, Gu K, Yu Y, M&#xf6;ller C, et&#xa0;al. A first-in-human study of BAN2401, a novel monoclonal antibody against amyloid-&#x3b2; protofibrils. Presented at AAIC 2013; Boston, MA.</Citation></Reference><Reference><Citation>West M., Harrison P. 2nd ed. Springer; New York: 1997. Bayesian Forecasting and Dynamic Models; pp. 97&#x2013;142. Chapter.</Citation></Reference><Reference><Citation>Berry S.M., Carlin B.P., Lee J.J., Muller P. CRC Press; Boca Raton: 2011. Bayesian Adaptive Methods for Clinical Trials; pp. 193&#x2013;247. Chapter 5.</Citation></Reference><Reference><Citation>Padmanabhan S.K., Berry S.M., Dragalin V., Krams M. A Bayesian dose-finding design adapting to efficacy and tolerability response. J Biopharm Stat. 2012;22:276&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">22251174</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry D.A. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16485344</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry D.A. Interim analysis in clinical trials: the role of the likelihood principle. Am Stat. 1987;41:117&#x2013;122.</Citation></Reference><Reference><Citation>Mehta C.R., Patel N.R. Adaptive, group sequential and decision theoretic approaches to sample size determination. Stat Med. 2006;25:3250&#x2013;3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16927402</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang-Stein C. Sample size and the probability of a successful trial. Pharm Stat. 2006;5:305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">17128428</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. Guidance for Industry: Adaptive design clinical trials for drugs and biologics. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed January 19, 2015.</Citation></Reference><Reference><Citation>Ritchie C.W., Lovestone S., Molinuevo J.L., Diaz C., Satlin A., van der Geyten S., on behalf of the EPAD project partners European prevention of Alzheimer's dementia (EPAD) project: An international platform to deliver proof of concept studies for secondary prevention of dementia. J Prev Alzheimers Dis. 2014;1:221. [Abstract OC7]</Citation></Reference><Reference><Citation>Vradenburg G., Rubinstein E., Lovestone S., Egan C., Duggan C., Lappin D.R. The global Alzheimer platform: a building block for accelerating clinical R&amp;D in AD. J Prev Alzheimers Dis. 2014;1:221. [Abstract P2&#x2013;15]</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27100199</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Familial Alzheimer's Disease Mutations in Presenilin Generate Amyloidogenic A&#x3b2; Peptide Seeds.</ArticleTitle><Pagination><StartPage>410</StartPage><EndPage>416</EndPage><MedlinePgn>410-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.03.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)00210-5</ELocationID><Abstract><AbstractText>Recently it was proposed that the familial Alzheimer's disease (FAD) causing presenilin (PSEN) mutations PSEN1-L435F and PSEN1-C410Y do not support the generation of A&#x3b2;-peptides from the amyloid precursor protein (APP). This challenges the amyloid hypothesis and disagrees with previous work showing that PSEN1 FAD causing mutations generate invariably long A&#x3b2; and seed amyloid. We contrast here the proteolytic activities of these mutant PSEN alleles with the complete loss-of-function PSEN1-D257A allele. We find residual carboxy- and endo-peptidase &#x3b3;-secretase activities, similar to the formerly characterized PSEN1-R278I. We conclude that the PSEN1-L435F and -C410Y mutations are extreme examples of the previously proposed "dysfunction" of &#x3b3;-secretase that characterizes FAD-associated PSEN. This Matters Arising paper is in response to Xia et&#xa0;al. (2015), published in Neuron. See also the response by Xia et&#xa0;al. (2016), published in this issue.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Veugelen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Center for Human Genetics, and Leuven Institute for Neurodegenerative Diseases (LIND), University of Leuven (KU Leuven), 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ch&#xe1;vez-Guti&#xe9;rrez</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Center for Human Genetics, and Leuven Institute for Neurodegenerative Diseases (LIND), University of Leuven (KU Leuven), 3000 Leuven, Belgium. Electronic address: lucia.chavezgutierrez@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium; Center for Human Genetics, and Leuven Institute for Neurodegenerative Diseases (LIND), University of Leuven (KU Leuven), 3000 Leuven, Belgium; Institute of Neurology, University College London, London, WC1N 3BG, UK. Electronic address: bart.destrooper@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neuron. 2015 Mar 4;85(5):967-81. doi: 10.1016/j.neuron.2015.02.010.</RefSource><PMID Version="1">25741723</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2016 Apr 20;90(2):417-22. doi: 10.1016/j.neuron.2016.03.009.</RefSource><PMID Version="1">27100200</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27100199</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.03.010</ArticleId><ArticleId IdType="pii">S0896-6273(16)00210-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27100200</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Loss of A&#x3b2;43 Production Caused by Presenilin-1 Mutations in the Knockin Mouse Brain.</ArticleTitle><Pagination><StartPage>417</StartPage><EndPage>422</EndPage><MedlinePgn>417-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.03.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)00209-9</ELocationID><Abstract><AbstractText>We recently reported that homozygous Presenilin-1 (Psen1) knockin (KI) mice carrying the familial Alzheimer's disease (FAD) mutation L435F or C410Y recapitulate the phenotypes of Psen1(-/-) mice. Production and steady-state levels of A&#x3b2;40 and A&#x3b2;42 are undetectable in KI/KI brains and reduced in KI/+ brains, though the A&#x3b2;42/A&#x3b2;40 ratio is slightly increased in KI/+ brains. Moreover, the FAD mutation impairs synaptic function, learning and memory, and age-dependent neuronal survival in the adult brain. Here we extend our analysis of the effects of the L435F and C410Y mutations to the generation of A&#x3b2;43. Similar to A&#x3b2;40 and A&#x3b2;42, production of A&#x3b2;43 is undetectable in KI/KI brains and reduced in KI/+ brains. These results support our previous conclusions that the L435F and C410Y mutations cause loss of Presenilin function and &#x3b3;-secretase activity, including impaired A&#x3b2; production in the brain. This Matters Arising Response paper addresses the Veugelen et&#xa0;al. (2016) Matters Arising paper, published concurrently in Neuron.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Center for Human Genetic Research, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Raymond J</ForeName><Initials>RJ</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Center for Human Genetic Research, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA. Electronic address: kelleher@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham &amp; Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA. Electronic address: jshen@rics.bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS075346</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042818</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041783</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 NS093185</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C098994">amyloid beta-protein (1-43)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neuron. 2015 Mar 4;85(5):967-81. doi: 10.1016/j.neuron.2015.02.010.</RefSource><PMID Version="1">25741723</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Neuron. 2016 Apr 20;90(2):410-6. doi: 10.1016/j.neuron.2016.03.010.</RefSource><PMID Version="1">27100199</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="Y">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27100200</ArticleId><ArticleId IdType="mid">NIHMS769571</ArticleId><ArticleId IdType="pmc">PMC4840410</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.03.009</ArticleId><ArticleId IdType="pii">S0896-6273(16)00209-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashe KH, Zahs KR. Probing the biology of Alzheimer&#x2019;s disease in mice. Neuron. 2010;66:631&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956420</ArticleId><ArticleId IdType="pubmed">20547123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemuru S, Kodali R, Wetzel R. C-Terminal Threonine Reduces Abeta Amyloidogenicity Compared with Abeta. J Mol Biol. 2016;428:274&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4691432</ArticleId><ArticleId IdType="pubmed">26122432</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A. 1994;91:11993&#x2013;11997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45362</ArticleId><ArticleId IdType="pubmed">7991571</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsenstein KM, Hunihan LW, Roberts SB. Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer&#x2019;s disease mutation. Nat Genet. 1994;6:251&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">8012386</ArticleId></ArticleIdList></Reference><Reference><Citation>Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development. 2000;127:2593&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821758</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Gutti U, Tai T, Shen J, Kelleher RJ., 3rd Trans-dominant negative effects of pathogenic PSEN1 mutations on gamma-secretase activity and Abeta production. J Neurosci. 2013;33:11606&#x2013;11617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724549</ArticleId><ArticleId IdType="pubmed">23843529</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilig EA, Xia W, Shen J, Kelleher RJ., 3rd A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. J Biol Chem. 2010;285:22350&#x2013;22359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903357</ArticleId><ArticleId IdType="pubmed">20460383</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997a;56:965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997b;17:7053&#x2013;7059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretner B, Fukumori A, Gutsmiedl A, Page RM, Luebbers T, Galley G, Baumann K, Haass C, Steiner H. Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem. 2011;286:15240&#x2013;15251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083200</ArticleId><ArticleId IdType="pubmed">21357415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Sharma M, Sudhof TC, Shen J. Synaptic function of nicastrin in hippocampal neurons. Proc Natl Acad Sci U S A. 2014;111:8973&#x2013;8978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066509</ArticleId><ArticleId IdType="pubmed">24889619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, et al. Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci. 2011;14:1023&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci. 2005;25:6755&#x2013;6764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725351</ArticleId><ArticleId IdType="pubmed">16033885</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, Chattarji S, Kelleher RJ, 3rd, Kandel ER, Duff K, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066262</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell. 1997;89:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Kelleher RJ., 3rd The presenilin hypothesis of Alzheimer&#x2019;s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007;104:403&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1766397</ArticleId><ArticleId IdType="pubmed">17197420</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci U S A. 1999;96:6959&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22024</ArticleId><ArticleId IdType="pubmed">10359821</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabuchi K, Chen G, Sudhof TC, Shen J. Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. J Neurosci. 2009;29:7290&#x2013;7301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719251</ArticleId><ArticleId IdType="pubmed">19494151</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, Natsugari H, Fukuyama T, Tomita T, Iwatsubo T. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem. 2003;278:18664&#x2013;18670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Wang B, He W, Zheng H. Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J Biol Chem. 2006;281:15330&#x2013;15336.</Citation><ArticleIdList><ArticleId IdType="pubmed">16574645</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Iqbal M, Zheng J, Wines-Samuelson M, Shen J. Partial loss of presenilin impairs age-dependent neuronal survival in the cerebral cortex. J Neurosci. 2014;34:15912&#x2013;15922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4244465</ArticleId><ArticleId IdType="pubmed">25429133</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Xia D, Kanekiyo T, Kelleher RJ, 3rd, Shen J. Familial frontotemporal dementia-associated presenilin-1 c.548G&gt;T mutation causes decreased mRNA expression and reduced presenilin function in knock-in mice. J Neurosci. 2012;32:5085&#x2013;5096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340902</ArticleId><ArticleId IdType="pubmed">22496554</ArticleId></ArticleIdList></Reference><Reference><Citation>Wines-Samuelson M, Schulte EC, Smith MJ, Aoki C, Liu X, Kelleher RJ, 3rd, Shen J. Characterization of age-dependent and progressive cortical neuronal degeneration in presenilin conditional mutant mice. PLoS One. 2010;5:e10195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855368</ArticleId><ArticleId IdType="pubmed">20419112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia D, Watanabe H, Wu B, Lee SH, Li Y, Tsvetkov E, Bolshakov VY, Shen J, Kelleher RJ., 3rd Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer&#x2019;s disease. Neuron. 2015;85:967&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358812</ArticleId><ArticleId IdType="pubmed">25741723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, Kawarabayashi T, Younkin L, Fedeles B, Wilson MA, et al. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron. 2001;31:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">11567612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu B, Beglopoulos V, Wines-Samuelson M, Zhang D, Dragatsis I, Sudhof TC, Shen J. Presenilins are essential for regulating neurotransmitter release. Nature. 2009;460:632&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744588</ArticleId><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Zhang C, Ho A, Kirkwood A, Sudhof TC, Shen J. Inactivation of presenilins causes pre-synaptic impairment prior to post-synaptic dysfunction. J Neurochem. 2010;115:1215&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972413</ArticleId><ArticleId IdType="pubmed">20854432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27114037</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Whole-Genome Sequencing of a Healthy Aging Cohort.</ArticleTitle><Pagination><StartPage>1002</StartPage><EndPage>1011</EndPage><MedlinePgn>1002-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.03.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)30278-1</ELocationID><Abstract><AbstractText>Studies of long-lived individuals have revealed few genetic mechanisms for protection against age-associated disease. Therefore, we pursued genome sequencing of a related phenotype-healthy aging-to understand the genetics of disease-free aging without medical intervention. In contrast with studies of exceptional longevity, usually focused on&#xa0;centenarians, healthy aging is not associated with known longevity variants, but is associated with reduced genetic susceptibility to Alzheimer and coronary artery disease. Additionally, healthy aging is not associated with a decreased rate of rare pathogenic variants, potentially indicating the presence of disease-resistance factors. In keeping with this possibility, we identify suggestive common and rare variant genetic associations implying that protection against cognitive decline is a genetic component of healthy aging. These findings, based on a relatively small cohort, require independent replication. Overall, our results suggest healthy aging is an overlapping but distinct phenotype from exceptional longevity that may be enriched with disease-protective genetic factors. VIDEO ABSTRACT.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erikson</LastName><ForeName>Galina A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodian</LastName><ForeName>Dale L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Inova Translational Medicine Institute, Inova Health System, Falls Church, VA 22042&#xa0;USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueda</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molparia</LastName><ForeName>Bhuvan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Erick R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott-Van Zeeland</LastName><ForeName>Ashley A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Cypher Genomics, Inc., San Diego, CA 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topol</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wineinger</LastName><ForeName>Nathan E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niederhuber</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Inova Translational Medicine Institute, Inova Health System, Falls Church, VA 22042&#xa0;USA; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topol</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: etopol@scripps.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torkamani</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA; Cypher Genomics, Inc., San Diego, CA 92121, USA. Electronic address: atorkama@scripps.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HG006476</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM114833</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025774</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Endocrinol. 2016 Jul;12(7):378-80. doi: 10.1038/nrendo.2016.79.</RefSource><PMID Version="1">27230948</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Mol Med. 2016 Aug;22(8):637-639. doi: 10.1016/j.molmed.2016.05.011.</RefSource><PMID Version="1">27312143</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066492" MajorTopicYN="N">Cognitive Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="Y">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27114037</ArticleId><ArticleId IdType="mid">NIHMS771120</ArticleId><ArticleId IdType="pmc">PMC4860090</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.03.022</ArticleId><ArticleId IdType="pii">S0092-8674(16)30278-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Tassan NA, et al. A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Scientific reports. 2015;5:10442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4438486</ArticleId><ArticleId IdType="pubmed">25990418</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander DH, Lange K. Enhancements to the ADMIXTURE algorithm for individual ancestry estimation. BMC bioinformatics. 2011;12:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146885</ArticleId><ArticleId IdType="pubmed">21682921</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzmon G, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS biology. 2006;4:e113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413567</ArticleId><ArticleId IdType="pubmed">16602826</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekman M, et al. Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:18046&#x2013;18049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964208</ArticleId><ArticleId IdType="pubmed">20921414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell FC, Miller ML. (Social Security Actuarial Study No 120).Life Tables for the United States Social Security Area 1900&#x2013;2100. 2005</Citation></Reference><Reference><Citation>Bodian DL, et al. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PloS one. 2014;9:e94554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984285</ArticleId><ArticleId IdType="pubmed">24728327</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle. 2008;7:158&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">18256523</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks-Wilson AR. Genetics of healthy aging and longevity. Human genetics. 2013;132:1323&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898394</ArticleId><ArticleId IdType="pubmed">23925498</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen K, et al. The quest for genetic determinants of human longevity: challenges and insights. Nature reviews Genetics. 2006;7:436&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726954</ArticleId><ArticleId IdType="pubmed">16708071</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium CAD, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nature genetics. 2013;45:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679547</ArticleId><ArticleId IdType="pubmed">23202125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505:550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Derrien T, et al. Fast computation and applications of genome mappability. PloS one. 2012;7:e30377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261895</ArticleId><ArticleId IdType="pubmed">22276185</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortney K, et al. Genome-Wide Scan Informed by Age-Related Disease Identifies Loci for Exceptional Human Longevity. PLoS genetics. 2015;11:e1005728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4683064</ArticleId><ArticleId IdType="pubmed">26677855</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. 2013;493:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676746</ArticleId><ArticleId IdType="pubmed">23201682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdes LU, et al. Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: apolipoprotein E gene is a &#x201c;frailty gene,&#x201d; not a &#x201c;longevity gene&#x201d;. Genet Epidemiol. 2000;19:202&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">11015124</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman DP, et al. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. Health Aff (Millwood) 2013;32:1698&#x2013;1705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938188</ArticleId><ArticleId IdType="pubmed">24101058</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in medicine: official journal of the American College of Medical Genetics. 2013;15:565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727274</ArticleId><ArticleId IdType="pubmed">23788249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurme M, et al. Interleukin-6 -174G/C polymorphism and longevity: a follow-up study. Mechanisms of ageing and development. 2005;126:417&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664628</ArticleId></ArticleIdList></Reference><Reference><Citation>International Schizophrenia, C et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AD, et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008;24:2938&#x2013;2939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720775</ArticleId><ArticleId IdType="pubmed">18974171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuyama H, et al. CLAC binds to aggregated Abeta and Abeta fragments, and attenuates fibril elongation. Biochemistry. 2005;44:15602&#x2013;15609.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilarski LL, et al. Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology. 2014;83:678&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4150131</ArticleId><ArticleId IdType="pubmed">25031287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuningas M, et al. SIRT1 gene, age-related diseases, and mortality: the Leiden 85-plus study. The journals of gerontology Series A, Biological sciences and medical sciences. 2007;62:960&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">17895433</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nature genetics. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic acids research. 2014;42:D980&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965032</ArticleId><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. American journal of human genetics. 2012;91:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415556</ArticleId><ArticleId IdType="pubmed">22863193</ArticleId></ArticleIdList></Reference><Reference><Citation>Libiger O, Schork NJ. A Method for Inferring an Individual&#x2019;s Genetic Ancestry and Degree of Admixture Associated with Six Major Continental Populations. Frontiers in genetics. 2012;3:322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543981</ArticleId><ArticleId IdType="pubmed">23335941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10790329</ArticleId><ArticleId IdType="pubmed">23245604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, et al. Temporal Trends in Mortality in the United States, 1969&#x2013;2013. Jama. 2015;314:1731&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pubmed">26505597</ArticleId></ArticleIdList></Reference><Reference><Citation>Melzer D, et al. A common variant of the p16(INK4a) genetic region is associated with physical function in older people. Mechanisms of ageing and development. 2007;128:370&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2074888</ArticleId><ArticleId IdType="pubmed">17459456</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailidou K, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature genetics. 2015;47:373&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549775</ArticleId><ArticleId IdType="pubmed">25751625</ArticleId></ArticleIdList></Reference><Reference><Citation>Murabito JM, et al. The search for longevity and healthy aging genes: insights from epidemiological studies and samples of long-lived individuals. The journals of gerontology Series A, Biological sciences and medical sciences. 2012;67:470&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326242</ArticleId><ArticleId IdType="pubmed">22499766</ArticleId></ArticleIdList></Reference><Reference><Citation>Osada Y, et al. CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils. J Biol Chem. 2005;280:8596&#x2013;8605.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlikowska L, et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging cell. 2009;8:460&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652804</ArticleId><ArticleId IdType="pubmed">19489743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham PH, et al. Scripps Genome ADVISER: Annotation and Distributed Variant Interpretation SERver. PLoS One. 2015;10:e0116815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338027</ArticleId><ArticleId IdType="pubmed">25706643</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010;26:2336&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DE, Goldstein DB. Detecting association in a case-control study while correcting for population stratification. Genet Epidemiol. 2001;20:4&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119293</ArticleId></ArticleIdList></Reference><Reference><Citation>Replication DIG, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nature genetics. 2014;46:234&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969612</ArticleId><ArticleId IdType="pubmed">24509480</ArticleId></ArticleIdList></Reference><Reference><Citation>Reumers J, et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nature biotechnology. 2012;30:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">22178994</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietveld CA, et al. Common genetic variants associated with cognitive performance identified using the proxy-phenotype method. Proc Natl Acad Sci U S A. 2014;111:13790&#x2013;13794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183313</ArticleId><ArticleId IdType="pubmed">25201988</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietveld CA, et al. GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science. 2013;340:1467&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751588</ArticleId><ArticleId IdType="pubmed">23722424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders AE, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. Jama. 2010;303:150&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047443</ArticleId><ArticleId IdType="pubmed">20068209</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani P, et al. Genetic signatures of exceptional longevity in humans. PloS one. 2012;7:e29848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261167</ArticleId><ArticleId IdType="pubmed">22279548</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460:753&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775422</ArticleId><ArticleId IdType="pubmed">19571809</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin SY, et al. An atlas of genetic influences on human blood metabolites. Nature genetics. 2014;46:543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064254</ArticleId><ArticleId IdType="pubmed">24816252</ArticleId></ArticleIdList></Reference><Reference><Citation>Soderberg L, et al. Characterization of the Alzheimer&#x2019;s disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site. J Biol Chem. 2005;280:1007&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudmant PH, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526:75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617611</ArticleId><ArticleId IdType="pubmed">26432246</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh Y, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:3438&#x2013;3442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265137</ArticleId><ArticleId IdType="pubmed">18316725</ArticleId></ArticleIdList></Reference><Reference><Citation>Timofeeva MN, et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Human molecular genetics. 2012;21:4980&#x2013;4995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607485</ArticleId><ArticleId IdType="pubmed">22899653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellcome Trust Case Control, C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Willcox BJ, et al. FOXO3A genotype is strongly associated with human longevity. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:13987&#x2013;13992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544566</ArticleId><ArticleId IdType="pubmed">18765803</ArticleId></ArticleIdList></Reference><Reference><Citation>Wokolorczyk D, et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer research. 2008;68:9982&#x2013;9986.</Citation><ArticleIdList><ArticleId IdType="pubmed">19047180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolpin BM, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature genetics. 2014;46:994&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191666</ArticleId><ArticleId IdType="pubmed">25086665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Pierce BL. Genetic susceptibility to accelerated cognitive decline in the US Health and Retirement Study. Neurobiol Aging. 2014;35:1512 e1511&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">24468470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng SL, et al. Cumulative association of five genetic variants with prostate cancer. The New England journal of medicine. 2008;358:910&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27114033</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.</ArticleTitle><Pagination><StartPage>921</StartPage><EndPage>935</EndPage><MedlinePgn>921-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.04.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)30392-0</ELocationID><Abstract><AbstractText>Microglia maintain homeostasis in the brain, but whether aberrant microglial activation can cause neurodegeneration remains controversial. Here, we use transcriptome profiling to demonstrate that deficiency in frontotemporal dementia (FTD) gene progranulin (Grn) leads to an age-dependent, progressive upregulation of lysosomal and innate immunity genes, increased complement production, and enhanced synaptic pruning in microglia. During aging, Grn(-/-) mice show profound microglia infiltration and preferential elimination of inhibitory synapses in the ventral thalamus, which lead to hyperexcitability in the thalamocortical circuits and obsessive-compulsive disorder (OCD)-like grooming behaviors. Remarkably, deleting C1qa gene significantly reduces synaptic pruning by Grn(-/-) microglia and mitigates neurodegeneration, behavioral phenotypes, and premature mortality in Grn(-/-) mice. Together, our results uncover a previously unrecognized role of progranulin in suppressing aberrant microglia activation during aging. These results represent an important conceptual advance that complement activation and microglia-mediated synaptic pruning are major drivers, rather than consequences, of neurodegeneration caused by progranulin deficiency.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>Hansen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiasheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makinson</LastName><ForeName>Stefanie R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Michelle K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Kevin W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Hsin-Yi</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Yulei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldham</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Lauren Herl</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>FORUM Pharmaceuticals, Waltham, MA 02451, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fuying</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behaviors, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behaviors, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Christine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Immunology Section, San Francisco VA Medical Center and Department of Medicine, University of California, San Francisco, San Francisco, CA 94121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Northwestern Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Northwestern Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Northwestern Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of British Columbia and Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology and Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Memory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia 25100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghidoni</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio, Fatebenefratelli, Brescia 25100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farese</LastName><ForeName>Robert V</ForeName><Initials>RV</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Genetics and Complex Diseases, School of Public Health, Harvard University, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paz</LastName><ForeName>Jeanne T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA; Pathology Service (113B), San Francisco VA Medical Center, San Francisco, CA 94121, USA. Electronic address: eric.huang2@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX001108</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS096369</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS078118</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002978</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX002690</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS062691</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI027763</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008568</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 RX002133</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077155">Granulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C120204">Grn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="Y">Complement Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077155" MajorTopicYN="N">Granulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27114033</ArticleId><ArticleId IdType="mid">NIHMS776426</ArticleId><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.04.001</ArticleId><ArticleId IdType="pii">S0092-8674(16)30392-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339:156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Belcastro V, Siciliano V, Gregoretti F, Mithbaokar P, Dharmalingam G, Berlingieri S, Iorio F, Oliva G, Polishchuck R, Brunetti-Pierri N, et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 2011;39:8677&#x2013;8688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203605</ArticleId><ArticleId IdType="pubmed">21785136</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguiere E, Monteiro P, Mallet L, Feng G, Graybiel AM. Striatal circuits, habits, and implications for obsessive-compulsive disorder. Curr Opin Neurobiol. 2015;30:59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4293232</ArticleId><ArticleId IdType="pubmed">25241072</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin RK, Grab DJ, Cohen RS, Siekevitz P. Isolation and characterization of postsynaptic densities from various brain regions: enrichment of different types of postsynaptic densities. J Cell Biol. 1980;86:831&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2110694</ArticleId><ArticleId IdType="pubmed">7410481</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaneda JA, Lim MJ, Cooper JD, Pearce DA. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol. 2008;115:159&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">17924126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman SL, Karaa A, Staropoli JF, Sims KB. Neuronal ceroid lipofuscinosis: impact of recent genetic advances and expansion of the clinicopathologic spectrum. Curr Neurol Neurosci Rep. 2013;13:366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3774306</ArticleId><ArticleId IdType="pubmed">23775425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald KD, Welsh RC, Stern ER, Angstadt M, Hanna GL, Abelson JL, Taylor SF. Developmental alterations of frontal-striatal-thalamic connectivity in obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:938&#x2013;948. e933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167379</ArticleId><ArticleId IdType="pubmed">21871375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;71:1235&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 2014;127:845&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">24619111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, Eisenhut RJ, Martens LH, Nakamura A, Huang A, Bagley JA, Zhou P, de Luis A, Neukomm LJ, Cabello J, et al. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc Natl Acad Sci U S A. 2011;108:4441&#x2013;4446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060230</ArticleId><ArticleId IdType="pubmed">21368173</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, Subias M, Pickering MC, Drouet C, Meri S, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39:1143&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865363</ArticleId><ArticleId IdType="pubmed">24315997</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, Min SW, Gan L, Finkbeiner S, Huang EJ, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Invest. 2012;122:3955&#x2013;3959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484443</ArticleId><ArticleId IdType="pubmed">23041626</ArticleId></ArticleIdList></Reference><Reference><Citation>Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, Okada K, Sakai T, Hashimoto A, Hara Y, et al. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell. 2012;149:1298&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529917</ArticleId><ArticleId IdType="pubmed">22682250</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, Hempstead BL, Littman DR, Gan WB. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz JT, Bryant AS, Peng K, Fenno L, Yizhar O, Frankel WN, Deisseroth K, Huguenard JR. A new mode of corticothalamic transmission revealed in the Gria4(&#x2212;/&#x2212;) model of absence epilepsy. Nat Neurosci. 2011;14:1167&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308017</ArticleId><ArticleId IdType="pubmed">21857658</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz JT, Davidson TJ, Frechette ES, Delord B, Parada I, Peng K, Deisseroth K, Huguenard JR. Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat Neurosci. 2013;16:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700812</ArticleId><ArticleId IdType="pubmed">23143518</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen CC. The functional organization of the barrel cortex. Neuron. 2007;56:339&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">17964250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">12058088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen EY, Wexler EM, Versano R, Coppola G, Gao F, Winden KD, Oldham MC, Martens LH, Zhou P, Farese RV, Jr, et al. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron. 2011;71:1030&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633414</ArticleId><ArticleId IdType="pubmed">21943601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, et al. Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci. 2015;35:13029&#x2013;13042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605437</ArticleId><ArticleId IdType="pubmed">26400934</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenberghe R, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">19288468</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, Rossi G, Pareyson D, Mole SE, Staropoli JF, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet. 2012;90:1102&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370276</ArticleId><ArticleId IdType="pubmed">22608501</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth MD, Cribbs DH, Tenner AJ, Shankle WR, Dick M, Kesslak JP, Cotman CW. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol Aging. 1994;15:609&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824052</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L, Tsai HH, Huang EJ, Rowitch DH, et al. A Dramatic Increase of C1q Protein in the CNS during Normal Aging. J Neurosci. 2013;33:13460&#x2013;13474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez CL, Colombo MI. Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol. 2009;452:85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">19200877</ArticleId></ArticleIdList></Reference><Reference><Citation>Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812536</ArticleId><ArticleId IdType="pubmed">20026663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266:17707&#x2013;17712.</Citation><ArticleIdList><ArticleId IdType="pubmed">1832676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4 Article17.</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F. Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. J Cell Biol. 2015;210:991&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576858</ArticleId><ArticleId IdType="pubmed">26370502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27112350</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2016</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain.</ArticleTitle><Pagination><StartPage>31</StartPage><MedlinePgn>31</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">31</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-016-0095-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Biological pathways that significantly contribute to sporadic Alzheimer's disease are largely unknown and cannot be observed directly. Cognitive symptoms appear only decades after the molecular disease onset, further complicating analyses. As a consequence, molecular research is often restricted to late-stage post-mortem studies of brain tissue. However, the disease process is expected to trigger numerous cellular signaling pathways and modulate the local and systemic environment, and resulting changes in secreted signaling molecules carry information about otherwise inaccessible pathological processes.</AbstractText><AbstractText Label="RESULTS">To access this information we probed relative levels of close to 600 secreted signaling proteins from patients' blood samples using antibody microarrays and mapped disease-specific molecular networks. Using these networks as seeds we then employed independent genome and transcriptome data sets to corroborate potential pathogenic pathways.</AbstractText><AbstractText Label="CONCLUSIONS">We identified Growth-Differentiation Factor (GDF) signaling as a novel Alzheimer's disease-relevant pathway supported by in vivo and in vitro follow-up experiments, demonstrating the existence of a highly informative link between cellular pathology and changes in circulatory signaling proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaeger</LastName><ForeName>Philipp A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. pjaeger@ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Chemistry and Biochemistry, Free University Berlin, Berlin, Germany. pjaeger@ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Bioengineering and Medicine, University of California San Diego, La Jolla, CA, USA. pjaeger@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucin</LastName><ForeName>Kurt M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Present address: Biology Department, Eastern Connecticut State University, Willimantic, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britschgi</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Present address: Roche Pharma Research and Early Development, NORD DTA, Roche Innovation, Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ruo-Pan</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>RayBiotech, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RayBiotech, Norcrosse, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Elizabeth D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbey</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine (Biomedical Genetics), Boston University Schools of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology, Ophthalmology, Genetics and Genomics, Epidemiology, and Biostatistics, Boston University Schools of Medicine and Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>NiCole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Nutritional Sciences and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofree</LastName><ForeName>Matan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ruochun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>RayBiotech, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RayBiotech, Norcrosse, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johns</LastName><ForeName>Hudson</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loboda</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Ramya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podtelezhnikov</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradhan</LastName><ForeName>Suraj</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Chung-Huan</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ideker</LastName><ForeName>Trey</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Bioengineering and Medicine, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System, Palo Alto, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG5131/AG/NIA</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30MH06226</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41GM103504</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH062261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM084279</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103504</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440/AG/NIA</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG16573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01HG005062</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM084279</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HG005062</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Mol Neurodegener. 2016 May 23;11(1):42. doi: 10.1186/s13024-016-0105-4.</RefSource><PMID Version="1">27216421</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27112350</ArticleId><ArticleId IdType="pmc">PMC4845325</ArticleId><ArticleId IdType="doi">10.1186/s13024-016-0095-2</ArticleId><ArticleId IdType="pii">10.1186/s13024-016-0095-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24:971&#x2013;83. doi: 10.1038/nbt1235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1235</ArticleId><ArticleId IdType="pubmed">16900146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallick P, Kuster B. Proteomics: a pragmatic perspective. Nat Biotechnol. 2010;28:695&#x2013;709. doi: 10.1038/nbt.1658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1658</ArticleId><ArticleId IdType="pubmed">20622844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, K&#x142;oszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJB. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis. 2014;38:515&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">24121966</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger PA, Villeda SA, Berdnik D, Britschgi M, Wyss-Coray T. Focused plasma proteomics for the study of brain aging and neurodegeneration. In: Coppola G, editor. The OMICS: Applications in Neuroscience. New York: Oxford Univ. Press; 2014. pp. 183&#x2013;91.</Citation></Reference><Reference><Citation>Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol. 2007;114:31&#x2013;8. doi: 10.1007/s00401-007-0236-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0236-3</ArticleId><ArticleId IdType="pubmed">17569065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133:300&#x2013;6. doi: 10.1093/brain/awp248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp248</ArticleId><ArticleId IdType="pubmed">19805492</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, Criswell LA, Jaeger PA, Stan T, Heggeli KA, Hsu SC, Karydas A, Khan BK, Grinberg LT, Gorno-Tempini M-L, Boxer AL, Rosen HJ, Kramer JH, Coppola G, Geschwind DH, Rademakers R, Seeley WW, Wyss-Coray T, Miller BL. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatr. 2013;84:956&#x2013;962. doi: 10.1136/jnnp-2012-304644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304644</ArticleId><ArticleId IdType="pmc">PMC3840954</ArticleId><ArticleId IdType="pubmed">23543794</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, P&#xe9;lerin A, M&#xe9;zenge F, Belliard S, de La Sayette V, Eustache F, Desgranges B, Ch&#xe9;telat G. Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer&#x2019;sand semantic dementia-targeted networks. Neuron. 2014;81:1417&#x2013;28. doi: 10.1016/j.neuron.2014.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.026</ArticleId><ArticleId IdType="pubmed">24656258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger PA. Cytokine and Leukocyte Profiling Reveal Pro-Inflammatory and Autoimmune Features in Frontotemporal Dementia Patients. http://dx.doi.org/10.1101/049791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/049791</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>de La Fuente A. From &#x2018;differential expression&#x2019; to &#x2018;differential networking&#x2019; &#x2013; identification of dysfunctional regulatory networks in diseases. Trends Genet. 2010;26:326&#x2013;33. doi: 10.1016/j.tig.2010.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2010.05.001</ArticleId><ArticleId IdType="pubmed">20570387</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863&#x2013;8. doi: 10.1073/pnas.95.25.14863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.25.14863</ArticleId><ArticleId IdType="pmc">PMC24541</ArticleId><ArticleId IdType="pubmed">9843981</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44&#x2013;57. doi: 10.1038/nprot.2008.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.211</ArticleId><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1&#x2013;13. doi: 10.1093/nar/gkn923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn923</ArticleId><ArticleId IdType="pmc">PMC2615629</ArticleId><ArticleId IdType="pubmed">19033363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis RD, Perry MJ, Guschina IA, Jackson CL, Morgan BP, Hughes TR. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. Am J Pathol. 2011;179:1601&#x2013;7. doi: 10.1016/j.ajpath.2011.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.06.015</ArticleId><ArticleId IdType="pmc">PMC3181373</ArticleId><ArticleId IdType="pubmed">21816131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu A, Hasegawa K. Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects. PLoS ONE. 2011;6 doi: 10.1371/journal.pone.0029351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029351</ArticleId><ArticleId IdType="pmc">PMC3243691</ArticleId><ArticleId IdType="pubmed">22206010</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickelberg O, Pansky A, Koehler E, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Kashgarian M, Roth M. Molecular mechanisms of TGF-(beta) antagonism by interferon (gamma) and cyclosporine A in lung fibroblasts. FASEB J. 2001;15:797&#x2013;806. doi: 10.1096/fj.00-0233com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.00-0233com</ArticleId><ArticleId IdType="pubmed">11259398</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickertsson JAB, D&#xf8;ssing KBV, Aabakke AJM, Nilsson H-O, Hansen TVO, Knigge U, Kj&#xe6;r A, Wadstr&#xf6;m T, Friis-Hansen L. Interferon-&#x3b3; inhibits ghrelin expression and secretion via a somatostatin-mediated mechanism. World J Gastroenterol. 2011;17:3117&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158411</ArticleId><ArticleId IdType="pubmed">21912454</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibanuma M, Mashimo J, Mita A, Kuroki T, Nose K. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem. 1993;217:13&#x2013;9. doi: 10.1111/j.1432-1033.1993.tb18212.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.1993.tb18212.x</ArticleId><ArticleId IdType="pubmed">7901004</ArticleId></ArticleIdList></Reference><Reference><Citation>Britschgi M, Rufibach K, Huang SLB, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics. 2011;10:M111. doi: 10.1074/mcp.M111.008862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M111.008862</ArticleId><ArticleId IdType="pmc">PMC3205866</ArticleId><ArticleId IdType="pubmed">21742799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359&#x2013;62. doi: 10.1038/nm1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1653</ArticleId><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea L-G, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153:707&#x2013;20. doi: 10.1016/j.cell.2013.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.03.030</ArticleId><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Podtelezhnikov AA, Tanis KQ, Nebozhyn M, Ray WJ, Stone DJ, Loboda AP. Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging. PLoS ONE. 2011;6 doi: 10.1371/journal.pone.0029610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029610</ArticleId><ArticleId IdType="pmc">PMC3247273</ArticleId><ArticleId IdType="pubmed">22216330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 2001;7:612&#x2013;8. doi: 10.1038/87945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/87945</ArticleId><ArticleId IdType="pubmed">11329064</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-&#x3b2;&#x2013;Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649699</ArticleId><ArticleId IdType="pubmed">18516051</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke RM, Norman TA, Haydar TF, Slack BE, Leeman SE, Blusztajn JK, Mellott TJ. BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2013;110:19567&#x2013;72. doi: 10.1073/pnas.1319297110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1319297110</ArticleId><ArticleId IdType="pmc">PMC3845152</ArticleId><ArticleId IdType="pubmed">24218590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hexige S, Guo J, Ma L, Sun Y, Liu X, Ma L, Yan X, Li Z, Yu L. Expression pattern of growth/differentiation factor 3 in human and murine cerebral cortex, hippocampus as well as cerebellum. Neurosci Lett. 2005;389:83&#x2013;7. doi: 10.1016/j.neulet.2005.06.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.06.071</ArticleId><ArticleId IdType="pubmed">16126341</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine AJ, Brivanlou AH. GDF3, a BMP inhibitor, regulates cell fate in stem cells and early embryos. Development. 2006;133:209&#x2013;16. doi: 10.1242/dev.02192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.02192</ArticleId><ArticleId IdType="pubmed">16339188</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine AJ, Brivanlou AH. GDF3 at the crossroads of TGF-beta signaling. Cell Cycle. 2006;5:1069&#x2013;73. doi: 10.4161/cc.5.10.2771.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.5.10.2771</ArticleId><ArticleId IdType="pubmed">16721050</ArticleId></ArticleIdList></Reference><Reference><Citation>Tykwinska K, Lauster R, Knaus P, Rosowski M. Growth and differentiation factor 3 induces expression of genes related to differentiation in a model of cancer stem cells and protects them from retinoic acid-induced apoptosis. PLoS ONE. 2013;8 doi: 10.1371/journal.pone.0070612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0070612</ArticleId><ArticleId IdType="pmc">PMC3741270</ArticleId><ArticleId IdType="pubmed">23950971</ArticleId></ArticleIdList></Reference><Reference><Citation>Calloni R, Cordero EAA, Henriques JAP, Bonatto D. Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev. 2013;22:1455&#x2013;76. doi: 10.1089/scd.2012.0637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2012.0637</ArticleId><ArticleId IdType="pmc">PMC3629778</ArticleId><ArticleId IdType="pubmed">23336433</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Liu X, Wu Y, An J, Hexige S, Ling Y, Zhang M, Yang X, Yu L. The conditioned medium from a stable human GDF3-expressing CHO cell line, induces the differentiation of PC12 cells. Mol Cell Biochem. 2011;359:115&#x2013;23. doi: 10.1007/s11010-011-1005-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-011-1005-0</ArticleId><ArticleId IdType="pubmed">21805089</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park J-S, Couillard-Despr&#xe9;s S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90&#x2013;4. doi: 10.1038/nature10357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10357</ArticleId><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y, Yang T-H, Kim H-M, Drake D, Liu XS, Bennett DA, Colai&#xe1;covo MP, Yankner BA. REST and stress resistance in ageing and Alzheimer's disease. Nature. 2014;507:448&#x2013;54. doi: 10.1038/nature13163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13163</ArticleId><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidder BL, Yang J, Palmer S. Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS ONE. 2008;3 doi: 10.1371/journal.pone.0003932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003932</ArticleId><ArticleId IdType="pmc">PMC2592696</ArticleId><ArticleId IdType="pubmed">19079543</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, Bostr&#xf6;m E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mash DC, Druid H, Fris&#xe9;n J. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;153:1219&#x2013;27. doi: 10.1016/j.cell.2013.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.002</ArticleId><ArticleId IdType="pmc">PMC4394608</ArticleId><ArticleId IdType="pubmed">23746839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai K-J, Tsai Y-C, Shen C-KJ. G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med. 2007;204:1273&#x2013;80. doi: 10.1084/jem.20062481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20062481</ArticleId><ArticleId IdType="pmc">PMC2118601</ArticleId><ArticleId IdType="pubmed">17517969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q-H, Futagawa T, Yang W-L, Jiang X-D, Zeng L, Takeda Y, Xu R-X, Bagnard D, Schachner M, Furley AJ, Karagogeos D, Watanabe K, Dawe GS, Xiao Z-C. A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. Nat Cell Biol. 2008;10:283&#x2013;94. doi: 10.1038/ncb1690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1690</ArticleId><ArticleId IdType="pubmed">18278038</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, Johnston C, Killick R, Simmons A, Westman E, Hodges A, Soininen H, K&#x142;oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Dobson RJB, Consortium TA. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 2014;10:724&#x2013;34. doi: 10.1016/j.jalz.2013.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.09.016</ArticleId><ArticleId IdType="pubmed">24768341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj TC, Holder DJ, Dai H, Weiner R, Laterza OF. A candidate plasma protein classifier to identify Alzheimer's disease. J Alzheimers Dis. 2015;43:549&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25114072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Li M, Deng Y, Pan Y. Recent advances in clustering methods for protein interaction networks. BMC Genomics. 2010;11:S10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2999340</ArticleId><ArticleId IdType="pubmed">21143777</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton L, Ballarin V, Brun M. Clustering algorithms: on learning, validation, performance, and applications to genomics. Curr Genomics. 2009;10:430&#x2013;45. doi: 10.2174/138920209789177601.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920209789177601</ArticleId><ArticleId IdType="pmc">PMC2766793</ArticleId><ArticleId IdType="pubmed">20190957</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnoes AM, Ream DC, Thorman AW, Babbitt PC, Friedberg I. Biases in the experimental annotations of protein function and their effect on Our understanding of protein function space. PLoS Comput Biol. 2013;9 doi: 10.1371/journal.pcbi.1003063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003063</ArticleId><ArticleId IdType="pmc">PMC3667760</ArticleId><ArticleId IdType="pubmed">23737737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutkowski J, Ono K, Kramer M, Yu M, Pratt D, Demchak B, Ideker T. NeXO Web: the NeXO ontology database and visualization platform. Nucleic Acids Res. 2013;42:D1269&#x2013;74. doi: 10.1093/nar/gkt1192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1192</ArticleId><ArticleId IdType="pmc">PMC3965056</ArticleId><ArticleId IdType="pubmed">24271398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer M, Dutkowski J, Yu M, Bafna V, Ideker T. Inferring gene ontologies from pairwise similarity data. Bioinformatics. 2014;30:i34&#x2013;42. doi: 10.1093/bioinformatics/btu282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu282</ArticleId><ArticleId IdType="pmc">PMC4058954</ArticleId><ArticleId IdType="pubmed">24932003</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, for the Texas Alzheimer's Research Consortium. Diaz-Arrastia R. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010;67:1077&#x2013;81. doi: 10.1001/archneurol.2010.215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.215</ArticleId><ArticleId IdType="pmc">PMC3069805</ArticleId><ArticleId IdType="pubmed">20837851</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Mccluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM-Y, Soares H, Trojanowski JQ. Biomarker discovery for Alzheimer&#x201c;s disease, frontotemporal lobar degeneration, and Parkinson&#x201d;s disease. Acta Neuropathol. 2010;120:385&#x2013;99. doi: 10.1007/s00401-010-0723-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0723-9</ArticleId><ArticleId IdType="pmc">PMC2982700</ArticleId><ArticleId IdType="pubmed">20652578</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS ONE. 2011;6 doi: 10.1371/journal.pone.0018850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018850</ArticleId><ArticleId IdType="pmc">PMC3079734</ArticleId><ArticleId IdType="pubmed">21526197</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012;69:1310&#x2013;7. doi: 10.1001/archneurol.2012.1070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.1070</ArticleId><ArticleId IdType="pmc">PMC3683865</ArticleId><ArticleId IdType="pubmed">22801723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Arch Neurol. 2012;69:757&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668092</ArticleId><ArticleId IdType="pubmed">22689192</ArticleId></ArticleIdList></Reference><Reference><Citation>Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam C-P, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging Initiative, Australian Imaging Biomarker and Lifestyle Research Group Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69:1318&#x2013;25. doi: 10.1001/archneurol.2012.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.1282</ArticleId><ArticleId IdType="pmc">PMC6287606</ArticleId><ArticleId IdType="pubmed">22801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, Mccluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM-Y, Morris JC, Trojanowski JQ, Soares H, Initi ADN. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897&#x2013;905. doi: 10.1212/WNL.0b013e318266fa70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318266fa70</ArticleId><ArticleId IdType="pmc">PMC3425844</ArticleId><ArticleId IdType="pubmed">22855860</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JSG, Rourke SB, Tsoukas C, Klein MB, CANOC Collaboration Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS ONE. 2013;8:e77665. doi: 10.1371/journal.pone.0077665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077665</ArticleId><ArticleId IdType="pmc">PMC3813720</ArticleId><ArticleId IdType="pubmed">24204912</ArticleId></ArticleIdList></Reference><Reference><Citation>Llano DA, Devanarayan V, Simon AJ, ADNI Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:233&#x2013;43. doi: 10.1097/WAD.0b013e31826d597a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31826d597a</ArticleId><ArticleId IdType="pubmed">23023094</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L-H, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R, Neuroimaging AD. Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:337&#x2013;42. doi: 10.1097/WAD.0b013e31827b60d2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31827b60d2</ArticleId><ArticleId IdType="pmc">PMC3626738</ArticleId><ArticleId IdType="pubmed">23314060</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL, Initiative ARSDN, Australian Imaging BALSRG A blood-based predictor for neocortical Ab burden in Alzheimer&#x2019;s disease: results from the AIBL study. Mol Psychiatry. 2013;19:519&#x2013;26. doi: 10.1038/mp.2013.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.40</ArticleId><ArticleId IdType="pubmed">23628985</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J, S&#xe9;verac D, Bu&#xe9;e L, R&#xe8;me T, Lehmann S. Central nervous system and peripheral inflammatory processes in Alzheimer&#x2019;s disease: biomarker profiling approach. Front Neurol. 2015;6:103. doi: 10.3389/fneur.2015.00181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2015.00181</ArticleId><ArticleId IdType="pmc">PMC4547499</ArticleId><ArticleId IdType="pubmed">26379616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehallier B, Essioux L, Gayan J, Alexandridis R, Nikolcheva T, Wyss-Coray T, Britschgi M, for the Alzheimer's Disease Neuroimaging Initiative. Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease. JAMA Neurol. 2015;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5214993</ArticleId><ArticleId IdType="pubmed">26659895</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiam JTW, Dobson RJB, Kiddle SJ, Sattlecker M. Are blood-based protein biomarkers for Alzheimer's disease also involved in other brain disorders? A systematic review. J Alzheimers Dis. 2015;43:303&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25096613</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the national institute on aging and the Alzheimer&#x2019;s association workgroup. Alzheimers Dement. 2011;1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;14. doi: 10.1212/WNL.0b013e31821103e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31821103e6</ArticleId><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen M, de Hoon M. Cluster 3.0 Manual. 2002. pp. 1&#x2013;34.</Citation></Reference><Reference><Citation>Storey JD. A direct approach to false discovery rates - Storey - 2002 - Journal of the Royal Statistical Society: Series B. J R Stat Soc Ser B. 2002;64:479&#x2013;98. doi: 10.1111/1467-9868.00346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-9868.00346</ArticleId></ArticleIdList></Reference><Reference><Citation>Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, Morris Q, Bader GD. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26:2927&#x2013;8. doi: 10.1093/bioinformatics/btq562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq562</ArticleId><ArticleId IdType="pmc">PMC2971582</ArticleId><ArticleId IdType="pubmed">20926419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498&#x2013;504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. PID: the Pathway Interaction Database. Nucleic Acids Res. 2009;37(Database):D674&#x2013;9. doi: 10.1093/nar/gkn653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkn653</ArticleId><ArticleId IdType="pmc">PMC2686461</ArticleId><ArticleId IdType="pubmed">18832364</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, Caudy M, Garapati P, Gopinath G, Jassal B, Jupe S, Kalatskaya I, Mahajan S, May B, Ndegwa N, Schmidt E, Shamovsky V, Yung C, Birney E, Hermjakob H, D'Eustachio P, Stein L. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2010;39(Database):D691&#x2013;7. doi: 10.1093/nar/gkq1018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq1018</ArticleId><ArticleId IdType="pmc">PMC3013646</ArticleId><ArticleId IdType="pubmed">21067998</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi-Tope G. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2004;33(Database issue):D428&#x2013;32. doi: 10.1093/nar/gki072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki072</ArticleId><ArticleId IdType="pmc">PMC540026</ArticleId><ArticleId IdType="pubmed">15608231</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, Caudy M, Garapati P, Gillespie M, Kamdar MR, Jassal B, Jupe S, Matthews L, May B, Palatnik S, Rothfels K, Shamovsky V, Song H, Williams M, Birney E, Hermjakob H, Stein L, D'Eustachio P. The reactome pathway knowledgebase. Nucleic Acids Res. 2013;42:D472&#x2013;7. doi: 10.1093/nar/gkt1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1102</ArticleId><ArticleId IdType="pmc">PMC3965010</ArticleId><ArticleId IdType="pubmed">24243840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010;11:R53. doi: 10.1186/gb-2010-11-5-r53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2010-11-5-r53</ArticleId><ArticleId IdType="pmc">PMC2898064</ArticleId><ArticleId IdType="pubmed">20482850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatr-aryamontri A, Breitkreutz BJ, Oughtred R, Boucher L, Heinicke S, Chen D, Stark C, Breitkreutz A, Kolas N, O'Donnell L, Reguly T, Nixon J, Ramage L, Winter A, Sellam A, Chang C, Hirschman J, Theesfeld C, Rust J, Livstone MS, Dolinski K, Tyers M. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 2015;43:D470&#x2013;8. doi: 10.1093/nar/gku1204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1204</ArticleId><ArticleId IdType="pmc">PMC4383984</ArticleId><ArticleId IdType="pubmed">25428363</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner B, Razick S, Turinsky AL, Vlasblom J, Crowdy EK, Cho E, Morrison K, Donaldson IM, Wodak SJ. iRefWeb: interactive analysis of consolidated protein interaction data and their supporting evidence. Database. 2010;2010:baq023&#x2013;3. doi: 10.1093/database/baq023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/database/baq023</ArticleId><ArticleId IdType="pmc">PMC2963317</ArticleId><ArticleId IdType="pubmed">20940177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G, Consortium GO. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25:25&#x2013;9. doi: 10.1038/75556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology Consortium Gene ontology consortium: going forward. Nucleic Acids Res. 2015;43:D1049&#x2013;56. doi: 10.1093/nar/gku1179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1179</ArticleId><ArticleId IdType="pmc">PMC4383973</ArticleId><ArticleId IdType="pubmed">25428369</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27&#x2013;30. doi: 10.1093/nar/28.1.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013;8:1551&#x2013;66. doi: 10.1038/nprot.2013.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.092</ArticleId><ArticleId IdType="pmc">PMC6519453</ArticleId><ArticleId IdType="pubmed">23868073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol. 2012;8:565. doi: 10.1038/msb.2011.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/msb.2011.99</ArticleId><ArticleId IdType="pmc">PMC3296360</ArticleId><ArticleId IdType="pubmed">22252388</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Li F, Qin Y, Bo X, Wu Y, Wang S. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics. 2010;26:976&#x2013;8. doi: 10.1093/bioinformatics/btq064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq064</ArticleId><ArticleId IdType="pubmed">20179076</ArticleId></ArticleIdList></Reference><Reference><Citation>Halekoh U, H&#xf8;jsgaard S. The R package geepack for generalized estimating equations. J Stat Softw. 2006.</Citation></Reference><Reference><Citation>Chen M-H, Yang Q. GWAF: an R package for genome-wide association analyses with family data. Bioinformatics. 2010;26:580&#x2013;1. doi: 10.1093/bioinformatics/btp710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp710</ArticleId><ArticleId IdType="pmc">PMC2852219</ArticleId><ArticleId IdType="pubmed">20040588</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190&#x2013;1. doi: 10.1093/bioinformatics/btq340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 2005;95:221&#x2013;7. doi: 10.1038/sj.hdy.6800717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.hdy.6800717</ArticleId><ArticleId IdType="pubmed">16077740</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, AMFS Investigators. Hayward NK, Montgomery GW, Visscher PM, Martin NG, Macgregor S. A versatile gene-based test for genome-wide association studies. Am J Hum Genet. 2010;87:139&#x2013;45. doi: 10.1016/j.ajhg.2010.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2010.06.009</ArticleId><ArticleId IdType="pmc">PMC2896770</ArticleId><ArticleId IdType="pubmed">20598278</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu H, Claasen J-H, Kannan S, R&#xfc;nker AE, Palmer T, Kempermann G. A protocol for isolation and enriched monolayer cultivation of neural precursor cells from mouse dentate gyrus. Front Neurosci. 2011;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140691</ArticleId><ArticleId IdType="pubmed">21811434</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurok U, Steinhoff C, Lipkowitz B, Ropers H-H, Scharff C, Nuber UA. Gene expression changes in the course of neural progenitor cell differentiation. J Neurosci. 2004;24:5982&#x2013;6002. doi: 10.1523/JNEUROSCI.0809-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0809-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729244</ArticleId><ArticleId IdType="pubmed">15229246</ArticleId></ArticleIdList></Reference><Reference><Citation>Casta&#xf1;o Z, Kypta RM. Housekeeping proteins: limitations as references during neuronal differentiation. Open Neurosci J. 2008;2.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27157073</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials.</ArticleTitle><Pagination><StartPage>631</StartPage><EndPage>632</EndPage><MedlinePgn>631-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2016.04.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(16)30207-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weninger</LastName><ForeName>Stacie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>F-Prime Biomedical Research Initiative, Cambridge, MA, USA. Electronic address: sweninger@fbri.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Medical &amp; Scientific Relations Division, Alzheimer's Association, Chicago, IL, USA. Electronic address: mcarrillo@alz.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Billy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Neurology Products, U.S. Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>University of Southern California Alzheimer's Therapeutic Research Institute, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotz</LastName><ForeName>Joanne D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>F-Prime Biomedical Research Initiative, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santacruz</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welsh-Bohmer</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Departments of Neurology &amp; Psychiatry, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046179</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG046150</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG041705</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="Y">Cooperative Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="N">Information Dissemination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27157073</ArticleId><ArticleId IdType="mid">NIHMS826714</ArticleId><ArticleId IdType="pmc">PMC5111162</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2016.04.001</ArticleId><ArticleId IdType="pii">S1552-5260(16)30207-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27164694</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>22</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>APOE &#x3b5;4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline.</ArticleTitle><Pagination><StartPage>2063</StartPage><EndPage>2070</EndPage><MedlinePgn>2063-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000002719</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To examine the association between consumption of seafood and long-chain n-3 fatty acids with change in 5 cognitive domains over an average of 4.9 years.</AbstractText><AbstractText Label="METHODS">From an ongoing longitudinal, community-based epidemiologic study of aging and dementia (the Rush Memory and Aging Project), we included 915 participants (age 81.4 &#xb1; 7.2 years, 25% men) who had completed at least one follow-up cognitive assessment and dietary data. Diet was assessed by semiquantitative food frequency questionnaire. Scores for global cognitive function and 5 cognitive domains (episodic, semantic, and working memory, perceptual speed, and visuospatial ability) were assessed using 19 cognitive tests. Mixed models adjusted for multiple risk factors of cognitive change were used to assess the associations.</AbstractText><AbstractText Label="RESULTS">Consumption of seafood was associated with slower decline in semantic memory (&#x3b2; = 0.024; p = 0.03) and perceptual speed (&#x3b2; = 0.020; p = 0.05) in separate models adjusted for age, sex, education, participation in cognitive activities, physical activity, alcohol consumption, smoking, and total energy intake. In secondary analyses, APOE &#x3b5;4 carriers demonstrated slower rates of decline in global cognition and in multiple cognitive domains with weekly seafood consumption and with moderate to high long-chain n-3 fatty acid intake from food. These associations were not present in APOE &#x3b5;4 noncarriers. Higher intake levels of &#x3b1;-linolenic acid were associated with slower global cognitive decline, but also only in APOE &#x3b5;4 carriers.</AbstractText><AbstractText Label="CONCLUSIONS">These results suggest protective relations of one meal per week of seafood and long-chain n-3 fatty acids against decline in multiple cognitive domains. The role of APOE &#x3b5;4 in this association needs further study.</AbstractText><CopyrightInformation>&#xa9; 2016 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van de Rest</LastName><ForeName>Ondine</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (O.v.d.R.), Wageningen University, the Netherlands; and Department of Internal Medicine, Section on Nutrition and Nutritional Epidemiology (Y.W., M.C.M.), Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Department of Behavioral Sciences (L.L.B.), Department of Clinical Nutrition (C.T.), and Department of Neurology (D.A.B.), Rush University Medical Center, Chicago, IL. Ondine.vandeRest@wur.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yamin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (O.v.d.R.), Wageningen University, the Netherlands; and Department of Internal Medicine, Section on Nutrition and Nutritional Epidemiology (Y.W., M.C.M.), Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Department of Behavioral Sciences (L.L.B.), Department of Clinical Nutrition (C.T.), and Department of Neurology (D.A.B.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (O.v.d.R.), Wageningen University, the Netherlands; and Department of Internal Medicine, Section on Nutrition and Nutritional Epidemiology (Y.W., M.C.M.), Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Department of Behavioral Sciences (L.L.B.), Department of Clinical Nutrition (C.T.), and Department of Neurology (D.A.B.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tangney</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (O.v.d.R.), Wageningen University, the Netherlands; and Department of Internal Medicine, Section on Nutrition and Nutritional Epidemiology (Y.W., M.C.M.), Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Department of Behavioral Sciences (L.L.B.), Department of Clinical Nutrition (C.T.), and Department of Neurology (D.A.B.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (O.v.d.R.), Wageningen University, the Netherlands; and Department of Internal Medicine, Section on Nutrition and Nutritional Epidemiology (Y.W., M.C.M.), Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Department of Behavioral Sciences (L.L.B.), Department of Clinical Nutrition (C.T.), and Department of Neurology (D.A.B.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Martha Clare</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>From the Division of Human Nutrition (O.v.d.R.), Wageningen University, the Netherlands; and Department of Internal Medicine, Section on Nutrition and Nutritional Epidemiology (Y.W., M.C.M.), Rush Alzheimer's Disease Center (L.L.B., D.A.B.), Department of Behavioral Sciences (L.L.B.), Department of Clinical Nutrition (C.T.), and Department of Neurology (D.A.B.), Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031553</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 ES021290</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2016 May 31;86(22):2069. doi: 10.1212/WNL.0000000000002728.</RefSource><PMID Version="1">27164701</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2016 May 31;86(22):e231-3. doi: 10.1212/WNL.0000000000002733.</RefSource><PMID Version="1">27242387</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="Y">Fatty Acids, Omega-3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005247" MajorTopicYN="N">Feeding Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060005" MajorTopicYN="N">Genotyping Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066829" MajorTopicYN="N">Neuroprotection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017747" MajorTopicYN="Y">Seafood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27164694</ArticleId><ArticleId IdType="pmc">PMC4891213</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002719</ArticleId><ArticleId IdType="pii">WNL.0000000000002719</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang TL. Omega-3 fatty acids, cognitive decline, and Alzheimer's disease: a critical review and evaluation of the literature. J Alzheimers Dis 2010;21:673&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">20634589</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Rest O, van Hooijdonk LW, Doets E, Schiepers OJ, Eilander A, de Groot LC. B vitamins and n-3 fatty acids for brain development and function: review of human studies. Ann Nutr Metab 2012;60:272&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">22678093</ArticleId></ArticleIdList></Reference><Reference><Citation>Solfrizzi V, D'Introno A, Colacicco AM, et al. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 2006;364:91&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">16139826</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush memory and aging project. Curr Alzheimer Res 2012;9:646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Tangney CC, Bienias JL, Evans DA, Wilson RS. Validity and reproducibility of a food frequency questionnaire by cognition in an older biracial sample. Am J Epidemiol 2003;158:1213&#x2013;1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">14652307</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 1986;124:17&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">3521261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc 2005;11:400&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">16209420</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhillips JB, Pellettera KM, Barrett-Connor E, Wingard DL, Criqui MH. Exercise patterns in a population of older adults. Am J Prev Med 1989;5:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">2730794</ArticleId></ArticleIdList></Reference><Reference><Citation>1985 Health Interview Survey. 1985 Health Interview Survey. Hyattsville, MD: National Center for Health Statistics; 1985.</Citation></Reference><Reference><Citation>Buchman AS, Boyle PA, Wilson RS, Beck TL, Kelly JF, Bennett DA. Apolipoprotein E e4 allele is associated with more rapid motor decline in older persons. Alzheimer Dis Assoc Disord 2009;23:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2662708</ArticleId><ArticleId IdType="pubmed">19266700</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002;325:932&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC130057</ArticleId><ArticleId IdType="pubmed">12399342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997;145:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8982020</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrieu S, Letenneur L, Helmer C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging 2004;8:150&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">15129300</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873849</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005;62:1849&#x2013;1853.</Citation><ArticleIdList><ArticleId IdType="pubmed">16216930</ArticleId></ArticleIdList></Reference><Reference><Citation>Egensperger R, Kosel S, von Eitzen U, Graeber MB. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 1998;8:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098510</ArticleId><ArticleId IdType="pubmed">9669695</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr SK, Bazinet RP. The emerging role of docosahexaenoic acid in neuroinflammation. Curr Opin Investig Drugs 2008;9:735&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">18600579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariv-Inbal Z, Yacobson S, Berkecz R, et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis 2012;28:667&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">22057027</ArticleId></ArticleIdList></Reference><Reference><Citation>Samieri C, Feart C, Proust-Lima C, et al. Omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. Neurobiol Aging 2011;32:2317 e13&#x2013;2317 e22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20570406</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007;69:1921&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998483</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005;65:1409&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275829</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley LJ, Deary IJ, Starr JM, et al. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 2008;87:449&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pubmed">18258638</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris MC, Brockman J, Schneider JA, et al. Association of seafood consumption, brain mercury level and APOE-&#x3b5;4 status with brain neuropathology in older adults. JAMA 2016;315:489&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5460535</ArticleId><ArticleId IdType="pubmed">26836731</ArticleId></ArticleIdList></Reference><Reference><Citation>Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR; Alzheimer's Disease Neuroimaging Initiative. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement 2015;11:226&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829435</ArticleId><ArticleId IdType="pubmed">24954371</ArticleId></ArticleIdList></Reference><Reference><Citation>Stonehouse W, Conlon CA, Podd J, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr 2013;97:1134&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">23515006</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008;71:430&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">18678826</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259852</ArticleId><ArticleId IdType="pubmed">21045096</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging 2011;32:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">19482376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 2009;48:239&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennebelle M, Plourde M, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P, Cunnane SC. Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline. Proc Nutr Soc 2014;73:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24103099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004;62:275&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745067</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007;85:1142&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413117</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen MH, Ngandu T, Helkala EL, et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry 2008;23:741&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">18188871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Grodstein F, Rosner B, et al. Seafood types and age-related cognitive decline in the Women's Health Study. J Gerontol A Biol Sci Med Sci 2013;68:1255&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779629</ArticleId><ArticleId IdType="pubmed">23554464</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007;85:1103&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413112</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Kaufman JS, Sloane PD, Heiss G, Ibrahim J. n-3 Fatty acids, hypertension and risk of cognitive decline among older adults in the Atherosclerosis Risk in Communities (ARIC) study. Public Health Nutr 2008;11:17&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4863651</ArticleId><ArticleId IdType="pubmed">17625029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangney CC, Bienias JL, Evans DA, Morris MC. Reasonable estimates of serum vitamin E, vitamin C, and beta-cryptoxanthin are obtained with a food frequency questionnaire in older black and white adults. J Nutr 2004;134:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">15051849</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris WS, Mozaffarian D, Lefevre M, et al. Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 2009;139:804S&#x2013;819S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459058</ArticleId><ArticleId IdType="pubmed">19244379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1406817</PMID><DateCompleted><Year>1992</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN><JournalIssue CitedMedium="Print"><Volume>327</Volume><Issue>18</Issue><PubDate><Year>1992</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.</ArticleTitle><Pagination><StartPage>1253</StartPage><EndPage>1259</EndPage><MedlinePgn>1253-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In Alzheimer's disease, there is a marked decline in the function of cholinergic neurons in the brain. However, studies of treatment with cholinesterase inhibitors have produced conflicting results. We conducted a multicenter trial to evaluate whether the cholinesterase inhibitor tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate) could improve cognition in patients with Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Of 632 eligible patients with probable Alzheimer's disease, 215 improved while receiving tacrine during a preliminary crossover phase to determine responsiveness and the best dose. The 215 patients were randomly assigned to receive either placebo or their best dose of tacrine (10 or 20 mg four times a day) in a six-week, double-blind trial. The primary measures of efficacy were the cognitive subscale of the Alzheimer's Disease Assessment Scale and the Clinical Global Impression of Change scale; the secondary measures included the Mini-Mental State Examination and the assessment of the activities of daily living.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the end of the six-week trial, the patients receiving tacrine had a mean adjusted cognitive-subscale score of 30.3 (Alzheimer's Disease Assessment Scale) as compared with 32.7 in patients receiving placebo. This represents a smaller decline (by 2.4 points) in cognitive performance in the tacrine group (P &lt; 0.001). There were no differences between the groups in their global-rating scores. The tacrine group had a significantly smaller decline in the activities of daily living. The results of the Mini-Mental State Examination favored tacrine, but the differences were small and not statistically significant (a score of 16.0 with tacrine vs. 15.3 with placebo; P = 0.08). Gastrointestinal symptoms, elevation of aminotransferase levels, and headache were the most frequent side effects; all could be reversed by reducing the dose or discontinuing treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this short-term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine, treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>K L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Mount Sinai Medical Center, New York, NY 10029-6574.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Gamzu</LastName><ForeName>E R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Woolson</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Gracon</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Drachman</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>L S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Whitehouse</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Hoover</LastName><ForeName>T M</ForeName><Initials>TM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01-RR-30</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR-36</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4VX7YNB537</RegistryNumber><NameOfSubstance UI="D013619">Tacrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 1992 Oct 29;327(18):1306-8. doi: 10.1056/NEJM199210293271810.</RefSource><PMID Version="1">1357552</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 1993 Mar 18;328(11):808; author reply 809-10. doi: 10.1056/NEJM199303183281114.</RefSource><PMID Version="1">8437603</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 1993 Mar 18;328(11):809-10.</RefSource><PMID Version="1">8437606</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013619" MajorTopicYN="N">Tacrine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>10</Month><Day>29</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>10</Month><Day>29</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1406817</ArticleId><ArticleId IdType="doi">10.1056/NEJM199210293271801</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27165780</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>427</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Gain-of-function mutations in protein kinase C&#x3b1; (PKC&#x3b1;) may promote synaptic defects in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>ra47</StartPage><MedlinePgn>ra47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aaf6209</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a progressive dementia disorder characterized by synaptic degeneration and amyloid-&#x3b2; (A&#x3b2;) accumulation in the brain. Through whole-genome sequencing of 1345 individuals from 410 families with late-onset AD (LOAD), we identified three highly penetrant variants in PRKCA, the gene that encodes protein kinase C&#x3b1; (PKC&#x3b1;), in five of the families. All three variants linked with LOAD displayed increased catalytic activity relative to wild-type PKC&#x3b1; as assessed in live-cell imaging experiments using a genetically encoded PKC activity reporter. Deleting PRKCA in mice or adding PKC antagonists to mouse hippocampal slices infected with a virus expressing the A&#x3b2; precursor CT100 revealed that PKC&#x3b1; was required for the reduced synaptic activity caused by A&#x3b2;. In PRKCA(-/-)&#x2009;neurons expressing CT100, introduction of PKC&#x3b1;, but not PKC&#x3b1; lacking a PDZ interaction moiety, rescued synaptic depression, suggesting that a scaffolding interaction bringing PKC&#x3b1; to the synapse is required for its mediation of the effects of A&#x3b2;. Thus, enhanced PKC&#x3b1; activity may contribute to AD, possibly by mediating the actions of A&#x3b2; on synapses. In contrast, reduced PKC&#x3b1; activity is implicated in cancer. Hence, these findings reinforce the importance of maintaining a careful balance in the activity of this enzyme.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alfonso</LastName><ForeName>Stephanie I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Department of Neurosciences and Division of Biology, Section of Neurobiology, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callender</LastName><ForeName>Julia A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooli</LastName><ForeName>Basavaraj</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antal</LastName><ForeName>Corina E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullin</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Mathew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55414, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesn&#xe9;</LastName><ForeName>Sylvain E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55414, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leitges</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biotechnology Centre of Oslo, University of Oslo, Oslo 0317, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Alexandra C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. anewton@ucsd.edu tanzi@helix.mgh.harvard.edu rmalinow@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. anewton@ucsd.edu tanzi@helix.mgh.harvard.edu rmalinow@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malinow</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences and Division of Biology, Section of Neurobiology, University of California, San Diego, La Jolla, CA 92093, USA. anewton@ucsd.edu tanzi@helix.mgh.harvard.edu rmalinow@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007752</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 GM043154</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM043154</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH049159</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS061847</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG031293</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="C496628">PRKCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="C496630">Prkca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D051571">Protein Kinase C-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ExpressionOfConcernIn"><RefSource>Sci Signal. 2022 Jun 21;15(739):eadd4323. doi: 10.1126/scisignal.add4323.</RefSource><PMID Version="1">35727862</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051571" MajorTopicYN="N">Protein Kinase C-alpha</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27165780</ArticleId><ArticleId IdType="mid">NIHMS831834</ArticleId><ArticleId IdType="pmc">PMC5154619</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aaf6209</ArticleId><ArticleId IdType="pii">9/427/ra47</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of A&#x3b2;1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular A&#x3b2; and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Lacor PN, Pitt J, Klein WL. A&#x3b2; oligomer-induced synapse degeneration in Alzheimer&#x2019;s disease. Cell Mol Neurobiol. 2011;31:939&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146579</ArticleId><ArticleId IdType="pubmed">21538118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies A&#x3b2;-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012;2:a011585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543098</ArticleId><ArticleId IdType="pubmed">23125202</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer&#x2019;s disease pathogenesis. J Neurosci. 2010;30:14946&#x2013;14954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J. Function and dysfunction of presenilin. Neurodegener Dis. 2014;13:61&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000081</ArticleId><ArticleId IdType="pubmed">24107444</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton AC. Protein kinase C: Poised to signal. Am J Physiol Endocrinol Metab. 2010;298:E395&#x2013;E402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838521</ArticleId><ArticleId IdType="pubmed">19934406</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfonso S, Kessels HW, Banos CC, Chan TR, Lin ET, Kumaravel G, Scannevin RH, Rhodes KJ, Huganir R, Guckian KM, Dunah AW, Malinow R. Synapto-depressive effects of amyloid beta require PICK1. Eur J Neurosci. 2014;39:1225&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983572</ArticleId><ArticleId IdType="pubmed">24713001</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitges M, Kovac J, Plomann M, Linden DJ. A unique PDZ ligand in PKC&#x3b1; confers induction of cerebellar long-term synaptic depression. Neuron. 2004;44:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541307</ArticleId></ArticleIdList></Reference><Reference><Citation>Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J, Newton AC. Cancer-associated protein kinase C mutations reveal kinase&#x2019;s role as tumor suppressor. Cell. 2015;160:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313737</ArticleId><ArticleId IdType="pubmed">25619690</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2:a006270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell. 2010;37:541&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3014287</ArticleId><ArticleId IdType="pubmed">20188672</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill AK, Gallegos LL, Justilien V, Garcia EL, Leitges M, Fields AP, Hall RA, Newton AC. Protein kinase Ca promotes cell migration through a PDZ-dependent interaction with its novel substrate discs large homolog 1 (DLG1) J Biol Chem. 2011;286:43559&#x2013;43568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234831</ArticleId><ArticleId IdType="pubmed">22027822</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudinger J, Lu J, Olson EN. Specific interaction of the PDZ domain protein PICK1 with the COOH terminus of protein kinase C-a. J Biol Chem. 1997;272:32019&#x2013;32024.</Citation><ArticleIdList><ArticleId IdType="pubmed">9405395</ArticleId></ArticleIdList></Reference><Reference><Citation>Violin JD, Zhang J, Tsien RY, Newton AC. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. J Cell Biol. 2003;161:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172956</ArticleId><ArticleId IdType="pubmed">12782683</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitges M, Plomann M, Standaert ML, Bandyopadhyay G, Sajan MP, Kanoh Y, Farese RV. Knockout of PKC&#x3b1; enhances insulin signaling through PI3K. Mol Endocrinol. 2002;16:847&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pubmed">11923480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nabavi S, Malinow R. Metabotropic NMDA receptor function is required for b-amyloid-induced synaptic depression. Proc Natl Acad Sci USA. 2013;110:4033&#x2013;4038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593880</ArticleId><ArticleId IdType="pubmed">23431156</ArticleId></ArticleIdList></Reference><Reference><Citation>Antal CE, Callender JA, Kornev AP, Taylor SS, Newton AC. Intramolecular C2 domain-mediated autoinhibition of protein kinase C &#x3b2;II. Cell Rep. 2015;12:1252&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551583</ArticleId><ArticleId IdType="pubmed">26279568</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Ha BH, Th&#xe9;venin AF, Lou HJ, Zhang R, Yip KY, Peterson JR, Gerstein M, Kim PM, Filippakopoulos P, Knapp S, Boggon TJ, Turk BE. Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity. Mol Cell. 2014;53:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898841</ArticleId><ArticleId IdType="pubmed">24374310</ArticleId></ArticleIdList></Reference><Reference><Citation>Creixell P, Schoof EM, Simpson CD, Longden J, Miller CJ, Lou HJ, Perryman L, Cox TR, Zivanovic N, Palmeri A, Wesolowska-Andersen A, Helmer-Citterich M, Ferkinghoff-Borg J, Itamochi H, Bodenmiller B, Erler JT, Turk BE, Linding R. Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. Cell. 2015;163:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644236</ArticleId><ArticleId IdType="pubmed">26388441</ArticleId></ArticleIdList></Reference><Reference><Citation>Keranen LM, Dutil EM, Newton AC. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol. 1995;5:1394&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pubmed">8749392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutil EM, Keranen LM, DePaoli-Roach AA, Newton AC. In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation. J Biol Chem. 1994;269:29359&#x2013;29362.</Citation><ArticleIdList><ArticleId IdType="pubmed">7961910</ArticleId></ArticleIdList></Reference><Reference><Citation>Antal CE, Violin JD, Kunkel MT, Skovs&#xf8; S, Newton AC. Intramolecular conformational changes optimize protein kinase C signaling. Chem Biol. 2014;21:459&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020788</ArticleId><ArticleId IdType="pubmed">24631122</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert J-C, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M, UK Brain Expression Consortium (UKBEC) Sassi C, Bras J, Gibbs JR, Hernandez DG, Lupton MK, Powell J, Forabosco P, Ridge PG, Corcoran CD, Tschanz JT, Norton MC, Munger RG, Schmutz C, Leary M, Demirci FY, Bamne MN, Wang X, Lopez OL, Ganguli M, Medway C, Turton J, Lord J, Braae A, Barber I, Brown K, Alzheimer&#x2019;s Research UK (ARUK) Consortium. Pastor P, Lorenzo-Betancor O, Brkanac Z, Scott E, Topol E, Morgan K, Rogaeva E, Singleton AB, Hardy J, Kamboh MI, St George-Hyslop P, Cairns N, Morris JC, Kauwe JSK, Goate AM. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature. 2014;505:550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Selkoe DJ. Neurotoxicity of amyloid b-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth HW, LaFerla FM. Alzheimer&#x2019;s disease. N Engl J Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz e Silva OAB, Rebelo S, Vieira SI, Gandy S, Da Cruz e Silva EF, Greengard P. Enhanced generation of Alzheimer&#x2019;s amyloid-b following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase. C J Neurochem. 2009;108:319&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911029</ArticleId><ArticleId IdType="pubmed">19012746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, Gatson JW, Small SA, Ehrlich ME, Gandy S. Protein kinase C and rho activated coiled coil protein kinase 2 (ROCK2) modulate Alzheimer&#x2019;s APP metabolism and phosphorylation of the Vps10-domain protein, SorL1. Mol Neurodegener. 2010;5:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036620</ArticleId><ArticleId IdType="pubmed">21192821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinouchi T, Sorimachi H, Maruyama K, Mizuno K, Ohno S, Ishiura S, Suzuki K. Conventional protein kinase C (PKC)-a and novel PKC&#x3b5;, but not -&#x3b4;, increase the secretion of an N-terminal fragment of Alzheimer&#x2019;s disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. FEBS Lett. 1995;364:203&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">7750571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Hinton DJ, Choi DS. Protein kinase C-regulated a&#x3b2; production and clearance. Int J Alzheimers Dis. 2011;2011:857368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026967</ArticleId><ArticleId IdType="pubmed">21274428</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagawa K, Homma H, Saito A, Fujita K, Chen X, Imoto S, Oka T, Ito H, Motoki K, Yoshida C, Hatsuta H, Murayama S, Iwatsubo T, Miyano S, Okazawa H. Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer&#x2019;s disease brain. Hum Mol Genet. 2015;24:540&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">25231903</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA. PKC&#x3b3; mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci. 2008;121:2339&#x2013;2349.</Citation><ArticleIdList><ArticleId IdType="pubmed">18577575</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Tang B, Liu Y-W, Wang X-F, Chen G-J. Alzheimer disease and cancer risk: A meta-analysis. J Cancer Res Clin Oncol. 2015;141:485&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11823988</ArticleId><ArticleId IdType="pubmed">25015770</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer disease and cancer. Neurology. 2005;64:895&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753432</ArticleId></ArticleIdList></Reference><Reference><Citation>Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, Kiel DP, Lu KP, Seshadri S, Wolf PA. Inverse association between cancer and Alzheimer&#x2019;s disease: Results from the Framingham Heart Study. BMJ. 2012;344:e1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647385</ArticleId><ArticleId IdType="pubmed">22411920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012;11:937&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3760692</ArticleId><ArticleId IdType="pubmed">23197040</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37:173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Efron B. Bootstrap methods: Another look at the jackknife. Ann Stat. 1979;7:1&#x2013;26.</Citation></Reference><Reference><Citation>Dutil EM, Toker A, Newton AC. Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1) Curr Biol. 1998;8:1366&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">9889098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman MA, Lesn&#xe9; SE. Detecting a&#x3b2;*56 oligomers in brain tissues. Methods Mol Biol. 2011;670:45&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20967582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallegos LL, Kunkel MT, Newton AC. Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. J Biol Chem. 2006;281:30947&#x2013;30956.</Citation><ArticleIdList><ArticleId IdType="pubmed">16901905</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RCP, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE, NIMH Genetics Initiative Alzheimer&#x2019;s Disease Study Group Results of a high-resolution genome screen of 437 Alzheimer&#x2019;s disease families. Hum Mol Genet. 2003;12:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490529</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Paila U, Chapman BA, Kirchner R, Quinlan AR. GEMINI: Integrative exploration of genetic variation and genome annotations. PLOS Comput Biol. 2013;9:e1003153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715403</ArticleId><ArticleId IdType="pubmed">23874191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner J, von Matt P, Sedrani R, Albert R, Cooke N, Ehrhardt C, Geiser M, Rummel G, Stark W, Strauss A, Cowan-Jacob SW, Beerli C, Weckbecker G, Evenou JP, Zenke G, Cottens S. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem. 2009;52:6193&#x2013;6196.</Citation><ArticleIdList><ArticleId IdType="pubmed">19827831</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27160897</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity.</ArticleTitle><Pagination><StartPage>1455</StartPage><EndPage>1466</EndPage><MedlinePgn>1455-1466</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.04.045</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)30472-7</ELocationID><Abstract><AbstractText>Dendritic mislocalization of microtubule associated protein tau is a hallmark of tauopathies, but the role of dendritic tau is unknown. We now report that tau interacts with the RNA-binding protein (RBP) TIA1 in brain tissue, and we present the brain-protein interactome network for TIA1. Analysis of the TIA1 interactome in brain tissue from wild-type (WT) and tau knockout mice demonstrates that tau is required for normal interactions of TIA1 with proteins linked to RNA metabolism, including ribosomal proteins and RBPs. Expression studies show that tau regulates the distribution of TIA1, and tau accelerates stress granule (SG) formation. Conversely, TIA1 knockdown or knockout inhibits tau misfolding and associated toxicity in cultured hippocampal neurons, while overexpressing TIA1 induces tau misfolding and stimulates neurodegeneration. Pharmacological interventions that prevent SG formation also inhibit tau pathophysiology. These studies suggest that the pathophysiology of tauopathy requires an intimate interaction with RNA-binding proteins.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vanderweyde</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apicco</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youmans-Kidder</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ash</LastName><ForeName>Peter E A</ForeName><Initials>PEA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lummertz da Rocha</LastName><ForeName>Edroaldo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frame</LastName><ForeName>Alissa A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citro</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leszyk</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pathology, University of Massachusetts Medical School, Shrewsbury, MA 01545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivanov</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abisambra</LastName><ForeName>Jose F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffen</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolozin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA. Electronic address: bwolozin@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA196631</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L32 MD009205</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020395</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS094918</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS091329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG042213</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS094489</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011500">Protein Synthesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074019">T-Cell Intracellular Antigen-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499367">Tia1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011500" MajorTopicYN="N">Protein Synthesis Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074019" MajorTopicYN="N">T-Cell Intracellular Antigen-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27160897</ArticleId><ArticleId IdType="mid">NIHMS780190</ArticleId><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.04.045</ArticleId><ArticleId IdType="pii">S2211-1247(16)30472-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SS, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C, et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2013;110:16562&#x2013;16567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799305</ArticleId><ArticleId IdType="pubmed">24023061</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 2005;307:935&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">15705855</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd JD, Lee-Armandt JP, Feiler MS, Zaarur N, Liu M, Kraemer B, Concannon JB, Ebata A, Wolozin B, Glicksman MA. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen. 2014;19:44&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913261</ArticleId><ArticleId IdType="pubmed">24019256</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, Silani V, Ratti A. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Mojsilovic-Petrovic J, Panossian S, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:2899&#x2013;2911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373238</ArticleId><ArticleId IdType="pubmed">22454397</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci. 2001;114:1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemiche ML, De Seranno S, Rush T, Borel E, Elie A, Arnal I, Lante&#xe9; F, Buisson A. Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. J Neurosci. 2014;34:6084&#x2013;6097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608293</ArticleId><ArticleId IdType="pubmed">24760868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996;399:344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM. Therapeutic modulation of eIF2&#x3b1; phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46:152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med. 2011;1:a006437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234455</ArticleId><ArticleId IdType="pubmed">22229117</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Rayman JB, Kandel ER, Derkatch IL. Functional role of Tia1/Pub1 and Sup35 prion domains: directing protein synthesis machinery to the tubulin cytoskeleton. Mol Cell. 2014;55:305&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425694</ArticleId><ArticleId IdType="pubmed">24981173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK, Parker R. Formation and maturation of phase-separated liquid droplets by RNA-binding proteins. Mol Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderweyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE. 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, Warren ST, Wolozin B. Local RNA translation at the synapse and in disease. J Neurosci. 2011;31:16086&#x2013;16093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241995</ArticleId><ArticleId IdType="pubmed">22072660</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Lin AY, Ebata A, Boon JY, Reid W, Xu YF, Kobrin K, Murphy GJ, Petrucelli L, Wolozin B. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci. 2014;34:4167&#x2013;4174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960463</ArticleId><ArticleId IdType="pubmed">24647938</ArticleId></ArticleIdList></Reference><Reference><Citation>Matenia D, Mandelkow EM. The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem Sci. 2009;34:332&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">19559622</ArticleId></ArticleIdList></Reference><Reference><Citation>Minjarez B, Valero Rustarazo ML, Sanchez del Pino MM, Gonz&#xe1;lez-Robles A, Sosa-Melgarejo JA, Luna-Mu&#xf1;oz J, Mena R, Luna-Arias JP. Identification of polypeptides in neurofibrillary tangles and total homogenates of brains with Alzheimer&#x2019;s disease by tandem mass spectrometry. J Alzheimers Dis. 2013;34:239&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">23229080</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott TJ, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, Craggs TD, Bazett-Jones DP, Pawson T, Forman-Kay JD, Baldwin AJ. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. Mol Cell. 2015;57:936&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352761</ArticleId><ArticleId IdType="pubmed">25747659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M. Roles of eIF2&#x3b1; kinases in the pathogenesis of Alzheimer&#x2019;s disease. Front Mol Neurosci. 2014;7:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3997008</ArticleId><ArticleId IdType="pubmed">24795560</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, Stoynov S, Mahamid J, Saha S, Franzmann TM, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Piecyk M, Wax S, Beck AR, Kedersha N, Gupta M, Maritim B, Chen S, Gueydan C, Kruys V, Streuli M, Anderson P. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 2000;19:4154&#x2013;4163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC306595</ArticleId><ArticleId IdType="pubmed">10921895</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell. 2013;154:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811119</ArticleId><ArticleId IdType="pubmed">23953108</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:320&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419926</ArticleId><ArticleId IdType="pubmed">15187187</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">19305406</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas MG, Loschi M, Desbats MA, Boccaccio GL. RNA granules: the good, the bad, and the ugly. Cell Signal. 2011;23:324&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3001194</ArticleId><ArticleId IdType="pubmed">20813183</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, Wolozin B. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. J Neurosci. 2012;32:8270&#x2013;8283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402380</ArticleId><ArticleId IdType="pubmed">22699908</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizcaino JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Rios D, Dianes JA, Sun Z, Farrah T, Bandeira N, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014;32:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3986813</ArticleId><ArticleId IdType="pubmed">24727771</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang D, Zhao J, Qu M, Zhou X, He H, He R. The proline-rich domain and the microtubule binding domain of protein tau acting as RNA-binding domains. Protein Pept Lett. 2006;13:679&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. Regulated protein aggregation: stress granules and neurodegeneration. Mol Neurodegener. 2012;7:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519755</ArticleId><ArticleId IdType="pubmed">23164372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 2014;37:721&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">25223701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM. Amyloid-&#x3b2; oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 2013;32:2920&#x2013;2937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831312</ArticleId><ArticleId IdType="pubmed">24065130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27169802</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>338</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Tau and A&#x3b2; imaging, CSF measures, and cognition in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>338ra66</StartPage><MedlinePgn>338ra66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf2362</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral &#x3b2;-amyloidosis in the form of &#x3b2;-amyloid (A&#x3b2;) plaques and tauopathy in the form of neurofibrillary tangles, neuritic plaques, and neuropil threads. Until recently, only A&#x3b2; could be studied in humans using positron emission tomography (PET) imaging owing to a lack of tau PET imaging agents. Clinical pathological studies have linked tau pathology closely to the onset and progression of cognitive symptoms in patients with AD. We report PET imaging of tau and A&#x3b2; in a cohort of cognitively normal older adults and those with mild AD. Multivariate analyses identified unique disease-related stereotypical spatial patterns (topographies) for deposition of tau and A&#x3b2;. These PET imaging tau and A&#x3b2; topographies were spatially distinct but correlated with disease progression. Cerebrospinal fluid measures of tau, often used to stage preclinical AD, correlated with tau deposition in the temporal lobe. Tau deposition in the temporal lobe more closely tracked dementia status and was a better predictor of cognitive performance than A&#x3b2; deposition in any region of the brain. These data support models of AD where tau pathology closely tracks changes in brain function that are responsible for the onset of early symptoms in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brier</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedrichsen</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldea</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA. Department of Pathology, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA. Department of Pathology, Washington University in St. Louis, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA. Department of Neurosurgery, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA. Department of Radiology, Washington University in St. Louis, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110, USA. bances@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG043434</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK094982</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27169802</ArticleId><ArticleId IdType="mid">NIHMS830812</ArticleId><ArticleId IdType="pmc">PMC5267531</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf2362</ArticleId><ArticleId IdType="pii">8/338/338ra66</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer'sdisease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: Early progress and future directions. Lancet Neurol. 2015;14:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Dominantly Inherited Alzheimer Network, Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: Time, space and &#x2018;wingmen&#x2019;. Nat Neurosci. 2015;18:800&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussi&#xe8;re T, Bouras C, K&#xf6;vari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, Mc Keel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early A&#x3b2; accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, G&#xf3;mez-Isla T. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Ch&#xe9;telat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL. Regional dynamics of amyloid-&#x3b2; deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126&#x2013;2139.</Citation><ArticleIdList><ArticleId IdType="pubmed">22628162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, B&#xfc;rger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631949</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, D'Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, Mintun MA, Benzinger TLS. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLOS One. 2013;8:e73377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819320</ArticleId><ArticleId IdType="pubmed">24223109</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, Christensen JJ, Friedrichsen K, Hornbeck RC, Farrar AM, Owen CJ, Mayeux R, Brickman AM, Klunk W, Price JC, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Schofield PR, Buckles V, Morris JC, Benzinger TLS. Dominantly Inherited Alzheimer Network, Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer'sdisease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart R, Taylor J, Tibshirani RJ, Tibshirani R. A significance test for the lasso. Ann Stat. 2014;42:413&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285373</ArticleId><ArticleId IdType="pubmed">25574062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. J Roy Stat Soc B Met. 1996;58:267&#x2013;288.</Citation></Reference><Reference><Citation>Zou H, Hastie T. Regularization and variable selection via the elastic net. J Roy Stat Soc B. 2005;67:301&#x2013;320.</Citation></Reference><Reference><Citation>Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage. 2008;43:236&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">18694837</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Su H, Szardenings AK, Walsh JC, Wang E, Yu C, Zhang W, Zhao T, Kolb HC. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134:1089&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">21436112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948934</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VMY, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137(Pt. 6):1762&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681664</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Dor&#xe9; V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:816&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">24514874</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Functional connectivity: The principal-component analysis of large (PET) data sets. J Cereb Blood Flow Metab. 1993;13:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8417010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat Neurosci. 1998;1:355&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196523</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between A&#x3b2;, tau, and &#x3b1;-synuclein: Acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30:7281&#x2013;7289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308018</ArticleId><ArticleId IdType="pubmed">20505094</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2010;4:51&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846664</ArticleId><ArticleId IdType="pubmed">20361010</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in amyloid-&#x3b2; and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66:1254&#x2013;1259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EH, Storandt M, Miller JP, Kinscherf DA, Grant EA, Morris JC, Berg L. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998;55:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale-Revised Manual. Harcourt Brace Jovanovich; San Antonio, TX: 1987.</Citation></Reference><Reference><Citation>Doppelt JE, Wallace WL. Standardization of the Wechsler adult intelligence scale for older persons. J Abnorm Psychol. 1955;51:312&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">13263050</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. Lea &amp; Febiger; Philadelphia, PA: 1983.</Citation></Reference><Reference><Citation>Armitage SG. Psychological Monographs: General and Applied. American Psychological Association; Washington, DC: 1946. An analysis of certain psychological tests used for the evaluation of brain injury.</Citation></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011;70:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussas GG. A First Course in Mathematical Statistics. Addison-Wesley Pub. Co.; Reading, MA: 1973.</Citation></Reference><Reference><Citation>Weatherburn CE. A First Course in Mathematical Statistics. The Cambridge Univ Press; Cambridge, MA: 1946.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27183206</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropathologic Associations of Learning and Memory in Primary Progressive Aphasia.</ArticleTitle><Pagination><StartPage>846</StartPage><EndPage>852</EndPage><MedlinePgn>846-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.0880</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The dementia syndrome of primary progressive aphasia (PPA) can be caused by 1 of several neuropathologic entities, including forms of frontotemporal lobar degeneration (FTLD) or Alzheimer disease (AD). Although episodic memory is initially spared in this syndrome, the subtle learning and memory features of PPA and their neuropathologic associations have not been characterized.</AbstractText><AbstractText Label="OBJECTIVE">To detect subtle memory differences on the basis of autopsy-confirmed neuropathologic diagnoses in PPA.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Retrospective analysis was conducted at the Northwestern Cognitive Neurology and Alzheimer's Disease Center in August 2015 using clinical and postmortem autopsy data that had been collected between August 1983 and June 2012. Thirteen patients who had the primary clinical diagnosis of PPA and an autopsy-confirmed diagnosis of either AD (PPA-AD) or a tau variant of FTLD (PPA-FTLD) and 6 patients who had the clinical diagnosis of amnestic dementia and autopsy-confirmed AD (AMN-AD) were included.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Scores on the effortless learning, delayed retrieval, and retention conditions of the Three Words Three Shapes test, a specialized measure of verbal and nonverbal episodic memory.</AbstractText><AbstractText Label="RESULTS">The PPA-FTLD (n&#x2009;=&#x2009;6), PPA-AD (n&#x2009;=&#x2009;7), and AMN-AD (n&#x2009;=&#x2009;6) groups did not differ by demographic composition (all P&#x2009;&gt;&#x2009;.05). The sample mean (SD) age was 64.1 (10.3) years at symptom onset and 67.9 (9.9) years at Three Words Three Shapes test administration. The PPA-FTLD group had normal (ie, near-ceiling) scores on all verbal and nonverbal test conditions. Both the PPA-AD and AMN-AD groups had deficits in verbal effortless learning (mean [SD] number of errors, 9.9 [4.6] and 14.2 [2.0], respectively) and verbal delayed retrieval (mean [SD] number of errors, 6.1 [5.9] and 12.0 [4.4], respectively). The AMN-AD group had additional deficits in nonverbal effortless learning (mean [SD] number of errors, 10.3 [4.0]) and verbal retention (mean [SD] number of errors, 8.33 [5.2]), which were not observed in the PPA-FTLD or PPA-AD groups (all P&#x2009;&lt;&#x2009;.005).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study identified neuropathologic associations of learning and memory in autopsy-confirmed cases of PPA. Among patients with clinical PPA syndrome, AD neuropathology appeared to interfere with effortless learning and delayed retrieval of verbal information, whereas FTLD-tau pathology did not. The results provide directions for future research on the interactions between limbic and language networks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois2Division of Clinical Psychology, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medici.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois2Division of Clinical Psychology, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medici.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieneke</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademaker</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois3Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigio</LastName><ForeName>Eileen H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois4Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois5Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogalski</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois2Division of Clinical Psychology, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medici.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045571</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DC008552</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 DC013386</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG020506</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS075075</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS047987</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028861">Nuclear Pore Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C049312">nuclear pore protein p62</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Jul 1;73(7):788-9. doi: 10.1001/jamaneurol.2016.0792.</RefSource><PMID Version="1">27182808</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018888" MajorTopicYN="N">Aphasia, Primary Progressive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007859" MajorTopicYN="N">Learning Disabilities</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028861" MajorTopicYN="N">Nuclear Pore Complex Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27183206</ArticleId><ArticleId IdType="mid">NIHMS787980</ArticleId><ArticleId IdType="pmc">PMC4940228</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.0880</ArticleId><ArticleId IdType="pii">2521476</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001;49(4):425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">11310619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, Weintraub S. Primary progressive aphasia and kindred disorders. In: Duyckaerts C, Litvan I, editors. Handbook of Clinical Neurology. New York, NY: Elsevier; 2008. pp. 573&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631780</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol. 2008;63(6):709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858311</ArticleId><ArticleId IdType="pubmed">18412267</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer&#x2019;s and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137(pt 4):1176&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959558</ArticleId><ArticleId IdType="pubmed">24574501</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130(pt 10):2636&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JM, Gall C, Thompson JC, et al. Classification and pathology of primary progressive aphasia. Neurology. 2013;81(21):1832&#x2013;1839.</Citation><ArticleIdList><ArticleId IdType="pubmed">24142474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M, Wieneke C, Rogalski E, Cobia D, Thompson C, Weintraub S. Quantitative template for subtyping primary progressive aphasia. Arch Neurol. 2009;66(12):1545&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796598</ArticleId><ArticleId IdType="pubmed">20008661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Rogalski EJ, Wieneke C, et al. Primary progressive aphasia and the evolving neurology of the language network. Nat Rev Neurol. 2014;10(10):554&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201050</ArticleId><ArticleId IdType="pubmed">25179257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Thompson CK, Weintraub S, Rogalski EJ. The Wernicke conundrum and the anatomy of language comprehension in primary progressive aphasia. Brain. 2015;138(pt 8):2423&#x2013;2437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805066</ArticleId><ArticleId IdType="pubmed">26112340</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Peavy GM, O&#x2019;Connor M, et al. Three Words Three Shapes: a clinical test of memory. J Clin Exp Neuropsychol. 2000;22(2):267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">10779840</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Rogalski E, Shaw E, et al. Verbal and nonverbal memory in primary progressive aphasia: the Three Words-Three Shapes Test. Behav Neurol. 2013;26(1&#x2013;2):67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534773</ArticleId><ArticleId IdType="pubmed">22713398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain. 2012;135(pt 5):1554&#x2013;1565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338929</ArticleId><ArticleId IdType="pubmed">22522938</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH. Making the diagnosis of frontotemporal lobar degeneration. Arch Pathol Lab Med. 2013;137(3):314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629720</ArticleId><ArticleId IdType="pubmed">23451743</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging: Alzheimer&#x2019;s Association. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD): part II. standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller GA. The magical number seven plus or minus two: some limits on our capacity for processing information. Psychol Rev. 1956;63(2):81&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">13310704</ArticleId></ArticleIdList></Reference><Reference><Citation>Foxe DG, Irish M, Hodges JR, Piguet O. Verbal and visuospatial span in logopenic progressive aphasia and Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2013;19(3):247&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">23298815</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer AM, Snider SF, Campbell RE, Friedman RB. Phonological short-term memory in logopenic variant primary progressive aphasia and mild Alzheimer&#x2019;s disease. Cortex. 2015;71:183&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521400</ArticleId><ArticleId IdType="pubmed">26232551</ArticleId></ArticleIdList></Reference><Reference><Citation>Tree J, Kay J. Longitudinal assessment of short-term memory deterioration in a logopenic variant primary progressive aphasia with post-mortem confirmed Alzheimer&#x2019;s disease pathology. J Neuropsychol. 2015;9(2):184&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">24751373</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Mesulam M-M. Mental state assessment of young and elderly adults in behavioral neurology. In: Mesulam M-M, editor. Principles of Behavioral Neurology. Philadelphia, PA: F.A. Davis; 1985. pp. 71&#x2013;123.</Citation></Reference><Reference><Citation>Johnson N, Barion A, Rademaker A, Rehkemper G, Weintraub S. The Activities of Daily Living Questionnaire: a validation study in patients with dementia. Alzheimer Dis Assoc Disord. 2004;18(4):223&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592135</ArticleId></ArticleIdList></Reference><Reference><Citation>Osher JE, Wicklund AH, Rademaker A, Johnson N, Weintraub S. The mini-mental state examination in behavioral variant frontotemporal dementia and primary progressive aphasia. Am J Alzheimers Dis Other Demen. 2007;22(6):468&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846276</ArticleId><ArticleId IdType="pubmed">18166606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia, PA: Lea and Febiger; 1983.</Citation></Reference><Reference><Citation>Fastenau PS, Denburg NL, Mauer BA. Parallel short forms for the Boston Naming Test: psychometric properties and norms for older adults. J Clin Exp Neuropsychol. 1998;20(6):828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">10484693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakzanis KK. The neuropsychological signature of primary progressive aphasia. Brain Lang. 1999;70(1):70&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">10534372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, Mishra M, Hatanpaa KJ, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol. 2010;120(1):43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903745</ArticleId><ArticleId IdType="pubmed">20361198</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitsch HJ. Memory and amnesia. In: Mesulam M-M, editor. Principles of Behavioral Neurology. 2nd. New York, NY: Oxford University Press; 2000. pp. 257&#x2013;283.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">4604978</PMID><DateCompleted><Year>1974</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>2</Issue><PubDate><Year>1974</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Brain research</Title><ISOAbbreviation>Brain Res</ISOAbbreviation></Journal><ArticleTitle>Protein changes in senile dementia.</ArticleTitle><Pagination><StartPage>337</StartPage><EndPage>343</EndPage><MedlinePgn>337-43</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Wi&#x15b;niewski</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Shelanski</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Brostoff</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Liwnicz</LastName><ForeName>B H</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Terry</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Res</MedlineTA><NlmUniqueID>0045503</NlmUniqueID><ISSNLinking>0006-8993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>368GB5141J</RegistryNumber><NameOfSubstance UI="D012967">Sodium Dodecyl Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008722" MajorTopicYN="N">Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008858" MajorTopicYN="N">Microscopy, Phase-Contrast</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012967" MajorTopicYN="N">Sodium Dodecyl Sulfate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013057" MajorTopicYN="N">Spectrum Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>9</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>9</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4604978</ArticleId><ArticleId IdType="doi">10.1016/0006-8993(74)90798-7</ArticleId><ArticleId IdType="pii">0006-8993(74)90798-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27117251</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>425</Issue><PubDate><Year>2016</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Sleep deprivation impairs memory by attenuating mTORC1-dependent protein synthesis.</ArticleTitle><Pagination><StartPage>ra41</StartPage><MedlinePgn>ra41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aad4949</ELocationID><Abstract><AbstractText>Sleep deprivation is a public health epidemic that causes wide-ranging deleterious consequences, including impaired memory and cognition. Protein synthesis in hippocampal neurons promotes memory and cognition. The kinase complex mammalian target of rapamycin complex 1 (mTORC1) stimulates protein synthesis by phosphorylating and inhibiting the eukaryotic translation initiation factor 4E-binding protein 2 (4EBP2). We investigated the involvement of the mTORC1-4EBP2 axis in the molecular mechanisms mediating the cognitive deficits caused by sleep deprivation in mice. Using an in vivo protein translation assay, we found that loss of sleep impaired protein synthesis in the hippocampus. Five hours of sleep loss attenuated both mTORC1-mediated phosphorylation of 4EBP2 and the interaction between eukaryotic initiation factor 4E (eIF4E) and eIF4G in the hippocampi of sleep-deprived mice. Increasing the abundance of 4EBP2 in hippocampal excitatory neurons before sleep deprivation increased the abundance of phosphorylated 4EBP2, restored the amount of eIF4E-eIF4G interaction and hippocampal protein synthesis to that seen in mice that were not sleep-deprived, and prevented the hippocampus-dependent memory deficits associated with sleep loss. These findings collectively demonstrate that 4EBP2-regulated protein synthesis is a critical mediator of the memory deficits caused by sleep deprivation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tudor</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Emily J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peixoto</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wimmer</LastName><ForeName>Mathieu E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Tilborg</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poplawski</LastName><ForeName>Shane G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Caroline W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havekes</LastName><ForeName>Robbert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiayan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Statistical Science, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatti</LastName><ForeName>Evelina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Universit&#xe9; UM2, INSERM U1104, CNRS UMR7280, 13288 Marseille, France. Institute for Research in Biomedicine (iBiMED) and Aveiro Health Sciences Program, University of Aveiro, 3810-193 Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierre</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Universit&#xe9; UM2, INSERM U1104, CNRS UMR7280, 13288 Marseille, France. Institute for Research in Biomedicine (iBiMED) and Aveiro Health Sciences Program, University of Aveiro, 3810-193 Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Ted</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA. abele@sas.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 MH099730</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007413</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH102703</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 GM081259</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017628</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491255">Eif4ebp2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091342">Endoplasmic Reticulum Chaperone BiP</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039561">Eukaryotic Initiation Factor-4E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039603">Eukaryotic Initiation Factor-4G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039642">Eukaryotic Initiation Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092069">activity regulated cytoskeletal-associated protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>4A6ZS6Q2CL</RegistryNumber><NameOfSubstance UI="D011691">Puromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Signal. 2016 Apr 26;9(425):fs7. doi: 10.1126/scisignal.aaf6196.</RefSource><PMID Version="1">27117249</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091342" MajorTopicYN="N">Endoplasmic Reticulum Chaperone BiP</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039561" MajorTopicYN="N">Eukaryotic Initiation Factor-4E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039603" MajorTopicYN="N">Eukaryotic Initiation Factor-4G</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039642" MajorTopicYN="N">Eukaryotic Initiation Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="Y">Protein Biosynthesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011691" MajorTopicYN="N">Puromycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27117251</ArticleId><ArticleId IdType="mid">NIHMS788603</ArticleId><ArticleId IdType="pmc">PMC4890572</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aad4949</ArticleId><ArticleId IdType="pii">9/425/ra41</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bourtchouladze R, Abel T, Berman N, Gordon R, Lapidus K, Kandel ER. Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learning &amp; memory. 1998;5:365&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC311273</ArticleId><ArticleId IdType="pubmed">10454361</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham WC, Williams JM. LTP maintenance and its protein synthesis-dependence. Neurobiology of learning and memory. 2008;89:260&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">17997332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelleher RJ, 3rd, Govindarajan A, Tonegawa S. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron. 2004;44:59&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450160</ArticleId></ArticleIdList></Reference><Reference><Citation>Dever TE. Gene-specific regulation by general translation factors. Cell. 2002;108:545&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">11909525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nature reviews Molecular cell biology. 2004;5:827&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097087</ArticleId><ArticleId IdType="pubmed">15459663</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffington SA, Huang W, Costa-Mattioli M. Translational control in synaptic plasticity and cognitive dysfunction. Annual review of neuroscience. 2014;37:17&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721605</ArticleId><ArticleId IdType="pubmed">25032491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton JO, Sahin M. The neurology of mTOR. Neuron. 2014;84:275&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223653</ArticleId><ArticleId IdType="pubmed">25374355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes &amp; development. 2004;18:1926&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pubmed">15314020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Guan KL. Expanding mTOR signaling. Cell research. 2007;17:666&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">17680028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends in neurosciences. 2010;33:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821969</ArticleId><ArticleId IdType="pubmed">19963289</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert V, Hall MN. mTOR signaling in cellular and organismal energetics. Current opinion in cell biology. 2015;33:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25554914</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukiyama-Kohara K, Poulin F, Kohara M, DeMaria CT, Cheng A, Wu Z, Gingras AC, Katsume A, Elchebly M, Spiegelman BM, Harper ME, Tremblay ML, Sonenberg N. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nature medicine. 2001;7:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11590436</ArticleId></ArticleIdList></Reference><Reference><Citation>Banko JL, Poulin F, Hou L, DeMaria CT, Sonenberg N, Klann E. The translation repressor 4E-BP2 is critical for eIF4F complex formation, synaptic plasticity, and memory in the hippocampus. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2005;25:9581&#x2013;9590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725736</ArticleId><ArticleId IdType="pubmed">16237163</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibt J, Dumoulin MC, Aton SJ, Coleman T, Watson A, Naidoo N, Frank MG. Protein synthesis during sleep consolidates cortical plasticity in vivo. Current biology: CB. 2012;22:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3350782</ArticleId><ArticleId IdType="pubmed">22386312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramm P, Smith CT. Rates of cerebral protein synthesis are linked to slow wave sleep in the rat. Physiology &amp; behavior. 1990;48:749&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">2082375</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H, Sun Y, Nakamura RK, Mori K, Ito M, Suda S, Namba H, Storch FI, Dang TP, Mendelson W, Mishkin M, Kennedy C, Gillin JC, Smith CB, Sokoloff L. Positive correlations between cerebral protein synthesis rates and deep sleep in Macaca mulatta. The European journal of neuroscience. 1997;9:271&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecsey CG, Peixoto L, Choi JH, Wimmer M, Jaganath D, Hernandez PJ, Blackwell J, Meda K, Park AJ, Hannenhalli S, Abel T. Genomic analysis of sleep deprivation reveals translational regulation in the hippocampus. Physiological genomics. 2012;44:981&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472468</ArticleId><ArticleId IdType="pubmed">22930738</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel T, Havekes R, Saletin JM, Walker MP. Sleep, plasticity and memory from molecules to whole-brain networks. Current biology: CB. 2013;23:R774&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4263505</ArticleId><ArticleId IdType="pubmed">24028961</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2007;3:519&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978335</ArticleId><ArticleId IdType="pubmed">17803017</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio G, Ferrara M, De Gennaro L. Sleep loss, learning capacity and academic performance. Sleep medicine reviews. 2006;10:323&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">16564189</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves LA, Heller EA, Pack AI, Abel T. Sleep deprivation selectively impairs memory consolidation for contextual fear conditioning. Learning &amp; memory. 2003;10:168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC202307</ArticleId><ArticleId IdType="pubmed">12773581</ArticleId></ArticleIdList></Reference><Reference><Citation>Havekes R, Vecsey CG, Abel T. The impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticity. Cellular signalling. 2012;24:1251&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622220</ArticleId><ArticleId IdType="pubmed">22570866</ArticleId></ArticleIdList></Reference><Reference><Citation>David A, Dolan BP, Hickman HD, Knowlton JJ, Clavarino G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. The Journal of cell biology. 2012;197:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317795</ArticleId><ArticleId IdType="pubmed">22472439</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annual review of pharmacology and toxicology. 2012;52:381&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">22017684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwinn DM, Schackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell. 2008;30:214&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674027</ArticleId><ArticleId IdType="pubmed">18439900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current biology: CB. 2004;14:1296&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">15268862</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. The Journal of biological chemistry. 2010;285:7866&#x2013;7879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832937</ArticleId><ArticleId IdType="pubmed">20022946</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecsey CG, Baillie GS, Jaganath D, Havekes R, Daniels A, Wimmer M, Huang T, Brown KM, Li XY, Descalzi G, Kim SS, Chen T, Shang YZ, Zhuo M, Houslay MD, Abel T. Sleep deprivation impairs cAMP signalling in the hippocampus. Nature. 2009;461:1122&#x2013;1125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783639</ArticleId><ArticleId IdType="pubmed">19847264</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber R, Deboer T, Tobler I. Effects of sleep deprivation on sleep and sleep EEG in three mouse strains: empirical data and simulations. Brain research. 2000;857:8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">10700548</ArticleId></ArticleIdList></Reference><Reference><Citation>Havekes R, Bruinenberg VM, Tudor JC, Ferri SL, Baumann A, Meerlo P, Abel T. Transiently increasing cAMP levels selectively in hippocampal excitatory neurons during sleep deprivation prevents memory deficits caused by sleep loss. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2014;34:15715&#x2013;15721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236401</ArticleId><ArticleId IdType="pubmed">25411499</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince TM, Wimmer M, Choi J, Havekes R, Aton S, Abel T. Sleep deprivation during a specific 3-hour time window post-training impairs hippocampal synaptic plasticity and memory. Neurobiology of learning and memory. 2014;109:122&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966473</ArticleId><ArticleId IdType="pubmed">24380868</ArticleId></ArticleIdList></Reference><Reference><Citation>Poplawski SG, Schoch H, Wimmer ME, Hawk JD, Walsh JL, Giese KP, Abel T. Object-location training elicits an overlapping but temporally distinct transcriptional profile from contextual fear conditioning. Neurobiology of learning and memory. 2014;116:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4262591</ArticleId><ArticleId IdType="pubmed">25242102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisor JP. The sleep-deprived hippocampus: a loss in translation. Physiological genomics. 2013;45:26&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">23188790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronli J, Soule J, Bramham CR. Sleep and protein synthesis-dependent synaptic plasticity: impacts of sleep loss and stress. Frontiers in behavioral neuroscience. 2013;7:224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896837</ArticleId><ArticleId IdType="pubmed">24478645</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronli J, Dagestad G, Milde AM, Murison R, Bramham CR. Post-transcriptional effects and interactions between chronic mild stress and acute sleep deprivation: regulation of translation factor and cytoplasmic polyadenylation element-binding protein phosphorylation. Behavioural brain research. 2012;235:251&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">22917528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman NW, Lin TV, Zhang L, Paquelet GE, Feliciano DM, Bordey A. mTORC1 targets the translational repressor 4E-BP2, but not S6 kinase 1/2, to regulate neural stem cell self-renewal in vivo. Cell reports. 2013;5:433&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139800</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll M, Dyer J, Sossin WS. Serotonin increases phosphorylation of synaptic 4EBP through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap- dependent translation in aplysia neurons. Molecular and cellular biology. 2006;26:8586&#x2013;8598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636790</ArticleId><ArticleId IdType="pubmed">16982686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidinosti M, Ran I, Sanchez-Carbente MR, Martineau Y, Gingras AC, Gkogkas C, Raught B, Bramham CR, Sossin WS, Costa-Mattioli M, DesGroseillers L, Lacaille JC, Sonenberg N. Postnatal deamidation of 4E-BP2 in brain enhances its association with raptor and alters kinetics of excitatory synaptic transmission. Molecular cell. 2010;37:797&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2861547</ArticleId><ArticleId IdType="pubmed">20347422</ArticleId></ArticleIdList></Reference><Reference><Citation>Graber TE, McCamphill PK, Sossin WS. A recollection of mTOR signaling in learning and memory. Learning &amp; memory. 2013;20:518&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">24042848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HW, Ha SH, Lee MN, Huston E, Kim DH, Jang SK, Suh PG, Houslay MD, Ryu SH. Cyclic AMP controls mTOR through regulation of the dynamic interaction between Rheb and phosphodiesterase 4D. Molecular and cellular biology. 2010;30:5406&#x2013;5420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2976372</ArticleId><ArticleId IdType="pubmed">20837708</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nature reviews Drug discovery. 2014;13:290&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4155750</ArticleId><ArticleId IdType="pubmed">24687066</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekelmann S, Born J. The memory function of sleep. Nature reviews Neuroscience. 2010;11:114&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20046194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikahisa S, Fujiki N, Kitaoka K, Shimizu N, Sei H. Central AMPK contributes to sleep homeostasis in mice. Neuropharmacology. 2009;57:369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">19615388</ArticleId></ArticleIdList></Reference><Reference><Citation>Dworak M, McCarley RW, Kim T, Kalinchuk AV, Basheer R. Sleep and brain energy levels: ATP changes during sleep. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30:9007&#x2013;9016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917728</ArticleId><ArticleId IdType="pubmed">20592221</ArticleId></ArticleIdList></Reference><Reference><Citation>Florian C, Vecsey CG, Halassa MM, Haydon PG, Abel T. Astrocyte-derived adenosine and A1 receptor activity contribute to sleep loss-induced deficits in hippocampal synaptic plasticity and memory in mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31:6956&#x2013;6962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140051</ArticleId><ArticleId IdType="pubmed">21562257</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM, Florian C, Fellin T, Munoz JR, Lee SY, Abel T, Haydon PG, Frank MG. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron. 2009;61:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673052</ArticleId><ArticleId IdType="pubmed">19186164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikahisa S, Sei H. The role of ATP in sleep regulation. Frontiers in neurology. 2011;2:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246291</ArticleId><ArticleId IdType="pubmed">22207863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagewoud R, Havekes R, Novati A, Keijser JN, Van der Zee EA, Meerlo P. Sleep deprivation impairs spatial working memory and reduces hippocampal AMPA receptor phosphorylation. Journal of sleep research. 2010;19:280&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">20050994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagewoud R, Whitcomb SN, Heeringa AN, Havekes R, Koolhaas JM, Meerlo P. A time for learning and a time for sleep: the effect of sleep deprivation on contextual fear conditioning at different times of the day. Sleep. 2010;33:1315&#x2013;1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941417</ArticleId><ArticleId IdType="pubmed">21061853</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecsey CG, Wimmer ME, Havekes R, Park AJ, Perron IJ, Meerlo P, Abel T. Daily acclimation handling does not affect hippocampal long-term potentiation or cause chronic sleep deprivation in mice. Sleep. 2013;36:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612265</ArticleId><ArticleId IdType="pubmed">23565007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, Attner MA, Cabrera SM, McDonough CB, Brindle PK, Abel T, Wood MA. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2007;27:6128&#x2013;6140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925045</ArticleId><ArticleId IdType="pubmed">17553985</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nature methods. 2009;6:275&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">19305406</ArticleId></ArticleIdList></Reference><Reference><Citation>Santini E, Huynh TN, MacAskill AF, Carter AG, Pierre P, Ruggero D, Kaphzan H, Klann E. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature. 2013;493:411&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548017</ArticleId><ArticleId IdType="pubmed">23263185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeffer CA, Tang W, Wong H, Santillan A, Patterson RJ, Martinez LA, Tejada-Simon MV, Paylor R, Hamilton SL, Klann E. Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron. 2008;60:832&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630531</ArticleId><ArticleId IdType="pubmed">19081378</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AM, Hawk JD, Abel T, Havekes R. Post-training reversible inactivation of the hippocampus enhances novel object recognition memory. Learning &amp; memory. 2010;17:155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832924</ArticleId><ArticleId IdType="pubmed">20189960</ArticleId></ArticleIdList></Reference><Reference><Citation>Havekes R, Canton DA, Park AJ, Huang T, Nie T, Day JP, Guercio LA, Grimes Q, Luczak V, Gelman IH, Baillie GS, Scott JD, Abel T. Gravin orchestrates protein kinase A and beta2-adrenergic receptor signaling critical for synaptic plasticity and memory. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32:18137&#x2013;18149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3533251</ArticleId><ArticleId IdType="pubmed">23238728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27196974</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy.</ArticleTitle><Pagination><StartPage>724</StartPage><EndPage>739</EndPage><MedlinePgn>724-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.05.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)30163-5</ELocationID><Abstract><AbstractText>Haplodeficiency of the microglia gene TREM2 increases risk for late-onset Alzheimer's disease (AD) but the mechanisms remain uncertain. To investigate this, we used high-resolution confocal and super-resolution (STORM) microscopy in AD-like mice and&#xa0;human AD tissue. We found that microglia processes, rich in TREM2, tightly surround early amyloid fibrils and plaques promoting their compaction and insulation. In Trem2- or DAP12-haplodeficient mice and in humans with R47H TREM2 mutations, microglia had a markedly reduced ability to envelop amyloid deposits. This led to an increase in less compact plaques with longer and branched amyloid fibrils resulting in greater surface exposure to adjacent neurites. This was associated with more severe neuritic tau hyperphosphorylation and axonal dystrophy around amyloid deposits. Thus, TREM2 deficiency may disrupt the formation of a neuroprotective microglia barrier that regulates amyloid compaction and insulation. Pharmacological modulation of this barrier could be a novel therapeutic strategy for AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT 06511, USA; Department of Neuroscience, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle, WA 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>The Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baddeley</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Yale University, New Haven, CT 06511, USA; Nanobiology Institute, Yale University, West Haven, CT 06515, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grutzendler</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT 06511, USA; Department of Neuroscience, Yale University, New Haven, CT 06511, USA. Electronic address: jaime.grutzendler@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG048181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089734</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089662</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL106815</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 CX001006</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest</b>. The authors claim no conflict of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27196974</ArticleId><ArticleId IdType="mid">NIHMS785018</ArticleId><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.05.003</ArticleId><ArticleId IdType="pii">S0896-6273(16)30163-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, Younkin S, Das P, Fryer JD, Bu G. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) J Biol Chem. 2015;290:26043&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley D, Cannell MB, Soeller C. Visualization of localization microscopy data. Microsc Microanal. 2010;16:64&#x2013;72. doi: 10.1017/S143192760999122X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S143192760999122X</ArticleId><ArticleId IdType="pubmed">20082730</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddeley D, Jayasinghe ID, Cremer C, Cannell MB, Soeller C. Light-induced dark states of organic fluochromes enable 30 nm resolution imaging in standard media. Biophys J. 2009;96:L22&#x2013;4. doi: 10.1016/j.bpj.2008.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2008.11.002</ArticleId><ArticleId IdType="pmc">PMC2716455</ArticleId><ArticleId IdType="pubmed">19167284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker AB, Hoek RM, Cerwenka A, Blom B, Lucian L, McNeil T, Murray R, Phillips LH, Sedgwick JD, Lanier LL. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity. 2000;13:345&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11021532</ArticleId></ArticleIdList></Reference><Reference><Citation>Birdsill AC, Walker DG, Lue L, Sue LI, Beach TG. Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank. 2011;12:311&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343031</ArticleId><ArticleId IdType="pubmed">20703815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Burgold S, Dorostkar MM, Fuhrmann M, Wegenast-Braun BM, Schmidt B, Kretzschmar H, Herms J. Amyloid plaque formation precedes dendritic spine loss. Acta Neuropathol. 2012;124:797&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508278</ArticleId><ArticleId IdType="pubmed">22993126</ArticleId></ArticleIdList></Reference><Reference><Citation>Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgold S, Filser S, Dorostkar MM, Schmidt B, Herms J. In vivo imaging reveals sigmoidal growth kinetic of &#x3b2;-amyloid plaques. Acta Neuropathol Commun. 2014;2:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050984</ArticleId><ArticleId IdType="pubmed">24678659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan G, White CC, Winn PA, Cimpean M, Replogle JM, Glick LR, Cuerdon NE, Ryan KJ, Johnson KA, Schneider JA, Bennett DA, Chibnik LB, Sperling RA, Bradshaw EM, De Jager PL. CD33 modulates TREM2: convergence of Alzheimer loci. Nat Neurosci. 2015;18:1556&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682915</ArticleId><ArticleId IdType="pubmed">26414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12776204</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Schain A, Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216507</ArticleId><ArticleId IdType="pubmed">22355538</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat Commun. 2015;6:6176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, West BL, Green KN. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J Neuroinflammation. 2015;12:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WBB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45:1375&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254070</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197:1657&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193948</ArticleId><ArticleId IdType="pubmed">12796468</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">18551625</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer&#x2019;s disease amyloid plaques. Proc Natl Acad Sci U S A. 2015;112:E3699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507205</ArticleId><ArticleId IdType="pubmed">26124111</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch UKK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer&#x2019;s disease beta A4 peptides. J Mol Biol. 1992;228:460&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">1453457</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med. 2015;212:287&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, Bertelsen S, Goate AM, Cruchaga C. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum Mol Genet. 2014;23:5838&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung CKE, Keppler K, Steinbach S, Blazquez-Llorca L, Herms J. Fibrillar amyloid plaque formation precedes microglial activation. PLoS One. 2015;10:e0119768.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4370641</ArticleId><ArticleId IdType="pubmed">25799372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepe V, Moghbel MC, L&#xe5;ngstr&#xf6;m B, Zaidi H, Vinters HV, Huang SC, Satyamurthy N, Doudet D, Mishani E, Cohen RM, H&#xf8;ilund-Carlsen PF, Alavi A, Barrio JR. Amyloid-&#x3b2; positron emission tomography imaging probes: a critical review. J Alzheimers Dis. 2013;36:613&#x2013;31. doi: 10.3233/JAD-130485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130485</ArticleId><ArticleId IdType="pmc">PMC3740015</ArticleId><ArticleId IdType="pubmed">23648516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer&#x2019;s disease. Neuron. 2009;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Su&#xe1;rez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lle&#xf3; A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, S&#xe1;nchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Korvatska O, Leverenz JB, Jayadev S, McMillan P, Kurtz I, Guo X, Rumbaugh M, Matsushita M, Girirajan S, Dorschner MO, Kiianitsa K, Yu CE, Brkanac Z, Garden GA, Raskind WH, Bird TD. R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study. JAMA Neurol. 2015;72:920&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825672</ArticleId><ArticleId IdType="pubmed">26076170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CYD, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm. 2010;117:949&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653296</ArticleId><ArticleId IdType="pubmed">20552234</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao CR, Rak M, Lund J, Unger M, Platt E, Albensi BC, Hirschmugl CJ, Gough KM. Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer&#x2019;s disease brain. Analyst. 2013;138:3991&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23586070</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-&#x3b2; phagocytosis. J Neurosci. 2010;30:17091&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077120</ArticleId><ArticleId IdType="pubmed">21159979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG. TREM2 Protein Expression Changes Correlate with Alzheimer&#x2019;s Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices. Brain Pathol. 2015;25:469&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427527</ArticleId><ArticleId IdType="pubmed">25186950</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, Nahaboo Solim MA, Moens TG, Paublete RM, Ali SS, Perona M, Desai R, Smith KJ, Latcham J, Fulleylove M, Richardson JC, Hardy J, Edwards FA. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015;10:633&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2014;2:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207354</ArticleId><ArticleId IdType="pubmed">25231068</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, Schetters STT, Sri S, Askew K, Mancuso R, Vargas-Caballero M, Holscher C, Perry VH, Gomez-Nicola D. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Kestil&#xe4; M, Wu J, Salminen A, B&#xf6;hling T, Ruotsalainen V, Hakola P, Bakker AB, Phillips JH, Pekkarinen P, Lanier LL, Timonen T, Peltonen L. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000;25:357&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Malhotra S, Torchia JA, Kerr WG, Coggeshall KM, Humphrey MB. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci Signal. 2010;3:ra38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900152</ArticleId><ArticleId IdType="pubmed">20484116</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rak M, Del Bigio MR, Mai S, Westaway D, Gough K. Dense-core and diffuse Abeta plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy. Biopolymers. 2007;87:207&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17680701</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci. 2009;29:11982&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodr&#xed;guez-Rodr&#xed;guez E, L&#xf3;pez de Munain A, de Pancorbo MM, P&#xe9;rez-Tur J, Alvarez V, Antonell A, L&#xf3;pez-Arrieta J, Hern&#xe1;ndez I, T&#xe1;rraga L, Boada M, Lle&#xf3; A, Blesa R, Frank-Garc&#xed;a A, Sastre I, Razquin C, Ortega-Cubero S, Lorenzo E, S&#xe1;nchez-Juan P, Combarros O, Moreno F, Gorostidi A, Elcoroaristizabal X, Baquero M, Coto E, S&#xe1;nchez-Valle R, Clarim&#xf3;n J. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer&#x2019;s disease and frontotemporal dementia. Neurobiol Aging 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">24041969</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83:1309&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi KI. TLR4 mutation reduces microglial activation, increases Abeta deposits and exacerbates cognitive deficits in a mouse model of Alzheimer&#x2019;s disease. J Neuroinflammation. 2011;8:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169468</ArticleId><ArticleId IdType="pubmed">21827663</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Deller T, Staufenbiel M, Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 2001;22:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378249</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Snyder SW, Ladror US, Wade WS, Miller MF, Perun TJ, Holzman TF, Krafft GA. The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem. 1996;15:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">8924204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM. Altered microglial response to A&#x3b2; plaques in APPPS1-21-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer&#x2019;s Disease Model. Cell. 2015;160:1061&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Grutzendler J. Attenuation of -Amyloid Deposition and Neurotoxicity by Chemogenetic Modulation of Neural Activity. J Neurosci. 2016;36:632&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4710779</ArticleId><ArticleId IdType="pubmed">26758850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27252647</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-4365</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Frontiers in aging neuroscience</Title><ISOAbbreviation>Front Aging Neurosci</ISOAbbreviation></Journal><ArticleTitle>In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.</ArticleTitle><Pagination><StartPage>108</StartPage><MedlinePgn>108</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">108</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnagi.2016.00108</ELocationID><Abstract><AbstractText>In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We hypothesized that treatment with GLP-1 or an analog of GLP-1 would prevent accumulation of A&#x3b2; and raise, or prevent decline of, glucose metabolism (CMRglc) in AD. In this 26-week trial, we randomized 38 patients with AD to treatment with the GLP-1 analog liraglutide (n = 18), or placebo (n = 20). We measured A&#x3b2; load in brain with tracer [(11)C]PIB (PIB), CMRglc with [(18)F]FDG (FDG), and cognition with the WMS-IV scale (ClinicalTrials.gov NCT01469351). The PIB binding increased significantly in temporal lobe in placebo and treatment patients (both P = 0.04), and in occipital lobe in treatment patients (P = 0.04). Regional and global increases of PIB retention did not differ between the groups (P &#x2265; 0.38). In placebo treated patients CMRglc declined in all regions, significantly so by the following means in precuneus (P = 0.009, 3.2 &#x3bc;mol/hg/min, 95% CI: 5.45; 0.92), and in parietal (P = 0.04, 2.1 &#x3bc;mol/hg/min, 95% CI: 4.21; 0.081), temporal (P = 0.046, 1.54 &#x3bc;mol/hg/min, 95% CI: 3.05; 0.030), and occipital (P = 0.009, 2.10 &#x3bc;mol/hg/min, 95% CI: 3.61; 0.59) lobes, and in cerebellum (P = 0.04, 1.54 &#x3bc;mol/hg/min, 95% CI: 3.01; 0.064). In contrast, the GLP-1 analog treatment caused a numerical but insignificant increase of CMRglc after 6 months. Cognitive scores did not change. We conclude that the GLP-1 analog treatment prevented the decline of CMRglc that signifies cognitive impairment, synaptic dysfunction, and disease evolution. We draw no firm conclusions from the A&#x3b2; load or cognition measures, for which the study was underpowered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gejl</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, Aarhus UniversityAarhus, Denmark; Department of Nuclear Medicine and PET Center, Aarhus University HospitalAarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gjedde</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET Center, Aarhus University HospitalAarhus, Denmark; Department of Neuroscience and Pharmacology, University of CopenhagenCopenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egefjord</LastName><ForeName>L&#xe6;rke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, Aarhus UniversityAarhus, Denmark; Department of Nuclear Medicine and PET Center, Aarhus University HospitalAarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Arne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET Center, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>S&#xf8;ren B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET Center, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vang</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET Center, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodell</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET Center, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe6;ndgaard</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dementia Clinic, Department of Neurology, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottrup</LastName><ForeName>Hanne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dementia Clinic, Department of Neurology, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schacht</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET Center, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Aarhus University Hospital Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Birgitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, Aarhus UniversityAarhus, Denmark; Department of Clinical Biochemistry, Aarhus University HospitalAarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rungby</LastName><ForeName>J&#xf8;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Biomedicine, Aarhus UniversityAarhus, Denmark; Center for Diabetes Research and Department of Clinical Pharmacology, Copenhagen University Hospital Gentofte and RigshospitaletCopenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01469351</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Aging Neurosci</MedlineTA><NlmUniqueID>101525824</NlmUniqueID><ISSNLinking>1663-4365</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">cerebral glucose metabolism</Keyword><Keyword MajorTopicYN="N">glucagon-like peptide-1</Keyword><Keyword MajorTopicYN="N">liraglutide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27252647</ArticleId><ArticleId IdType="pmc">PMC4877513</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2016.00108</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahren B., Winzell M. S., Wierup N., Sundler F., Burkey B., Hughes T. E. (2007). DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
<i>Regul. Pept.</i>
143
97&#x2013;103. 10.1016/j.regpep.2007.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.regpep.2007.03.008</ArticleId><ArticleId IdType="pubmed">17482289</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander G. E., Chen K., Pietrini P., Rapoport S. I., Reiman E. M. (2002). Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in alzheimer&#x2019;s disease treatment studies.
<i>Am. J. Psychiatry</i>
159
738&#x2013;745. 10.1176/appi.ajp.159.5.738</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.159.5.738</ArticleId><ArticleId IdType="pubmed">11986126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomfim T. R., Forny-Germano L., Sathler L. B., Brito-Moreira J., Houzel J. C., Decker H., et al.  (2012). An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer&#x2019;s disease- associated <i>Abeta oligomers</i>.
<i>J. Clin. Invest.</i>
122
1339&#x2013;1353. 10.1172/JCI57256</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57256</ArticleId><ArticleId IdType="pmc">PMC3314445</ArticleId><ArticleId IdType="pubmed">22476196</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S., Baker L. D., Montine T. J., Minoshima S., Watson G. S., Claxton A., et al.  (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
<i>Arch. Neurol.</i>
69
29&#x2013;38. 10.1001/archneurol.2011.233</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.233</ArticleId><ArticleId IdType="pmc">PMC3260944</ArticleId><ArticleId IdType="pubmed">21911655</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B., Feldman H. H., Jacova C., Hampel H., Molinuevo J. L., Blennow K., et al.  (2014). Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria.
<i>Lancet Neurol.</i>
13
614&#x2013;629. 10.1016/S1474-4422(14)70090-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70090-0</ArticleId><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>During M. J., Cao L., Zuzga D. S., Francis J. S., Fitzsimons H. L., Jiao X., et al.  (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
<i>Nat. Med.</i>
9
1173&#x2013;1179. 10.1038/nm919</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm919</ArticleId><ArticleId IdType="pubmed">12925848</ArticleId></ArticleIdList></Reference><Reference><Citation>Egefjord L., Gejl M., Moller A., Braendgaard H., Gottrup H., Antropova O., et al.  (2012). Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial.
<i>Dan. Med. J.</i>
59:A4519.</Citation><ArticleIdList><ArticleId IdType="pubmed">23158895</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., et al.  (2006). Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease.
<i>Brain</i>
129
2856&#x2013;2866. 10.1093/brain/awl178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl178</ArticleId><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Femminella G. D., Edison P. (2014). Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging.
<i>Alzheimers Dement</i>
10
S55&#x2013;S61. 10.1016/j.jalz.2013.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.12.012</ArticleId><ArticleId IdType="pubmed">24529526</ArticleId></ArticleIdList></Reference><Reference><Citation>Freiherr J., Hallschmid M., Frey W. H., Brunner Y. F., Chapman C. D., Holscher C., et al.  (2013). Intranasal insulin as a treatment for Alzheimer&#x2019;s disease: a review of basic research and clinical evidence.
<i>CNS Drugs</i>
27
505&#x2013;514. 10.1007/s40263-013-0076-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-013-0076-8</ArticleId><ArticleId IdType="pmc">PMC3709085</ArticleId><ArticleId IdType="pubmed">23719722</ArticleId></ArticleIdList></Reference><Reference><Citation>Gejl M., Egefjord L., Lerche S., Vang K., Bibby B. M., Holst J. J., et al.  (2012). Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.
<i>J. Cereb. Blood Flow Metab.</i>
32
2146&#x2013;2152. 10.1038/jcbfm.2012.118</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2012.118</ArticleId><ArticleId IdType="pmc">PMC3519409</ArticleId><ArticleId IdType="pubmed">22929437</ArticleId></ArticleIdList></Reference><Reference><Citation>Gejl M., Lerche S., Egefjord L., Brock B., Moller N., Vang K., et al.  (2013). Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.
<i>Front. Neuroenerget.</i>
5:2
10.3389/fnene.2013.00002</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnene.2013.00002</ArticleId><ArticleId IdType="pmc">PMC3608902</ArticleId><ArticleId IdType="pubmed">23543638</ArticleId></ArticleIdList></Reference><Reference><Citation>Gejl M., Rungby J., Brock B., Gjedde A. (2014). At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.
<i>Basic Clin. Pharmacol. Toxicol.</i>
115
162&#x2013;171. 10.1111/bcpt.12240</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.12240</ArticleId><ArticleId IdType="pubmed">24684709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjedde A. (1982). Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination.
<i>Brain Res.</i>
257
237&#x2013;274. 10.1016/0165-0173(82)90018-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0173(82)90018-2</ArticleId><ArticleId IdType="pubmed">7104768</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjedde A. (1983). Modulation of substrate transport to the brain.
<i>Acta Neurol. Scand.</i>
67
3&#x2013;25. 10.1111/j.1600-0404.1983.tb04541.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1983.tb04541.x</ArticleId><ArticleId IdType="pubmed">6301198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen H. H., Fabricius K., Barkholt P., Niehoff M. L., Morley J. E., Jelsing J., et al.  (2015). The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal ca1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer&#x2019;s Disease.
<i>J. Alzheimers Dis.</i>
46
877&#x2013;888. 10.3233/JAD-143090</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-143090</ArticleId><ArticleId IdType="pmc">PMC4878312</ArticleId><ArticleId IdType="pubmed">25869785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. A., Higgins G. A. (1992). Alzheimer&#x2019;s disease: the amyloid cascade hypothesis.
<i>Science</i>
256
184&#x2013;185. 10.1126/science.1566067</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1566067</ArticleId><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher C. (2014). New drug treatments show neuroprotective effects in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases.
<i>Neural Regen. Res.</i>
9
1870&#x2013;1873. 10.4103/1673-5374.145342</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.145342</ArticleId><ArticleId IdType="pmc">PMC4281420</ArticleId><ArticleId IdType="pubmed">25558231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt A., Schonknecht P., Henze M., Seidl U., Haberkorn U., Schroder J. (2007). Reduced cerebral glucose metabolism in patients at risk for Alzheimer&#x2019;s disease.
<i>Psychiatry Res.</i>
155
147&#x2013;154. 10.1016/j.pscychresns.2006.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2006.12.003</ArticleId><ArticleId IdType="pubmed">17524628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter K., Holscher C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
<i>BMC Neurosci.</i>
13:33
10.1186/1471-2202-13-33</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-13-33</ArticleId><ArticleId IdType="pmc">PMC3352246</ArticleId><ArticleId IdType="pubmed">22443187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jendle J., Nauck M. A., Matthews D. R., Frid A., Hermansen K., During M., et al.  (2009). Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
<i>Diabetes Obes Metab.</i>
11
1163&#x2013;1172. 10.1111/j.1463-1326.2009.01158.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1326.2009.01158.x</ArticleId><ArticleId IdType="pubmed">19930006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A., Almkvist O., Forsberg A., Wall A., Engler H., Langstrom B., et al.  (2012). Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer&#x2019;s disease.
<i>Neurobiol. Aging</i>
33
198&#x2013;214. 10.1016/j.neurobiolaging.2010.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.06.015</ArticleId><ArticleId IdType="pubmed">20688420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly P., McClean P. L., Ackermann M., Konerding M. A., Holscher C., Mitchell C. A. (2015). Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide.
<i>Microcirculation</i>
22
133&#x2013;145. 10.1111/micc.12186</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/micc.12186</ArticleId><ArticleId IdType="pubmed">25556713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwabara H., Evans A. C., Gjedde A. (1990). Michaelis-Menten constraints improved cerebral glucose metabolism and regional lumped constant measurements with [18F] fluorodeoxyglucose.
<i>J. Cereb Blood Flow Metab.</i>
10
180&#x2013;189. 10.1038/jcbfm.1990.33</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.1990.33</ArticleId><ArticleId IdType="pubmed">2303534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacalle-Aurioles M., Mateos-Perez J. M., Guzman-De-Villoria J. A., Olazaran J., Cruz-Orduna I., Aleman-Gomez Y., et al.  (2014). Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer&#x2019;s disease.
<i>J. Cereb. Blood Flow Metab.</i>
34
654&#x2013;659. 10.1038/jcbfm.2013.241</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2013.241</ArticleId><ArticleId IdType="pmc">PMC3982085</ArticleId><ArticleId IdType="pubmed">24424381</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V., Alafuzoff I., Aalto S., Suotunen T., Savolainen S., Nagren K., et al.  (2008). Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
<i>Arch. Neurol.</i>
65
1304&#x2013;1309. 10.1001/archneur.65.10.noc80013</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.10.noc80013</ArticleId><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerche S., Brock B., Rungby J., Botker H. E., Moller N., Rodell A., et al.  (2008). Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.
<i>Diabetes</i>
57
325&#x2013;331. 10.2337/db07-1162</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db07-1162</ArticleId><ArticleId IdType="pubmed">17991759</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean P. L., Gault V. A., Harriott P., Holscher C. (2010). Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer&#x2019;s disease.
<i>Eur. J. Pharmacol.</i>
630
158&#x2013;162. 10.1016/j.ejphar.2009.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2009.12.023</ArticleId><ArticleId IdType="pubmed">20035739</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean P. L., Holscher C. (2014). Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer&#x2019;s disease.
<i>Neuropharmacology</i>
76(Pt A), 57&#x2013;67. 10.1016/j.neuropharm.2013.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2013.08.005</ArticleId><ArticleId IdType="pubmed">23973293</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean P. L., Jalewa J., Holscher C. (2015). Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
<i>Behav. Brain Res.</i>
293
96&#x2013;106. 10.1016/j.bbr.2015.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2015.07.024</ArticleId><ArticleId IdType="pubmed">26205827</ArticleId></ArticleIdList></Reference><Reference><Citation>McClean P. L., Parthsarathy V., Faivre E., Holscher C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer&#x2019;s disease.
<i>J. Neurosci.</i>
31
6587&#x2013;6594. 10.1523/JNEUROSCI.0529-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0529-11.2011</ArticleId><ArticleId IdType="pmc">PMC6622662</ArticleId><ArticleId IdType="pubmed">21525299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooradian A. D., Chung H. C., Shah G. N. (1997). GLUT-1 expression in the cerebra of patients with Alzheimer&#x2019;s disease.
<i>Neurobiol. Aging</i>
18
469&#x2013;474. 10.1016/S0197-4580(97)00111-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(97)00111-5</ArticleId><ArticleId IdType="pubmed">9390772</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer&#x2019;s disease. FDG-PET studies in MCI and AD.
<i>Eur. J. Nucl. Med. Mol. Imaging</i>
32
486&#x2013;510. 10.1007/s00259-005-1762-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-005-1762-7</ArticleId><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck M. A. (2004). Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
<i>Horm. Metab. Res.</i>
36
852&#x2013;858. 10.1055/s-2004-826175</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2004-826175</ArticleId><ArticleId IdType="pubmed">15655719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A., Rinne J. O., Kadir A., Langstrom B. (2010). The use of PET in Alzheimer disease.
<i>Nat. Rev. Neurol.</i>
6
78&#x2013;87. 10.1038/nrneurol.2009.217</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2009.217</ArticleId><ArticleId IdType="pubmed">20139997</ArticleId></ArticleIdList></Reference><Reference><Citation>Patlak C. S., Blasberg R. G., Fenstermacher J. D. (1983). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.
<i>J. Cereb. Blood Flow Metab.</i>
3
1&#x2013;7. 10.1038/jcbfm.1983.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.1983.1</ArticleId><ArticleId IdType="pubmed">6822610</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry T., Greig N. H. (2005). Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer&#x2019;s disease.
<i>Curr. Alzheimer Res.</i>
2
377&#x2013;385. 10.2174/1567205054367892</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205054367892</ArticleId><ArticleId IdType="pubmed">15974903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodell A., Aanerud J., Braendgaard H., Gjedde A. (2013). Washout allometric reference method (WARM) for parametric analysis of [(11)C]PIB in human brains.
<i>Front. Aging Neurosci.</i>
5:45
10.3389/fnagi.2013.00045</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2013.00045</ArticleId><ArticleId IdType="pmc">PMC3842163</ArticleId><ArticleId IdType="pubmed">24348416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodell A. B., Aanerud J., Braendgaard H., Gjedde A. (2012). Low residual CBF variability in Alzheimer&#x2019;s Disease after correction for CO<sub>2</sub> effect.
<i>Front. Neuroenerget.</i>
4:8
10.3389/fnene.2012.00008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnene.2012.00008</ArticleId><ArticleId IdType="pmc">PMC3389721</ArticleId><ArticleId IdType="pubmed">22783187</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., Kamphuis P. J., Verhey F. R., Olde Rikkert M. G., Wurtman R. J., Wilkinson D., et al.  (2010). Efficacy of a medical food in mild Alzheimer&#x2019;s disease: a randomized, controlled trial.
<i>Alzheimers Dement</i>
6
1&#x2013;10. 10.1016/j.jalz.2009.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2009.10.003</ArticleId><ArticleId IdType="pubmed">20129316</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson I. A., Chundu K. R., Davies-Hill T., Honer W. G., Davies P. (1994). Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer&#x2019;s disease.
<i>Ann Neurol</i>
35
546&#x2013;551. 10.1002/ana.410350507</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410350507</ArticleId><ArticleId IdType="pubmed">8179300</ArticleId></ArticleIdList></Reference><Reference><Citation>Small G. W., Ercoli L. M., Silverman D. H., Huang S. C., Komo S., Bookheimer S. Y., et al.  (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer&#x2019;s disease.
<i>Proc. Natl. Acad. Sci. U.S.A.</i>
97
6037&#x2013;6042. 10.1073/pnas.090106797</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.090106797</ArticleId><ArticleId IdType="pmc">PMC18554</ArticleId><ArticleId IdType="pubmed">10811879</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith G. S., Laxton A. W., Tang-Wai D. F., McAndrews M. P., Diaconescu A. O., Workman C. I., et al.  (2012). Increased cerebral metabolism after 1 year of deep brain stimulation in Alzheimer disease.
<i>Arch. Neurol.</i>
69
1141&#x2013;1148. 10.1001/archneurol.2012.590</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.590</ArticleId><ArticleId IdType="pubmed">22566505</ArticleId></ArticleIdList></Reference><Reference><Citation>Solbach C., Uebele M., Reischl G., Machulla H. J. (2005). Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer&#x2019;s Disease with PET.
<i>Appl. Radiat. Isot.</i>
62
591&#x2013;595. 10.1016/j.apradiso.2004.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apradiso.2004.09.003</ArticleId><ArticleId IdType="pubmed">15701414</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J., Tournoux P. (1988). <i>Co-Planar Stereotaxic Atlas of the Human Brain.</i>
New York, NY: Thieme Verlag.</Citation></Reference><Reference><Citation>Talbot K., Wang H. Y., Bakshi K., Trojanowski J., Arnold S. (2011). The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer&#x2019;s disease (AD) cases.
<i>Alzheimer&#x2019;s Dementia</i>
7:e65
10.1016/j.jalz.2011.09.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.09.137</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E. A., Nishida Y., Sagare A. P., Rege S. V., Bell R. D., Perlmutter D., et al.  (2015). GLUT1 reductions exacerbate Alzheimer&#x2019;s disease vasculo-neuronal dysfunction and degeneration.
<i>Nat. Neurosci.</i>
18
521&#x2013;530. 10.1038/nn.3966</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3966</ArticleId><ArticleId IdType="pmc">PMC4734893</ArticleId><ArticleId IdType="pubmed">25730668</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W. L., von Stranss E., Qiu C. X., Winblad B., Fratiglioni L. (2009). Uncontrolled diabetes increases the risk of Alzheimer&#x2019;s disease: a population-based cohort study.
<i>Diabetologia</i>
52
1031&#x2013;1039. 10.1007/s00125-009-1323-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-009-1323-x</ArticleId><ArticleId IdType="pubmed">19280172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27210751</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model.</ArticleTitle><Pagination><StartPage>1859</StartPage><EndPage>1865</EndPage><MedlinePgn>1859-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.04.077</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)30522-8</ELocationID><Abstract><AbstractText>Beta-amyloid (A&#x3b2;) oligomers contribute to the pathophysiology of Alzheimer disease (AD), and metabotropic glutamate receptor 5 (mGluR5) has been shown to act as a receptor for both A&#x3b2; oligomers and cellular prion proteins. Furthermore, the genetic deletion of mGluR5 in an APPswe/PS1&#x394;E9 mouse model of AD improves cognitive function and reduces A&#x3b2; plaques and A&#x3b2; oligomer concentrations. Here, we show that chronic administration of the orally bioavailable mGluR5-selective negative allosteric modulator CTEP, which is similar in structure, potency, and selectivity to Basimglurant (RO4917523), which is currently in phase II clinical development for major depressive disorder and fragile X syndrome, reverses cognitive decline in APPswe/PS1&#x394;E9 mice and reduces A&#x3b2; plaque deposition and soluble A&#x3b2; oligomer concentrations in both APPswe/PS1&#x394;E9 and 3xTg-AD male mice. These findings suggest that CTEP or its analogue Basimglutant might potentially be an effective therapeutic for the treatment of AD patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Institute, Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasefi</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Robarts Research Institute, 100 Perth Drive, London, ON N6A 5K8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vander Tuin</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Robarts Research Institute, 100 Perth Drive, London, ON N6A 5K8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuaid</LastName><ForeName>Robyn J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anisman</LastName><ForeName>Hymie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Carleton University, Ottawa, ON K1S 5B6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Stephen S G</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>University of Ottawa Brain and Mind Institute, Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada. Electronic address: sferguso@uottawa.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-119437</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569289">2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064529" MajorTopicYN="N">Receptor, Metabotropic Glutamate 5</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27210751</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.04.077</ArticleId><ArticleId IdType="pii">S2211-1247(16)30522-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2899791</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>8607</Issue><PubDate><Year>1988</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>392</EndPage><MedlinePgn>391-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>McRae</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>McEwen</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH35976</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH36969</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS15638</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005951" MajorTopicYN="N">Glucose Tolerance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2899791</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(88)92855-3</ArticleId><ArticleId IdType="pii">S0140-6736(88)92855-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1563356</PMID><DateCompleted><Year>1992</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0261-4189</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>1992</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region.</ArticleTitle><Pagination><StartPage>1593</StartPage><EndPage>1597</EndPage><MedlinePgn>1593-7</MedlinePgn></Pagination><Abstract><AbstractText>The paired helical filaments (PHFs) of Alzheimer's disease consist mainly of the microtubule-associated protein tau. PHF tau differs from normal human brain tau in that it has a higher Mr and a special state of phosphorylation. However, the protein kinase(s) involved, the phosphorylation sites on tau and the resulting conformational changes are only poorly understood. Here we show that a new monoclonal antibody, AT8, records the PHF-like state of tau in vitro, and we describe a kinase activity that turns normal tau into a PHF-like state. The epitope of AT8 is around residue 200, outside the region of internal repeats and requires the phosphorylation of serines 199 and/or 202. Both of these are followed by a proline, suggesting that the kinase activity belongs to the family of proline-directed kinases. The epitope of AT8 is nearly coincident with that of another phosphorylation-dependent antibody, TAU1 [Binder, L.I., Frankfurter, A. and Rebhun, L. (1985) J. Cell Biol., 101, 1371-1378], but the two are complementary since TAU1 requires a dephosphorylated epitope.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, Hamburg, FRG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Schr&#xf6;ter</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lichtenberg-Kraag</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Berling</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vandermeeren</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010748">Phosphopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010748" MajorTopicYN="N">Phosphopeptides</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="Y">Proline</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="Y">Serine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1993</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1563356</ArticleId><ArticleId IdType="pmc">PMC556608</ArticleId><ArticleId IdType="doi">10.1002/j.1460-2075.1992.tb05204.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurosci Lett. 1991 Jul 22;128(2):195-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1658692</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Aug;87(15):5827-31</Citation><ArticleIdList><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1990;185:60-89</Citation><ArticleIdList><ArticleId IdType="pubmed">2199796</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1989 Oct;3(4):519-26</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1989 Apr;9(4):1381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2498649</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1987 Sep 14;221(2):403-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3114005</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1988 Jun 15;263(17):7943-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3131333</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1985 Oct;101(4):1371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 1990 Mar;25(3):412-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1691308</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1991 May 27;126(2):149-54</Citation><ArticleIdList><ArticleId IdType="pubmed">1717895</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem J. 1991 Jan 1;273(Pt 1):127-33</Citation><ArticleIdList><ArticleId IdType="pubmed">1899184</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1991;201:169-85</Citation><ArticleIdList><ArticleId IdType="pubmed">1943763</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1990 Nov;9(11):3539-44</Citation><ArticleIdList><ArticleId IdType="pubmed">2120043</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Biochem Sci. 1990 Sep;15(9):342-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2238044</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1988 Nov;1(9):817-25</Citation><ArticleIdList><ArticleId IdType="pubmed">2483104</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1989 Apr 24;247(2):213-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2497028</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1989 Oct;109(4 Pt 1):1643-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2507554</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jan 15;239(4837):285-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3122323</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1991 Feb 8;251(4994):675-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1639844</PMID><DateCompleted><Year>1992</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9525</ISSN><JournalIssue CitedMedium="Print"><Volume>118</Volume><Issue>3</Issue><PubDate><Year>1992</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of cell biology</Title><ISOAbbreviation>J Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro.</ArticleTitle><Pagination><StartPage>573</StartPage><EndPage>584</EndPage><MedlinePgn>573-84</MedlinePgn></Pagination><Abstract><AbstractText>Recent evidence from several laboratories shows that the paired helical filaments of Alzheimer's disease brains consist mainly of the protein tau in an abnormally phosphorylated form, but the mode of assembly is not understood. Here we use EM to study several constructs derived from human brain tau and expressed in Escherichia coli. All constructs or tau isoforms are rodlike molecules with a high tendency to dimerize in an antiparallel fashion, as shown by antibody labeling and chemical crosslinking. The length of the rods is largely determined by the region of internal repeats that is also responsible for microtubule binding. One unit length of the repeat domain (three or four repeats) is around 22-25 nm, comparable to the cross-section of Alzheimer PHF cores. Constructs corresponding roughly to the repeat region of tau can form synthetic paired helical filaments resembling those from Alzheimer brain tissue. A similar self-assembly occurs with the chemically cross-linked dimers. In both cases there is no need for phosphorylation of the protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wille</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drewes</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cell Biol</MedlineTA><NlmUniqueID>0375356</NlmUniqueID><ISSNLinking>0021-9525</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1993</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1639844</ArticleId><ArticleId IdType="pmc">PMC2289542</ArticleId><ArticleId IdType="doi">10.1083/jcb.118.3.573</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>EMBO J. 1992 Jun;11(6):2131-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1376245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1970 Aug 15;227(5259):680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5432063</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1992 Apr;11(4):1593-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1563356</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1992 Jan;8(1):159-68</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1991 Oct;10(10):2725-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1915258</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1991 May;6(5):717-28</Citation><ArticleIdList><ArticleId IdType="pubmed">1709023</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1991 Feb 8;251(4994):675-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 1990 Nov;9(11):3539-44</Citation><ArticleIdList><ArticleId IdType="pubmed">2120043</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1992 May 25;267(15):10737-42</Citation><ArticleIdList><ArticleId IdType="pubmed">1375231</ArticleId></ArticleIdList></Reference><Reference><Citation>J Struct Biol. 1992 Jan-Feb;108(1):49-61</Citation><ArticleIdList><ArticleId IdType="pubmed">1373291</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1991 Oct 5;266(28):18854-60</Citation><ArticleIdList><ArticleId IdType="pubmed">1717454</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Cytol. 1991;124:217-73</Citation><ArticleIdList><ArticleId IdType="pubmed">2001917</ArticleId></ArticleIdList></Reference><Reference><Citation>J Struct Biol. 1990 Oct-Dec;105(1-3):46-53</Citation><ArticleIdList><ArticleId IdType="pubmed">2129217</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1990 May-Aug;15(2):101-20</Citation><ArticleIdList><ArticleId IdType="pubmed">2282447</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1989 Oct;3(4):519-26</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1985 Jun;100(6):1905-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2581978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1988 Nov;1(9):827-34</Citation><ArticleIdList><ArticleId IdType="pubmed">2483105</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biochem. 1987 Dec;102(6):1415-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3129414</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1987 Dec 25;262(36):17577-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3121601</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1988 Oct;107(4):1449-59</Citation><ArticleIdList><ArticleId IdType="pubmed">3139677</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Jan 15;239(4837):285-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3122323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1986 Dec;103(6 Pt 2):2739-46</Citation><ArticleIdList><ArticleId IdType="pubmed">3098742</ArticleId></ArticleIdList></Reference><Reference><Citation>J Microsc. 1986 Jan;141(Pt 1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3083106</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1989 Oct;109(4 Pt 1):1643-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2507554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 1989 Apr;9(4):1381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2498649</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1985 Nov;101(5 Pt 1):1782-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4055896</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Enzymol. 1990;185:60-89</Citation><ArticleIdList><ArticleId IdType="pubmed">2199796</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Aug;87(15):5827-31</Citation><ArticleIdList><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Cell Biol. 1990 Feb;2(1):101-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2109621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ultrastruct Res. 1980 May;71(2):95-102</Citation><ArticleIdList><ArticleId IdType="pubmed">6155474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ultrastruct Res. 1982 Sep;80(3):374-82</Citation><ArticleIdList><ArticleId IdType="pubmed">7131650</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1977 Mar;72(3):642-54</Citation><ArticleIdList><ArticleId IdType="pubmed">65355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 1977 Oct 25;116(2):227-47</Citation><ArticleIdList><ArticleId IdType="pubmed">146092</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cell Biol. 1979 Jun;19(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">467462</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1979 Feb;80(2):266-76</Citation><ArticleIdList><ArticleId IdType="pubmed">457745</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1978 Dec 1;92(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">729584</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 1991 Oct;1(3):441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1821689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27221710</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>429</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Platelets contribute to amyloid-&#x3b2; aggregation in cerebral vessels through integrin &#x3b1;IIb&#x3b2;3-induced outside-in signaling and clusterin release.</ArticleTitle><Pagination><StartPage>ra52</StartPage><MedlinePgn>ra52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aaf6240</ELocationID><Abstract><AbstractText>Cerebral amyloid angiopathy (CAA) is a vascular dysfunction disorder characterized by deposits of amyloid-&#x3b2; (A&#x3b2;) in the walls of cerebral vessels. CAA and A&#x3b2; deposition in the brain parenchyma contribute to dementia and Alzheimer's disease (AD). We investigated the contribution of platelets, which accumulate at vascular A&#x3b2; deposits, to CAA. We found that synthetic monomeric A&#x3b2;40 bound through its RHDS (Arg-His-Asp-Ser) sequence to integrin &#x3b1;IIb&#x3b2;3, which is the receptor for the extracellular matrix protein fibrinogen, and stimulated the secretion of adenosine diphosphate (ADP) and the chaperone protein clusterin from platelets. Clusterin promoted the formation of fibrillar A&#x3b2; aggregates, and ADP acted through its receptors P2Y1 and P2Y12 on platelets to enhance integrin &#x3b1;IIb&#x3b2;3 activation, further increasing the secretion of clusterin and A&#x3b2;40 binding to platelets. Platelets from patients with Glanzmann's thrombasthenia, a bleeding disorder in which platelets have little or dysfunctional &#x3b1;IIb&#x3b2;3, indicated that the abundance of this integrin dictated A&#x3b2;-induced clusterin release and platelet-induced A&#x3b2; aggregation. The antiplatelet agent clopidogrel, which irreversibly inhibits P2Y12, inhibited A&#x3b2; aggregation in platelet cultures; in transgenic AD model mice, this drug reduced the amount of clusterin in the circulation and the incidence of CAA. Our findings indicate that activated platelets directly contribute to CAA by promoting the formation of A&#x3b2; aggregates and that A&#x3b2;, in turn, activates platelets, creating a feed-forward loop. Thus, antiplatelet therapy may alleviate fibril formation in cerebral vessels of AD patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donner</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe4;lker</LastName><ForeName>Knut</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Centre, &#xd6;rebro University, SE-701 82 &#xd6;rebro, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gremer</LastName><ForeName>Lothar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Physical Biology, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany. Institute of Structural Biochemistry (ICS-6), Research Centre J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klinker</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Physical Biology, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagani</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Pharmaceutical and Medicinal Chemistry, Department of Mathematics and Natural Sciences, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ljungberg</LastName><ForeName>Liza U</ForeName><Initials>LU</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Centre, &#xd6;rebro University, SE-701 82 &#xd6;rebro, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lothmann</LastName><ForeName>Kimberley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Physical Biology, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzi</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Biotechnological, and Translation Sciences, University of Parma, Via Volturno 39/a, 43126 Parma, Italy. Centre for Molecular and Translational Oncology (COMT), University of Parma, Parco Area delle Scienze 11/a, 43124 Parma, Italy. National Institute of Biostructure and Biosystems (INBB), Viale Medaglie d'Oro 305, 00136 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaller</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of T&#xfc;bingen, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gohlke</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute for Pharmaceutical and Medicinal Chemistry, Department of Mathematics and Natural Sciences, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willbold</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Physical Biology, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany. Institute of Structural Biochemistry (ICS-6), Research Centre J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenegard</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Centre, &#xd6;rebro University, SE-701 82 &#xd6;rebro, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elvers</LastName><ForeName>Margitta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University, 40225 D&#xfc;sseldorf, Germany. margitta.elvers@med.uni-duesseldorf.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495243">Clu protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C056564">ITGA2B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039421">Integrin alpha2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016023">Integrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019039">Platelet Glycoprotein GPIIb-IIIa Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-32-5</RegistryNumber><NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Signal. 2016 May 24;9(429):fs9. doi: 10.1126/scisignal.aaf8702.</RefSource><PMID Version="1">27221708</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003433" MajorTopicYN="N">Crosses, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039421" MajorTopicYN="N">Integrin alpha2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016023" MajorTopicYN="N">Integrins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019039" MajorTopicYN="N">Platelet Glycoprotein GPIIb-IIIa Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27221710</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aaf6240</ArticleId><ArticleId IdType="pii">9/429/ra52</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27225182</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>340</Issue><PubDate><Year>2016</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Amyloid-&#x3b2; peptide protects against microbial infection in mouse and worm models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>340ra72</StartPage><MedlinePgn>340ra72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf1059</ELocationID><Abstract><AbstractText>The amyloid-&#x3b2; peptide (A&#x3b2;) is a key protein in Alzheimer's disease (AD) pathology. We previously reported in vitro evidence suggesting that A&#x3b2; is an antimicrobial peptide. We present in vivo data showing that A&#x3b2; expression protects against fungal and bacterial infections in mouse, nematode, and cell culture models of AD. We show that A&#x3b2; oligomerization, a behavior traditionally viewed as intrinsically pathological, may be necessary for the antimicrobial activities of the peptide. Collectively, our data are consistent with a model in which soluble A&#x3b2; oligomers first bind to microbial cell wall carbohydrates via a heparin-binding domain. Developing protofibrils inhibited pathogen adhesion to host cells. Propagating &#x3b2;-amyloid fibrils mediate agglutination and eventual entrapment of unatttached microbes. Consistent with our model, Salmonella Typhimurium bacterial infection of the brains of transgenic 5XFAD mice resulted in rapid seeding and accelerated &#x3b2;-amyloid deposition, which closely colocalized with the invading bacteria. Our findings raise the intriguing possibility that &#x3b2;-amyloid may play a protective role in innate immunity and infectious or sterile inflammatory stimuli may drive amyloidosis. These data suggest a dual protective/damaging role for A&#x3b2;, as has been described for other antimicrobial peptides.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Deepak Kumar Vijaya</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Washicosky</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eimer</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghofrani</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefkowitz</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McColl</LastName><ForeName>Gawain</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lee E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Boston University, Boston, MA 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. moir@helix.mgh.harvard.edu tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. moir@helix.mgh.harvard.edu tanzi@helix.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI081990</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Microbiol. 2016 Jul 26;1(8):16129. doi: 10.1038/nmicrobiol.2016.129.</RefSource><PMID Version="1">27573123</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012486" MajorTopicYN="N">Salmonella typhimurium</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors have no competing interests pertaining to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27225182</ArticleId><ArticleId IdType="mid">NIHMS872639</ArticleId><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf1059</ArticleId><ArticleId IdType="pii">8/340/340ra72</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2018;s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna S, Cameron DJ, Ethell DW. Amyloid-|3 and APP deficiencies cause severe cerebrovascular defects: important work for an old villain. PLoS ONE. 2013;8:e75052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3764155</ArticleId><ArticleId IdType="pubmed">24040383</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD. The Alzheimer&#x2018;s disease-associated amyloid-|3 protein is an antimicrobial peptide. PLoS ONE. 2010;5:e9505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan BL, Jang H, Capone R, Teran Arce F, Ramachandran S, Lal R, Nussinov R. Antimicrobial properties of amyloid peptides. Mol Pharm. 2012;9:708&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297685</ArticleId><ArticleId IdType="pubmed">22081976</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence. 2010;1:440&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">21178486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi Y, Nagase T, Tomita T, Nakamura K, Fukuhara S, Amano T, Yamamoto H, Ide Y, Suzuki M, Teramoto S, Asano T, Kangawa K, Nakagata N, Ouchi Y, Kurihara H. &#x3b1;-defensin overexpression induces progressive muscle degeneration in mice. Am. J. Physiol, Cell Physiol. 2007;292:C2141&#x2013;C2149.</Citation><ArticleIdList><ArticleId IdType="pubmed">17215327</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24:126&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346901</ArticleId><ArticleId IdType="pubmed">22577261</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Chtarbanova S, Petersen AJ, Ganetzky B. Dnr1 mutations cause neurodegeneration in Drosophila by activating the innate immune response in the brain. PNAS. 2013;110:E1752&#x2013;1760. &#x3b2;.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651420</ArticleId><ArticleId IdType="pubmed">23613578</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause A, Liepke C, Meyer M, Adermann K, Forssmann WG, Maronde E. Human natriuretic peptides exhibit antimicrobial activity. Eur. J. Med. Res. 2001;6:215&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">11410403</ArticleId></ArticleIdList></Reference><Reference><Citation>White MR, Kandel R, Tripathi S, Condon D, Qi L, Taubenberger J, Hartshorn KL. Alzheimer&#x2018;s associated &#x3b2;-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS ONE. 2014;9:e101364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4079246</ArticleId><ArticleId IdType="pubmed">24988208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, Frost EH, Fulop T., Jr &#x3b2;-Amyloid peptides display Alzheimer's disease-associated herpes simplex virus-1. Bioger ontology. 2015;16:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25376108</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal &#x3b2;-amyloid aggregates neurodegeneration and neuron loss in transgenic mice. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Hopkins R, Sirinathsinghji DJ, Stevens KA, Conner MW, Slunt HH, Sisodia SS, Chen HY, Van der Ploeg LH. Mice deficient for the amyloid precursor protein gene. Ann N Y Acad Sci. 1996;777:421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624124</ArticleId></ArticleIdList></Reference><Reference><Citation>McColl G, Roberts BR, Pukala TL, Kenche VB, Roberts CM, Link CD, Ryan TM, Masters CL, Barnham KJ, Bush AI, Cherny RA. Utility of an improved model of amyloid- &#x3b2;(A &#x3b2;1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener. 2012;7:57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3519830</ArticleId><ArticleId IdType="pubmed">23171715</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardizzi JP, Epstein HF. Immunochemical localization of myosin heavy chain isoforms and paramyosin in developmentally and structurally diverse muscle cell types of the nematode Caenorhabditis elegans. J Cell Biol. 1987;105:2763&#x2013;2770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114684</ArticleId><ArticleId IdType="pubmed">3320053</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum-Krammer CI, Park KW, Li L, Melki R, Morimoto RI. Spreading of a prion domain from cell-to-cell by vesicular transport in Caenorhabditis elegans. PLoS Genet. 2013;9:e1003351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610634</ArticleId><ArticleId IdType="pubmed">23555277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisa D, Alonso R, Rabano A, Rodal I, Carrasco L. Different Brain Regions are Infected with Fungi in Alzheimer's Disease. Sci Rep. 2015;5:15015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4606562</ArticleId><ArticleId IdType="pubmed">26468932</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso R, Pisa D, Marina AI, Morato E, R&#xe1;bano A, Carrasco L. Fungal infection in patients with Alzheimer&#x2018;s disease. J Alzheimers Dis. 2014;41:301&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis PA, Piper S, Baker M, Onstead L, Murphy MP, Hardy J, Wang R, McGowan E, Golde TE. Expression of BRI-amyloid-&#x3b2;peptide fusion proteins: a novel method for specific high-level expression of amyloid-&#x3b2; peptides. Biochim Biophys Acta. 2001;1537:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476963</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn S, Br&#xfc;ning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer&#x2018;s disease attenuate the response of cultured cells to &#x3b3;-secretase modulators regardless of their potency and structure. J Neurochem. 2011;116:385&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">21091478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Golombowski S, M&#xfc;ller-Spahn F, Naser W, Beyreuther K, M&#xf6;nning U, Schenk D, Vigo-Pelfrey C, Bush AM, Moir R, Tanzi RE, Growdon JH, Nitsch RM. Cerebrospinal fluid levels of amyloid precursor protein and amyloid &#x3b2;-peptide in Alzheimer&#x2018;s disease and major depression - inverse correlation with dementia severity. Eur Neurol. 1998;39:111&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P-W, Yang C-Y, Chang H-T, Lan C-Y. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS ONE. 2011;6:e17755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056723</ArticleId><ArticleId IdType="pubmed">21448240</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner AM, Housley M, Murphy MP, LeVine H. Purified high molecular weight synthetic A&#x3b2; (1-42) and biological A&#x3b2; oligomers are equipotent in rapidly inducing MTT formazan exocytosis. Neurosci Lett. 2011;497:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110692</ArticleId><ArticleId IdType="pubmed">21504780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible nonfibrillar ligands derived from A&#x3b2;1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, Malley TO, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid-&#x3b2; protein detect natural A&#x3b2; oligomers in human brain but not CSF. Alzheimers Dement. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Sood R, Domanov Y, Pieti&#xe4;inen M, Kontinen VP, Kinnunen PKJ. Binding of LL-37 to model biomembranes: insight into target vs host cell recognition. Biochim Biophys Acta. 2008;1778:983&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">18166145</ArticleId></ArticleIdList></Reference><Reference><Citation>Feder R, Dagan A, Mor A. Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J Biol Chem. 2000;275:4230&#x2013;4238.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660589</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonova L, Kokryakov VN, Aleshina G, Hong T, Nguyen T, Zhao C, Waring AJ, Lehrer RI. Circular minidefensins and posttranslational generation of molecular diversity. J Leukoc Biol. 2001;70:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527997</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer RI. Paradise lost and paradigm found. Nat Immunol. 2004;5:775&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">15282557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sal-Man N, Oren Z, Shai Y. Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry. 2002;41:11921&#x2013;11930.</Citation><ArticleIdList><ArticleId IdType="pubmed">12269837</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson DJ, Lander AD, Selkoe DJ. Heparin-binding properties of the amyloidogenic peptides A&#x3b2; and amylin. Dependence on aggregation state and inhibition by Congo red. J Biol Chem. 1997;272:31617&#x2013;31624.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai P-W, Yang C-Y, Chang H-T, Lan C-Y. Characterizing the role of cell-wall &#x3b2;-1,3-exoglucanase Xog1p in Candida albicans adhesion by the human antimicrobial peptide LL-37. PLoS ONE. 2011;6:e21394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119699</ArticleId><ArticleId IdType="pubmed">21713010</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvete JJ, Campanero-Rhodes MA, Raida M, Sanz L. Characterisation of the conformational and quaternary structure-dependent heparin-binding region of bovine seminal plasma protein PDC-109. FEBS Lett. 1999;444:260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">10050771</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Wesseling P, van den Heuvel LPWJ, de Waal RMW, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer&#x2018;s disease and amyloid-related disorders. Lancet Neurol. 2003;2:482&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12878436</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrent M, Pulido D, Nogu&#xe9;s MVr, Boix E. Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog. 2012;8:e1003005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486885</ArticleId><ArticleId IdType="pubmed">23133388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, Pazgier M, Jung G, Nuccio S-P, Castillo PA, de Jong MF, Winter MG, Winter SE, Wehkamp J, Shen B, Salzman NH, Underwood MA, Tsolis RM, Young GM, Lu W, Lehrer RI, B&#xe4;umler AJ, Bevins CL. Human &#x3b1;-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science. 2012;337:477&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332406</ArticleId><ArticleId IdType="pubmed">22722251</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xfc;tsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet. 2002;360:1144&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">12387964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciornei CD, Tapper H, Bjartell A, Sternby NH, Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovas Disord. 2006;6:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764755</ArticleId><ArticleId IdType="pubmed">17181861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg JM, Kaplan MJ. Little peptide big effects: the role of LL-37 in inflammation and autoimmune disease. J Immuno. 2013;191:4895&#x2013;4901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836506</ArticleId><ArticleId IdType="pubmed">24185823</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinkai Y, Yoshimura M, Morishima-Kawashima M, Ito Y, Shimada H, Yanagisawa K, Ihara Y. Amyloid &#x3b2;-protein deposition in the leptomeninges and cerebral cortex. Ann Neurol. 1997;42:899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403483</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandenburg L-O, Varoga D, Nicolaeva N, Leib SL, Wilms H, Podschun R, Wruck CJ, Schr&#xf6;der J-M, Pufe T, Lucius R. Role of glial cells in the functional expression of LL-37/rat cathelin-related antimicrobial peptide in meningitis. J Neuropathol Exp Neurol. 2008;67:1041&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular &#x3b2;-amyloid accumulation and secretase upregulation. Neurosci Lett. 2007;429:95&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">17980964</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of Spirochetes. J Alzheimers Dis. 2008;13:381&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">18487847</ArticleId></ArticleIdList></Reference><Reference><Citation>Boelen E, Stassen FR, van der Ven AJ, Lemmens MA, Steinbusch HP, Bruggeman CA, Schmitz C, Steinbusch HW. Detection of amyloid-&#x3b2; aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection. Acta Neuropathol. 2007;114:255&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2039821</ArticleId><ArticleId IdType="pubmed">17581756</ArticleId></ArticleIdList></Reference><Reference><Citation>Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004;25:419&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013562</ArticleId></ArticleIdList></Reference><Reference><Citation>Papo N, Shai Y. Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides. 2003;24:1693&#x2013;1703.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019200</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomin VH. Heparin-Binding Proteins (Chemokines and Defensins) and their complexes with glycosaminoglycans from the solution NMR perspective. Curr Protein Pept Sci. 2014;15:738&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">25175334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Li Y, Wang X, Chen W, Sun H, Wang J. Lipopolysaccharide induces amyloid formation of antimicrobial peptide HAL-2. Biochim Biophys Acta. 2014;1838:2910&#x2013;2918.</Citation><ArticleIdList><ArticleId IdType="pubmed">25109934</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann O, Medina E. The expanding world of extracellular traps: not only neutrophils but much more. Front Immunol. 2012;3:420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3542634</ArticleId><ArticleId IdType="pubmed">23335924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol. 2013;425:4965&#x2013;4980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842434</ArticleId><ArticleId IdType="pubmed">24095897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman P, Johansson L, Wan H, Jones A, Gallo RL, Gudmundsson GH, H&#xf6;kfelt T, Jonsson A-B, Agerberth B. Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun. 2006;74:6982&#x2013;6991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698100</ArticleId><ArticleId IdType="pubmed">17030578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun. 1999;67:6084&#x2013;6089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC96996</ArticleId><ArticleId IdType="pubmed">10531270</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 APLP-2 involves &#x3b1;-, &#x3b2;- gamma-and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem. 2004;279:18146&#x2013;18156.</Citation><ArticleIdList><ArticleId IdType="pubmed">14970212</ArticleId></ArticleIdList></Reference><Reference><Citation>Shariati SA, De Strooper B. Redundancy and divergence in the amyloid precursor protein family. FEBS Lett. 2013;587:2036&#x2013;2045.</Citation><ArticleIdList><ArticleId IdType="pubmed">23707420</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W, Masters CL. Regulation expression of the Alzheimer's &#x3b2;/A4 amyloid protein precursor in health disease and Down's syndrome. Ann N Y Acad Sci. 1993;695:91&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8239320</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJM, Schwake M, Hooge RD, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, de Strooper B. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">9302305</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan BL. Antimicrobial amyloids? Biophys J. 2011;100:1597&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072652</ArticleId><ArticleId IdType="pubmed">21463571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Liu Q, Chen J-C, Cui Y-X, Zhou B, Chen Y-X, Zhao Y-f, Li Y-m. Antimicrobial activity of human islet amyloid polypeptides: an insight into amyloid peptides&#x2019;s; connection with antimicrobial peptides. Biol Chem. 2012;393:641&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">22944668</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasupuleti M, Roupe M, Rydeng&#xe5;rd V, Surewicz K, Surewicz WK, Chalupka A, Malmsten M, S&#xf6;rensen OE, Schmidtchen A. Antimicrobial activity of human prion protein is mediated by its N-terminal region. PLoS ONE. 2009;4:e7358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752989</ArticleId><ArticleId IdType="pubmed">19809501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernekar V, Velhal S, Bandivdekar A. Evaluation of cystatin C activities against HIV. Indian J Med Res. 2015;141:423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510722</ArticleId><ArticleId IdType="pubmed">26112843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasupuleti M, Davoudi M, Malmsten M, Schmidtchen A. Antimicrobial activity of a C-terminal peptide from human extracellular superoxide dismutase. BMC Res Notes. 2009;2:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717103</ArticleId><ArticleId IdType="pubmed">19604396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagan BL, Jang H, Capone R, Teran Arce F, Ramachandran S, Lal R, Nussinov R. Antimicrobial properties of amyloid peptides. MolPharm. 2012;9:708&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297685</ArticleId><ArticleId IdType="pubmed">22081976</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood. 2006;108:1751&#x2013;1757.</Citation><ArticleIdList><ArticleId IdType="pubmed">16735604</ArticleId></ArticleIdList></Reference><Reference><Citation>Millucci L, Paccagnini E, Ghezzi L, Bernardini G, Braconi D, Laschi M, Consumi M, Spreafico A, Tanganelli P, Lupetti P, Magnani A, Santucci A. Different factors affecting human ANP amyloid aggregation and their implications in congestive heart failure. PLoS ONE. 2011;6:e21870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144199</ArticleId><ArticleId IdType="pubmed">21814559</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J. Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med. 2011;13:e30.</Citation><ArticleIdList><ArticleId IdType="pubmed">21933454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, Liang CR, Wang QH, Wang X, Cao HY, Yi X, Deng B, Liu CH, Xu J, Zhang LL, Gao CY, Xu ZQ, Zhang M, Wang L, Tan XL, Xu X, Zhou HD, Wang YJ. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24910016</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB. Preparation of amyloid &#x3b2;-protein for structural and functional studies. Meth Enzymol. 2006;413:20&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruatto M, Gremmi M, Nardacchione A, Amerio M. Effect of glucose starvation on germ-tube production by Candida albicans. Mycopathologia. 1993;123:105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">8264767</ArticleId></ArticleIdList></Reference><Reference><Citation>Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006;1:1810&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487163</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SD, Karpus WJ. Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol. 2007 Chapter 15, Unit 15.11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915550</ArticleId><ArticleId IdType="pubmed">18432984</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron. 2008;59:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell JR, Ausubel FM. Models of Caenorhabditis elegans infection by bacterial and fungal pathogens. Methods Mol Biol. 2008;415:403&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">18370168</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry-Stanley MJ, Garni RM, Wells CL. Adaptation of FUN-1 and Calcofluor white stains to assess the ability of viable and nonviable yeast to adhere to and be internalized by cultured mammalian cells. Journal of Microbiological Methods. 2004;59:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">15369865</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27231129</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1208</StartPage><EndPage>1219</EndPage><MedlinePgn>1208-1219</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2016.05.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(16)30149-5</ELocationID><Abstract><AbstractText>Men have a shorter life expectancy compared with women but the underlying factor(s) are not clear. Late-onset, sporadic Alzheimer disease (AD) is a common and lethal neurodegenerative disorder and many germline inherited variants have been found to influence the risk of developing AD. Our previous results show that a fundamentally different genetic variant, i.e., lifetime-acquired loss of chromosome Y (LOY) in blood cells, is associated with all-cause mortality and an increased risk of non-hematological tumors and that LOY could be induced by tobacco smoking. We tested here a hypothesis that men with LOY are more susceptible to AD and show that LOY is associated with AD in three independent studies of different types. In a case-control study, males with AD diagnosis had higher degree of LOY mosaicism (adjusted odds ratio = 2.80, p = 0.0184, AD events = 606). Furthermore, in two prospective studies, men with LOY at&#xa0;blood sampling had greater risk for incident AD diagnosis during follow-up time (hazard ratio [HR] = 6.80, 95% confidence interval [95% CI] = 2.16-21.43, AD events = 140, p = 0.0011). Thus, LOY in blood is associated with risks of both AD and cancer, suggesting a role of LOY in blood cells on disease processes in other tissues, possibly via defective immunosurveillance. As a male-specific risk factor, LOY might explain why males on average live shorter lives than females.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dumanski</LastName><ForeName>Jan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics, and Pathology, Uppsala University, 75108&#xa0;Uppsala, Sweden; Science for Life Laboratory, Uppsala University, 75123&#xa0;Uppsala, Sweden. Electronic address: jan.dumanski@igp.uu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics, and Pathology, Uppsala University, 75108&#xa0;Uppsala, Sweden; Science for Life Laboratory, Uppsala University, 75123&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giedraitis</LastName><ForeName>Vilmantas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Uppsala University, 75185&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics, and Pathology, Uppsala University, 75108&#xa0;Uppsala, Sweden; Science for Life Laboratory, Uppsala University, 75123&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grenier-Boley</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindgren</LastName><ForeName>Cecilia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, OX3 7BN Oxford, UK; Broad Institute of MIT and Harvard University, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CNR-MAJ, Inserm, U1079, Rouen University Hospital, Rouen 76031 France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufouil</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inserm, U708, Victor Segalen University, Bordeaux 33076, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>European Alzheimer&#x2019;s Disease Initiative Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, CNR-MAJ, Inserm 1171, Distalz, Lille 59000, France; CHU, Lille 59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amouyel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Uppsala University, 75185&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Uppsala University, 75185&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilander</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Uppsala University, 75185&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Sciences, Uppsala University, 75185&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forsberg</LastName><ForeName>Lars A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics, and Pathology, Uppsala University, 75108&#xa0;Uppsala, Sweden; Science for Life Laboratory, Uppsala University, 75123&#xa0;Uppsala, Sweden. Electronic address: lars.forsberg@igp.uu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>679744</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041322" MajorTopicYN="N">Chromosomes, Human, Y</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009030" MajorTopicYN="Y">Mosaicism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27231129</ArticleId><ArticleId IdType="pmc">PMC4908225</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2016.05.014</ArticleId><ArticleId IdType="pii">S0002-9297(16)30149-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bettens K., Sleegers K., Van Broeckhoven C. Genetic insights in Alzheimer&#x2019;s disease. Lancet Neurol. 2013;12:92&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">23237904</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., Pedersen N.L. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E., Hannequin D., Wallon D., Sleegers K., Hiltunen M., Combarros O., Bullido M.J., Engelborghs S., De Deyn P., Berr C. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry. 2011;16:903&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., European Alzheimer&#x2019;s Disease Initiative (EADI) Genetic and Environmental Risk in Alzheimer&#x2019;s Disease. Alzheimer&#x2019;s Disease Genetic Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V., Bellenguez C., Wang L.S., Choi S.H., Harold D., Jones L., Holmans P., Gerrish A., Vedernikov A., Richards A., United Kingdom Brain Expression Consortium. Cardiovascular Health Study (CHS) Gene-wide analysis detects two new susceptibility genes for Alzheimer&#x2019;s disease. PLoS ONE. 2014;9:e94661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055488</ArticleId><ArticleId IdType="pubmed">24922517</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer&#x2019;s disease. N.&#xa0;Engl. J. Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Grenier-Boley B., Harold D., Zelenika D., Chouraki V., Kamatani Y., Sleegers K., Ikram M.A., Hiltunen M., Reitz C. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer&#x2019;s disease. Mol. Psychiatry. 2013;18:461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606943</ArticleId><ArticleId IdType="pubmed">22430674</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez B.A., Jin S.C., Guerreiro R., Graham R., Lord J., Harold D., Sims R., Lambert J.C., Gibbs J.R., Bras J., 3C Study Group. EADI consortium. Alzheimer&#x2019;s Disease Genetic Consortium (ADGC) Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) GERAD Consortium Missense variant in TREML2 protects against Alzheimer&#x2019;s disease. Neurobiol. Aging. 2014;35:1510.e19&#x2013;1510.e26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961557</ArticleId><ArticleId IdType="pubmed">24439484</ArticleId></ArticleIdList></Reference><Reference><Citation>International Genomics of Alzheimer&#x2019;s Disease Consortium (IGAP) Convergent genetic and expression data implicate immunity in Alzheimer&#x2019;s disease. Alzheimers Dement. 2014;11:658&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672734</ArticleId><ArticleId IdType="pubmed">25533204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman J., Rees E., Harold D., Ivanov D., Gerrish A., Sims R., Hollingworth P., Stretton A., Holmans P., Owen M.J., GERAD1 Consortium A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer&#x2019;s disease risk. Hum. Mol. Genet. 2013;22:816&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554198</ArticleId><ArticleId IdType="pubmed">23148125</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg L.A., Absher D., Dumanski J.P. Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime. J.&#xa0;Med. Genet. 2013;50:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534255</ArticleId><ArticleId IdType="pubmed">23172682</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg L.A., Rasi C., Razzaghian H.R., Pakalapati G., Waite L., Thilbeault K.S., Ronowicz A., Wineinger N.E., Tiwari H.K., Boomsma D. Age-related somatic structural changes in the nuclear genome of human blood cells. Am. J. Hum. Genet. 2012;90:217&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276669</ArticleId><ArticleId IdType="pubmed">22305530</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs K.B., Yeager M., Zhou W., Wacholder S., Wang Z., Rodriguez-Santiago B., Hutchinson A., Deng X., Liu C., Horner M.J. Detectable clonal mosaicism and its relationship to aging and cancer. Nat. Genet. 2012;44:651&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372921</ArticleId><ArticleId IdType="pubmed">22561519</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie C.C., Laurie C.A., Rice K., Doheny K.F., Zelnick L.R., McHugh C.P., Ling H., Hetrick K.N., Pugh E.W., Amos C. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat. Genet. 2012;44:642&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366033</ArticleId><ArticleId IdType="pubmed">22561516</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese G., K&#xe4;hler A.K., Handsaker R.E., Lindberg J., Rose S.A., Bakhoum S.F., Chambert K., Mick E., Neale B.M., Fromer M. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N.&#xa0;Engl. J. Med. 2014;371:2477&#x2013;2487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290021</ArticleId><ArticleId IdType="pubmed">25426838</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S., Fontanillas P., Flannick J., Manning A., Grauman P.V., Mar B.G., Lindsley R.C., Mermel C.H., Burtt N., Chavez A. Age-related clonal hematopoiesis associated with adverse outcomes. N.&#xa0;Engl. J. Med. 2014;371:2488&#x2013;2498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306669</ArticleId><ArticleId IdType="pubmed">25426837</ArticleId></ArticleIdList></Reference><Reference><Citation>Score J., Chase A., Forsberg L.A., Feng L., Waghorn K., Jones A.V., Rasi C., Linch D.C., Dumanski J.P., Gale R.E., Cross N.C. Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals. Leukemia. 2015;29:1600&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">25627638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnefond A., Skrobek B., Lobbens S., Eury E., Thuillier D., Cauchi S., Lantieri O., Balkau B., Riboli E., Marre M. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat. Genet. 2013;45:1040&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852171</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho C.M., Santos F.R. Human Y-chromosome variation and male dysfunction. J.&#xa0;Mol. Genet. Med. 2005;1:63&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702067</ArticleId><ArticleId IdType="pubmed">19565015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes J.F., Rozen S. Genomics and genetics of human and primate y chromosomes. Annu. Rev. Genomics Hum. Genet. 2012;13:83&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">22483277</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs P.A., Brunton M., Court Brown W.M., Doll R., Goldstein H. Change of human chromosome count distribution with age: evidence for a sex differences. Nature. 1963;197:1080&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">13964326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierre R.V., Hoagland H.C. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer. 1972;30:889&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">4116908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowinski G.P., Van Dyke D.L., Tilley B.C., Jacobsen G., Babu V.R., Worsham M.J., Wilson G.N., Weiss L. The frequency of aneuploidy in cultured lymphocytes is correlated with age and gender but not with reproductive history. Am. J. Hum. Genet. 1990;46:1101&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683821</ArticleId><ArticleId IdType="pubmed">2339703</ArticleId></ArticleIdList></Reference><Reference><Citation>United Kingdom Cancer Cytogenetics Group (UKCCG) Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chromosomes Cancer. 1992;5:83&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1384666</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiktor A., Rybicki B.A., Piao Z.S., Shurafa M., Barthel B., Maeda K., Van Dyke D.L. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer. 2000;27:11&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">10564581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.K., Fang B., Zhang L., Guo X., Lee S., Schreck R. Loss of the Y chromosome: an age-related or clonal phenomenon in acute myelogenous leukemia/myelodysplastic syndrome? Arch. Pathol. Lab. Med. 2008;132:1329&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pubmed">18684036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiktor A.E., Van Dyke D.L., Hodnefield J.M., Eckel-Passow J., Hanson C.A. The significance of isolated Y chromosome loss in bone marrow metaphase cells from males over age 50 years. Leuk. Res. 2011;35:1297&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">21703685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs P.A., Maloney V., Cooke R., Crolla J.A., Ashworth A., Swerdlow A.J. Male breast cancer, age and sex chromosome aneuploidy. Br. J. Cancer. 2013;108:959&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590654</ArticleId><ArticleId IdType="pubmed">23299533</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg L.A., Rasi C., Malmqvist N., Davies H., Pasupulati S., Pakalapati G., Sandgren J., Diaz de St&#xe5;hl T., Zaghlool A., Giedraitis V. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat. Genet. 2014;46:624&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536222</ArticleId><ArticleId IdType="pubmed">24777449</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanski J.P., Rasi C., L&#xf6;nn M., Davies H., Ingelsson M., Giedraitis V., Lannfelt L., Magnusson P.K., Lindgren C.M., Morris A.P. Mutagenesis. Smoking is associated with mosaic loss of chromosome Y. Science. 2015;347:81&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356728</ArticleId><ArticleId IdType="pubmed">25477213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L.J., Shin E.S., Yu Z.X., Li S.B. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders. Chin. Med. J. (Engl.) 2007;120:2002&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">18067786</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi N.O. Y chromosome structural and functional changes in human malignant diseases. Mutat. Res. 2009;682:21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19699459</ArticleId></ArticleIdList></Reference><Reference><Citation>Veiga L.C.S., B&#xe9;rgamo N.A., Reis P.P., Kowalski L.P., Rogatto S.R. Loss of Y-chromosome does not correlate with age at onset of head and neck carcinoma: a case-control study. Braz. J. Med. Biol. Res. 2012;45:172&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3854262</ArticleId><ArticleId IdType="pubmed">22249426</ArticleId></ArticleIdList></Reference><Reference><Citation>Duijf P.H., Schultz N., Benezra R. Cancer cells preferentially lose small chromosomes. Int. J. Cancer. 2013;132:2316&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587043</ArticleId><ArticleId IdType="pubmed">23124507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganster C., K&#xe4;mpfe D., Jung K., Braulke F., Shirneshan K., Machherndl-Spandl S., Suessner S., Bramlage C.P., Legler T.J., Koziolek M.J. New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes. Genes Chromosomes Cancer. 2015;54:717&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">26394808</ArticleId></ArticleIdList></Reference><Reference><Citation>Noveski P., Madjunkova S., Sukarova Stefanovska E., Matevska Geshkovska N., Kuzmanovska M., Dimovski A., Plaseska-Karanfilska D. Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients. PLoS ONE. 2016;11:e0146264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706411</ArticleId><ArticleId IdType="pubmed">26745889</ArticleId></ArticleIdList></Reference><Reference><Citation>Persani L., Bonomi M., Lleo A., Pasini S., Civardi F., Bianchi I., Campi I., Finelli P., Miozzo M., Castronovo C. Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. J.&#xa0;Autoimmun. 2012;38:J193&#x2013;J196.</Citation><ArticleIdList><ArticleId IdType="pubmed">22196921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A., Oertelt-Prigione S., Bianchi I., Caliari L., Finelli P., Miozzo M., Lazzari R., Floreani A., Donato F., Colombo M. Y chromosome loss in male patients with primary biliary cirrhosis. J.&#xa0;Autoimmun. 2013;41:87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23375847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., European Alzheimer&#x2019;s Disease Initiative Investigators Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>3C Study Group Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups. J. Med. Sci. Suppl. 1975;19:1&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">1216390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind L., Fors N., Hall J., Marttala K., Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler. Thromb. Vasc. Biol. 2005;25:2368&#x2013;2375.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141402</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeva V., Popova T., Bleakley K., Chiche P., Cappo J., Schleiermacher G., Janoueix-Lerosey I., Delattre O., Barillot E. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28:423&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268243</ArticleId><ArticleId IdType="pubmed">22155870</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team . R Foundation for Statistical Computing; Vienna, Austria: 2012. R: A language and environment for statistical computing.</Citation></Reference><Reference><Citation>Cataldo J.K., Prochaska J.J., Glantz S.A. Cigarette smoking is a risk factor for Alzheimer&#x2019;s Disease: an analysis controlling for tobacco industry affiliation. J.&#xa0;Alzheimers Dis. 2010;19:465&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906761</ArticleId><ArticleId IdType="pubmed">20110594</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton S., Matthews F.E., Barnes D.E., Yaffe K., Brayne C. Potential for primary prevention of Alzheimer&#x2019;s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pubmed">25030513</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R.N., McAfee T., Peto R. 21st-century hazards of smoking and benefits of cessation in the United States. N.&#xa0;Engl. J. Med. 2013;368:341&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23343063</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A.R., Soulet D., Gowing G., Julien J.P., Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer&#x2019;s disease. Neuron. 2006;49:489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M., Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: The missing link between health and disease. Mol. Psychiatry. 2010;15:342&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">20332793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ousman S.S., Kubes P. Immune surveillance in the central nervous system. Nat. Neurosci. 2012;15:1096&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097282</ArticleId><ArticleId IdType="pubmed">22837040</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwari P., Eslick G.D. Bacterial infection and Alzheimer&#x2019;s disease: a meta-analysis. J.&#xa0;Alzheimers Dis. 2015;43:957&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">25182736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovheim H., Gilthorpe J., Johansson A., Eriksson S., Hallmans G., Elgh F. Herpes simplex infection and the risk of Alzheimer&#x2019;s disease-A nested case-control study. Alzheimers Dement. 2015;11:587&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">25304990</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Cell cycle activation and aneuploid neurons in Alzheimer&#x2019;s disease. Mol. Neurobiol. 2012;46:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">22528601</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell M.J., Lindberg M.R., Brennand K.J., Piper J.C., Voet T., Cowing-Zitron C., Shumilina S., Lasken R.S., Vermeesch J.R., Hall I.M., Gage F.H. Mosaic copy number variation in human neurons. Science. 2013;342:632&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975283</ArticleId><ArticleId IdType="pubmed">24179226</ArticleId></ArticleIdList></Reference><Reference><Citation>Case L.K., Wall E.H., Dragon J.A., Saligrama N., Krementsov D.N., Moussawi M., Zachary J.F., Huber S.A., Blankenhorn E.P., Teuscher C. The Y chromosome as a regulatory element shaping immune cell transcriptomes and susceptibility to autoimmune disease. Genome Res. 2013;23:1474&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759723</ArticleId><ArticleId IdType="pubmed">23800453</ArticleId></ArticleIdList></Reference><Reference><Citation>James B.D., Leurgans S.E., Hebert L.E., Scherr P.A., Yaffe K., Bennett D.A. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82:1045&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962992</ArticleId><ArticleId IdType="pubmed">24598707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad A.S., Ormiston-Smith N., Sasieni P.D. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br. J. Cancer. 2015;112:943&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4453943</ArticleId><ArticleId IdType="pubmed">25647015</ArticleId></ArticleIdList></Reference><Reference><Citation>Blatt Kalben B. Why Men Die Younger. N.&#xa0;Am. Actuar. J. 2000;4:83&#x2013;111.</Citation></Reference><Reference><Citation>Central Intelligence Agency . Central Intelligence Agency; Washington, DC: 2013. The World Factbook 2013-14.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">6976816</PMID><DateCompleted><Year>1982</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8950</ISSN><JournalIssue CitedMedium="Print"><Volume>104</Volume><Issue>Pt 4</Issue><PubDate><Year>1981</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography.</ArticleTitle><Pagination><StartPage>753</StartPage><EndPage>778</EndPage><MedlinePgn>753-78</MedlinePgn></Pagination><Abstract><AbstractText>The cerebral blood flow, oxygen extraction and oxygen utilization has been measured regionally in 22 dements, and 14 aged normal volunteers. Ten demented patients were studied twice at a six-month interval from initial measurements. The use of a steady-state 15O technique and positron tomography for measuring regional cerebral blood flow, regional oxygen extraction fraction and mean cerebral oxygen utilization is discussed. The limitations of measurements are reviewed in the light of the present results and the current state of technological development in positron emission tomography is discussed. A decline in cerebral blood flow and mean cerebral oxygen utilization was correlated with increasing severity of dementia in both degenerative and vascular dements. The decline was coupled, both for the cerebral hemisphere as a whole and regionally. There was no increase in oxygen extraction ratio globally, and therefore no evidence to support the existence of a chronic ischaemic brain syndrome. Focal abnormalities in oxygen utilization were observed for both vascular and degenerative groups. In the vascular group, parietal defects were the most pronounced. Individual derangements of the regional pattern varied, reflecting the different unique patterns of ischaemic damage in these patients. In the degenerative group, parietal and temporal defects were seen in the less severe group, but a profound depression in the frontal regions with relative sparing of occipital area characterized the severe degenerative dements.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frackowiak</LastName><ForeName>R S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Pozzilli</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Legg</LastName><ForeName>N J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Du Boulay</LastName><ForeName>G H</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lenzi</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010104">Oxygen Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002544" MajorTopicYN="N">Cerebral Infarction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010101" MajorTopicYN="Y">Oxygen Consumption</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010104" MajorTopicYN="N">Oxygen Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6976816</ArticleId><ArticleId IdType="doi">10.1093/brain/104.4.753</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27249364</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice.</ArticleTitle><Pagination><StartPage>11761</StartPage><MedlinePgn>11761</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11761</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms11761</ELocationID><Abstract><AbstractText>Earlier diagnosis and treatment of Alzheimer's disease would greatly benefit from the identification of biomarkers at the prodromal stage. Using a prominent animal model of aspects of the disease, we here show using clinically relevant methodologies that very young, pre-pathological PDAPP mice, which overexpress mutant human amyloid precursor protein in the brain, exhibit two cryptic deficits that are normally undetected using standard methods of assessment. Despite learning a spatial memory task normally and displaying normal brain glucose uptake, they display faster forgetting after a long delay following performance to a criterion, together with a strong impairment of brain glucose uptake at the time of attempted memory retrieval. Preliminary observations suggest that these deficits, likely caused by an impairment in systems consolidation, could be rescued by immunotherapy with an anti-&#x3b2;-amyloid antibody. Our data suggest a biomarker strategy for the early detection of &#x3b2;-amyloid-related abnormalities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beglopoulos</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tulloch</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mass General Institute for Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daumas</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience Paris Seine, Institut de Biologie Paris Seine, Sorbonne Universit&#xe9;s, Pierre and Marie Curie University, UM CR18, INSERM U1130, CNRS UMR 8246, 75005 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrington</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dietetics, Nutrition and Biological Sciences, School of Health Sciences, Queen Margaret University, Musselburgh EH21 6UU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mass General Institute for Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mass General Institute for Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>P A T</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bard</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &amp;Johnson, 3210 Merryfield Row, San Diego, California 92121, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>R G M</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Centre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Neurociencias, CSIC-UMH, San Juan de Alicante 03550, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0700447</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9G2MP84A8W</RegistryNumber><NameOfSubstance UI="D003847">Deoxyglucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003847" MajorTopicYN="N">Deoxyglucose</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>F.B. is an employee at Johnson &amp; Johnson. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27249364</ArticleId><ArticleId IdType="pmc">PMC4895343</ArticleId><ArticleId IdType="doi">10.1038/ncomms11761</ArticleId><ArticleId IdType="pii">ncomms11761</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann G. et al.. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox N. C., Warrington E. K., Seiffer A. L., Agnew S. K. &amp; Rossor M. N. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain 121 (Pt 9), 1631&#x2013;1639 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9762953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R. J. et al.. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H., Lista S. &amp; Khachaturian Z. S. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement. 8, 312&#x2013;336 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22748938</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. Preventing Alzheimer's disease. Science 337, 1488&#x2013;1492 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22997326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik K. S. Diseases: study neuron networks to tackle Alzheimer's. Nature 503, 31&#x2013;32 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24218661</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr. &amp; Holtzman D. M. Biomarker modeling of Alzheimer's disease. Neuron 80, 1347&#x2013;1358 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Mapstone M. et al.. Plasma phospholipids identify antecedent memory impairment in older adults. Nature Med. 20, 415&#x2013;418 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360460</ArticleId><ArticleId IdType="pubmed">24608097</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M. et al.. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26, (Suppl 3) 321&#x2013;329 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>DianTrial. http://www.dian-info.org.</Citation></Reference><Reference><Citation>Donohue M. C. et al.. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961&#x2013;970 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D. et al.. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523&#x2013;527 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K. et al.. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99&#x2013;102 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K. et al.. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710&#x2013;713 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L. et al.. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050&#x2013;4058 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S. et al.. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia A. Y. et al.. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 3228&#x2013;3233 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D. et al.. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483&#x2013;6492 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop J. J. &amp; Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812&#x2013;818 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L. &amp; Selkoe D. J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Laczo J. et al.. Human analogue of the morris water maze for testing subjects at risk of Alzheimer's disease. Neurodegener. Dis. 7, 148&#x2013;152 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20197695</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J. &amp; Nadel L. The Hippocampus as a Cognitive Map Clarendon Press (1978).</Citation></Reference><Reference><Citation>Moser E. I., Kropff E. &amp; Moser M. B. Place cells, grid cells, and the brain's spatial representation system. Annu. Rev. Neurosci. 31, 69&#x2013;89 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18284371</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. G., Anderson E., Lynch G. S. &amp; Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319, 774&#x2013;776 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">2869411</ArticleId></ArticleIdList></Reference><Reference><Citation>Bontempi B., Laurent-Demir C., Destrade C. &amp; Jaffard R. Time-dependent reorganization of brain circuitry underlying long-term memory storage. Nature 400, 671&#x2013;675 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10458162</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland P. W. &amp; Bontempi B. The organization of recent and remote memories. Nat. Rev. Neurosci. 6, 119&#x2013;130 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky S. T. &amp; Scheff S. W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457&#x2013;464 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. Alzheimer's disease is a synaptic failure. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. G. M., Garrud P., Rawlins J. N. &amp; O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297, 681&#x2013;683 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert F. A. &amp; Piercy M. Dissociation between learning and remembering in organic amnesia. Nature 275, 317&#x2013;318 (1978).</Citation><ArticleIdList><ArticleId IdType="pubmed">692708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopelman M. D. Disorders of memory. Brain 125, 2152&#x2013;2190 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12244076</ArticleId></ArticleIdList></Reference><Reference><Citation>Daumas S. et al.. Faster forgetting contributes to impaired spatial memory in the PDAPP mouse: deficit in memory retrieval associated with increased sensitivity to interference? Learn. Mem. 15, 625&#x2013;632 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632784</ArticleId><ArticleId IdType="pubmed">18772249</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes K. J. The backward curve: a method for the study of learning. Psychol. Rev. 60, 269&#x2013;275 (1953).</Citation><ArticleIdList><ArticleId IdType="pubmed">13089005</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokoloff L. et al.. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28, 897&#x2013;916 (1977).</Citation><ArticleIdList><ArticleId IdType="pubmed">864466</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart J. C., Mathis C., Bales K. R., Paul S. M. &amp; Ungerer A. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Neurosci. Lett. 277, 49&#x2013;52 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10643895</ArticleId></ArticleIdList></Reference><Reference><Citation>Spooner R. I., Thomson A., Hall J., Morris R. G. M. &amp; Salter S. H. The Atlantis platform: a new design and further developments of Buresova's on-demand platform for the water maze. Learn. Mem. 1, 203&#x2013;211 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">10467597</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire L. R. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 99, 195&#x2013;231 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1594723</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F. et al.. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916&#x2013;919 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. et al.. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173&#x2013;177 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J. et al.. Normal cognition in transgenic BRI2-Abeta mice. Mol. Neurodegener. 8, 15 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3658944</ArticleId><ArticleId IdType="pubmed">23663320</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnikova T. et al.. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J. Neurosci. 33, 3765&#x2013;3779 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711622</ArticleId><ArticleId IdType="pubmed">23447589</ArticleId></ArticleIdList></Reference><Reference><Citation>Born H. A. et al.. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J. Neurosci. 34, 3826&#x2013;3840 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="pubmed">24623762</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C. et al.. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979&#x2013;982 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D. et al.. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982&#x2013;985 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Basi G. S. et al.. Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 285, 3417&#x2013;3427 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823416</ArticleId><ArticleId IdType="pubmed">19923222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K. et al.. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 29, 11393&#x2013;11398 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665926</ArticleId><ArticleId IdType="pubmed">19741145</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T. L. &amp; Hyman B. T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82, 756&#x2013;771 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T. E., Das P. &amp; Levites Y. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol. Disord. Drug Targets 8, 31&#x2013;49 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19275635</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy D. S. et al.. Memory retrieval by activating engram cells in mouse models of early Alzheimer's disease. Nature 531, 508&#x2013;512 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4847731</ArticleId><ArticleId IdType="pubmed">26982728</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedel G. et al.. Reversible neural inactivation reveals hippocampal participation in several memory processes. Nat. Neurosci. 2, 898&#x2013;905 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10491611</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey C. A. et al.. Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice. J. Neurochem. 88, 434&#x2013;442 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14690531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G. et al.. Active Abeta immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J. Neurosci. 27, 2654&#x2013;2662 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672499</ArticleId><ArticleId IdType="pubmed">17344403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillen H. et al.. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J. Neurosci. 30, 10369&#x2013;10379 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634649</ArticleId><ArticleId IdType="pubmed">20685980</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel K. A. et al.. Tau reduction prevents Abeta-induced defects in axonal transport. Science 330, 198 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024010</ArticleId><ArticleId IdType="pubmed">20829454</ArticleId></ArticleIdList></Reference><Reference><Citation>Possin K. L. et al.. Cross-species translation of the Morris maze for Alzheimer's disease. J. Clin. Invest. 126, 779&#x2013;783 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731157</ArticleId><ArticleId IdType="pubmed">26784542</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M. Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol. Aging 32, 44&#x2013;47 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343736</ArticleId><ArticleId IdType="pubmed">21983241</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius M. D., Srivastava G., Reiss A. L. &amp; Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl Acad. Sci. USA 101, 4637&#x2013;4642 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunz L. et al.. Reduced grid-cell-like representations in adults at genetic risk for Alzheimer's disease. Science 350, 430&#x2013;433 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26494756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H. &amp; Lista S. Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat. Rev. Neurol. 8, 598&#x2013;600 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23007701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R. A.
Results from two phase 3 trials of bapineuzumab in mild to moderate Alzheimers disease patients. Am. Neurol. Assoc.
https://cms.psav.com/library/ana (2012).</Citation></Reference><Reference><Citation>Cummings J. L., Morstoff T. &amp; Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res. Ther. 6, 37&#x2013;42 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E. &amp; Hardy J. Antiamyloid therapy for Alzheimer's disease--are we on the right road? N. Engl. J. Med. 370, 377&#x2013;378 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24450897</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Seifert H. et al.. Cognitive impairment precedes and predicts functional impairment in mild Alzheimer's disease. J. Alzheimers Dis. 47, 205&#x2013;214 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923754</ArticleId><ArticleId IdType="pubmed">26402769</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson N., Ferrington L., Olverman H. J. &amp; Kelly P. A. Novel analysis for improved validity in semi-quantitative 2-deoxyglucose autoradiographic imaging. J. Neurosci. Methods 175, 25&#x2013;35 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18762213</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S. et al.. Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB J. 27, 3239&#x2013;3248 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714573</ArticleId><ArticleId IdType="pubmed">23640054</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27261198</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>14</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins.</ArticleTitle><Pagination><StartPage>1537</StartPage><EndPage>1549</EndPage><MedlinePgn>1537-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.201593489</ELocationID><Abstract><AbstractText>It is now known that proteins associated with neurodegenerative disease can spread throughout the brain in a prionlike manner. However, the mechanisms regulating the trans-synaptic spread propagation, including the neuronal release of these proteins, remain unknown. The interaction of neurodegenerative disease-associated proteins with the molecular chaperone Hsc70 is well known, and we hypothesized that much like disaggregation, refolding, degradation, and even normal function, Hsc70 may dictate the extracellular fate of these proteins. Here, we show that several proteins, including TDP-43, &#x3b1;-synuclein, and the microtubule-associated protein tau, can be driven out of the cell by an Hsc70 co-chaperone, DnaJC5. In fact, DnaJC5 overexpression induced tau release in cells, neurons, and brain tissue, but only when activity of the chaperone Hsc70 was intact and when tau was able to associate with this chaperone. Moreover, release of tau from neurons was reduced in mice lacking the DnaJC5 gene and when the complement of DnaJs in the cell was altered. These results demonstrate that the dynamics of DnaJ/Hsc70 complexes are critically involved in the release of neurodegenerative disease proteins.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA James A. Haley Veteran's Hospital, Tampa, FL, USA sarah.fontaine@uky.edu cdickey@health.usf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Dali</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Jonathan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA James A. Haley Veteran's Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Mackenzie D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA James A. Haley Veteran's Hospital, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaput</LastName><ForeName>Dale</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cell, Molecular and Life Sciences, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darling</LastName><ForeName>April</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trotter</LastName><ForeName>Justin H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stothert</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordhues</LastName><ForeName>Bryce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lussier</LastName><ForeName>April</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Mahnoor</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Stanley M</ForeName><Initials>SM</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Cell, Molecular and Life Sciences, University of South Florida, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickey</LastName><ForeName>Chad A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-3834-3159</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, College of Medicine, Byrd Alzheimer's Institute, University of South Florida, Tampa, FL, USA James A. Haley Veteran's Hospital, Tampa, FL, USA sarah.fontaine@uky.edu cdickey@health.usf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX001637</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073899</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050883">HSC70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050956">HSP40 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494371">HSPA8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C088460">cysteine string protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050883" MajorTopicYN="N">HSC70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050956" MajorTopicYN="N">HSP40 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DnaJ</Keyword><Keyword MajorTopicYN="N">Hsc70</Keyword><Keyword MajorTopicYN="N">extracellular</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27261198</ArticleId><ArticleId IdType="pmc">PMC4946142</ArticleId><ArticleId IdType="doi">10.15252/embj.201593489</ArticleId><ArticleId IdType="pii">embj.201593489</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abisambra JF, Jinwal UK, Suntharalingam A, Arulselvam K, Brady S, Cockman M, Jin Y, Zhang B, Dickey CA (2012) DnaJA1 antagonizes constitutive Hsp70&#x2010;mediated stabilization of tau. J Mol Biol 421: 653&#x2013;661</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371317</ArticleId><ArticleId IdType="pubmed">22343013</ArticleId></ArticleIdList></Reference><Reference><Citation>Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, Li X, Seguin SP, Wang L, Jin Y, Bacon J, Brady S, Cockman M, Guidi C, Zhang J, Koren J, Young ZT, Atkins CA, Zhang B, Lawson LY, Weeber EJ et&#xa0;al (2013) Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry 74: 367&#x2013;374</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740016</ArticleId><ArticleId IdType="pubmed">23607970</ArticleId></ArticleIdList></Reference><Reference><Citation>Arispe N, Doh M, De Maio A (2002) Lipid interaction differentiates the constitutive and stress&#x2010;induced heat shock proteins Hsc70 and Hsp70. Cell Stress Chaperones 7: 330&#x2013;338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC514832</ArticleId><ArticleId IdType="pubmed">12653477</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, K&#xfc;gler S, Ikezu T (2015) Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18: 1584&#x2013;1593</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HYE, Trojanowski JQ, Lee VMY, Bonini NM (2002) Chaperone suppression of alpha&#x2010;synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295: 865&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Babcock DT, Ganetzky B (2015) Transcellular spreading of huntingtin aggregates in the Drosophila brain. Proc Natl Acad Sci USA 112: E5427&#x2013;E5433</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4593132</ArticleId><ArticleId IdType="pubmed">26351672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae E&#x2010;J, Yang NY, Lee C, Kim S, Lee H&#x2010;J, Lee S&#x2010;J (2015) Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell&#x2010;to&#x2010;cell transmission of &#x3b1;&#x2010;synuclein aggregates. Cell Death Dis 6: e1901</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632307</ArticleId><ArticleId IdType="pubmed">26448324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM (2008) The chaperone&#x2010;mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol 28: 5747&#x2013;5763</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546938</ArticleId><ArticleId IdType="pubmed">18644871</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann RP, Mizzen LE, Welch WJ (1990) Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science 248: 850&#x2013;854</Citation><ArticleIdList><ArticleId IdType="pubmed">2188360</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell&#x2010;Temin H, Zhang P, Chaput D, King MA, You M, Liu B, Stevens SM (2013) Quantitative proteomic characterization of ethanol&#x2010;responsive pathways in rat microglial cells. J Proteome Res 12: 2067&#x2013;2077</Citation><ArticleIdList><ArticleId IdType="pubmed">23495833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercovich B, Stancovski I, Mayer A, Blumenfeld N, Laszlo A, Schwartz AL, Ciechanover A (1997) Ubiquitin&#x2010;dependent degradation of certain protein substrates in&#xa0;vitro requires the molecular chaperone Hsc70. J Biol Chem 272: 9002&#x2013;9010</Citation><ArticleIdList><ArticleId IdType="pubmed">9083024</ArticleId></ArticleIdList></Reference><Reference><Citation>Black MM, Chestnut MH, Pleasure IT, Keen JH (1991) Stable clathrin: uncoating protein (hsc70) complexes in intact neurons and their axonal transport. J Neurosci Off J Soc Neurosci 11: 1163&#x2013;1172</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575316</ArticleId><ArticleId IdType="pubmed">1709204</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddul SV, Meng J, Dolly JO, Wang J (2014) SNAP&#x2010;23 and VAMP&#x2010;3 contribute to the release of IL&#x2010;6 and TNF&#x3b1; from a human synovial sarcoma cell line. FEBS J 281: 750&#x2013;765</Citation><ArticleIdList><ArticleId IdType="pubmed">24373201</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer&#x2010;related changes. Acta Neuropathol 82: 239&#x2013;259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB, Kuwabara S, Shibuya K, Irwin DJ, Fang L, Van Deerlin VM, Elman L, McCluskey L, Ludolph AC, Lee VM&#x2010;Y, Braak H, Trojanowski JQ (2014) TDP&#x2010;43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol 128: 423&#x2013;437</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadwell RD, Balin BJ (1985) Endocytic and exocytic pathways of the neuronal secretory process and trans&#x2010;synaptic transfer of wheat germ&#xa0;agglutinin&#x2010;horseradish peroxidase in&#xa0;vivo . J Comp Neurol 242: 632&#x2013;650</Citation><ArticleIdList><ArticleId IdType="pubmed">2418083</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S&#xfc;dhof TC (2010) Alpha&#x2010;synuclein promotes SNARE&#x2010;complex assembly in&#xa0;vivo and in&#xa0;vitro . Science 329: 1663&#x2013;1667</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Calafate S, Buist A, Miskiewicz K, Vijayan V, Daneels G, de Strooper B, de Wit J, Verstreken P, Moechars D (2015) Synaptic contacts enhance cell&#x2010;to&#x2010;cell tau pathology propagation. Cell Rep 11: 1176&#x2013;1183</Citation><ArticleIdList><ArticleId IdType="pubmed">25981034</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez&#x2010;Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires&#x2010;Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73: 685&#x2013;697</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain LH, Burgoyne RD (1997) The molecular chaperone function of the secretory vesicle cysteine string proteins. J Biol Chem 272: 31420&#x2013;31426</Citation><ArticleIdList><ArticleId IdType="pubmed">9395474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain LH, Burgoyne RD (1998) Cysteine string protein functions directly in regulated exocytosis. Mol Biol Cell 9: 2259&#x2013;2267</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25479</ArticleId><ArticleId IdType="pubmed">9693380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fern&#xe1;ndez&#x2010;Chac&#xf3;n R, Schl&#xfc;ter OM, S&#xfc;dhof TC (2005) Alpha&#x2010;synuclein cooperates with CSP alpha in preventing neurodegeneration. Cell 123: 383&#x2013;396</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell TG, Welch WJ, Schlossman DM, Palter KB, Schlesinger MJ, Rothman JE (1986) Uncoating ATPase is a member of the 70 kilodalton family of stress proteins. Cell 45: 3&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pubmed">2937542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham ME, Brion JP, Anderton BH (1992) Human homologues of the bacterial heat&#x2010;shock protein DnaJ are preferentially expressed in neurons. Biochem J 284(Pt 2): 469&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1132662</ArticleId><ArticleId IdType="pubmed">1599432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham ME, Anderton BH, Jackson AP (1996) Inhibition of hsc70&#x2010;catalysed clathrin uncoating by HSJ1 proteins. Biochem J 319(Pt 1): 103&#x2013;108</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1217741</ArticleId><ArticleId IdType="pubmed">8870655</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang N, Hsiao Y&#x2010;T, Yang H&#x2010;J, Lin Y&#x2010;C, Lu J&#x2010;C, Wang C&#x2010;T (2014) Phosphomimetic mutation of cysteine string protein&#x2010;&#x3b1; increases the rate of regulated exocytosis by modulating fusion pore dynamics in PC12 cells. PLoS ONE 9: e99180</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067274</ArticleId><ArticleId IdType="pubmed">24956274</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado&#x2010;Mart&#xed;nez I, Nehring RB, S&#xf8;rensen JB (2007) Differential abilities of SNAP&#x2010;25 homologs to support neuronal function. J Neurosci Off J Soc Neurosci 27: 9380&#x2013;9391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673127</ArticleId><ArticleId IdType="pubmed">17728451</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, Lee H&#x2010;J, Bae E&#x2010;J, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee S&#x2010;J (2009) Inclusion formation and neuronal cell death through neuron&#x2010;to&#x2010;neuron transmission of &#x3b1;&#x2010;synuclein. Proc Natl Acad Sci USA 106: 13010&#x2013;13015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Ash P, Klosak N, Lee WC, Petrucelli L, Hutton M, Eckman CB (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener 1: 6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570347</ArticleId><ArticleId IdType="pubmed">16930453</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA 100: 721&#x2013;726</Citation><ArticleIdList><ArticleId IdType="pmc">PMC141063</ArticleId><ArticleId IdType="pubmed">12522269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubuke ML, Maniatis S, Shaffer SA, Munson M (2015) The exocyst subunit Sec6 interacts with assembled exocytic SNARE complexes. J Biol Chem 290: 28245&#x2013;28256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653681</ArticleId><ArticleId IdType="pubmed">26446795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, L&#xe9;colle K, Caillierez R, B&#xe9;gard S, Zommer N, Lachaud C, Carrier S, Dufour N, Aur&#xe9;gan G, Winderickx J, Hantraye P, D&#xe9;glon N, Colin M, Bu&#xe9;e L (2014) Neuron&#x2010;to&#x2010;neuron wild&#x2010;type Tau protein transfer through a trans&#x2010;synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun 2: 14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922636</ArticleId><ArticleId IdType="pubmed">24479894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejlerskov P, Rasmussen I, Nielsen TT, Bergstr&#xf6;m A&#x2010;L, Tohyama Y, Jensen PH, Vilhardt F (2013) Tubulin polymerization&#x2010;promoting protein (TPPP/p25&#x3b1;) promotes unconventional secretion of &#x3b1;&#x2010;synuclein through exophagy by impairing autophagosome&#x2010;lysosome fusion. J Biol Chem 288: 17313&#x2013;17335</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682534</ArticleId><ArticleId IdType="pubmed">23629650</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans GJ, Wilkinson MC, Graham ME, Turner KM, Chamberlain LH, Burgoyne RD, Morgan A (2001) Phosphorylation of cysteine string protein by protein kinase A. Implications for the modulation of exocytosis. J Biol Chem 276: 47877&#x2013;47885</Citation><ArticleIdList><ArticleId IdType="pubmed">11604405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Chac&#xf3;n R, W&#xf6;lfel M, Nishimune H, Tabares L, Schmitz F, Castellano&#x2010;Mu&#xf1;oz M, Rosenmund C, Montesinos ML, Sanes JR, Schneggenburger R, S&#xfc;dhof TC (2004) The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. Neuron 42: 237&#x2013;251</Citation><ArticleIdList><ArticleId IdType="pubmed">15091340</ArticleId></ArticleIdList></Reference><Reference><Citation>Finka A, Goloubinoff P (2013) Proteomic data from human cell cultures refine mechanisms of chaperone&#x2010;mediated protein homeostasis. Cell Stress Chaperones 18: 591&#x2013;605</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3745260</ArticleId><ArticleId IdType="pubmed">23430704</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine SN, Martin MD, Akoury E, Assimon VA, Borysov S, Nordhues BA, Sabbagh JJ, Cockman M, Gestwicki JE, Zweckstetter M, Dickey CA (2015a) The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet 24: 3971&#x2013;3981</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4560066</ArticleId><ArticleId IdType="pubmed">25882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine SN, Rauch JN, Nordhues BA, Assimon VA, Stothert AR, Jinwal UK, Sabbagh JJ, Chang L, Stevens SM, Zuiderweg ERP, Gestwicki JE, Dickey CA (2015b) Isoform&#x2010;selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client tau degradation using an altered co&#x2010;chaperone complement. J Biol Chem 290: 13115&#x2013;13127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505567</ArticleId><ArticleId IdType="pubmed">25864199</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, Modugno N, Siciliano G, Isidoro C, Murri L, Ruggieri S, Paparelli A (2008) Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 105: 2052&#x2013;2057</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538879</ArticleId><ArticleId IdType="pubmed">18250315</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank SPC, Thon K&#x2010;P, Bischoff SC, Lorentz A (2011) SNAP&#x2010;23 and syntaxin&#x2010;3 are required for chemokine release by mature human mast cells. Mol Immunol 49: 353&#x2013;358</Citation><ArticleIdList><ArticleId IdType="pubmed">21981832</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick KK, Debelouchina GT, Kayatekin C, Dorminy T, Jacavone AC, Griffin RG, Lindquist S (2014) Distinct prion strains are defined by amyloid core structure and chaperone binding site dynamics. Chem Biol 21: 295&#x2013;305</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030713</ArticleId><ArticleId IdType="pubmed">24485763</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Carroni M, Nussbaum&#x2010;Krammer C, Mogk A, Nillegoda NB, Szlachcic A, Guilbride DL, Saibil HR, Mayer MP, Bukau B (2015) Human Hsp70 disaggregase reverses Parkinson's&#x2010;linked &#x3b1;&#x2010;synuclein amyloid fibrils. Mol Cell 59: 781&#x2013;793</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5072489</ArticleId><ArticleId IdType="pubmed">26300264</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Junco&#x2010;Clemente P, Cantero G, G&#xf3;mez&#x2010;S&#xe1;nchez L, Linares&#x2010;Clemente P, Mart&#xed;nez&#x2010;L&#xf3;pez JA, Luj&#xe1;n R, Fern&#xe1;ndez&#x2010;Chac&#xf3;n R (2010) Cysteine string protein&#x2010;alpha prevents activity&#x2010;dependent degeneration in GABAergic synapses. J Neurosci Off J Soc Neurosci 30: 7377&#x2013;7391</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632397</ArticleId><ArticleId IdType="pubmed">20505105</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham ME, Burgoyne RD (2000) Comparison of cysteine string protein (Csp) and mutant alpha&#x2010;SNAP overexpression reveals a role for csp in late steps of membrane fusion in dense&#x2010;core granule exocytosis in adrenal chromaffin cells. J Neurosci Off J Soc Neurosci 20: 1281&#x2013;1289</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772362</ArticleId><ArticleId IdType="pubmed">10662817</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant NJ, Hepp R, Krause W, Aunis D, Oehme P, Langley K (1999) Differential expression of SNAP&#x2010;25 isoforms and SNAP&#x2010;23 in the adrenal gland. J&#xa0;Neurochem 72: 363&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">9886089</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM&#x2010;Y (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer&#x2010;like tangles. J Biol Chem 286: 15317&#x2013;15331</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C, Angot E, Bergstr&#xf6;m A&#x2010;L, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li J&#x2010;Y, Brundin P (2011) &#x3b1;&#x2010;Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121: 715&#x2013;725</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026723</ArticleId><ArticleId IdType="pubmed">21245577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy F, Cheetham ME, Dirr HW, Blatch GL (2000) Analysis of the levels of conservation of the J domain among the various types of DnaJ&#x2010;like proteins. Cell Stress Chaperones 5: 347&#x2013;358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC312864</ArticleId><ArticleId IdType="pubmed">11048657</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy&#x2010;Garcia D, Diamond MI (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110: E3138&#x2013;E3147</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, McBride JD, Guo JL, Zhang B, Trojanowski JQ, Lee VM&#x2010;Y (2015) Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections. Acta Neuropathol 130: 349&#x2013;362</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545685</ArticleId><ArticleId IdType="pubmed">26150341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsson G, Meister B (1996) Molecular components of the exocytotic machinery in the rat pituitary gland. Endocrinology 137: 5344&#x2013;5356</Citation><ArticleIdList><ArticleId IdType="pubmed">8940356</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, O'Leary JC, Borysov SI, Jones JR, Li Q, Koren J, Abisambra JF, Vestal GD, Lawson LY, Johnson AG, Blair LJ, Jin Y, Miyata Y, Gestwicki JE, Dickey CA (2010) Hsc70 rapidly engages tau after microtubule destabilization. J&#xa0;Biol Chem 285: 16798&#x2013;16805</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2878041</ArticleId><ArticleId IdType="pubmed">20308058</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinwal UK, Akoury E, Abisambra JF, O'Leary JC, Thompson AD, Blair LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, Zhang J, Li P, Zhang B, Borysov S, Uversky VN, Biernat J, Mandelkow E, Gestwicki JE, Zweckstetter M, Dickey CA (2013) Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J Off Publ Fed Am Soc Exp Biol 27: 1450&#x2013;1459</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606536</ArticleId><ArticleId IdType="pubmed">23271055</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglekar AP, Hay JC (2005) Evidence for regulation of ER/Golgi SNARE complex formation by hsc70 chaperones. Eur J Cell Biol 84: 529&#x2013;542</Citation><ArticleIdList><ArticleId IdType="pubmed">16003907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, M&#xfc;ller H&#x2010;P, Del Tredici K, Brettschneider J, Pinkhardt EH, Lul&#xe9; D, B&#xf6;hm S, Braak H, Ludolph AC (2014) Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP&#x2010;43 pathology. Brain J Neurol 137: 1733&#x2013;1740</Citation><ArticleIdList><ArticleId IdType="pubmed">24736303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul S, Mittal SK, Feigenbaum L, Kruhlak MJ, Roche PA (2015) Expression of the SNARE protein SNAP&#x2010;23 is essential for cell survival. PLoS ONE 10: e0118311</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338070</ArticleId><ArticleId IdType="pubmed">25706117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D, Coppolino MG (2009) VAMP3, syntaxin&#x2010;13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci 122: 4089&#x2013;4098</Citation><ArticleIdList><ArticleId IdType="pubmed">19910495</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster A, Nola S, Dingli F, Vacca B, Gauchy C, Beaujouan J&#x2010;C, Nunez M, Moncion T, Loew D, Formstecher E, Galli T, Proux&#x2010;Gillardeaux V (2015) The Q&#x2010;soluble&#x2010;N&#x2010;ethylmaleimide&#x2010;sensitive factor attachment protein receptor (Q&#x2010;SNARE) SNAP&#x2010;47 regulates trafficking of selected vesicle&#x2010;associated membrane proteins (VAMPs). J Biol Chem 290: 28056&#x2013;28069</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653666</ArticleId><ArticleId IdType="pubmed">26359495</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Lindquist S (2000) Creating a protein&#x2010;based element of inheritance. Science 287: 661&#x2013;664</Citation><ArticleIdList><ArticleId IdType="pubmed">10650001</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans&#x2010;synaptic spread of tau pathology in&#xa0;vivo . PLoS ONE 7: e31302</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real&#x2010;time quantitative PCR and the 2(&#x2010;Delta Delta C(T)) method. Methods San Diego Calif 25: 402&#x2013;408</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandolesi G, Vanni V, Cesa R, Grasselli G, Puglisi F, Cesare P, Strata P (2009) Distribution of the SNAP25 and SNAP23 synaptosomal&#x2010;associated protein isoforms in rat cerebellar cortex. Neuroscience 164: 1084&#x2013;1096</Citation><ArticleIdList><ArticleId IdType="pubmed">19735702</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda&#x2010;Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA, Hasegawa M (2013) Prion&#x2010;like spreading of pathological &#x3b1;&#x2010;synuclein in brain. Brain 136(pt 4): 1128&#x2013;1138</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M, Avila J (2014) The role of extracellular tau in neurofibrillary pathology. Front Cell Neurosci 8: 113</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005959</ArticleId><ArticleId IdType="pubmed">24795568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez M, Gaisano HY (2013) Role of the SNARE protein SNAP23 on cAMP&#x2010;stimulated renin release in mouse juxtaglomerular cells. Am J Physiol Renal Physiol 304: F498&#x2013;F504</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602711</ArticleId><ArticleId IdType="pubmed">23269646</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsellier E, Redeker V, Ruiz&#x2010;Arlandis G, Bousset L, Melki R (2015) Molecular interaction between the chaperone Hsc70 and the N&#x2010;terminal flank of huntingtin exon 1 modulates aggregation. J Biol Chem 290: 2560&#x2013;2576</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317008</ArticleId><ArticleId IdType="pubmed">25505179</ArticleId></ArticleIdList></Reference><Reference><Citation>Morelli E, Ginefra P, Mastrodonato V, Beznoussenko GV, Rusten TE, Bilder D, Stenmark H, Mironov AA, Vaccari T (2014) Multiple functions of the SNARE protein Snap29 in autophagy, endocytic, and exocytic trafficking during epithelial formation in Drosophila . Autophagy 10: 2251&#x2013;2268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502674</ArticleId><ArticleId IdType="pubmed">25551675</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, Watakabe A, Hioki H, Fujiyama F, Tanaka Y, Yamamori T, Kaneko T (2007) Transiently increased colocalization of vesicular glutamate transporters 1 and 2 at single axon terminals during postnatal development of mouse neocortex: a quantitative analysis with correlation coefficient. Eur J Neurosci 26: 3054&#x2013;3067</Citation><ArticleIdList><ArticleId IdType="pubmed">18028110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nillegoda NB, Kirstein J, Szlachcic A, Berynskyy M, Stank A, Stengel F, Arnsburg K, Gao X, Scior A, Aebersold R, Guilbride DL, Wade RC, Morimoto RI, Mayer MP, Bukau B (2015) Crucial HSP70 co&#x2010;chaperone complex unlocks metazoan protein disaggregation. Nature 524: 247&#x2013;251</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830470</ArticleId><ArticleId IdType="pubmed">26245380</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce MMP, Spartz EJ, Hong W, Luo L, Kopito RR (2015) Prion&#x2010;like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nat Commun 6: 6768</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4515032</ArticleId><ArticleId IdType="pubmed">25866135</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecho&#x2010;Vrieseling E, Rieker C, Fuchs S, Bleckmann D, Esposito MS, Botta P, Goldstein C, Bernhard M, Galimberti I, M&#xfc;ller M, L&#xfc;thi A, Arber S, Bouwmeester T, van der Putten H, Di Giorgio FP (2014) Transneuronal propagation of mutant huntingtin contributes to non&#x2010;cell autonomous pathology in neurons. Nat Neurosci 17: 1064&#x2013;1072</Citation><ArticleIdList><ArticleId IdType="pubmed">25017010</ArticleId></ArticleIdList></Reference><Reference><Citation>Pemberton S, Madiona K, Pieri L, Kabani M, Bousset L, Melki R (2011) Hsc70 protein interaction with soluble and fibrillar alpha&#x2010;synuclein. J Biol Chem 286: 34690&#x2013;34699</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3186418</ArticleId><ArticleId IdType="pubmed">21832061</ArticleId></ArticleIdList></Reference><Reference><Citation>Poehler A&#x2010;M, Xiang W, Spitzer P, May VEL, Meixner H, Rockenstein E, Chutna O, Outeiro TF, Winkler J, Masliah E, Klucken J (2014) Autophagy modulates SNCA/&#x3b1;&#x2010;synuclein release, thereby generating a hostile microenvironment. Autophagy 10: 2171&#x2013;2192</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502760</ArticleId><ArticleId IdType="pubmed">25484190</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, Pitstick R, Carlson GA, Staley KJ, Spires&#x2010;Jones TL, Hyman BT (2014) Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol 127: 257&#x2013;270</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946978</ArticleId><ArticleId IdType="pubmed">24271788</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 14: 389&#x2013;394</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao SK, Huynh C, Proux&#x2010;Gillardeaux V, Galli T, Andrews NW (2004) Identification of SNAREs involved in synaptotagmin VII&#x2010;regulated lysosomal exocytosis. J Biol Chem 279: 20471&#x2013;20479</Citation><ArticleIdList><ArticleId IdType="pubmed">14993220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JV, McMahon C, Baryshnikova A, Hughson FM, Rose MD (2014) ER&#x2010;associated retrograde SNAREs and the Dsl1 complex mediate an alternative, Sey1p&#x2010;independent homotypic ER fusion pathway. Mol Biol Cell 25: 3401&#x2013;3412</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214786</ArticleId><ArticleId IdType="pubmed">25187651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousaki A, Miyata Y, Jinwal UK, Dickey CA, Gestwicki JE, Zuiderweg ERP (2011) Allosteric drugs: the interaction of antitumor compound MKT&#x2010;077 with human Hsp70 chaperones. J Mol Biol 411: 614&#x2013;632</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146629</ArticleId><ArticleId IdType="pubmed">21708173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozas JL, G&#xf3;mez&#x2010;S&#xe1;nchez L, Mircheski J, Linares&#x2010;Clemente P, Nieto&#x2010;Gonz&#xe1;lez JL, V&#xe1;zquez ME, Luj&#xe1;n R, Fern&#xe1;ndez&#x2010;Chac&#xf3;n R (2012) Motorneurons require cysteine string protein&#x2010;&#x3b1; to maintain the readily releasable vesicular pool and synaptic vesicle recycling. Neuron 74: 151&#x2013;165</Citation><ArticleIdList><ArticleId IdType="pubmed">22500637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz R, Casa&#xf1;as JJ, S&#xfc;dhof TC, Tabares L (2008) Cysteine string protein&#x2010;alpha is essential for the high calcium sensitivity of exocytosis in a vertebrate synapse. Eur J Neurosci 27: 3118&#x2013;3131</Citation><ArticleIdList><ArticleId IdType="pubmed">18598257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenzi A, Potolicchio I, Nieves E, Cuervo AM, Santambrogio L (2011) Microautophagy of cytosolic proteins by late endosomes. Dev Cell 20: 131&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025279</ArticleId><ArticleId IdType="pubmed">21238931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar M, Kuret J, Lee G (2008) Two motifs within the tau microtubule&#x2010;binding domain mediate its association with the hsc70 molecular chaperone. J Neurosci Res 86: 2763&#x2013;2773</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4271846</ArticleId><ArticleId IdType="pubmed">18500754</ArticleId></ArticleIdList></Reference><Reference><Citation>Seagar M, L&#xe9;v&#xea;que C, Charvin N, Marqu&#xe8;ze B, Martin&#x2010;Moutot N, Boudier JA, Boudier JL, Shoji&#x2010;Kasai Y, Sato K, Takahashi M (1999) Interactions between proteins implicated in exocytosis and voltage&#x2010;gated calcium channels. Philos Trans R Soc Lond B Biol Sci 354: 289&#x2013;297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692480</ArticleId><ArticleId IdType="pubmed">10212477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, Burr&#xe9; J, S&#xfc;dhof TC (2011) CSP&#x3b1; promotes SNARE&#x2010;complex assembly by chaperoning SNAP&#x2010;25 during synaptic activity. Nat Cell Biol 13: 30&#x2013;39</Citation><ArticleIdList><ArticleId IdType="pubmed">21151134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, Burr&#xe9; J, Bronk P, Zhang Y, Xu W, S&#xfc;dhof TC (2012) CSP&#x3b1; knockout causes neurodegeneration by impairing SNAP&#x2010;25 function. EMBO J 31: 829&#x2013;841</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280561</ArticleId><ArticleId IdType="pubmed">22187053</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J, Lindquist S (2006) Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 23: 425&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1540446</ArticleId><ArticleId IdType="pubmed">16885031</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha&#x2010;synuclein in Lewy bodies. Nature 388: 839&#x2013;840</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh YH, Yoshimoto&#x2010;Furusawa A, Weih KA, Tessarollo L, Roche KW, Mackem S, Roche PA (2011) Deletion of SNAP&#x2010;23 results in pre&#x2010;implantation embryonic lethality in mice. PLoS ONE 6: e18444</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3066230</ArticleId><ArticleId IdType="pubmed">21479242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari SS, d'Orange M, Troakes C, Shurovi BN, Engmann O, Noble W, Hortob&#xe1;gyi T, Giese KP (2015) Evidence that the presynaptic vesicle protein CSP alpha is a key player in synaptic degeneration and protection in Alzheimer's disease. Mol Brain 8: 6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314762</ArticleId><ArticleId IdType="pubmed">25631211</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tuite MF, Marchante R, Kushnirov V (2011) Fungal prions: structure, function and propagation In Prion Proteins, Tatzelt J. (ed.), pp 257&#x2013;298. Berlin, Heidelberg: Springer;  Available at: http://link.springer.com/chapter/10.1007/128_2011_172 [Accessed September 30, 2015]</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/128_2011_172</ArticleId><ArticleId IdType="pubmed">21717344</ArticleId></ArticleIdList></Reference><Reference><Citation>Umbach JA, Gundersen CB (1997) Evidence that cysteine string proteins regulate an early step in the Ca2+&#x2010;dependent secretion of neurotransmitter at Drosophila neuromuscular junctions. J Neurosci Off J Soc Neurosci 17: 7203&#x2013;7209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573444</ArticleId><ArticleId IdType="pubmed">9295366</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Maury EA, Kirk MJ, Saqran L, Roe A, DeVos SL, Nicholls S, Fan Z, Takeda S, Cagsal&#x2010;Getkin O, William CM, Spires&#x2010;Jones TL, Pitstick R, Carlson GA, Pooler AM, Hyman BT (2015) Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J 34: 3028&#x2013;3041</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687785</ArticleId><ArticleId IdType="pubmed">26538322</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng N, Baumler MD, Thomas DDH, Falkowski MA, Swayne LA, Braun JEA, Groblewski GE (2009) Functional role of J domain of cysteine string protein in Ca2+&#x2010;dependent secretion from acinar cells. Am J Physiol Gastrointest Liver Physiol 296: G1030&#x2013;G1039</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696211</ArticleId><ArticleId IdType="pubmed">19282376</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x15b;niewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6: 359&#x2013;362</Citation><ArticleIdList><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgr&#xe4;fe K, Mandelkow E&#x2010;M, Holtzman DM (2014) Neuronal&#xa0;activity regulates extracellular tau in&#xa0;vivo . J Exp Med 211: 387&#x2013;393</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu A, Shibata Y, Shah B, Calamini B, Lo DC, Morimoto RI (2014) Protein aggregation can inhibit clathrin&#x2010;mediated endocytosis by chaperone competition. Proc Natl Acad Sci USA 111: E1481&#x2013;E1490</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992642</ArticleId><ArticleId IdType="pubmed">24706768</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Yamakuchi M, Lowenstein CJ (2015) SNAP23 regulates endothelial exocytosis of von willebrand factor. PLoS ONE 10: e0118737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4534191</ArticleId><ArticleId IdType="pubmed">26266817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N (1999) Recombinant adeno&#x2010;associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973&#x2013;985</Citation><ArticleIdList><ArticleId IdType="pubmed">10455399</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27292537</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>66</EndPage><MedlinePgn>56-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)30197-0</ELocationID><Abstract><AbstractText>A majority of current disease-modifying therapeutic&#xa0;approaches for age-related neurodegenerative diseases target their characteristic proteopathic lesions (&#x3b1;-synuclein, Tau, A&#x3b2;). To monitor such treatments, fluid biomarkers reflecting the underlying disease process are crucial. We found robust increases of neurofilament light chain (NfL) in CSF and blood in murine models of &#x3b1;-synucleinopathies, tauopathy, and &#x3b2;-amyloidosis. Blood and CSF NfL levels were strongly correlated, and NfL increases coincided with the onset and progression of the corresponding proteopathic lesions in brain. Experimental induction of &#x3b1;-synuclein lesions increased CSF and blood NfL levels, while blocking A&#x3b2; lesions attenuated the NfL increase. Consistently, we also found NfL increases in CSF and blood of human &#x3b1;-synucleinopathies, tauopathies, and Alzheimer's disease. Our results suggest that CSF and particularly blood NfL can serve as a reliable and easily accessible biomarker to monitor disease progression and treatment response in mouse models and potentially in human proteopathic neurodegenerative diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bacioglu</LastName><ForeName>Mehtap</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany; Graduate School of Cellular and Molecular Neuroscience, University of Tuebingen, D-72074 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Luis F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany; Department of Neurology, Hospital de Santo Ant&#xf3;nio-CHP, 4099-001 Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preische</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Psychiatry and Psychotherapy, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schelle</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany; Graduate School of Cellular and Molecular Neuroscience, University of Tuebingen, D-72074 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apel</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweighauser</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany; Graduate School of Cellular and Molecular Neuroscience, University of Tuebingen, D-72074 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eninger</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany; Graduate School of Cellular and Molecular Neuroscience, University of Tuebingen, D-72074 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marius</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilotto</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimshek</LastName><ForeName>Derya R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahle</LastName><ForeName>Philipp J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Neuropathology, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maetzler</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhle</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, CH-4031 Basel, Switzerland. Electronic address: jens.kuhle@usb.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Tuebingen, D-72076 Tuebingen, Germany; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, D-72076 Tuebingen, Germany. Electronic address: mathias.jucker@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2016 Jul 6;91(1):1-3. doi: 10.1016/j.neuron.2016.06.030.</RefSource><PMID Version="1">27387643</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Neuron. 2016 Jul 20;91(2):494-496. doi: 10.1016/j.neuron.2016.07.007.</RefSource><PMID Version="1">27477021</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27292537</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.05.018</ArticleId><ArticleId IdType="pii">S0896-6273(16)30197-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27293189</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>166</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Restricted Location of PSEN2/&#x3b3;-Secretase Determines Substrate Specificity and Generates an Intracellular A&#x3b2; Pool.</ArticleTitle><Pagination><StartPage>193</StartPage><EndPage>208</EndPage><MedlinePgn>193-208</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.05.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)30568-2</ELocationID><Abstract><AbstractText>&#x3b3;-Secretases are a family of intramembrane-cleaving proteases involved in various signaling pathways and diseases, including Alzheimer's disease (AD). Cells co-express differing &#x3b3;-secretase complexes, including two homologous presenilins (PSENs). We examined the significance of this heterogeneity and identified a unique motif in PSEN2 that directs this &#x3b3;-secretase to late endosomes/lysosomes via a phosphorylation-dependent interaction with the AP-1 adaptor complex. Accordingly, PSEN2 selectively cleaves late endosomal/lysosomal localized substrates and generates the prominent pool of intracellular A&#x3b2; that contains longer A&#x3b2;; familial AD (FAD)-associated mutations in PSEN2 increased the levels of longer A&#x3b2; further. Moreover, a subset of FAD mutants in PSEN1, normally more broadly distributed in the cell, phenocopies PSEN2 and shifts its localization to late endosomes/lysosomes. Thus, localization of &#x3b3;-secretases determines substrate specificity, while FAD-causing mutations strongly enhance accumulation of aggregation-prone A&#x3b2;42 in intracellular acidic compartments. The findings reveal potentially important roles for specific intracellular, localized reactions contributing to AD pathogenesis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sannerud</LastName><ForeName>Ragna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esselens</LastName><ForeName>Cary</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ejsmont</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattera</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cell Biology and Neurobiology Branch, NICHD, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochin</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut Curie, PSL Research University, CNRS, UMR 144, Paris 75005, France; CNRS, UMR 144, Paris 75005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tharkeshwar</LastName><ForeName>Arun Kumar</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Baets</LastName><ForeName>Greet</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VIB Switch Laboratory, KU Leuven, 3000 Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Wever</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habets</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy (MAASTRO)/GROW, Maastricht University, 6211 Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baert</LastName><ForeName>Veerle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeire</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groot</LastName><ForeName>Arjan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy (MAASTRO)/GROW, Maastricht University, 6211 Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wouters</LastName><ForeName>Rosanne</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dillen</LastName><ForeName>Katleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vints</LastName><ForeName>Katlijn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>VIB BioImaging Core, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baatsen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB BioImaging Core, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munck</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VIB BioImaging Core, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derua</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waelkens</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basi</LastName><ForeName>Guriqbal S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Avalanche Biotechnology, Menlo Park, CA 94025, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Pharmaceutica, 2340 Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vooijs</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy (MAASTRO)/GROW, Maastricht University, 6211 Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollen</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB Switch Laboratory, KU Leuven, 3000 Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>VIB Switch Laboratory, KU Leuven, 3000 Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonifacino</LastName><ForeName>Juan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Cell Biology and Neurobiology Branch, NICHD, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Niel</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut Curie, PSL Research University, CNRS, UMR 144, Paris 75005, France; CNRS, UMR 144, Paris 75005, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium; Department of Molecular Neuroscience, UCL Institute of Neurology, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annaert</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, KU Leuven, 3000 Leuven, Belgium; Department of Human Genetics, KU Leuven, 3000 Leuven, Belgium. Electronic address: wim.annaert@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z01 HD001607</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA HD001607</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033961">Adaptor Protein Complex 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2016 Jun 30;166(1):13-5. doi: 10.1016/j.cell.2016.06.034.</RefSource><PMID Version="1">27368096</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D033961" MajorTopicYN="N">Adaptor Protein Complex 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27293189</ArticleId><ArticleId IdType="mid">NIHMS1017101</ArticleId><ArticleId IdType="pmc">PMC7439524</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.05.020</ArticleId><ArticleId IdType="pii">S0092-8674(16)30568-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acx H, Chavez-Gutierrez L, Serneels L, Lismont S, Benurwar M, Elad N, and De Strooper B (2014). Signature amyloid beta profiles are produced by different gamma-secretase complexes. The Journal of biological chemistry 289, 4346&#x2013;4355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924297</ArticleId><ArticleId IdType="pubmed">24338474</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Takahashi RH, and Gouras GK (2006). Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. The Journal of neuroscience : the official journal of the Society for Neuroscience 26, 4277&#x2013;4288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="pubmed">16624948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer TA, and Wirths O (2011). Intraneuronal Abeta as a trigger for neuron loss: can this be translated into human pathology? Biochemical Society transactions 39, 857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">21787313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, and De Strooper B (2006). Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. Journal of neurochemistry 96, 732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS (2014). Adaptor proteins involved in polarized sorting. The Journal of cell biology 204, 7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882786</ArticleId><ArticleId IdType="pubmed">24395635</ArticleId></ArticleIdList></Reference><Reference><Citation>Braulke T, and Bonifacino JS (2009). Sorting of lysosomal proteins. Biochimica et biophysica acta 1793, 605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">19046998</ArticleId></ArticleIdList></Reference><Reference><Citation>Canevelli M, Piscopo P, Talarico G, Vanacore N, Blasimme A, Crestini A, Tosto G, Troili F, Lenzi GL, Confaloni A, et al. (2014). Familial Alzheimer&#x2019;s disease sustained by presenilin 2 mutations: systematic review of literature and genotype-phenotype correlation. Neuroscience and biobehavioral reviews 42, 170&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">24594196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, and Nixon RA (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. The American journal of pathology 157, 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, et al. (2012). The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. The EMBO journal 31, 2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Theuns J, and Van Broeckhoven C (2012). Locus-specific mutation databases for neurodegenerative brain diseases. Human mutation 33, 1340&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, and Annaert W (2010). Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annual review of cell and developmental biology 26, 235&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20604710</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, and Haass C (2003).Reconstitution of gamma-secretase activity. Nature cell biology 5, 486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679784</ArticleId></ArticleIdList></Reference><Reference><Citation>Esbjorner EK, Chan F, Rees E, Erdelyi M, Luheshi LM, Bertoncini CW, Kaminski CF, Dobson CM, and Kaminski Schierle GS (2014). Direct observations of amyloid beta self-assembly in live cells provide insights into differences in the kinetics of Abeta(1&#x2013;40) and Abeta(1&#x2013;42) aggregation. Chemistry &amp; biology 21, 732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067742</ArticleId><ArticleId IdType="pubmed">24856820</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias GG, Cuitino L, Guo X, Ren X, Jarnik M, Mattera R, and Bonifacino JS (2012). Signal-mediated, AP-1/clathrin-dependent sorting of transmembrane receptors to the somatodendritic domain of hippocampal neurons. Neuron 75, 810&#x2013;823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439821</ArticleId><ArticleId IdType="pubmed">22958822</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman M (2014). The Rhomboid-Like Superfamily: Molecular Mechanisms and Biological Roles. Annual review of cell and developmental biology.</Citation><ArticleIdList><ArticleId IdType="pubmed">25062361</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich RP, Tepper K, Ronicke R, Soom M, Westermann M, Reymann K, Kaether C, and Fandrich M (2010). Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proceedings of the National Academy of Sciences of the United States of America 107, 1942&#x2013;1947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836607</ArticleId><ArticleId IdType="pubmed">20133839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, et al. (2010). Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer&#x2019;s disease progression. Biological psychiatry 68, 885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965820</ArticleId><ArticleId IdType="pubmed">20655510</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Wolfe MS, and Greenbaum DC (2009). Signal peptide peptidases: a family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins. Seminars in cell &amp; developmental biology 20, 225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701170</ArticleId><ArticleId IdType="pubmed">19429495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tampellini D, Takahashi RH, and Capetillo-Zarate E (2010). Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer&#x2019;s disease. Acta neuropathologica 119, 523&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183823</ArticleId><ArticleId IdType="pubmed">20354705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Crick SL, Bu G, Frieden C, Pappu RV, and Lee JM (2009). Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proceedings of the National Academy of Sciences of the United States of America 106, 20324&#x2013;20329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, Guatelli J, and Xiong Y (2014). Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. eLife 3, e02362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018625</ArticleId><ArticleId IdType="pubmed">24843023</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurisch-Yaksi N, Sannerud R, and Annaert W (2013). A fast growing spectrum of biological functions of gamma-secretase in development and disease. Biochimica et biophysica acta 1828, 2815&#x2013;2827.</Citation><ArticleIdList><ArticleId IdType="pubmed">24099003</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, and Goate AM (2015). Alzheimer&#x2019;s disease risk genes and mechanisms of disease pathogenesis. Biological psychiatry 77, 43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, and Counter CM (2011). RALA and RALBP1 regulate mitochondrial fission at mitosis. Nature cell biology 13, 1108&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167028</ArticleId><ArticleId IdType="pubmed">21822277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BT, McCoy AJ, Spate K, Miller SE, Evans PR, Honing S, and Owen DJ (2008). A structural explanation for the binding of endocytic dileucine motifs by the AP2 complex. Nature 456, 976&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340503</ArticleId><ArticleId IdType="pubmed">19140243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopan R, and Ilagan MX (2004). Gamma-secretase: proteasome of the membrane? Nature reviews Molecular cell biology 5, 499&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">15173829</ArticleId></ArticleIdList></Reference><Reference><Citation>Krawitz P, Haffner C, Fluhrer R, Steiner H, Schmid B, and Haass C (2005). Differential localization and identification of a critical aspartate suggest non-redundant proteolytic functions of the presenilin homologues SPPL2b and SPPL3. The Journal of biological chemistry 280, 39515&#x2013;39523.</Citation><ArticleIdList><ArticleId IdType="pubmed">15998642</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger E, Koraimann G, and Vriend G (2002). Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins 47, 393&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11948792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der Werf K, Subramaniam V, et al. (2010). Neurotoxicity of Alzheimer&#x2019;s disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. The EMBO journal 29, 3408&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="pubmed">20818335</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et al. (2014). Tumor vessel normalization by chloroquine independent of autophagy. Cancer cell 26, 190&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">25117709</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattera R, Boehm M, Chaudhuri R, Prabhu Y, and Bonifacino JS (2011). Conservation and diversification of dileucine signal recognition by adaptor protein (AP) complex variants. The Journal of biological chemistry 286, 2022&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023499</ArticleId><ArticleId IdType="pubmed">21097499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr., and Golemis EA (2013). Aurora A kinase (AURKA) in normal and pathological cell division. Cellular and molecular life sciences : CMLS 70, 661&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607959</ArticleId><ArticleId IdType="pubmed">22864622</ArticleId></ArticleIdList></Reference><Reference><Citation>Peden AA, Oorschot V, Hesser BA, Austin CD, Scheller RH, and Klumperman J(2004). Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal membrane proteins. The Journal of cell biology 164, 1065&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172074</ArticleId><ArticleId IdType="pubmed">15051738</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, Albay R 3rd, Rasool S, Wu JW, Hatami A, Arai H, Margol L, Milton S, Poon WW, Corrada MM, et al. (2014). Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiology of disease 71, 53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4179983</ArticleId><ArticleId IdType="pubmed">25092575</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, Chen X, Stokin GB, and Koo EH (1999). Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. The Journal of biological chemistry 274, 18851&#x2013;18856.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383380</ArticleId></ArticleIdList></Reference><Reference><Citation>Peric A, and Annaert W (2015). Early etiology of Alzheimer&#x2019;s disease: tipping the balance toward autophagy or endosomal dysfunction? Acta neuropathologica 129, 363&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331606</ArticleId><ArticleId IdType="pubmed">25556159</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotnikova OV, Pugacheva EN, Dunbrack RL, and Golemis EA (2010). Rapid calcium-dependent activation of Aurora-A kinase. Nature communications 1, 64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963827</ArticleId><ArticleId IdType="pubmed">20842194</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G, and Marks MS (2007). Melanosomes--dark organelles enlighten endosomal membrane transport. Nature reviews Molecular cell biology 8, 786&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786984</ArticleId><ArticleId IdType="pubmed">17878918</ArticleId></ArticleIdList></Reference><Reference><Citation>Saftig P, and Klumperman J (2009). Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nature reviews Molecular cell biology 10, 623&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">19672277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sannerud R, and Annaert W (2009). Trafficking, a key player in regulated intramembrane proteolysis. Seminars in cell &amp; developmental biology 20, 183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056506</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, and Serrano L (2005). The FoldX web server: an online force field. Nucleic acids research 33, W382&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160148</ArticleId><ArticleId IdType="pubmed">15980494</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M, Martens G, Zwijsen A, et al. (2005). Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proceedings of the National Academy of Sciences of the United States of America 102, 1719&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547495</ArticleId><ArticleId IdType="pubmed">15665098</ArticleId></ArticleIdList></Reference><Reference><Citation>Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul S, Schafer MK, Berezovska O, et al. (2009). gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer&#x2019;s disease. Science 324, 639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740474</ArticleId><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagami S, Okochi M, Yanagida K, Ikuta A, Fukumori A, Matsumoto N, Ishizuka-Katsura Y, Nakayama T, Itoh N, Jiang J, et al. (2008). Regulation of Notch signaling by dynamic changes in the precision of S3 cleavage of Notch-1. Molecular and cellular biology 28, 165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2223315</ArticleId><ArticleId IdType="pubmed">17967888</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Nam EE, Edgar M, and Gouras GK (2002). Alzheimer beta-amyloid peptides: normal and abnormal localization. Histology and histopathology 17, 239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813874</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, and Iwatsubo T (2003). The role of presenilin cofactors in the gamma-secretase complex. Nature 422, 438&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660785</ArticleId></ArticleIdList></Reference><Reference><Citation>Takitoh T, Kumamoto K, Wang CC, Sato M, Toba S, Wynshaw-Boris A, and Hirotsune S (2012). Activation of Aurora-A is essential for neuronal migration via modulation of microtubule organization. The Journal of neuroscience : the official journal of the Society for Neuroscience 32, 11050&#x2013;11066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621011</ArticleId><ArticleId IdType="pubmed">22875938</ArticleId></ArticleIdList></Reference><Reference><Citation>Traub LM, and Bonifacino JS (2013). Cargo recognition in clathrin-mediated endocytosis. Cold Spring Harbor perspectives in biology 5, a016790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809577</ArticleId><ArticleId IdType="pubmed">24186068</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss M, Schroder B, and Fluhrer R (2013). Mechanism, specificity, and physiology of signal peptide peptidase (SPP) and SPP-like proteases. Biochimica et biophysica acta 1828, 2828&#x2013;2839.</Citation><ArticleIdList><ArticleId IdType="pubmed">24099004</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, Capell A, Grunberg J, Pesold B, Schindzielorz A, Prior R, Podlisny MB, Fraser P, Hyslop PS, Selkoe DJ, et al. (1996). The Alzheimer&#x2019;s disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol Med 2, 673&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230134</ArticleId><ArticleId IdType="pubmed">8972483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Tang P, Wang P, Boissy RE, and Zheng H (2006). Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer&#x2019;s disease mutation. Proceedings of the National Academy of Sciences of the United States of America 103, 353&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326180</ArticleId><ArticleId IdType="pubmed">16384915</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt B, van Niel G, Raposo G, and Marks MS (2013). PMEL: a pigment cell-specific model for functional amyloid formation. Pigment cell &amp; melanoma research 26, 300&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633693</ArticleId><ArticleId IdType="pubmed">23350640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS (2009). Intramembrane-cleaving proteases. The Journal of biological chemistry 284, 13969&#x2013;13973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2682844</ArticleId><ArticleId IdType="pubmed">19189971</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27271785</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Cerebral Microbleeds With Cognitive Decline and Dementia.</ArticleTitle><Pagination><StartPage>934</StartPage><EndPage>943</EndPage><MedlinePgn>934-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.1017</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Cerebral microbleeds are hypothesized downstream markers of brain damage caused by vascular and amyloid pathologic mechanisms. To date, whether their presence is associated with cognitive deterioration in the general population remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether microbleeds, and more specifically microbleed count and location, are associated with an increased risk for cognitive impairment and dementia in the general population.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Rotterdam Study, a prospective population-based study set in the general community, assessed the presence, number, and location of microbleeds at baseline (August 2005 to December 2011) on magnetic resonance imaging studies of the brain in 4841 participants 45 years or older. Participants underwent neuropsychological testing at 2 points a mean (SD) of 5.9 (0.6) years apart and were followed up for incident dementia throughout the study period until January 1, 2013. The association of microbleeds with cognitive decline and dementia was studied using multiple linear regression, linear mixed-effects modeling, and Cox proportional hazards.</AbstractText><AbstractText Label="EXPOSURES">Cerebral microbleed presence, location, and number.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Cognitive decline measured by a decrease in neuropsychological test battery scores (Mini-Mental State Examination, Letter Digit Substitution Task, Word Fluency Test, Stroop test, 15-word Verbal Learning Test, and Purdue Pegboard Test) and compound scores (eg, G factor, executive function, information processing speed, memory, motor speed) and dementia.</AbstractText><AbstractText Label="RESULTS">In total, 3257 participants (1758 women [54.7%]; mean [SD] age, 59.6 [7.8] years) underwent baseline and follow-up cognitive testing. Microbleed prevalence was 15.3% (median [interquartile range] count, 1 [1-88]). The presence of more than 4 microbleeds was associated with cognitive decline. Lobar (with or without cerebellar) microbleeds were associated with a decline in executive functions (mean difference in z score, -0.31; 95% CI, -0.51 to -0.11; P&#x2009;=&#x2009;.003), information processing (mean difference in z score, -0.44; 95% CI, -0.65 to -0.22; P&#x2009;&lt;&#x2009;.001), and memory function (mean difference in z score, -0.34; 95% CI, -0.64 to -0.03; P&#x2009;=&#x2009;.03), whereas microbleeds in other brain regions were associated with a decline in information processing and motor speed (mean difference in z score, -0.61; 95% CI, -1.05 to -0.17; P&#x2009;=&#x2009;.007). After a mean (SD) follow-up of 4.8 (1.4) years, 72 participants developed dementia, of whom 53 had Alzheimer dementia. The presence of microbleeds was associated with an increased risk for dementia after adjustment for age, sex, and educational level (hazard ratio, 2.02; 95% CI, 1.25-3.24), including Alzheimer dementia (hazard ratio, 2.10; 95% CI, 1.21-3.64).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In the general population, a high microbleed count was associated with an increased risk for cognitive deterioration and dementia. Microbleeds thus mark the presence of diffuse vascular and neurodegenerative brain damage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akoudad</LastName><ForeName>Saloua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands2Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands3Department of Neurology, Erasmus MC, University Me.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands3Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Anand</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bruijn</LastName><ForeName>Ren&#xe9;e F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands3Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Aad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koudstaal</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>M Arfan</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands2Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands3Department of Neurology, Erasmus MC, University Me.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vernooij</LastName><ForeName>Meike W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands2Department of Radiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG047975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Aug 1;73(8):908-10. doi: 10.1001/jamaneurol.2016.1388.</RefSource><PMID Version="1">27271086</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018672" MajorTopicYN="N">Community Health Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="Y">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. None of the authors report disclosures in relationship to this manuscript. Dr. Aad van der Lugt received a research grant from GE healthcare and he serves on the speakers&#x2019; bureau of GE Health Care.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27271785</ArticleId><ArticleId IdType="mid">NIHMS866419</ArticleId><ArticleId IdType="pmc">PMC5966721</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.1017</ArticleId><ArticleId IdType="pii">2526492</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Sep;42(9):2672&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3778669</ArticleId><ArticleId IdType="pubmed">21778438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke. 2012 Sep;43(9):2526&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pubmed">22879100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantoni L, Simoni M. Pathophysiology of cerebral small vessels in vascular cognitive impairment. Int Psychogeriatr. 2003;15( Suppl 1):59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">16191218</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: overview and implications in cognitive impairment. Alzheimers Res Ther. 2014;6(3):33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075149</ArticleId><ArticleId IdType="pubmed">24987468</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke. 2008 Oct;39(10):2712&#x2013;2719.</Citation><ArticleIdList><ArticleId IdType="pubmed">18635849</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernooij MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology. 2008 Apr 1;70(14):1208&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">18378884</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Vlies AE, Goos JD, Barkhof F, Scheltens P, van der Flier WM. Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology. 2012 Aug 21;79(8):763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">22875093</ArticleId></ArticleIdList></Reference><Reference><Citation>Poels MM, Ikram MA, van der Lugt A, et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology. 2012 Jan 31;78(5):326&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262748</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology. 2010 Dec 14;75(24):2221&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013588</ArticleId><ArticleId IdType="pubmed">21172845</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima Y, Mori T, Hashimoto M, et al. Clinical correlating factors and cognitive function in community-dwelling healthy subjects with cerebral microbleeds. J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):105&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">20580259</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakushiji Y, Noguchi T, Hara M, et al. Distributional impact of brain microbleeds on global cognitive function in adults without neurological disorder. Stroke. 2012 Jul;43(7):1800&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pubmed">22581820</ArticleId></ArticleIdList></Reference><Reference><Citation>van Norden AG, van den Berg HA, de Laat KF, Gons RA, van Dijk EJ, de Leeuw FE. Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. Stroke. 2011 Dec;42(12):3382&#x2013;3386.</Citation><ArticleIdList><ArticleId IdType="pubmed">21940975</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es AC, van der Grond J, de Craen AJ, et al. Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology. 2011 Oct 11;77(15):1446&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">21956727</ArticleId></ArticleIdList></Reference><Reference><Citation>Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain. 2004 Oct;127(Pt 10):2265&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pubmed">15282216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregoire SM, Scheffler G, Jager HR, et al. Strictly lobar microbleeds are associated with executive impairment in patients with ischemic stroke or transient ischemic attack. Stroke. 2013 May;44(5):1267&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">23482601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, Darwish Murad S, van Duijn CM, et al. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013 Nov;28(11):889&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">24258680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikram MA, van der Lugt A, Niessen WJ, et al. The Rotterdam Scan Study: design and update up to 2012. Eur J Epidemiol. 2011 Oct;26(10):811&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218266</ArticleId><ArticleId IdType="pubmed">22002080</ArticleId></ArticleIdList></Reference><Reference><Citation>Loehrer E, Ikram MA, Akoudad S, et al. Apolipoprotein E genotype influences spatial distribution of cerebral microbleeds. Neurobiology of aging. 2014 Apr;35(4):899&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119543</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer R, Vrooman HA, van der Lijn F, et al. White matter lesion extension to automatic brain tissue segmentation on MRI. Neuroimage. 2009 May 1;45(4):1151&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">19344687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendam YY, Hofman A, van der Geest JN, van der Lugt A, Ikram MA. Patterns of cognitive function in aging: the Rotterdam Study. Eur J Epidemiol. 2014 Feb;29(2):133&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">24553905</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AP. Diagnostic and Statistical Manual of Mental Disorders. 3. Washington, DC: American Psychiatric Association; 1987. rev ed.</Citation></Reference><Reference><Citation>Liem MK, Lesnik Oberstein SA, Haan J, et al. MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. Neurology. 2009 Jan 13;72(2):143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">19139365</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SW, Hwa Lee B, Kim EJ, et al. Clinical significance of microbleeds in subcortical vascular dementia. Stroke. 2007 Jun;38(6):1949&#x2013;1951.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510457</ArticleId></ArticleIdList></Reference><Reference><Citation>Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke. 2009 Nov;40(11):3455&#x2013;3460.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762705</ArticleId></ArticleIdList></Reference><Reference><Citation>Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology. 2010 Jun 15;74(24):1954&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">20548041</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 2008 Jun;65(6):790&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">18541799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanyu H, Tanaka Y, Shimizu S, Takasaki M, Abe K. Cerebral microbleeds in Alzheimer&#x2019;s disease. J Neurol. 2003 Dec;250(12):1496&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pubmed">14673587</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006 May 9;66(9):1356&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682667</ArticleId></ArticleIdList></Reference><Reference><Citation>Werring DJ, Gregoire SM, Cipolotti L. Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci. 2010 Dec 15;299(1&#x2013;2):131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">20850134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka A, Ueno Y, Nakayama Y, Takano K, Takebayashi S. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke. 1999 Aug;30(8):1637&#x2013;1642.</Citation><ArticleIdList><ArticleId IdType="pubmed">10436114</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Gurol ME, Eng JA, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology. 2004 Nov 9;63(9):1606&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15534243</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM. Cerebral amyloid angiopathy and vessel dysfunction. Cerebrovasc Dis. 2002;13( Suppl 2):42&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">11901242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwa VI, Franke CL, Verbeeten B, Jr, Stam J. Silent intracerebral microhemorrhages in patients with ischemic stroke. Amsterdam Vascular Medicine Group. Ann Neurol. 1998 Sep;44(3):372&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749604</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner RW, Sidler C, Mosso M, Georgiadis D. Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke. 2003 Mar;34(3):653&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">12624287</ArticleId></ArticleIdList></Reference><Reference><Citation>Janaway BM, Simpson JE, Hoggard N, et al. Brain haemosiderin in older people: pathological evidence for an ischaemic origin of magnetic resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol. 2014 Apr;40(3):258&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282337</ArticleId><ArticleId IdType="pubmed">23678850</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesker DJ, Poels MM, Ikram MA, et al. Lobar distribution of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol. 2011 May;68(5):656&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer&#x2019;s disease: innocent observation or key player? Brain. 2011 Feb;134(Pt 2):335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257651</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DA. The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer&#x2019;s disease. Alzheimers Dement. 2014 May;10(3):372&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">24589433</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchesi VT. Alzheimer&#x2019;s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 2011 Jan;25(1):5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21205781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27270108</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Identification of TMEM230 mutations in familial Parkinson's disease.</ArticleTitle><Pagination><StartPage>733</StartPage><EndPage>739</EndPage><MedlinePgn>733-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.3589</ELocationID><Abstract><AbstractText>Parkinson's disease is the second most common neurodegenerative disorder without effective treatment. It is generally sporadic with unknown etiology. However, genetic studies of rare familial forms have led to the identification of mutations in several genes, which are linked to typical Parkinson's disease or parkinsonian disorders. The pathogenesis of Parkinson's disease remains largely elusive. Here we report a locus for autosomal dominant, clinically typical and Lewy body-confirmed Parkinson's disease on the short arm of chromosome 20 (20pter-p12) and identify TMEM230 as the disease-causing gene. We show that TMEM230 encodes a transmembrane protein of secretory/recycling vesicles, including synaptic vesicles in neurons. Disease-linked TMEM230 mutants impair synaptic vesicle trafficking. Our data provide genetic evidence that a mutant transmembrane protein of synaptic vesicles in neurons is etiologically linked to Parkinson's disease, with implications for understanding the pathogenic mechanism of Parkinson's disease and for developing rational therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Han-Xiang</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmeti</LastName><ForeName>Kreshnik B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Nimrod</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Departments of Pediatrics, Lurie Children's Hospital of Chicago Research Center, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Cao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuytemans</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Myung Jong</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Experimental Medicine, Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Beisha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Laboratory of Medical Genetics of China, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ziquang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yanming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Piu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xiao-Ping</ForeName><Initials>XP</Initials><AffiliationInfo><Affiliation>Department of Neurology, People's Hospital of Hunan Province, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhenhua</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fecto</LastName><ForeName>Faisal</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddique</LastName><ForeName>Nailah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krainc</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melen</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vance</LastName><ForeName>Jeffery M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yong-Chao</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Departments of Pediatrics, Lurie Children's Hospital of Chicago Research Center, Northwestern University, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Ali H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of Saskatchewan and Saskatoon Health Region, Saskatoon, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddique</LastName><ForeName>Teepu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG043970</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094564</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078287</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047073</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA060553</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS037167</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG050767</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS074366</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095972</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS071674</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000622360">TMEM230 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2016 Oct;31(10):1480. doi: 10.1002/mds.26735.</RefSource><PMID Version="1">27477200</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Parkinsonism Relat Disord. 2017 Feb;35:100-101. doi: 10.1016/j.parkreldis.2016.12.015.</RefSource><PMID Version="1">28017548</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Genet. 2019 Mar;51(3):367-368. doi: 10.1038/s41588-019-0354-6.</RefSource><PMID Version="1">30804554</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Genet. 2019 Mar;51(3):366. doi: 10.1038/s41588-019-0353-7.</RefSource><PMID Version="1">30804555</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosci Bull. 2022 Jun;38(6):652-656. doi: 10.1007/s12264-022-00862-5.</RefSource><PMID Version="1">35536503</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Financial Interests</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27270108</ArticleId><ArticleId IdType="mid">NIHMS787788</ArticleId><ArticleId IdType="pmc">PMC6047531</ArticleId><ArticleId IdType="doi">10.1038/ng.3589</ArticleId><ArticleId IdType="pii">ng.3589</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Langston JW, Schule B, Rees L, Nichols RJ, Barlow C. Multisystem Lewy body disease and the other parkinsonian disorders. Nat Genet. 2015;47:1378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">26620112</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C, Westenberger A. Genetics of Parkinson&#x2019;s disease. Cold Spring Harb Perspect Med. 2012;2:a008888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253033</ArticleId><ArticleId IdType="pubmed">22315721</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson&#x2019;s disease. Neuron. 2010;66:646&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917798</ArticleId><ArticleId IdType="pubmed">20547124</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy E, et al. The ubiquitin pathway in Parkinson&#x2019;s disease. Nature. 1998;395:451&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774100</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson&#x2019;s disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lautier C, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008;82:822&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427211</ArticleId><ArticleId IdType="pubmed">18358451</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss KM, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson&#x2019;s disease. Hum Mol Genet. 2005;14:2099&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15961413</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89:162&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135796</ArticleId><ArticleId IdType="pubmed">21763482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89:168&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135812</ArticleId><ArticleId IdType="pubmed">21763483</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169825</ArticleId><ArticleId IdType="pubmed">21907011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, et al. Hereditary early-onset Parkinson&#x2019;s disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446870</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol. 2009;65:19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016626</ArticleId><ArticleId IdType="pubmed">18570303</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaee S, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet. 2008;82:1375&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427312</ArticleId><ArticleId IdType="pubmed">18513678</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs CE, et al. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. Hum Mutat. 2013;34:1200&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790461</ArticleId><ArticleId IdType="pubmed">23804563</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri M, et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat. 2013;34:1208&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23804577</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38:1184&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Edvardson S, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One. 2012;7:e36458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341348</ArticleId><ArticleId IdType="pubmed">22563501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mata IF, et al. The RAB39B p.G192R mutation causes X-linked dominant Parkinson&#x2019;s disease. Mol Neurodegener. 2015;10:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4581468</ArticleId><ArticleId IdType="pubmed">26399558</ArticleId></ArticleIdList></Reference><Reference><Citation>Key mendelian variants. Nat Genet. 2015;47:1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">26620107</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson&#x2019;s disease. Annu Rev Genomics Hum Genet. 2011;12:301&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120236</ArticleId><ArticleId IdType="pubmed">21639795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc. 2009;4:363&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">19247286</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5:725&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2849174</ArticleId><ArticleId IdType="pubmed">20360767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallberg M, et al. Template-based protein structure modeling using the RaptorX web server. Nat Protoc. 2012;7:1511&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730388</ArticleId><ArticleId IdType="pubmed">22814390</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhof TC. The synaptic vesicle cycle. Annu Rev Neurosci. 2004;27:509&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15217342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci C, et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell. 1992;70:715&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">1516130</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009;19:147&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930405</ArticleId><ArticleId IdType="pubmed">19269181</ArticleId></ArticleIdList></Reference><Reference><Citation>Song AH, et al. A selective filter for cytoplasmic transport at the axon initial segment. Cell. 2009;136:1148&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19268344</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007;68:916&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63:743&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850281</ArticleId><ArticleId IdType="pubmed">18571778</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302:841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilarino-Guell C, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014;23:1794&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3999380</ArticleId><ArticleId IdType="pubmed">24218364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wszolek ZK, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology. 2004;62:1619&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15136696</ArticleId></ArticleIdList></Reference><Reference><Citation>Spanaki C, Latsoudis H, Plaitakis A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology. 2006;67:1518&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, et al. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord. 2008;14:465&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18342564</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger M, et al. Phosphoproteomics reveals that Parkinson&#x2019;s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769169</ArticleId><ArticleId IdType="pubmed">26824392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardiff DF, et al. Yeast reveal a &#x201c;druggable&#x201d; Rsp5/Nedd4 network that ameliorates alpha-synuclein toxicity in neurons. Science. 2013;342:979&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3993916</ArticleId><ArticleId IdType="pubmed">24158909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science. 2013;342:983&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022187</ArticleId><ArticleId IdType="pubmed">24158904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27280685</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>342</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.</ArticleTitle><Pagination><StartPage>342ra78</StartPage><MedlinePgn>342ra78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf3634</ELocationID><Abstract><AbstractText>&#x3b1;-Synuclein accumulation and mitochondrial dysfunction have both been strongly implicated in the pathogenesis of Parkinson's disease (PD), and the two appear to be related. Mitochondrial dysfunction leads to accumulation and oligomerization of &#x3b1;-synuclein, and increased levels of &#x3b1;-synuclein cause mitochondrial impairment, but the basis for this bidirectional interaction remains obscure. We now report that certain posttranslationally modified species of &#x3b1;-synuclein bind with high affinity to the TOM20 (translocase of the outer membrane 20) presequence receptor of the mitochondrial protein import machinery. This binding prevented the interaction of TOM20 with its co-receptor, TOM22, and impaired mitochondrial protein import. Consequently, there were deficient mitochondrial respiration, enhanced production of reactive oxygen species, and loss of mitochondrial membrane potential. Examination of postmortem brain tissue from PD patients revealed an aberrant &#x3b1;-synuclein-TOM20 interaction in nigrostriatal dopaminergic neurons that was associated with loss of imported mitochondrial proteins, thereby confirming this pathogenic process in the human disease. Modest knockdown of endogenous &#x3b1;-synuclein was sufficient to maintain mitochondrial protein import in an in vivo model of PD. Furthermore, in in vitro systems, overexpression of TOM20 or a mitochondrial targeting signal peptide had beneficial effects and preserved mitochondrial protein import. This study characterizes a pathogenic mechanism in PD, identifies toxic species of wild-type &#x3b1;-synuclein, and reveals potential new therapeutic strategies for neuroprotection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Maio</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Ri.MED Foundation, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Eric K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Caitlyn W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zharikov</LastName><ForeName>Alevtina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borah</LastName><ForeName>Anupom</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Life Science and Bioinformatics, Assam University, Silchar 788011, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCoy</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Charleen T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burton</LastName><ForeName>Edward A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hastings</LastName><ForeName>Teresa G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenamyre</LastName><ForeName>J Timothy</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA 15213, USA. Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA. Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA. jgreena@pitt.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG024827</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS065789</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095387</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES022644</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 NS065789</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020718</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS086749</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026389</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020327</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS059806</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX000548</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090622">Mitochondrial Precursor Protein Import Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489998">Tomm20 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2017 Jan;32(1):107. doi: 10.1002/mds.26889.</RefSource><PMID Version="1">28004858</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090622" MajorTopicYN="N">Mitochondrial Precursor Protein Import Complex Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011922" MajorTopicYN="N">Rats, Mutant Strains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27280685</ArticleId><ArticleId IdType="mid">NIHMS813831</ArticleId><ArticleId IdType="pmc">PMC5016095</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf3634</ArticleId><ArticleId IdType="pii">8/342/342ra78</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kalia LV, Lang AE. Parkinson&#x2019;s disease. Lancet. 2015 Apr 17;</Citation><ArticleIdList><ArticleId IdType="pubmed">25904081</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaltieri M, et al. Mitochondrial Dysfunction and alpha-Synuclein Synaptic Pathology in Parkinson&#x2019;s Disease: Who&#x2019;s on First? Parkinsons Dis. 2015;2015:108029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396726</ArticleId><ArticleId IdType="pubmed">25918668</ArticleId></ArticleIdList></Reference><Reference><Citation>Betarbet R, et al. Chronic systemic pesticide exposure reproduces features of Parkinson&#x2019;s disease. Nat Neurosci. 2000 Dec;3:1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100151</ArticleId></ArticleIdList></Reference><Reference><Citation>Betarbet R, et al. Intersecting pathways to neurodegeneration in Parkinson&#x2019;s disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis. 2006 May;22:404.</Citation><ArticleIdList><ArticleId IdType="pubmed">16439141</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon JR, et al. A highly reproducible rotenone model of Parkinson&#x2019;s disease. Neurobiol Dis. 2009 May;34:279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757935</ArticleId><ArticleId IdType="pubmed">19385059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu LJ, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 2000 Aug;157:401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850140</ArticleId><ArticleId IdType="pubmed">10934145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet. 2012 Dec;13:878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959762</ArticleId><ArticleId IdType="pubmed">23154810</ArticleId></ArticleIdList></Reference><Reference><Citation>Elstner M, et al. MitoP2: an integrative tool for the analysis of the mitochondrial proteome. Molecular biotechnology. 2008 Nov;40:306.</Citation><ArticleIdList><ArticleId IdType="pubmed">18780189</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehler CM. Protein translocation pathways of the mitochondrion. FEBS Lett. 2000 Jun 30;476:27.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878244</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, Schendzielorz A, Rehling P. Unlocking the presequence import pathway. Trends in cell biology. 2015 May;25:265.</Citation><ArticleIdList><ArticleId IdType="pubmed">25542066</ArticleId></ArticleIdList></Reference><Reference><Citation>Model K, Meisinger C, Kuhlbrandt W. Cryo-electron microscopy structure of a yeast mitochondrial preprotein translocase. J Mol Biol. 2008 Nov 28;383:1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">18706915</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998 Apr 17;273:9443.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson&#x2019;s disease. Trends Pharmacol Sci. 2010 Jan 21;31:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846992</ArticleId><ArticleId IdType="pubmed">20096940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner CM, et al. Rotenone, Paraquat and Parkinson&#x2019;s Disease. Environ Health Perspect. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114824</ArticleId><ArticleId IdType="pubmed">21269927</ArticleId></ArticleIdList></Reference><Reference><Citation>Koos B, et al. Analysis of protein interactions in situ by proximity ligation assays. Curr Top Microbiol Immunol. 2014;377:111.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson&#x2019;s disease? Neurobiol Dis. 2007 Jan;25:134.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zharikov A, et al. shRNA targeting &#x3b1;-synuclein prevents neurodegeneration in a Parkinson&#x2019;s disease model. J Clin Invest. 2015;125</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4563670</ArticleId><ArticleId IdType="pubmed">26075822</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimant H, et al. Direct detection of alpha synuclein oligomers in vivo. Acta neuropathologica communications. 2013;1:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776213</ArticleId><ArticleId IdType="pubmed">24252244</ArticleId></ArticleIdList></Reference><Reference><Citation>Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012 Mar;45:939.</Citation><ArticleIdList><ArticleId IdType="pubmed">22182688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn KJ, Paik SR, Chung KC, Kim J. Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J Neurochem. 2006 Apr;97:265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16524375</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal CH, Chandra SS. Monomeric synucleins generate membrane curvature. J Biol Chem. 2013 Jan 18;288:1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548493</ArticleId><ArticleId IdType="pubmed">23184946</ArticleId></ArticleIdList></Reference><Reference><Citation>Theillet FX, et al. Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature. 2016 Jan 25;</Citation><ArticleIdList><ArticleId IdType="pubmed">26808899</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Vicente M, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 2008 Feb;118:777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2157565</ArticleId><ArticleId IdType="pubmed">18172548</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Rochet JC, Bieganski RM, Lansbury PT., Jr Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001 Nov 9;294:1346.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701929</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe Y, et al. Structural basis of presequence recognition by the mitochondrial protein import receptor Tom20. Cell. 2000 Mar 3;100:551.</Citation><ArticleIdList><ArticleId IdType="pubmed">10721992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Langen R, Hummel PA, Gray HB, Winkler JR. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson&#x2019;s disease. Proc Natl Acad Sci U S A. 2004 Nov 23;101:16466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534538</ArticleId><ArticleId IdType="pubmed">15536128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C, Schendzielorz A, Rehling P. Unlocking the presequence import pathway. Trends in cell biology. 2014 Dec 23;</Citation><ArticleIdList><ArticleId IdType="pubmed">25542066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan M, Jensen PH, Marsh D. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Biochemistry. 2006 Mar 14;45:3386.</Citation><ArticleIdList><ArticleId IdType="pubmed">16519533</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieteren CE, et al. Subunit-specific incorporation efficiency and kinetics in mitochondrial complex I homeostasis. J Biol Chem. 2012 Dec 7;287:41851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516733</ArticleId><ArticleId IdType="pubmed">23038253</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhane S, Kanzaki H, Arumugaswami V, Murali R, Ramanujan VK. Mitochondrial NDUFS3 regulates the ROS-mediated onset of metabolic switch in transformed cells. Biology open. 2013 Mar 15;2:295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603411</ArticleId><ArticleId IdType="pubmed">23519235</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz MP, et al. Single-Cell Redox Imaging Demonstrates a Distinctive Response of Dopaminergic Neurons to Oxidative Insults. Antioxid Redox Signal. 2011 Jun 6;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135271</ArticleId><ArticleId IdType="pubmed">21395478</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008 Apr 4;283:9089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2431021</ArticleId><ArticleId IdType="pubmed">18245082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A, et al. TOM40 mediates mitochondrial dysfunction induced by alpha-synuclein accumulation in Parkinson&#x2019;s disease. PLoS One. 2013;8:e62277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633917</ArticleId><ArticleId IdType="pubmed">23626796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolin G, et al. The TOMM machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance. Autophagy. 2013 Nov 1;9:1801.</Citation><ArticleIdList><ArticleId IdType="pubmed">24149440</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleologou KE, et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem. 2008 Jun 13;283:16895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2423264</ArticleId><ArticleId IdType="pubmed">18343814</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, et al. Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun. 2015;6:7314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490410</ArticleId><ArticleId IdType="pubmed">26076669</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunewald A, et al. Quantitative quadruple-label immunofluorescence of mitochondrial and cytoplasmic proteins in single neurons from human midbrain tissue. J Neurosci Methods. 2014 Jul 30;232:143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076514</ArticleId><ArticleId IdType="pubmed">24880043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastroberardino PG, et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson&#x2019;s disease. Neurobiol Dis. 2009 Jun;34:417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784936</ArticleId><ArticleId IdType="pubmed">19250966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders LH, et al. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson&#x2019;s disease. Neurobiology of disease. 2014 Oct;70:214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4144978</ArticleId><ArticleId IdType="pubmed">24981012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosharov EV, et al. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci. 2006 Sep 6;26:9304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674515</ArticleId><ArticleId IdType="pubmed">16957086</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano M, et al. Visualization of mitochondrial protein import in cultured mammalian cells with green fluorescent protein and effects of overexpression of the human import receptor Tom20. J Biol Chem. 1997 Mar 28;272:8459.</Citation><ArticleIdList><ArticleId IdType="pubmed">9079673</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lansbury PT., Jr Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007 Mar 9;366:1510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868670</ArticleId><ArticleId IdType="pubmed">17222866</ArticleId></ArticleIdList></Reference><Reference><Citation>Schleiff E, Shore GC, Goping IS. Interactions of the human mitochondrial protein import receptor, hTom20, with precursor proteins in vitro reveal pleiotropic specificities and different receptor domain requirements. J Biol Chem. 1997 Jul 11;272:17784.</Citation><ArticleIdList><ArticleId IdType="pubmed">9211931</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CT, et al. Ubiquitin immunochemistry as a diagnostic aid for community pathologists evaluating patients who have dementia. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2000 Apr;13:420.</Citation><ArticleIdList><ArticleId IdType="pubmed">10786809</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009 Jun;117:635.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330340</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maio R, Mastroberardino PG, Hu X, Montero LM, Greenamyre JT. Thiol oxidation and altered NR2B/NMDA receptor functions in in vitro and in vivo pilocarpine models: implications for epileptogenesis. Neurobiol Dis. 2013 Jan;49:87.</Citation><ArticleIdList><ArticleId IdType="pubmed">22824136</ArticleId></ArticleIdList></Reference><Reference><Citation>Horowitz MP, et al. Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid Redox Signal. 2011 Aug 15;15:855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135271</ArticleId><ArticleId IdType="pubmed">21395478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27295555</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells.</ArticleTitle><Pagination><StartPage>765</StartPage><EndPage>776</EndPage><MedlinePgn>765-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncb3372</ELocationID><Abstract><AbstractText>To safeguard proteomic integrity, cells rely on the proteasome to degrade aberrant polypeptides, but it is unclear how cells remove defective proteins that have escaped degradation owing to proteasome insufficiency or dysfunction. Here we report a pathway termed misfolding-associated protein secretion, which uses the endoplasmic reticulum (ER)-associated deubiquitylase USP19 to preferentially export aberrant cytosolic proteins. Intriguingly, the catalytic domain of USP19 possesses an unprecedented chaperone activity, allowing recruitment of misfolded proteins to the ER surface for deubiquitylation. Deubiquitylated cargos are encapsulated into ER-associated late endosomes and secreted to the cell exterior. USP19-deficient cells cannot efficiently secrete unwanted proteins, and grow more slowly than wild-type cells following exposure to a proteasome inhibitor. Together, our findings delineate a protein quality control (PQC) pathway that, unlike degradation-based PQC mechanisms, promotes protein homeostasis by exporting misfolded proteins through an unconventional protein secretion process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Gu</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahama</LastName><ForeName>Shokichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Retinal Cell &amp;Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guofeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Engineering and Physical Science Shared Resource, NIBIB, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomarev</LastName><ForeName>Stanislav I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Laboratory of Retinal Cell &amp;Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Yihong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA DK075044</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="C559917">USP19 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060746" MajorTopicYN="N">Endoplasmic Reticulum-Associated Degradation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>COMPETING FINANCIAL INTERESTS. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27295555</ArticleId><ArticleId IdType="mid">NIHMS1828659</ArticleId><ArticleId IdType="pmc">PMC10701763</ArticleId><ArticleId IdType="doi">10.1038/ncb3372</ArticleId><ArticleId IdType="pii">ncb3372</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolff S, Weissman JS &amp; Dillin A. Differential scales of protein quality control. Cell 157, 52&#x2013;64 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24679526</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukau B, Weissman J. &amp; Horwich A. Molecular chaperones and protein quality control. Cell 125, 443&#x2013;451 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16678092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag EM, Vonk WI &amp; Frydman J. Sorting out the trash: the spatial nature of eukaryotic protein quality control. Curr. Opin. Cell Biol. 26, 139&#x2013;146 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4204729</ArticleId><ArticleId IdType="pubmed">24463332</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchberger A, Bukau B. &amp; Sommer T. Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. Mol. Cell 40, 238&#x2013;252 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20965419</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Retzlaff M, Roos T. &amp; Frydman J. Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 3, a004374 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140689</ArticleId><ArticleId IdType="pubmed">21746797</ArticleId></ArticleIdList></Reference><Reference><Citation>Clague MJ et al. Deubiquitylases from genes to organism. Physiol. Rev. 93, 1289&#x2013;1315 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23899565</ArticleId></ArticleIdList></Reference><Reference><Citation>Eletr ZM &amp; Wilkinson KD Regulation of proteolysis by human deubiquitinating enzymes. Biochim. Biophys. Acta 1843, 114&#x2013;128 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833951</ArticleId><ArticleId IdType="pubmed">23845989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassink GC et al. The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Rep. 10, 755&#x2013;761 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727442</ArticleId><ArticleId IdType="pubmed">19465887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JG, Kim W, Gygi S. &amp; Ye Y. Characterization of the deubiquitinating activity of USP19 and its role in endoplasmic reticulum-associated degradation. J. Biol. Chem. 289, 3510&#x2013;3517 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916552</ArticleId><ArticleId IdType="pubmed">24356957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiles B. et al. USP19 deubiquitinating enzyme inhibits muscle cell differentiation by suppressing unfolded-protein response signaling. Mol. Biol. Cell 26, 913&#x2013;923 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342027</ArticleId><ArticleId IdType="pubmed">25568336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Y, Hahn AA, Hu S. &amp; Yang X. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J. Biol. Chem. 286, 35380&#x2013;35387 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195621</ArticleId><ArticleId IdType="pubmed">21849505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y. et al. USP19 deubiquitinating enzyme supports cell proliferation by stabilizing KPC1, a ubiquitin ligase for p27Kip1. Mol. Cell Biol. 29, 547&#x2013;558 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2612522</ArticleId><ArticleId IdType="pubmed">19015242</ArticleId></ArticleIdList></Reference><Reference><Citation>Combaret L. et al. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am. J. Physiol. Endocrinol. Metab. 288, E693&#x2013;E700 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15562254</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TP, Vendruscolo M. &amp; Dobson CM The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryno LM, Wiseman RL &amp; Kelly JW Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Curr. Opin. Chem. Biol. 17, 346&#x2013;352 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5859939</ArticleId><ArticleId IdType="pubmed">23647985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C. &amp; Mollereau B. Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat. Rev. Neurosci. 15, 233&#x2013;249 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24619348</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Melki R. &amp; Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301&#x2013;307 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Baixauli F, Lopez-Otin C. &amp; Mittelbrunn M. Exosomes and autophagy: coordinated mechanisms for the maintenance of cellular fitness. Front. Immunol. 5, 403 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4138502</ArticleId><ArticleId IdType="pubmed">25191326</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed NV, Herrou T, Plouffe V, Piperno N. &amp; Leclerc N. Spreading of tau pathology in Alzheimer&#x2019;s disease by cell-to-cell transmission. Eur. J. Neurosci. 37, 1939&#x2013;1948 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23773063</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S. et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842&#x2013;3849 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel W. &amp; Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat. Rev. Mol. Cell Biol. 10, 148&#x2013;155 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19122676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Cicero A, Stahl PD &amp; Raposo G. Extracellular vesicles shuffling intercellular messages: for good or for bad. Curr. Opin. Cell Biol. 35, 69&#x2013;77 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26001269</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabouille C, Malhotra V. &amp; Nickel W. Diversity in unconventional protein secretion. J. Cell Sci. 125, 5251&#x2013;5255 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23377655</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M. &amp; Schekman R. Cell biology. Unconventional secretion, unconventional solutions. Science 340, 559&#x2013;561 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23641104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel W. Pathways of unconventional protein secretion. Curr. Opin. Biotechnol. 21, 621&#x2013;626 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20637599</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra V. Unconventional protein secretion: an evolving mechanism. EMBO J. 32, 1660&#x2013;1664 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680731</ArticleId><ArticleId IdType="pubmed">23665917</ArticleId></ArticleIdList></Reference><Reference><Citation>Steringer JP, Muller HM &amp; Nickel W. Unconventional secretion of fibroblast growth factor 2&#x2014;A novel type of protein translocation across membranes? J. Mol. Biol. 427, 1202&#x2013;1210 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25051502</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara T, Oda K, Yokota S, Takatsuki A. &amp; Ikehara Y. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J. Biol. Chem. 263, 18545&#x2013;18552 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3192548</ArticleId></ArticleIdList></Reference><Reference><Citation>Baneyx F. &amp; Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat. Biotechnol. 22, 1399&#x2013;1408 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15529165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JG &amp; Ye Y. Bag6/Bat3/Scythe: a novel chaperone activity with diverse regulatory functions in protein biogenesis and degradation. BioEssays 35, 377&#x2013;385 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9379985</ArticleId><ArticleId IdType="pubmed">23417671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsunemi T, Hamada K. &amp; Krainc D. ATP13A2/PARK9 regulates secretion of exosomes and &#x3b1;-synuclein. J. Neurosci. 34, 15281&#x2013;15287 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4228131</ArticleId><ArticleId IdType="pubmed">25392495</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa T. et al. The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of &#x3b1;-synuclein. PLoS ONE 6, e29460 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245276</ArticleId><ArticleId IdType="pubmed">22216284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380&#x2013;1389 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3856256</ArticleId><ArticleId IdType="pubmed">23992846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano Y. et al. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J. Biol. Chem. 278, 51504&#x2013;51514 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14506261</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman JR, Dibenedetto JR, West M, Rowland AA &amp; Voeltz GK Endoplasmic reticulum-endosome contact increases as endosomes traffic and mature. Mol. Biol. Cell 24, 1030&#x2013;1040 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3608491</ArticleId><ArticleId IdType="pubmed">23389631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Kenny SJ, Ge L, Xu K. &amp; Schekman R. Translocation of interleukin-1&#x3b2; into a vesicle intermediate in autophagy-mediated secretion. eLife 4, e11205 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4728131</ArticleId><ArticleId IdType="pubmed">26523392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinseth MA et al. The Golgi-associated protein GRASP is required for unconventional protein secretion during development. Cell 130, 524&#x2013;534 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17655921</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran JM, Anjard C, Stefan C, Loomis WF &amp; Malhotra V. Unconventional secretion of Acb1 is mediated by autophagosomes. J. Cell Biol. 188, 527&#x2013;536 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828925</ArticleId><ArticleId IdType="pubmed">20156967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C. et al. &#x3b1;-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715&#x2013;725 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026723</ArticleId><ArticleId IdType="pubmed">21245577</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SH et al. Mesenchymal stem cells inhibit transmission of &#x3b1;-synuclein by modulating clathrin-mediated endocytosis in a Parkinsonian model. Cell Rep. 14, 835&#x2013;849 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26776513</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of &#x3b1;-synuclein. Proc. Natl Acad. Sci. USA 106, 13010&#x2013;13015 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernace VA, Arnaud L, Schmidt-Glenewinkel T. &amp; Figueiredo-Pereira ME Aging perturbs 26S proteasome assembly in Drosophila melanogaster. FASEB J. 21, 2672&#x2013;2682 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3435146</ArticleId><ArticleId IdType="pubmed">17413001</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson V, Hanzen S, Liu B, Molin M. &amp; Nystrom T. Enhancing protein disaggregation restores proteasome activity in aged cells. Aging 5, 802&#x2013;812 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868723</ArticleId><ArticleId IdType="pubmed">24243762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bence NF, Sampat RM &amp; Kopito RR Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552&#x2013;1555 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11375494</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai B, Ye Y. &amp; Rapoport TA Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat. Rev. Mol. Cell Biol. 3, 246&#x2013;255 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11994744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q. et al. A ubiquitin ligase-associated chaperone holdase maintains polypeptides in soluble states for proteasome degradation. Mol. Cell 42, 758&#x2013;770 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138499</ArticleId><ArticleId IdType="pubmed">21636303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JG, Baek K, Soetandyo N. &amp; Ye Y. Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells. Nat. Commun. 4, 1568 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615374</ArticleId><ArticleId IdType="pubmed">23463011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27322420</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neuronal activity enhances tau propagation and tau pathology in vivo.</ArticleTitle><Pagination><StartPage>1085</StartPage><EndPage>1092</EndPage><MedlinePgn>1085-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4328</ELocationID><Abstract><AbstractText>Tau protein can transfer between neurons transneuronally and trans-synaptically, which is thought to explain the progressive spread of tauopathy observed in the brain of patients with Alzheimer's disease. Here we show that physiological tau released from donor cells can transfer to recipient cells via the medium, suggesting that at least one mechanism by which tau can transfer is via the extracellular space. Neuronal activity has been shown to regulate tau secretion, but its effect on tau pathology is unknown. Using optogenetic and chemogenetic approaches, we found that increased neuronal activity stimulates the release of tau in vitro and enhances tau pathology in vivo. These data have implications for disease pathogenesis and therapeutic strategies for Alzheimer's disease and other tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jessica W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussaini</LastName><ForeName>S Abid</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastille</LastName><ForeName>Isle M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Gustavo A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mrejeru</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rilett</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Hongjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boonen</LastName><ForeName>Rick A C M</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahmani</LastName><ForeName>Eden</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emrani</LastName><ForeName>Sheina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Y Helen</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's and Neurodegenerative Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clelland</LastName><ForeName>Catherine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, Institute of Neurology, University College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Taub Institute, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Neuroscience, New York State Psychiatric Institute, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM008151</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050425</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081555</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA019801</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Financial Interests. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27322420</ArticleId><ArticleId IdType="mid">NIHMS788500</ArticleId><ArticleId IdType="pmc">PMC4961585</ArticleId><ArticleId IdType="doi">10.1038/nn.4328</ArticleId><ArticleId IdType="pii">nn.4328</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302. doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, et al. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One. 2012;7:e45881. doi: 10.1371/journal.pone.0045881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045881</ArticleId><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110:9535&#x2013;9540. doi: 10.1073/pnas.1301175110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci. 2013;33:1024&#x2013;1037. doi: 10.1523/JNEUROSCI.2642-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288. doi: 10.1016/j.neuron.2014.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem. 2013;288:1856&#x2013;1870. doi: 10.1074/jbc.M112.394528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394528</ArticleId><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillierez R, et al. Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain. Mol Ther. 2013;21:1358&#x2013;1368. doi: 10.1038/mt.2013.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.66</ArticleId><ArticleId IdType="pmc">PMC3702115</ArticleId><ArticleId IdType="pubmed">23609018</ArticleId></ArticleIdList></Reference><Reference><Citation>Osinde M, Clavaguera F, May-Nass R, Tolnay M, Dev KK. Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation. Neuropathol Appl Neurobiol. 2008;34:523&#x2013;531. doi:NAN936[pii] 10.1111/j.1365-2990.2008.00936.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">18282162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012 doi:M112.346072 [pii] 10.1074/jbc.M112.346072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gousset K, et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol. 2009;11:328&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">19198598</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S, et al. Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease. J Biol Chem. 2012;287:3842&#x2013;3849. doi:M111.277061 [pii] 10.1074/jbc.M111.277061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584&#x2013;1593. doi: 10.1038/nn.4132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4132</ArticleId><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, et al. Tau Overexpression Results in Its Secretion via Membrane Vesicles. Neurodegener Dis. 2012 doi:000334915 [pii] 10.1159/000334915.</Citation><ArticleIdList><ArticleId IdType="pubmed">22269430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One. 2014;9:e100760. doi: 10.1371/journal.pone.0100760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100760</ArticleId><ArticleId IdType="pmc">PMC4074092</ArticleId><ArticleId IdType="pubmed">24971751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110&#x2013;13117. doi: 10.1523/JNEUROSCI.2569-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2569-11.2011</ArticleId><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, et al. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis. 2011;24(Suppl 2):127&#x2013;141. doi:W3V1180601X3532U [pii] 10.3233/JAD-2011-110161.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422517</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer&#x2019;s disease brain. Nat Commun. 2015;6:8490. doi: 10.1038/ncomms9490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9490</ArticleId><ArticleId IdType="pmc">PMC4608380</ArticleId><ArticleId IdType="pubmed">26458742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz A, et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12:372&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">9876968</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389&#x2013;394. doi: 10.1038/embor.2013.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014;211:387&#x2013;393. doi: 10.1084/jem.20131685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20131685</ArticleId><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer&#x2019;s disease. Science. 2008;321:1686&#x2013;1689. doi:321/5896/1686 [pii] 10.1126/science.1162844 [doi]</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2012;109:8740&#x2013;8745. doi: 10.1073/pnas.1206171109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206171109</ArticleId><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Siskova Z, et al. Dendritic structural degeneration is functionally linked to cellular hyperexcitability in a mouse model of Alzheimer&#x2019;s disease. Neuron. 2014;84:1023&#x2013;1033. doi: 10.1016/j.neuron.2014.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.024</ArticleId><ArticleId IdType="pubmed">25456500</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, et al. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462. doi: 10.1523/JNEUROSCI.5215-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5215-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall AM, et al. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2015;35:6221&#x2013;6230. doi: 10.1523/JNEUROSCI.2552-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2552-14.2015</ArticleId><ArticleId IdType="pmc">PMC4397611</ArticleId><ArticleId IdType="pubmed">25878292</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi:309/5733/476 [pii] 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker KL, Meyer M, Barde YA. Neurotrophins are required for nerve growth during development. Nat Neurosci. 2001;4:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135642</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, et al. A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods. 2005;2:599&#x2013;605. doi:nmeth777 [pii] 10.1038/nmeth777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer&#x2019;s disease pathology. J Histochem Cytochem. 2000;48:1223&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7:1836&#x2013;1846. doi: 10.1038/nprot.2012.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.116</ArticleId><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci. 2012;15:477&#x2013;486, S471. doi: 10.1038/nn.3041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3041</ArticleId><ArticleId IdType="pmc">PMC3882590</ArticleId><ArticleId IdType="pubmed">22306606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T, et al. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Hum Mol Genet. 2015;24:5260&#x2013;5269. doi: 10.1093/hmg/ddv246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv246</ArticleId><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon KW, Covey DF, Rothman SM. Multiple mechanisms of picrotoxin block of GABA-induced currents in rat hippocampal neurons. J Physiol. 1993;464:423&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1175394</ArticleId><ArticleId IdType="pubmed">8229811</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005;8:1263&#x2013;1268. doi: 10.1038/nn1525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1525</ArticleId><ArticleId IdType="pubmed">16116447</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Roth BL. DREADD: a chemogenetic GPCR signaling platform. Int J Neuropsychopharmacol. 2015;18 doi: 10.1093/ijnp/pyu007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyu007</ArticleId><ArticleId IdType="pmc">PMC4368861</ArticleId><ArticleId IdType="pubmed">25522378</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852. doi:M808759200 [pii] 10.1074/jbc.M808759200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286:15317&#x2013;15331. doi:M110.209296 [pii] 10.1074/jbc.M110.209296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel CH, et al. Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J Biol Chem. 2014;289:956&#x2013;967. doi: 10.1074/jbc.M113.515445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.515445</ArticleId><ArticleId IdType="pmc">PMC3887218</ArticleId><ArticleId IdType="pubmed">24235150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, et al. Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol Neurodegener. 2015;10:55. doi: 10.1186/s13024-015-0052-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0052-5</ArticleId><ArticleId IdType="pmc">PMC4621881</ArticleId><ArticleId IdType="pubmed">26502977</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013;110:E3138&#x2013;3147. doi: 10.1073/pnas.1301440110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301440110</ArticleId><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirbaha H, Holmes BB, Sanders DW, Bieschke J, Diamond MI. Tau Trimers Are the Minimal Propagation Unit Spontaneously Internalized to Seed Intracellular Aggregation. J Biol Chem. 2015;290:14893&#x2013;14903. doi: 10.1074/jbc.M115.652693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.652693</ArticleId><ArticleId IdType="pmc">PMC4463437</ArticleId><ArticleId IdType="pubmed">25887395</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, et al. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem. 2012;287:20522&#x2013;20533. doi: 10.1074/jbc.M111.323279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.323279</ArticleId><ArticleId IdType="pmc">PMC3370237</ArticleId><ArticleId IdType="pubmed">22496370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomben V, et al. Bexarotene reduces network excitability in models of Alzheimer&#x2019;s disease and epilepsy. Neurobiol Aging. 2014;35:2091&#x2013;2095. doi: 10.1016/j.neurobiolaging.2014.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.03.029</ArticleId><ArticleId IdType="pmc">PMC4053509</ArticleId><ArticleId IdType="pubmed">24767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer&#x2019;s disease model. Proc Natl Acad Sci U S A. 2012;109:E2895&#x2013;2903. doi: 10.1073/pnas.1121081109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121081109</ArticleId><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, et al. Rescue of long-range circuit dysfunction in Alzheimer&#x2019;s disease models. Nat Neurosci. 2015;18:1623&#x2013;1630. doi: 10.1038/nn.4137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4137</ArticleId><ArticleId IdType="pubmed">26457554</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom M, et al. Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study. Brain. 2011;134:2969&#x2013;2981. doi: 10.1093/brain/awr209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr209</ArticleId><ArticleId IdType="pmc">PMC3187539</ArticleId><ArticleId IdType="pubmed">21903728</ArticleId></ArticleIdList></Reference><Reference><Citation>Acker CM, Forest SK, Zinkowski R, Davies P, d&#x2019;Abramo C. Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging. 2013;34:338&#x2013;350. doi: 10.1016/j.neurobiolaging.2012.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.05.010</ArticleId><ArticleId IdType="pmc">PMC3474864</ArticleId><ArticleId IdType="pubmed">22727277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27210553</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model.</ArticleTitle><Pagination><StartPage>941</StartPage><EndPage>947</EndPage><MedlinePgn>941-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.04.042</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)30156-8</ELocationID><Abstract><AbstractText>Pathological evidence for selective four-repeat (4R) tau deposition in certain dementias and exon 10-positioned MAPT mutations together suggest a 4R-specific role in causing disease. However, direct assessments of 4R toxicity have not yet been accomplished in&#xa0;vivo. Increasing 4R-tau expression without change to total tau in human tau-expressing mice induced more severe seizures and nesting behavior abnormality, increased tau phosphorylation, and produced a shift toward oligomeric tau. Exon 10 skipping could also be accomplished in&#xa0;vivo, providing support for a 4R-tau targeted approach to target 4R-tau toxicity and, in cases of primary MAPT mutation, eliminate the disease-causing mutation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schoch</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Seung J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norrbom</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Taylor Family Institute for Innovative Psychiatric Research, Department of Psychiatry, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Hana N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University Medical Center, Durham, NC 27710.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>C Frank</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110. Electronic address: millert@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS089225</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG044719</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS074194</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057967" MajorTopicYN="N">Infusions, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009425" MajorTopicYN="Y">Nesting Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Antisense oligonucleotides used for experimental studies were generously provided by Ionis Pharmaceuticals. Washington University in St. Louis has filed patents in conjunction with Ionis Pharmaceuticals regarding use of Tau ASOs in neurodegenerative syndrome. S.J.C., M.N., C.F.B., and F.R. are paid employees of Ionis Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27210553</ArticleId><ArticleId IdType="mid">NIHMS783883</ArticleId><ArticleId IdType="pmc">PMC5040069</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.04.042</ArticleId><ArticleId IdType="pii">S0896-6273(16)30156-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ADAMS SJ, DETURE MA, MCBRIDE M, DICKSON DW, PETRUCELLI L. Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One. 2010;5:e10810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876030</ArticleId><ArticleId IdType="pubmed">20520830</ArticleId></ArticleIdList></Reference><Reference><Citation>ANDORFER C, KRESS Y, ESPINOZA M, DE SILVA R, TUCKER KL, BARDE YA, DUFF K, DAVIES P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>ARAI T, IKEDA K, AKIYAMA H, SHIKAMOTO Y, TSUCHIYA K, YAGISHITA S, BEACH T, ROGERS J, SCHWAB C, MCGEER PL. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick&#x2019;s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 2001;101:167&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11271372</ArticleId></ArticleIdList></Reference><Reference><Citation>BRAAK H, BRAAK E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;8. discussion 278&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>BUNKER JM, WILSON L, JORDAN MA, FEINSTEIN SC. Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration. Mol Biol Cell. 2004;15:2720&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420096</ArticleId><ArticleId IdType="pubmed">15020716</ArticleId></ArticleIdList></Reference><Reference><Citation>COMBS B, VOSS K, GAMBLIN TC. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry. 2011;50:9446&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224825</ArticleId><ArticleId IdType="pubmed">21942206</ArticleId></ArticleIdList></Reference><Reference><Citation>CRUTS M, THEUNS J, VAN BROECKHOVEN C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. 2012;33:1340&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;SOUZA I, POORKAJ P, HONG M, NOCHLIN D, LEE VM, BIRD TD, SCHELLENBERG GD. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA. 1999;96:5598&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21906</ArticleId><ArticleId IdType="pubmed">10318930</ArticleId></ArticleIdList></Reference><Reference><Citation>DAWSON HN, CANTILLANA V, CHEN L, VITEK MP. The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J Neurosci. 2007;27:9155&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672194</ArticleId><ArticleId IdType="pubmed">17715352</ArticleId></ArticleIdList></Reference><Reference><Citation>DAWSON HN, CANTILLANA V, JANSEN M, WANG H, VITEK MP, WILCOCK DM, LYNCH JR, LASKOWITZ DT. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer&#x2019;s disease. Neuroscience. 2010;169:516&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900546</ArticleId><ArticleId IdType="pubmed">20434528</ArticleId></ArticleIdList></Reference><Reference><Citation>DE SILVA R, LASHLEY T, GIBB G, HANGER D, HOPE A, REID A, BANDOPADHYAY R, UTTON M, STRAND C, JOWETT T, KHAN N, ANDERTON B, WOOD N, HOLTON J, REVESZ T, LEES A. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol. 2003;29:288&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12787326</ArticleId></ArticleIdList></Reference><Reference><Citation>DEACON RM. Assessing nest building in mice. Nat Protoc. 2006;1:1117&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406392</ArticleId></ArticleIdList></Reference><Reference><Citation>DEVOS SL, GONCHAROFF DK, CHEN G, KEBODEAUX CS, YAMADA K, STEWART FR, SCHULER DR, MALONEY SE, WOZNIAK DF, RIGO F, BENNETT CF, CIRRITO JR, HOLTZMAN DM, MILLER TM. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33:12887&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728694</ArticleId><ArticleId IdType="pubmed">23904623</ArticleId></ArticleIdList></Reference><Reference><Citation>DEVOS SL, MILLER TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics. 2013a;10:486&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701770</ArticleId><ArticleId IdType="pubmed">23686823</ArticleId></ArticleIdList></Reference><Reference><Citation>DEVOS SL, MILLER TM. Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp. 2013b:e50326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>DINKEL PD, SIDDIQUA A, HUYNH H, SHAH M, MARGITTAI M. Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry. 2011;50:4330&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21510682</ArticleId></ArticleIdList></Reference><Reference><Citation>GHETTI B, OBLAK AL, BOEVE BF, JOHNSON KA, DICKERSON BC, GOEDERT M. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol. 2015;41:24&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>GHEYARA AL, PONNUSAMY R, DJUKIC B, CRAFT RJ, HO K, GUO W, FINUCANE MM, SANCHEZ PE, MUCKE L. Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol. 2014;76:443&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338764</ArticleId><ArticleId IdType="pubmed">25042160</ArticleId></ArticleIdList></Reference><Reference><Citation>GLAXOSMITHKLINE. Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy.  [Online]. Available:  https://www.clinicaltrials.gov/ct2/show/NCT01153932.</Citation></Reference><Reference><Citation>HALFMANN R, LINDQUIST S. Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723713</ArticleId><ArticleId IdType="pubmed">19066511</ArticleId></ArticleIdList></Reference><Reference><Citation>HONG M, ZHUKAREVA V, VOGELSBERG-RAGAGLIA V, WSZOLEK Z, REED L, MILLER BI, GESCHWIND DH, BIRD TD, MCKEEL D, GOATE A, MORRIS JC, WILHELMSEN KC, SCHELLENBERG GD, TROJANOWSKI JQ, LEE VM. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>HU J, MATSUI M, GAGNON KT, SCHWARTZ JC, GABILLET S, ARAR K, WU J, BEZPROZVANNY I, COREY DR. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol. 2009;27:478&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765218</ArticleId><ArticleId IdType="pubmed">19412185</ArticleId></ArticleIdList></Reference><Reference><Citation>IONIS PHARMACEUTICALS. A Study to Assess the Efficacy and Safety of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy.  [Online]. Available:  https://clinicaltrials.gov/ct2/show/NCT02193074.</Citation></Reference><Reference><Citation>ITTNER LM, KE YD, DELERUE F, BI M, GLADBACH A, VAN EERSEL J, WOLFING H, CHIENG BC, CHRISTIE MJ, NAPIER IA, ECKERT A, STAUFENBIEL M, HARDEMAN E, GOTZ J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>LEI P, AYTON S, FINKELSTEIN DI, SPOERRI L, CICCOTOSTO GD, WRIGHT DK, WONG BX, ADLARD PA, CHERNY RA, LAM LQ, ROBERTS BR, VOLITAKIS I, EGAN GF, MCLEAN CA, CAPPAI R, DUCE JA, BUSH AI. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18:291&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286308</ArticleId></ArticleIdList></Reference><Reference><Citation>LU QL, MANN CJ, LOU F, BOU-GHARIOS G, MORRIS GE, XUE SA, FLETCHER S, PARTRIDGE TA, WILTON SD. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 2003;9:1009&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847521</ArticleId></ArticleIdList></Reference><Reference><Citation>MA QL, ZUO X, YANG F, UBEDA OJ, GANT DJ, ALAVERDYAN M, KIOSEA NC, NAZARI S, CHEN PP, NOTHIAS F, CHAN P, TENG E, FRAUTSCHY SA, COLE GM. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci. 2014;34:7124&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028492</ArticleId><ArticleId IdType="pubmed">24849348</ArticleId></ArticleIdList></Reference><Reference><Citation>MAEDA S, DJUKIC B, TANEJA P, YU GQ, LO I, DAVIS A, CRAFT R, GUO W, WANG X, KIM D, PONNUSAMY R, GILL TM, MASLIAH E, MUCKE L. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>MILLER TM, PESTRONK A, DAVID W, ROTHSTEIN J, SIMPSON E, APPEL SH, ANDRES PL, MAHONEY K, ALLRED P, ALEXANDER K, OSTROW LW, SCHOENFELD D, MACKLIN EA, NORRIS DA, MANOUSAKIS G, CRISP M, SMITH R, BENNETT CF, BISHOP KM, CUDKOWICZ ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>MILLER VM, XIA H, MARRS GL, GOUVION CM, LEE G, DAVIDSON BL, PAULSON HL. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA. 2003;100:7195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165852</ArticleId><ArticleId IdType="pubmed">12782788</ArticleId></ArticleIdList></Reference><Reference><Citation>POLYDORO M, ACKER CM, DUFF K, CASTILLO PE, DAVIES P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>ROBERSON ED, SCEARCE-LEVIE K, PALOP JJ, YAN F, CHENG IH, WU T, GERSTEIN H, YU GQ, MUCKE L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>SANDERS DW, KAUFMAN SK, DEVOS SL, SHARMA AM, MIRBAHA H, LI A, BARKER SJ, FOLEY AC, THORPE JR, SERPELL LC, MILLER TM, GRINBERG LT, SEELEY WW, DIAMOND MI. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>SPILLANTINI MG, GOEDERT M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>STOOTHOFF W, JONES PB, SPIRES-JONES TL, JOYNER D, CHHABRA E, BERCURY K, FAN Z, XIE H, BACSKAI B, EDD J, IRIMIA D, HYMAN BT. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J Neurochem. 2009;111:417&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831412</ArticleId><ArticleId IdType="pubmed">19686388</ArticleId></ArticleIdList></Reference><Reference><Citation>TORRES-LISTA V, GIMENEZ-LLORT L. Impairment of nesting behaviour in 3xTg-AD mice. Behav Brain Res. 2013;247:153&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23523959</ArticleId></ArticleIdList></Reference><Reference><Citation>VON BERGEN M, BARGHORN S, LI L, MARX A, BIERNAT J, MANDELKOW EM, MANDELKOW E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276:48165&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27348499</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity.</ArticleTitle><Pagination><StartPage>869</StartPage><EndPage>878</EndPage><MedlinePgn>869-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.4130</ELocationID><Abstract><AbstractText>Genetic mutations in TAR DNA-binding protein 43 (TARDBP, also known as TDP-43) cause amyotrophic lateral sclerosis (ALS), and an increase in the presence of TDP-43 (encoded by TARDBP) in the cytoplasm is a prominent histopathological feature of degenerating neurons in various neurodegenerative diseases. However, the molecular mechanisms by which TDP-43 contributes to ALS pathophysiology remain elusive. Here we have found that TDP-43 accumulates in the mitochondria of neurons in subjects with ALS or frontotemporal dementia (FTD). Disease-associated mutations increase TDP-43 mitochondrial localization. In mitochondria, wild-type (WT) and mutant TDP-43 preferentially bind mitochondria-transcribed messenger RNAs (mRNAs) encoding respiratory complex I subunits ND3 and ND6, impair their expression and specifically cause complex I disassembly. The suppression of TDP-43 mitochondrial localization abolishes WT and mutant TDP-43-induced mitochondrial dysfunction and neuronal loss, and improves phenotypes of transgenic mutant TDP-43 mice. Thus, our studies link TDP-43 toxicity directly to mitochondrial bioenergetics and propose the targeting of TDP-43 mitochondrial localization as a promising therapeutic approach for neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenzhang</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4426-019X</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Luwen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Junjie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatric Newborn Medicine, Brigham &amp;Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siedlak</LastName><ForeName>Sandra L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujioka</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Electron Microscopy Core Facility, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Sirui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaopin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Rocha</LastName><ForeName>Edroaldo Lummertz</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0003-0537-4223</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pharmacology &amp;Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Heewon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerou</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology &amp;Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinglong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R03 AG044680</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN275200900011C</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS085747</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS077888</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089604</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007250</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C507225">MT-ND6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="D009245">NADH Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.1.1.2</RegistryNumber><NameOfSubstance UI="D042967">Electron Transport Complex I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.1.1.2</RegistryNumber><NameOfSubstance UI="C114961">MT-ND3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042967" MajorTopicYN="N">Electron Transport Complex I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009245" MajorTopicYN="N">NADH Dehydrogenase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare no competing financial interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27348499</ArticleId><ArticleId IdType="mid">NIHMS789731</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pii">nm.4130</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nature reviews. Neurology. 2014;10:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nature reviews. Neurology. 2012;8:423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Clery A, Blatter M, Allain FH. RNA recognition motifs: boring? Not quite. Current opinion in structural biology. 2008;18:290&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">18515081</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Frontiers in bioscience: a journal and virtual library. 2008;13:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci. 2012;37:237&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">22534659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nature reviews. Neuroscience. 2012;13:38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet. Neurology. 2010;9:995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Annals of neurology. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, et al. Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta neuropathologica. 2014;127:441&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanson JB, et al. TDP43-positive intraneuronal inclusions in a patient with motor neuron disease and Parkinson&#x2019;s disease. Neurodegener Dis. 2010;7:260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">20197650</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, et al. TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. Acta Neuropathol. 2009;118:359&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330339</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:E736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin JA, et al. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:4309&#x2013;4314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964094</ArticleId><ArticleId IdType="pubmed">24591609</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Cytoplasmic Mislocalization of TDP-43 Is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis. Journal of Neuroscience. 2010;30:639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson Petersen CA, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:13145&#x2013;13150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527349</ArticleId><ArticleId IdType="pubmed">18757748</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuelsson O, Brunak S, von Heijne G, Nielsen H. Locating proteins in the cell using TargetP, SignalP and related tools. Nature protocols. 2007;2:953&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">17446895</ArticleId></ArticleIdList></Reference><Reference><Citation>Claros MG, Vincens P. Computational method to predict mitochondrially imported proteins and their targeting sequences. European journal of biochemistry/FEBS. 1996;241:779&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">8944766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolender N, Sickmann A, Wagner R, Meisinger C, Pfanner N. Multiple pathways for sorting mitochondrial precursor proteins. EMBO reports. 2008;9:42&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2246611</ArticleId><ArticleId IdType="pubmed">18174896</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt O, Pfanner N, Meisinger C. Mitochondrial protein import: from proteomics to functional mechanisms. Nat Rev Mol Cell Biol. 2010;11:655&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">20729931</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Current protein &amp; peptide science. 2005;6:151&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">15853652</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewyn S, et al. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Mol Neurodegener. 2014;9:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4088917</ArticleId><ArticleId IdType="pubmed">24938805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain research. 2014;1584:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang TN, et al. Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Front Aging Neurosci. 2014;6:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920072</ArticleId><ArticleId IdType="pubmed">24575040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang TN, et al. Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model. Disease models &amp; mechanisms. 2013;6:1198&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759339</ArticleId><ArticleId IdType="pubmed">23798570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, et al. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta neuropathologica. 2008;116:193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Annals of neurology. 2008;64:60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandmeir NJ, et al. Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta neuropathologica. 2008;115:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">18004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:E1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. The Journal of biological chemistry. 2012;287:27335&#x2013;27344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer S, Woellhaf MW, Herrmann JM, Forster F. Organization of the mitochondrial translation machinery studied in situ by cryoelectron tomography. Nature communications. 2015;6:6019.</Citation><ArticleIdList><ArticleId IdType="pubmed">25609543</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature neuroscience. 2011;14:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. The Journal of biological chemistry. 2011;286:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nature neuroscience. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan RK, et al. Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brain. Amyotrophic lateral sclerosis &amp; frontotemporal degeneration. 2013;14:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">23134510</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland R, et al. De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy and complex I deficiency. Annals of neurology. 2004;55:58&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">14705112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnery PF, et al. The mitochondrial ND6 gene is a hot spot for mutations that cause Leber&#x2019;s hereditary optic neuropathy. Brain: a journal of neurology. 2001;124:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">11133798</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, et al. Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc Natl Acad Sci U S A. 2011;108:12920&#x2013;12924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150934</ArticleId><ArticleId IdType="pubmed">21768365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogliati S, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell. 2013;155:160&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790458</ArticleId><ArticleId IdType="pubmed">24055366</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30:10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, et al. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener. 2011;6:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrane J, Cortez C, Gan WB, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Human molecular genetics. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Human molecular genetics. 2013;22:4706&#x2013;4719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558479</ArticleId></ArticleIdList></Reference><Reference><Citation>Galluzzi L, Kroemer G. Necroptosis: A Specialized Pathway of Programmed Necrosis. Cell. 2008;135:1161&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">19109884</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolmetsch R, Geschwind DH. The Human Brain in a Dish: The Promise of iPSC-Derived Neurons. Cell. 2011;145:831&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691069</ArticleId><ArticleId IdType="pubmed">21663789</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JD, et al. Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. Cell stem cell. 2013;13:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4153390</ArticleId><ArticleId IdType="pubmed">24315443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu XW, et al. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. Journal of neuropathology and experimental neurology. 2000;59:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer&#x2019;s disease patients. The American journal of pathology. 2008;173:470&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2475784</ArticleId><ArticleId IdType="pubmed">18599615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JJ, et al. The Distribution of Genomic Variations in Human iPSCs Is Related to Replication-Timing Reorganization during Reprogramming. Cell Rep. 2014;7:70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133748</ArticleId><ArticleId IdType="pubmed">24685138</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SW, Gerencser AA, Nicholls DG. Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. Journal of neurochemistry. 2009;109:1179&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696043</ArticleId><ArticleId IdType="pubmed">19519782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer&#x2019;s disease. J Neurosci. 2009;29:9090&#x2013;9103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735241</ArticleId><ArticleId IdType="pubmed">19605646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby DM, Thorburn DR, Turnbull DM, Taylor RW. Biochemical assays of respiratory chain complex activity. Methods in cell biology. 2007;80:93&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">17445690</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BJ, Roberts DJ. A rotarod suitable for quantitative measurements of motor incoordination in naive mice. Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie. 1968;259:211.</Citation><ArticleIdList><ArticleId IdType="pubmed">4232694</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujioka H, et al. Decreased cytochrome c oxidase subunit VIIa in aged rat heart mitochondria: immunocytochemistry. Anatomical record. 2011;294:1825&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744322</ArticleId><ArticleId IdType="pubmed">21972221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanaichi T, et al. A stable lead by modification of Sato&#x2019;s method. Journal of electron microscopy. 1986;35:304&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440973</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujioka H, Tandler B, Hoppel CL. Mitochondrial division in rat cardiomyocytes: an electron microscope study. Anatomical record. 2012;295:1455&#x2013;1461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744323</ArticleId><ArticleId IdType="pubmed">22753088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:19318&#x2013;19323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2614759</ArticleId><ArticleId IdType="pubmed">19050078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27327500</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Jun</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.</ArticleTitle><Pagination><StartPage>11934</StartPage><MedlinePgn>11934</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11934</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms11934</ELocationID><Abstract><AbstractText>Multifactorial mechanisms underlying late-onset Alzheimer's disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-&#x3b2; deposition, metabolism, vascular, functional activity at rest, structural properties, cognitive integrity and peripheral proteins levels are characterized in relation to LOAD progression. We analyse over 7,700 brain images and tens of plasma and cerebrospinal fluid biomarkers from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Through a multifactorial data-driven analysis, we obtain dynamic LOAD-abnormality indices for all biomarkers, and a tentative temporal ordering of disease progression. Imaging results suggest that intra-brain vascular dysregulation is an early pathological event during disease development. Cognitive decline is noticeable from initial LOAD stages, suggesting early memory deficit associated with the primary disease factors. High abnormality levels are also observed for specific proteins associated with the vascular system's integrity. Although still subjected to the sensitivity of the algorithms and biomarkers employed, our results might contribute to the development of preventive therapeutic interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iturria-Medina</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp;Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludmer Centre for NeuroInformatics and Mental Health, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotero</LastName><ForeName>R C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Radiology and Hotchkiss Brain institute, University of Calgary, Calgary, Alberta, Canada T2N 4N1.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toussaint</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp;Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludmer Centre for NeuroInformatics and Mental Health, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateos-P&#xe9;rez</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp;Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludmer Centre for NeuroInformatics and Mental Health, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology &amp;Neurosurgery, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludmer Centre for NeuroInformatics and Mental Health, Montreal, Quebec, Canada H3A 2B4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007090" MajorTopicYN="Y">Image Interpretation, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorensen</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lew</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raichle</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fillit</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefti</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holtzman</LastName><ForeName>Davie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M Marcel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckholtz</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marylyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiao</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Toledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>AnnMarie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neylan</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grafman</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finley</LastName><ForeName>Shannon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedl</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleischman</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>James</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massoglia</LastName><ForeName>Dino</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fruehling</LastName><ForeName>J Jay</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harding</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>Elaine R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furst</LastName><ForeName>Ansgar J</ForeName><Initials>AJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27327500</ArticleId><ArticleId IdType="pmc">PMC4919512</ArticleId><ArticleId IdType="doi">10.1038/ncomms11934</ArticleId><ArticleId IdType="pii">ncomms11934</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buckner R. et al.. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 25, 7709&#x2013;7717 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R. &amp; Diamond M. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845&#x2013;12852 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Review The Pathobiology of Vascular Dementia. Neuron 80, 844&#x2013;866 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842016</ArticleId><ArticleId IdType="pubmed">24267647</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5, 347&#x2013;360 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15100718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic B. V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723&#x2013;738 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036520</ArticleId><ArticleId IdType="pubmed">22048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. &amp; Higgins G. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184&#x2013;185 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Demetrius L. A. &amp; Driver J. Alzheimer's as a metabolic disease. Biogerontology 14, 641&#x2013;649 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24249045</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner R., Andrews-Hanna J. &amp; Schacter D. The brain's default network: anatomy, function, and relevance to disease. Ann. NY Acad. Sci. 1124, 1&#x2013;38 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr et al.. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119&#x2013;128 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. et al.. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A. L. et al.. A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain 137, 2564&#x2013;2577 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132648</ArticleId><ArticleId IdType="pubmed">25012224</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonteijn H. M. et al.. An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. Neuroimage 60, 1&#x2013;10 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22281676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukart J. et al.. Generative FDG-PET and MRI model of aging and disease progression in Alzheimer ' s disease. PLoS Comput. Biol. 9, 1&#x2013;11 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616972</ArticleId><ArticleId IdType="pubmed">23592957</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue M. C. et al.. Estimating long-term multivariate progression from short-term data. Alzheimer's Dement. 10, S400&#x2013;S410 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169767</ArticleId><ArticleId IdType="pubmed">24656849</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A. &amp; Tourville J. 101 labeled brain images and a consistent human cortical labeling protocol. Front. Neurosci. 6, 171 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514540</ArticleId><ArticleId IdType="pubmed">23227001</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R. et al.. Region-specific hierarchy between atrophy, hypometabolism, and &#x3b2;-amyloid (A&#x3b2;) load in Alzheimer's disease dementia. J. Neurosci. 32, 16265&#x2013;16273 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794030</ArticleId><ArticleId IdType="pubmed">23152610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jedynak B. M. et al.. A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease neuroimaging initiative cohort. Neuroimage 63, 1478&#x2013;1486 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472161</ArticleId><ArticleId IdType="pubmed">22885136</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., Hampel H., Weiner M. &amp; Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131&#x2013;144 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S. et al.. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signalling proteins. Nat. Med. 13, 1359&#x2013;1362 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasserini D. et al.. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J. Alzheimers. Dis. 22, 1281&#x2013;1288 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20930282</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Alexopoulos P. &amp; Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 263, 553&#x2013;560 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23591828</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan R. S. et al.. Heart fatty acid binding protein and A&#x3b2;-associated AD neurodegeneration. Mol Neurodegener. 8, 39 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3850652</ArticleId><ArticleId IdType="pubmed">24088526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A. H. B., Graff L., Petry C. &amp; Arm G. Role of heart-type fatty acid-binding protein in early detection of acute myocardial infarction. Clin. Chem. 46, 1999&#x2013;2000 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10794758</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo J. B. et al.. Cardiovascular risk factors, cortisol, and amyloid-&#x3b2; deposition in Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 8, 483&#x2013;489 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668456</ArticleId><ArticleId IdType="pubmed">23102118</ArticleId></ArticleIdList></Reference><Reference><Citation>Czech C. et al.. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS ONE 7, e31501 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281064</ArticleId><ArticleId IdType="pubmed">22359596</ArticleId></ArticleIdList></Reference><Reference><Citation>Erqou S. et al.. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J. Am. Coll. Cardiol. 55, 2160&#x2013;2167 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20447543</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxenkrug G. Interferon-gamma - inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis. 2, 474&#x2013;486 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295064</ArticleId><ArticleId IdType="pubmed">22396896</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnar R. J., Yates C. C. &amp; Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ. Res. 98, 617&#x2013;625 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826264</ArticleId><ArticleId IdType="pubmed">16484616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara N. &amp; Kerbel R. Angiogenesis as a therapeutic target. Nature 438, 967&#x2013;974 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16355214</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhou C., Zhou X., Li L. &amp; Hui R. Pregnancy-associated plasma protein A predicts adverse vascular events in patients with coronary heart disease: a systematic review and meta-analysis. Arch. Med. Sci. 9, 389&#x2013;397 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3701985</ArticleId><ArticleId IdType="pubmed">23847657</ArticleId></ArticleIdList></Reference><Reference><Citation>Wands J. R. Alzheimer's disease is type 3 diabetes&#x2014;evidence reviewed. J. Diabetes Sci. Technol. 2, 1101&#x2013;1113 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2769828</ArticleId><ArticleId IdType="pubmed">19885299</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks W. a., Owen J. B. &amp; Erickson M. a. Insulin in the brain: there and back again. Pharmacol. Ther. 136, 82&#x2013;93 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134675</ArticleId><ArticleId IdType="pubmed">22820012</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A. et al.. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296&#x2013;302 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350773</ArticleId><ArticleId IdType="pubmed">25611508</ArticleId></ArticleIdList></Reference><Reference><Citation>Xaio H., Banks W. A., Niehoff M. L. &amp; Morley J. E. Effect of LPS on the permeability of the blood &#x2013; brain barrier to insulin. Brain Res. 896, 36&#x2013;42 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11277970</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia S. C. et al.. Insulin signalling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res. 1441, 64&#x2013;78 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22290178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocernich C. B. &amp; Butterfield D. A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. Biophys. Acta 1822, 625&#x2013;630 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277671</ArticleId><ArticleId IdType="pubmed">22015471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. &amp; Michaelis E. K. Selective neuronal vulnerability to oxidative stress in the brain. Front. Aging Neurosci. 2, 12 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874397</ArticleId><ArticleId IdType="pubmed">20552050</ArticleId></ArticleIdList></Reference><Reference><Citation>Enciu A., Gherghiceanu M. &amp; Popescu B. O. Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxid. Med. Cell Longev. 2013, 297512 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606793</ArticleId><ArticleId IdType="pubmed">23533687</ArticleId></ArticleIdList></Reference><Reference><Citation>Leake A., Morris C. M. &amp; Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer ' s disease. Neurosci. Lett. 291, 201&#x2013;203 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10984641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke M. et al.. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J. Alzheimers Dis. 27, 665&#x2013;676 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21860087</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg G. a. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 8, 205&#x2013;216 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19161911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin A. S. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 84, 594&#x2013;607 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4254637</ArticleId><ArticleId IdType="pubmed">25442938</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y., Sotero R. C., Toussaint P. J. &amp; Evans A. C. Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. PLoS Comput. Biol. 10, e1003956 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238950</ArticleId><ArticleId IdType="pubmed">25412207</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A., Kuceyeski A. &amp; Weiner M. A network diffusion model of disease progression in dementia. Neuron 73, 1204&#x2013;1215 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider J. A., Arvanitakis Z. &amp; Bennett D. A. Mixed brain pathologies account for most dementia cases in community- dwelling older persons. Neurology 69, 2197&#x2013;2204 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega K. G. et al.. Decreased clearance of CNS amyloid-&#x3b2; in Alzheimer's disease. Science 330, 1&#x2013;4 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C. et al.. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2, 157&#x2013;161 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10195200</ArticleId></ArticleIdList></Reference><Reference><Citation>Qosa H. et al.. Differences in amyloid-&#x3b2; clearance across mouse and human blood&#x2013;brain barrier models. Neuropharmacology 79, 668&#x2013;678 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965363</ArticleId><ArticleId IdType="pubmed">24467845</ArticleId></ArticleIdList></Reference><Reference><Citation>Crush J., Africa S. &amp; Hughes C. Brain drain. Sci. Am. 314, 342&#x2013;347 (2016).</Citation></Reference><Reference><Citation>Religa P. et al.. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci. Rep. 3, 2053 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690383</ArticleId><ArticleId IdType="pubmed">23792494</ArticleId></ArticleIdList></Reference><Reference><Citation>Readnower R., Sauerbeck A. &amp; Sullivan P. Mitochondria, amyloid &#x3b2;, and Alzheimer's disease. Int. J. Alzheimers Dis 2011, 104545 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087417</ArticleId><ArticleId IdType="pubmed">21547208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane S., Nugent S., Roy M. &amp; Al E. Brain fuel metabolism, aging and Alzheimer's disease. Nutrition 27, 3&#x2013;20 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478067</ArticleId><ArticleId IdType="pubmed">21035308</ArticleId></ArticleIdList></Reference><Reference><Citation>Scremin O. The Human Nervous System - Cerebral Vascular System Academic Press (2012).</Citation></Reference><Reference><Citation>Lacoste B. et al.. Sensory-related neural activity regulates the structure of vascular networks in the cerebral cortex. Neuron 83, 1117&#x2013;1130 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166422</ArticleId><ArticleId IdType="pubmed">25155955</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rster S. et al.. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol. Psychiatry 71, 792&#x2013;797 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21679929</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y. &amp; Evans A. On the central role of brain connectivity in neurodegenerative disease progression. Front. Aging Neurosci. 7, 90 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439541</ArticleId><ArticleId IdType="pubmed">26052284</ArticleId></ArticleIdList></Reference><Reference><Citation>Klupp E. et al.. In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions. Brain Connect. 4, 371&#x2013;383 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24870443</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y. Anatomical brain networks on the prediction of abnormal brain states. Brain Connect. 3, 1&#x2013;41 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23249224</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturria-Medina Y. et al.. Characterizing brain anatomical connections using diffusion weighted MRI and graph theory. Neuroimage 36, 645&#x2013;660 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17466539</ArticleId></ArticleIdList></Reference><Reference><Citation>Street J. O., Carroll R. J. &amp; Ruppert D. A note on computing robust regression estimates via iteratively reweighted least squares. Am. Stat. 42, 152&#x2013;154 (1988).</Citation></Reference><Reference><Citation>Bernal-Rusiel J. L., Greve D. N., Reuter M., Fischl B. &amp; Sabuncu M. R. Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage 66, 249&#x2013;260 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586747</ArticleId><ArticleId IdType="pubmed">23123680</ArticleId></ArticleIdList></Reference><Reference><Citation>Trujillo-Ortiz A., Hernandez-Walls R., Castro-Perez A. &amp; Barba-Rojo K. MOUTLIER1:Detection of Outlier in Multivariate Samples Test. A MATLAB file [WWW Doc. Available at http://www.mathworks.com/matlabcentral/fileexchange/loadFile.do?objectId=12252 (2006).</Citation></Reference><Reference><Citation>Sled J. G., Zijdenbos A. P. &amp; Evans A. C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87&#x2013;97 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. et al.. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimers Dement. 6, 221&#x2013;229 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao-Gan Y. &amp; Yu-Feng Z. DPARSF: A MATLAB toolbox for &#x2018;Pipeline' data analysis of resting-state fMRI. Front. Syst. Neurosci. 4, 13 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889691</ArticleId><ArticleId IdType="pubmed">20577591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Q.-H. et al.. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF. J. Neurosci. Methods 172, 137&#x2013;141 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902859</ArticleId><ArticleId IdType="pubmed">18501969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang Y., Jiang T., Lu Y., He Y. &amp; Tian L. Regional homogeneity approach to fMRI data analysis. Neuroimage 22, 394&#x2013;400 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15110032</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel M. P. &amp; Hulshoff Pol H. E. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur. Neuropsychopharmacol. 20, 519&#x2013;534 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20471808</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski J. Q. et al.. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Dement. 6, 230&#x2013;238 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867838</ArticleId><ArticleId IdType="pubmed">20451871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27371494</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>547</EndPage><MedlinePgn>539-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000002923</ELocationID><Abstract><AbstractText>Biomarkers have become an essential component of Alzheimer disease (AD) research and because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used in cognitive aging research. A number of current issues suggest that an unbiased descriptive classification scheme for these biomarkers would be useful. We propose the "A/T/N" system in which 7 major AD biomarkers are divided into 3 binary categories based on the nature of the pathophysiology that each measures. "A" refers to the value of a &#x3b2;-amyloid biomarker (amyloid PET or CSF A&#x3b2;42); "T," the value of a tau biomarker (CSF phospho tau, or tau PET); and "N," biomarkers of neurodegeneration or neuronal injury ([(18)F]-fluorodeoxyglucose-PET, structural MRI, or CSF total tau). Each biomarker category is rated as positive or negative. An individual score might appear as A+/T+/N-, or A+/T-/N-, etc. The A/T/N system includes the new modality tau PET. It is agnostic to the temporal ordering of mechanisms underlying AD pathogenesis. It includes all individuals in any population regardless of the mix of biomarker findings and therefore is suited to population studies of cognitive aging. It does not specify disease labels and thus is not a diagnostic classification system. It is a descriptive system for categorizing multidomain biomarker findings at the individual person level in a format that is easy to understand and use. Given the present lack of consensus among AD specialists on terminology across the clinically normal to dementia spectrum, a biomarker classification scheme will have broadest acceptance if it is independent from any one clinically defined diagnostic scheme.</AbstractText><CopyrightInformation>&#xa9; 2016 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France. jack.clifford@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Departments of Radiology (C.R.J.) and Neurology (D.S.K., R.C.P.), Mayo Clinic, Rochester, MN; Rush Alzheimer's Disease Center (D.A.B.), Rush University Medical Center, Chicago, IL; Clinical Neurochemistry Lab (K.B.), Department of Neuroscience and Physiology, University of Gothenburg, M&#xf6;lndal Hospital, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Alzheimer's Association (M.C.C.), Chicago, IL; Division of Neurology (H.H.F.), UBC Hospital Clinic for Alzheimer's Disease and Related Disorders, University of British Columbia, Vancouver, Canada; Memory Clinic (G.B.F.), University Hospitals and University of Geneva, Switzerland; IRCCS Fatebenefratelli (G.B.F.), The National Centre for Alzheimer's Disease, Brescia, Italy; Sorbonne Universit&#xe9;s (H.H.), Universit&#xe9; Pierre et Marie Curie, Paris; Institut de la M&#xe9;moire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re (ICM) (H.H.), D&#xe9;partement de Neurologie, H&#xf4;pital de la Piti&#xe9;-Salp&#xe9;tri&#xe8;re, Paris, France; Helen Wills Neuroscience Institute (W.J.J.), University of California, Berkeley; Departments of Radiology and Neurology (K.A.J.), Massachusetts General Hospital, Harvard Medical School, Boston; Alzheimer Center and Department of Neurology (P.S.), Vrije Universiteit Amsterdam, the Netherlands; Center for Alzheimer Research and Treatment (R.A.S.), Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston; Centre des Maladies Cognitives et Comportementales (B.D.), Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris; and Universit&#xe9; Pierre et Marie Curie-Paris 6 (B.D.), AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG043392</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 87(5):456.</RefSource><PMID Version="1">27371486</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27371494</ArticleId><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId><ArticleId IdType="pii">WNL.0000000000002923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Albert MS, Knopman DS, et al. . Introduction to the recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Frank R, Broich K, et al. . Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592748</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol 2015;14:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin MD, Vanderburg CR, et al. . Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Shultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer's disease. Ann Neurol 2016;79:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl M, Lockhart SN, Schonhaut DR, et al. . PET Imaging of tau deposition in the aging human brain. Neuron 2016;89:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70:960&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion JP, et al. . PART is part of Alzheimer disease. Acta Neuropathol 2015;129:749&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol 2011;121:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">21225273</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013;80:1347&#x2013;1358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G. Alzheimer disease: Abeta-independent processes&#x2014;rethinking preclinical AD. Nat Rev Neurol 2013;9:123&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935395</ArticleId><ArticleId IdType="pubmed">23399647</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. . Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Verhey F, Frolich L, et al. . Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 2015;138:1327&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013930</ArticleId><ArticleId IdType="pubmed">25693589</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Weigand SD, et al. . An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Ann Neurol 2012;71:765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, et al. . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA Study: a prospective cohort study. Lancet Neurol 2009;8:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, et al. . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Besson FL, La Joie R, Doeuvre L, et al. . Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J Neurosci 2015;35:10402&#x2013;10411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605120</ArticleId><ArticleId IdType="pubmed">26203136</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, et al. . Relationships between biomarkers in aging and dementia. Neurology 2009;73:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, et al. . Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong YT, Veenith T, Dewar D, et al. . Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 2014;71:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084932</ArticleId><ArticleId IdType="pubmed">24217171</ArticleId></ArticleIdList></Reference><Reference><Citation>Krut JJ, Zetterberg H, Blennow K, et al. . Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J Neurol 2013;260:620&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">23052602</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003;18:186&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">12539213</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">8748926</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, et al. . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S, Ohrfelt A, Constantinescu R, et al. . Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pubmed">22925882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesse C, Rosengren L, Andreasen N, et al. . Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ost M, Nylen K, Csajbok L, et al. . Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006;67:1600&#x2013;1604.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101890</ArticleId></ArticleIdList></Reference><Reference><Citation>Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 2014;71:476&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">24566866</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Otto M, Teipel SJ, et al. . Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 2006;27:10&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298235</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol 2012;8:189&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">22410582</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Duffy JR, Fossett TR, et al. . Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. Arch Neurol 2010;67:596&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20457960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, Haase CM, et al. . Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013;70:1512&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962545</ArticleId><ArticleId IdType="pubmed">24166579</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ, Furst AJ, et al. . Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008;64:388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648510</ArticleId><ArticleId IdType="pubmed">18991338</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulos P, Kriett L, Haller B, et al. . Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimers Dement 2014;10:684&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857233</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, et al. . Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitworth JA. 2003 World Health Organization (WHO)/International Society of hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">14597836</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, et al. . Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015;138:1370&#x2013;1381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Beach TG, Zanette M, et al. . [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. Alzheimers Dement 2015;11:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">26141264</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JT Jr, Williamson JD, Whelton PK, et al. . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasbeck R. The evolution of the reference value concept. Clin Chem Lab Med 2004;42:692&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pubmed">15327001</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR Jr, Wiste HJ, et al. . Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. . MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71:743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Schneider LS, Giacobini E, et al. . Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother 2015;15:83&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">25537424</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Zetterberg H, Skillback T, et al. . Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain 2015;138:3373&#x2013;3385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643642</ArticleId><ArticleId IdType="pubmed">26373605</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeneuve S, Reed BR, Madison CM, et al. . Vascular risk and Abeta interact to reduce cortical thickness in AD vulnerable brain regions. Neurology 2014;83:40&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114172</ArticleId><ArticleId IdType="pubmed">24907234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27385740</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>87</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Polygenic risk of Alzheimer disease is associated with early- and late-life processes.</ArticleTitle><Pagination><StartPage>481</StartPage><EndPage>488</EndPage><MedlinePgn>481-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000002922</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine associations between aggregate genetic risk and Alzheimer disease (AD) markers in stages preceding the clinical symptoms of dementia using data from 2 large observational cohort studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We computed polygenic risk scores (PGRS) using summary statistics from the International Genomics of Alzheimer's Project genome-wide association study of AD. Associations between PGRS and AD markers (cognitive decline, clinical progression, hippocampus volume, and &#x3b2;-amyloid) were assessed within older participants with dementia. Associations between PGRS and hippocampus volume were additionally examined within healthy younger participants (age 18-35 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within participants without dementia, elevated PGRS was associated with worse memory (p = 0.002) and smaller hippocampus (p = 0.002) at baseline, as well as greater longitudinal cognitive decline (memory: p = 0.0005, executive function: p = 0.01) and clinical progression (p &lt; 0.00001). High PGRS was associated with AD-like levels of &#x3b2;-amyloid burden as measured with florbetapir PET (p = 0.03) but did not reach statistical significance for CSF &#x3b2;-amyloid (p = 0.11). Within the younger group, higher PGRS was associated with smaller hippocampus volume (p = 0.05). This pattern was evident when examining a PGRS that included many loci below the genome-wide association study (GWAS)-level significance threshold (16,123 single nucleotide polymorphisms), but not when PGRS was restricted to GWAS-level significant loci (18 single nucleotide polymorphisms).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Effects related to common genetic risk loci distributed throughout the genome are detectable among individuals without dementia. The influence of this genetic risk may begin in early life and make an individual more susceptible to cognitive impairment in late life. Future refinement of polygenic risk scores may help identify individuals at risk for AD dementia.</AbstractText><CopyrightInformation>&#xa9; 2016 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge. bmormino@nmr.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Avram J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smoller</LastName><ForeName>Jordan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabuncu</LastName><ForeName>Mert R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>From the Departments of Neurology (E.C.M., R.A.S.) and Radiology (R.A.S.), Massachusetts General Hospital, Harvard Medical School, Charlestown; Center for Alzheimer Research and Treatment, Department of Neurology (R.A.S.), and Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry (P.L.D.), Brigham and Women's Hospital, Harvard Medical School (P.L.D.), Boston, MA; Department of Psychology (A.J.H.), Yale University, New Haven, CT; Department of Psychiatry (A.J.H.), Massachusetts General Hospital, Harvard Medical School, Boston; Athinoula A. Martinos Center for Biomedical Imaging (A.J.H.) and Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research (J.W.S.), Massachusetts General Hospital, Boston; Department of Psychology and Center for Brain Science (R.L.B.), Harvard University, Cambridge; Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (R.L.B., M.R.S.), Massachusetts General Hospital, Charlestown; Program in Medical and Population Genetics (P.L.D.), Broad Institute; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard (J.W.S.); and Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K25 EB013649</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH094614</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG044054</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH099232</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG050122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG051718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 AG052246</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>Aliza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc-Adams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robin Hsiung</LastName><ForeName>Ging-Yuek</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek-Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bwayo</LastName><ForeName>Salome K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Dr Rob</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boles Ponto</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27385740</ArticleId><ArticleId IdType="pmc">PMC4970660</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002922</ArticleId><ArticleId IdType="pii">WNL.0000000000002922</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. . Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JB, Fleisher AS, et al. . Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl 3):321&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014;6:228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, et al. . Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Escott-Price V, Sims R, Bannister C, et al. . Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain 2015;138:3673&#x2013;3684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006219</ArticleId><ArticleId IdType="pubmed">26490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Harold D, Nyholt DR, et al. . Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum Mol Genet 2013;22:832&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554206</ArticleId><ArticleId IdType="pubmed">23193196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge PG, Mukherjee S, Crane PK, Kauwe JS; Alzheimer's Disease Genetics Consortium. Alzheimer's disease: analyzing the missing heritability. PLoS One 2013;8:e79771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820606</ArticleId><ArticleId IdType="pubmed">24244562</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Schork AJ, Wang Y, et al. . Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation 2015;131:2061&#x2013;2069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677995</ArticleId><ArticleId IdType="pubmed">25862742</ArticleId></ArticleIdList></Reference><Reference><Citation>International Genomics of Alzheimer's Disease Consortium. Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement 2015;11:658&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672734</ArticleId><ArticleId IdType="pubmed">25533204</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 2015;77:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan K. The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol 2011;37:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">21486313</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue M, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative 2 clinical core: progress and plans. Alzheimers Dement 2015;11:734&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643840</ArticleId><ArticleId IdType="pubmed">26194309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge T, Nichols TE, Lee PH, et al. . Massively expedited genome-wide heritability analysis (MEGHA). Proc Natl Acad Sci USA 2015;112:2479&#x2013;2484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4345618</ArticleId><ArticleId IdType="pubmed">25675487</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes AJ, Hollinshead MO, O'Keefe TM, et al. . Brain genomics Superstruct project initial data release with structural, functional, and behavioral measures. Sci Data 2015;2:150031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493828</ArticleId><ArticleId IdType="pubmed">26175908</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Yao X, et al. . Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement 2015;11:792&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4510473</ArticleId><ArticleId IdType="pubmed">26194313</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes AJ, Lee PH, Hollinshead MO, et al. . Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. J Neurosci 2012;32:18087&#x2013;18100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674506</ArticleId><ArticleId IdType="pubmed">23238724</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomes Project C, Abecasis GR, Auton A, et al. . An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696580</ArticleId><ArticleId IdType="pubmed">22820512</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bernstein MA, Fox NC, et al. . The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, et al. . Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012;6:502&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, et al. . A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 2012;6:517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Dima D, Breen G. Polygenic risk scores in imaging genetics: usefulness and applications. J Psychopharmacol 2015;29:867&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">25944849</ArticleId></ArticleIdList></Reference><Reference><Citation>International Schizophrenia Consortium; Purcell SM, Wray NR, Stone JL, et al. . Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, et al. . Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Genet 2014;10:e1004606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Maruff P, Pietrzak RH, et al. . Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2013;137:221&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">24176981</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Dueck AC, Osborne D, et al. . Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 2009;361:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928998</ArticleId><ArticleId IdType="pubmed">19605830</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Buckner RL, Smoller JW, et al. . The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb Cortex 2012;22:2653&#x2013;2661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464416</ArticleId><ArticleId IdType="pubmed">22169231</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris SE, Davies G, Luciano M, et al. . Polygenic risk for Alzheimer's disease is not associated with cognitive ability or cognitive aging in non-demented older people. J Alzheimers Dis 2014;39:565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">24246418</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. . Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok E, Haikonen S, Luoto T, et al. . Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19557866</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2013;2:a006346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf AB, Valla J, Bu G, et al. . Apolipoprotein E as a beta-amyloid-independent factor in Alzheimer&#x2019;s disease. Alzheimers Res Ther 2013;5:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979087</ArticleId><ArticleId IdType="pubmed">23998393</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Chen K, Keenan BT, et al. . Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol 2013;70:1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773291</ArticleId><ArticleId IdType="pubmed">23836404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP, Stein JL, Renteria ME, et al. . Common genetic variants influence human subcortical brain structures. Nature 2015;520:224&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393366</ArticleId><ArticleId IdType="pubmed">25607358</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27400367</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings.</ArticleTitle><Pagination><StartPage>1062</StartPage><EndPage>1069</EndPage><MedlinePgn>1062-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.1948</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The late effects of traumatic brain injury (TBI) are of great interest, but studies characterizing these effects are limited.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether TBI with loss of consciousness (LOC) is associated with an increased risk for clinical and neuropathologic findings of Alzheimer disease (AD), Parkinson disease (PD), and other dementias.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study analyzed data from the Religious Orders Study (ROS), Memory and Aging Project (MAP), and Adult Changes in Thought study (ACT). All ROS and MAP participants and a subset of ACT participants consent to autopsy. Studies performed annual (ROS and MAP) or biennial (ACT) cognitive and clinical testing to identify incident cases of dementia and AD. The 7130 participants included members of a Seattle-area health care delivery system (ACT), priests and nuns living in orders across the United States (ROS), and Chicago-area adults in retirement communities (MAP). Of these, 1589 underwent autopsy. Primary hypothesis was that TBI with LOC would be associated with increased risk for AD and neurofibrillary tangles. Data were accrued from 1994 to April 1, 2014.</AbstractText><AbstractText Label="EXPOSURES">Self-reported TBI when the participant was free of dementia, categorized as no more than 1 vs more than 1 hour of LOC.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Clinical outcomes included incident all-cause dementia, AD, and PD in all studies and incident mild cognitive impairment and progression of parkinsonian signs in ROS and MAP. Neuropathologic outcomes included neurofibrillary tangles, neuritic plaques, microinfarcts, cystic infarcts, Lewy bodies, and hippocampal sclerosis in all studies.</AbstractText><AbstractText Label="RESULTS">Of 7130 participants (2879 [40.4%] men; overall mean [SD] age, 79.9 [6.9] years), 865 reported a history of TBI with LOC. In 45&#x202f;190 person-years of follow-up, 1537 incident cases of dementia and 117 of PD were identified. No association was found between TBI with LOC and incident dementia (ACT: HR for TBI with LOC &#x2264;1 hour, 1.03; 95% CI, 0.83-1.27; HR for TBI with LOC &gt;1 hour, 1.18; 95% CI, 0.77-1.78; ROS and MAP: HR for TBI with LOC &#x2264;1 hour, 0.87; 95% CI, 0.58-1.29; HR for TBI with LOC &gt;1 hour, 0.84; 95% CI, 0.44-1.57) or AD (findings similar to those for dementia). Associations were found for TBI with LOC and incident PD in ACT (HR for TBI with LOC &gt;1 hour, 3.56; 95% CI, 1.52-8.28) and progression of parkinsonian signs in ROS and MAP (odds ratio [OR] for TBI with LOC &#x2264;1 hour, 1.65; 95% CI, 1.23-2.21; OR for TBI with LOC &gt;1 hour, 2.23; 95% CI, 1.16-4.29). Traumatic brain injury with LOC was associated with Lewy bodies (any Lewy body in ACT: RR for TBI with LOC &gt;1 hour, 2.64; 95% CI, 1.40-4.99; Lewy bodies in substantia nigra and/or locus ceruleus in ACT: RR for TBI with LOC &gt;1 hour, 3.30; 95% CI, 1.71-6.38; Lewy bodies in frontal or temporal cortex in ACT: RR for TBI with LOC &gt;1 hour, 5.73; 95% CI, 2.18-15.0; ROS and MAP: RR for TBI with LOC &#x2264;1 hour, 1.64; 95% CI, 1.00-2.70; pooled RR for TBI with LOC &#x2264;1 hour, 1.59; 95% CI, 1.06-2.39) and microinfarcts (any cortical microinfarct in ROS and MAP: RR for TBI with LOC &gt;1 hour, 2.12; 95% CI, 1.12-4.01; pooled RR for TBI with LOC &gt;1 hour, 1.58; 95% CI, 1.06-2.35).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Pooled clinical and neuropathologic data from 3 prospective cohort studies indicate that TBI with LOC is associated with risk for Lewy body accumulation, progression of parkinsonism, and PD, but not dementia, AD, neuritic plaques, or neurofibrillary tangles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crane</LastName><ForeName>Paul K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dams-O'Connor</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Mt Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trittschuh</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonnen</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Utah, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Washington, Seattle10now with the Department of Pathology, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>Sue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Center for Health Studies, Group Health Research Institute, Seattle, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 NS086625</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 HD074651</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R49 CE002092</GrantID><Acronym>CE</Acronym><Agency>NCIPC CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="N">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003244" MajorTopicYN="N">Consciousness Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27400367</ArticleId><ArticleId IdType="mid">NIHMS819688</ArticleId><ArticleId IdType="pmc">PMC5319642</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.1948</ArticleId><ArticleId IdType="pii">2532818</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol. 2013;9(4):211&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513655</ArticleId><ArticleId IdType="pubmed">23458973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mac Donald CL, Johnson AM, Cooper D, et al. Detection of blast-related traumatic brain injury in U.S. military personnel. N Engl J Med. 2011;364(22):2091&#x2013;2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146351</ArticleId><ArticleId IdType="pubmed">21631321</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley GT, Maas AI. Traumatic brain injury: an international knowledge-based approach. JAMA. 2013;310(5):473&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">23925611</ArticleId></ArticleIdList></Reference><Reference><Citation>Abner EL, Nelson PT, Schmitt FA, et al. Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Disord. 2014;37(5&#x2013;6):294&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057973</ArticleId><ArticleId IdType="pubmed">24401791</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington PM, Villapol S, Burns MP. Polypathology and dementia after brain trauma: Does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy? Exp Neurol. 2016;275(Pt 3):381&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681695</ArticleId><ArticleId IdType="pubmed">26091850</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine. Gulf War and Health, Volume 7: Long-term Consequences of Traumatic Brain Injury. Washington, D.C: National Academies Press; 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">25009909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res. 2012;9(6):628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006;144(2):73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6):540&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3955123</ArticleId><ArticleId IdType="pubmed">23924004</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6(1):45&#x2013;58. discussion 62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054493</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th. Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol. 2012;72(4):599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490232</ArticleId><ArticleId IdType="pubmed">23109154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27(3):169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol. 2012;71(2):258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367476</ArticleId><ArticleId IdType="pubmed">22367997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Walker RL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology. 2010;75(13):1203&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013492</ArticleId><ArticleId IdType="pubmed">20811000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62(4):406&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">17879383</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol. 2011;69(2):320&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228518</ArticleId><ArticleId IdType="pubmed">21387377</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul M, Xu L, Wald MW, Coronado VG. Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths 2002&#x2013;2006. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.</Citation></Reference><Reference><Citation>Whiteneck GG, Cuthbert JP, Corrigan JD, Bogner JA. Prevalence of self-reported lifetime history of traumatic brain injury and associated disability: a statewide population-based survey. J Head Trauma Rehabil. 2016;31(1):E55&#x2013;E62.</Citation><ArticleIdList><ArticleId IdType="pubmed">25931187</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner RC, Burke JF, Nettiksimmons J, Goldman S, Tanner CM, Yaffe K. Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol. 2015;77(6):987&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447556</ArticleId><ArticleId IdType="pubmed">25726936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Ross OA, Cormier KA, et al. Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655127</ArticleId><ArticleId IdType="pubmed">26518018</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington PM, Villapol S, Burns MP. Polypathology and dementia after brain trauma: Does brain injury trigger distinct neurodegenerative diseases, or should they be classified together as traumatic encephalopathy? Exp Neurol. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681695</ArticleId><ArticleId IdType="pubmed">26091850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27402340</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance.</ArticleTitle><Pagination><StartPage>992</StartPage><EndPage>1004</EndPage><MedlinePgn>992-1004</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201606370</ELocationID><Abstract><AbstractText>Immunotherapeutic approaches are currently the most advanced treatments for Alzheimer's disease (AD). Antibodies against amyloid &#x3b2;-peptide (A&#x3b2;) bind to amyloid plaques and induce their clearance by microglia via Fc receptor-mediated phagocytosis. Dysfunctions of microglia may play a pivotal role in AD pathogenesis and could result in reduced efficacy of antibody-mediated A&#x3b2; clearance. Recently, heterozygous mutations in the triggering receptor expressed on myeloid cells 2 (TREM2), a microglial gene involved in phagocytosis, were genetically linked to late onset AD Loss of TREM2 reduces the ability of microglia to engulf A&#x3b2;. We have now investigated whether loss of TREM2 affects the efficacy of immunotherapeutic approaches. We show that anti-A&#x3b2; antibodies stimulate A&#x3b2; uptake and amyloid plaque clearance in a dose-dependent manner in the presence or absence of TREM2. However, TREM2-deficient N9 microglial cell lines, macrophages as well as primary microglia showed significantly reduced uptake of antibody-bound A&#x3b2; and as a consequence reduced clearance of amyloid plaques. Titration experiments revealed that reduced efficacy of amyloid plaque clearance by Trem2 knockout cells can be compensated by elevating the concentration of therapeutic antibodies.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xianyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohrmann</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research and Early Development NORD Discovery &amp; Translational Area, Roche Innovation Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesz</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Klinikum der Universit&#xe4;t M&#xfc;nchen, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazaheri</LastName><ForeName>Fargol</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capell</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany Helmholtz Center Munich, German Research Center for Environmental Health, Institute for Diabetes and Obesity Core Facility Monoclonal Antibody Development, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knuesel</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Roche Pharmaceutical Research and Early Development NORD Discovery &amp; Translational Area, Roche Innovation Center Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinberger</LastName><ForeName>Gernot</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2629-0723</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Biochemistry, Ludwig-Maximilians-University Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany christian.haass@mail03.med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>321366</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="Y">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27402340</ArticleId><ArticleId IdType="pmc">PMC5009806</ArticleId><ArticleId IdType="doi">10.15252/emmm.201606370</ArticleId><ArticleId IdType="pii">emmm.201606370</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barao S, Moechars D, Lichtenthaler SF, De Strooper B (2016) BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease. Trends Neurosci 39: 158&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pubmed">26833257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson&#x2010;Wood K et&#xa0;al (2000) Peripherally administered antibodies against amyloid beta&#x2010;peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF et&#xa0;al (2012) Gantenerumab: a novel human anti&#x2010;Abeta antibody demonstrates sustained cerebral amyloid&#x2010;beta binding and elicits cell&#x2010;mediated removal of human amyloid&#x2010;beta. J Alzheimer's Dis 28: 49&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C, Piaceri I, Archetti S, Bonvicini C et&#xa0;al (2014) Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35: 934.e7&#x2013;934.e10</Citation><ArticleIdList><ArticleId IdType="pubmed">24139279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel&#x2010;Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH et&#xa0;al (2014) TREM2 variant p. R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71: 449&#x2013;453</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS et&#xa0;al (2015) TREM2 regulates microglial cell activation in response to demyelination in&#xa0;vivo. Acta Neuropathol 129: 429&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667728</ArticleId><ArticleId IdType="pubmed">25631124</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C (2000) Presenilin&#x2010;1 differentially facilitates endoproteolysis of the beta&#x2010;amyloid precursor protein and Notch. Nat Cell Biol 2: 205&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pubmed">10783238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheret C, Willem M, Fricker FR, Wende H, Wulf&#x2010;Goldenberg A, Tahirovic S, Nave KA, Saftig P, Haass C, Garratt AN et&#xa0;al (2013) Bace1 and Neuregulin&#x2010;1 cooperate to control formation and maintenance of muscle spindles. EMBO J 32: 2015&#x2013;2028</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715864</ArticleId><ArticleId IdType="pubmed">23792428</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Turnbull I, Klesney&#x2010;Tait J (2007) The enigmatic function of TREM&#x2010;2 in osteoclastogenesis. Adv Exp Med Biol 602: 97&#x2013;105</Citation><ArticleIdList><ArticleId IdType="pubmed">17966394</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17: 201&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowley MT, Costello PS, Fitzer&#x2010;Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL (1997) A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med 186: 1027&#x2013;1039</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199061</ArticleId><ArticleId IdType="pubmed">9314552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N et&#xa0;al (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35(726): e711&#x2013;e729</Citation><ArticleIdList><ArticleId IdType="pubmed">24119542</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG et&#xa0;al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369: 341&#x2013;350</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher&#x2010;Berkovich S, Filipovich&#x2010;Rimon T, Ben&#x2010;Shmuel S, Hulsmann C, Kummer MP, Heneka MT (2010) Distinct modulation of microglial amyloid beta phagocytosis and migration by neuropeptides (i). J&#xa0;Neuroinflammation 7: 61</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964654</ArticleId><ArticleId IdType="pubmed">20937084</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S, Chang P, Silverstein SC (1994) Tyrosine phosphorylation of the gamma subunit of Fc gamma receptors, p72syk, and paxillin during Fc receptor&#x2010;mediated phagocytosis in macrophages. J Biol Chem 269: 3897&#x2013;3902</Citation><ArticleIdList><ArticleId IdType="pubmed">7508923</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S et&#xa0;al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368: 117&#x2013;127</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C (2004) Take five&#x2013;BACE and the gamma&#x2010;secretase quartet conduct Alzheimer's amyloid beta&#x2010;peptide generation. EMBO J 23: 483&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109: 1144&#x2013;1156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL et&#xa0;al (2015) TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med 212: 287&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et&#xa0;al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368: 107&#x2013;116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez&#x2010;Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger&#x2010;Weinzierl A, Mazaheri F et&#xa0;al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6: 243ra286</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A et&#xa0;al (2012) Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J 31: 3157&#x2013;3168</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3400020</ArticleId><ArticleId IdType="pubmed">22728825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathuiliere A, Laversenne V, Astolfo A, Kopetzki E, Jacobsen H, Stampanoni M, Bohrmann B, Schneider BL, Aebischer P (2016) A subcutaneous cellular implant for passive immunization against amyloid&#x2010;beta reduces brain amyloid and tau pathologies. Brain 139: 1587&#x2013;1604</Citation><ArticleIdList><ArticleId IdType="pubmed">26956423</ArticleId></ArticleIdList></Reference><Reference><Citation>Marim FM, Silveira TN, Lima DS Jr, Zamboni DS (2010) A method for generation of bone marrow&#x2010;derived macrophages from cryopreserved mouse bone marrow cells. PLoS ONE 5: e15263</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003694</ArticleId><ArticleId IdType="pubmed">21179419</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Rogers J (1992) Anti&#x2010;inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42: 447&#x2013;449</Citation><ArticleIdList><ArticleId IdType="pubmed">1736183</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D et&#xa0;al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982&#x2013;985</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX et&#xa0;al (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69: 198&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradowska&#x2010;Gorycka A, Jurkowska M (2013) Structure, expression pattern and biological activity of molecular complex TREM&#x2010;2/DAP12. Hum Immunol 74: 730&#x2013;737</Citation><ArticleIdList><ArticleId IdType="pubmed">23459077</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S et&#xa0;al (2006) Abeta42&#x2010;driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940&#x2013;946</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR&#x2010;Cas9 system. Nat Protoc 8: 2281&#x2013;2308</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen&#x2010;Hoerth C, Kertesz A, Bigio EH et&#xa0;al (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener 8: 19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon S (2015) Antibody drugs for Alzheimer's show glimmers of promise. Nature 523: 509&#x2013;510</Citation><ArticleIdList><ArticleId IdType="pubmed">26223602</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA et&#xa0;al (2010) 11C&#x2010;PiB PET assessment of change in fibrillar amyloid&#x2010;beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double&#x2010;blind, placebo&#x2010;controlled, ascending&#x2010;dose study. Lancet Neurol 9: 363&#x2013;372</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson&#x2010;Wood K, Khan K et&#xa0;al (1999) Immunization with amyloid&#x2010;beta attenuates Alzheimer&#x2010;disease&#x2010;like pathology in the PDAPP mouse. Nature 400: 173&#x2013;177</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25&#xa0;years of image analysis. Nat Methods 9: 671&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P, Meldolesi J (2004) Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 20: 2617&#x2013;2628</Citation><ArticleIdList><ArticleId IdType="pubmed">15548205</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H (2007) Pathological activity of familial Alzheimer's disease&#x2010;associated mutant presenilin can be executed by six different gamma&#x2010;secretase complexes. Neurobiol Dis 27: 102&#x2013;107</Citation><ArticleIdList><ArticleId IdType="pubmed">17560791</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez&#x2010;Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD et&#xa0;al (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early&#x2010;stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8: 466&#x2013;476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120370</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells&#x2010;2. J Exp Med 201: 647&#x2013;657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE (2015) TREM2 and risk of Alzheimer's disease&#x2010;Friend or Foe? N Engl J Med 372: 2564&#x2013;2565</Citation><ArticleIdList><ArticleId IdType="pubmed">26107057</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM&#x2010;2 attenuates macrophage activation. J Immunol 177: 3520&#x2013;3524</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Holtzman DM (2016) TREM2 Function in Alzheimer's disease and neurodegeneration. ACS Chem Neurosci 7: 420&#x2013;427</Citation><ArticleIdList><ArticleId IdType="pubmed">26854967</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas&#x2010;Llerena C, Phillips A, Garcia&#x2010;Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol 36: 74&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">26517285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH et&#xa0;al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160: 1061&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S et&#xa0;al (2016) TREM2&#x2010;mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213: 667&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta&#x2010;secretase BACE1. Science 314: 664&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, Hornburg D, Evans LD, Moore S, Daria A et&#xa0;al (2015) eta&#x2010;Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526: 443&#x2013;447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570618</ArticleId><ArticleId IdType="pubmed">26322584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Goni F (2015) Immunotherapeutic approaches for Alzheimer's disease. Neuron 85: 1162&#x2013;1176</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366618</ArticleId><ArticleId IdType="pubmed">25789753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Byers DE, Jin X, Agapov E, Alexander&#x2010;Brett J, Patel AC, Cella M, Gilfilan S, Colonna M, Kober DL et&#xa0;al (2015) TREM&#x2010;2 promotes macrophage survival and lung disease after respiratory viral infection. J Exp Med 212: 681&#x2013;697</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419356</ArticleId><ArticleId IdType="pubmed">25897174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaert K et&#xa0;al (2012) The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in&#xa0;vivo. J Biol Chem 287: 25927&#x2013;25940</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27412785</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>347</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease.</ArticleTitle><Pagination><StartPage>347ra93</StartPage><MedlinePgn>347ra93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf6038</ELocationID><Abstract><AbstractText>C9ORF72 mutations are found in a significant fraction of patients suffering from amyotrophic lateral sclerosis and frontotemporal dementia, yet the function of the C9ORF72 gene product remains poorly understood. We show that mice harboring loss-of-function mutations in the ortholog of C9ORF72 develop splenomegaly, neutrophilia, thrombocytopenia, increased expression of inflammatory cytokines, and severe autoimmunity, ultimately leading to a high mortality rate. Transplantation of mutant mouse bone marrow into wild-type recipients was sufficient to recapitulate the phenotypes observed in the mutant animals, including autoimmunity and premature mortality. Reciprocally, transplantation of wild-type mouse bone marrow into mutant mice improved their phenotype. We conclude that C9ORF72 serves an important function within the hematopoietic system to restrict inflammation and the development of autoimmunity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burberry</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jin-Yuan</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moccia</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mordes</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Morag H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Program in Cellular and Molecular Medicine, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki-Uematsu</LastName><ForeName>Satomi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Sulagna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merkle</LastName><ForeName>Florian T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koszka</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Quan-Zhen</ForeName><Initials>QZ</Initials><AffiliationInfo><Affiliation>Departments of Immunology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zon</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Derrick J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Program in Cellular and Molecular Medicine, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA. Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trowbridge</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME 04609, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Notarangelo</LastName><ForeName>Luigi D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA. Division of Immunology, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggan</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. eggan@mcb.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS089742</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC4 DK104218</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL048801</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/P501967/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K99 NS083713</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA034196</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606498">C9orf72 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Transl Med. 2017 Feb;5(3):60. doi: 10.21037/atm.2017.01.33.</RefSource><PMID Version="1">28251139</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007938" MajorTopicYN="N">Leukemia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013163" MajorTopicYN="N">Splenomegaly</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27412785</ArticleId><ArticleId IdType="mid">NIHMS813782</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pii">8/347/347ra93</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ludolph AC, Brettschneider J, Weishaupt JH. Amyotrophic lateral sclerosis. Curr Opin Neurol. 2012;25:530&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">22918486</ArticleId></ArticleIdList></Reference><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14:248&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GYR, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O'Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Fifita JA, Vucic S, Durnall JC, Kiernan MC, Blair IP, Nicholson GA. Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry. 2013;84:931&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EAJ, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, Rothstein JD, Wang J. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, Haass C, Edbauer D. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. 2013;74:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, Maragakis N, Tienari PJ, Petrucelli L, Traynor BJ, Wang J, Rigo F, Bennett CF, Blackshaw S, Sattler R, Rothstein JD. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, Wong LH, Hayes MJ. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinforma Oxf Engl. 2013;29:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RAK, Levina V, Halloran MA, Gleeson PA, Blair IP, Soo KY, King AE, Atkin JD. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet. 2014;23:3579&#x2013;3595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA, Parker JA. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PloS One. 2013;8:e83450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Maroof AM, Merkle FT, Koszka K, Intoh A, Armstrong I, Moccia R, Davis-Dusenbery BN, Eggan K. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat Neurosci. 2013;16:1725&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397902</ArticleId><ArticleId IdType="pubmed">24185425</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M, Blokhuis AM, Westeneng H-J, Terpstra ML, Zundel CAC, Vieira de S&#xe1; R, Schellevis RD, Waite AJ, Blake DJ, Veldink JH, van den Berg LH, Pasterkamp RJ. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol. 2015 doi: 10.1002/ana.24453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24453</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijli FM, Doll&#xe9; P, Fraulob V, LeMeur M, Chambon P. Insertion of a targeting construct in a Hoxd-10 allele can influence the control of Hoxd-9 expression. Dev Dyn Off Publ Am Assoc Anat. 1994;201:366&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">7894075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, Lewis P, Pevny L, McMahon AP. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev. 2002;119(Suppl1):S97&#x2013;S101.</Citation><ArticleIdList><ArticleId IdType="pubmed">14516668</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehurst CE, Chattopadhyay S, Chen J. Control of V(D)J Recombinational Accessibility of the D&#x3b2;1 Gene Segment at the TCR&#x3b2; Locus by a Germline Promoter. Immunity. 1999;10:313&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">10204487</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozman C, Montserrat E, Rodriguez-Fernandez JM, Ayats R, Vallespi T, Parody R, Rios A, Prados D, Morey M, Gomis F. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984;64:642&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">6466871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Zhou X, Chang M, Nakaya M, Chang JH, Xiao Y, Lindsey JW, Dorta-Estremera S, Cao W, Zal A, Zal T, Sun SC. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat Commun. 2015;6:6074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302769</ArticleId><ArticleId IdType="pubmed">25606824</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore SW, Schneider JW, Schaaf HS. Diagnostic aspects of cervical lymphadenopathy in children in the developing world: a study of 1,877 surgical specimens. Pediatr Surg Int. 2003;19:240&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700919</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami J, Shimizu Y, Murakami J, Shimizu Y. Hepatic Manifestations in Hematological Disorders, Hepatic Manifestations in Hematological Disorders. Int J Hepatol Int J Hepatol. 2013:e484903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3626309</ArticleId><ArticleId IdType="pubmed">23606974</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell ES, Neufeld EF, Higgins CT. Comparison of normal blood picture of young adults from 18 inbred strains of mice. Proc Soc Exp Biol Med Soc Exp Biol Med N Y N. 1951;78:761&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">14912022</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman J. Autoimmune Hemolysis: A Journey through Time. Transfus Med Hemotherapy. 2015;42:278&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4678316</ArticleId><ArticleId IdType="pubmed">26696795</ArticleId></ArticleIdList></Reference><Reference><Citation>Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res. 2013;55:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018221</ArticleId><ArticleId IdType="pubmed">22941560</ArticleId></ArticleIdList></Reference><Reference><Citation>Su KY, Pisetsky DS. The Role of Extracellular DNA in Autoimmunity in SLE. Scand J Immunol. 2009;70:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">19703007</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QZ, Xie C, Wu T, Mackay M, Aranow C, Putterman C, Mohan C. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest. 2005;115:3428&#x2013;3439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1297234</ArticleId><ArticleId IdType="pubmed">16322790</ArticleId></ArticleIdList></Reference><Reference><Citation>Heng TSP, Painter MW. Immunological Genome Project Consortium, The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008;9:1091&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">18800157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco N, Swee LK, B&#xe9;nard A, Ceredig R, Rolink A. Auto-reconstitution of the T-cell compartment by radioresistant hematopoietic cells following lethal irradiation and bone marrow transplantation. Exp Hematol. 2010;38:222&#x2013;232.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">20045443</ArticleId></ArticleIdList></Reference><Reference><Citation>Crampton SP, Morawski PA, Bolland S. Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. Dis Model Mech. 2014;7:1033&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142724</ArticleId><ArticleId IdType="pubmed">25147296</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281037</ArticleId><ArticleId IdType="pubmed">25145755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH, Carroll MC. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 2008;105:17913&#x2013;17918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Baruch K. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. J Autoimmun. 2014;54:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25199710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP, O'Neill L, Beyaert R, Piette J, Chariot A. Are the IKKs and IKK-related kinases TBK1 and IKK-&#x3b5; similarly activated? Trends Biochem Sci. 2008;33:171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">18353649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt C, Houlden H. Exome sequencing uncovers hidden pathways in familial and sporadic ALS. Nat Neurosci. 2015;18:611&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">25919956</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchlik E, Thakker P, Carlson T, Jiang Z, Ryan M, Marusic S, Goutagny N, Kuang W, Askew GR, Roberts V, Benoit S, Zhou T, Ling V, Pfeifer R, Stedman N, Fitzgerald KA, Lin LL, Hall JP. Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality. J Leukoc Biol. 2010;88:1171&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">20651301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2013;8:888&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani MR, Gonzalez LE, Uchitel OD, Pagani MR, Gonzalez LE, Uchitel OD. Autoimmunity in Amyotrophic Lateral Sclerosis: Past and Present. Neurol Res Int. 2011:e497080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150148</ArticleId><ArticleId IdType="pubmed">21826267</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, van den Oord JJ, de Jong JM, Swaab DF. Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin Neuropathol. 1989;8:289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">2533530</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Sikl&#xf3;s L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55:221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos A, Alexakis T, Tsoutsou A, Samakovli A, Michalopoulou M, Evdokimidis J. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand. 2010;122:425&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013;81:1222&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, Siao CJ, Brydges S, LaRosa E, Bai Y, Fury W, Burfeind P, Zamfirova R, Warshaw G, Orengo J, Oyejide A, Fralish M, Auerbach W, Poueymirou W, Freudenberg J, Gong G, Zambrowicz B, Valenzuela D, Yancopoulos G, Murphy A, Thurston G, Lai KMV. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AKMG, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid-Burgk JL, Schmidt T, Gaidt MM, Pelka K, Latz E, Ebert TS, Hornung V. OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines. Genome Res. 2014;24:1719&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199374</ArticleId><ArticleId IdType="pubmed">25186908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27413148</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>28</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.</ArticleTitle><Pagination><StartPage>7364</StartPage><EndPage>7374</EndPage><MedlinePgn>7364-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0639-16.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">We provide a comparative in vivo examination of the brain network-based distribution of two hallmarks of Alzheimer's disease (AD) pathology in cognitively normal individuals: (1) Tau, detected with a novel positron emission tomography (PET) tracer known as (18)F-AV-1451; and (2) amyloid-&#x3b2;, quantified with (11)C-PiB PET. We used a high-resolution graph-based approach to investigate local-to-local and local-to-distributed cortical associations between the maps of Tau, amyloid-&#x3b2;, and gray matter intensity. Our study shows that Tau and amyloid-&#x3b2; deposits are associated with distinctive spatial patterns of brain tissue loss. Moreover, Tau and amyloid-&#x3b2; accumulations have strong network interdigitations in heteromodal and associative areas of the cortical mantle, particularly the inferior-lateral temporal lobe. These findings contribute significantly to our understanding of how these two main hallmarks of AD pathology propagate across the elderly human brain.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT">It has been postulated that Alzheimer's disease (AD) pathology interacts and resides within system-level circuits of the human brain, long before the onset of cognitive symptoms. However, a side-by-side comparison of tissue loss, amyloid-&#x3b2;, and Tau deposition in early stages of the disease has been precluded until the recent advent of Tau tracer-based neuroimaging. In this study, we used Tau positron emission tomography and network analyses to disentangle these pathological relationships. We found that Tau and amyloid-&#x3b2; deposits are associated with distinctive spatial patterns of brain tissue loss. Moreover, we uncovered the network interdigitations of Tau and amyloid-&#x3b2; in the cortical mantle. These findings contribute significantly to our understanding of how two main hallmarks of AD pathology propagate across the elderly human brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 the authors 0270-6474/16/367364-11$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4199-2304</Identifier><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, and sepulcre@nmr.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabuncu</LastName><ForeName>Mert</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7792-1698</Identifier><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts 02129, and Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, Centre for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K25 EB013649</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 EB019023</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG049087</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R41 AG052246</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">gray matter</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27413148</ArticleId><ArticleId IdType="pmc">PMC4945661</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0639-16.2016</ArticleId><ArticleId IdType="pii">36/28/7364</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1:103&#x2013;116. doi: 10.1093/cercor/1.1.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/1.1.103</ArticleId><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry&#x2014;the methods. Neuroimage. 2000;11:805&#x2013;821. doi: 10.1006/nimg.2000.0582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2000.0582</ArticleId><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72:1048&#x2013;1055. doi: 10.1212/01.wnl.0000340981.97664.2f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000340981.97664.2f</ArticleId><ArticleId IdType="pmc">PMC2677470</ArticleId><ArticleId IdType="pubmed">19109536</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032&#x2013;1042. doi: 10.1002/ana.22333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22333</ArticleId><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1991a;1:213&#x2013;216. doi: 10.1111/j.1750-3639.1991.tb00661.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1991.tb00661.x</ArticleId><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991b;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44:195&#x2013;208. doi: 10.1016/j.neuron.2004.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.09.006</ArticleId><ArticleId IdType="pubmed">15450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos A, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873. doi: 10.1523/JNEUROSCI.5062-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5062-08.2009</ArticleId><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage. 2003;18:525&#x2013;541. doi: 10.1016/S1053-8119(02)00026-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1053-8119(02)00026-5</ArticleId><ArticleId IdType="pubmed">12595205</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2014;38:171&#x2013;184. doi: 10.3233/JAD-130098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130098</ArticleId><ArticleId IdType="pubmed">23948934</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755&#x2013;766. doi: 10.1007/s00401-014-1349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, Papp KV, Amariglio RE, Blacker D, Rentz DM, Johnson KA, Sperling RA, Schultz AP. Harvard Aging Brain Study: dataset and accessibility. Neuroimage. 2015 doi: 10.1016/j.neuroimage.2015.03.069. doi: 10.1016/j.neuroimage.2015.03.069. Advance online publication. Retrieved May 25, 2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.03.069</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2015.03.069</ArticleId><ArticleId IdType="pmc">PMC4592689</ArticleId><ArticleId IdType="pubmed">25843019</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nooy W, Mrvar A, Batageli V. Exploratory social network analysis with Pajek. Cambridge, UK: Cambridge UP; 2005.</Citation></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510. doi: 10.1093/cercor/bhn113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhn113</ArticleId><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642. doi: 10.1073/pnas.0308627101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308627101</ArticleId><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572. doi: 10.1192/bjp.140.6.566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.140.6.566</ArticleId><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170. doi: 10.1126/science.6474172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6474172</ArticleId><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1&#x2013;13. doi: 10.1016/j.jalz.2011.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630&#x2013;1645. doi: 10.1093/brain/awn016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn016</ArticleId><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925&#x2013;931. doi: 10.1212/01.WNL.0000115115.98960.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000115115.98960.37</ArticleId><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR., Jr PART and SNAP. Acta Neuropathol. 2014;128:773&#x2013;776. doi: 10.1007/s00401-014-1362-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1362-3</ArticleId><ArticleId IdType="pmc">PMC4231211</ArticleId><ArticleId IdType="pubmed">25380757</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, O'Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42:183&#x2013;188. doi: 10.1212/WNL.42.1.183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.1.183</ArticleId><ArticleId IdType="pubmed">1734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol. 2016;79:110&#x2013;119. doi: 10.1002/ana.24546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006213. doi: 10.1101/cshperspect.a006213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006213</ArticleId><ArticleId IdType="pmc">PMC3312396</ArticleId><ArticleId IdType="pubmed">22474610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalus P, Braak H, Braak E, Bohl J. The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes. Brain Res. 1989;494:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">2765920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada T, Kawai S. An algorithm for drawing general undirected graphs. Inf Process Lett. 1989;31:7&#x2013;15. doi: 10.1016/0020-0190(89)90102-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0020-0190(89)90102-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319. doi: 10.1002/ana.20009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20009</ArticleId><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Wegmann S, Kopeikina KJ, Hawkes J, Rudinskiy N, Andermann ML, Spires-Jones TL, Bacskai BJ, Hyman BT. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A. 2014;111:510&#x2013;514. doi: 10.1073/pnas.1318807111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318807111</ArticleId><ArticleId IdType="pmc">PMC3890777</ArticleId><ArticleId IdType="pubmed">24368848</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x2212;)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, G&#xf3;mez-Isla T. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787&#x2013;800. doi: 10.1002/ana.24517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24517</ArticleId><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094&#x2013;1108. doi: 10.1016/j.neuron.2013.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.037</ArticleId><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Masdeu JC, Kreisl WC, Berman KF. The neurobiology of Alzheimer disease defined by neuroimaging. Curr Opin Neurol. 2012;25:410&#x2013;420. doi: 10.1097/WCO.0b013e3283557b36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283557b36</ArticleId><ArticleId IdType="pubmed">22766722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;2754. doi: 10.1021/jm030026b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030026b</ArticleId><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639. doi: 10.1038/nature02621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02621</ArticleId><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci. 2014;8:113. doi: 10.3389/fncel.2014.00113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00113</ArticleId><ArticleId IdType="pmc">PMC4005959</ArticleId><ArticleId IdType="pubmed">24795568</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94. doi: 10.1002/ana.410420114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420114</ArticleId><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452. doi: 10.1212/01.wnl.0000228230.26044.a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000228230.26044.a4</ArticleId><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging. 2014;35:301&#x2013;308. doi: 10.1016/j.neurobiolaging.2013.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.08.007</ArticleId><ArticleId IdType="pmc">PMC3977862</ArticleId><ArticleId IdType="pubmed">24080173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, Abe M. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol. 1989;134:243&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879581</ArticleId><ArticleId IdType="pubmed">2464938</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne V, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420&#x2013;1427. doi: 10.2967/jnumed.112.117341.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.117341</ArticleId><ArticleId IdType="pubmed">23857514</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson RC, Powell TP. The neuroanatomy of Alzheimer's disease. Rev Neurosci. 1989;2:101&#x2013;122. doi: 10.1515/REVNEURO.1989.2.2.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/REVNEURO.1989.2.2.101</ArticleId><ArticleId IdType="pubmed">21561251</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73:1204&#x2013;1215. doi: 10.1016/j.neuron.2011.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.12.040</ArticleId><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040&#x2013;1048. doi: 10.1001/archneurol.2011.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.167</ArticleId><ArticleId IdType="pmc">PMC3248949</ArticleId><ArticleId IdType="pubmed">21825241</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J. Atrophy of medial temporal lobes on MRI in &#x201c;probable&#x201d; Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967&#x2013;972. doi: 10.1136/jnnp.55.10.967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.55.10.967</ArticleId><ArticleId IdType="pmc">PMC1015202</ArticleId><ArticleId IdType="pubmed">1431963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52. doi: 10.1016/j.neuron.2009.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.03.024</ArticleId><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain. 2013;136:2239&#x2013;2252. doi: 10.1093/brain/awt146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt146</ArticleId><ArticleId IdType="pmc">PMC3692037</ArticleId><ArticleId IdType="pubmed">23801740</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup T, Yokell D, Rice P, Jackson R, Livni E, Johnson K, Brady T, Vasdev N. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm. 2013;56:736&#x2013;740. doi: 10.1002/jlcr.3098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlcr.3098</ArticleId><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, Ferrucci L, Pletnikova O, Mathis CA, Klunk WE, O'Brien RJ, Wong DF, Troncoso JC, Resnick SM. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011;68:232&#x2013;240. doi: 10.1001/archneurol.2010.357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.357</ArticleId><ArticleId IdType="pmc">PMC3082956</ArticleId><ArticleId IdType="pubmed">21320990</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800. doi: 10.1212/WNL.58.12.1791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC. A population-average, landmark- and surface-based (PALS) atlas of human cerebral cortex. Neuroimage. 2005;28:635&#x2013;662. doi: 10.1016/j.neuroimage.2005.06.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2005.06.058</ArticleId><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference><Reference><Citation>Villain N, Fouquet M, Baron JC, M&#xe9;zenge F, Landeau B, de La Sayette V, Viader F, Eustache F, Desgranges B, Ch&#xe9;telat G. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain. 2010;133:3301&#x2013;3314. doi: 10.1093/brain/awq203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq203</ArticleId><ArticleId IdType="pmc">PMC3291528</ArticleId><ArticleId IdType="pubmed">20688814</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Ch&#xe9;telat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181&#x2013;192. doi: 10.1002/ana.22248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22248</ArticleId><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Dor&#xe9; V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:816&#x2013;826. doi: 10.1007/s00259-013-2681-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2681-7</ArticleId><ArticleId IdType="pubmed">24514874</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, Benzinger TL, Morris JC. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70:857&#x2013;861. doi: 10.1002/ana.22608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22608</ArticleId><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Diamond MI, Duff KE, Hyman BT. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013;70:304&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665718</ArticleId><ArticleId IdType="pubmed">23599928</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213&#x2013;228. doi: 10.2174/0929866043407174.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929866043407174</ArticleId><ArticleId IdType="pubmed">15182223</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Tosakulwong N, Weigand SD, Senjem ML, Lowe VJ, Gunter JL, Boeve BF, Knopman DS, Dickerson BC, Petersen RC, Jack CR., Jr Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin. 2013;2:249&#x2013;257. doi: 10.1016/j.nicl.2013.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2013.01.006</ArticleId><ArticleId IdType="pmc">PMC3778266</ArticleId><ArticleId IdType="pubmed">24179779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216&#x2013;1227. doi: 10.1016/j.neuron.2012.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.004</ArticleId><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">64712</PMID><DateCompleted><Year>1977</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>8004</Issue><PubDate><Year>1977</Year><Month>Jan</Month><Day>22</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Necropsy evidence of central cholinergic deficits in senile dementia.</ArticleTitle><Pagination><StartPage>189</StartPage><MedlinePgn>189</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>E K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>R H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Blessed</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011950">Receptors, Cholinergic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.-</RegistryNumber><NameOfSubstance UI="D000123">Acetyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000123" MajorTopicYN="N">Acetyltransferases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010296" MajorTopicYN="N">Parietal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011950" MajorTopicYN="Y">Receptors, Cholinergic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="Y">Receptors, Muscarinic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>1</Month><Day>22</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>1</Month><Day>22</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">64712</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(77)91780-9</ArticleId><ArticleId IdType="pii">S0140-6736(77)91780-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27357684</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>28</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates.</ArticleTitle><Pagination><StartPage>7900</StartPage><EndPage>7905</EndPage><MedlinePgn>7900-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1602413113</ELocationID><Abstract><AbstractText>The most widely used task functional magnetic resonance imaging (fMRI) analyses use parametric statistical methods that depend on a variety of assumptions. In this work, we use real resting-state data and a total of 3 million random task group analyses to compute empirical familywise error rates for the fMRI software packages SPM, FSL, and AFNI, as well as a nonparametric permutation method. For a nominal familywise error rate of 5%, the parametric statistical methods are shown to be conservative for voxelwise inference and invalid for clusterwise inference. Our results suggest that the principal cause of the invalid cluster inferences is spatial autocorrelation functions that do not follow the assumed Gaussian shape. By comparison, the nonparametric permutation test is found to produce nominal results for voxelwise as well as clusterwise inference. These findings speak to the need of validating the statistical methods being used in the field of neuroimaging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eklund</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Medical Informatics, Department of Biomedical Engineering, Link&#xf6;ping University, S-581 85 Link&#xf6;ping, Sweden; Division of Statistics and Machine Learning, Department of Computer and Information Science, Link&#xf6;ping University, S-581 83 Link&#xf6;ping, Sweden; Center for Medical Image Science and Visualization, Link&#xf6;ping University, S-581 83 Link&#xf6;ping, Sweden; anders.eklund@liu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Warwick, Coventry CV4 7AL, United Kingdom; WMG, University of Warwick, Coventry CV4 7AL, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knutsson</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Medical Informatics, Department of Biomedical Engineering, Link&#xf6;ping University, S-581 85 Link&#xf6;ping, Sweden; Center for Medical Image Science and Visualization, Link&#xf6;ping University, S-581 83 Link&#xf6;ping, Sweden;</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 MH091657</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7699-700. doi: 10.1073/pnas.1608146113.</RefSource><PMID Version="1">27357671</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4929. doi: 10.1073/pnas.1612033113.</RefSource><PMID Version="1">27503879</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cogn Neurosci. 2017 Jul;8(3):141-143. doi: 10.1080/17588928.2016.1273892.</RefSource><PMID Version="1">28002981</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3374-E3375. doi: 10.1073/pnas.1620285114.</RefSource><PMID Version="1">28420795</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3372-E3373. doi: 10.1073/pnas.1614502114.</RefSource><PMID Version="1">28420796</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3368-E3369. doi: 10.1073/pnas.1705513114.</RefSource><PMID Version="1">28420797</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3370-E3371. doi: 10.1073/pnas.1614961114.</RefSource><PMID Version="1">28420798</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>World Neurosurg. 2017 Aug;104:967. doi: 10.1016/j.wneu.2017.06.101.</RefSource><PMID Version="1">28645589</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Front Hum Neurosci. 2017 Jun 28;11:345. doi: 10.3389/fnhum.2017.00345.</RefSource><PMID Version="1">28701944</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2017 Aug 8;89(6):640. doi: 10.1212/WNL.0000000000004204.</RefSource><PMID Version="1">28784636</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2017 Aug 8;89(6):640-641. doi: 10.1212/WNL.0000000000004203.</RefSource><PMID Version="1">28784637</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="Y">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cluster inference</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">false positives</Keyword><Keyword MajorTopicYN="N">permutation test</Keyword><Keyword MajorTopicYN="N">statistics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27357684</ArticleId><ArticleId IdType="pmc">PMC4948312</ArticleId><ArticleId IdType="doi">10.1073/pnas.1602413113</ArticleId><ArticleId IdType="pii">1602413113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ogawa S, et al. Intrinsic signal changes accompanying sensory stimulation: Functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA. 1992;89(13):5951&#x2013;5955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC402116</ArticleId><ArticleId IdType="pubmed">1631079</ArticleId></ArticleIdList></Reference><Reference><Citation>Logothetis NK. What we can do and what we cannot do with fMRI. Nature. 2008;453(7197):869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">18548064</ArticleId></ArticleIdList></Reference><Reference><Citation>Welvaert M, Rosseel Y. A review of fMRI simulation studies. PLoS One. 2014;9(7):e101953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105464</ArticleId><ArticleId IdType="pubmed">25048024</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal BB, et al. Toward discovery science of human brain function. Proc Natl Acad Sci USA. 2010;107(10):4734&#x2013;4739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842060</ArticleId><ArticleId IdType="pubmed">20176931</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC, et al. WU-Minn HCP Consortium The WU-Minn Human Connectome Project: An overview. Neuroimage. 2013;80:62&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724347</ArticleId><ArticleId IdType="pubmed">23684880</ArticleId></ArticleIdList></Reference><Reference><Citation>Poldrack RA, Gorgolewski KJ. Making big data open: Data sharing in neuroimaging. Nat Neurosci. 2014;17(11):1510&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pubmed">25349916</ArticleId></ArticleIdList></Reference><Reference><Citation>Poldrack RA, et al. Toward open sharing of task-based fMRI data: The OpenfMRI project. Front Neuroinform. 2013;7(12):12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703526</ArticleId><ArticleId IdType="pubmed">23847528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller SG, et al. The Alzheimer&#x2019;s disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15(4):869&#x2013;877, xi&#x2013;xii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Poline JB, et al. Data sharing in neuroimaging research. Front Neuroinform. 2012;6(9):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319918</ArticleId><ArticleId IdType="pubmed">22493576</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpazza C, Sartori G, De Simone MS, Mechelli A. When the single matters more than the group: Very high false positive rates in single case voxel based morphometry. Neuroimage. 2013;70:175&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">23291189</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J, Friston KJ. Voxel-based morphometry&#x2014;the methods. Neuroimage. 2000;11(6 Pt 1):805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver M, Montana G, Nichols TE. Alzheimer&#x2019;s Disease Neuroimaging Initiative False positives in neuroimaging genetics using voxel-based morphometry data. Neuroimage. 2011;54(2):992&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063336</ArticleId><ArticleId IdType="pubmed">20849959</ArticleId></ArticleIdList></Reference><Reference><Citation>Eklund A, Andersson M, Josephson C, Johannesson M, Knutsson H. Does parametric fMRI analysis with SPM yield valid results? An empirical study of 1484 rest datasets. Neuroimage. 2012;61(3):565&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">22507229</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston K, Ashburner J, Kiebel S, Nichols T, Penny W. Statistical Parametric Mapping: The Analysis of Functional Brain Images. Elsevier/Academic; London: 2007.</Citation></Reference><Reference><Citation>Ashburner J. SPM: A history. Neuroimage. 2012;62(2):791&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480642</ArticleId><ArticleId IdType="pubmed">22023741</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. FSL. Neuroimage. 2012;62(2):782&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">21979382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox RW. AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res. 1996;29(3):162&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">8812068</ArticleId></ArticleIdList></Reference><Reference><Citation>Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp. 1994;1(3):210&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">24578041</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman SD, et al. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): Use of a cluster-size threshold. Magn Reson Med. 1995;33(5):636&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596267</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo CW, Krishnan A, Wager TD. Cluster-extent based thresholding in fMRI analyses: Pitfalls and recommendations. Neuroimage. 2014;91:412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4214144</ArticleId><ArticleId IdType="pubmed">24412399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: A primer with examples. Hum Brain Mapp. 2002;15(1):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage. 2014;92:381&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010955</ArticleId><ArticleId IdType="pubmed">24530839</ArticleId></ArticleIdList></Reference><Reference><Citation>Brammer MJ, et al. Generic brain activation mapping in functional magnetic resonance imaging: A nonparametric approach. Magn Reson Imaging. 1997;15(7):763&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">9309607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore ET, et al. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Transactions on Medical Imaging. 1999;18(1):32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10193695</ArticleId></ArticleIdList></Reference><Reference><Citation>Carp J. The secret lives of experiments: Methods reporting in the fMRI literature. Neuroimage. 2012;63(1):289&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">22796459</ArticleId></ArticleIdList></Reference><Reference><Citation>Eklund A, Dufort P, Villani M, Laconte S. BROCCOLI: Software for fast fMRI analysis on many-core CPUs and GPUs. Front Neuroinform. 2014;8:24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953750</ArticleId><ArticleId IdType="pubmed">24672471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman MD, Cunningham WA. Type I and type II error concerns in fMRI research: Re-balancing the scale. Soc Cogn Affect Neurosci. 2009;4(4):423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799956</ArticleId><ArticleId IdType="pubmed">20035017</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM. Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage. 2004;21(4):1732&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayasaka S, Nichols TE. Validating cluster size inference: Random field and permutation methods. Neuroimage. 2003;20(4):2343&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pubmed">14683734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegeskorte N, et al. Artifactual time-course correlations in echo-planar fMRI with implications for studies of brain function. Int J Imaging Syst Technol. 2008;18(5-6):345&#x2013;349.</Citation></Reference><Reference><Citation>Kiebel SJ, Poline JB, Friston KJ, Holmes AP, Worsley KJ. Robust smoothness estimation in statistical parametric maps using standardized residuals from the general linear model. Neuroimage. 1999;10(6):756&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">10600421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayasaka S, Phan KL, Liberzon I, Worsley KJ, Nichols TE. Nonstationary cluster-size inference with random field and permutation methods. Neuroimage. 2004;22(2):676&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">15193596</ArticleId></ArticleIdList></Reference><Reference><Citation>Salimi-Khorshidi G, Smith SM, Nichols TE. Adjusting the effect of nonstationarity in cluster-based and TFCE inference. Neuroimage. 2011;54(3):2006&#x2013;2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955803</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom SM, Fox CR, Trepel C, Poldrack RA. The neural basis of loss aversion in decision-making under risk. Science. 2007;315(5811):515&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">17255512</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan KJ, Pattamadilok C, Knierim I, Devlin JT. Consistency and variability in functional localisers. Neuroimage. 2009;46(4):1018&#x2013;1026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686646</ArticleId><ArticleId IdType="pubmed">19289173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182327</ArticleId><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlicov&#xe1; M, Cressie NA, Santner TJ. Testing for activation in data from FMRI experiments. J Data Sci. 2006;4(3):275&#x2013;289.</Citation></Reference><Reference><Citation>Scarpazza C, Tognin S, Frisciata S, Sartori G, Mechelli A. False positive rates in voxel-based morphometry studies of the human brain: Should we be worried? Neurosci Biobehav Rev. 2015;52:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">25701614</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Lindenberg A, et al. False positives in imaging genetics. Neuroimage. 2008;40(2):655&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols T, Hayasaka S. Controlling the familywise error rate in functional neuroimaging: A comparative review. Stat Methods Med Res. 2003;12(5):419&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">14599004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair DA, et al. A method for using blocked and event-related fMRI data to study &#x201c;resting state&#x201d; functional connectivity. Neuroimage. 2007;35(1):396&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563954</ArticleId><ArticleId IdType="pubmed">17239622</ArticleId></ArticleIdList></Reference><Reference><Citation>Eklund A, Dufort P, Forsberg D, LaConte SM. Medical image processing on the GPU&#x2014;past, present and future. Med Image Anal. 2013;17(8):1073&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">23906631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgolewski KJ, et al. NeuroVault.org: A repository for sharing unthresholded statistical maps, parcellations, and atlases of the human brain. Neuroimage. 2016;124(Pt B):1242&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806527</ArticleId><ArticleId IdType="pubmed">25869863</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3670729</PMID><DateCompleted><Year>1987</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>79</Volume><Issue>1-2</Issue><PubDate><Year>1987</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci Lett</ISOAbbreviation></Journal><ArticleTitle>Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>200</EndPage><MedlinePgn>195-200</MedlinePgn></Pagination><Abstract><AbstractText>HLA-DR is a class II cell surface glycoprotein of the human histocompatibility complex usually expressed on the surface of cells that are simultaneously presenting foreign antigen to T-lymphocytes. Using immunohistochemical procedures with two specific monoclonal antibodies to HLA-DR, HLA-DR-positive reactive microglia were found in gray matter throughout the cortex of postmortem brains of patients with senile dementia of the Alzheimer type (SDAT) and were particularly concentrated in the areas of senile plaque formation. Double immunostaining with antibodies to glial fibrillary acidic protein (GFAP) showed that the HLA-DR-positive cells were different from the reactive astrocytes although the occasional positively staining giant astrocyte was also seen. Small numbers of resting microglia were HLA-DR-positive in white matter of both normal and SDAT brains. The SDAT cases also had reduced cortical choline acetyltransferase (ChAT) levels. In the 11 brains studied, the number of hippocampal HLA-DR-positive cells was positively correlated with the numbers of plaques and negatively correlated with average cortical ChAT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>P L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itagaki</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tago</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>E G</ForeName><Initials>EG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006681">HLA-D Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006681" MajorTopicYN="N">HLA-D Antigens</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>8</Month><Day>18</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>8</Month><Day>18</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId><ArticleId IdType="doi">10.1016/0304-3940(87)90696-3</ArticleId><ArticleId IdType="pii">0304-3940(87)90696-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27440727</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>348</Issue><PubDate><Year>2016</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Imaging synaptic density in the living human brain.</ArticleTitle><Pagination><StartPage>348ra96</StartPage><MedlinePgn>348ra96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf6667</ELocationID><Abstract><AbstractText>Chemical synapses are the predominant neuron-to-neuron contact in the central nervous system. Presynaptic boutons of neurons contain hundreds of vesicles filled with neurotransmitters, the diffusible signaling chemicals. Changes in the number of synapses are associated with numerous brain disorders, including Alzheimer's disease and epilepsy. However, all current approaches for measuring synaptic density in humans require brain tissue from autopsy or surgical resection. We report the use of the synaptic vesicle glycoprotein 2A (SV2A) radioligand [(11)C]UCB-J combined with positron emission tomography (PET) to quantify synaptic density in the living human brain. Validation studies in a baboon confirmed that SV2A is an alternative synaptic density marker to synaptophysin. First-in-human PET studies demonstrated that [(11)C]UCB-J had excellent imaging properties. Finally, we confirmed that PET imaging of SV2A was sensitive to synaptic loss in patients with temporal lobe epilepsy. Thus, [(11)C]UCB-J PET imaging is a promising approach for in vivo quantification of synaptic density with several potential applications in diagnosis and therapeutic monitoring of neurological and psychiatric disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finnema</LastName><ForeName>Sjoerd J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA. sjoerd.finnema@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabulsi</LastName><ForeName>Nabeel B</ForeName><Initials>NB</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eid</LastName><ForeName>Tore</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Detyniecki</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Shu-Fei</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming-Kai</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhaher</LastName><ForeName>Roni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matuskey</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baum</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holden</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Dennis D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Jo&#xeb;l</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UCB Pharma, B-1420 Braine-l'Alleud, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannestad</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UCB Pharma, B-1420 Braine-l'Alleud, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yiyun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Yale Positron Emission Tomography Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT 06520, USA. Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>148845-93-6</RegistryNumber><NameOfSubstance UI="C076414">SV2A protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27440727</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf6667</ArticleId><ArticleId IdType="pii">8/348/348ra96</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27429218</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration.</ArticleTitle><Pagination><StartPage>1078</StartPage><EndPage>1088</EndPage><MedlinePgn>1078-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.2016</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Clearer delineation of the phenotypic heterogeneity within behavioral variant frontotemporal dementia (bvFTD) will help uncover underlying biological mechanisms and improve clinicians' ability to predict disease course and to design targeted management strategies.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify subtypes of bvFTD syndrome based on distinctive patterns of atrophy defined by selective vulnerability of specific functional networks targeted in bvFTD using statistical classification approaches.</AbstractText><AbstractText Label="DESIGN, SETTING AND PARTICIPANTS" NlmCategory="METHODS">In this retrospective observational study, 90 patients meeting the Frontotemporal Dementia Consortium consensus criteria for bvFTD underwent evaluation at the Memory and Aging Center of the Department of Neurology at University of California, San Francisco. Patients underwent a multidisciplinary clinical evaluation, including clinical demographics, genetic testing, symptom evaluation, neurologic examination, neuropsychological bedside testing, and socioemotional assessments. All patients underwent structural magnetic resonance imaging at their earliest evaluation at the memory clinic. From each patient's structural imaging scans, the mean volumes of 18 regions of interest (ROI) constituting the functional networks specifically vulnerable in bvFTD, including the salience network (SN), with key nodes in the frontoinsula and pregenual anterior cingulate, and the semantic appraisal network (SAN), anchored in the anterior temporal lobe and subgenual cingulate, were estimated. Principal component and cluster analyses of ROI volumes were used to identify patient clusters with anatomically distinct atrophy patterns. Data were collected from from June 19, 2002, to January 13, 2015.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Evaluation of brain morphology and other clinical features, including presenting symptoms, neurologic examination signs, neuropsychological performance, rate of dementia progression, and socioemotional function, in each patient cluster.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ninety patients (54 men [60%]; 36 women [40%]; mean [SD] age at evaluation, 55.1 [9.7] years) were included in the analysis. Four subgroups of patients with bvFTD with distinct anatomic patterns of network degeneration were identified, including 2 salience network-predominant subgroups (frontal/temporal [SN-FT] and frontal [SN-F]), a semantic appraisal network-predominant group (SAN), and a subcortical-predominant group. Subgroups demonstrated distinct patterns of cognitive, socioemotional, and motor symptoms, as well as genetic compositions and estimated rates of disease progression.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Divergent patterns of vulnerability in specific functional network components make an important contribution to the clinical heterogeneity of bvFTD. The data-driven anatomic classification identifies biologically meaningful anatomic phenotypes and provides a replicable approach to disambiguate the bvFTD syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ranasinghe</LastName><ForeName>Kamalini G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Katherine P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pressman</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobach</LastName><ForeName>Iryna V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco2Department of Epidemiology and Biostatistics, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco3Department of Pathology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco3Department of Pathology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shany-Ur</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorno-Tempini</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiong</LastName><ForeName>Winston</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeMay</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Possin</LastName><ForeName>Katherine L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturm</LastName><ForeName>Virginia E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bettcher</LastName><ForeName>Brianne M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco5Departments of Neurosurgery and Neurology, University of Colorado Anschutz School of Medicine, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neylan</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zackey</LastName><ForeName>Diana D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Lauren A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketelle</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Block</LastName><ForeName>Nikolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Teresa Q</ForeName><Initials>TQ</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dallich</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russek</LastName><ForeName>Natanya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caplan</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Center for Autism Research and Treatment, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vossel</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco7Gladstone Institute of Neurological Disease, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG040127</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG039414</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG038791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG021606</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG045289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG042492</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS050915</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092089</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG038357</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG029577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 RR022879</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DC015544</GrantID><Acronym>DC</Acronym><Agency>NIDCD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052943</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG037566</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG038306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG048291</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Sep 1;73(9):1051-2. doi: 10.1001/jamaneurol.2016.1793.</RefSource><PMID Version="1">27428243</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27429218</ArticleId><ArticleId IdType="mid">NIHMS812305</ArticleId><ArticleId IdType="pmc">PMC5024785</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.2016</ArticleId><ArticleId IdType="pii">2533709</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Neary D, Mann DM. Frontotemporal dementia. Br J Psychiatry. 2002;180:140&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodges JR. Frontotemporal dementia (Pick's disease): clinical features and assessment. Neurology. 2001;56(11 Suppl 4):S6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11402143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol. 2011;10(9):829&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219874</ArticleId><ArticleId IdType="pubmed">21778116</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73(6):1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo BT, Krienen FM, Sepulcre J, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106(3):1125&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174820</ArticleId><ArticleId IdType="pubmed">21653723</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Zhou J, Kim EJ. Frontotemporal dementia: what can the behavioral variant teach us about human brain organization? Neuroscientist. 2012;18(4):373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">21670424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Seeley WW. Network dysfunction in Alzheimer's disease and frontotemporal dementia: implications for psychiatry. Biol Psychiatry. 2014;75(7):565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">24629669</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo CC, Gorno-Tempini ML, Gesierich B, et al. Anterior temporal lobe degeneration produces widespread network-driven dysfunction. Brain. 2013;136:2979&#x2013;2991. Pt 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857932</ArticleId><ArticleId IdType="pubmed">24072486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477. Pt 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald S, Bornhofen C, Shum D, Long E, Saunders C, Neulinger K. Reliability and validity of The Awareness of Social Inference Test (TASIT): a clinical test of social perception. Disabil Rehabil. 2006;28(24):1529&#x2013;1542.</Citation><ArticleIdList><ArticleId IdType="pubmed">17178616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shany-Ur T, Poorzand P, Grossman SN, et al. Comprehension of insincere communication in neurodegenerative disease: lies, sarcasm, and theory of mind. Cortex. 2012;48(10):1329&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257415</ArticleId><ArticleId IdType="pubmed">21978867</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MH. Measuring individual differences in empathy: Evidence for a multidimensional approach. Journal of Personality &amp; Social Psychology. 1983;44(1):113&#x2013;126.</Citation></Reference><Reference><Citation>Rankin KP, Gorno-Tempini ML, Allison SC, et al. Structural anatomy of empathy in neurodegenerative disease. Brain. 2006;129:2945&#x2013;2956. Pt 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562652</ArticleId><ArticleId IdType="pubmed">17008334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiggins JS, Trapnell P, Phillips N. Psychometric and geometric characteristics of the Revised Interpersonal Adjective Scales (IAS--R) Multivariate Behavioral Research. 1988;23(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">26761163</ArticleId></ArticleIdList></Reference><Reference><Citation>Interpersonal Adjective Scales (IAS) Scoring Program [Computer Software] [computer program]. Version 1. Psychological Assessment Resources, Inc.; Odessa, FL: 1995.</Citation></Reference><Reference><Citation>Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011;24(6):542&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">21986680</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Agosti C, Premi E, et al. The FTLD-modified Clinical Dementia Rating scale is a reliable tool for defining disease severity in frontotemporal lobar degeneration: evidence from a brain SPECT study. Eur J Neurol. 2010;17(5):703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">20050899</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008;65(8):1091&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409562</ArticleId><ArticleId IdType="pubmed">18695059</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100(1):253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, Fair DA, Miezin FM, et al. Distinct brain networks for adaptive and stable task control in humans. Proc Natl Acad Sci U S A. 2007;104(26):11073&#x2013;11078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904171</ArticleId><ArticleId IdType="pubmed">17576922</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, Fair DA, Cohen AL, Schlaggar BL, Petersen SE. A dual-networks architecture of top-down control. Trends Cogn Sci. 2008;12(3):99&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632449</ArticleId><ArticleId IdType="pubmed">18262825</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Przybelski SA, Weigand SD, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain. 2009;132:2932&#x2013;2946. Pt 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768663</ArticleId><ArticleId IdType="pubmed">19762452</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Xu J, Mandrekar J, et al. Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. Neurobiol Aging. 2013;34(2):636&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404265</ArticleId><ArticleId IdType="pubmed">22502999</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Avula R, Senjem ML, et al. Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. Neurology. 2010;74(16):1279&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860485</ArticleId><ArticleId IdType="pubmed">20404309</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Allman JM, Carlin DA, et al. Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: reciprocal networks and neuronal evolution. Alzheimer Dis Assoc Disord. 2007;21(4):S50&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090425</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Knopman DS, et al. Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology. 2009;73(18):1443&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779005</ArticleId><ArticleId IdType="pubmed">19884571</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD. Behavioural variant frontotemporal dementia--defining genetic and pathological subtypes. J Mol Neurosci. 2011;45(3):583&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">21559874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipps CM, Hodges JR, Hornberger M. Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the 'bvFTD phenocopy syndrome'. Curr Opin Neurol. 2010;23(6):628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">20962637</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry. 2012;83(4):358&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference><Reference><Citation>Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10(2):162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Khazenzon AM, Trujillo AJ, et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain. 2014;137:3047&#x2013;3060. Pt 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4208465</ArticleId><ArticleId IdType="pubmed">25273996</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Doherty J, Kringelbach ML, Rolls ET, Hornak J, Andrews C. Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci. 2001;4(1):95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11135651</ArticleId></ArticleIdList></Reference><Reference><Citation>Roesch MR, Olson CR. Neuronal activity related to reward value and motivation in primate frontal cortex. Science. 2004;304(5668):307&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15073380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rankin KP, Salazar A, Gorno-Tempini ML, et al. Detecting sarcasm from paralinguistic cues: anatomic and cognitive correlates in neurodegenerative disease. Neuroimage. 2009;47(4):2005&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2720152</ArticleId><ArticleId IdType="pubmed">19501175</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollberger M, Neuhaus J, Ketelle R, et al. Interpersonal traits change as a function of disease type and severity in degenerative brain diseases. J Neurol Neurosurg Psychiatry. 2011;82(7):732&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062743</ArticleId><ArticleId IdType="pubmed">21172858</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollberger M, Rankin KP, Miller BL. Social cognition. Continuum (Minneap Minn) 2010;16(4):69&#x2013;85. Behavioral Neurology.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7846265</ArticleId><ArticleId IdType="pubmed">22810514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27454922</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between &#x3b2;-Amyloid and Tauopathy.</ArticleTitle><Pagination><StartPage>1070</StartPage><EndPage>1077</EndPage><MedlinePgn>1070-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.2078</ELocationID><Abstract><AbstractText Label="IMPORTANCE">In vivo tau imaging may become a diagnostic marker for Alzheimer disease (AD) and provides insights into the pathophysiology of AD.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the usefulness of [18F]-AV-1451 positron emission tomography (PET) imaging to stage AD and assess the associations among &#x3b2;-amyloid (A&#x3b2;), tau, and volume loss.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">An imaging study conducted at Knight Alzheimer Disease Research Center at Washington University in St Louis, Missouri. A total of 59 participants who were cognitively normal (CN) (Clinical Dementia Rating [CDR] score, 0) or had AD dementia (CDR score, &gt;0) were included.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Standardized uptake value ratio (SUVR) of [18F]-AV-1451 in the hippocampus and a priori-defined AD cortical signature regions, cerebrospinal fluid A&#x3b2;42, hippocampal volume, and AD signature cortical thickness.</AbstractText><AbstractText Label="RESULTS">Of the 59 participants, 38 (64%) were male; mean (SD) age was 74 (6) years. The [18F]-AV-1451 SUVR in the hippocampus and AD cortical signature regions distinguished AD from CN participants (area under the receiver operating characteristic curve range [95% CI], 0.89 [0.73-1.00] to 0.98 [0.92-1.00]). An [18F]-AV-1451 SUVR cutoff value of 1.19 (sensitivity, 100%; specificity, 86%) from AD cortical signature regions best separated cerebrospinal fluid A&#x3b2;42-positive (A&#x3b2;+) AD from cerebrospinal fluid A&#x3b2;42-negative (A&#x3b2;-) CN participants. This same cutoff also divided A&#x3b2;+ CN participants into low vs high tau groups. Moreover, the presence of A&#x3b2;+ was associated with an elevated [18F]-AV-1451 SUVR in AD cortical signature regions (A&#x3b2;+ participants: mean [SD], 1.3 [0.3]; A&#x3b2;- participants: 1.1 [0.1]; F&#x2009;=&#x2009;4.3, P&#x2009;=&#x2009;.04) but not in the hippocampus. The presence of A&#x3b2;+ alone was not related to hippocampal volume or AD signature cortical thickness. An elevated [18F]-AV-1451 SUVR was associated with volumetric loss in both the hippocampus and AD cortical signature regions. The observed [18F]-AV-1451 SUVR volumetric association was modified by A&#x3b2; status in the hippocampus but not in AD cortical signature regions. An inverse association between hippocampal [18F]-AV-1451 SUVR and volume was seen in A&#x3b2;+ participants (R2&#x2009;=&#x2009;0.55; P&#x2009;&lt;&#x2009;.001) but not A&#x3b2;- (R2&#x2009;=&#x2009;0; P&#x2009;=&#x2009;.97) participants.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Use of [18F]-AV-1451 has a potential for staging of the preclinical and clinical phases of AD. &#x3b2;-Amyloid interacts with hippocampal and cortical tauopathy to affect neurodegeneration. In the absence of A&#x3b2;, hippocampal tau deposition may be insufficient for the neurodegenerative process that leads to AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, Missouri2The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri3Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedrichsen</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldea</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McConathy</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Alabama, Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, Missouri2The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, Missouri2The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri5The Hope Center for Neurological Disorders at Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, Missouri2The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri5The Hope Center for Neurological Disorders at Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St Louis, Missouri2The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri3Department of Radiology, Washington University, St Louis, Missouri5The Hope Center for Neurological Disorders at Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG043434</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH099979</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR012907</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR014449</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NR012657</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Sep 1;73(9):1049-50. doi: 10.1001/jamaneurol.2016.2481.</RefSource><PMID Version="1">27454015</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: Dr Fagan is a member of the scientific advisory boards of IBL International and Roche and is a consultant for AbbVie, Novartis, and DiamiR. Drs Benzinger and Morris and are currently participating in a clinical trial of antidementia drugs: A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer&#x2019;s Disease) trial. Dr Benzinger also participates in the Dominantly Inherited Alzheimer Network Trials Unit and in clinical trials sponsored by Eli Lilly/Avid Radiopharmaceuticals. Dr Morris has served as a consultant for Lilly USA and Takeda Pharmaceuticals. Drs Benzinger and Morris receive research support from Eli Lilly/Avid Radiopharmaceuticals. Dr McConathy has served as a consultant for Eli Lilly/Avid Radiopharmaceuticals, GE Healthcare, and Siemens Healthcare. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27454922</ArticleId><ArticleId IdType="mid">NIHMS830807</ArticleId><ArticleId IdType="pmc">PMC5237382</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.2078</ArticleId><ArticleId IdType="pii">2537339</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;&#x2212;deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer&#x2019;s disease. Neurology. 1999;52(6):1158&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">10214737</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttil&#xe4; T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129(pt 11):3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9(6):666&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809845</ArticleId><ArticleId IdType="pubmed">24050400</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer&#x2019;s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137(pt 6):1762&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681664</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2):338&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382124</ArticleId><ArticleId IdType="pubmed">25448043</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer&#x2019;s disease. Ann Neurol. 2016;79(1):110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(pt 5):1539&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer&#x2019;s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage. 2008;42(2):559&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097053</ArticleId><ArticleId IdType="pubmed">18572417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Benzinger TL, Hassenstab J, et al. Spatially distinct atrophy is linked to &#x3b2;-amyloid and tau in preclinical Alzheimer disease. Neurology. 2015;84(12):1254&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366088</ArticleId><ArticleId IdType="pubmed">25716355</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Time for tau. Brain. 2014;137(pt 6):1570&#x2013;1571.</Citation><ArticleIdList><ArticleId IdType="pubmed">24736306</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and &#x201c;wingmen.&#x201d;. Nat Neurosci. 2015;18(6):800&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer&#x2019;s disease: implications for prevention trials. Neuron. 2014;84(3):608&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285623</ArticleId><ArticleId IdType="pubmed">25442939</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Sergeant N, Wattez A, et al. Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol. 2002;37(10-11):1291&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lace G, Savva GM, Forster G, et al. MRC-CFAS. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain. 2009;132(pt 5):1324&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">19321462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. Quantitative amyloid imaging using image-derived arterial input function. PLoS One. 2015;10(4):e0122920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388540</ArticleId><ArticleId IdType="pubmed">25849581</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. Dominantly Inherited Alzheimer Network. Partial volume correction in quantitative amyloid imaging. Neuro image. 2015;107:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.</Citation></Reference><Reference><Citation>Jack CR, Jr, Vemuri P, Wiste HJ, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68(12):1526&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Villain N, et al. AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high &#x3b2;-amyloid deposition. Neurology. 2012;78(7):477&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">22302548</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(4):474&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396131</ArticleId><ArticleId IdType="pubmed">21784356</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73(4):685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27466814</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>7</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>3D Visualization of the Temporal and Spatial Spread of Tau Pathology Reveals Extensive Sites of Tau Accumulation Associated with Neuronal Loss and Recognition Memory Deficit in Aged Tau Transgenic Mice.</ArticleTitle><Pagination><StartPage>e0159463</StartPage><MedlinePgn>e0159463</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0159463</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0159463</ELocationID><Abstract><AbstractText>3D volume imaging using iDISCO+ was applied to observe the spatial and temporal progression of tau pathology in deep structures of the brain of a mouse model that recapitulates the earliest stages of Alzheimer's disease (AD). Tau pathology was compared at four timepoints, up to 34 months as it spread through the hippocampal formation and out into the neocortex along an anatomically connected route. Tau pathology was associated with significant gliosis. No evidence for uptake and accumulation of tau by glia was observed. Neuronal cells did appear to have internalized tau, including in extrahippocampal areas as a small proportion of cells that had accumulated human tau protein did not express detectible levels of human tau mRNA. At the oldest timepoint, mature tau pathology in the entorhinal cortex (EC) was associated with significant cell loss. As in human AD, mature tau pathology in the EC and the presence of tau pathology in the neocortex correlated with cognitive impairment. 3D volume imaging is an ideal technique to easily monitor the spread of pathology over time in models of disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Hongjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussaini</LastName><ForeName>S Abid</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegmann</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Profaci</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>Jacob D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emrani</LastName><ForeName>Sheina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Helen Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Litwin-Zucker Center for Research in Alzheimer's Disease, Feinstein Institute for Medical Research, North Shore/LIJ Health System, Manhasset, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050425</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081555</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27466814</ArticleId><ArticleId IdType="pmc">PMC4965059</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0159463</ArticleId><ArticleId IdType="pii">PONE-D-15-55842</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ando K, Laborde Q, Lazar A, Godefroy D, Youssef I, Amar M, et al. Inside Alzheimer brain with CLARITY: senile plaques, neurofibrillary tangles and axons in 3-D. Acta Neuropathol. 2014;128(3):457&#x2013;9. 10.1007/s00401-014-1322-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1322-y</ArticleId><ArticleId IdType="pmc">PMC4131133</ArticleId><ArticleId IdType="pubmed">25069432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama H, Hioki H, Namiki K, Hoshida T, Kurokawa H, Ishidate F, et al. ScaleS: an optical clearing palette for biological imaging. Nat Neurosci. 2015;18(10):1518&#x2013;29. 10.1038/nn.4107 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4107</ArticleId><ArticleId IdType="pubmed">26368944</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Skwarek-Maruszewska A, Horre K, Vandewyer E, Wolfs L, Snellinx A, et al. Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models. Sci Transl Med. 2015;7(309):309ra164 10.1126/scitranslmed.aab3492 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aab3492</ArticleId><ArticleId IdType="pubmed">26468326</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;59. .</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225(4667):1168&#x2013;70. .</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain. 2015;138(Pt 10):2814&#x2013;33. 10.1093/brain/awv236 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv236</ArticleId><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7(2):e31302 10.1371/journal.pone.0031302</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73(4):685&#x2013;97. 10.1016/j.neuron.2011.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, et al. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One. 2012;7(9):e45881 10.1371/journal.pone.0045881</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045881</ArticleId><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker K, Jahrling N, Saghafi S, Weiler R, Dodt HU. Chemical clearing and dehydration of GFP expressing mouse brains. PLoS One. 2012;7(3):e33916 10.1371/journal.pone.0033916</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033916</ArticleId><ArticleId IdType="pmc">PMC3316521</ArticleId><ArticleId IdType="pubmed">22479475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung K, Deisseroth K. CLARITY for mapping the nervous system. Nat Methods. 2013;10(6):508&#x2013;13. 10.1038/nmeth.2481 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2481</ArticleId><ArticleId IdType="pubmed">23722210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung K, Wallace J, Kim SY, Kalyanasundaram S, Andalman AS, Davidson TJ, et al. Structural and molecular interrogation of intact biological systems. Nature. 2013;497(7449):332&#x2013;7. 10.1038/nature12107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12107</ArticleId><ArticleId IdType="pmc">PMC4092167</ArticleId><ArticleId IdType="pubmed">23575631</ArticleId></ArticleIdList></Reference><Reference><Citation>Erturk A, Becker K, Jahrling N, Mauch CP, Hojer CD, Egen JG, et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nat Protoc. 2012;7(11):1983&#x2013;95. 10.1038/nprot.2012.119 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2012.119</ArticleId><ArticleId IdType="pubmed">23060243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama H, Kurokawa H, Kawano H, Ando R, Shimogori T, Noda H, et al. Scale: a chemical approach for fluorescence imaging and reconstruction of transparent mouse brain. Nat Neurosci. 2011;14(11):1481&#x2013;8. 10.1038/nn.2928 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2928</ArticleId><ArticleId IdType="pubmed">21878933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke MT, Fujimoto S, Imai T. SeeDB: a simple and morphology-preserving optical clearing agent for neuronal circuit reconstruction. Nat Neurosci. 2013;16(8):1154&#x2013;61. 10.1038/nn.3447 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3447</ArticleId><ArticleId IdType="pubmed">23792946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwajima T, Sitko AA, Bhansali P, Jurgens C, Guido W, Mason C. ClearT: a detergent- and solvent-free clearing method for neuronal and non-neuronal tissue. Development. 2013;140(6):1364&#x2013;8. 10.1242/dev.091844</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.091844</ArticleId><ArticleId IdType="pmc">PMC3912244</ArticleId><ArticleId IdType="pubmed">23444362</ArticleId></ArticleIdList></Reference><Reference><Citation>Susaki EA, Tainaka K, Perrin D, Kishino F, Tawara T, Watanabe TM, et al. Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell. 2014;157(3):726&#x2013;39. 10.1016/j.cell.2014.03.042 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.042</ArticleId><ArticleId IdType="pubmed">24746791</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell. 2014;159(4):896&#x2013;910. 10.1016/j.cell.2014.10.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.10.010</ArticleId><ArticleId IdType="pubmed">25417164</ArticleId></ArticleIdList></Reference><Reference><Citation>Renier N, Adams EL, Kirst C, Wu Z, Azevedo R, Kohl J, et al. Mapping of Brain Activity by Automated Volume Analysis of Immediate Early Genes. Cell. 2016. 10.1016/j.cell.2016.05.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.007</ArticleId><ArticleId IdType="pmc">PMC4912438</ArticleId><ArticleId IdType="pubmed">27238021</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Dzhala VI, Pooler AM, Nicholls SB, McKinney AP, Sanchez L, et al. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta neuropathologica. 2014;127(2):257&#x2013;70. 10.1007/s00401-013-1215-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1215-5</ArticleId><ArticleId IdType="pmc">PMC3946978</ArticleId><ArticleId IdType="pubmed">24271788</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci. 2014;17(2):304&#x2013;11. 10.1038/nn.3606</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3606</ArticleId><ArticleId IdType="pmc">PMC4044925</ArticleId><ArticleId IdType="pubmed">24362760</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Berenfeld B, Davies P. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res. 1999;55(6):713&#x2013;23. .</Citation><ArticleIdList><ArticleId IdType="pubmed">10220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeren-Wiemers N, Gerfin-Moser A. A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes. Histochemistry. 1993;100(6):431&#x2013;40. .</Citation><ArticleIdList><ArticleId IdType="pubmed">7512949</ArticleId></ArticleIdList></Reference><Reference><Citation>Price SR, De Marco Garcia NV, Ranscht B, Jessell TM. Regulation of motor neuron pool sorting by differential expression of type II cadherins. Cell. 2002;109(2):205&#x2013;16. .</Citation><ArticleIdList><ArticleId IdType="pubmed">12007407</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira VC, Carrara RC, Simoes DL, Saggioro FP, Carlotti CG Jr, Covas DT, et al. Sudan Black B treatment reduces autofluorescence and improves resolution of in situ hybridization specific fluorescent signals of brain sections. Histology and histopathology. 2010;25(8):1017&#x2013;24. .</Citation><ArticleIdList><ArticleId IdType="pubmed">20552552</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AM, Hawk JD, Abel T, Havekes R. Post-training reversible inactivation of the hippocampus enhances novel object recognition memory. Learning &amp; memory. 2010;17(3):155&#x2013;60. 10.1101/lm.1625310</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.1625310</ArticleId><ArticleId IdType="pmc">PMC2832924</ArticleId><ArticleId IdType="pubmed">20189960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1996;16(14):4491&#x2013;500. .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of neurology. 1997;41(1):17&#x2013;24. 10.1002/ana.410410106 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410106</ArticleId><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60(9):1495&#x2013;500. .</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harbor perspectives in medicine. 2011;1(1):a006189 10.1101/cshperspect.a006189</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Horinek D, Petrovicky P, Hort J, Krasensky J, Brabec J, Bojar M, et al. Amygdalar volume and psychiatric symptoms in Alzheimer's disease: an MRI analysis. Acta Neurol Scand. 2006;113(1):40&#x2013;5. 10.1111/j.1600-0404.2006.00540.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2006.00540.x</ArticleId><ArticleId IdType="pubmed">16367898</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC, Alzheimer's Disease Neuroimaging I. Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Res. 2011;194(1):7&#x2013;13. 10.1016/j.pscychresns.2011.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pscychresns.2011.06.014</ArticleId><ArticleId IdType="pmc">PMC3185127</ArticleId><ArticleId IdType="pubmed">21920712</ArticleId></ArticleIdList></Reference><Reference><Citation>Doty RL, Reyes PF, Gregor T. Presence of both odor identification and detection deficits in Alzheimer's disease. Brain Res Bull. 1987;18(5):597&#x2013;600. .</Citation><ArticleIdList><ArticleId IdType="pubmed">3607528</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP, Michaels-Marston KS, Liu X, Pelton GH, Padilla M, Marder K, et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry. 2000;157(9):1399&#x2013;405. .</Citation><ArticleIdList><ArticleId IdType="pubmed">10964854</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476&#x2013;81. 10.1126/science.1113694</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda M, Mayford MR. CaMKII activation in the entorhinal cortex disrupts previously encoded spatial memory. Neuron. 2006;50(2):309&#x2013;18. 10.1016/j.neuron.2006.03.035 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.03.035</ArticleId><ArticleId IdType="pubmed">16630840</ArticleId></ArticleIdList></Reference><Reference><Citation>Yetman MJ, Lillehaug S, Bjaalie JG, Leergaard TB, Jankowsky JL. Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex. Brain Struct Funct. 2015. 10.1007/s00429-015-1040-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-015-1040-9</ArticleId><ArticleId IdType="pmc">PMC4605847</ArticleId><ArticleId IdType="pubmed">25869275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha+ microglia and S100&#x3b2;&#x3b5;&#x3c4;&#x3b1;+ astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol. 1997;56(3):285&#x2013;90. .</Citation><ArticleIdList><ArticleId IdType="pubmed">9056542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8(9):663&#x2013;72. 10.1038/nrn2194 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D, et al. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 2012;9:47 10.1186/1742-2094-9-47</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-47</ArticleId><ArticleId IdType="pmc">PMC3334709</ArticleId><ArticleId IdType="pubmed">22397366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol. 2004;165(5):1643&#x2013;52. 10.1016/S0002-9440(10)63421-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63421-9</ArticleId><ArticleId IdType="pmc">PMC1618683</ArticleId><ArticleId IdType="pubmed">15509534</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#x2013;51. 10.1016/j.neuron.2007.01.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol. 2005;166(2):521&#x2013;31. 10.1016/S0002-9440(10)62274-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)62274-2</ArticleId><ArticleId IdType="pmc">PMC1602315</ArticleId><ArticleId IdType="pubmed">15681835</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H, et al. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L. Brain Res. 2008;1214:159&#x2013;68. 10.1016/j.brainres.2008.02.084 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.02.084</ArticleId><ArticleId IdType="pubmed">18457819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol. 2009;209(1&#x2013;2):16&#x2013;25. 10.1016/j.jneuroim.2009.01.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2009.01.013</ArticleId><ArticleId IdType="pubmed">19232747</ArticleId></ArticleIdList></Reference><Reference><Citation>Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M. Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease. J Neuroinflammation. 2010;7:64 10.1186/1742-2094-7-64</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-64</ArticleId><ArticleId IdType="pmc">PMC2958906</ArticleId><ArticleId IdType="pubmed">20937161</ArticleId></ArticleIdList></Reference><Reference><Citation>Majerova P, Zilkova M, Kazmerova Z, Kovac A, Paholikova K, Kovacech B, et al. Microglia display modest phagocytic capacity for extracellular tau oligomers. J Neuroinflammation. 2014;11:161 10.1186/s12974-014-0161-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0161-z</ArticleId><ArticleId IdType="pmc">PMC4172893</ArticleId><ArticleId IdType="pubmed">25217135</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Liu W, Hu X, Hanna M, Caravaca A, Paul SM. Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 2015;5:11161 10.1038/srep11161</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11161</ArticleId><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin SS, Goldman JE. Glial inclusions in CNS degenerative diseases. J Neuropathol Exp Neurol. 1996;55(5):499&#x2013;508. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8627339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano I, Iwatsubo T, Otsuka N, Kamei M, Matsumura K, Mannen T. Paired helical filaments in astrocytes: electron microscopy and immunohistochemistry in a case of atypical Alzheimer's disease. Acta Neuropathol. 1992;83(3):228&#x2013;32. .</Citation><ArticleIdList><ArticleId IdType="pubmed">1557954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura M, Tomimoto H, Suenaga T, Namba Y, Ikeda K, Akiguchi I, et al. Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain. Am J Pathol. 1995;146(5):1052&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869277</ArticleId><ArticleId IdType="pubmed">7747799</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584&#x2013;93. 10.1038/nn.4132 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4132</ArticleId><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138(Pt 6):1738&#x2013;55. 10.1093/brain/awv081</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv081</ArticleId><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold CA, Budson AE. Memory loss in Alzheimer's disease: implications for development of therapeutics. Expert review of neurotherapeutics. 2008;8(12):1879&#x2013;91. 10.1586/14737175.8.12.1879</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.8.12.1879</ArticleId><ArticleId IdType="pmc">PMC2655107</ArticleId><ArticleId IdType="pubmed">19086882</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterini F, Della Sala S, Spinnler H, Stangalino C, Tumbull OH. Object recognition and object orientation in Alzheimer's disease. Neuropsychology. 2002;16(2):146&#x2013;55. .</Citation><ArticleIdList><ArticleId IdType="pubmed">11949706</ArticleId></ArticleIdList></Reference><Reference><Citation>Budson AE, Price BH. Memory dysfunction. The New England journal of medicine. 2005;352(7):692&#x2013;9. 10.1056/NEJMra041071 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra041071</ArticleId><ArticleId IdType="pubmed">15716563</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley MJ. The role of the perirhinal cortex and hippocampus in learning, memory, and perception. The Quarterly journal of experimental psychology B, Comparative and physiological psychology. 2005;58(3&#x2013;4):246&#x2013;68. 10.1080/02724990444000186 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02724990444000186</ArticleId><ArticleId IdType="pubmed">16194968</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauvage MM, Beer Z, Ekovich M, Ho L, Eichenbaum H. The caudal medial entorhinal cortex: a selective role in recollection-based recognition memory. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30(46):15695&#x2013;9. 10.1523/JNEUROSCI.4301-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4301-10.2010</ArticleId><ArticleId IdType="pmc">PMC3073554</ArticleId><ArticleId IdType="pubmed">21084625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DI, Langston RF, Schlesiger MI, Wagner M, Watanabe S, Ainge JA. Lateral entorhinal cortex is critical for novel object-context recognition. Hippocampus. 2013;23(5):352&#x2013;66. 10.1002/hipo.22095</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.22095</ArticleId><ArticleId IdType="pmc">PMC3648979</ArticleId><ArticleId IdType="pubmed">23389958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DI, Watanabe S, Milner H, Ainge JA. Lateral entorhinal cortex is necessary for associative but not nonassociative recognition memory. Hippocampus. 2013;23(12):1280&#x2013;90. 10.1002/hipo.22165</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.22165</ArticleId><ArticleId IdType="pmc">PMC4030623</ArticleId><ArticleId IdType="pubmed">23836525</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh SS, Johnson JL, Knierim JJ. Perirhinal cortex represents nonspatial, but not spatial, information in rats foraging in the presence of objects: comparison with lateral entorhinal cortex. Hippocampus. 2012;22(10):2045&#x2013;58. 10.1002/hipo.22046</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.22046</ArticleId><ArticleId IdType="pmc">PMC3870144</ArticleId><ArticleId IdType="pubmed">22987681</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki K, et al. Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(21):13896&#x2013;901. 10.1073/pnas.202205599</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.202205599</ArticleId><ArticleId IdType="pmc">PMC129794</ArticleId><ArticleId IdType="pubmed">12368474</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi T, Doe N, Matsuyama S, Kitamura Y, Mori H, Saito N, et al. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS letters. 2005;579(25):5704&#x2013;12. 10.1016/j.febslet.2005.09.047 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2005.09.047</ArticleId><ArticleId IdType="pubmed">16219306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, et al. Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. The EMBO journal. 2007;26(24):5143&#x2013;52. 10.1038/sj.emboj.7601917</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601917</ArticleId><ArticleId IdType="pmc">PMC2140104</ArticleId><ArticleId IdType="pubmed">18007595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011;31(7):2511&#x2013;25. 10.1523/JNEUROSCI.5245-10.2011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5245-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623704</ArticleId><ArticleId IdType="pubmed">21325519</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27470171</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-9726</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Aging cell</Title><ISOAbbreviation>Aging Cell</ISOAbbreviation></Journal><ArticleTitle>Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein-specific antibodies.</ArticleTitle><Pagination><StartPage>953</StartPage><EndPage>963</EndPage><MedlinePgn>953-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acel.12508</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is histopathologically characterized by neurodegeneration, the formation of intracellular neurofibrillary tangles and extracellular A&#x3b2; deposits that derive from proteolytic processing of the amyloid precursor protein (APP). As rodents do not normally develop A&#x3b2; pathology, various transgenic animal models of AD were designed to overexpress human APP with mutations favouring its amyloidogenic processing. However, these mouse models display tremendous differences in the spatial and temporal appearance of A&#x3b2; deposits, synaptic dysfunction, neurodegeneration and the manifestation of learning deficits which may be caused by age-related and brain region-specific differences in APP transgene levels. Consequentially, a comparative temporal and regional analysis of the pathological effects of A&#x3b2; in mouse brains is difficult complicating the validation of therapeutic AD treatment strategies in different mouse models. To date, no antibodies are available that properly discriminate endogenous rodent and transgenic human APP in brains of APP-transgenic animals. Here, we developed and characterized rat monoclonal antibodies by immunohistochemistry and Western blot that detect human but not murine APP in brains of three APP-transgenic mouse and one APP-transgenic rat model. We observed remarkable differences in expression levels and brain region-specific expression of human APP among the investigated transgenic mouse lines. This may explain the differences between APP-transgenic models mentioned above. Furthermore, we provide compelling evidence that our new antibodies specifically detect endogenous human APP in immunocytochemistry, FACS and immunoprecipitation. Hence, we propose these antibodies as standard tool for monitoring expression of endogenous or transfected APP in human cells and APP expression in transgenic animals.</AbstractText><CopyrightInformation>&#xa9; 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xf6;fling</LastName><ForeName>Corinna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morawski</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeitschel</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanier</LastName><ForeName>Elisa R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moschke</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serdaroglu</LastName><ForeName>Alperen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Pathologie und Pathologische Anatomie, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canneva</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental Therapy, Pr&#xe4;klinisches Experimentelles Tierzentrum (PETZ), Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von H&#xf6;rsten</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Experimental Therapy, Pr&#xe4;klinisches Experimentelles Tierzentrum (PETZ), Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Simoni</LastName><ForeName>Maria-Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forloni</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xe4;ger</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremmer</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health, Institute of Molecular Immunology, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ro&#xdf;ner</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, Klinikum rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Peer-Hendrik</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Study, Technische Universit&#xe4;t M&#xfc;nchen, Garching, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Pathologie und Pathologische Anatomie, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, Klinikum rechts der Isar, Technische Universit&#xe4;t M&#xfc;nchen, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Cell</MedlineTA><NlmUniqueID>101130839</NlmUniqueID><ISSNLinking>1474-9718</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="Y">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">immunohistochemistry</Keyword><Keyword MajorTopicYN="N">monoclonal antibody</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword><Keyword MajorTopicYN="N">transgenic animal models</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27470171</ArticleId><ArticleId IdType="pmc">PMC5013031</ArticleId><ArticleId IdType="doi">10.1111/acel.12508</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bates K, Vink R, Martins R, Harvey A (2014) Aging, cortical injury and Alzheimer's disease&#x2010;like pathology in the guinea pig brain. Neurobiol. Aging 35, 1345&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">24360504</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck M, Bigl V, Rossner S (2003) Guinea pigs as a nontransgenic model for APP processing in&#xa0;vitro and in&#xa0;vivo . Neurochem. Res. 28, 637&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">12675155</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease&#x2010;related cognitive deficits in transgenic mice. Neuron 45, 675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K, Dotti CG (1995) Production of intracellular amyloid&#x2010;containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. EMBO J. 14, 4932&#x2013;4938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394596</ArticleId><ArticleId IdType="pubmed">7588622</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyrks T, Dyrks E, Masters CL, Beyreuther K (1993) Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 324, 231&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">8508926</ArticleId></ArticleIdList></Reference><Reference><Citation>Eketj&#xe4;ll S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Rades&#xe4;ter AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlstr&#xf6;m S, Swahn BM, F&#xe4;lting J (2013) AZ&#x2010;4217: a high potency BACE inhibitor displaying acute central efficacy in different in&#xa0;vivo models and reduced amyloid deposition in Tg2576 mice. J. Neurosci. 33, 10075&#x2013;10084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618391</ArticleId><ArticleId IdType="pubmed">23761903</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson&#x2010;Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya&#x2010;Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J (1995) Alzheimer&#x2010;type neuropathology in transgenic mice overexpressing V717F beta&#x2010;amyloid precursor protein. Nature 373, 523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Li H, Gaddam SS, Justice NJ, Robertson CS, Zheng H (2012) Amyloid precursor protein revisited: neuron&#x2010;specific expression and highly stable nature of soluble derivatives. J. Biol. Chem. 287, 2437&#x2013;2445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268404</ArticleId><ArticleId IdType="pubmed">22144675</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L (1999) Plaque&#x2010;independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early&#x2010;onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5161&#x2013;5166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1405622</ArticleId><ArticleId IdType="pubmed">16549764</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D (1991) Antibodies to non&#x2010;beta regions of the beta&#x2010;amyloid precursor protein detect a subset of senile plaques. Am. J. Pathol. 138, 373&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886178</ArticleId><ArticleId IdType="pubmed">1704190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Lammich S, Edbauer D, Ertl M, Rietdorf J, Capell A, Steiner H, Haass C (2002) Presenilin&#x2010;1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane. J. Cell Biol. 158, 551&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173840</ArticleId><ArticleId IdType="pubmed">12147673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age&#x2010;dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>King DL, Arendash GW (2002) Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19&#xa0;months. Physiol. Behav. 75, 627&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H (2013) Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12, 487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alpha&#x2010;secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 3020&#x2013;3032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944055</ArticleId><ArticleId IdType="pubmed">20676056</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC (2010) A novel transgenic rat model with a full Alzheimer's&#x2010;like amyloid pathology displays pre&#x2010;plaque intracellular amyloid&#x2010;beta&#x2010;associated cognitive impairment. J. Alzheimers Dis. 20, 113&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">20164597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane proteolysis&#x2013;lessons from amyloid precursor protein processing. J. Neurochem. 117, 779&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">21413990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitterreiter S, Page RM, Kamp F, Hopson J, Winkler E, Ha HR, Hamid R, Herms J, Mayer TU, Nelson DJ, Steiner H, Stahl T, Zeitschel U, Rossner S, Haass C, Lichtenthaler SF (2010) Bepridil and amiodarone simultaneously target the Alzheimer's disease beta&#x2010; and gamma&#x2010;secretase via distinct mechanisms. J.&#xa0;Neurosci. 30, 8974&#x2013;8983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632893</ArticleId><ArticleId IdType="pubmed">20592218</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno&#x2010;Gonzalez I, Soto C (2012) Natural animal models of neurodegenerative protein misfolding diseases. Curr. Pharm. Des. 18, 1148&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">22288404</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson&#x2010;Wood K, McConlogue L (2000) High&#x2010;level neuronal expression of abeta 1&#x2013;42 in wild&#x2010;type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet&#x2010;Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta&#x2010;amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple&#x2010;transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L Jr, Szendrei GI, Lee VM, Mantsch HH (1993) Human and rodent Alzheimer beta&#x2010;amyloid peptides acquire distinct conformations in membrane&#x2010;mimicking solvents. Eur. J. Biochem. 211, 249&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8425535</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW (1996) Enhanced amyloidogenic processing of the beta&#x2010;amyloid precursor protein in gene&#x2010;targeted mice bearing the Swedish familial Alzheimer's disease mutations and a &#x201c;humanized&#x201d; Abeta sequence. J. Biol. Chem. 271, 23380&#x2013;23388.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798542</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller AJ, Roos RA, Bots GT, Kamphorst W, Eikelenboom P, Van Nostrand WE (1993) Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis&#x2010;Dutch type and Alzheimer's disease. Am. J. Pathol. 142, 1449&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886931</ArticleId><ArticleId IdType="pubmed">7684195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, Eimer WA, Cole SL, Vassar R (2015) Abeta reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol. Neurodegener. 10, 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297413</ArticleId><ArticleId IdType="pubmed">25567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarasa M, Pesini P (2009) Natural non&#x2010;transgenic animal models for research in Alzheimer's disease. Curr. Alzheimer Res. 6, 171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825666</ArticleId><ArticleId IdType="pubmed">19355852</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson&#x2010;Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid&#x2010;beta attenuates Alzheimer&#x2010;disease&#x2010;like pathology in the PDAPP mouse. Nature 400, 173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharman MJ, Moussavi Nik SH, Chen MM, Ong D, Wijaya L, Laws SM, Taddei K, Newman M, Lardelli M, Martins RN, Verdile G (2013) The guinea pig as a model for sporadic Alzheimer's disease (AD): the impact of cholesterol intake on expression of AD&#x2010;related genes. PLoS ONE 8, e66235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689723</ArticleId><ArticleId IdType="pubmed">23805206</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ (2012) A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>Slunt HH, Thinakaran G, Von Koch C, Lo AC, Tanzi RE, Sisodia SS (1994) Expression of a ubiquitous, cross&#x2010;reactive homologue of the mouse beta&#x2010;amyloid precursor protein (APP). J. Biol. Chem. 269, 2637&#x2013;2644.</Citation><ArticleIdList><ArticleId IdType="pubmed">8300594</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in&#xa0;vitro fibrillar aggregation of the Alzheimer beta&#x2010;amyloid peptide. Proc. Natl Acad. Sci. USA 93, 452&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40256</ArticleId><ArticleId IdType="pubmed">8552659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler&#x2010;Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, B&#xfc;rki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease&#x2010;like pathology. Proc. Natl Acad. Sci. USA 94, 13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf8;nnesen J, N&#xe4;gerl UV (2013) Superresolution imaging for neuroscience. Exp. Neurol. 242, 33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">23063602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF (2014) Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 130, 4&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086641</ArticleId><ArticleId IdType="pubmed">24646365</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster MT, Groome N, Francis PT, Pearce BR, Sherriff FE, Thinakaran G, Felsenstein KM, Wasco W, Tanzi RE, Bowen DM (1995) A novel protein, amyloid precursor&#x2010;like protein 2, is present in human brain, cerebrospinal fluid and conditioned media. Biochem. J.&#xa0;310(Pt 1), 95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1135859</ArticleId><ArticleId IdType="pubmed">7646477</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, K&#xf6;nig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57, 115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">2649245</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G, Ran Y, Fromholt SE, Fu C, Yachnis AT, Golde TE, Borchelt DR (2015) Murine A&#x3b2; over&#x2010;production produces diffuse and compact Alzheimer&#x2010;type amyloid deposits. Acta Neuropathol. Commun. 3, 72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644287</ArticleId><ArticleId IdType="pubmed">26566997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27474376</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>388</Volume><Issue>10046</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial.</ArticleTitle><Pagination><StartPage>797</StartPage><EndPage>805</EndPage><MedlinePgn>797-805</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(16)30950-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(16)30950-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cardiovascular risk factors are associated with an increased risk of dementia. We assessed whether a multidomain intervention targeting these factors can prevent dementia in a population of community-dwelling older people.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this open-label, cluster-randomised controlled trial, we recruited individuals aged 70-78 years through participating general practices in the Netherlands. General practices within each health-care centre were randomly assigned (1:1), via a computer-generated randomisation sequence, to either a 6-year nurse-led, multidomain cardiovascular intervention or control (usual care). The primary outcomes were cumulative incidence of dementia and disability score (Academic Medical Center Linear Disability Score [ALDS]) at 6 years of follow-up. The main secondary outcomes were incident cardiovascular disease and mortality. Outcome assessors were masked to group assignment. Analyses included all participants with available outcome data. This trial is registered with ISRCTN, number ISRCTN29711771.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between June 7, 2006, and March 12, 2009, 116 general practices (3526 participants) within 26 health-care centres were recruited and randomly assigned: 63 (1890 participants) were assigned to the intervention group and 53 (1636 participants) to the control group. Primary outcome data were obtained for 3454 (98%) participants; median follow-up was 6&#xb7;7 years (21&#x2008;341 person-years). Dementia developed in 121 (7%) of 1853 participants in the intervention group and in 112 (7%) of 1601 participants in the control group (hazard ratio [HR] 0&#xb7;92, 95% CI 0&#xb7;71-1&#xb7;19; p=0&#xb7;54). Mean ALDS scores measured during follow-up did not differ between groups (85&#xb7;7 [SD 6&#xb7;8] in the intervention group and 85&#xb7;7 [7&#xb7;1] in the control group; adjusted mean difference -0&#xb7;02, 95% CI -0&#xb7;38 to 0&#xb7;42; p=0&#xb7;93). 309 (16%) of 1885 participants died in the intervention group, compared with 269 (16%) of 1634 participants in the control group (HR 0&#xb7;98, 95% CI 0&#xb7;80-1&#xb7;18; p=0&#xb7;81). Incident cardiovascular disease did not differ between groups (273 [19%] of 1469 participants in the intervention group and 228 [17%] of 1307 participants in the control group; HR 1&#xb7;06, 95% CI 0&#xb7;86-1&#xb7;31; p=0&#xb7;57).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">A nurse-led, multidomain intervention did not result in a reduced incidence of all-cause dementia in an unselected population of older people. This absence of effect might have been caused by modest baseline cardiovascular risks and high standards of usual care. Future studies should assess the efficacy of such interventions in selected populations.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Dutch Ministry of Health, Welfare and Sport; Dutch Innovation Fund of Collaborative Health Insurances; and Netherlands Organisation for Health Research and Development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moll van Charante</LastName><ForeName>Eric P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Edo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands; Department of Neurology, Radboud University Medical Centre, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eurelings</LastName><ForeName>Lisa S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dalen</LastName><ForeName>Jan-Willem</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ligthart</LastName><ForeName>Suzanne A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Bussel</LastName><ForeName>Emma F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of General Practice, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoevenaar-Blom</LastName><ForeName>Marieke P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeulen</LastName><ForeName>Marinus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gool</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands. Electronic address: w.a.vangool@amc.uva.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2016 Aug 20;388(10046):738-40. doi: 10.1016/S0140-6736(16)31129-1.</RefSource><PMID Version="1">27475274</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2017 Jan 14;389(10065):152-153. doi: 10.1016/S0140-6736(17)30016-8.</RefSource><PMID Version="1">28102135</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058006" MajorTopicYN="N">General Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057187" MajorTopicYN="N">Independent Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024802" MajorTopicYN="N">Nurse's Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27474376</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)30950-3</ArticleId><ArticleId IdType="pii">S0140-6736(16)30950-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27532692</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis.</ArticleTitle><Pagination><StartPage>1208</StartPage><EndPage>1216</EndPage><MedlinePgn>1208-1216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.1924</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. Animal and in vitro studies also indicate that DHA prevents amyloid deposition in the brain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the association between serum DHA levels, cerebral amyloidosis, and the volumes of brain areas affected by Alzheimer disease.</AbstractText><AbstractText Label="DESIGN, SETTINGS, AND PARTICIPANTS" NlmCategory="METHODS">Cross-sectional analysis of serum DHA levels together with measures of amyloid deposition (Pittsburgh Compound B index), brain volumes, and neuropsychological testing scores from 61 participants in the Aging Brain Study. The study was conducted between June 2008 and May 2013, and the data were analyzed between October 2015 and April 2016. Linear models were adjusted for age, sex, years of education, and apolipoprotein E status.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Serum DHA levels with cerebral amyloidosis measured using PIB PET.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Samples were available from 61 Aging Brain Study participants (41 women and 20 men) who underwent amyloid PET imaging. The mean (SD) age of the participants was 77 (6) years and ranged from 67 to 88 years. Serum DHA levels (percentage of total fatty acids) were 23% lower in participants with cerebral amyloidosis than those without (0.97 vs 1.25, P&#x2009;=&#x2009;.007) and were inversely correlated with brain amyloid load (r = -0.32, P&#x2009;=&#x2009;.01) independent of age, sex, apolipoprotein E genotype, and years of education. Moreover, greater serum DHA levels were positively associated with brain volume in several subregions affected by AD, in particular the left subiculum (r = 0.38, P&#x2009;=&#x2009;.005) and the left entorhinal volumes (r = 0.51, P&#x2009;=&#x2009;.001). Serum DHA levels were also associated with nonverbal memory scores (r = 0.28, P&#x2009;=&#x2009;.03).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In this study, serum DHA levels were associated with pathogenesis of cerebral amyloidosis and with preservation of entorhinal and hippocampal volumes. These findings suggest an important role for DHA metabolism in brain amyloid deposition during the preclinical or early symptomatic stages of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yassine</LastName><ForeName>Hussein N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Qingru</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azizkhanian</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawat</LastName><ForeName>Varun</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castor</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institute, Pasadena, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonteh</LastName><ForeName>Alfred N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institute, Pasadena, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Huntington Medical Research Institute, Pasadena, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Bruce R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Davis, Sacarmento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California Davis, Sacarmento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>25167-62-8</RegistryNumber><NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Oct 1;73(10):1183-1184. doi: 10.1001/jamaneurol.2016.2534.</RefSource><PMID Version="1">27533600</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004281" MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27532692</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.1924</ArticleId><ArticleId IdType="pii">2538230</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27510902</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>351</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Insights into neuroepigenetics through human histone deacetylase PET imaging.</ArticleTitle><Pagination><StartPage>351ra106</StartPage><MedlinePgn>351ra106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaf7551</ELocationID><Abstract><AbstractText>Epigenetic dysfunction is implicated in many neurological and psychiatric diseases, including Alzheimer's disease and schizophrenia. Consequently, histone deacetylases (HDACs) are being aggressively pursued as therapeutic targets. However, a fundamental knowledge gap exists regarding the expression and distribution of HDACs in healthy individuals for comparison to disease states. Here, we report the first-in-human evaluation of neuroepigenetic regulation in vivo. Using positron emission tomography with [(11)C]Martinostat, an imaging probe selective for class I HDACs (isoforms 1, 2, and 3), we found that HDAC expression is higher in cortical gray matter than in white matter, with conserved regional distribution patterns within and between healthy individuals. Among gray matter regions, HDAC expression was lowest in the hippocampus and amygdala. Through biochemical profiling of postmortem human brain tissue, we confirmed that [(11)C]Martinostat selectively binds HDAC isoforms 1, 2, and 3, the HDAC subtypes most implicated in regulating neuroplasticity and cognitive function. In human stem cell-derived neural progenitor cells, pharmacologic-level doses of Martinostat induced changes in genes closely associated with synaptic plasticity, including BDNF (brain-derived neurotrophic factor) and SYP (synaptophysin), as well as genes implicated in neurodegeneration, including GRN (progranulin), at the transcript level, in concert with increased acetylation at both histone H3 lysine 9 and histone H4 lysine 12. This study quantifies HDAC expression in the living human brain and provides the foundation for gaining unprecedented in vivo epigenetic information in health and disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wey</LastName><ForeName>Hsiao-Ying</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>Tonya M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;rcher</LastName><ForeName>Nicole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>She</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhanot</LastName><ForeName>Anisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taillon</LastName><ForeName>Brendan D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Fredrick A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Changing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooker</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. hooker@nmr.mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 RR022976</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA030321</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR017208</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR026666</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 DA037928</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN271201300030C</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001102</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR019933</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023401</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>58IFB293JI</RegistryNumber><NameOfSubstance UI="D000077337">Vorinostat</NameOfSubstance></Chemical><Chemical><RegistryNumber>8JJC99KHGL</RegistryNumber><NameOfSubstance UI="C000605558">martinostat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D006655">Histone Deacetylases</NameOfSubstance></Chemical><Chemical><RegistryNumber>PJY633525U</RegistryNumber><NameOfSubstance UI="D000218">Adamantane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006655" MajorTopicYN="N">Histone Deacetylases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006877" MajorTopicYN="N">Hydroxamic Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077337" MajorTopicYN="N">Vorinostat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> Intellectual property (IP) has been filed around [<sup>11</sup>C]Martinostat by J.M.H, C.W. and F.A.S. A portion of this IP has been licensed. S.J.H. has financial interests in Rodin Therapeutics and is an inventor on HDAC inhibitor-related IP licensed to this entity that is unrelated to the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27510902</ArticleId><ArticleId IdType="mid">NIHMS931986</ArticleId><ArticleId IdType="pmc">PMC5784409</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaf7551</ArticleId><ArticleId IdType="pii">8/351/351ra106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Penney J, Tsai LH. Histone deacetylases in memory and cognition. Sci Signal. 2014;7:re12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25492968</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215088</ArticleId><ArticleId IdType="pubmed">19065135</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498958</ArticleId><ArticleId IdType="pubmed">19424149</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggarty SJ, Tsai LH. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem. 2011;96:41&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3188418</ArticleId><ArticleId IdType="pubmed">21545841</ArticleId></ArticleIdList></Reference><Reference><Citation>Haettig J, Stefanko DP, Multani ML, Figueroa DX, McQuown SC, Wood MA. HDAC inhibition modulates hippocampus-dependent long-term memory for object location in a CBP-dependent manner. Learn Mem. 2011;18:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032579</ArticleId><ArticleId IdType="pubmed">21224411</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai LH. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483:222&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498952</ArticleId><ArticleId IdType="pubmed">22388814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurita M, Holloway T, Garcia-Bea A, Kozlenkov A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gabilondo AM, Hanks J, Umali A, Callado LF, Gallitano AL, Neve RL, Shen L, Buxbaum JD, Han MH, Nestler EJ, Meana JJ, Russo SJ, Gonzalez-Maeso J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15:1245&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431440</ArticleId><ArticleId IdType="pubmed">22864611</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakovcevski M, Bharadwaj R, Straubhaar J, Gao G, Gavin DP, Jakovcevski I, Mitchell AC, Akbarian S. Prefrontal cortical dysfunction after overexpression of histone deacetylase 1. Biol Psychiatry. 2013;74:696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3797203</ArticleId><ArticleId IdType="pubmed">23664640</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447:178&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468743</ArticleId></ArticleIdList></Reference><Reference><Citation>Covington HE, 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, Fass DM, Renthal W, Rush AJ, 3rd, Wu EY, Ghose S, Krishnan V, Russo SJ, Tamminga C, Haggarty SJ, Nestler EJ. Antidepressant actions of histone deacetylase inhibitors. J Neurosci. 2009;29:11451&#x2013;11460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775805</ArticleId><ArticleId IdType="pubmed">19759294</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, Gale J, Zhao WN, Reis S, Barker DD, Berry-Scott E, Kim SW, Clore EL, Hooker JM, Holson EB, Haggarty SJ, Petryshen TL. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One. 2013;8:e71323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743770</ArticleId><ArticleId IdType="pubmed">23967191</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumbaugh G, Sillivan SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, Kilgore M, Kudugunti S, Puthanveettil SV, Sweatt JD, Rusche J, Miller CA. Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue. Neuropsychopharmacology. 2015;40:2307&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4538358</ArticleId><ArticleId IdType="pubmed">25837283</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, Yu K, Niu W, Coppola G, Coughlin SE, Lee SE, Dries DR, Almeida S, Geschwind DH, Gao FB, Miller BL, Farese RV, Jr, Posner BA, Yu G, Herz J. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011;286:16101&#x2013;16108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091219</ArticleId><ArticleId IdType="pubmed">21454553</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson KW, Chen J, Wang M, Mast N, Pikuleva IA, Turko IV. Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. PLoS One. 2015;10:e0126592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427357</ArticleId><ArticleId IdType="pubmed">25962138</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, Rusche JR, Wood MA. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013;110:2647&#x2013;2652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3574934</ArticleId><ArticleId IdType="pubmed">23297220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Fan W, Zhang X, Dong E. Gestational stress induces depressive-like and anxiety-like phenotypes through epigenetic regulation of BDNF expression in offspring hippocampus. Epigenetics. 2016:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846107</ArticleId><ArticleId IdType="pubmed">26890656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Eessalu TE, Barth VN, Mitch CH, Wagner FF, Hong Y, Neelamegam R, Schroeder FA, Holson EB, Haggarty SJ, Hooker JM. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain. Am J Nucl Med Mol Imaging. 2013;4:29&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867727</ArticleId><ArticleId IdType="pubmed">24380043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wey HY, Wang C, Schroeder FA, Logan J, Price JC, Hooker JM. Kinetic Analysis and Quantification of [(1)(1)C]Martinostat for in Vivo HDAC Imaging of the Brain. ACS Chem Neurosci. 2015;6:708&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439341</ArticleId><ArticleId IdType="pubmed">25768025</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, Sreekumar L, Cao Y, Nordlund P. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">23828940</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, Martinez Molina D. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100&#x2013;2122.</Citation><ArticleIdList><ArticleId IdType="pubmed">25101824</ArticleId></ArticleIdList></Reference><Reference><Citation>Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, Cota P, Wittnam JL, Gogol-Doering A, Opitz L, Salinas-Riester G, Dettenhofer M, Kang H, Farinelli L, Chen W, Fischer A. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science. 2010;328:753&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer&#x2019;s disease. Neuropsychopharmacology. 2010;35:870&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055373</ArticleId><ArticleId IdType="pubmed">20010553</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardai FH, Price V, Zaayman M, Wang L, D&#x2019;Mello SR. Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death. J Biol Chem. 2012;287:35444&#x2013;35453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471765</ArticleId><ArticleId IdType="pubmed">22918830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci. 2010;13:180&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829989</ArticleId><ArticleId IdType="pubmed">20037577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011;29:255&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">21258344</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher I, Dittmann A, Savitski MM, Hopf C, Drewes G, Bantscheff M. Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem Biol. 2014;9:1736&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">24877719</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff J, Joseph NF, Horn ME, Samiei A, Meng J, Seo J, Rei D, Bero AW, Phan TX, Wagner F, Holson E, Xu J, Sun J, Neve RL, Mach RH, Haggarty SJ, Tsai LH. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell. 2014;156:261&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3986862</ArticleId><ArticleId IdType="pubmed">24439381</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi C, Angelucci A, Costantin L, Braschi C, Mazzantini M, Babbini F, Fabbri ME, Tessarollo L, Maffei L, Berardi N, Caleo M. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur J Neurosci. 2006;24:1850&#x2013;1856.</Citation><ArticleIdList><ArticleId IdType="pubmed">17040481</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkenberg T, Mohammed AK, Henriksson B, Persson H, Winblad B, Lindefors N. Increased expression of brain-derived neurotrophic factor mRNA in rat hippocampus is associated with improved spatial memory and enriched environment. Neurosci Lett. 1992;138:153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407655</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer&#x2019;s disease. Neuron. 1991;7:695&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">1742020</ArticleId></ArticleIdList></Reference><Reference><Citation>AIfB. Science. Allen Institute for Brain Science; 2015.</Citation></Reference><Reference><Citation>Izquierdo-Garcia D, Hansen AE, Forster S, Benoit D, Schachoff S, Furst S, Chen KT, Chonde DB, Catana C. An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: application to simultaneous PET/MR brain imaging. J Nucl Med. 2014;55:1825&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246705</ArticleId><ArticleId IdType="pubmed">25278515</ArticleId></ArticleIdList></Reference><Reference><Citation>Catana C, Benner T, van der Kouwe A, Byars L, Hamm M, Chonde DB, Michel CJ, El Fakhri G, Schmand M, Sorensen AG. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med. 2011;52:154&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125596</ArticleId><ArticleId IdType="pubmed">21189415</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(Suppl 1):S208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501092</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, Loring JF, Haggarty SJ. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One. 2011;6:e26203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192166</ArticleId><ArticleId IdType="pubmed">22022567</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WN, Cheng C, Theriault KM, Sheridan SD, Tsai LH, Haggarty SJ. A high-throughput screen for Wnt/beta-catenin signaling pathway modulators in human iPSC-derived neural progenitors. J Biomol Screen. 2012;17:1252&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903585</ArticleId><ArticleId IdType="pubmed">22923789</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27533593</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1231</StartPage><EndPage>1237</EndPage><MedlinePgn>1231-1237</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.2539</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The contribution of cardiovascular disease (CV) and cerebrovascular disease to the risk for late-onset Alzheimer disease (LOAD) has been long debated. Investigations have shown that antecedent CV risk factors increase the risk for LOAD, although other investigations have failed to validate this association.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the contribution of CV risk factors (type 2 diabetes, hypertension, and heart disease) and the history of stroke to LOAD in a data set of large families multiply affected by LOAD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease family study (hereinafter referred to as NIA-LOAD study) is a longitudinal study of families with multiple members affected with LOAD. A multiethnic community-based longitudinal study (Washington Heights-Inwood Columbia Aging Project [WHICAP]) was used to replicate findings. The 6553 participants in the NIA-LOAD study were recruited from 23 US Alzheimer disease centers with ongoing data collection since 2003; the 5972 WHICAP participants were recruited at Columbia University with ongoing data collection since 1992. Data analysis was performed from 2003 to 2015.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Generalized mixed logistic regression models tested the association of CV risk factors (primary association) with LOAD. History of stroke was used for the secondary association. A secondary model adjusted for the presence of an apolipoprotein E (APOE) &#x3b5;4 allele. A genetic risk score, based on common variants associated with LOAD, was used to account for LOAD genetic risk beyond the APOE &#x3b5;4 effect. Mediation analyses evaluated stroke as a mediating factor between the primary association and LOAD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 6553 NIA-LOAD participants were included in the analyses (4044 women [61.7%]; 2509 men [38.3%]; mean [SD] age, 77.0 [9] years), with 5972 individuals from the WHICAP study included in the replication sample (4072 women [68.2%]; 1900 men [31.8%]; mean [SD] age, 76.5 [7.0] years). Hypertension was associated with decreased LOAD risk (odds ratio [OR], 0.63; 95% CI, 0.55-0.72); type 2 diabetes and heart disease were not. History of stroke conferred greater than 2-fold increased risk for LOAD (OR, 2.23; 95% CI, 1.75-2.83). Adjustment for APOE &#x3b5;4 did not alter results. The genetic risk score was associated with LOAD (OR, 2.85; 95% CI, 2.05-3.97) but did not change the independent association of LOAD with hypertension or stroke. In the WHICAP sample, hypertension was not associated with LOAD (OR, 0.99; 95% CI,&#x2009;0.88-1.11), whereas history of stroke increased the risk for LOAD (OR, 1.96; 95% CI, 1.56-2.46). The effect of hypertension on LOAD risk was also mediated by stroke in the NIA-LOAD and the WHICAP samples.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In familial and sporadic LOAD, a history of stroke was significantly associated with increased disease risk and mediated the association between selected CV risk factors and LOAD, which appears to be independent of the LOAD-related genetic background.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tosto</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York2Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York3New York Presbyterian Hospital in New York City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle5Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brickman</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York2Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York3New York Presbyterian Hospital in New York City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University Center for Alzheimer's Disease and Related Disorders, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mount Sinai School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantigua</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York2Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York3New York Presbyterian Hospital in New York City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottman</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York14Department of Epidemiology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas16Editor, JAMA Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaid</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schupf</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York2Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York3New York Presbyterian Hospital in New York City14Department of Epidemiology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York2Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York3New York Presbyterian Hospital in New York City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania19Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania20Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease, The Aging Brain and the Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York2Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York3New York Presbyterian Hospital in New York City14Department of Epidemiology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National Institute on Aging Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) Family Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG007232</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037212</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054023</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018522</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Jan 1;74(1):128-129. doi: 10.1001/jamaneurol.2016.4381.</RefSource><PMID Version="1">27842151</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Jan 1;74(1):129-130. doi: 10.1001/jamaneurol.2016.4384.</RefSource><PMID Version="1">27842174</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Dr Boeve reports serving as an investigator for clinical trials sponsored by Cephalon, Inc, Allon Pharmaceuticals, and GE Healthcare; receiving royalties from the publication of a book titled Behavioral Neurology of Dementia (Cambridge Medicine; 2009); receiving honoraria from the American Academy of Neurology; serving on the Scientific Advisory Board of the Tau Consortium; and receiving research support from the National Institute on Aging (NIA) (grants P50 AG016574, U01 AG006786, RO1 AG032306, RO1 AG041797) and the Mangurian Foundation. Dr Farlow reports receiving grant and research support from Accera, Biogen, Eisai Med Res, Eli Lilly &amp; Company, Genentech, MedAvante/AstraZeneca, and Navidea; serving on the speaker's bureau at Eisai Med Res, Pfizer, Inc, Forest, Novartis, and Eli Lilly &amp; Company; serving on the consultant or advisory boards at Accera, Alltech, Avanir, Eisai Med Res, Inc, Helicon, Medavante, Medivation, Inc, Merck and Co, Inc, Novartis, Pfizer, Inc, Prana Biotech, QR Pharma, Roche, Sanofi-Aventis, Schering-Plough, Toyama Pharm, Eli Lilly &amp; Company, UCB Pharma, and Elan. Dr Rosenberg reports holding a US patent for Amyloid &#x3b2; Gene Vaccines and serving on the editorial board of the Journal of the Neurological Sciences. Disclosures:No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27533593</ArticleId><ArticleId IdType="mid">NIHMS833021</ArticleId><ArticleId IdType="pmc">PMC5155512</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.2539</ArticleId><ArticleId IdType="pii">2542674</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA. Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31(6):424&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142096</ArticleId><ArticleId IdType="pubmed">21757907</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154(7):635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">11581097</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65(4):545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1619350</ArticleId><ArticleId IdType="pubmed">16116114</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol. 2010;67(12):1491&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065942</ArticleId><ArticleId IdType="pubmed">21149810</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol. 2010;67(7):835&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068839</ArticleId><ArticleId IdType="pubmed">20625090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangen KJ, Nation DA, Clark LR, et al. Interactive effects of vascular risk burden and advanced age on cerebral blood flow. Front Aging Neurosci. 2014;6:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083452</ArticleId><ArticleId IdType="pubmed">25071567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010;68(suppl 2):S74&#x2013;S87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058404</ArticleId><ArticleId IdType="pubmed">21091952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? an evidence-based review. Alzheimers Res Ther. 2012;4(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471388</ArticleId><ArticleId IdType="pubmed">22182734</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 2013;136(pt 9):2697&#x2013;2706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858112</ArticleId><ArticleId IdType="pubmed">23842566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(pt 12):3749&#x2013;3756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577102</ArticleId><ArticleId IdType="pubmed">23204143</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60(12):1707&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676044</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease: lessons from pathology. BMC Med. 2014;12(1):206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226890</ArticleId><ArticleId IdType="pubmed">25385447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, Faber KM, Bird TD, et al. NIA-LOAD/NCRAD Family Study Group. Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) JAMA Neurol. 2014;71(3):315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000602</ArticleId><ArticleId IdType="pubmed">24425039</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosto G, Fu H, Vardarajan BN, et al. F-box/LRR-repeat protein 7 is genetically associated with Alzheimer's disease. Ann Clin Transl Neurol. 2015;2(8):810&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4554442</ArticleId><ArticleId IdType="pubmed">26339675</ArticleId></ArticleIdList></Reference><Reference><Citation>Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656957</ArticleId></ArticleIdList></Reference><Reference><Citation>Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ. 1980;58(1):113&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395897</ArticleId><ArticleId IdType="pubmed">6966542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Pankratz ND, Choi Y, et al. NIA-LOAD/NCRAD Family Study Group. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011;7(2):e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelder JA, Mead R. A simplex method for function minimization. Comput J. 1965;7(4):308&#x2013;313.</Citation></Reference><Reference><Citation>Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">18697684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol. 1982;13:290&#x2013;312.</Citation></Reference><Reference><Citation>Djouss&#xe9; L, Myers RH, Province MA, et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke. 2002;33(5):1357&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988615</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard SD, Mukherjee S, Sharp SJ, et al. Alzheimer's Disease Genetics Consortium; GERAD1 Consortium; EPIC-InterAct Consortium. Associations between potentially modifiable risk factors and Alzheimer disease: a mendelian randomization study. PLoS Med. 2015;12(6):e1001841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469461</ArticleId><ArticleId IdType="pubmed">26079503</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996;312(7034):805&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2350725</ArticleId><ArticleId IdType="pubmed">8608286</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese E, Lombardo FL, Prince MJ, Stewart R. Dementia and lower blood pressure in Latin America, India, and China: a 10/66 cross-cohort study. Neurology. 2013;81(3):228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770159</ArticleId><ArticleId IdType="pubmed">23771488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang YF, Breitner JC, Chiu YL, et al. Cache County Investigators. Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study. Neurobiol Aging. 2014;35(11):2429&#x2013;2435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366136</ArticleId><ArticleId IdType="pubmed">24910391</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, White LR. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885214</ArticleId><ArticleId IdType="pubmed">23911753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol. 2013;169(6):1203&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831702</ArticleId><ArticleId IdType="pubmed">23638877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Horiuchi M. Effects of angiotensin II receptor blockers on dementia. Hypertens Res. 2009;32(9):738&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">19727113</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasar S, Xia J, Yao W, et al. Ginkgo Evaluation of Memory (GEM) Study Investigators. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885216</ArticleId><ArticleId IdType="pubmed">23911756</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Mwamburi M, Besser LM, et al. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis. 2013;37(2):421&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972060</ArticleId><ArticleId IdType="pubmed">23948883</ArticleId></ArticleIdList></Reference><Reference><Citation>Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Risk of incident stroke in patients with Alzheimer disease or vascular dementia. Neurology. 2013;81(10):910&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">23902701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes AF, Preacher KJ. Quantifying and testing indirect effects in simple mediation models when the constituent paths are nonlinear. Multivariate Behav Res. 2010;45(4):627&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">26735713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosto G, Zimmerman ME, Carmichael OT, Brickman AM. Alzheimer's Disease Neuroimaging Initiative. Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities. JAMA Neurol. 2014;71(7):872&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107926</ArticleId><ArticleId IdType="pubmed">24821476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosto G, Zimmerman ME, Hamilton JL, Carmichael OT, Brickman AM. Alzheimer's Disease Neuroimaging Initiative. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement. 2015;11(12):1510&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677059</ArticleId><ArticleId IdType="pubmed">26079417</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Song D, Leng SX. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin Interv Aging. 2015;10:549&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4360697</ArticleId><ArticleId IdType="pubmed">25792818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75(13):1195&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739645</ArticleId></ArticleIdList></Reference><Reference><Citation>Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51(4):1256&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11916953</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology. 2006;67(11):1960&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159101</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V. Alzheimer's Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015;85(13):1123&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573049</ArticleId><ArticleId IdType="pubmed">26333802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27532054</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e1600947</StartPage><MedlinePgn>e1600947</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1600947</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.1600947</ELocationID><Abstract><AbstractText>In Alzheimer's disease, aggregates of A&#x3b2; and tau in amyloid plaques and neurofibrillary tangles spread progressively across brain tissues following a characteristic pattern, implying a tissue-specific vulnerability to the disease. We report a transcriptional analysis of healthy brains and identify an expression signature that predicts-at ages well before the typical onset-the tissue-specific progression of the disease. We obtain this result by finding a quantitative correlation between the histopathological staging of the disease and the expression patterns of the proteins that coaggregate in amyloid plaques and neurofibrillary tangles, together with those of the protein homeostasis components that regulate A&#x3b2; and tau. Because this expression signature is evident in healthy brains, our analysis provides an explanatory link between a tissue-specific environmental risk of protein aggregation and a corresponding vulnerability to Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freer</LastName><ForeName>Rosie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4203-0964</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sormanni</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vecchi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciryam</LastName><ForeName>Prajwal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1445-0577</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.; Department of Molecular Biosciences, Northwestern University, Evanston, IL 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vendruscolo</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword><Keyword MajorTopicYN="N">protein homeostasis</Keyword><Keyword MajorTopicYN="N">tissue vulnerability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27532054</ArticleId><ArticleId IdType="pmc">PMC4980108</ArticleId><ArticleId IdType="doi">10.1126/sciadv.1600947</ArticleId><ArticleId IdType="pii">1600947</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Alzheimer&#x2019;s disease is a synaptic failure. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E., Alzheimer&#x2019;s disease. Lancet 377, 1019&#x2013;1031 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H. W., LaFerla F. M., Alzheimer&#x2019;s disease. N. Engl. J. Med. 362, 329&#x2013;344 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D. M., Morris J. C., Goate A. M., Alzheimer&#x2019;s disease: The challenge of the second century. Sci. Transl. Med. 3, 77sr1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., Frosch M. P., Masliah E., Hyman B. T., Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., Selkoe D. J., Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., Ashe K. H., A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature 440, 352&#x2013;357 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D. J., Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer&#x2019;s amyloid &#x3b2;-peptide. Nat. Rev. Mol. Cell Biol. 8, 101&#x2013;112 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R. A., Laviolette P. S., O&#x2019;Keefe K., O&#x2019;Brien J., Rentz D. M., Pihlajamaki M., Marshall G., Hyman B. T., Selkoe D. J., Hedden T., Buckner R. L., Becker J. A., Johnson K. A., Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178&#x2013;188 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M. P., Magnus T., Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7, 278&#x2013;294 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J. A., Woltjer R. L., Goodenbour J. M., Horvath S., Geschwind D. H., Genes and pathways underlying regional and cell type changes in Alzheimer&#x2019;s disease. Genome Med. 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706780</ArticleId><ArticleId IdType="pubmed">23705665</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero A. W., Yan P., Roh J. H., Cirrito J. R., Stewart F. R., Raichle M. E., Lee J.-M., Holtzman D. M., Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat. Neurosci. 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K., Tanei Z.-i., Hashimoto T., Wakabayashi T., Okuno H., Naka Y., Yizhar O., Fenno L. E., Fukayama M., Bito H., Cirrito J. R., Holtzman D. M., Deisseroth K., Iwatsubo T., Chronic optogenetic activation augments A&#x3b2; pathology in a mouse model of Alzheimer disease. Cell Rep. 11, 859&#x2013;865 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25937280</ArticleId></ArticleIdList></Reference><Reference><Citation>Balch W. E., Morimoto R. I., Dillin A., Kelly J. W., Adapting proteostasis for disease intervention. Science 319, 916&#x2013;919 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18276881</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles T. P. J., Vendruscolo M., Dobson C. M., The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl F. U., Bracher A., Hayer-Hartl M., Molecular chaperones in protein folding and proteostasis. Nature 475, 324&#x2013;332 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21776078</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehme M., Voisine C., Rolland T., Wachi S., Soper J. H., Zhu Y., Orton K., Villella A., Garza D., Vidal M., Ge H., Morimoto R. I., A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep. 9, 1135&#x2013;1150 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255334</ArticleId><ArticleId IdType="pubmed">25437566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T., Ben-Zvi A., Ho K. H., Brignull H. R., Morimoto R. I., Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 1471&#x2013;1474 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbadia J., Morimoto R. I., The biology of proteostasis in aging and disease. Annu. Rev. Biochem. 84, 435&#x2013;464 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539002</ArticleId><ArticleId IdType="pubmed">25784053</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H., Schermann S. M., Woerner A. C., Pinkert S., Hecht M. H., Tartaglia G. G., Vendruscolo M., Hayer-Hartl M., Hartl F. U., Vabulas R. M., Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67&#x2013;78 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P., Tartaglia G. G., Morimoto R. I., Dobson C. M., Vendruscolo M., Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 5, 781&#x2013;790 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883113</ArticleId><ArticleId IdType="pubmed">24183671</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther D. M., Kasturi P., Zheng M., Pinkert S., Vecchi G., Ciryam P., Morimoto R. I., Dobson C. M., Vendruscolo M., Mann M., Hartl F. U., Widespread proteome remodeling and aggregation in aging C. Elegans. Cell 161, 919&#x2013;932 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643853</ArticleId><ArticleId IdType="pubmed">25957690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P., Kundra R., Freer R., Morimoto R. I., Dobson C. M., Vendruscolo M., A transcriptional signature of Alzheimer&#x2019;s disease is associated with a metastable subproteome at risk for aggregation. Proc. Natl. Acad. Sci. U.S.A. 113, 4753&#x2013;4758 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855616</ArticleId><ArticleId IdType="pubmed">27071083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M., Lockhart S. N., Schonhaut D. R., O&#x2019;Neil J. P., Janabi M., Ossenkoppele R., Baker S. L., Vogel J. W., Faria J., Schwimmer H. D., Rabinovici G. D., Jagust W. J., PET imaging of tau deposition in the aging human brain. Neuron 89, 971&#x2013;982 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz A. J., Yu P., Miller B. B., Shcherbinin S., Dickson J., Navitsky M., Joshi A. D., Devous M. D. Sr, Mintun M. S., Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139, 1539&#x2013;1550 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: The prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science 349, 1255555 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz M. J., Lein E. S., Guillozet-Bongaarts A. L., Shen E. H., Ng L., Miller J. A., van de Lagemaat L. N., Smith K. A., Ebbert A., Riley Z. L., Abajian C., Beckmann C. F., Bernard A., Bertagnolli D., Boe A. F., Cartagena P. M., Chakravarty M. M., Chapin M., Chong J., Dalley R. A., Daly B. D., Dang C., Datta S., Dee N., Dolbeare T. A., Faber V., Feng D., Fowler D. R., Goldy J., Gregor B. W., Haradon Z., Haynor D. R., Hohmann J. G., Horvath S., Howard R. E., Jeromin A., Jochim J. M., Kinnunen M., Lau C., Lazarz E. T., Lee C., Lemon T. A., Li L., Li Y., Morris J. A., Overly C. C., Parker P. D., Parry S. E., Reding M., Royall J. J., Schulkin J., Sequeira P. A., Slaughterbeck C. R., Smith S. C., Sodt A. J., Sunkin S. M., Swanson B. E., Vawter M. P., Williams D., Wohnoutka P., Zielke H. R., Geschwind D. H., Hof P. R., Smith S. M., Koch C., Grant S. G. N., Jones A. R., An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391&#x2013;399 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243026</ArticleId><ArticleId IdType="pubmed">22996553</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel C., Marcotte E. M., Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227&#x2013;232 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654667</ArticleId><ArticleId IdType="pubmed">22411467</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M., Fagerberg L., Hallstr&#xf6;m B. M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson &#xc5;., Kampf C., Sj&#xf6;stedt E., Asplund A., Olsson I. M., Edlund K., Lundberg E., Navani S., Szigyarto C. A.-K., Odeberg J., Djureinovic D., Takanen J. O., Hober S., Alm T., Edqvist P.-H., Berling H., Tegel H., Mulder J., Rockberg J., Nilsson P., Schwenk J. M., Hamsten M., von Feilitzen K., Forsberg M., Persson L., Johansson F., Zwahlen M., von Heijne G., Nielsen J., Pont&#xe9;n F., Tissue-based map of the human proteome. Science 347, 1260419 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x10c;au&#x161;evi&#x107; M., Farooq U., Lovestone S., Killick R., &#x3b2;-amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alzheimer&#x2019;s type neurodegeneration. Neurosci. Lett. 485, 162&#x2013;166 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20826196</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Q., Liao L., Cheng D., Duong D. M., Gearing M., Lah J. J., Levey A. I., Peng J., Proteomic identification of novel proteins associated with Lewy bodies. Front. Biosci. 13, 3850&#x2013;3856 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663966</ArticleId><ArticleId IdType="pubmed">18508479</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M. G., Schmidt M. L., Lee V. M.-Y., Trojanowski J. Q., Jakes R., Goedert M., &#x3b1;-Synuclein in Lewy bodies. Nature 388, 839&#x2013;840 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearnley J. M., Lees A. J., Ageing and Parkinson&#x2019;s disease: Substantia nigra regional selectivity. Brain 114, 2283&#x2013;2301 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1933245</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K., Schmitt S., Bergner C. G., Tyanova S., Kannaiyan N., Manrique-Hoyos N., Kongi K., Cantuti L., Hanisch U.-K., Philips M.-A., Rossner M. J., Mann M., Simons M., Cell type&#x2013; and brain region&#x2013;resolved mouse brain proteome. Nat. Neurosci. 18, 1819&#x2013;1831 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116867</ArticleId><ArticleId IdType="pubmed">26523646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E., Pfenning A. R., Mathys H., Quon G., Kundaje A., Tsai L.-H., Kellis M., Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature 518, 365&#x2013;369 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan E. G., Reed Q. W., Cramer P. E., Landreth G. E., Deletion of CD14 attenuates Alzheimer&#x2019;s disease pathology by influencing the brain&#x2019;s inflammatory milieu. J. Neurosci. 30, 15369&#x2013;15373 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997622</ArticleId><ArticleId IdType="pubmed">21084593</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M., Goto S., Furumichi M., Tanabe M., Hirakawa M., KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355&#x2013;D360 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808910</ArticleId><ArticleId IdType="pubmed">19880382</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmanis S., Sloan S. A., Zhang Y., Enge M., Caneda C., Shuer L. M., Hayden Gephart M. G., Barres B. A., Quake S. R., A survey of human brain transcriptome diversity at the single cell level. Proc. Natl. Acad. Sci. U.S.A. 112, 7285&#x2013;7290 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466750</ArticleId><ArticleId IdType="pubmed">26060301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Guerrero-Munoz M. J., Kiritoshi T., Neugebauer V., Jackson G. R., Kayed R., Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2, 700 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath S., Agholme L., Kurudenkandy F. R., Granseth B., Marcusson J., Hallbeck M., Spreading of neurodegenerative pathology via neuron-to-neuron transmission of &#x3b2;-amyloid. J. Neurosci. 32, 8767&#x2013;8777 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6622335</ArticleId><ArticleId IdType="pubmed">22745479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P., Melki R., Kopito R., Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 11, 301&#x2013;307 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892479</ArticleId><ArticleId IdType="pubmed">20308987</ArticleId></ArticleIdList></Reference><Reference><Citation>Habchi J., Arosio P., Perni M., Costa A. R., Yagi-Utsumi M., Joshi P., Chia S., Cohen S. I. A., M&#xfc;ller M. B. D., Linse S., Nollen E. A. A., Dobson C. M., Knowles T. P. J., Vendruscolo M., An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A&#x3b2;42 aggregates linked with Alzheimer&#x2019;s disease. Sci. Adv. 2, e1501244 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758743</ArticleId><ArticleId IdType="pubmed">26933687</ArticleId></ArticleIdList></Reference><Reference><Citation>UniProt Consortium, UniProt: A hub for protein information. Nucleic Acids Res. 43, D204&#x2013;D212 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384041</ArticleId><ArticleId IdType="pubmed">25348405</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell J., Josephs K. A., Murray M. E., Kantarci K., Przybelski S. A., Weigand S. D., Vemuri P., Senjem M. L., Parisi J. E., Knopman D. S., Boeve B. F., Petersen R. C., Dickson D. W., Jack C. R., MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study. Neurology 71, 743&#x2013;749 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>K. Kompoliti, L. Verhagen, Encyclopedia of Movement Disorders, Three-Volume Set (Academic Press, Cambridge, 2010), 1632 pp.</Citation></Reference><Reference><Citation>Mann H. B., Whitney D. R., On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 18, 50&#x2013;60 (1947).</Citation></Reference><Reference><Citation>R. A. Fisher, Statistical Methods for Research Workers (Oliver and Boyd Ltd., Edinburg, Scotland, 1925).</Citation></Reference><Reference><Citation>Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Pawitan Y., Michiels S., Koscielny S., Gusnanto A., Ploner A., False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21, 3017&#x2013;3024 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15840707</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey J. D., Tibshirani R., Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 100, 9440&#x2013;9445 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan R. S., S&#xe9;gonnec F., Fischl B., Quinn B. T., Dickerson B. C., Blacker D., Buckner R. L., Dale A. M., Maguire R. P., Hyman B. T., Albert M. S., Killiany R. J., An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968&#x2013;980 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Destrieux C., Fischl B., Dale A., Halgren E., Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage 53, 1&#x2013;15 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937159</ArticleId><ArticleId IdType="pubmed">20547229</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A., Tourville J., 101 labeled brain images and a consistent human cortical labeling protocol. Front. Neurosci. 6, 171 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514540</ArticleId><ArticleId IdType="pubmed">23227001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27535533</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>536</Volume><Issue>7616</Issue><PubDate><Year>2016</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Analysis of protein-coding genetic variation in 60,706 humans.</ArticleTitle><Pagination><StartPage>285</StartPage><EndPage>291</EndPage><MedlinePgn>285-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature19057</ELocationID><Abstract><AbstractText>Large-scale reference data sets of human genetic variation are critical for the medical and functional interpretation of DNA sequence changes. Here we describe the aggregation and analysis of high-quality exome (protein-coding region) DNA sequence data for 60,706 individuals of diverse ancestries generated as part of the Exome Aggregation Consortium (ExAC). This catalogue of human genetic diversity contains an average of one variant every eight bases of the exome, and provides direct evidence for the presence of widespread mutational recurrence. We have used this catalogue to calculate objective metrics of pathogenicity for sequence variants, and to identify genes subject to strong selection against various classes of mutation; identifying 3,230 genes with near-complete depletion of predicted protein-truncating variants, with 72% of these genes having no currently established human disease phenotype. Finally, we demonstrate that these data can be used for the efficient filtering of candidate disease-causing variants, and for the discovery of human 'knockout' variants in protein-coding genes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lek</LastName><ForeName>Monkol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Paediatrics and Child Health, University of Sydney, Sydney, New South Wales 2145, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Neuroscience and Muscle Research, Children's Hospital at Westmead, Sydney, New South Wales 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karczewski</LastName><ForeName>Konrad J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minikel</LastName><ForeName>Eric V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samocha</LastName><ForeName>Kaitlin E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banks</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fennell</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell-Luria</LastName><ForeName>Anne H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ware</LastName><ForeName>James S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Royal Brompton Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London SW3 6NP, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Clinical Sciences Centre, Imperial College London, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genome Sciences, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tukiainen</LastName><ForeName>Taru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birnbaum</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosmicki</LastName><ForeName>Jack A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Bioinformatics and Integrative Genomics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Laramie E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Karol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Fengmei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce-Hoffman</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berghout</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mouse Genome Informatics, Jackson Laboratory, Bar Harbor, Maine 04609, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics and Biostatistics, University of Arizona, Tucson, Arizona 85721, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Institute of Medical Genetics, Cardiff University, Cardiff CF10 3XQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deflaux</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Google, Mountain View, California 94043, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DePristo</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Statistical Genetics, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flannick</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fromer</LastName><ForeName>Menachem</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Jackie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Namrata</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howrigan</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiezun</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurki</LastName><ForeName>Mitja I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moonshine</LastName><ForeName>Ami Levy</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orozco</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Immunogenomics and Metabolic Disease Laboratory, Instituto Nacional de Medicina Gen&#xf3;mica, Mexico City 14610, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peloso</LastName><ForeName>Gina M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poplin</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivas</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruano-Rubio</LastName><ForeName>Valentin</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Samuel A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruderfer</LastName><ForeName>Douglas M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakir</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stenson</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Institute of Medical Genetics, Cardiff University, Cardiff CF10 3XQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Brett P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiao</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tusie-Luna</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Molecular Biology and Genomic Medicine Unit, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n, Mexico City 14080, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisburd</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Won</LastName><ForeName>Hong-Hee</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vertex Pharmaceuticals, Boston, Massachusetts 02210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardissino</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital, 43100 Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehnke</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danesh</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elosua</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiovascular Epidemiology and Genetics, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florez</LastName><ForeName>Jose C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Getz</LastName><ForeName>Gad</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, 02114 USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatt</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Psychiatric Genetic Epidemiology &amp;Neurobiology Laboratory, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Physiology, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hultman</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kathiresan</LastName><ForeName>Sekar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laakso</LastName><ForeName>Markku</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Eastern Finland and Kuopio University Hospital, 70211 Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Mark I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Foundation Trust, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGovern</LastName><ForeName>Dermot</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Disease and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McPherson</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Atherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neale</LastName><ForeName>Benjamin M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00100 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purcell</LastName><ForeName>Shaun M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saleheen</LastName><ForeName>Danish</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Non-Communicable Diseases, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scharf</LastName><ForeName>Jeremiah M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sklar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet SE-171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuomilehto</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Public Health, University of Helsinki, 00100 Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Ming T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radcliffe Department of Medicine, University of Oxford, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>James G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Exome Aggregation Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54HG003067</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS085048</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020572</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MOP82810</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>RC2F DK088389</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-DK085545</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH077139</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201300049C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>098381</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 DK085545</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201300046C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIMHRC2MH089905</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1RC2DK088389</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>090367</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RG/13/13/30194</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0801418</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 DK085501</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2P50MH066392-05A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077139</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK043351</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH095034</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MOP136936</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>R01HL107816</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK098032</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01DK085526</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS040024</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201300047C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L003120/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01DK062370</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U41 HG000330</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 HL125751</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL007208</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0800509</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 DK085584</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MOP77682</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>HHSN268201300048C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK085524</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_1102/20</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>5U54HG003067-11</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK098032</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2DK088389</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK085545</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK085526</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH085521</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH094421</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS40024-09S1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK088389</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK098032</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK062370</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG038072</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>090532</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS40024-09S1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2-DK088389</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>FS/14/55/30806</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01HL24799</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 DK105566</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 U54 HG003067-13</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH094432</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM104371</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201300050C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01HL125751</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32GM115208</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH089905</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH085560</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS085048</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601261</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Aug 17;536(7616):277-8. doi: 10.1038/536277a.</RefSource><PMID Version="1">27535530</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Oct 12;538(7624):140. doi: 10.1038/538140a.</RefSource><PMID Version="1">27734882</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Dec 29;541(7635):123-124. doi: 10.1038/541123a.</RefSource><PMID Version="1">28054618</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Lek</LastName><ForeName>Monkol</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karczewski</LastName><ForeName>Konrad J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minikel</LastName><ForeName>Eric V</ForeName><Initials>EV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samocha</LastName><ForeName>Kaitlin E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banks</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fennell</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donnell-Luria</LastName><ForeName>Anne H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ware</LastName><ForeName>James S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl B</ForeName><Initials>BB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tukiainen</LastName><ForeName>Taru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birnbaum</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosmicki</LastName><ForeName>Jack A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duncan</LastName><ForeName>Laramie E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Estrada</LastName><ForeName>Karol</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhao</LastName><ForeName>Fengmei</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zou</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce-Hoffman</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berghout</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>David N</ForeName><Initials>DN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deflaux</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DePristo</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Do</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flannick</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fromer</LastName><ForeName>Menachem</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Jackie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Namrata</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howrigan</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiezun</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurki</LastName><ForeName>Mitja I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moonshine</LastName><ForeName>Ami Levy</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orozco</LastName><ForeName>Lorena</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peloso</LastName><ForeName>Gina M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poplin</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas</LastName><ForeName>Manuel A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruano-Rubio</LastName><ForeName>Valentin</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rose</LastName><ForeName>Samuel A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruderfer</LastName><ForeName>Douglas M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shakir</LastName><ForeName>Khalid</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stenson</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Brett P</ForeName><Initials>BP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiao</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tusie-Luna</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weisburd</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Won</LastName><ForeName>Hong-Hee</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altshuler</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ardissino</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boehnke</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danesh</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Stacey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elosua</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Florez</LastName><ForeName>Jose C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Stacey B</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Getz</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glatt</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hultman</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kathiresan</LastName><ForeName>Sekar</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laakso</LastName><ForeName>Markku</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Mark I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGovern</LastName><ForeName>Dermot</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McPherson</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neale</LastName><ForeName>Benjamin M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palotie</LastName><ForeName>Aarno</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Purcell</LastName><ForeName>Shaun M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saleheen</LastName><ForeName>Danish</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharf</LastName><ForeName>Jeremiah M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sklar</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuomilehto</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuang</LastName><ForeName>Ming T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Hugh C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>James G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abboud</LastName><ForeName>Hanna E</ForeName><Initials>HE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Goncalo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilar-Salinas</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arellano-Campos</LastName><ForeName>Olimpia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atzmon</LastName><ForeName>Gil</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aukrust</LastName><ForeName>Ingvild</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barr</LastName><ForeName>Cathy L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Graeme I</ForeName><Initials>GI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Graeme I</ForeName><Initials>GI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bj&#xf8;rkhaug</LastName><ForeName>Lise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blangero</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowden</LastName><ForeName>Donald W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budman</LastName><ForeName>Cathy L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burtt</LastName><ForeName>No&#xeb;l P</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Centeno-Cruz</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chambers</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chambert</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>Rory</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>C&#xf3;rdova</LastName><ForeName>Emilio J</ForeName><Initials>EJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortes</LastName><ForeName>Maria L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>Nancy J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duggirala</LastName><ForeName>Ravindranath</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrall</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez-Lopez</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontanillas</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frayling</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freimer</LastName><ForeName>Nelson B</ForeName><Initials>NB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuchsberger</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a-Ortiz</LastName><ForeName>Humberto</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goel</LastName><ForeName>Anuj</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xf3;mez-V&#xe1;zquez</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez-Villalpando</LastName><ForeName>Mar&#xed;a E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez-Villalpando</LastName><ForeName>Clicerio</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grados</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groop</LastName><ForeName>Leif</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haiman</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanis</LastName><ForeName>Craig L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanis</LastName><ForeName>Craig L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hattersley</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hopewell</LastName><ForeName>Jemma C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huerta-Chagoya</LastName><ForeName>Alicia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Islas-Andrade</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Suzanne B R</ForeName><Initials>SB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jalilzadeh</LastName><ForeName>Shapour</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkinson</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moran</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jim&#xe9;nez-Morale</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>K&#xe4;hler</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirov</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kooner</LastName><ForeName>Jaspal S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kyriakou</LastName><ForeName>Theodosios</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jong-Young</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehman</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyon</LastName><ForeName>Gholson</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacMahon</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magnusson</LastName><ForeName>Patrik K E</ForeName><Initials>PK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahajan</LastName><ForeName>Anubha</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marrugat</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez-Hern&#xe1;ndez</LastName><ForeName>Ang&#xe9;lica</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>McVean</LastName><ForeName>Gilean</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meigs</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meitinger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendoza-Caamal</LastName><ForeName>Elvia</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mercader</LastName><ForeName>Josep M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohlke</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno-Mac&#xed;as</LastName><ForeName>Hortensia</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Najmi</LastName><ForeName>Laeya A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nj&#xf8;lstad</LastName><ForeName>P&#xe5;l R</ForeName><Initials>PR</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ord&#xf3;&#xf1;ez-S&#xe1;nchez</LastName><ForeName>Maria L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owen</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Taesung</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pauls</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Posthuma</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revilla-Monsalve</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riba</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ripke</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez-Guill&#xe9;n</LastName><ForeName>Rosario</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez-Torres</LastName><ForeName>Maribel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandor</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seielstad</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sladek</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sober&#xf3;n</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spector</LastName><ForeName>Timothy D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tai</LastName><ForeName>Shyong E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teslovich</LastName><ForeName>Tanya M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walford</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkens</LastName><ForeName>Lynne R</ForeName><Initials>LR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27535533</ArticleId><ArticleId IdType="mid">NIHMS798561</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pii">nature19057</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fu W, et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. 2013;493:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676746</ArticleId><ArticleId IdType="pubmed">23201682</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium et al. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Inference of human population history from individual whole-genome sequences. Nature. 2011;475:493&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154645</ArticleId><ArticleId IdType="pubmed">21753753</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoneking M, Krause J. Learning about human population history from ancient and modern genomes. Nat. Rev. Genet. 2011;12:603&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">21850041</ArticleId></ArticleIdList></Reference><Reference><Citation>MacArthur DG, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012;335:823&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299548</ArticleId><ArticleId IdType="pubmed">22344438</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamshad MJ, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 2011;12:745&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">21946919</ArticleId></ArticleIdList></Reference><Reference><Citation>MacArthur DG, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508:469&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180223</ArticleId><ArticleId IdType="pubmed">24759409</ArticleId></ArticleIdList></Reference><Reference><Citation>Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519:223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5955210</ArticleId><ArticleId IdType="pubmed">25533962</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237002</ArticleId><ArticleId IdType="pubmed">24463507</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum. Genet. 1988;78:151&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">3338800</ArticleId></ArticleIdList></Reference><Reference><Citation>Samocha KE, et al. A framework for the interpretation of de novo mutation in human disease. Nat. Genet. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222185</ArticleId><ArticleId IdType="pubmed">25086666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennessen Ja, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337:64&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708544</ArticleId><ArticleId IdType="pubmed">22604720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson DF, et al. Large-scale whole-genome sequencing of the Icelandic population. Nat. Genet. 2015;47:435&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807286</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 2013;9:e1003709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3749936</ArticleId><ArticleId IdType="pubmed">23990802</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicoso B, Charlesworth B. Evolution on the X chromosome: unusual patterns and processes. Nat. Rev. Genet. 2006;7:645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">16847464</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H, Mason SP, Barab&#xe1;si, a L, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411:41&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11333967</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh K-I, et al. The human disease network. Proc. Natl. Acad. Sci. U. S. A. 2007;104:8685&#x2013;8690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885563</ArticleId><ArticleId IdType="pubmed">17502601</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolland T, et al. Resource A Proteome-Scale Map of the Human Interactome Network. Cell. 2014;159:1212&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266588</ArticleId><ArticleId IdType="pubmed">25416956</ArticleId></ArticleIdList></Reference><Reference><Citation>Itan Y, et al. The human gene damage index as a gene-level approach to prioritizing exome variants. Proc. Natl. Acad. Sci. U. S. A. 2015;112:13615&#x2013;13620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4640721</ArticleId><ArticleId IdType="pubmed">26483451</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547484</ArticleId><ArticleId IdType="pubmed">25954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell CJ, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci. Transl. Med. 2011;3:65ra4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740116</ArticleId><ArticleId IdType="pubmed">21228398</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y, et al. Deleterious- and disease-allele prevalence in healthy individuals: Insights from current predictions, mutation databases, and population-scale resequencing. Am. J. Hum. Genet. 2012;91:1022&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516590</ArticleId><ArticleId IdType="pubmed">23217326</ArticleId></ArticleIdList></Reference><Reference><Citation>Piton A, Redin C, Mandel J-L. XLID-Causing Mutations and Associated Genes Challenged in Light of Data From Large-Scale Human Exome Sequencing. Am. J. Hum. Genet. 2013;93:368&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738825</ArticleId><ArticleId IdType="pubmed">23871722</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chagnon P, et al. A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis. Am. J. Hum. Genet. 2002;71:1443&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC378590</ArticleId><ArticleId IdType="pubmed">12417987</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenson PD, et al. The Human Gene Mutation Database: Building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 2014;133:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898141</ArticleId><ArticleId IdType="pubmed">24077912</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey FE, et al. Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. PLOS Genet. 2015;11:e1005496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598191</ArticleId><ArticleId IdType="pubmed">26448358</ArticleId></ArticleIdList></Reference><Reference><Citation>Blekhman R, et al. Natural Selection on Genes that Underlie Human Disease Susceptibility. Curr. Biol. 2008;18:883&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2474766</ArticleId><ArticleId IdType="pubmed">18571414</ArticleId></ArticleIdList></Reference><Reference><Citation>Minikel EV, et al. Quantifying prion disease penetrance using large population control cohorts. Sci. Transl. Med. 2016;8:322ra9&#x2013;322ra9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4774245</ArticleId><ArticleId IdType="pubmed">26791950</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong JX, et al. The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities. Am. J. Hum. Genet. 2015:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573249</ArticleId><ArticleId IdType="pubmed">26166479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kathiresan S. Developing Medicines That Mimic the Natural Successes of the Human Genome. J. Am. Coll. Cardiol. 2015;65:1562&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">25881938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ET, et al. Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population. PLoS Genet. 2014;10:e1004494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117444</ArticleId><ArticleId IdType="pubmed">25078778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulem P, et al. Identification of a large set of rare complete human knockouts. Nat. Genet. 2015;47:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">25807282</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan VM, et al. Health and population effects of rare gene knockouts in adult humans with related parents. Science (80-.) 2016;8624:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985238</ArticleId><ArticleId IdType="pubmed">26940866</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleheen D, et al. Human knockouts in a cohort with a high rate of consanguinity. bioRxiv. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600291</ArticleId><ArticleId IdType="pubmed">28406212</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo Ma, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011;43:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083463</ArticleId><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>Voight BF, et al. The Metabochip, a Custom Genotyping Array for Genetic Studies of Metabolic, Cardiovascular, and Anthropometric Traits. PLoS Genet. 2012;8:e1002793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410907</ArticleId><ArticleId IdType="pubmed">22876189</ArticleId></ArticleIdList></Reference><Reference><Citation>Zook JM, et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat. Biotechnol. 2014;32:246&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">24531798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27452526</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Tau mediates microtubule bundle architectures mimicking fascicles of microtubules found in the axon initial segment.</ArticleTitle><Pagination><StartPage>12278</StartPage><MedlinePgn>12278</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12278</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms12278</ELocationID><Abstract><AbstractText>Tau, an intrinsically disordered protein confined to neuronal axons, binds to and regulates microtubule dynamics. Although there have been observations of string-like microtubule fascicles in the axon initial segment (AIS) and hexagonal bundles in neurite-like processes in non-neuronal cells overexpressing Tau, cell-free reconstitutions have not replicated either geometry. Here we map out the energy landscape of Tau-mediated, GTP-dependent 'active' microtubule bundles at 37&#x2009;&#xb0;C, as revealed by synchrotron SAXS and TEM. Widely spaced bundles (wall-to-wall distance Dw-w&#x2248;25-41&#x2009;nm) with hexagonal and string-like symmetry are observed, the latter mimicking bundles found in the AIS. A second energy minimum (Dw-w&#x2248;16-23&#x2009;nm) is revealed under osmotic pressure. The wide spacing results from a balance between repulsive forces, due to Tau's projection domain (PD), and a stabilizing sum of transient sub-kBT cationic/anionic charge-charge attractions mediated by weakly penetrating opposing PDs. This landscape would be significantly affected by charge-altering modifications of Tau associated with neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Materials Department, Physics Department, Molecular, Cellular, and Developmental Biology Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Chaeyeon</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Materials Department, Physics Department, Molecular, Cellular, and Developmental Biology Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deek</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chemistry and Biochemistry Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Herbert P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Molecular, Cellular, and Developmental Biology Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Youli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Materials Research Laboratory, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Myung Chul</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Molecular, Cellular, and Developmental Biology Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feinstein</LastName><ForeName>Stuart C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Neuroscience Research Institute and Molecular, Cellular, and Developmental Biology Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safinya</LastName><ForeName>Cyrus R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Materials Department, Physics Department, Molecular, Cellular, and Developmental Biology Department, University of California, Santa Barbara, California 93106, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS013560</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS035010</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071040" MajorTopicYN="N">Axon Initial Segment</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009997" MajorTopicYN="N">Osmotic Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053838" MajorTopicYN="N">Scattering, Small Angle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014961" MajorTopicYN="N">X-Ray Diffraction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27452526</ArticleId><ArticleId IdType="pmc">PMC4962469</ArticleId><ArticleId IdType="doi">10.1038/ncomms12278</ArticleId><ArticleId IdType="pii">ncomms12278</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Desai A. &amp; Mitchison T. J. Microtubule polymerization dynamics. Annu. Rev. Cell Dev. Biol. 13, 83&#x2013;117 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9442869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik K. S., Joachim C. L. &amp; Selkoe D. J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044&#x2013;4048 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M. et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702&#x2013;705 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee A. C. et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68, 709&#x2013;735 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945234</ArticleId><ArticleId IdType="pubmed">19535999</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A., Palay S. L. &amp; Webster H. deF. The Fine Structure of the Nervous System: Neurons and Their Supporting Cells Oxford Univ. Press (1991).</Citation></Reference><Reference><Citation>Palay S. L., Sotelo C., Peters A. &amp; Orkand P. M. The axon hillock and the initial segment. J. Cell Biol. 38, 193&#x2013;201 (1968).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2107452</ArticleId><ArticleId IdType="pubmed">5691973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasband M. N. The axon initial segment and the maintenance of neuronal polarity. Nat. Rev. Neurosci. 11, 552&#x2013;562 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20631711</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Kanai Y., Cowan N. J. &amp; Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 360, 674&#x2013;677 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1465130</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas P. W., Pienkowski T. P. &amp; Kosik K. S. Processes induced by tau expression in Sf9 cells have an axon-like microtubule organization. J. Cell Biol. 115, 1333&#x2013;1344 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289232</ArticleId><ArticleId IdType="pubmed">1955477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke N., Trinczek B., Biernat J., Mandelkow E. M. &amp; Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry 33, 9511&#x2013;9522 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R. &amp; Lee G. Orientation, assembly, and stability of microtubule bundles induced by a fragment of tau protein. Cell Motil. Cytoskeleton 28, 143&#x2013;154 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8087873</ArticleId></ArticleIdList></Reference><Reference><Citation>Derry W. B., Wilson L. &amp; Jordan M. A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34, 2203&#x2013;2211 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7857932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojeda-Lopez M. A. et al. Transformation of taxol-stabilized microtubules into inverted tubulin tubules triggered by a tubulin conformation switch. Nat. Mater. 13, 195&#x2013;203 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3946914</ArticleId><ArticleId IdType="pubmed">24441880</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M. C. et al. Human microtubule-associated-protein tau regulates the number of protofilaments in microtubules: a synchrotron X-ray scattering study. Biophys. J. 97, 519&#x2013;527 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711315</ArticleId><ArticleId IdType="pubmed">19619466</ArticleId></ArticleIdList></Reference><Reference><Citation>Black M. M., Slaughter T., Moshiach S., Obrocka M. &amp; Fischer I. Tau is enriched on dynamic microtubules in the distal region of growing axons. J. Neurosci. 16, 3601&#x2013;3619 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578833</ArticleId><ArticleId IdType="pubmed">8642405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R. &amp; Lee G. Functional organization of microtubule-associated protein tau. Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro. J. Biol. Chem. 268, 3414&#x2013;3419 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8429017</ArticleId></ArticleIdList></Reference><Reference><Citation>Needleman D. J. et al. Higher-order assembly of microtubules by counterions: from hexagonal bundles to living necklaces. Proc. Natl Acad. Sci. USA 101, 16099&#x2013;16103 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528963</ArticleId><ArticleId IdType="pubmed">15534220</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreu J. M. et al. Low resolution structure of microtubules in solution. J. Mol. Biol. 226, 169&#x2013;184 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1352357</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek B., Biernat J., Baumann K., Mandelkow E. M. &amp; Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol. Biol. Cell 6, 1887&#x2013;1902 (1995).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC366657</ArticleId><ArticleId IdType="pubmed">8590813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mylonas E. et al. Domain conformation of tau protein studied by solution small-angle X-ray scattering. Biochemistry 47, 10345&#x2013;10353 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18771286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung P. J. et al. Direct force measurements reveal protein Tau confers short-range attractions and isoform-dependent steric stabilization to microtubules. Proc. Natl Acad. Sci. USA 112, E6416&#x2013;E6425 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664379</ArticleId><ArticleId IdType="pubmed">26542680</ArticleId></ArticleIdList></Reference><Reference><Citation>Leermakers F. A. M., Jho Y.-S. &amp; Zhulina E. B. Modeling of the 3RS tau protein with self-consistent field method and Monte Carlo simulation. Soft Matter 6, 5533 (2010).</Citation></Reference><Reference><Citation>Makrides V. et al. Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J. Biol. Chem. 278, 33298&#x2013;33304 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12805366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando D., Colvin M., Rexach M. &amp; Gopinathan A. Physical motif clustering within intrinsically disordered nucleoporin sequences reveals universal functional features. PLoS One 8, e73831 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3774778</ArticleId><ArticleId IdType="pubmed">24066078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada J. et al. A bimodal distribution of two distinct categories of intrinsically disordered structures with separate functions in FG nucleoporins. Mol. Cell. Proteomics 9, 2205&#x2013;2224 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953916</ArticleId><ArticleId IdType="pubmed">20368288</ArticleId></ArticleIdList></Reference><Reference><Citation>Deek J., Chung P. J., Kayser J., Bausch A. R. &amp; Safinya C. R. Neurofilament sidearms modulate parallel and crossed-filament orientations inducing nematic to isotropic and re-entrant birefringent hydrogels. Nat. Commun. 4, 2224 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23892390</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck R., Deek J., Jones J. B. &amp; Safinya C. R. Gel-expanded to gel-condensed transition in neurofilament networks revealed by direct force measurements. Nat. Mater. 9, 40&#x2013;46 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">19915555</ArticleId></ArticleIdList></Reference><Reference><Citation>Deek J., Chung P. J. &amp; Safinya C. R. Neurofilament networks: Salt-responsive hydrogels with sidearm-dependent phase behavior. Biochim. Biophys. Acta 1860, 1560&#x2013;1569 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26993199</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlier M. F. &amp; Pantaloni D. Taxol effect on tubulin polymerization and associated guanosine 5'-triphosphate hydrolysis. Biochemistry 22, 4814&#x2013;4822 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6138095</ArticleId></ArticleIdList></Reference><Reference><Citation>Solis F. J. &amp; Olvera de la Cruz M. Attractive interactions between rodlike polyelectrolytes: polarization, crystallization, and packing. Phys. Rev. E Stat. Phys. Plasmas Fluids Relat. Interdiscip. Topics 60, 4496&#x2013;4499 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">11970304</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatter O. &amp; Kratky O. (eds) Small angle x-ray scattering. Academic Press Inc. Ltd (1982).</Citation></Reference><Reference><Citation>Grundke-Iqbal I. et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913&#x2013;4917 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A. C., Zaidi T., Grundke-Iqbal I. &amp; Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 5562&#x2013;5566 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44036</ArticleId><ArticleId IdType="pubmed">8202528</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahama K., Inomata H. &amp; Saito S. Measurement of osmotic pressure in aqueous solutions of poly(ethylene glycol) and poly(N-isopropylacrylamide). Fluid Phase Equilib. 96, 203&#x2013;214 (1994).</Citation></Reference><Reference><Citation>Rau D. C., Lee B. &amp; Parsegian V. a. Measurement of the repulsive force between polyelectrolyte molecules in ionic solution: hydration forces between parallel DNA double helices. Proc. Natl Acad. Sci. USA 81, 2621&#x2013;2625 (1984).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC345121</ArticleId><ArticleId IdType="pubmed">6585818</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand K. &amp; Selser J. C. Asymptotic behavior and long-range interactions in aqueous solutions of poly (ethylene oxide). Macromolecules 24, 5943&#x2013;5947 (1991).</Citation></Reference><Reference><Citation>Kohn J. E. et al. Random-coil behavior and the dimensions of chemically unfolded proteins. Proc. Natl Acad. Sci. USA 101, 12491&#x2013;12496 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC515087</ArticleId><ArticleId IdType="pubmed">15314214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27545621</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>ALS Mutations Disrupt Phase Separation Mediated by &#x3b1;-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain.</ArticleTitle><Pagination><StartPage>1537</StartPage><EndPage>1549</EndPage><MedlinePgn>1537-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2016.07.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(16)30192-7</ELocationID><Abstract><AbstractText>RNA-binding protein TDP-43 mediates essential RNA processing but forms cytoplasmic neuronal inclusions via its C-terminal domain (CTD) in amyotrophic lateral sclerosis (ALS). It remains unclear if aggregated TDP-43 is neurotoxic and if &#x223c;50 ALS-associated missense mutations in TDP-43 CTD promote aggregation, or if loss of normal function plays a role in disease. Recent work points to the ability of related proteins to assemble into functional phase-separated ribonucleoprotein granules via their structurally disordered prion-like domains. Here, we provide atomic details on the structure and assembly of the low-complexity CTD of TDP-43 into liquid-liquid phase-separated in&#xa0;vitro granules and demonstrate that ALS-associated variants disrupt interactions within granules. Using nuclear magnetic resonance spectroscopy, simulation, and microscopy, we find&#xa0;that a subregion cooperatively but transiently folds&#xa0;into a helix that mediates TDP-43 phase separation. ALS-associated mutations disrupt phase separation by inhibiting interaction and helical stabilization. Therefore, ALS-associated mutations can disrupt TDP-43 interactions, affecting function beyond encouraging aggregation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conicella</LastName><ForeName>Alexander E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Graduate Program in Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerze</LastName><ForeName>G&#xfc;l H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Lehigh University, Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Jeetain</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemical and Biomolecular Engineering, Lehigh University, Bethlehem, PA 18015, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fawzi</LastName><ForeName>Nicolas L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, RI 02912, USA. Electronic address: nicolas_fawzi@brown.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007601</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 GM103410</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM104937</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM118530</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 RR031153</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 RR018728</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Structure. 2016 Sep 6;24(9):1435-6. doi: 10.1016/j.str.2016.08.003.</RefSource><PMID Version="1">27602988</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020816" MajorTopicYN="N">Amino Acid Motifs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072756" MajorTopicYN="N">Protein Conformation, alpha-Helical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072757" MajorTopicYN="N">Protein Conformation, beta-Strand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27545621</ArticleId><ArticleId IdType="mid">NIHMS805438</ArticleId><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="doi">10.1016/j.str.2016.07.007</ArticleId><ArticleId IdType="pii">S0969-2126(16)30192-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SS, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, Link CD. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet. 2010;19:3206&#x2013;3218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908471</ArticleId><ArticleId IdType="pubmed">20530643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, Marchetti C, Romano M, Baralle FE. Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005;348:575&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A, Herzog F, Rinner O, Ellenberg J, Aebersold R. The quantitative proteome of a human cell line. Molecular Systems Biology. 2011;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261713</ArticleId><ArticleId IdType="pubmed">22068332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43) The Journal of biological chemistry. 2012;287:23079&#x2013;23094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Best RB, Zheng W, Mittal J. Balanced Protein-Water Interactions Improve Properties of Disordered Proteins and Non-Specific Protein Association. J Chem Theory Comput. 2014;10:5113&#x2013;5124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230380</ArticleId><ArticleId IdType="pubmed">25400522</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne CP, Eckmann CR, Courson DS, Rybarska A, Hoege C, Gharakhani J, Julicher F, Hyman AA. Germline P granules are liquid droplets that localize by controlled dissolution/condensation. Science. 2009;324:1729&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">19460965</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Romano V, Avendano-Vazquez SE, Bembich S, Buratti E, Baralle FE. Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. Brain Res. 2012;1462:139&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406069</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Romano V, Quadri Z, Buratti E, Baralle FE. TDP-43 loss of cellular function through aggregation requires additional structural determinants beyond its C-terminal Q/N prion-like domain. Hum Mol Genet. 2015;24:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4262490</ArticleId><ArticleId IdType="pubmed">25122661</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional Significance of TDP-43 Mutations in Disease. Adv Genet. 2015;91:1&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280:37572&#x2013;37584.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20:1774&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke KA, Janke AM, Rhine CL, Fawzi NL. Residue-by-Residue View of In Vitro FUS Granules that Bind the C-Terminal Domain of RNA Polymerase II. Mol Cell. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609301</ArticleId><ArticleId IdType="pubmed">26455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CK, Wu TH, Wu CY, Chiang MH, Toh EK, Hsu YC, Lin KF, Liao YH, Huang TH, Huang JJ. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012;425:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, Silani V, Ratti A. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Alton S, Altshuler M, Cannon A, Dickson DW, Petrucelli L, Lewis J. Divergent phenotypes in mutant TDP-43 transgenic mice highlight potential confounds in TDP-43 transgenic modeling. PLoS One. 2014;9:e86513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899264</ArticleId><ArticleId IdType="pubmed">24466128</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, Ayala YM, Baralle FE. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 2009;37:4116&#x2013;4126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709582</ArticleId><ArticleId IdType="pubmed">19429692</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammer EB, Fallini C, Gozal YM, Duong DM, Rossoll W, Xu P, Lah JJ, Levey AI, Peng J, Bassell GJ, et al. Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS One. 2012;7:e38658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3380899</ArticleId><ArticleId IdType="pubmed">22761693</ArticleId></ArticleIdList></Reference><Reference><Citation>Daura X, Gademann K, Jaun B, Seebach D, van Gunsteren WF, Mark AE. Peptide folding: When simulation meets experiment. Angew Chem Int Edit. 1999;38:236&#x2013;240.</Citation></Reference><Reference><Citation>Deighan M, Bonomi M, Pfaendtner J. Efficient Simulation of Explicitly Solvated Proteins in the Well-Tempered Ensemble. J Chem Theory Comput. 2012;8:2189&#x2013;2192.</Citation><ArticleIdList><ArticleId IdType="pubmed">26588950</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum Mol Genet. 2011;20:2308&#x2013;2321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3098735</ArticleId><ArticleId IdType="pubmed">21441568</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9:1104&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897173</ArticleId><ArticleId IdType="pubmed">20020773</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias J, Sanchez-Mart&#xed;nez M, Crehuet R. SS-map. Intrinsically Disordered Proteins. 2013;1:e25323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5424797</ArticleId><ArticleId IdType="pubmed">28516013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R. ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure. Cell. 2016;164:487&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733397</ArticleId><ArticleId IdType="pubmed">26777405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, Che MX, Zhao J, Zhou CJ, Xie MY, Li HY, He JH, Hu HY. Structural transformation of the amyloidogenic core region of TDP-43 protein initiates its aggregation and cytoplasmic inclusion. J Biol Chem. 2013;288:19614&#x2013;19624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707662</ArticleId><ArticleId IdType="pubmed">23689371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LL, Zhao J, Yin XF, He WT, Yang H, Che MX, Hu HY. Two mutations G335D and Q343R within the amyloidogenic core region of TDP-43 influence its aggregation and inclusion formation. Sci Rep. 2016;6:23928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4814915</ArticleId><ArticleId IdType="pubmed">27030292</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22:2577&#x2013;2637.</Citation><ArticleIdList><ArticleId IdType="pubmed">6667333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H, Hasegawa M. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun. 2009;382:405&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon MJ, Baek W, Ki CS, Kim HY, Koh SH, Kim JW, Kim SH. Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS. Neurobiol Aging. 2012;33:1017 e1017&#x2013;1017 e1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">22244934</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon SC, Yi H, Eichelbaum K, Fohr S, Fischer B, You KT, Castello A, Krijgsveld J, Hentze MW, Kim VN. The RNA-binding protein repertoire of embryonic stem cells. Nat Struct Mol Biol. 2013;20:1122&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">23912277</ArticleId></ArticleIdList></Reference><Reference><Citation>Libich DS, Fawzi NL, Ying J, Clore GM. Probing the transient dark state of substrate binding to GroEL by relaxation-based solution NMR. Proc Natl Acad Sci U S A. 2013;110:11361&#x2013;11366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710837</ArticleId><ArticleId IdType="pubmed">23798407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L, Wei Y, Lu Y, Song J. ALS-Causing Mutations Significantly Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43. PLoS Biol. 2016;14:e1002338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK, Parker R. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol Cell. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S-C, Polymenidou M, Cleveland DW. Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukavsky PJ, Daujotyte D, Tollervey JR, Ule J, Stuani C, Buratti E, Baralle FE, Damberger FF, Allain FH. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat Struct Mol Biol. 2013;20:1443&#x2013;1449.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240615</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh JA, Singh VK, Jia Z, Forman-Kay JD. Sensitivity of secondary structure propensities to sequence differences between alpha-and gamma-synuclein: implications for fibrillation. Protein Sci. 2006;15:2795&#x2013;2804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2242444</ArticleId><ArticleId IdType="pubmed">17088319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrea DM, Kriwacki RW. Phase separation in biology; functional organization of a higher order. Cell Commun Signal. 2016;14:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4700675</ArticleId><ArticleId IdType="pubmed">26727894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittal J, Yoo TH, Georgiou G, Truskett TM. Structural ensemble of an intrinsically disordered polypeptide. J Phys Chem B. 2013;117:118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">23205890</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. Phase Separation by Low Complexity Domains Promotes Stress Granule Assembly and Drives Pathological Fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompean M, Buratti E, Guarnaccia C, Brito RM, Chakrabartty A, Baralle FE, Laurents DV. Structural characterization of the minimal segment of TDP-43 competent for aggregation. Arch Biochem Biophys. 2014;545:53&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24440310</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompean M, Romano V, Pantoja-Uceda D, Stuani C, Baralle FE, Buratti E, Laurents DV. The TDP-43 N-Terminal Domain Structure at High Resolution. FEBS J. 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">26756435</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Suzuki G, Tanaka Y, Kametani F, Hirai S, Okado H, Miyashita T, Saitoe M, Akiyama H, Masai H, et al. Phosphorylation of TAR DNA-binding Protein of 43 kDa (TDP-43) by Truncated Casein Kinase 1&#x3b4; Triggers Mislocalization and Accumulation of TDP-43. Journal of Biological Chemistry. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott TJ, Petsalaki E, Farber P, Jervis D, Fussner E, Plochowietz A, Craggs TD, Bazett-Jones DP, Pawson T, Forman-Kay JD, et al. Phase transition of a disordered nuage protein generates environmentally responsive membraneless organelles. Mol Cell. 2015;57:936&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352761</ArticleId><ArticleId IdType="pubmed">25747659</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee, Hyun O, Jawerth L, Maharana S, Jahnel M, Hein, Marco Y, Stoynov S, Mahamid J, Saha S, Franzmann, Titus M, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Peti W, Page R. Strategies to maximize heterologous protein expression in Escherichia coli with minimal cost. Protein expression and purification. 2007;51:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904906</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan AT, Kuryavyi V, Darnell JC, Serganov A, Majumdar A, Ilin S, Raslin T, Polonskaia A, Chen C, Clain D, et al. Structure-function studies of FMRP RGG peptide recognition of an RNA duplex-quadruplex junction. Nat Struct Mol Biol. 2011;18:796&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130835</ArticleId><ArticleId IdType="pubmed">21642970</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz JC, Wang X, Podell ER, Cech TR. RNA seeds higher-order assembly of FUS protein. Cell Rep. 2013;5:918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925748</ArticleId><ArticleId IdType="pubmed">24268778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Bax A. SPARTA+: a modest improvement in empirical NMR chemical shift prediction by means of an artificial neural network. J Biomol NMR. 2010;48:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935510</ArticleId><ArticleId IdType="pubmed">20628786</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LJ, Bolin KA, Schwalbe H, MacArthur MW, Thornton JM, Dobson CM. Analysis of main chain torsion angles in proteins: prediction of NMR coupling constants for native and random coil conformations. J Mol Biol. 1996;255:494&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">8568893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormanni P, Camilloni C, Fariselli P, Vendruscolo M. The s2D method: simultaneous sequence-based prediction of the statistical populations of ordered and disordered regions in proteins. J Mol Biol. 2015;427:982&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">25534081</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang C, Iwahara J, Clore GM. Visualization of transient encounter complexes in protein-protein association. Nature. 2006;444:383&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051159</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogeli B, Ying J, Grishaev A, Bax A. Limits on variations in protein backbone dynamics from precise measurements of scalar couplings. J Am Chem Soc. 2007;129:9377&#x2013;9385.</Citation><ArticleIdList><ArticleId IdType="pubmed">17608477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Grey MJ, Palmer AG., 3rd CPMG sequences with enhanced sensitivity to chemical exchange. J Biomol NMR. 2001;21:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">11824755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jardetzky O. Probability-based protein secondary structure identification using combined NMR chemical-shift data. Protein Sci. 2002;11:852&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373532</ArticleId><ArticleId IdType="pubmed">11910028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YT, Kuo PH, Chiang CH, Liang JR, Chen YR, Wang S, Shen JC, Yuan HS. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J Biol Chem. 2013;288:9049&#x2013;9057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610977</ArticleId><ArticleId IdType="pubmed">23372158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106:18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Sykes BD, Richards FM. The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry. 1992;31:1647&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pubmed">1737021</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang S, Kato M, Wu LC, Lin Y, Ding M, Zhang Y, Yu Y, McKnight SL. The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei. Cell. 2015;163:829&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879888</ArticleId><ArticleId IdType="pubmed">26544936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerze GH, Best RB, Mittal J. Sequence- and Temperature-Dependent Properties of Unfolded and Disordered Proteins from Atomistic Simulations. J Phys Chem B. 2015;119:14622&#x2013;14630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6141988</ArticleId><ArticleId IdType="pubmed">26498157</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Neal S, Wishart DS. RefDB: a database of uniformly referenced protein chemical shifts. J Biomol NMR. 2003;25:173&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">12652131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27559087</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>36</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes.</ArticleTitle><Pagination><StartPage>10186</StartPage><EndPage>10191</EndPage><MedlinePgn>10186-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1609896113</ELocationID><Abstract><AbstractText>The strongest genetic risk factor influencing susceptibility to late-onset Alzheimer's disease (AD) is apolipoprotein E (APOE) genotype. APOE has three common isoforms in humans, E2, E3, and E4. The presence of two copies of the E4 allele increases risk by &#x223c;12-fold whereas E2 allele is associated with an &#x223c;twofold decreased risk for AD. These data put APOE central to AD pathophysiology, but it is not yet clear how APOE alleles modify AD risk. Recently we found that astrocytes, a major central nervous system cell type that produces APOE, are highly phagocytic and participate in normal synapse pruning and turnover. Here, we report a novel role for APOE in controlling the phagocytic capacity of astrocytes that is highly dependent on APOE isoform. APOE2 enhances the rate of phagocytosis of synapses by astrocytes, whereas APO4 decreases it. We also found that the amount of C1q protein accumulation in hippocampus, which may represent the accumulation of senescent synapses with enhanced vulnerability to complement-mediated degeneration, is highly dependent on APOE alleles: C1q accumulation was significantly reduced in APOE2 knock-in (KI) animals and was significantly increased in APOE4 KI animals compared with APOE3 KI animals. These studies reveal a novel allele-dependent role for APOE in regulating the rate of synapse pruning by astrocytes. They also suggest the hypothesis that AD susceptibility of APOE4 may originate in part from defective phagocytic capacity of astrocytes which accelerates the rate of accumulation of C1q-coated senescent synapses, enhancing synaptic vulnerability to classical-complement-cascade mediated neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Won-Suk</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0003-1060-9007</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, CA 94305; wonsuk.chung@kaist.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verghese</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, School of Medicine, St. Louis, MO 63110;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakraborty</LastName><ForeName>Chandrani</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, CA 94305;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joung</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, CA 94305;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Massachusetts Alzheimer Disease Research Center, Massachusetts General Hospital, Charlestown, MA 02129; Department of Neurology, Massachusetts General Hospital, Boston, MA 02129.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, School of Medicine, St. Louis, MO 63110;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University, School of Medicine, St. Louis, MO 63110;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, School of Medicine, Stanford University, Stanford, CA 94305; barres@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 EY024690</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS072556</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-33-6</RegistryNumber><NameOfSubstance UI="D015922">Complement C1q</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015922" MajorTopicYN="N">Complement C1q</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE allele</Keyword><Keyword MajorTopicYN="N">C1q</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">phagocytosis</Keyword><Keyword MajorTopicYN="N">synapse elimination</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27559087</ArticleId><ArticleId IdType="pmc">PMC5018780</ArticleId><ArticleId IdType="doi">10.1073/pnas.1609896113</ArticleId><ArticleId IdType="pii">1609896113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Alzheimer&#x2019;s disease is a synaptic failure. Science. 2002;298(5594):789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: The story so far. Nat Rev Neurol. 2016;12(1):15&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">26635213</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">3283935</ArticleId></ArticleIdList></Reference><Reference><Citation>Teter B. Apolipoprotein E isotype-specific effects in neurodegeneration. Alzheimers Rep. 2000;3:199&#x2013;212.</Citation></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Erikson GA, et al. Whole-genome sequencing of a healthy aging cohort. Cell. 2016;165(4):1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860090</ArticleId><ArticleId IdType="pubmed">27114037</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2000;97(6):2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10(7):719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2005;102(4):1211&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC544620</ArticleId><ArticleId IdType="pubmed">15657137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RE, et al. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer&#x2019;s-like neuropathology. Exp Neurol. 2001;170(2):326&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476599</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females. Proc Natl Acad Sci USA. 1998;95(18):10914&#x2013;10919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27995</ArticleId><ArticleId IdType="pubmed">9724804</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, et al. Apolipoprotein E and cognitive performance. Nature. 2000;404(6776):352&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bour A, et al. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res. 2008;193(2):174&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">18572260</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanis SB, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29(48):15317&#x2013;15322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846754</ArticleId><ArticleId IdType="pubmed">19955384</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature. 2013;504(7480):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969024</ArticleId><ArticleId IdType="pubmed">24270812</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 2004;173(10):6366&#x2013;6375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528376</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3(89):89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo LC, et al. Development of a method for the purification and culture of rodent astrocytes. Neuron. 2011;71(5):799&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172573</ArticleId><ArticleId IdType="pubmed">21903074</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L, et al. TAM receptors regulate multiple features of microglial physiology. Nature. 2016;532(7598):240&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M, Yang WL, Wang P. 2013. Measurement of phagocytic engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. Curr Protocols Immunol Chapter 14:Unit 14.31.</Citation></Reference><Reference><Citation>Colas C, et al. An improved flow cytometry assay to monitor phagosome acidification. J Immunol Methods. 2014;412:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24952246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013;8:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3640999</ArticleId><ArticleId IdType="pubmed">23601557</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, et al. ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc Natl Acad Sci USA. 2013;110(19):E1807&#x2013;E1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz J, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46(8):1721&#x2013;1731.</Citation><ArticleIdList><ArticleId IdType="pubmed">15863833</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M, et al. Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. J Biochem. 2002;132(5):743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417024</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269(38):23403&#x2013;23406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8089103</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, et al. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 1995;270(16):9039&#x2013;9042.</Citation><ArticleIdList><ArticleId IdType="pubmed">7721816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoy JD, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J Neurosci. 2008;28(1):264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671143</ArticleId><ArticleId IdType="pubmed">18171944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew ED, et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. eLife. 2014;3:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206827</ArticleId><ArticleId IdType="pubmed">25265470</ArticleId></ArticleIdList></Reference><Reference><Citation>Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015;16(9):907&#x2013;917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826466</ArticleId><ArticleId IdType="pubmed">26287597</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74(4):691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell GR, et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest. 2011;121(4):1429&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069778</ArticleId><ArticleId IdType="pubmed">21383504</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephan AH, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33(33):13460&#x2013;13474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenner AJ, Fonseca MI. The double-edged flower: Roles of complement protein C1q in neurodegenerative diseases. Adv Exp Med Biol. 2006;586:153&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">16893071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165(4):921&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Yoon H, Basak J, Kim J. Apolipoprotein E in synaptic plasticity and Alzheimer's disease: Potential cellular and molecular mechanisms. Mol Cells. 2014;37(11):767&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255096</ArticleId><ArticleId IdType="pubmed">25358504</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaultier A, et al. Low-density lipoprotein receptor-related protein 1 is an essential receptor for myelin phagocytosis. J Cell Sci. 2009;122(Pt 8):1155&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714439</ArticleId><ArticleId IdType="pubmed">19299462</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitten MM, Tew IF, Lee BL, Ratcliffe NA. A novel role for an insect apolipoprotein (apolipophorin III) in beta-1,3-glucan pattern recognition and cellular encapsulation reactions. J Immunol. 2004;172(4):2177&#x2013;2185.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764684</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp Neurol. 1998;151(2):314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">9628766</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstyn-Cohen T, et al. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron. 2012;76(6):1123&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530147</ArticleId><ArticleId IdType="pubmed">23259948</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkley PR, Jarvie PE, Robinson PJ. A rapid Percoll gradient procedure for preparation of synaptosomes. Nat Protoc. 2008;3(11):1718&#x2013;1728.</Citation><ArticleIdList><ArticleId IdType="pubmed">18927557</ArticleId></ArticleIdList></Reference><Reference><Citation>Beletskii A, et al. High-throughput phagocytosis assay utilizing a pH-sensitive fluorescent dye. Biotechniques. 2005;39(6):894&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382909</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85(3):890&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111442</ArticleId><ArticleId IdType="pubmed">6248568</ArticleId></ArticleIdList></Reference><Reference><Citation>Matz CE, Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982;257(8):4535&#x2013;4540.</Citation><ArticleIdList><ArticleId IdType="pubmed">6802835</ArticleId></ArticleIdList></Reference><Reference><Citation>Hime NJ, Drew KJ, Hahn C, Barter PJ, Rye KA. Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry. 2004;43(38):12306&#x2013;12314.</Citation><ArticleIdList><ArticleId IdType="pubmed">15379569</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27580372</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2016</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>The amyloid-beta forming tripeptide cleavage mechanism of &#x3b3;-secretase.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e17578</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.17578</ELocationID><Abstract><AbstractText>&#x3b3;-secretase is responsible for the proteolysis of amyloid precursor protein (APP) into short, aggregation-prone amyloid-beta (A&#x3b2;) peptides, which are centrally implicated in the pathogenesis of Alzheimer's disease (AD). Despite considerable interest in developing &#x3b3;-secretase targeting therapeutics for the treatment of AD, the precise mechanism by which &#x3b3;-secretase produces A&#x3b2; has remained elusive. Herein, we demonstrate that &#x3b3;-secretase catalysis is driven by the stabilization of an enzyme-substrate scission complex via three distinct amino-acid-binding pockets in the enzyme's active site, providing the mechanism by which &#x3b3;-secretase preferentially cleaves APP in three amino acid increments. Substrate occupancy of these three pockets occurs after initial substrate binding but precedes catalysis, suggesting a conformational change in substrate may be required for cleavage. We uncover and exploit substrate cleavage preferences dictated by these three pockets to investigate the mechanism by which familial Alzheimer's disease mutations within APP increase the production of pathogenic A&#x3b2; species.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bolduc</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-2000-5728</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montagna</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seghers</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-2446-7102</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Elife. 2016 Aug 31;5:e20043. doi: 10.7554/eLife.20043.</RefSource><PMID Version="1">27580373</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="Y">Proteolysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">biochemistry</Keyword><Keyword MajorTopicYN="N">cell biology</Keyword><Keyword MajorTopicYN="N">gamma-secretase</Keyword><Keyword MajorTopicYN="N">intramembrane protease</Keyword></KeywordList><CoiStatement>The authors declare that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27580372</ArticleId><ArticleId IdType="pmc">PMC5134833</ArticleId><ArticleId IdType="doi">10.7554/eLife.17578</ArticleId><ArticleId IdType="pii">e17578</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama K, Mizuno S, Hizukuri Y, Mori H, Nogi T, Akiyama Y. Roles of the membrane-reentrant &#x3b2;-hairpin-like loop of RseP protease in selective substrate cleavage. eLife. 2015;4:08928. doi: 10.7554/eLife.08928.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.08928</ArticleId><ArticleId IdType="pmc">PMC4597795</ArticleId><ArticleId IdType="pubmed">26447507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolduc DM, Montagna DR, Gu Y, Selkoe DJ, Wolfe MS. Nicastrin functions to sterically hinder &#x3b3;-secretase-substrate interactions driven by substrate transmembrane domain. PNAS. 2016;113:E509&#x2013;E518. doi: 10.1073/pnas.1512952113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1512952113</ArticleId><ArticleId IdType="pmc">PMC4747693</ArticleId><ArticleId IdType="pubmed">26699478</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Gamache E, Rosenman DJ, Xie J, Lopez MM, Li YM, Wang C. Familial Alzheimer's mutations within APPTM increase A&#x3b2;42 production by enhancing accessibility of &#x3b5;-cleavage site. Nature Communications. 2014;5:3037. doi: 10.1038/ncomms4037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4037</ArticleId><ArticleId IdType="pmc">PMC4082030</ArticleId><ArticleId IdType="pubmed">24390130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Dickey SW, Urban S. Crystal structures and inhibition kinetics reveal a two-stage catalytic mechanism with drug design implications for rhomboid proteolysis. Molecular Cell. 2016;61:329&#x2013;340. doi: 10.1016/j.molcel.2015.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2015.12.022</ArticleId><ArticleId IdType="pmc">PMC4744120</ArticleId><ArticleId IdType="pubmed">26805573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, Wiltfang J, Serneels L, Karran E, Gijsen H, Schymkowitz J, Rousseau F, Broersen K, De Strooper B. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. The EMBO Journal. 2012;31:2261&#x2013;2274. doi: 10.1038/emboj.2012.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.79</ArticleId><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Das C, Berezovska O, Diehl TS, Genet C, Buldyrev I, Tsai JY, Hyman BT, Wolfe MS. Designed helical peptides inhibit an intramembrane protease. Journal of the American Chemical Society. 2003;125:11794&#x2013;11795. doi: 10.1021/ja037131v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja037131v</ArticleId><ArticleId IdType="pubmed">14505382</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Lessons from a failed &#x3b3;-secretase Alzheimer trial. Cell. 2014;159:721&#x2013;726. doi: 10.1016/j.cell.2014.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.10.016</ArticleId><ArticleId IdType="pubmed">25417150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey SW, Baker RP, Cho S, Urban S. Proteolysis inside the membrane is a rate-governed reaction not driven by substrate affinity. Cell. 2013;155:1270&#x2013;1281. doi: 10.1016/j.cell.2013.10.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.10.053</ArticleId><ArticleId IdType="pmc">PMC3917317</ArticleId><ArticleId IdType="pubmed">24315097</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov M, Alattia JR, Lemmin T, Lehal R, Fligier A, Houacine J, Hussain I, Radtke F, Dal Peraro M, Beher D, Fraering PC. Alzheimer's disease mutations in APP but not &#x3b3;-secretase modulators affect epsilon-cleavage-dependent AICD production. Nature Communications. 2013;4:2246. doi: 10.1038/ncomms3246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3246</ArticleId><ArticleId IdType="pubmed">23907250</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee. Semagacestat Study Group A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine. 2013;369:341&#x2013;350. doi: 10.1056/NEJMoa1210951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1210951</ArticleId><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Esler WP, Das C, Wolfe MS. Probing pockets S2-S4' of the gamma-secretase active site with (hydroxyethyl)urea peptidomimetics. Bioorganic &amp; Medicinal Chemistry Letters. 2004;14:1935&#x2013;1938. doi: 10.1016/j.bmcl.2004.01.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2004.01.077</ArticleId><ArticleId IdType="pubmed">15050631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid &#x3b2;-peptides (A&#x3b2;) by &#x3b3;-secretase to increase 42-to-40-residue A&#x3b2;. Journal of Biological Chemistry. 2014;289:31043&#x2013;31052. doi: 10.1074/jbc.M114.581165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.581165</ArticleId><ArticleId IdType="pmc">PMC4223309</ArticleId><ArticleId IdType="pubmed">25239621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluhrer R, Martin L, Klier B, Haug-Kr&#xf6;per M, Grammer G, Nuscher B, Haass C. The &#x3b1;-helical content of the transmembrane domain of the British dementia protein-2 (Bri2) determines its processing by signal peptide peptidase-like 2b (SPPL2b) Journal of Biological Chemistry. 2012;287:5156&#x2013;5163. doi: 10.1074/jbc.M111.328104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.328104</ArticleId><ArticleId IdType="pmc">PMC3281599</ArticleId><ArticleId IdType="pubmed">22194595</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, van Dorsselaer A, Wang R, Selkoe DJ, Wolfe MS. Purification and characterization of the human gamma-secretase complex. Biochemistry. 2004;43:9774&#x2013;9789. doi: 10.1021/bi0494976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0494976</ArticleId><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. &#x3b3;-Secretase inhibitors and modulators. Biochimica Et Biophysica Acta (BBA) - Biomembranes. 2013;1828:2898&#x2013;2907. doi: 10.1016/j.bbamem.2013.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2013.06.005</ArticleId><ArticleId IdType="pmc">PMC3857966</ArticleId><ArticleId IdType="pubmed">23791707</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Baquero M, Blesa R, Boada M, Br&#xe1;s JM, Bullido MJ, Calado A, Crook R, Ferreira C, Frank A, G&#xf3;mez-Isla T, Hern&#xe1;ndez I, Lle&#xf3; A, Machado A, Mart&#xed;nez-Lage P, Masdeu J, Molina-Porcel L, Molinuevo JL, Pastor P, P&#xe9;rez-Tur J, Relvas R, Oliveira CR, Ribeiro MH, Rogaeva E, Sa A, Samaranch L, S&#xe1;nchez-Valle R, Santana I, T&#xe0;rraga L, Valdivieso F, Singleton A, Hardy J, Clarim&#xf3;n J. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging. 2010;31:725&#x2013;731. doi: 10.1016/j.neurobiolaging.2008.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.06.012</ArticleId><ArticleId IdType="pmc">PMC2850052</ArticleId><ArticleId IdType="pubmed">18667258</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo A, Kovacs DM. The many substrates of presenilin/&#x3b3;-secretase. Journal of Alzheimer's Disease. 2011;25:3&#x2013;28. doi: 10.3233/JAD-2011-101065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101065</ArticleId><ArticleId IdType="pmc">PMC3281584</ArticleId><ArticleId IdType="pubmed">21335653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, Ihara Y. Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. Journal of Biological Chemistry. 2006;281:14776&#x2013;14786. doi: 10.1074/jbc.M513453200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M513453200</ArticleId><ArticleId IdType="pubmed">16595682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova AY, Das C, Wolfe MS. Differential effects of inhibitors on the gamma-secretase complex. implications. The Journal of Biological Chemistry. 2003;278:16470&#x2013;16473. doi: 10.1074/jbc.C300019200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C300019200</ArticleId><ArticleId IdType="pubmed">12644463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. PNAS. 2005;102:3230&#x2013;3235. doi: 10.1073/pnas.0407640102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0407640102</ArticleId><ArticleId IdType="pmc">PMC552920</ArticleId><ArticleId IdType="pubmed">15722417</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvelil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689&#x2013;694. doi: 10.1038/35015085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35015085</ArticleId><ArticleId IdType="pubmed">10864326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. PNAS. 1999;96:3053&#x2013;3058. doi: 10.1073/pnas.96.6.3053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.6.3053</ArticleId><ArticleId IdType="pmc">PMC15893</ArticleId><ArticleId IdType="pubmed">10077635</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumura N, Takami M, Okochi M, Wada-Kakuda S, Fujiwara H, Tagami S, Funamoto S, Ihara Y, Morishima-Kawashima M. &#x3b3;-Secretase associated with lipid rafts: multiple interactive pathways in the stepwise processing of &#x3b2;-carboxyl-terminal fragment. Journal of Biological Chemistry. 2014;289:5109&#x2013;5121. doi: 10.1074/jbc.M113.510131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.510131</ArticleId><ArticleId IdType="pmc">PMC3931069</ArticleId><ArticleId IdType="pubmed">24375443</ArticleId></ArticleIdList></Reference><Reference><Citation>Moin SM, Urban S. Membrane immersion allows rhomboid proteases to achieve specificity by reading transmembrane segment dynamics. eLife. 2012;1:00173. doi: 10.7554/eLife.00173.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.00173</ArticleId><ArticleId IdType="pmc">PMC3494066</ArticleId><ArticleId IdType="pubmed">23150798</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Steiner H, Fukumori A, Tanii H, Tomita T, Tanaka T, Iwatsubo T, Kudo T, Takeda M, Haass C. Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. The EMBO Journal. 2002;21:5408&#x2013;5416. doi: 10.1093/emboj/cdf541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdf541</ArticleId><ArticleId IdType="pmc">PMC129073</ArticleId><ArticleId IdType="pubmed">12374741</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, Nakayama T, Ihara Y, Takeda M. &#x3b3;-secretase modulators and presenilin 1 mutants act differently on presenilin/&#x3b3;-secretase function to cleave A&#x3b2;42 and A&#x3b2;43. Cell Reports. 2013;3:42&#x2013;51. doi: 10.1016/j.celrep.2012.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.11.028</ArticleId><ArticleId IdType="pubmed">23291095</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S, Lendahl U, Multhaup G, Lundkvist J. Characterization of intermediate steps in amyloid beta (A&#x3b2;) production under near-native conditions. Journal of Biological Chemistry. 2014;289:1540&#x2013;1550. doi: 10.1074/jbc.M113.498246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.498246</ArticleId><ArticleId IdType="pmc">PMC3894335</ArticleId><ArticleId IdType="pubmed">24225948</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, Li H, Ye W, Li D, Aeschbach L, Fraering PC, Wolfe MS, Selkoe DJ, Li H. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. Journal of Molecular Biology. 2009;385:642&#x2013;652. doi: 10.1016/j.jmb.2008.10.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2008.10.078</ArticleId><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintero-Monzon O, Martin MM, Fernandez MA, Cappello CA, Krzysiak AJ, Osenkowski P, Wolfe MS. Dissociation between the processivity and total activity of &#x3b3;-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations. Biochemistry. 2011;50:9023&#x2013;9035. doi: 10.1021/bi2007146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi2007146</ArticleId><ArticleId IdType="pmc">PMC3205908</ArticleId><ArticleId IdType="pubmed">21919498</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama H, Koo EH, Haass C, Takio K, Morishima-Kawashima M, Ishiura S, Ihara Y. Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. Journal of Biological Chemistry. 2003;278:24294&#x2013;24301. doi: 10.1074/jbc.M211161200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211161200</ArticleId><ArticleId IdType="pubmed">12707272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Tanimura Y, Hirotani N, Saido TC, Morishima-Kawashima M, Ihara Y. Blocking the cleavage at midportion between gamma- and epsilon-sites remarkably suppresses the generation of amyloid beta-protein. FEBS Letters. 2005;579:2907&#x2013;2912. doi: 10.1016/j.febslet.2005.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2005.04.037</ArticleId><ArticleId IdType="pubmed">15890346</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. Journal of Neuroscience. 2009;29:13042&#x2013;13052. doi: 10.1523/JNEUROSCI.2362-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2362-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban S, Freeman M. Substrate specificity of rhomboid intramembrane proteases is governed by helix-breaking residues in the substrate transmembrane domain. Molecular Cell. 2003;11:1425&#x2013;1434. doi: 10.1016/S1097-2765(03)00181-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(03)00181-3</ArticleId><ArticleId IdType="pubmed">12820957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517. doi: 10.1038/19077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19077</ArticleId><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J, Dav&#xe9; UP, Grishin NV, Goldstein JL, Brown MS. Asparagine-proline sequence within membrane-spanning segment of SREBP triggers intramembrane cleavage by site-2 protease. PNAS. 2000;97:5123&#x2013;5128. doi: 10.1073/pnas.97.10.5123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.10.5123</ArticleId><ArticleId IdType="pmc">PMC25792</ArticleId><ArticleId IdType="pubmed">10805775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27582220</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>537</Volume><Issue>7618</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>56</EndPage><MedlinePgn>50-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature19323</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by deposition of amyloid-&#x3b2; (A&#x3b2;) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against A&#x3b2; to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated A&#x3b2;. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal A&#x3b2;, and reduce soluble and insoluble A&#x3b2; in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain A&#x3b2; in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sevigny</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiao</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bussi&#xe8;re</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinreb</LastName><ForeName>Paul H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurimmune, Schlieren-Zurich 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunstan</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital, Providence, Rhode Island 02906, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tianle</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Gorman</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arastu</LastName><ForeName>Mahin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mingwei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chollate</LastName><ForeName>Sowmya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Melanie S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintero-Monzon</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scannevin</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>H Moore</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engber</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhodes</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hang</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikulskis</LastName><ForeName>Alvydas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurimmune, Schlieren-Zurich 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hock</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurimmune, Schlieren-Zurich 8952, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Regenerative Medicine, University of Zurich, Zurich 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitsch</LastName><ForeName>Roger M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Neurimmune, Schlieren-Zurich 8952, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Regenerative Medicine, University of Zurich, Zurich 8952, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandrock</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts 02142, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01677572</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Aug 31;537(7618):36-7. doi: 10.1038/537036a.</RefSource><PMID Version="1">27582214</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2016 Nov;31(11):1631. doi: 10.1002/mds.26833.</RefSource><PMID Version="1">27739124</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Immunity. 2016 Oct 18;45(4):717-718. doi: 10.1016/j.immuni.2016.10.006.</RefSource><PMID Version="1">27760336</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Nov 09;539(7628):156-158. doi: 10.1038/539156a.</RefSource><PMID Version="1">27830826</PMID></CommentsCorrections><CommentsCorrections RefType="UpdateIn"><RefSource>Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809.</RefSource><PMID Version="1">28640269</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pii">nature19323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Nucl Med. 2013 Jan;54(1):70-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23166389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1989 Oct 15;143(8):2595-601</Citation><ArticleIdList><ArticleId IdType="pubmed">2507634</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):4012-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2013 Apr;12(4):357-67</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1550-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1992 Apr 10;256(5054):184-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jul 19;297(5580):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2012 Mar;11(3):241-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 Aug;14(8):837-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Jul;7(4):367-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Mar 16;31(11):4124-36</Citation><ArticleIdList><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2012 Jan 29;15(3):349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Aug;6(8):916-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jan 23;370(4):311-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2015 Jan 29;6:6176</Citation><ArticleIdList><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2013 Apr 2;80(14):1307-14</Citation><ArticleIdList><ArticleId IdType="pubmed">23468542</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2013 Oct;9(5 Suppl):S105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23583235</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5819-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2002 Nov;8(11):1270-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12379846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2013 Sep;74(3):328-36</Citation><ArticleIdList><ArticleId IdType="pubmed">25813842</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Sep 4;79(5):887-902</Citation><ArticleIdList><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Dec;131(Pt 12):3299-310</Citation><ArticleIdList><ArticleId IdType="pubmed">18953056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2012 Aug;11(8):669-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Res Ther. 2014 Jul 03;6(4):37</Citation><ArticleIdList><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2006 Dec;20(14):2576-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17068112</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Feb;69(2):198-207</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2015 Mar;93(3):475-86</Citation><ArticleIdList><ArticleId IdType="pubmed">25400096</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2014 Jan 23;370(4):322-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2013;33 Suppl 1:S67-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22531422</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2016 Feb 12;291(7):3174-83</Citation><ArticleIdList><ArticleId IdType="pubmed">26719327</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2015 Nov;98(5):469-71</Citation><ArticleIdList><ArticleId IdType="pubmed">26250900</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">26885819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2010 Nov;9(11):1118-27</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2012;28(1):49-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21955818</ArticleId></ArticleIdList></Reference><Reference><Citation>Peptides. 2002 Dec;23(12):2223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12535702</ArticleId></ArticleIdList></Reference><Reference><Citation>AJNR Am J Neuroradiol. 2013 Oct;34(10):1958-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23578674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27598869</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Preclinical Assessment of Young Blood Plasma for Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1325</StartPage><EndPage>1333</EndPage><MedlinePgn>1325-1333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.3185</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Alzheimer disease (AD) pathology starts long before clinical symptoms manifest, and there is no therapy to treat, delay, or prevent the disease. A shared blood circulation between 2 mice (aka parabiosis) or repeated injections of young blood plasma (plasma from 2- to 3-month-old mice) into old mice has revealed benefits of young plasma on synaptic function and behavior. However, to our knowledge, the potential benefit of young blood has not been tested in preclinical models of neurodegeneration or AD.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether young blood plasma ameliorates pathology and cognition in a mouse model for AD and could be a possible future treatment for the disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">In this preclinical study, mice that harbor a human mutant APP gene, which causes familial AD, were aged to develop AD-like disease including accumulation of amyloid plaques, loss of synaptic and neuronal proteins, and behavioral deficits. The initial parabiosis studies were done in 2010, and the final studies were conducted in 2014. Alzheimer disease model mice were then treated either by surgically connecting them with a young healthy mouse, thus providing a shared blood circulation through parabiosis, or through repeated injections of plasma from young mice.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Neuropathological parameters and changes in hippocampal gene expression in response to the treatment were assessed. In addition, cognition was tested in AD model mice intravenously injected with young blood plasma.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Aged mutant amyloid precursor protein mice with established disease showed a near complete restoration in levels of synaptic and neuronal proteins after exposure to young blood in parabiosis (synaptophysin P&#x2009;=&#x2009;.02; calbindin P&#x2009;=&#x2009;.02) or following intravenous plasma administration (synaptophysin P &lt; .001; calbindin P&#x2009;=&#x2009;.14). Amyloid plaques were not affected, but the beneficial effects in neurons in the hippocampus were accompanied by a reversal of abnormal extracellular receptor kinase signaling (P&#x2009;=&#x2009;.05), a kinase implicated in AD. Moreover, young plasma administration was associated with improved working memory (P&#x2009;=&#x2009;.01) and associative memory (P&#x2009;=&#x2009;.02) in amyloid precursor protein mice.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Factors in young blood have the potential to ameliorate disease in a model of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Middeldorp</LastName><ForeName>Jinte</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehallier</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villeda</LastName><ForeName>Saul A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Anatomy, University of California, San Francisco3The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miedema</LastName><ForeName>Suzanne S M</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czirr</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stan</LastName><ForeName>Trisha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosher</LastName><ForeName>Kira I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego, La Jolla5Department of Pathology, University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California6Center for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 AG034045</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG040877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016913" MajorTopicYN="N">Blood Component Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003427" MajorTopicYN="N">Cross Circulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27598869</ArticleId><ArticleId IdType="mid">NIHMS833718</ArticleId><ArticleId IdType="pmc">PMC5172595</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.3185</ArticleId><ArticleId IdType="pii">2546925</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer&#x2019;s disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology. 2001;56(1):127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20(11):4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc Natl Acad Sci U S A. 2003;100(16):9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta (1&#x2013;42) J Neurosci Res. 2001;66(4):573&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="pubmed">24793238</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsimpardi L, Litterman NK, Schein PA, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344(6184):630&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123747</ArticleId><ArticleId IdType="pubmed">24797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Faizi M, Bader PL, Saw N, et al. Thy1-hAPP (Lond/Swe+) mouse model of Alzheimer&#x2019;s disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2012;2(2):142&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345358</ArticleId><ArticleId IdType="pubmed">22574282</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925520</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012;28(4):573&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278763</ArticleId><ArticleId IdType="pubmed">22247279</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Elwood F, Britschgi M, et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J Exp Med. 2013;210(1):157&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549715</ArticleId><ArticleId IdType="pubmed">23296467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer&#x2019;s disease. Nat Med. 2009;15(3):331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickford F, Masliah E, Britschgi M, et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid &#x3b2; accumulation in mice. J Clin Invest. 2008;118(6):2190&#x2013;2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2391284</ArticleId><ArticleId IdType="pubmed">18497889</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association. 2014 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2014;10(2):e47&#x2013;e92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818261</ArticleId></ArticleIdList></Reference><Reference><Citation>He G, Luo W, Li P, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer&#x2019;s disease. Nature. 2010;467(7311):95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936959</ArticleId><ArticleId IdType="pubmed">20811458</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakopoulos A, Xu J, Xu C, Mauger G, Barthet G, Robakis NK. Presenilin1/gamma-secretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein. FASEB J. 2011;25(10):3594&#x2013;3604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3177584</ArticleId><ArticleId IdType="pubmed">21746865</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer&#x2019;s disease. J Neurosci. 2001;21(12):4125&#x2013;4133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762764</ArticleId><ArticleId IdType="pubmed">11404397</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster B, Hansen L, Adame A, et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol. 2006;65(2):142&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">16462205</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry G, Roder H, Nunomura A, et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport. 1999;10(11):2411&#x2013;2415.</Citation><ArticleIdList><ArticleId IdType="pubmed">10439473</ArticleId></ArticleIdList></Reference><Reference><Citation>Dineley KT, Weeber EJ, Atkins C, Adams JP, Anderson AE, Sweatt JD. Leitmotifs in the biochemistry of LTP induction: amplification, integration and coordination. J Neurochem. 2001;77(4):961&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">11359861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27601731</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>444</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Familial Alzheimer's disease-associated presenilin 1 mutants promote &#x3b3;-secretase cleavage of STIM1 to impair store-operated Ca2+ entry.</ArticleTitle><Pagination><StartPage>ra89</StartPage><MedlinePgn>ra89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.aaf1371</ELocationID><Abstract><AbstractText>Some forms of familial Alzheimer's disease (FAD) are caused by mutations in presenilins (PSs), catalytic components of a &#x3b3;-secretase complex that cleaves target proteins, including amyloid precursor protein (APP). Calcium (Ca(2+)) dysregulation in cells with these FAD-causing PS mutants has been attributed to attenuated store-operated Ca(2+) entry [SOCE; also called capacitative Ca(2+) entry (CCE)]. CCE occurs when STIM1 detects decreases in Ca(2+) in the endoplasmic reticulum (ER) and activates ORAI channels to replenish Ca(2+) stores in the ER. We showed that CCE was attenuated by PS1-associated &#x3b3;-secretase activity. Endogenous PS1 and STIM1 interacted in human neuroblastoma SH-SY5Y cells, patient fibroblasts, and mouse primary cortical neurons. Forms of PS1 with FAD-associated mutations enhanced &#x3b3;-secretase cleavage of the STIM1 transmembrane domain at a sequence that was similar to the &#x3b3;-secretase cleavage sequence of APP. Cultured hippocampal neurons expressing mutant PS1 had attenuated CCE that was associated with destabilized dendritic spines, which were rescued by either &#x3b3;-secretase inhibition or overexpression of STIM1. Our results indicate that &#x3b3;-secretase activity may physiologically regulate CCE by targeting STIM1 and that restoring STIM1 may be a therapeutic approach in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Benjamin Chun-Kit</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Claire Shuk-Kwan</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Wing-Hei</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Kwok-On</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. State Key Laboratory of Brain and Cognitive Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foskett</LastName><ForeName>J Kevin</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Departments of Physiology and Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>King-Ho</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. State Key Laboratory of Brain and Cognitive Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. HKU-Shenzhen Institute of Research and Innovation, Shenzhen, Guangdong, China. kingho.cheung@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000607793">Psen1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C103530">STIM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C100757">Stim1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C518857">Stim1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071737">Stromal Interaction Molecule 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071737" MajorTopicYN="N">Stromal Interaction Molecule 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27601731</ArticleId><ArticleId IdType="mid">NIHMS853360</ArticleId><ArticleId IdType="pmc">PMC5384262</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aaf1371</ArticleId><ArticleId IdType="pii">9/444/ra89</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J. A hundred years of Alzheimer&#x2019;s disease research. Neuron. 2006;52:3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015223</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Hardy J. The presenilins and Alzheimer&#x2019;s disease. Hum Mol Genet. 1997;6:1639&#x2013;1646.</Citation><ArticleIdList><ArticleId IdType="pubmed">9300655</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The genetics and molecular pathology of Alzheimer&#x2019;s disease: Roles of amyloid and the presenilins. Neurol Clin. 2000;18:903&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">11072267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Stutzmann GE. Calcium channelopathies and Alzheimer&#x2019;s disease: Insight into therapeutic success and failures. Eur J Pharmacol. 2014;739:83&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">24316360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullane K, Williams M. Alzheimer&#x2019;s therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol. 2013;85:289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">23178653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer&#x2019;s disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer&#x2019;s disease. Nat Rev Neurosci. 2002;3:862&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer&#x2019;s disease: Recent advances gained from genetically modified animals. Cell Calcium. 2005;38:427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125228</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ. Calcium hypothesis of Alzheimer&#x2019;s disease. Pflugers Arch. 2010;459:441&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">19795132</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J Cell Biol. 2000;149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, Saunders AJ, Ding K, Frosch MP, Tanzi RE, Kim TW. Presenilin-mediated modulation of capacitative calcium entry. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, LaFerla FM. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid &#x3b2; production. J Cell Biol. 2008;181:1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442205</ArticleId><ArticleId IdType="pubmed">18591429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee S-F, Hao Y-H, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer&#x2019;s disease-linked mutations. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Mei L, Mak DOD, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer&#x2019;s disease&#x2013;linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Shineman D, M&#xfc;ller M, C&#xe1;rdenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK. Mechanism of Ca2+ disruption in Alzheimer&#x2019;s disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58:871&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="pubmed">18579078</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, Safrina O, Kozak JA, Wagner SL, Cahalan MD, Veli&#xe7;elebi G, Stauderman KA. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol. 2005;169:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171946</ArticleId><ArticleId IdType="pubmed">15866891</ArticleId></ArticleIdList></Reference><Reference><Citation>Soboloff J, Spassova MA, Tang XD, Hewavitharana T, Xu W, Gill DL. Orai1 and STIM reconstitute store-operated calcium channel function. J Biol Chem. 2006;281:20661&#x2013;20665.</Citation><ArticleIdList><ArticleId IdType="pubmed">16766533</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari Y, Hitt BD, Murphy MP, Dagher NN, Tseng BP, Green KN, Golde TE, LaFerla FM. Presenilin regulates capacitative calcium entry dependently and independently of &#x3b3;-secretase activity. Biochem Biophys Res Commun. 2004;322:1145&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15336962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojarski L, Pomorski P, Szybinska A, Drab M, Skibinska-Kijek A, Gruszczynska-Biegala J, Kuznicki J. Presenilin-dependent expression of STIM proteins and dysregulation of capacitative Ca2+ entry in familial Alzheimer&#x2019;s disease. Biochim Biophys Acta. 2009;1793:1050&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">19111578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Zhang H, Liu J, Popugaeva E, Xu N-J, Feske S, White CL, III, Bezprozvanny I. Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice. Neuron. 2014;82:79&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007018</ArticleId><ArticleId IdType="pubmed">24698269</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou J, Fivaz M, Inoue T, Meyer T. Live-cell imaging reveals sequential oligomerization and local plasma membrane targeting of stromal interaction molecule 1 after Ca2+ store depletion. Proc Natl Acad Sci USA. 2007;104:9301&#x2013;9306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890489</ArticleId><ArticleId IdType="pubmed">17517596</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro-Borelly L, Somasundaram A, Yamashita M, Ren D, Miller RJ, Prakriya M. STIM1&#x2013;Orai1 interactions and Orai1 conformational changes revealed by live-cell FRET microscopy. J Physiol. 2008;586:5383&#x2013;5401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655373</ArticleId><ArticleId IdType="pubmed">18832420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; M. Activity of &#x3b3;-secretase on substrates other than APP. Curr Top Med Chem. 2008;8:9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18220928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DH, Goldberg AL. Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol. 1998;8:397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">9789328</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L-F, Zhang R, Xie X. Development of a high-throughput assay for screening of &#x3b3;-secretase inhibitor with endogenous human, mouse or Drosophila &#x3b3;-secretase. Molecules. 2009;14:3589&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6254802</ArticleId><ArticleId IdType="pubmed">19783945</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of &#x3b3;-secretase substrates and mapping of substrate requirements. PLOS Biol. 2008;6:e257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570425</ArticleId><ArticleId IdType="pubmed">18942891</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris KM. Calcium from internal stores modifies dendritic spine shape. Proc Natl Acad Sci USA. 1999;96:12213&#x2013;12215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34250</ArticleId><ArticleId IdType="pubmed">10535897</ArticleId></ArticleIdList></Reference><Reference><Citation>McNair K, Spike R, Guilding C, Prendergast GC, Stone TW, Cobb SR, Morris BJ. A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci. 2010;30:3508&#x2013;3517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634083</ArticleId><ArticleId IdType="pubmed">20203211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojarski L, Herms J, Kuznicki J. Calcium dysregulation in Alzheimer&#x2019;s disease. Neurochem Int. 2008;52:621&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035450</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello L, Zampese E, Florean C, Pozzan T, Pizzo P, Fasolato C. Presenilin-2 dampens intracellular Ca2+ stores by increasing Ca2+ leakage and reducing Ca2+ uptake. J Cell Mol Med. 2009;13:3358&#x2013;3369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516491</ArticleId><ArticleId IdType="pubmed">19382908</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombs JE, Gibson EA, Palmer AE. Using a genetically targeted sensor to investigate the role of presenilin-1 in ER Ca2+ levels and dynamics. Mol Biosyst. 2010;6:1640&#x2013;1649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155245</ArticleId><ArticleId IdType="pubmed">20379593</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P, Fasolato C. Presenilin mutations linked to familial Alzheimer&#x2019;s disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium. 2006;39:539&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">16620965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shideman CR, Reinardy JL, Thayer SA. &#x3b3;-Secretase activity modulates store-operated Ca2+ entry into rat sensory neurons. Neurosci Lett. 2009;451:124&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634821</ArticleId><ArticleId IdType="pubmed">19114088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. &#x3b3;-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2. Proc Natl Acad Sci USA. 2003;100:6382&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164455</ArticleId><ArticleId IdType="pubmed">12740439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horr&#xe9; K, Wiltfang J, Esselmann H, De Strooper B. Presenilin clinical mutations can affect &#x3b3;-secretase activity by different mechanisms. J Neurochem. 2006;96:732&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang B, Jia L, Jia J. Chinese Presenilin-1 V97L mutation enhanced A&#x3b2;42 levels in SH-SY5Y neuroblastoma cells. Neurosci Lett. 2006;406:33&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">16916581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng L, Stathopulos PB, Li GY, Ikura M. Biophysical characterization of the EF-hand and SAM domain containing Ca2+ sensory region of STIM1 and STIM2. Biochem Biophys Res Commun. 2008;369:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">18166150</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K, Dotti CG. Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. EMBO J. 1995;14:4932&#x2013;4938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394596</ArticleId><ArticleId IdType="pubmed">7588622</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Pijak DS, Doms RW, Lee VM. A distinct ER/IC &#x3b3;-secretase competes with the proteasome for cleavage of APP. Biochemistry. 2000;39:810&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">10651647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann T, Bieger SC, Br&#xfc;hl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K. Distinct sites of intracellular production for Alzheimer&#x2019;s disease A&#x3b2;40/42 amyloid peptides. Nat Med. 1997;3:1016&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Honig L, Tang M-X, Manly J, Stern Y, Schupf N, Mehta P. Plasma A&#x3b2;40 and A&#x3b2;42 and Alzheimer&#x2019;s disease: Relation to age, mortality, and risk. Neurology. 2003;61:1185&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">14610118</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuttleworth TJ, Thompson JL, Mignen O. STIM1 and the noncapacitative ARC channels. Cell Calcium. 2007;42:183&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995027</ArticleId><ArticleId IdType="pubmed">17391754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zbidi H, Jardin I, Woodard GE, Lopez JJ, Berna-Erro A, Salido GM, Rosado JA. STIM1 and STIM2 are located in the acidic Ca2+ stores and associates with Orai1 upon depletion of the acidic stores in human platelets. J Biol Chem. 2011;286:12257&#x2013;12270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069429</ArticleId><ArticleId IdType="pubmed">21321120</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez JJ, Jardin I, Bobe R, Pariente JA, Enouf J, Salido GM, Rosado JA. STIM1 regulates acidic Ca2+ store refilling by interaction with SERCA3 in human platelets. Biochem Pharmacol. 2008;75:2157&#x2013;2164.</Citation><ArticleIdList><ArticleId IdType="pubmed">18439569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper R, Rothberg BS, Soboloff J. Neuronal STIMulation at rest. Sci Signal. 2014;7:pe18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4150084</ArticleId><ArticleId IdType="pubmed">25056876</ArticleId></ArticleIdList></Reference><Reference><Citation>Usachev YM, Thayer SA. Ca2+ influx in resting rat sensory neurones that regulates and is regulated by ryanodine-sensitive Ca2+ stores. J Physiol. 1999;519(Pt 1):115&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2269497</ArticleId><ArticleId IdType="pubmed">10432343</ArticleId></ArticleIdList></Reference><Reference><Citation>Putney JW., Jr Capacitative calcium entry in the nervous system. Cell Calcium. 2003;34:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">12909080</ArticleId></ArticleIdList></Reference><Reference><Citation>Emptage NJ, Reid CA, Fine A. Calcium stores in hippocampal synaptic boutons mediate short-term plasticity, store-operated Ca2+ entry, and spontaneous transmitter release. Neuron. 2001;29:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182091</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DH, Zhang S, Gan WB. Dendritic spine dynamics. Annu Rev Physiol. 2009;71:261&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">19575680</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530413</ArticleId><ArticleId IdType="pubmed">21346746</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Lessons from a failed &#x3b3;-secretase Alzheimer trial. Cell. 2014;159:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">25417150</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Marquis KL. Acute &#x3b3;-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:8898&#x2013;8902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP, Giardina GAM. &#x3b3;-Secretase inhibitors and modulators for the treatment of Alzheimer&#x2019;s disease: Disappointments and hopes. Curr Top Med Chem. 2011;11:1555&#x2013;1570.</Citation><ArticleIdList><ArticleId IdType="pubmed">21510832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Arslanova D, Gu Y, Augelli-Szafran C, Xia W. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein. Mol Brain. 2008;1:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637266</ArticleId><ArticleId IdType="pubmed">18983676</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreses-Werringloer U, Lambert J-C, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, Pasquier F, Galimberti D, Scarpini E, Mann D, Lendon C, Campion D, Amouyel P, Davies P, Foskett JK, Campagne F, Marambaud P. A polymorphism in CALHM1 influences Ca2+ homeostasis, A&#x3b2; levels, and Alzheimer&#x2019;s disease risk. Cell. 2008;133:1149&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577842</ArticleId><ArticleId IdType="pubmed">18585350</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto A, Kaneko Y. Thapsigargin, a Ca2+-ATPase inhibitor, depletes the intracellular Ca2+ pool and induces apoptosis in human hepatoma cells. Cell Biol Int. 1993;17:969&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287027</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Guo Q, Holtsberg F, Bruce-Keller A, Mattson MP. Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J Neurosci. 1998;18:4439&#x2013;4450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792705</ArticleId><ArticleId IdType="pubmed">9614221</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the &#x3b2;-amyloid precursor protein. Neuron. 1993;10:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Q, Deng Y, Qing H. Potential therapeutic strategies for alzheimer&#x2019;s disease targeting or beyond &#x3b2;-amyloid: Insights from clinical trials. BioMed Res Int. 2014;2014:837157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124758</ArticleId><ArticleId IdType="pubmed">25136630</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Cardenas C, Mei L, Cheung KH, Foskett JK. Constitutive cAMP response element binding protein (CREB) activation by Alzheimer&#x2019;s disease presenilin- driven inositol trisphosphate receptor (InsP3R) Ca2+ signaling. Proc Natl Acad Sci USA. 2011;108:13293&#x2013;13298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156223</ArticleId><ArticleId IdType="pubmed">21784978</ArticleId></ArticleIdList></Reference><Reference><Citation>Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440&#x2013;3450.</Citation><ArticleIdList><ArticleId IdType="pubmed">3838314</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE, Jr, Meyer T. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol. 2005;15:1235&#x2013;1241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3186072</ArticleId><ArticleId IdType="pubmed">16005298</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z, Liu Y. Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes. Biophys J. 2001;81:2395&#x2013;2402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301710</ArticleId><ArticleId IdType="pubmed">11566809</ArticleId></ArticleIdList></Reference><Reference><Citation>Feige JN, Sage D, Wahli W, Desvergne B, Gelman L. PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs. Microsc Res Tech. 2005;68:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">16208719</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwozdz T, Dutko-Gwozdz J, Zarayskiy V, Peter K, Bolotina VM. How strict is the correlation between STIM1 and Orai1 expression, puncta formation, and ICRAC activation? Am J Physiol. 2008;295:C1133&#x2013;C1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584986</ArticleId><ArticleId IdType="pubmed">18768920</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao B, Coste B, Mathur J, Patapoutian A. Temperature-dependent STIM1 activation induces Ca2+ influx and modulates gene expression. Nat Chem Biol. 2011;7:351&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097298</ArticleId><ArticleId IdType="pubmed">21499266</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruszczynska-Biegala J, Pomorski P, Wisniewska MB, Kuznicki J. Differential roles for STIM1 and STIM2 in store-operated calcium entry in rat neurons. PLOS One. 2011;6:e19285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082561</ArticleId><ArticleId IdType="pubmed">21541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikanth S, Jung H-J, Kim K-D, Souda P, Whitelegge J, Gwack Y. A novel EF-hand protein, CRACR2A, is a cytosolic Ca2+ sensor that stabilizes CRAC channels in T cells. Nat Cell Biol. 2010;12:436&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875865</ArticleId><ArticleId IdType="pubmed">20418871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai KO, Wong ASL, Cheung MC, Xu P, Liang Z, Lok KC, Xie H, Palko ME, Yung WH, Tessarollo L, Cheung ZH, Ip NY. TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory. Nat Neurosci. 2012;15:1506&#x2013;1515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511999</ArticleId><ArticleId IdType="pubmed">23064382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron. 2001;31:115&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">11498055</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27617292</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy.</ArticleTitle><Pagination><StartPage>e1601167</StartPage><MedlinePgn>e1601167</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1601167</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.1601167</ELocationID><Abstract><AbstractText>The intronic GGGGCC hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) is a prevalent genetic abnormality identified in both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Smith-Magenis syndrome chromosomal region candidate gene 8 (SMCR8) is a protein with unclear functions. We report that C9ORF72 is a component of a multiprotein complex containing SMCR8, WDR41, and ATG101 (an important regulator of autophagy). The C9ORF72 complex displays guanosine triphosphatase (GTPase) activity and acts as a guanosine diphosphate-guanosine 5'-triphosphate (GDP-GTP) exchange factor (GEF) for RAB39B. We created Smcr8 knockout mice and found that Smcr8 mutant cells exhibit impaired autophagy induction, which is similarly observed in C9orf72 knockdown cells. Mechanistically, SMCR8/C9ORF72 interacts with the key autophagy initiation ULK1 complex and regulates expression and activity of ULK1. The complex has an additional role in regulating later stages of autophagy. Whereas autophagic flux is enhanced in C9orf72 knockdown cells, depletion of Smcr8 results in a reduced flux with an abnormal expression of lysosomal enzymes. Thus, C9ORF72 and SMCR8 have similar functions in modulating autophagy induction by regulating ULK1 and play distinct roles in regulating autophagic flux.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mei</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7207-3159</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetics and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Kunchithapadam</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7940-1090</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore, 117543 Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrlinger</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6049-0246</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Fan</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0568-2616</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiekhattar</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jian-Fu</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Genetics and Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS096176</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 HD073269</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM105754</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA010815</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM078455</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097231</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000618232">SMCR8 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071189">Autophagy-Related Protein-1 Homolog</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C112444">Ulk1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071189" MajorTopicYN="N">Autophagy-Related Protein-1 Homolog</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">SMCR8</Keyword><Keyword MajorTopicYN="N">ULK1</Keyword><Keyword MajorTopicYN="N">autophagic flux</Keyword><Keyword MajorTopicYN="N">autophagy induction</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27617292</ArticleId><ArticleId IdType="pmc">PMC5010369</ArticleId><ArticleId IdType="doi">10.1126/sciadv.1601167</ArticleId><ArticleId IdType="pii">1601167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bang J., Spina S., Miller B. L., Frontotemporal dementia. Lancet 386, 1672&#x2013;1682 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Neumann M., Mackenzie I. R., Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8, 423&#x2013;434 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.-C., Polymenidou M., Cleveland D. W., Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron 79, 416&#x2013;438 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Langenhove T., van der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., Engelborghs S., Sieben A., De Jonghe P., Vandenberghe R., Santens P., De Bleecker J., Maes G., B&#xe4;umer V., Dillen L., Joris G., Cuijt I., Corsmit E., Elinck E., Van Dongen J., Vermeulen S., Van den Broeck M., Vaerenberg C., Mattheijssens M., Peeters K., Robberecht W., Cras P., Martin J.-J., De Deyn P. P., Cruts M., Van Broeckhoven C., A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study. Lancet Neurol. 11, 54&#x2013;65 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A. E., Majounie E., Waite A., Sim&#xf3;n-S&#xe1;nchez J., Rollinson S., Gibbs J. R., Schymick J. C., Laaksovirta H., van Swieten J. C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A. M., Kaganovich A., Scholz S. W., Duckworth J., Ding J., Harmer D. W., Hernandez D. G., Johnson J. O., Mok K., Ryten M., Trabzuni D., Guerreiro R. J., Orrell R. W., Neal J., Murray A., Pearson J., Jansen I. E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J. B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M. A., Peuralinna T., Jansson L., Isoviita V.-M., Kaivorinne A.-L., H&#xf6;ltt&#xe4;-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chi&#xf2; A., Restagno G., Borghero G., Sabatelli M.; ITALSGEN Consortium, Heckerman D., Rogaeva E., Zinman L., Rothstein J. D., Sendtner M., Drepper C., Eichler E. E., Alkan C., Abdullaev Z., Pack S. D., Dutra A., Pak E., Hardy J., Singleton A., Williams N. M., Heutink P., Pickering-Brown S., Morris H. R., Tienari P. J., Traynor B. J., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F., Boxer A. L., Baker M., Rutherford N. J., Nicholson A. M., Finch N. A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.-Y. R., Karydas A., Seeley W. W., Josephs K. A., Coppola G., Geschwind D. H., Wszolek Z. K., Feldman H., Knopman D. S., Petersen R. C., Miller B. L., Dickson D. W., Boylan K. B., Graff-Radford N. R., Rademakers R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245&#x2013;256 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A. E., Mok K., Dopper E. G. P., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J., van Swieten J. C., Abramzon Y., Johnson J. O., Sendtner M., Pamphlett R., Orrell R. W., Mead S., Sidle K. C., Houlden H., Rohrer J. D., Morrison K. E., Pall H., Talbot K., Ansorge O.; Chromosome 9-ALS/FTD Consortium; French research network on FTLD/FTLD/ALS; ITALSGEN Consortium, Hernandez D. G., Arepalli S., Sabatelli M., Mora G., Corbo M., Giannini F., Calvo A., Englund E., Borghero G., Floris G. L., Remes A. M., Laaksovirta H., McCluskey L., Trojanowski J. Q., Van Deerlin V. M., Schellenberg G. D., Nalls M. A., Drory V. E., Lu C.-S., Yeh T.-H., Ishiura H., Takahashi Y., Tsuji S., Le Ber I., Brice A., Drepper C., Williams N., Kirby J., Shaw P., Hardy J., Tienari P. J., Heutink P., Morris H. R., Pickering-Brown S., Traynor B. J., Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 11, 323&#x2013;330 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Poidevin M., Li X., Li Y., Shu L., Nelson D. L., Li H., Hales C. M., Gearing M., Wingo T. S., Jin P., Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 110, 7778&#x2013;7783 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C. J., Zhang P.-W., Pham J. T., Haeusler A. R., Mistry N. A., Vidensky S., Daley E. L., Poth E. M., Hoover B., Fines D. M., Maragakis N., Tienari P. J., Petrucelli L., Traynor B. J., Wang J., Rigo F., Bennett C. F., Blackshaw S., Sattler R., Rothstein J. D., RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415&#x2013;428 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z., Wang H., Xia Q., Li K., Li K., Jiang X., Xu G., Wang G., Ying Z., Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum. Mol. Genet. 24, 2426&#x2013;2441 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25575510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.-M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H. A., Cruts M., Van Broeckhoven C., Haass C., Edbauer D., The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335&#x2013;1338 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., Liu Y., Ba&#xf1;ez-Coronel M., Reid T., Pletnikova O., Lewis J., Miller T. M., Harms M. B., Falchook A. E., Subramony S. H., Ostrow L. W., Rothstein J. D., Troncoso J. C., Ranum L. P. W., RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 110, E4968&#x2013;E4977 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.-R., Jiang J., Watt A. T., Chun S., Katz M., Qiu J., Sun Y., Ling S.-C., Zhu Q., Polymenidou M., Drenner K., Artates J. W., McAlonis-Downes M., Markmiller S., Hutt K. R., Pizzo D. P., Cady J., Harms M. B., Baloh R. H., Vandenberg S. R., Yeo G. W., Fu X.-D., Bennett C. F., Cleveland D. W., Ravits J., Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A. 110, E4530&#x2013;E4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P. E. A., Bieniek K. F., Gendron T. F., Caulfield T., Lin W.-L., DeJesus-Hernandez M., van Blitterswijk M. M., Jansen-West K., Paul J. W. III, Rademakers R., Boylan K. B., Dickson D. W., Petrucelli L., Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639&#x2013;646 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gr&#xf6;nke S., Niccoli T., Ridler C. E., Clayton E. L., Devoy A., Moens T., Norona F. E., Woollacott I. O. C., Pietrzyk J., Cleverley K., Nicoll A. J., Pickering-Brown S., Dols J., Cabecinha M., Hendrich O., Fratta P., Fisher E. M. C., Partridge L., Isaacs A. M., C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192&#x2013;1194 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S. S., Shi Y., Lin S., Shneider N. A., Monaghan J., Pandey U. B., Pasinelli P., Ichida J. K., Trotti D., Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213&#x2013;1225 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., Xiang S., Kato M., Wu L., Theodoropoulos P., Wang T., Kim J., Yun J., Xie Y., McKnight S. L., Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139&#x2013;1145 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J. G., Bogdanik L., Y&#xe1;&#xf1;ez A., Lall D., Wolf A. J., Muhammad A. K. M. G., Ho R., Carmona S., Vit J. P., Zarrow J., Kim K. J., Bell S., Harms M. B., Miller T. M., Dangler C. A., Underhill D. M., Goodridge H. S., Lutz C. M., Baloh R. H., C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., Blokhuis A. M., Westeneng H.-J., Terpstra M. L., Zundel C. A. C., Vieira de S&#xe1; R., Schellevis R. D., Waite A. J., Blake D. J., Veldink J. H., van den Berg L. H., Pasterkamp R. J., C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 78, 426&#x2013;438 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A., Decman V., White D., Ramos M., Ikiz B., Lee H.-C., Siao C.-J., Brydges S., LaRosa E., Bai Y., Fury W., Burfeind P., Zamfirova R., Warshaw G., Orengo J., Oyejide A., Fralish M., Auerbach W., Poueymirou W., Freudenberg J., Gong G., Zambrowicz B., Valenzuela D., Yancopoulos G., Murphy A., Thurston G., Lai K.-M. V., C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci. Rep. 6, 23204 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Lashley T., Norona F. E., Clayton E. L., Ridler C. E., Fratta P., Isaacs A. M., C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845&#x2013;857 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite A. J., B&#xe4;umer D., East S., Neal J., Morris H. R., Ansorge O., Blake D. J., Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging 35, 1779.e5&#x2013;1779.e13 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ktistakis N. T., Tooze S. A., Digesting the expanding mechanisms of autophagy. Trends Cell Biol. 26, 624&#x2013;635 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27050762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N., Levine B., Cuervo A. M., Klionsky D. J., Autophagy fights disease through cellular self-digestion. Nature 451, 1069&#x2013;1075 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670399</ArticleId><ArticleId IdType="pubmed">18305538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N., Komatsu M., Autophagy: Renovation of cells and tissues. Cell 147, 728&#x2013;741 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22078875</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R. L., Matus S., Bargsted L., Hetz C., Targeting autophagy in neurodegenerative diseases. Trends Pharmacol. Sci. 35, 583&#x2013;591 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25270767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong E., Cuervo A. M., Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805&#x2013;811 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038747</ArticleId><ArticleId IdType="pubmed">20581817</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenmark H., Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10, 513&#x2013;525 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19603039</ArticleId></ArticleIdList></Reference><Reference><Citation>Marat A. L., Dokainish H., McPherson P. S., DENN domain proteins: Regulators of Rab GTPases. J. Biol. Chem. 286, 13791&#x2013;13800 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077579</ArticleId><ArticleId IdType="pubmed">21330364</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura S.-i., Gerondopoulos A., Linford A., Rigden D. J., Barr F. A., Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. J. Cell Biol. 191, 367&#x2013;381 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958468</ArticleId><ArticleId IdType="pubmed">20937701</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine T. P., Daniels R. D., Gatta A. T., Wong L. H., Hayes M. J., The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 29, 499&#x2013;503 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Iyer L. M., He F., Aravind L., Discovery of novel DENN proteins: Implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front. Genet. 3, 283 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521125</ArticleId><ArticleId IdType="pubmed">23248642</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M. A., Sundaramoorthy V., Sultana J. M., Yang S., Atkinson R. A. K., Levina V., Halloran M. A., Gleeson P. A., Blair I. P., Soo K. Y., King A. E., Atkin J. D., C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 23, 3579&#x2013;3595 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C., Campanari M.-L., Julie Corbier C., Gaucherot A., Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S., Kabashi E., Charlet-Berguerand N., Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. EMBO J. 35, 1276&#x2013;1297 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrends C., Sowa M. E., Gygi S. P., Harper J. W., Network organization of the human autophagy system. Nature 466, 68&#x2013;76 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901998</ArticleId><ArticleId IdType="pubmed">20562859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., Iemura S.-i., Natsume T., Takehana K., Yamada N., Guan J.-L., Oshiro N., Mizushima N., Nutrient-dependent mTORC1 association with the ULK1&#x2013;Atg13&#x2013;FIP200 complex required for autophagy. Mol. Biol. Cell 20, 1981&#x2013;1991 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663915</ArticleId><ArticleId IdType="pubmed">19211835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Kundu M., Viollet B., Guan K.-L., AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132&#x2013;141 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3987946</ArticleId><ArticleId IdType="pubmed">21258367</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Chen S., Du F., Li S., Zhao L., Wang X., Nutrient starvation elicits an acute autophagic response mediated by Ulk1 dephosphorylation and its subsequent dissociation from AMPK. Proc. Natl. Acad. Sci. U.S.A. 108, 4788&#x2013;4793 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064373</ArticleId><ArticleId IdType="pubmed">21383122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosokawa N., Sasaki T., Iemura S.-i., Natsume T., Hara T., Mizushima N., Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 5, 973&#x2013;979 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19597335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer C. A., Kaliappan A., Dennis P. B., A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. Autophagy 5, 649&#x2013;662 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19287211</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Roberts R., WD-repeat proteins: Structure characteristics, biological function, and their involvement in human diseases. Cell. Mol. Life Sci. 58, 2085&#x2013;2097 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11337334</ArticleId><ArticleId IdType="pubmed">11814058</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson G. R., Sim J. C. H., McLean C., Giannandrea M., Galea C. A., Riseley J. R., Stephenson S. E. M., Fitzpatrick E., Haas S. A., Pope K., Hogan K. J., Gregg R. G., Bromhead C. J., Wargowski D. S., Lawrence C. H., James P. A., Churchyard A., Gao Y., Phelan D. G., Gillies G., Salce N., Stanford L., Marsh A. P. L., Mignogna M. L., Hayflick S. J., Leventer R. J., Delatycki M. B., Mellick G. D., Kalscheuer V. M., D&#x2019;Adamo P., Bahlo M., Amor D. J., Lockhart P. J., Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with &#x3b1;-synuclein pathology. Am. J. Hum. Genet. 95, 729&#x2013;735 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4259921</ArticleId><ArticleId IdType="pubmed">25434005</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannandrea M., Bianchi V., Mignogna M. L., Sirri A., Carrabino S., D&#x2019;Elia E., Vecellio M., Russo S., Cogliati F., Larizza L., Ropers H.-H., Tzschach A., Kalscheuer V., Oehl-Jaschkowitz B., Skinner C., Schwartz C. E., Gecz J., Van Esch H., Raynaud M., Chelly J., de Brouwer A. P. M., Toniolo D., D&#x2019;Adamo P., Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. Am. J. Hum. Genet. 86, 185&#x2013;195 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820185</ArticleId><ArticleId IdType="pubmed">20159109</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong B., Bayat V., Jaiswal M., Zhang K., Sandoval H., Charng W.-L., Li T., David G., Duraine L., Lin Y.-Q., Neely G. G., Yamamoto S., Bellen H. J., Crag is a GEF for Rab11 required for rhodopsin trafficking and maintenance of adult photoreceptor cells. PLOS Biol. 10, e1001438 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514319</ArticleId><ArticleId IdType="pubmed">23226104</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky D. J., Abdelmohsen K., Abe A., Abedin M. J., Abeliovich H., Acevedo Arozena A., Adachi H., Adams C. M., Adams P. D., Adeli K., Adhihetty P. J., Adler S. G., Agam G., Agarwal R., Aghi M. K., Agnello M., Agostinis P., Aguilar P. V., Aguirre-Ghiso J., Airoldi E. M., Ait-Si-Ali S., Akematsu T., Akporiaye E. T., Al-Rubeai M., Albaiceta G. M., Albanese C., Albani D., Albert M. L., Aldudo J., Alg&#xfc;l H., Alirezaei M., Alloza I., Almasan A., Almonte-Beceril M., Alnemri E. S., Alonso C., Altan-Bonnet N., Altieri D. C., Alvarez S., Alvarez-Erviti L., Alves S., Amadoro G., Amano A., Amantini C., Ambrosio S., Amelio I., Amer A. O., Amessou M., Amon A., An Z., Anania F. A., Andersen S. U., Andley U. P., Andreadi C. K., Andrieu-Abadie N., Anel A., Ann D. K., Anoopkumar-Dukie S., Antonioli M., Aoki H., Apostolova N., Aquila S., Aquilano K., Araki K., Arama E., Aranda A., Araya J., Arcaro A., Arias E., Arimoto H., Ariosa A. R., Armstrong J. L., Arnould T., Arsov I., Asanuma K., Askanas V., Asselin E., Atarashi R., Atherton S. S., Atkin J. D., Attardi L. D., Auberger P., Auburger G., Aurelian L., Autelli R., Avagliano L., Avantaggiati M. L., Avrahami L., Awale S., Azad N., Bachetti T., Backer J. M., Bae D.-H., Bae J.-s., Bae O.-N., Bae S. H., Baehrecke E. H., Baek S.-H., Baghdiguian S., Bagniewska-Zadworna A., Bai H., Bai J., Bai X.-Y., Bailly Y., Balaji K. N., Balduini W., Ballabio A., Balzan R., Banerjee R., B&#xe1;nhegyi G., Bao H., Barbeau B., Barrachina M. D., Barreiro E., Bartel B., Bartolom&#xe9; A., Bassham D. C., Bassi M. T., Bast R. C. Jr, Basu A., Batista M. T., Batoko H., Battino M., Bauckman K., Baumgarner B. L., Bayer K. U., Beale R., Beaulieu J.-F., Beck G. R. Jr, Becker C., Beckham J. D., B&#xe9;dard P.-A., Bednarski P. J., Begley T. J., Behl C., Behrends C., Behrens G. M. N., Behrns K. E., Bejarano E., Belaid A., Belleudi F., B&#xe9;nard G., Berchem G., Bergamaschi D., Bergami M., Berkhout B., Berliocchi L., Bernard A., Bernard M., Bernassola F., Bertolotti A., Bess A. S., Besteiro S., Bettuzzi S., Bhalla S., Bhattacharyya S., Bhutia S. K., Biagosch C., Bianchi M. W., Biard-Piechaczyk M., Billes V., Bincoletto C., Bingol B., Bird S. W., Bitoun M., Bjedov I., Blackstone C., Blanc L., Blanco G. A., Blomhoff H. K., Boada-Romero E., B&#xf6;ckler S., Boes M., Boesze-Battaglia K., Boise L. H., Bolino A., Boman A., Bonaldo P., Bordi M., Bosch J., Botana L. M., Botti J., Bou G., Bouch&#xe9; M., Bouchecareilh M., Boucher M.-J., Boulton M. E., Bouret S. G., Boya P., Boyer-Guittaut M., Bozhkov P. V., Brady N., Braga V. M. M., Brancolini C., Braus G. H., Bravo-San Pedro J. M., Brennan L. A., Bresnick E. H., Brest P., Bridges D., Bringer M.-A., Brini M., Brito G. C., Brodin B., Brookes P. S., Brown E. J., Brown K., Broxmeyer H. E., Bruhat A., Brum P. C., Brumell J. H., Brunetti-Pierri N., Bryson-Richardson R. J., Buch S., Buchan A. M., Budak H., Bulavin D. V., Bultman S. J., Bultynck G., Bumbasirevic V., Burelle Y., Burke R. E., Burmeister M., B&#xfc;tikofer P., Caberlotto L., Cadwell K., Cahova M., Cai D., Cai J., Cai Q., Calatayud S., Camougrand N., Campanella M., Campbell G. R., Campbell M., Campello S., Candau R., Caniggia I., Cantoni L., Cao L., Caplan A. B., Caraglia M., Cardinali C., Cardoso S. M., Carew J. S., Carleton L. A., Carlin C. R., Carloni S., Carlsson S. R., Carmona-Gutierrez D., Carneiro L. A. M., Carnevali O., Carra S., Carrier A., Carroll B., Casas C., Casas J., Cassinelli G., Castets P., Castro-Obregon S., Cavallini G., Ceccherini I., Cecconi F., Cederbaum A. I., Ce&#xf1;a V., Cenci S., Cerella C., Cervia D., Cetrullo S., Chaachouay H., Chae H.-J., Chagin A. S., Chai C.-Y., Chakrabarti G., Chamilos G., Chan E. Y. W., Chan M. T. V., Chandra D., Chandra P., Chang C.-P., Chang R. C.-C., Chang T. Y., Chatham J. C., Chatterjee S., Chauhan S., Che Y., Cheetham M. E., Cheluvappa R., Chen C.-J., Chen G., Chen G.-C., Chen G., Chen H., Chen J. W., Chen J.-K., Chen M., Chen M., Chen P., Chen Q., Chen Q., Chen S.-D., Chen S., Chen S. S.-L., Chen W., Chen W.-J., Chen W. Q., Chen W., Chen X., Chen Y.-H., Chen Y.-G., Chen Y., Chen Y., Chen Y., Chen Y.-J., Chen Y.-Q., Chen Y., Chen Z., Chen Z., Cheng A., Cheng C. H. K., Cheng H., Cheong H., Cherry S., Chesney J., Cheung C. H. A., Chevet E., Chi H. C., Chi S.-G., Chiacchiera F., Chiang H.-L., Chiarelli R., Chiariello M., Chieppa M., Chin L.-S., Chiong M., Chiu G. N. C., Cho D.-H., Cho S.-G., Cho W. C., Cho Y.-Y., Cho Y.-S., Choi A. M. K., Choi E.-J., Choi E.-K., Choi J., Choi M. E., Choi S.-I., Chou T.-F., Chouaib S., Choubey D., Choubey V., Chow K.-C., Chowdhury K., Chu C. T., Chuang T.-H., Chun T., Chung H., Chung T., Chung Y.-L., Chwae Y.-J., Cianfanelli V., Ciarcia R., Ciechomska I. A., Ciriolo M. R., Cirone M., Claerhout S., Clague M. J., Cl&#xe0;ria J., Clarke P. G. H., Clarke R., Clementi E., Cleyrat C., Cnop M., Coccia E. M., Cocco T., Codogno P., Coers J., Cohen E. E. W., Colecchia D., Coletto L., Coll N. S., Colucci-Guyon E., Comincini S., Condello M., Cook K. L., Coombs G. H., Cooper C. D., Cooper J. M., Coppens I., Corasaniti M. T., Corazzari M., Corbalan R., Corcelle-Termeau E., Cordero M. D., Corral-Ramos C., Corti O., Cossarizza A., Costelli P., Costes S., Cotman S. L., Coto-Montes A., Cottet S., Couve E., Covey L. R., Cowart L. A., Cox J. S., Coxon F. P., Coyne C. B., Cragg M. S., Craven R. J., Crepaldi T., Crespo J. L., Criollo A., Crippa V., Cruz M. T., Cuervo A. M., Cuezva J. M., Cui T., Cutillas P. R., Czaja M. J., Czyzyk-Krzeska M. F., Dagda R. K., Dahmen U., Dai C., Dai W., Dai Y., Dalby K. N., Dalla Valle L., Dalmasso G., D&#x2019;Amelio M., Damme M., Darfeuille-Michaud A., Dargemont C., Darley-Usmar V. M., Dasarathy S., Dasgupta B., Dash S., Dass C. R., Davey H. M., Davids L. M., D&#xe1;vila D., Davis R. J., Dawson T. M., Dawson V. L., Daza P., de Belleroche J., de Figueiredo P., de Figueiredo R. C. B. Q., de la Fuente J., De Martino L., De Matteis A., De Meyer G. R. Y., De Milito A., De Santi M., de Souza W., De Tata V., De Zio D., Debnath J., Dechant R., Decuypere J.-P., Deegan S., Dehay B., Del Bello B., Del Re D. P., Delage-Mourroux R., Delbridge L. M. D., Deldicque L., Delorme-Axford E., Deng Y., Dengjel J., Denizot M., Dent P., Der C. J., Deretic V., Derrien B., Deutsch E., Devarenne T. P., Devenish R. J., Di Bartolomeo S., Di Daniele N., Di Domenico F., Di Nardo A., Di Paola S., Di Pietro A., Di Renzo L., DiAntonio A., D&#xed;az-Araya G., D&#xed;az-Laviada I., Diaz-Meco M. T., Diaz-Nido J., Dickey C. A., Dickson R. C., Diederich M., Digard P., Dikic I., Dinesh-Kumar S. P., Ding C., Ding W.-X., Ding Z., Dini L., Distler J. H. W., Diwan A., Djavaheri-Mergny M., Dmytruk K., Dobson R. C. J., Doetsch V., Dokladny K., Dokudovskaya S., Donadelli M., Dong X. C., Dong X., Dong Z., Donohue T. M. Jr, Doran K. S., D&#x2019;Orazi G., Dorn G. W. II, Dosenko V., Dridi S., Drucker L., Du J., Du L.-L., Du L., du Toit A., Dua P., Duan L., Duann P., Dubey V. K., Duchen M. R., Duchosal M. A., Duez H., Dugail I., Dumit V. I., Duncan M. C., Dunlop E. A., Dunn W. A. Jr, Dupont N., Dupuis L., Dur&#xe1;n R. V., Durcan T. M., Duvezin-Caubet S., Duvvuri U., Eapen V., Ebrahimi-Fakhari D., Echard A., Eckhart L., Edelstein C. L., Edinger A. L., Eichinger L., Eisenberg T., Eisenberg-Lerner A., Eissa N. T., El-Deiry W. S., El-Khoury V., Elazar Z., Eldar-Finkelman H., Elliott C. J. H., Emanuele E., Emmenegger U., Engedal N., Engelbrecht A.-M., Engelender S., Enserink J. M., Erdmann R., Erenpreisa J., Eri R., Eriksen J. L., Erman A., Escalante R., Eskelinen E.-L., Espert L., Esteban-Mart&#xed;nez L., Evans T. J., Fabri M., Fabrias G., Fabrizi C., Facchiano A., F&#xe6;rgeman N. J., Faggioni A., Fairlie W. D., Fan C., Fan D., Fan J., Fang S., Fanto M., Fanzani A., Farkas T., Faure M., Favier F. B., Fearnhead H., Federici M., Fei E., Felizardo T. C., Feng H., Feng Y., Feng Y., Ferguson T. A., Fern&#xe1;ndez &#xc1;. F., Fernandez-Barrena M. G., Fernandez-Checa J. C., Fern&#xe1;ndez-L&#xf3;pez A., Fernandez-Zapico M. E., Feron O., Ferraro E., Ferreira-Halder C. V., Fesus L., Feuer R., Fiesel F. C., Filippi-Chiela E. C., Filomeni G., Fimia G. M., Fingert J. H., Finkbeiner S., Finkel T., Fiorito F., Fisher P. B., Flajolet M., Flamigni F., Florey O., Florio S., Floto R. A., Folini M., Follo C., Fon E. A., Fornai F., Fortunato F., Fraldi A., Franco R., Francois A., Fran&#xe7;ois A., Frankel L. B., Fraser I. D. C., Frey N., Freyssenet D. G., Frezza C., Friedman S. L., Frigo D. E., Fu D., Fuentes J. M., Fueyo J., Fujitani Y., Fujiwara Y., Fujiya M., Fukuda M., Fulda S., Fusco C., Gabryel B., Gaestel M., Gailly P., Gajewska M., Galadari S., Galili G., Galindo I., Galindo M. F., Galliciotti G., Galluzzi L., Galluzzi L., Galy V., Gammoh N., Gandy S., Ganesan A. K., Ganesan S., Ganley I. G., Gannag&#xe9; M., Gao F.-B., Gao F., Gao J.-X., Nannig L. G., Garc&#xed;a V&#xe9;scovi E., Garcia-Mac&#xed;a M., Garcia-Ruiz C., Garg A. D., Garg P. K., Gargini R., Gassen N. C., Gatica D., Gatti E., Gavard J., Gavathiotis E., Ge L., Ge P., Ge S., Gean P.-W., Gelmetti V., Genazzani A. A., Geng J., Genschik P., Gerner L., Gestwicki J. E., Gewirtz D. A., Ghavami S., Ghigo E., Ghosh D., Giammarioli A. M., Giampieri F., Giampietri C., Giatromanolaki A., Gibbings D. J., Gibellini L., Gibson S. B., Ginet V., Giordano A., Giorgini F., Giovannetti E., Girardin S. E., Gispert S., Giuliano S., Gladson C. L., Glavic A., Gleave M., Godefroy N., Gogal R. M. Jr, Gokulan K., Goldman G. H., Goletti D., Goligorsky M. S., Gomes A. V., Gomes L. C., Gomez H., Gomez-Manzano C., G&#xf3;mez-S&#xe1;nchez R., Gon&#xe7;alves D. A. P., Goncu E., Gong Q., Gongora C., Gonzalez C. B., Gonzalez-Alegre P., Gonzalez-Cabo P., Gonz&#xe1;lez-Polo R. A., Goping I. S., Gorbea C., Gorbunov N. V., Goring D. R., Gorman A. M., Gorski S. M., Goruppi S., Goto-Yamada S., Gotor C., Gottlieb R. A., Gozes I., Gozuacik D., Graba Y., Graef M., Granato G. E., Grant G. D., Grant S., Gravina G. L., Green D. R., Greenhough A., Greenwood M. T., Grimaldi B., Gros F., Grose C., Groulx J.-F., Gruber F., Grumati P., Grune T., Guan J.-L., Guan K.-L., Guerra B., Guillen C., Gulshan K., Gunst J., Guo C., Guo L., Guo M., Guo W., Guo X.-G., Gust A. A., Gustafsson &#xc5;. B., Gutierrez E., Gutierrez M. G., Gwak H.-S., Haas A., Haber J. E., Hadano S., Hagedorn M., Hahn D. R., Halayko A. J., Hamacher-Brady A., Hamada K., Hamai A., Hamann A., Hamasaki M., Hamer I., Hamid Q., Hammond E. M., Han F., Han W., Handa J. T., Hanover J. A., Hansen M., Harada M., Harhaji-Trajkovic L., Harper J. W., Harrath A. H., Harris A. L., Harris J., Hasler U., Hasselblatt P., Hasui K., Hawley R. G., Hawley T. S., He C., He C. Y., He F., He G., He R.-R., He X.-H., He Y.-W., He Y.-Y., Heath J. K., H&#xe9;bert M.-J., Heinzen R. A., Helgason G. V., Hensel M., Henske E. P., Her C., Herman P. K., Hern&#xe1;ndez A., Hernandez C., Hern&#xe1;ndez-Tiedra S., Hetz C., Hiesinger P. R., Higaki K., Hilfiker S., Hill B. G., Hill J. A., Hill W. D., Hino K., Hofius D., Hofman P., H&#xf6;glinger G. U., H&#xf6;hfeld J., Holz M. K., Hong Y., Hood D. A., Hoozemans J. J. M., Hoppe T., Hsu C., Hsu C.-Y., Hsu L.-C., Hu D., Hu G., Hu H.-M., Hu H., Hu M. C., Hu Y.-C., Hu Z.-W., Hua F., Hua Y., Huang C., Huang H.-L., Huang K.-H., Huang K.-Y., Huang S., Huang S., Huang W.-P., Huang Y.-R., Huang Y., Huang Y., Huber T. B., Huebbe P., Huh W.-K., Hulmi J. J., Hur G. M., Hurley J. H., Husak Z., Hussain S. N. A., Hussain S., Hwang J. J., Hwang S., Hwang T. I. S., Ichihara A., Imai Y., Imbriano C., Inomata M., Into T., Iovane V., Iovanna J. L., Iozzo R. V., Ip N. Y., Irazoqui J. E., Iribarren P., Isaka Y., Isakovic A. J., Ischiropoulos H., Isenberg J. S., Ishaq M., Ishida H., Ishii I., Ishmael J. E., Isidoro C., Isobe K.-i., Isono E., Issazadeh-Navikas S., Itahana K., Itakura E., Ivanov A. I., Iyer A. K. V., Izquierdo J. M., Izumi Y., Izzo V., J&#xe4;&#xe4;ttel&#xe4; M., Jaber N., Jackson D. J., Jackson W. T., Jacob T. G., Jacques T. S., Jagannath C., Jain A., Jana N. R., Jang B. K., Jani A., Janji B., Jannig P. R., Jansson P. J., Jean S., Jendrach M., Jeon J.-H., Jessen N., Jeung E.-B., Jia K., Jia L., Jiang H., Jiang H., Jiang L., Jiang T., Jiang X., Jiang X., Jiang X., Jiang Y., Jiang Y., Jim&#xe9;nez A., Jin C., Jin H., Jin L., Jin M., Jin S., Jinwal U. K., Jo E.-K., Johansen T., Johnson D. E., Johnson G. V. W., Johnson J. D., Jonasch E., Jones C., Joosten L. A. B., Jordan J., Joseph A.-M., Joseph B., Joubert A. M., Ju D., Ju J., Juan H.-F., Juenemann K., Juh&#xe1;sz G., Seung Jung H., Jung J. U., Jung Y.-K., Jungbluth H., Justice M. J., Jutten B., Kaakoush N. O., Kaarniranta K., Kaasik A., Kabuta T., Kaeffer B., K&#xe5;gedal K., Kahana A., Kajimura S., Kakhlon O., Kalia M., Kalvakolanu D. V., Kamada Y., Kambas K., Kaminskyy V. O., Kampinga H. H., Kandouz M., Kang C., Kang R., Kang T.-C., Kanki T., Kanneganti T.-D., Kanno H., Kanthasamy A. G., Kantorow M., Kaparakis-Liaskos M., Kapuy O., Karantza V., Razaul Karim M., Karmakar P., Kaser A., Kaushik S., Kawula T., Kaynar A. M., Ke P.-Y., Ke Z.-J., Kehrl J. H., Keller K. E., Kemper J. K., Kenworthy A. K., Kepp O., Kern A., Kesari S., Kessel D., Ketteler R., Kettelhut I. d. C., Khambu B., Khan M. M., Khandelwal V. K. M., Khare S., Kiang J. G., Kiger A. A., Kihara A., Kim A. L., Kim C. H., Kim D. R., Kim D.-H., Kim E. K., Kim H. Y., Kim H.-R., Kim J.-S., Kim J. H., Kim J. C., Kim J. H., Kim K. W., Kim M. D., Kim M.-M., Kim P. K., Kim S. W., Kim S.-Y., Kim Y.-S., Kim Y., Kimchi A., Kimmelman A. C., Kimura T., King J. S., Kirkegaard K., Kirkin V., Kirshenbaum L. A., Kishi S., Kitajima Y., Kitamoto K., Kitaoka Y., Kitazato K., Kley R. A., Klimecki W. T., Klinkenberg M., Klucken J., Kn&#xe6;velsrud H., Knecht E., Knuppertz L., Ko J.-L., Kobayashi S., Koch J. C., Koechlin-Ramonatxo C., Koenig U., Koh Y. H., K&#xf6;hler K., Kohlwein S. D., Koike M., Komatsu M., Kominami E., Kong D., Kong H. J., Konstantakou E. G., Kopp B. T., Korcsmaros T., Korhonen L., Korolchuk V. I., Koshkina N. V., Kou Y., Koukourakis M. I., Koumenis C., Kov&#xe1;cs A. L., Kov&#xe1;cs T., Kovacs W. J., Koya D., Kraft C., Krainc D., Kramer H., Kravic-Stevovic T., Krek W., Kretz-Remy C., Krick R., Krishnamurthy M., Kriston-Vizi J., Kroemer G., Kruer M. C., Kruger R., Ktistakis N. T., Kuchitsu K., Kuhn C., Pratap Kumar A., Kumar A., Kumar A., Kumar D., Kumar D., Kumar R., Kumar S., Kundu M., Kung H.-J., Kuno A., Kuo S.-H., Kuret J., Kurz T., Kwok T., Kyu Kwon T., Tae Kwon Y., Kyrmizi I., La Spada A. R., Lafont F., Lahm T., Lakkaraju A., Lam T., Lamark T., Lancel S., Landowski T. H., Lane D. J. R., Lane J. D., Lanzi C., Lapaquette P., Lapierre L. R., Laporte J., Laukkarinen J., Laurie G. W., Lavandero S., Lavie L., LaVoie M. J., Law B. Y. K., Law H. K.-w., Law K. B., Layfield R., Lazo P. A., Le Cam L., Le Roch K. G., Le Stunff H., Leardkamolkarn V., Lecuit M., Lee B.-H., Lee C.-H., Lee E. F., Lee G. M., Lee H.-J., Lee H., Lee J. K., Lee J., Lee J.-h., Lee J. H., Lee M., Lee M.-S., Lee P. J., Lee S. W., Lee S.-J., Lee S.-J., Lee S. Y., Lee S. H., Lee S. S., Lee S.-J., Lee S., Lee Y.-R., Lee Y. J., Lee Y. H., Leeuwenburgh C., Lefort S., Legouis R., Lei J., Lei Q.-Y., Leib D. A., Leibowitz G., Lekli I., Lemaire S. D., Lemasters J. J., Lemberg M. K., Lemoine A., Leng S., Lenz G., Lenzi P., Lerman L. O., Lettieri Barbato D., Leu J. I.-J., Leung H. Y., Levine B., Lewis P. A., Lezoualc&#x2019;h F., Li C., Li F., Li F.-J., Li J., Li K., Li L., Li M., Li M., Li Q., Li R., Li S., Li W., Li W., Li X., Li Y., Lian J., Liang C., Liang Q., Liao Y., Liberal J., Liberski P. P., Lie P., Lieberman A. P., Lim H. J., Lim K.-L., Lim K., Lima R. T., Lin C.-S., Lin C.-F., Lin F., Lin F., Lin F.-C., Lin K., Lin K.-H., Lin P.-H., Lin T., Lin W.-W., Lin Y.-S., Lin Y., Linden R., Lindholm D., Lindqvist L. M., Lingor P., Linkermann A., Liotta L. A., Lipinski M. M., Lira V. A., Lisanti M. P., Liton P. B., Liu B., Liu C., Liu C.-F., Liu F., Liu H.-J., Liu J., Liu J.-J., Liu J.-L., Liu K., Liu L., Liu L., Liu Q., Liu R.-Y., Liu S., Liu S., Liu W., Liu X.-D., Liu X., Liu X.-H., Liu X., Liu X., Liu X., Liu Y., Liu Y., Liu Z., Liu Z., Liuzzi J. P., Lizard G., Ljujic M., Lodhi I. J., Logue S. E., Lokeshwar B. L., Long Y. C., Lonial S., Loos B., L&#xf3;pez-Ot&#xed;n C., L&#xf3;pez-Vicario C., Lorente M., Lorenzi P. L., L&#xf5;rincz P., Los M., Lotze M. T., Lovat P. E., Lu B., Lu B., Lu J., Lu Q., Lu S.-M., Lu S., Lu Y., Luciano F., Luckhart S., Lucocq J. M., Ludovico P., Lugea A., Lukacs N. W., Lum J. J., Lund A. H., Luo H., Luo J., Luo S., Luparello C., Lyons T., Ma J., Ma Y., Ma Y., Ma Z., Machado J., Machado-Santelli G. M., Macian F., MacIntosh G. C., MacKeigan J. P., Macleod K. F., MacMicking J. D., MacMillan-Crow L. A., Madeo F., Madesh M., Madrigal-Matute J., Maeda A., Maeda T., Maegawa G., Maellaro E., Maes H., Magari&#xf1;os M., Maiese K., Maiti T. K., Maiuri L., Maiuri M. C., Maki C. G., Malli R., Malorni W., Maloyan A., Mami-Chouaib F., Man N., Mancias J. D., Mandelkow E.-M., Mandell M. A., Manfredi A. A., Mani&#xe9; S. N., Manzoni C., Mao K., Mao Z., Mao Z.-W., Marambaud P., Marconi A. M., Marelja Z., Marfe G., Margeta M., Margittai E., Mari M., Mariani F. V., Marin C., Marinelli S., Mari&#xf1;o G., Markovic I., Marquez R., Martelli A. M., Martens S., Martin K. R., Martin S. J., Martin S., Martin-Acebes M. A., Mart&#xed;n-Sanz P., Martinand-Mari C., Martinet W., Martinez J., Martinez-Lopez N., Martinez-Outschoorn U., Mart&#xed;nez-Vel&#xe1;zquez M., Martinez-Vicente M., Martins W. K., Mashima H., Mastrianni J. A., Matarese G., Matarrese P., Mateo R., Matoba S., Matsumoto N., Matsushita T., Matsuura A., Matsuzawa T., Mattson M. P., Matus S., Maugeri N., Mauvezin C., Mayer A., Maysinger D., Mazzolini G. D., McBrayer M. K., McCall K., McCormick C., McInerney G. M., McIver S. C., McKenna S., McMahon J. J., McNeish I. A., Mechta-Grigoriou F., Medema J. P., Medina D. L., Megyeri K., Mehrpour M., Mehta J. L., Mei Y., Meier U.-C., Meijer A. J., Mel&#xe9;ndez A., Melino G., Melino S., de Melo E. J. T., Mena M. A., Meneghini M. D., Menendez J. A., Menezes R., Meng L., Meng L.-h., Meng S., Menghini R., Menko A. S., Menna-Barreto R. F. S., Menon M. B., Meraz-R&#xed;os M. A., Merla G., Merlini L., Merlot A. M., Meryk A., Meschini S., Meyer J. N., Mi M.-t., Miao C.-Y., Micale L., Michaeli S., Michiels C., Migliaccio A. R., Mihailidou A. S., Mijaljica D., Mikoshiba K., Milan E., Miller-Fleming L., Mills G. B., Mills I. G., Minakaki G., Minassian B. A., Ming X.-F., Minibayeva F., Minina E. A., Mintern J. D., Minucci S., Miranda-Vizuete A., Mitchell C. H., Miyamoto S., Miyazawa K., Mizushima N., Mnich K., Mograbi B., Mohseni S., Moita L. F., Molinari M., Molinari M., M&#xf8;ller A. B., Mollereau B., Mollinedo F., Mongillo M., Monick M. M., Montagnaro S., Montell C., Moore D. J., Moore M. N., Mora-Rodriguez R., Moreira P. I., Morel E., Beatrice Morelli M., Moreno S., Morgan M. J., Moris A., Moriyasu Y., Morrison J. L., Morrison L. A., Morselli E., Moscat J., Moseley P. L., Mostowy S., Motori E., Mottet D., Mottram J. C., Moussa C. E.-H., Mpakou V. E., Mukhtar H., Mulcahy Levy J. M., Muller S., Mu&#xf1;oz-Moreno R., Mu&#xf1;oz-Pinedo C., M&#xfc;nz C., Murphy M. E., Murray J. T., Murthy A., Mysorekar I. U., Nabi I. R., Nabissi M., Nader G. A., Nagahara Y., Nagai Y., Nagata K., Nagelkerke A., Nagy P., Naidu S. R., Nair S., Nakano H., Nakatogawa H., Nanjundan M., Napolitano G., Naqvi N. I., Nardacci R., Narendra D. P., Narita M., Nascimbeni A. C., Natarajan R., Navegantes L. C., Nawrocki S. T., Nazarko T. Y., Nazarko V. Y., Neill T., Neri L. M., Netea M. G., Netea-Maier R. T., Neves B. M., Ney P. A., Nezis I. P., Nguyen H. T. T., Nguyen H. P., Nicot A.-S., Nilsen H., Nilsson P., Nishimura M., Nishino I., Niso-Santano M., Niu H., Nixon R. A., Njar V. C. O., Noda T., Noegel A. A., Nolte E. M., Norberg E., Norga K. K., Kazemi Noureini S., Notomi S., Notterpek L., Nowikovsky K., Nukina N., N&#xfc;rnberger T., O&#x2019;Donnell V. B., O&#x2019;Donovan T., O&#x2019;Dwyer P. J., Oehme I., Oeste C. L., Ogawa M., Ogretmen B., Ogura Y., Oh Y. J., Ohmuraya M., Ohshima T., Ojha R., Okamoto K., Okazaki T., Oliver F. J., Ollinger K., Olsson S., Orban D. P., Ordonez P., Orhon I., Orosz L., O&#x2019;Rourke E. J., Orozco H., Ortega A. L., Ortona E., Osellame L. D., Oshima J., Oshima S., Osiewacz H. D., Otomo T., Otsu K., Ou J.-h. J., Outeiro T. F., Ouyang D.-y., Ouyang H., Overholtzer M., Ozbun M. A., Ozdinler P. H., Ozpolat B., Pacelli C., Paganetti P., Page G., Pages G., Pagnini U., Pajak B., Pak S. C., Pakos-Zebrucka K., Pakpour N., Palkov&#xe1; Z., Palladino F., Pallauf K., Pallet N., Palmieri M., Paludan S. R., Palumbo C., Palumbo S., Pampliega O., Pan H., Pan W., Panaretakis T., Pandey A., Pantazopoulou A., Papackova Z., Papademetrio D. L., Papassideri I., Papini A., Parajuli N., Pardo J., Parekh V. V., Parenti G., Park J.-I., Park J., Park O. K., Parker R., Parlato R., Parys J. B., Parzych K. R., Pasquet J.-M., Pasquier B., Pasumarthi K. B. S., Patschan D., Patterson C., Pattingre S., Pattison S., Pause A., Pavenst&#xe4;dt H., Pavone F., Pedrozo Z., Pe&#xf1;a F. J., Pe&#xf1;alva M. A., Pende M., Peng J., Penna F., Penninger J. M., Pensalfini A., Pepe S., Pereira G. J. S., Pereira P. C., P&#xe9;rez-de la Cruz V., P&#xe9;rez-P&#xe9;rez M. E., P&#xe9;rez-Rodr&#xed;guez D., P&#xe9;rez-Sala D., Perier C., Perl A., Perlmutter D. H., Perrotta I., Pervaiz S., Pesonen M., Pessin J. E., Peters G. J., Petersen M., Petrache I., Petrof B. J., Petrovski G., Phang J. M., Piacentini M., Pierdominici M., Pierre P., Pierrefite-Carle V., Pietrocola F., Pimentel-Mui&#xf1;os F. X., Pinar M., Pineda B., Pinkas-Kramarski R., Pinti M., Pinton P., Piperdi B., Piret J. M., Platanias L. C., Platta H. W., Plowey E. D., P&#xf6;ggeler S., Poirot M., Pol&#x10d;ic P., Poletti A., Poon A. H., Popelka H., Popova B., Poprawa I., Poulose S. M., Poulton J., Powers S. K., Powers T., Pozuelo-Rubio M., Prak K., Prange R., Prescott M., Priault M., Prince S., Proia R. L., Proikas-Cezanne T., Prokisch H., Promponas V. J., Przyklenk K., Puertollano R., Pugazhenthi S., Puglielli L., Pujol A., Puyal J., Pyeon D., Qi X., Qian W.-b., Qin Z.-H., Qiu Y., Qu Z., Quadrilatero J., Quinn F., Raben N., Rabinowich H., Radogna F., Ragusa M. J., Rahmani M., Raina K., Ramanadham S., Ramesh R., Rami A., Randall-Demllo S., Randow F., Rao H., Rao V. A., Rasmussen B. B., Rasse T. M., Ratovitski E. A., Rautou P.-E., Ray S. K., Razani B., Reed B. H., Reggiori F., Rehm M., Reichert A. S., Rein T., Reiner D. J., Reits E., Ren J., Ren X., Renna M., Reusch J. E. B., Revuelta J. L., Reyes L., Rezaie A. R., Richards R. I., Richardson D. R., Richetta C., Riehle M. A., Rihn B. H., Rikihisa Y., Riley B. E., Rimbach G., Rippo M. R., Ritis K., Rizzi F., Rizzo E., Roach P. J., Robbins J., Roberge M., Roca G., Roccheri M. C., Rocha S., Rodrigues C. M. P., Rodr&#xed;guez C. I., Rodriguezde Cordoba S., Rodriguez-Muela N., Roelofs J., Rogov V. V., Rohn T. T., Rohrer B., Romanelli D., Romani L., Romano P. S., Roncero M. I. G., Rosa J. L., Rosello A., Rosen K. V., Rosenstiel P., Rost-Roszkowska M., Roth K. A., Rou&#xe9; G., Rouis M., Rouschop K. M., Ruan D. T., Ruano D., Rubinsztein D. C., Rucker E. B. III, Rudich A., Rudolf E., Rudolf R., Ruegg M. A., Ruiz-Roldan C., Ruparelia A. A., Rusmini P., Russ D. W., Russo G. L., Russo G., Russo R., Rusten T. E., Ryabovol V., Ryan K. M., Ryter S. W., Sabatini D. M., Sacher M., Sachse C., Sack M. N., Sadoshima J., Saftig P., Sagi-Eisenberg R., Sahni S., Saikumar P., Saito T., Saitoh T., Sakakura K., Sakoh-Nakatogawa M., Sakuraba Y., Salazar-Roa M., Salomoni P., Saluja A. K., Salvaterra P. M., Salvioli R., Samali A., Sanchez A. M. J., S&#xe1;nchez-Alc&#xe1;zar J. A., Sanchez-Prieto R., Sandri M., Sanjuan M. A., Santaguida S., Santambrogio L., Santoni G., Dos Santos C. N., Saran S., Sardiello M., Sargent G., Sarkar P., Sarkar S., Rosa Sarrias M., Sarwal M. M., Sasakawa C., Sasaki M., Sass M., Sato K., Sato M., Satriano J., Savaraj N., Saveljeva S., Schaefer L., Schaible U. E., Scharl M., Schatzl H. M., Schekman R., Scheper W., Schiavi A., Schipper H. M., Schmeisser H., Schmidt J., Schmitz I., Schneider B. E., Schneider E. M., Schneider J. L., Schon E. A., Sch&#xf6;nenberger M. J., Sch&#xf6;nthal A. H., Schorderet D. F., Schr&#xf6;der B., Schuck S., Schulze R. J., Schwarten M., Schwarz T. L., Sciarretta S., Scotto K., Scovassi A. I., Screaton R. A., Screen M., Seca H., Sedej S., Segatori L., Segev N., Seglen P. O., Segu&#xed;-Simarro J. M., Segura-Aguilar J., Seki E., Seiliez I., Sell C., Semenkovich C. F., Semenza G. L., Sen U., Serra A. L., Serrano-Puebla A., Sesaki H., Setoguchi T., Settembre C., Shacka J. J., Shajahan-Haq A. N., Shapiro I. M., Sharma S., She H., Shen C.-K. J., Shen C.-C., Shen H.-M., Shen S., Shen W., Sheng R., Sheng X., Sheng Z.-H., Shepherd T. G., Shi J., Shi Q., Shi Q., Shi Y., Shibutani S., Shibuya K., Shidoji Y., Shieh J.-J., Shih C.-M., Shimada Y., Shimizu S., Shin D. W., Shinohara M. L., Shintani M., Shintani T., Shioi T., Shirabe K., Shiri-Sverdlov R., Shirihai O., Shore G. C., Shu C.-W., Shukla D., Sibirny A. A., Sica V., Sigurdson C. J., Sigurdsson E. M., Sijwali P. S., Sikorska B., Silveira W. A., Silvente-Poirot S., Silverman G. A., Simak J., Simmet T., Simon A. K., Simon H.-U., Simone C., Simons M., Simonsen A., Singh R., Singh S. V., Singh S. K., Sinha D., Sinha S., Sinicrope F. A., Sirko A., Sirohi K., Sishi B. J. N., Sittler A., Siu P. M., Sivridis E., Skwarska A., Slack R., Slaninov&#xe1; I., Slavov N., Smaili S. S., Smalley K. S. M., Smith D. R., Soenen S. J., Soleimanpour S. A., Solhaug A., Somasundaram K., Son J. H., Sonawane A., Song C., Song F., Song H. K., Song J.-X., Song W., Soo K. Y., Sood A. K., Soong T. W., Soontornniyomkij V., Sorice M., Sotgia F., Soto-Pantoja D. R., Sotthibundhu A., Sousa M. J., Spaink H. P., Span P. N., Spang A., Sparks J. D., Speck P. G., Spector S. A., Spies C. D., Springer W., St Clair D., Stacchiotti A., Staels B., Stang M. T., Starczynowski D. T., Starokadomskyy P., Steegborn C., Steele J. W., Stefanis L., Steffan J., Stellrecht C. M., Stenmark H., Stepkowski T. M., Stern S. T., Stevens C., Stockwell B. R., Stoka V., Storchova Z., Stork B., Stratoulias V., Stravopodis D. J., Strnad P., Marie Strohecker A., Str&#xf6;m A.-L., Stromhaug P., Stulik J., Su Y.-X., Su Z., Subauste C. S., Subramaniam S., Sue C. M., Suh S. W., Sui X., Sukseree S., Sulzer D., Sun F.-L., Sun J., Sun J., Sun S.-Y., Sun Y., Sun Y., Sun Y., Sundaramoorthy V., Sung J., Suzuki H., Suzuki K., Suzuki N., Suzuki T., Suzuki Y. J., Swanson M. S., Swanton C., Sw&#xe4;rd K., Swarup G., Sweeney S. T., Sylvester P. W., Szatmari Z., Szegezdi E., Szlosarek P. W., Taegtmeyer H., Tafani M., Taillebourg E., Tait S. W. G., Takacs-Vellai K., Takahashi Y., Tak&#xe1;ts S., Takemura G., Takigawa N., Talbot N. J., Tamagno E., Tamburini J., Tan C.-P., Tan L., Tan M. L., Tan M., Tan Y.-J., Tanaka K., Tanaka M., Tang D., Tang D., Tang G., Tanida I., Tanji K., Tannous B. A., Tapia J. A., Tasset-Cuevas I., Tatar M., Tavassoly I., Tavernarakis N., Taylor A., Taylor G. S., Taylor G. A., Taylor J. P., Taylor M. J., Tchetina E. V., Tee A. R., Teixeira-Clerc F., Telang S., Tencomnao T., Teng B.-B., Teng R.-J., Terro F., Tettamanti G., Theiss A. L., Theron A. E., Thomas K. J., Thom&#xe9; M. P., Thomes P. G., Thorburn A., Thorner J., Thum T., Thumm M., Thurston T. L. M., Tian L., Till A., Ting J. P.-y., Titorenko V. I., Toker L., Toldo S., Tooze S. A., Topisirovic I., Torgersen M. L., Torosantucci L., Torriglia A., Torrisi M. R., Tournier C., Towns R., Trajkovic V., Travassos L. H., Triola G., Tripathi D. N., Trisciuoglio D., Troncoso R., Trougakos I. P., Truttmann A. C., Tsai K.-J., Tschan M. P., Tseng Y.-H., Tsukuba T., Tsung A., Tsvetkov A. S., Tu S., Tuan H.-Y., Tucci M., Tumbarello D. A., Turk B., Turk V., Turner R. F. B., Tveita A. A., Tyagi S. C., Ubukata M., Uchiyama Y., Udelnow A., Ueno T., Umekawa M., Umemiya-Shirafuji R., Underwood B. R., Ungermann C., Ureshino R. P., Ushioda R., Uversky V. N., Uzc&#xe1;tegui N. L., Vaccari T., Vaccaro M. I., V&#xe1;chov&#xe1; L., Vakifahmetoglu-Norberg H., Valdor R., Valente E. M., Vallette F., Valverde A. M., Van den Berghe G., Van Den Bosch L., van den Brink G. R., van der Goot F. G., van der Klei I. J., van der Laan L. J. W., van Doorn W. G., van Egmond M., van Golen K. L., Van Kaer L., van Lookeren Campagne M., Vandenabeele P., Vandenberghe W., Vanhorebeek I., Varela-Nieto I., Vasconcelos M. H., Vasko R., Vavvas D. G., Vega-Naredo I., Velasco G., Velentzas A. D., Velentzas P. D., Vellai T., Vellenga E., Vendelbo M. H., Venkatachalam K., Ventura N., Ventura S., Veras P. S. T., Verdier M., Vertessy B. G., Viale A., Vidal M., Vieira H. L. A., Vierstra R. D., Vigneswaran N., Vij N., Vila M., Villar M., Villar V. H., Villarroya J., Vindis C., Viola G., Teresa Viscomi M., Vitale G., Vogl D. T., Voitsekhovskaja O. V., von Haefen C., von Schwarzenberg K., Voth D. E., Vouret-Craviari V., Vuori K., Vyas J. M., Waeber C., Lyn Walker C., Walker M. J., Walter J., Wan L., Wan X., Wang B., Wang C., Wang C.-Y., Wang C., Wang C., Wang C., Wang D., Wang F., Wang F., Wang G., Wang H.-j., Wang H., Wang H.-G., Wang H., Wang H.-D., Wang J., Wang J., Wang M., Wang M.-Q., Wang P.-Y., Wang P., Wang R. C., Wang S., Wang T.-F., Wang X., Wang X.-j., Wang X.-W., Wang X., Wang X., Wang Y., Wang Y., Wang Y., Wang Y.-J., Wang Y., Wang Y., Wang Y. T., Wang Y., Wang Z.-N., Wappner P., Ward C., Ward D. M. V., Warnes G., Watada H., Watanabe Y., Watase K., Weaver T. E., Weekes C. D., Wei J., Weide T., Weihl C. C., Weindl G., Weis S. N., Wen L., Wen X., Wen Y., Westermann B., Weyand C. M., White A. R., White E., Whitton J. L., Whitworth A. J., Wiels J., Wild F., Wildenberg M. E., Wileman T., Wilkinson D. S., Wilkinson S., Willbold D., Williams C., Williams K., Williamson P. R., Winklhofer K. F., Witkin S. S., Wohlgemuth S. E., Wollert T., Wolvetang E. J., Wong E., Wong G. W., Wong R. W., Wong V. K. W., Woodcock E. A., Wright K. L., Wu C., Wu D., Wu G. S., Wu J., Wu J., Wu M., Wu M., Wu S., Wu W. K. K., Wu Y., Wu Z., Xavier C. P. R., Xavier R. J., Xia G.-X., Xia T., Xia W., Xia Y., Xiao H., Xiao J., Xiao S., Xiao W., Xie C.-M., Xie Z., Xie Z., Xilouri M., Xiong Y., Xu C., Xu C., Xu F., Xu H., Xu H., Xu J., Xu J., Xu J., Xu L., Xu X., Xu Y., Xu Y., Xu Z.-X., Xu Z., Xue Y., Yamada T., Yamamoto A., Yamanaka K., Yamashina S., Yamashiro S., Yan B., Yan B., Yan X., Yan Z., Yanagi Y., Yang D.-S., Yang J.-M., Yang L., Yang M., Yang P.-M., Yang P., Yang Q., Yang W., Yang W. Y., Yang X., Yang Y., Yang Y., Yang Z., Yang Z., Yao M.-C., Yao P. J., Yao X., Yao Z., Yao Z., Yasui L. S., Ye M., Yedvobnick B., Yeganeh B., Yeh E. S., Yeyati P. L., Yi F., Yi L., Yin X.-M., Yip C. K., Yoo Y.-M., Yoo Y. H., Yoon S.-Y., Yoshida K.-I., Yoshimori T., Young K. H., Yu H., Yu J. J., Yu J.-T., Yu J., Yu L., Yu W. H., Yu X.-F., Yu Z., Yuan J., Yuan Z.-M., Yue B. Y. J. T., Yue J., Yue Z., Zacks D. N., Zacksenhaus E., Zaffaroni N., Zaglia T., Zakeri Z., Zecchini V., Zeng J., Zeng M., Zeng Q., Zervos A. S., Zhang D. D., Zhang F., Zhang G., Zhang G.-C., Zhang H., Zhang H., Zhang H., Zhang H., Zhang J., Zhang J., Zhang J., Zhang J., Zhang J.-p., Zhang L., Zhang L., Zhang L., Zhang L., Zhang M.-Y., Zhang X., Zhang X. D., Zhang Y., Zhang Y., Zhang Y., Zhang Y., Zhang Y., Zhao M., Zhao W.-L., Zhao X., Zhao Y. G., Zhao Y., Zhao Y., Zhao Y.-x., Zhao Z., Zhao Z. J., Zheng D., Zheng X.-L., Zheng X., Zhivotovsky B., Zhong Q., Zhou G.-Z., Zhou G., Zhou H., Zhou S.-F., Zhou X.-j., Zhu H., Zhu H., Zhu W.-G., Zhu W., Zhu X.-F., Zhu Y., Zhuang S.-M., Zhuang X., Ziparo E., Zois C. E., Zoladek T., Zong W.-X., Zorzano A., Zughaier S. M., Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1&#x2013;222 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4835977</ArticleId><ArticleId IdType="pubmed">26799652</ArticleId></ArticleIdList></Reference><Reference><Citation>Laplante M., Sabatini D. M., mTOR signaling in growth control and disease. Cell 149, 274&#x2013;293 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331679</ArticleId><ArticleId IdType="pubmed">22500797</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S. A., Pacold M. E., Cervantes C. L., Lim D., Lou H. J., Ottina K., Gray N. S., Turk B. E., Yaffe M. B., Sabatini D. M., mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341, 1236566 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771538</ArticleId><ArticleId IdType="pubmed">23888043</ArticleId></ArticleIdList></Reference><Reference><Citation>Korolchuk V. I., Mansilla A., Menzies F. M., Rubinsztein D. C., Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol. Cell 33, 517&#x2013;527 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669153</ArticleId><ArticleId IdType="pubmed">19250912</ArticleId></ArticleIdList></Reference><Reference><Citation>Progida C., Cogli L., Piro F., De Luca A., Bakke O., Bucci C., Rab7b controls trafficking from endosomes to the TGN. J. Cell Sci. 123, 1480&#x2013;1491 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20375062</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre G. F., Erickson A. H., Procathepsins L and D are membrane-bound in acidic microsomal vesicles. J. Biol. Chem. 266, 15438&#x2013;15445 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1869563</ArticleId></ArticleIdList></Reference><Reference><Citation>Khundadze M., Kollmann K., Koch N., Biskup C., Nietzsche S., Zimmer G., Hennings J. C., Huebner A. K., Symmank J., Jahic A., Ilina E. I., Karle K., Sch&#xf6;ls L., Kessels M., Braulke T., Qualmann B., Kurth I., Beetz C., H&#xfc;bner C. A., A hereditary spastic paraplegia mouse model supports a role of ZFYVE26/SPASTIZIN for the endolysosomal system. PLOS Genet. 9, e1003988 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868532</ArticleId><ArticleId IdType="pubmed">24367272</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt F. M., Boland B., van der Spoel A. C., The cell biology of disease: Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. J. Cell Biol. 199, 723&#x2013;734 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514785</ArticleId><ArticleId IdType="pubmed">23185029</ArticleId></ArticleIdList></Reference><Reference><Citation>Riederer M. A., Soldati T., Shapiro A. D., Lin J., Pfeffer S. R., Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J. Cell Biol. 125, 573&#x2013;582 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119986</ArticleId><ArticleId IdType="pubmed">7909812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan P. M., Zhou X., Robins A. M., Paushter D. H., Kim D., Smolka M. B., Hu F., The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol. Commun. 4, 51 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H., Kaizuka T., Mizushima N., Noda N. N., Structure of the Atg101&#x2013;Atg13 complex reveals essential roles of Atg101 in autophagy initiation. Nat. Struct. Mol. Biol. 22, 572&#x2013;580 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26030876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N., Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885&#x2013;889 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16625204</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M., Waguri S., Chiba T., Murata S., Iwata J.-i., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K., Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880&#x2013;884 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16625205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejlerskov P., Hultberg J. G., Wang J., Carlsson R., Ambj&#xf8;rn M., Kuss M., Liu Y., Porcu G., Kolkova K., Friis Rundsten C., Ruscher K., Pakkenberg B., Goldmann T., Loreth D., Prinz M., Rubinsztein D. C., Issazadeh-Navikas S., Lack of neuronal IFN-&#x3b2;-IFNAR causes Lewy body- and Parkinson&#x2019;s disease-like dementia. Cell 163, 324&#x2013;339 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601085</ArticleId><ArticleId IdType="pubmed">26451483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha N. P., de Miranda A. S., Teixeira A. L., Insights into neuroinflammation in Parkinson&#x2019;s disease: From biomarkers to anti-inflammatory based therapies. Biomed. Res. Int. 2015, 628192 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532803</ArticleId><ArticleId IdType="pubmed">26295044</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster C. P., Smith E. F., Bauer C. S., Moller A., Hautbergue G. M., Ferraiuolo L., Myszczynska M. A., Higginbottom A., Walsh M. J., Whitworth A. J., Kaspar B. K., Meyer K., Shaw P. J., Grierson A. J., De Vos K. J., The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 35, 1656&#x2013;1676 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., MacNair L., McLean J., McGoldrick P., McKeever P., Soleimani S., Keith J., Zinman L., Rogaeva E., Robertson J., C9orf72 isoforms in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Brain Res. 10.1016/j.brainres.2016.04.062 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27134035</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., MacNair L., McGoldrick P., McKeever P. M., McLean J. R., Zhang M., Keith J., Zinman L., Rogaeva E., Robertson J., Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann. Neurol. 78, 568&#x2013;583 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26174152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.-F., Zhang Y., Wilde J., Hansen K. C., Lai F., Niswander L., Microcephaly disease gene Wdr62 regulates mitotic progression of embryonic neural stem cells and brain size. Nat. Commun. 5, 3885 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4216695</ArticleId><ArticleId IdType="pubmed">24875059</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27656030</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>38</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression.</ArticleTitle><Pagination><StartPage>9933</StartPage><EndPage>9936</EndPage><MedlinePgn>9933-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1907-16.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">Intraneuronal calcium stimulates the calpain-dependent conversion of p35 to p25, a CDK5 activator. It is widely believed that amyloid &#x3b2; peptide (A&#x3b2;) induces this conversion that, in turn, has an essential role in Alzheimer's disease pathogenesis. However, in vivo studies on p25 generation used transgenic mice overexpressing mutant amyloid precursor protein (APP) and presenilin (PS). Here, using single App knock-in mice, we show that p25 generation is an artifact caused by membrane protein overexpression. We show that massive A&#x3b2;42 accumulation without overexpression of APP or presenilin does not produce p25, whereas p25 generation occurred with APP/PS overexpression and in postmortem mouse brain. We further support this finding using mice deficient for calpastatin, the sole calpain-specific inhibitor protein. Thus, the intracerebral environment of the APP/PS mouse brain and postmortem brain is an unphysiological state.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT">We recently estimated using single App knock-in mice that accumulate amyloid &#x3b2; peptide without transgene overexpression that 60% of the phenotypes observed in Alzheimer's model mice overexpressing mutant amyloid precursor protein (APP) or APP and presenilin are artifacts (Saito et al., 2014). The current study further supports this estimate by invalidating key results from papers that were published in Cell These findings suggest that more than 3000 publications based on APP and APP/PS overexpression must be reevaluated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Saito et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuba</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Shoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako 351-0198, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0003-1970-6903</Identifier><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako 351-0198, Japan saido@brain.riken.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002135">Calcium-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062550">NAV1.1 Voltage-Gated Sodium Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568249">Scn1a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410340">calpain activator</NameOfSubstance></Chemical><Chemical><RegistryNumber>79079-11-1</RegistryNumber><NameOfSubstance UI="C033668">calpastatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002135" MajorTopicYN="N">Calcium-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062550" MajorTopicYN="N">NAV1.1 Voltage-Gated Sodium Channel</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nav1.1</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">calpain</Keyword><Keyword MajorTopicYN="N">p25</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27656030</ArticleId><ArticleId IdType="pmc">PMC5030353</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1907-16.2016</ArticleId><ArticleId IdType="pii">36/38/9933</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borkham-Kamphorst E, Steffen BT, Van de Leur E, Haas U, Tihaa L, Friedman SL, Weiskirchen R. CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. Cell Signal. 2016;28:34&#x2013;42. doi: 10.1016/j.cellsig.2015.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2015.10.013</ArticleId><ArticleId IdType="pubmed">26515130</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhari N, Talwar P, Parimisetty A, Lefebvre d'Hellencourt C, Ravanan P. A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci. 2014;8:213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114208</ArticleId><ArticleId IdType="pubmed">25120434</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M. The maze of APP processing in Alzheimer's disease: where did we go wrong in reasoning? Front Cell Neurosci: 2015;9:186. doi: 10.3389/fncel.2015.00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00186</ArticleId><ArticleId IdType="pmc">PMC4447002</ArticleId><ArticleId IdType="pubmed">26052267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebensperger G, Ebensperger R, Herrera EA, Riquelme RA, Sanhueza EM, Lesage F, Marengo JJ, Tejo RI, Llanos AJ, Reyes RV. Fetal brain hypometabolism during prolonged hypoxaemia in the llama. J Physiol. 2005;567:963&#x2013;975. doi: 10.1113/jphysiol.2005.094524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2005.094524</ArticleId><ArticleId IdType="pmc">PMC1474220</ArticleId><ArticleId IdType="pubmed">16037083</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527. doi: 10.1038/373523a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/373523a0</ArticleId><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Tomioka M, Takano J, Shirotani K, Iwata N, Masumoto H, Maki M, Itohara S, Saido TC. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J Biol Chem. 2005;280:15229&#x2013;15237. doi: 10.1074/jbc.M500939200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500939200</ArticleId><ArticleId IdType="pubmed">15699033</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Iwata N, Matsuba Y, Takano J, Suemoto T, Maeda J, Ji B, Ono M, Staufenbiel M, Suhara T, Saido TC. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 2012;26:1204&#x2013;1217. doi: 10.1096/fj.11-187740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-187740</ArticleId><ArticleId IdType="pubmed">22173972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannfelt L, Relkin NR, Siemers ER. Amyloid-&#x3b2;-directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275:284&#x2013;295. doi: 10.1111/joim.12168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12168</ArticleId><ArticleId IdType="pmc">PMC4238820</ArticleId><ArticleId IdType="pubmed">24605809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431&#x2013;1568.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010;9:702&#x2013;716. doi: 10.1016/S1474-4422(10)70119-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70119-8</ArticleId><ArticleId IdType="pubmed">20610346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N. Differential effects between &#x3b3;-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012;32:2037&#x2013;2050. doi: 10.1523/JNEUROSCI.4264-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4264-11.2012</ArticleId><ArticleId IdType="pmc">PMC6621706</ArticleId><ArticleId IdType="pubmed">22323718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson P, Loganathan K, Sekiguchi M, Matsuba Y, Hui K, Tsubuki S, Tanaka M, Iwata N, Saito T, Saido TC. A&#x3b2; secretion and plaque formation depend on autophagy. Cell Rep. 2013;5:61&#x2013;69. doi: 10.1016/j.celrep.2013.08.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.08.042</ArticleId><ArticleId IdType="pubmed">24095740</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson P, Saito T, Saido TC. New mouse model of Alzheimer's. ACS Chem Neurosci. 2014;5:499&#x2013;502. doi: 10.1021/cn500105p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn500105p</ArticleId><ArticleId IdType="pmc">PMC4102956</ArticleId><ArticleId IdType="pubmed">24852598</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, Takeuchi T, Itohara S, Yanagawa Y, Obata K, Furuichi T, Hensch TK, Yamakawa K. Nav1.1 localizes to axon of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007;27:5903&#x2013;5914. doi: 10.1523/JNEUROSCI.5270-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5270-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672241</ArticleId><ArticleId IdType="pubmed">17537961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogiwara I, Iwasato T, Miyamoto H, Iwata R, Yamagata T, Mazaki E, Yanagawa Y, Tamamaki N, Hensch TK, Itohara S, Yamakawa K. Nav1.1 haploinsufficiency in excitatory neurons ameliorates seizure-associated sudden death in a mouse model of Dravet syndrome. Hum Mol Genet. 2013;22:4784&#x2013;4804. doi: 10.1093/hmg/ddt331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt331</ArticleId><ArticleId IdType="pmc">PMC3820136</ArticleId><ArticleId IdType="pubmed">23922229</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 1994;8:814&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">8070630</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014;217:661&#x2013;663. doi: 10.1038/nn.3697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322&#x2013;333. doi: 10.1056/NEJMoa1304839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J, Giusti-Rodr&#xed;guez P, Zhou Y, Rudenko A, Cho S, Ota KT, Park C, Patzke H, Madabhushi R, Pan L, Mungenast AE, Guan JS, Delalle I, Tsai LH. Activity-dependent p25 generation regulates synaptic plasticity and A&#x3b2;-induced cognitive impairment. Cell. 2014;157:486&#x2013;498. doi: 10.1016/j.cell.2014.01.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.01.065</ArticleId><ArticleId IdType="pmc">PMC4327772</ArticleId><ArticleId IdType="pubmed">24725413</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M, Murray ME, Frank RD, Shinohara M, DeTure M, Yamazaki Y, Tachibana M, Atagi Y, Davis MD, Liu CC, Zhao N, Painter MM, Petersen RC, Fryer JD, Crook JE, Dickson DW, Bu G, Kanekiyo T. Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer's disease. Acta Neuropathol. 2016;132:225&#x2013;234. doi: 10.1007/s00401-016-1580-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1580-y</ArticleId><ArticleId IdType="pmc">PMC4947445</ArticleId><ArticleId IdType="pubmed">27179972</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S, Maki M, Saido TC. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem. 2005;280:16175&#x2013;16184. doi: 10.1074/jbc.M414552200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M414552200</ArticleId><ArticleId IdType="pubmed">15691848</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi S, Fujita Y, Hayashi S, Kakita A, Takahashi H, Murayama S, Saido TC, Hisanaga S, Iwatsubo T, Hasegawa M. Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett. 2001;489:46&#x2013;50. doi: 10.1016/S0014-5793(00)02431-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(00)02431-5</ArticleId><ArticleId IdType="pubmed">11231011</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149:708&#x2013;721. doi: 10.1016/j.cell.2012.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.046</ArticleId><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27654968</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.</ArticleTitle><Pagination><StartPage>1334</StartPage><EndPage>1341</EndPage><MedlinePgn>1334-1341</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.3338</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The causes of cognitive impairment in dementia with Lewy bodies (DLB) and Parkinson disease (PD) are multifactorial. Tau pathologic changes are commonly observed at autopsy in individuals with DLB and PD dementia, but their contribution to these diseases during life is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To contrast tau aggregation in DLB, cognitively impaired persons with PD (PD-impaired), cognitively normal individuals with PD (PD-normal), and healthy persons serving as control participants, and to evaluate the association between tau aggregation, amyloid deposition, and cognitive function.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This cross-sectional study was conducted from January 1, 2014, to April 28, 2016, in a tertiary care center's memory and movement disorders units. Twenty-four patients with Lewy body disease (7 DLB, 8 PD-impaired, and 9 PD-normal) underwent multimodal brain imaging, cognitive testing, and neurologic evaluation, and imaging measures were compared with those of an independently acquired group of 29 controls with minimal brain amyloid burden as measured with carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET).</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Imaging with fluorine 18-labeled AV-1451 ([18F]AV-1451) (formerly known as [18F]T807), [11C]PiB PET, magnetic resonance imaging (MRI), neurologic examination, and detailed cognitive testing using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating scale.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Main outcomes were differentiation of diagnostic groups on the basis of [18F]AV-1451 binding, the association of [18F]AV-1451 binding with [11C]PiB binding, and the association of [18F]AV-1451 binding with cognitive impairment. All but 3 individuals underwent amyloid imaging with [11C]PiB PET. The hypotheses being tested were formulated before data collection. Mini-Mental State Examination (range, 0-30, with 30 being best) and Clinical Dementia Rating scale sum-of-boxes scale (range, 0-18, with 0 being best) were used for assessment of cognitive function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In patients with DLB, cortical [18F]AV-1451 uptake was highly variable and greater than in the controls, particularly in the inferior temporal gyrus and precuneus. Foci of increased [18F]AV-1451 binding in the inferior temporal gyrus and precuneus were also evident in PD-impaired patients. Elevated cortical [18F]AV-1451 binding was observed in 4 of 17 patients with Lewy body disease with low cortical [11C]PiB retention. For DLB and PD-impaired patients, greater [18F]AV-1451 uptake in the inferior temporal gyrus and precuneus was associated with increased cognitive impairment as measured with the MMSE and the Clinical Dementia Rating scale sum-of-boxes score.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Patients with Lewy body disease manifest a spectrum of tau pathology. Cortical aggregates of tau are common in patients with DLB and in PD-impaired patients, even in those without elevated amyloid levels. When present, tau deposition is associated with cognitive impairment. These findings support a role for tau copathology in the Lewy body diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gomperts</LastName><ForeName>Stephen N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Charlestown, Massachusetts2Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locascio</LastName><ForeName>Joseph J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makaretz</LastName><ForeName>Sara J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caso</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasdev</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown4Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown5Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Growdon</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown3Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown4Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown4Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown5Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS090243</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS084156</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="Y">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>BCD has provided consulting services for Merck DSMB, Forum, Ionis, Piramal, and receives royalties from Oxford University Press. RAS has provided providing consulting services for Roche, Genentech, Biogen and Bracket, Abbvie, received support from a joint NIH-Lilly-sponsored clinical trial (A4 Study &#x2013; U19AG10483), and research funding from the National Institutes of Health/National Institute on Aging (R01 AG046396, P01 AG036694, P50 AG00513421) and the Alzheimer&#x2019;s Association. KJ has provided consulting services for Lilly, Novartis, Janssen, Roche, Piramal, GE Healthcare, Siemens, ISIS Pharma, AZTherapy, Abbvie, Lundbeck, and Biogen, received support from a joint NIH-Lilly-sponsored clinical trial (A4 Study &#x2013; U19AG10483), and received research support from National Institutes of Health/National Institute on Aging (R01 AG046396, P01 AG036694, P50 AG00513421, U19AG10483, U01AG024904-S1), Fidelity Biosciences, the Michael J. Fox Foundation, the Marr Foundation, and the Alzheimer&#x2019;s Association.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27654968</ArticleId><ArticleId IdType="mid">NIHMS845559</ArticleId><ArticleId IdType="pmc">PMC5287290</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.3338</ArticleId><ArticleId IdType="pii">2553326</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001;102(4):355&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603811</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson&#x2019;s disease. J Neural Transm (Vienna) 2002 Mar;109(3):329&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">11956955</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol. 2008;115(4):427&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">18273624</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kovari E. Neuropathology of dementia in a large cohort of patients with Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2013;19(10):864&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746454</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett DR, Whitfield D, Johnson M, et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. Brain Pathol. 2015;25(4):401&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029273</ArticleId><ArticleId IdType="pubmed">25103200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffmann C, Calboli FC, Bravi I, et al. Cortical Lewy bodies and A&#x3b2; burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol. 2015 Nov 3; doi: 10.1111/nan.12294. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12294</ArticleId><ArticleId IdType="pubmed">26527105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN. Imaging the role of amyloid in PD dementia and dementia with Lewy bodies. Curr Neurol Neurosci Rep. 2014;14(8):472.</Citation><ArticleIdList><ArticleId IdType="pubmed">25011528</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015 Jan;14(1):114&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">25496902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637553</ArticleId><ArticleId IdType="pubmed">18794492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Locascio JJ, Marquie-Sayagues M, et al. Brain amyloid and cognition in Lewy body diseases. Movement Disorders. 2012;27(8):965&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725259</ArticleId><ArticleId IdType="pubmed">22693110</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson&#x2019;s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18653550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012 Sep;33(9):2091&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3288845</ArticleId><ArticleId IdType="pubmed">22018896</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Marquie-Sayagues M, Locascio JJ, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589197</ArticleId><ArticleId IdType="pubmed">23243071</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Marquie M, Locascio JJ, Bayer S, Johnson KA, Growdon JH. PET Radioligands Reveal the Basis of Dementia in Parkinson&#x2019;s Disease and Dementia with Lewy Bodies. Neurodegener Dis. 2016;16(1&#x2013;2):118&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838335</ArticleId><ArticleId IdType="pubmed">26655867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012 May;71(5):362&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, R&#xfc;b U, Schultz C, Del Tredici K. Vulnerability of cortical neurons to Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J Alzheimers Dis. 2006;9(3 Suppl):35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914843</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer&#x2019;s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Curr Alzheimer Res. 2015;12(8):712&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5384474</ArticleId><ArticleId IdType="pubmed">26412218</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42(3 Pt 1):631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Qian J, Monsell SE, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 2013;72(12):1182&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962953</ArticleId><ArticleId IdType="pubmed">24226270</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L, McAleese KE, Thomas AJ, et al. Neuropathologically mixed Alzheimer&#x2019;s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129(5):729&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25758940</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimers Dement. 2013;9(6):666&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23411393</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">23234879</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [&lt;sup&gt;18&lt;/sup&gt;F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016 Feb 15; doi: 10.1016/j.jalz.2016.01.003. pii: S1552-5260(16)00033-9. [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.003</ArticleId><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson&#x2019;s disease. Arch Neurol. 1993;50(2):140&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431132</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I, Goldman JG, Tr&#xf6;ster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson&#x2019;s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641655</ArticleId><ArticleId IdType="pubmed">22275317</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson&#x2019;s disease. Mov Disord. 2007;22(12):1689&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KRA, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62(2):181&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745051</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12(5):445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083495</ArticleId><ArticleId IdType="pubmed">21349763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang A, Fahn S. Assesment of parkinson&#x2019;s disease. In: Munstat TL, editor. Quantification of Neurologic Deficit. Boston: Butterworths; 1989. pp. 285&#x2013;309.</Citation></Reference><Reference><Citation>Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17(5):427&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">6067254</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoup TM, Yokell DL, Rice PA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm. 2013;56(14):736&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4114396</ArticleId><ArticleId IdType="pubmed">24339014</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25(11):1528&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. Alzheimers Res Ther. 2014;6(5&#x2013;8):52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245149</ArticleId><ArticleId IdType="pubmed">25429309</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve DN, Salat DH, Bowen SL, et al. Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging. Neuroimage. 2016 Feb 23; pii: S1053-8119(16)00151-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4851886</ArticleId><ArticleId IdType="pubmed">26915497</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, van der Kouwe AJ, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage. 2004;23(suppl 1):S69&#x2013;S84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501102</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Brain. 2009;132(Pt 8):2048&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714061</ArticleId><ArticleId IdType="pubmed">19460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89(5):971&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016 Mar 8; ii: aww027 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016 Mar 2; pii: aww023 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggerty T, Credle J, Rodriguez O, et al. Hyperphosphorylated Tau in an &#x3b1;-synuclein-overexpressing transgenic model of Parkinson&#x2019;s disease. Eur J Neurosci. 2011;33(9):1598&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086951</ArticleId><ArticleId IdType="pubmed">21453448</ArticleId></ArticleIdList></Reference><Reference><Citation>Credle JJ, George JL, Wills J, et al. GSK-3&#x3b2; dysregulation contributes to parkinson&#x2019;s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and &#x3b1;-synuclein. Cell Death Differ. 2015;22(5):838&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4392080</ArticleId><ArticleId IdType="pubmed">25394490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27(6):1405&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27654934</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury.</ArticleTitle><Pagination><StartPage>1308</StartPage><EndPage>1315</EndPage><MedlinePgn>1308-1315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.2038</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Evidence is accumulating that repeated mild traumatic brain injury (mTBI) incidents can lead to persistent, long-term debilitating symptoms and in some cases a progressive neurodegenerative condition referred to as chronic traumatic encephalopathy. However, to our knowledge, there are no objective tools to examine to which degree persistent symptoms after mTBI are caused by neuronal injury.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether persistent symptoms after mTBI are associated with brain injury as evaluated by cerebrospinal fluid biochemical markers for axonal damage and other aspects of central nervous system injury.</AbstractText><AbstractText Label="DESIGN, SETTINGS, AND PARTICIPANTS" NlmCategory="METHODS">A multicenter cross-sectional study involving professional Swedish ice hockey players who have had repeated mTBI, had postconcussion symptoms for more than 3 months, and fulfilled the criteria for postconcussion syndrome (PCS) according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) matched with neurologically healthy control individuals. The participants were enrolled between January 2014 and February 2016. The players were also assessed with Rivermead Post Concussion Symptoms Questionnaire and magnetic resonance imaging.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Neurofilament light protein, total tau, glial fibrillary acidic protein, amyloid &#x3b2;, phosphorylated tau, and neurogranin concentrations in cerebrospinal fluid.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 31 participants (16 men with PCS; median age, 31 years; range, 22-53 years; and 15 control individuals [11 men and 4 women]; median age, 25 years; range, 21-35 years) were assessed. Of 16 players with PCS, 9 had PCS symptoms for more than 1 year, while the remaining 7 returned to play within a year. Neurofilament light proteins were significantly increased in players with PCS for more than 1 year (median, 410 pg/mL; range, 230-1440 pg/mL) compared with players whose PCS resolved within 1 year (median, 210 pg/mL; range, 140-460 pg/mL) as well as control individuals (median 238 pg/mL, range 128-526 pg/mL; P&#x2009;=&#x2009;.04 and P&#x2009;=&#x2009;.02, respectively). Furthermore, neurofilament light protein concentrations correlated with Rivermead Post Concussion Symptoms Questionnaire scores and lifetime concussion events (&#x3c1;&#x2009;=&#x2009;0.58, P&#x2009;=&#x2009;.02 and &#x3c1;&#x2009;=&#x2009;0.52, P&#x2009;=&#x2009;.04, respectively). Overall, players with PCS had significantly lower cerebrospinal fluid amyloid-&#x3b2; levels compared with control individuals (median, 1094 pg/mL; range, 845-1305 pg/mL; P&#x2009;=&#x2009;.05).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Increased cerebrospinal fluid neurofilament light proteins and reduced amyloid &#x3b2; were observed in patients with PCS, suggestive of axonal white matter injury and amyloid deposition. Measurement of these biomarkers may be an objective tool to assess the degree of central nervous system injury in individuals with PCS and to distinguish individuals who are at risk of developing chronic traumatic encephalopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shahim</LastName><ForeName>Pashtun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tegner</LastName><ForeName>Yelverton</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Medical Sciences, Department of Health Sciences, Lule&#xe5; University of Technology, Lule&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gustafsson</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Capio Artro Clinic, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gren</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc4;rlig</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehto</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Medical Sciences, Department of Health Sciences, Lule&#xe5; University of Technology, Lule&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf6;m</LastName><ForeName>&#xc5;sa</ForeName><Initials>&#xc5;</Initials><AffiliationInfo><Affiliation>Division of Medical Sciences, Department of Health Sciences, Lule&#xe5; University of Technology, Lule&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;glund</LastName><ForeName>Kina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden4Department of Molecular Neuroscience, University College London Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>132654-77-4</RegistryNumber><NameOfSubstance UI="D051579">Neurogranin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2016 Nov 1;73(11):1280-1282. doi: 10.1001/jamaneurol.2016.3169.</RefSource><PMID Version="1">27654455</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Mar 1;74(3):363. doi: 10.1001/jamaneurol.2016.5908.</RefSource><PMID Version="1">28135354</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Mar 1;74(3):363-364. doi: 10.1001/jamaneurol.2016.5905.</RefSource><PMID Version="1">28135356</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001265" MajorTopicYN="N">Athletic Injuries</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006688" MajorTopicYN="N">Hockey</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051579" MajorTopicYN="N">Neurogranin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038223" MajorTopicYN="N">Post-Concussion Syndrome</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27654934</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.2038</ArticleId><ArticleId IdType="pii">2553325</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">27671749</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein.</ArticleTitle><Pagination><StartPage>33928</StartPage><MedlinePgn>33928</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">33928</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep33928</ELocationID><Abstract><AbstractText>The protein alpha-synuclein (&#x3b1;S) self-assembles into toxic beta-sheet aggregates in Parkinson's disease, while it is proposed that &#x3b1;S forms soluble alpha-helical multimers in healthy neurons. Here, we have made &#x3b1;S multimers in vitro using arachidonic acid (ARA), one of the most abundant fatty acids in the brain, and characterized them by a combination of bulk experiments and single-molecule F&#x4e7;rster resonance energy transfer (sm-FRET) measurements. The data suggest that ARA-induced oligomers are alpha-helical, resistant to fibril formation, more prone to disaggregation, enzymatic digestion and degradation by the 26S proteasome, and lead to lower neuronal damage and reduced activation of microglia compared to the oligomers formed in the absence of ARA. These multimers can be formed at physiologically-relevant concentrations, and pathological mutants of &#x3b1;S form less multimers than wild-type &#x3b1;S. Our work provides strong biophysical evidence for the formation of alpha-helical multimers of &#x3b1;S in the presence of a biologically relevant fatty acid, which may have a protective role with respect to the generation of beta-sheet toxic structures during &#x3b1;S fibrillation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iljina</LastName><ForeName>Marija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosatto</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Minee L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sang</LastName><ForeName>Jason C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Harvard Medical School, Boston, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Craig D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University Of Cambridge, Madingley Road, Cambridge, CB3 0ES, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryant</LastName><ForeName>Clare E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University Of Cambridge, Madingley Road, Cambridge, CB3 0ES, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klenerman</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27671749</ArticleId><ArticleId IdType="pmc">PMC5037366</ArticleId><ArticleId IdType="doi">10.1038/srep33928</ArticleId><ArticleId IdType="pii">srep33928</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cookson M. R. alpha-Synuclein and neuronal cell death. Molecular Neurodegeneration 4, doi: 10.1186/1750-1326-4-9 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-4-9</ArticleId><ArticleId IdType="pmc">PMC2646729</ArticleId><ArticleId IdType="pubmed">19193223</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M. et al.. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson&#x2019;s disease and dementia with Lewy bodies. Neuroscience Letters 251, 205&#x2013;208 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9726379</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway K. et al.. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson&#x2019;s disease: Implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America 97, 571&#x2013;576, doi: 10.1073/pnas.97.2.571 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.97.2.571</ArticleId><ArticleId IdType="pmc">PMC15371</ArticleId><ArticleId IdType="pubmed">10639120</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf O. &amp; Irvine G. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochemical Society Transactions 30, 559&#x2013;565 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12196137</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleologou K. E., Irvine G. B. &amp; El-Agnaf O. M. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem Soc Trans 33, 1106&#x2013;1110, doi: 10.1042/BST20051106 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20051106</ArticleId><ArticleId IdType="pubmed">16246056</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai A. et al.. The precursor protein of non-a-beta component of Alzheimer&#x2019;s-disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467&#x2013;475, doi: 10.1016/0896-6273(95)90302-X (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90302-X</ArticleId><ArticleId IdType="pubmed">7857654</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvet B. et al.. &#x3b1;-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287, 15345&#x2013;15364, doi: 10.1074/jbc.M111.318949 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.318949</ArticleId><ArticleId IdType="pmc">PMC3346117</ArticleId><ArticleId IdType="pubmed">22315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Theillet F. X. et al.. Structural disorder of monomeric &#x3b1;-synuclein persists in mammalian cells. Nature 530, 45&#x2013;50, doi: 10.1038/nature16531 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16531</ArticleId><ArticleId IdType="pubmed">26808899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T., Choi J. G. &amp; Selkoe D. J. &#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107&#x2013;110, doi: 10.1038/nature10324 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10324</ArticleId><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U., Newman A. J., Luth E. S., Bartels T. &amp; Selkoe D. In vivo cross-linking reveals principally oligomeric forms of &#x3b1;-synuclein and &#x3b2;-synuclein in neurons and non-neural cells. J Biol Chem 288, 6371&#x2013;6385, doi: 10.1074/jbc.M112.403311 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.403311</ArticleId><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Westphal C. H. &amp; Chandra S. S. Monomeric synucleins generate membrane curvature. J Biol Chem 288, 1829&#x2013;1840, doi: 10.1074/jbc.M112.418871 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.418871</ArticleId><ArticleId IdType="pmc">PMC3548493</ArticleId><ArticleId IdType="pubmed">23184946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould N. et al.. Evidence of native &#x3b1;-synuclein conformers in the human brain. J Biol Chem 289, 7929&#x2013;7934, doi: 10.1074/jbc.C113.538249 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C113.538249</ArticleId><ArticleId IdType="pmc">PMC3953303</ArticleId><ArticleId IdType="pubmed">24474688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibayama-Imazu T. et al.. Cell and tissue distribution and developmental change of neuron specific 14&#x2009;kDa protein (phosphoneuroprotein 14). Brain Res 622, 17&#x2013;25 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7694766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellani S. et al.. The regulation of synaptic function by alpha-synuclein. Commun Integr Biol 3, 106&#x2013;109 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889964</ArticleId><ArticleId IdType="pubmed">20585500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonini N. M. &amp; Giasson B. I. Snaring the function of alpha-synuclein. Cell 123, 359&#x2013;361, doi: 10.1016/j.cell.2005.10.017 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.10.017</ArticleId><ArticleId IdType="pubmed">16269324</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk M. R. &amp; De Camilli P. Protein-lipid interactions and phosphoinositide metabolism in membrane traffic: Insights from vesicle recycling in nerve terminals. Proceedings of the National Academy of Sciences of the United States of America 101, 8262&#x2013;8269, doi: 10.1073/pnas.0401874101 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401874101</ArticleId><ArticleId IdType="pmc">PMC420382</ArticleId><ArticleId IdType="pubmed">15146067</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigoni M. et al.. Equivalent effects of snake PLA2 neurotoxins and lysophospholipid-fatty acid mixtures. Science 310, 1678&#x2013;1680, doi: 10.1126/science.1120640 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1120640</ArticleId><ArticleId IdType="pubmed">16339444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang T., Halemani N. D. &amp; Rammner B. Interplay between lipids and the proteinaceous membrane fusion machinery. Progress in Lipid Research 47, 461&#x2013;469, doi: 10.1016/j.plipres.2008.08.002 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2008.08.002</ArticleId><ArticleId IdType="pubmed">18805437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader M.-F. &amp; Vitale N. Phospholipase D in calcium-regulated exocytosis: Lessons from chromaffin cells. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 1791, 936&#x2013;941, doi: 10.1016/j.bbalip.2009.02.016 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2009.02.016</ArticleId><ArticleId IdType="pubmed">19289180</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon R. et al.. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci USA 98, 9110&#x2013;9115, doi: 10.1073/pnas.171300598 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.171300598</ArticleId><ArticleId IdType="pmc">PMC55381</ArticleId><ArticleId IdType="pubmed">11481478</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford M. A. &amp; Sinclair A. J. Nutritional influences in the evolution of mammalian brain. In: lipids, malnutrition &amp; the developing brain. Ciba Foundation symposium, 267&#x2013;292 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">4949878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetto O., Morbiato L., Caccin P., Rigoni M. &amp; Montecucco C. Presynaptic enzymatic neurotoxins. Journal of Neurochemistry 97, 1534&#x2013;1545, doi: 10.1111/j.1471-4159.2006.03965.x (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.03965.x</ArticleId><ArticleId IdType="pubmed">16805767</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R. J., Woods W. S., Clayton D. F. &amp; George J. M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. Journal of Biological Chemistry 276, 41958&#x2013;41962, doi: 10.1074/jbc.M105022200 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M105022200</ArticleId><ArticleId IdType="pubmed">11553616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon R. et al.. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson&#x2019;s disease. Neuron 37, 583&#x2013;595, doi: 10.1016/s0896-6273(03)00024-2 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(03)00024-2</ArticleId><ArticleId IdType="pubmed">12597857</ArticleId></ArticleIdList></Reference><Reference><Citation>Necula M., Chirita C. &amp; Kuret J. Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. Journal of Biological Chemistry 278, 46674&#x2013;46680, doi: 10.1074/jbc.M308231200 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M308231200</ArticleId><ArticleId IdType="pubmed">14506232</ArticleId></ArticleIdList></Reference><Reference><Citation>Broersen K., van den Brink D., Fraser G., Goedert M. &amp; Davletov B. alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. Biochemistry 45, 15610&#x2013;15616, doi: 10.1021/bi061743l (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi061743l</ArticleId><ArticleId IdType="pubmed">17176082</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurry T. et al.. The dynamic structure of &#x3b1;-synuclein multimers. J Am Chem Soc 135, 3865&#x2013;3872, doi: 10.1021/ja310518p (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja310518p</ArticleId><ArticleId IdType="pubmed">23398399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U., Selkoe D. &amp; Bartels T. New insights into cellular &#x3b1;-synuclein homeostasis in health and disease. Curr Opin Neurobiol 36, 15&#x2013;22, doi: 10.1016/j.conb.2015.07.007 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2015.07.007</ArticleId><ArticleId IdType="pubmed">26282834</ArticleId></ArticleIdList></Reference><Reference><Citation>De Franceschi G. et al.. Structural and morphological characterization of aggregated species of &#x3b1;-synuclein induced by docosahexaenoic acid. J Biol Chem 286, 22262&#x2013;22274, doi: 10.1074/jbc.M110.202937 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.202937</ArticleId><ArticleId IdType="pmc">PMC3121372</ArticleId><ArticleId IdType="pubmed">21527634</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson W. S., Jonas A., Clayton D. F. &amp; George J. M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. Journal of Biological Chemistry 273, 9443&#x2013;9449, doi: 10.1074/jbc.273.16.9443 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.16.9443</ArticleId><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreon A. C., Gambin Y., Lemke E. A. &amp; Deniz A. A. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci USA 106, 5645&#x2013;5650, doi: doi: 10.1073/pnas.0809232106 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0809232106</ArticleId><ArticleId IdType="pmc">PMC2667048</ArticleId><ArticleId IdType="pubmed">19293380</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton E. &amp; Rhoades E. Effects of Curvature and Composition on alpha-Synuclein Binding to Lipid Vesicles. Biophysical Journal 99, 2279&#x2013;2288, doi: 10.1016/j.bpj.2010.07.056 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2010.07.056</ArticleId><ArticleId IdType="pmc">PMC3042580</ArticleId><ArticleId IdType="pubmed">20923663</ArticleId></ArticleIdList></Reference><Reference><Citation>Trexler A. J. &amp; Rhoades E. Alpha-synuclein binds large unilamellar vesicles as an extended helix. Biochemistry 48, 2304&#x2013;2306, doi: 10.1021/bi900114z (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi900114z</ArticleId><ArticleId IdType="pmc">PMC2837115</ArticleId><ArticleId IdType="pubmed">19220042</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvagnion C. et al.. Lipid vesicles trigger &#x3b1;-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol 11, 229&#x2013;234, doi: 10.1038/nchembio.1750 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1750</ArticleId><ArticleId IdType="pmc">PMC5019199</ArticleId><ArticleId IdType="pubmed">25643172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremades N. et al.. Direct observation of the interconversion of normal and toxic forms of &#x3b1;-synuclein. Cell 149, 1048&#x2013;1059, doi: 10.1016/j.cell.2012.03.037 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.037</ArticleId><ArticleId IdType="pmc">PMC3383996</ArticleId><ArticleId IdType="pubmed">22632969</ArticleId></ArticleIdList></Reference><Reference><Citation>Horrocks M. H. et al.. Fast Flow Microfluidics and Single-Molecule Fluorescence for the Rapid Characterization of &#x3b1;-Synuclein Oligomers. Anal Chem, doi: 10.1021/acs.analchem.5b01811 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.5b01811</ArticleId><ArticleId IdType="pubmed">26258431</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosatto L. et al.. Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson&#x2019;s disease genetically related mutants. Sci Rep 5, 16696, doi: 10.1038/srep16696 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16696</ArticleId><ArticleId IdType="pmc">PMC4652217</ArticleId><ArticleId IdType="pubmed">26582456</ArticleId></ArticleIdList></Reference><Reference><Citation>Iljina M. et al.. Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proc Natl Acad Sci USA, doi: 10.1073/pnas.1524128113 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1524128113</ArticleId><ArticleId IdType="pmc">PMC4780632</ArticleId><ArticleId IdType="pubmed">26884195</ArticleId></ArticleIdList></Reference><Reference><Citation>Serth J., Lautwein A., Frech M., Wittinghofer A. &amp; Pingoud A. The inhibition of the GTPase activating protein-Ha-ras interaction by acidic lipids is due to physical association of the C-terminal domain of the GTPase activating protein with micellar structures. EMBO J 10, 1325&#x2013;1330 (1991).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452790</ArticleId><ArticleId IdType="pubmed">2026138</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell L. C., Berriman J., Jakes R., Goedert M. &amp; Crowther R. A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 97, 4897&#x2013;4902 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18329</ArticleId><ArticleId IdType="pubmed">10781096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett M. C. et al.. Degradation of alpha-synuclein by proteasome. J Biol Chem 274, 33855&#x2013;33858 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10567343</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder H. et al.. Aggregated and monomeric alpha-synuclein bind to the S6&#x2019; proteasomal protein and inhibit proteasomal function. J Biol Chem 278, 11753&#x2013;11759, doi: 10.1074/jbc.M208641200 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M208641200</ArticleId><ArticleId IdType="pubmed">12551928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrand E., Nowacka A., Topgaard D., Linse S. &amp; Sparr E. Membrane lipid co-aggregation with &#x3b1;-synuclein fibrils. PLoS one 8, e77235, doi: 10.1371/journal.pone.0077235 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0077235</ArticleId><ArticleId IdType="pmc">PMC3795653</ArticleId><ArticleId IdType="pubmed">24146972</ArticleId></ArticleIdList></Reference><Reference><Citation>Brash A. R. Arachidonic acid as a bioactive molecule. Journal of Clinical Investigation 107, 1339&#x2013;1345, doi: 10.1172/jci13210 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci13210</ArticleId><ArticleId IdType="pmc">PMC209328</ArticleId><ArticleId IdType="pubmed">11390413</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Guajardo V., Tentillier N. &amp; Romero-Ramos M. The relation between &#x3b1;-synuclein and microglia in Parkinson&#x2019;s disease: Recent developments. Neuroscience 302, 47&#x2013;58, doi: 10.1016/j.neuroscience.2015.02.008 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.02.008</ArticleId><ArticleId IdType="pubmed">25684748</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanova N. et al.. Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. J Neurosci Res 73, 334&#x2013;340, doi: 10.1002/jnr.10662 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10662</ArticleId><ArticleId IdType="pubmed">12868067</ArticleId></ArticleIdList></Reference><Reference><Citation>Meves H. Arachidonic acid and ion channels: an update. Br J Pharmacol 155, 4&#x2013;16, doi: 10.1038/bjp.2008.216 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjp.2008.216</ArticleId><ArticleId IdType="pmc">PMC2527843</ArticleId><ArticleId IdType="pubmed">18552881</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U. et al.. Parkinson-causing &#x3b1;-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat Commun 6, 7314, doi: 10.1038/ncomms8314 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8314</ArticleId><ArticleId IdType="pmc">PMC4490410</ArticleId><ArticleId IdType="pubmed">26076669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet M. et al.. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson&#x2019;s disease. FASEB J 22, 1213&#x2013;1225, doi: 10.1096/fj.07-9677com (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-9677com</ArticleId><ArticleId IdType="pubmed">18032633</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet M., Calon F. &amp; Cicchetti F. Impact of &#x3c9;-3 fatty acids in Parkinson&#x2019;s disease. Ageing Res Rev 10, 453&#x2013;463, doi: 10.1016/j.arr.2011.03.001 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2011.03.001</ArticleId><ArticleId IdType="pubmed">21414422</ArticleId></ArticleIdList></Reference><Reference><Citation>Luth E. S., Bartels T., Dettmer U., Kim N. C. &amp; Selkoe D. J. Purification of &#x3b1;-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry 54, 279&#x2013;292, doi: 10.1021/bi501188a (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi501188a</ArticleId><ArticleId IdType="pmc">PMC4303315</ArticleId><ArticleId IdType="pubmed">25490121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer W. et al.. Dependence of alpha-synuclein aggregate morphology on solution conditions. Journal of Molecular Biology 322, 383&#x2013;393, doi: 10.1016/S0022-2836(02)00775-1 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(02)00775-1</ArticleId><ArticleId IdType="pubmed">12217698</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero C., Tagwerker C., Kaiser P. &amp; Huang L. An integrated mass spectrometry-based proteomic approach: quantitative analysis of tandem affinity-purified in vivo cross-linked protein complexes (QTAX) to decipher the 26 S proteasome-interacting network. Mol Cell Proteomics 5, 366&#x2013;378, doi: 10.1074/mcp.M500303-MCP200 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M500303-MCP200</ArticleId><ArticleId IdType="pubmed">16284124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al.. Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46, 3553&#x2013;3565, doi: 10.1021/bi061994u (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi061994u</ArticleId><ArticleId IdType="pubmed">17323924</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaarmann A., Gandhi S., Gourine A. V. &amp; Abramov A. Y. Novel pathway for an old neurotransmitter: dopamine-induced neuronal calcium signalling via receptor-independent mechanisms. Cell Calcium 48, 176&#x2013;182, doi: 10.1016/j.ceca.2010.08.008 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2010.08.008</ArticleId><ArticleId IdType="pubmed">20846720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27671637</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>41</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau &#x394;K280.</ArticleTitle><Pagination><StartPage>11597</StartPage><EndPage>11602</EndPage><MedlinePgn>11597-11602</MedlinePgn></Pagination><Abstract><AbstractText>Accumulation of Tau is a characteristic hallmark of several neurodegenerative diseases but the mode of toxic action of Tau is poorly understood. Here, we show that the Tau protein is toxic due to its aggregation propensity, whereas phosphorylation and/or missorting is not sufficient to cause neuronal dysfunction. Aggregate-prone Tau accumulates, when expressed in vitro at near-endogenous levels, in axons as spindle-shaped grains. These axonal grains contain Tau that is folded in a pathological (MC-1) conformation. Proaggregant Tau induces a reduction of neuronal ATP, concomitant with loss of dendritic spines. Counterintuitively, axonal grains of Tau are not targeted for degradation and do not induce a molecular stress response. Proaggregant Tau causes neuronal and astrocytic hypoactivity and presynaptic dysfunction instead. Here, we show that the adenosine A<sub>1</sub> receptor antagonist rolofylline (KW-3902) is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro. Oral administration of rolofylline for 2-wk to 14-mo-old proaggregant Tau transgenic mice restores the spatial memory deficits and normalizes the basic synaptic transmission. These findings make rolofylline an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dennissen</LastName><ForeName>Frank J A</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 53127 Bonn, Germany; Center of Advanced European Studies and Research, 53175 Bonn, Germany; frank.dennissen@DZNE.de eva.mandelkow@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anglada-Huguet</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 53127 Bonn, Germany; Max Planck Institute for Metabolism Research, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sydow</LastName><ForeName>Astrid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 53127 Bonn, Germany; Max Planck Institute for Metabolism Research, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 53127 Bonn, Germany; Center of Advanced European Studies and Research, 53175 Bonn, Germany; Max Planck Institute for Metabolism Research, 22607 Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, 53127 Bonn, Germany; Center of Advanced European Studies and Research, 53175 Bonn, Germany; Max Planck Institute for Metabolism Research, 22607 Hamburg, Germany frank.dennissen@DZNE.de eva.mandelkow@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058916">Adenosine A1 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014970">Xanthines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>7805S5HIHX</RegistryNumber><NameOfSubstance UI="C073525">rolofylline</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058916" MajorTopicYN="N">Adenosine A1 Receptor Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057567" MajorTopicYN="N">Memory, Long-Term</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017384" MajorTopicYN="Y">Sequence Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014970" MajorTopicYN="N">Xanthines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">axons</Keyword><Keyword MajorTopicYN="N">hypoactivity</Keyword><Keyword MajorTopicYN="N">rolofylline</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27671637</ArticleId><ArticleId IdType="pmc">PMC5068267</ArticleId><ArticleId IdType="doi">10.1073/pnas.1603119113</ArticleId><ArticleId IdType="pii">1603119113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takashima A. Tauopathies and tau oligomers. J Alzheimers Dis. 2013;37(3):565&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pubmed">23948895</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in The Netherlands. Am J Hum Genet. 1999;64(2):414&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1377751</ArticleId><ArticleId IdType="pubmed">9973279</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39(38):11714&#x2013;11721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni P, et al. Clinical and pathological features of an Alzheimer&#x2019;s disease patient with the MAPT Delta K280 mutation. Neurobiol Aging. 2009;30(3):388&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666148</ArticleId><ArticleId IdType="pubmed">17723255</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K, et al. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem. 2007;282(43):31755&#x2013;31765.</Citation><ArticleIdList><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A, et al. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 2012;123(6):787&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming beta structure. Proc Natl Acad Sci USA. 2000;97(10):5129&#x2013;5134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25793</ArticleId><ArticleId IdType="pubmed">10805776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mocanu MM, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci. 2008;28(3):737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670355</ArticleId><ArticleId IdType="pubmed">18199773</ArticleId></ArticleIdList></Reference><Reference><Citation>von Lubitz DK. Adenosine and cerebral ischemia: Therapeutic future or death of a brave concept? Eur J Pharmacol. 1999;371(1):85&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">10355598</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddington M, Lee KS, Schubert P. An A1-adenosine receptor, characterized by [3H] cyclohexyladenosine binding, mediates the depression of evoked potentials in a rat hippocampal slice preparation. Neurosci Lett. 1982;28(3):275&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">6281693</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283304</ArticleId></ArticleIdList></Reference><Reference><Citation>Renard D, et al. Brain FDG-PET changes in ALS and ALS-FTD. Acta Neurol Belg. 2011;111(4):306&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">22368970</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl J, et al. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging. 2004;25(8):1051&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">15212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarmiello A, et al. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39(6):1030&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">22526956</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, et al. Pathological tau disrupts ongoing network activity. Neuron. 2015;85(5):959&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez RD, Grinberg LT. Argyrophilic grain disease: An underestimated tauopathy. Dement Neuropsychol. 2015;9(1):2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5618985</ArticleId><ArticleId IdType="pubmed">29213935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol. 2004;167(1):99&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172520</ArticleId><ArticleId IdType="pubmed">15466480</ArticleId></ArticleIdList></Reference><Reference><Citation>Amniai L, et al. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J. 2009;23(4):1146&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hering H, Sheng M. Dendritic spines: Structure, dynamics and regulation. Nat Rev Neurosci. 2001;2(12):880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11733795</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura H, et al. Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc Natl Acad Sci USA. 2009;106(37):15651&#x2013;15656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735558</ArticleId><ArticleId IdType="pubmed">19720993</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias RB, Rombo DM, Ribeiro JA, Henley JM, Sebasti&#xe3;o AM. Adenosine: Setting the stage for plasticity. Trends Neurosci. 2013;36(4):248&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">23332692</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams M, Braunwalder A, Erickson TJ. Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue. Naunyn Schmiedebergs Arch Pharmacol. 1986;332(2):179&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">3703020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem. 2013;56(11):4135&#x2013;4155.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484434</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer TM, Poucher SM, Jacobson KA, Stiles GL. 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol. 1995;48(6):970&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479638</ArticleId><ArticleId IdType="pubmed">8848012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartley AF, Dobrunz LE. Short-term plasticity regulates the excitation/inhibition ratio and the temporal window for spike integration in CA1 pyramidal cells. Eur J Neurosci. 2015;41(11):1402&#x2013;1415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4767019</ArticleId><ArticleId IdType="pubmed">25903384</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunwiddie TV, Hoffer BJ. Adenine nucleotides and synaptic transmission in the in vitro rat hippocampus. Br J Pharmacol. 1980;69(1):59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2044173</ArticleId><ArticleId IdType="pubmed">6247005</ArticleId></ArticleIdList></Reference><Reference><Citation>Latini S, Pedata F. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. J Neurochem. 2001;79(3):463&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedata F, et al. Purinergic signalling in brain ischemia. Neuropharmacology. 2016;104:105&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">26581499</ArticleId></ArticleIdList></Reference><Reference><Citation>Normile HJ, Barraco RA. N6-Cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors. Brain Res Bull. 1991;27(1):101&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">1933421</ArticleId></ArticleIdList></Reference><Reference><Citation>Massie BM, et al. PROTECT Investigators and Committees Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419&#x2013;1428.</Citation><ArticleIdList><ArticleId IdType="pubmed">20925544</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo E, et al. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003;13(4):440&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095992</ArticleId><ArticleId IdType="pubmed">14655750</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocchi V, Magnani M, Cucchiarini L, Novelli G, Dallapiccola B. Red blood cell adenine nucleotides abnormalities in Down syndrome. Am J Med Genet. 1985;20(1):131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">3155912</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989;256(4 Pt 1):C799&#x2013;C806.</Citation><ArticleIdList><ArticleId IdType="pubmed">2539728</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(4):a006213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312396</ArticleId><ArticleId IdType="pubmed">22474610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kljajevic V, Grothe MJ, Ewers M, Teipel S. Alzheimer&#x2019;s Disease Neuroimaging Initiative Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer&#x2019;s disease. Neurobiol Aging. 2014;35(9):1973&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">24811241</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy AM, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer&#x2019;s disease. Neurosci Lett. 1995;186(1):17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783942</ArticleId></ArticleIdList></Reference><Reference><Citation>Billioti de Gage S, et al. Benzodiazepine use and risk of Alzheimer&#x2019;s disease: Case-control study. BMJ. 2014;349:g5205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159609</ArticleId><ArticleId IdType="pubmed">25208536</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20(Suppl 1):S167&#x2013;S174.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182054</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy DS, et al. Memory retrieval by activating engram cells in mouse models of early Alzheimer&#x2019;s disease. Nature. 2016;531(7595):508&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4847731</ArticleId><ArticleId IdType="pubmed">26982728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JX, et al. Targeted enhancement of cortical-hippocampal brain networks and associative memory. Science. 2014;345(6200):1054&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4307924</ArticleId><ArticleId IdType="pubmed">25170153</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991;37(2):173&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1715499</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods G, Zito K. Preparation of gene gun bullets and biolistic transfection of neurons in slice culture. J Vis Exp. 2008;2008(12):e675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582847</ArticleId><ArticleId IdType="pubmed">19066564</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabold GK, Daunais JB, Rau A, Grant KA, Alvarez VA. DiOLISTIC labeling of neurons from rodent and non-human primate brain slices. J Vis Exp. 2010;2010(41):e2081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156079</ArticleId><ArticleId IdType="pubmed">20644510</ArticleId></ArticleIdList></Reference><Reference><Citation>Misgeld T, Kerschensteiner M, Bareyre FM, Burgess RW, Lichtman JW. Imaging axonal transport of mitochondria in vivo. Nat Methods. 2007;4(7):559&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558414</ArticleId></ArticleIdList></Reference><Reference><Citation>Anglada-Huguet M, et al. Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington&#x2019;s disease. Mol Neurobiol. 2014;49(2):784&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">24198227</ArticleId></ArticleIdList></Reference><Reference><Citation>Curzon P, Rustay NR, Browman KE. 2009. Cued and contextual fear conditioning for rodents. Methods of Behavior Analysis in Neuroscience, Frontiers in Neuroscience, ed Buccafusco JJ (CRC, Boca Raton, FL), 2nd Ed.</Citation><ArticleIdList><ArticleId IdType="pubmed">21204331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27683909</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>39</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.</ArticleTitle><Pagination><StartPage>10141</StartPage><EndPage>10150</EndPage><MedlinePgn>10141-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1054-16.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">Alzheimer's disease (AD) is the most common form of dementia in individuals over the age of 65 years. The most prevalent genetic risk factor for AD is the &#x3b5;4 allele of apolipoprotein E (ApoE4), and novel AD treatments that target ApoE are being considered. One unresolved question in ApoE biology is whether ApoE is necessary for healthy brain function. ApoE knock-out (KO) mice have synaptic loss and cognitive dysfunction; however, these findings are complicated by the fact that ApoE knock-out mice have highly elevated plasma lipid levels, which may independently affect brain function. To bypass the effect of ApoE loss on plasma lipids, we generated a novel mouse model that expresses ApoE normally in peripheral tissues, but has severely reduced ApoE in the brain, allowing us to study brain ApoE loss in the context of a normal plasma lipid profile. We found that these brain ApoE knock-out (bEKO) mice had synaptic loss and dysfunction similar to that of ApoE KO mice; however, the bEKO mice did not have the learning and memory impairment observed in ApoE KO mice. Moreover, we found that the memory deficit in the ApoE KO mice was specific to female mice and was fully rescued in female bEKO mice. Furthermore, while the AMPA/NMDA ratio was reduced in ApoE KO mice, it was unchanged in bEKO mice compared with controls. These findings suggest that plasma lipid levels can influence cognition and synaptic function independent of ApoE expression in the brain.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT">One proposed treatment strategy for Alzheimer's disease (AD) is the reduction of ApoE, whose &#x3b5;4 isoform is the most common genetic risk factor for the disease. A major concern of this strategy is that an animal model of ApoE deficiency, the ApoE knock-out (KO) mouse, has reduced synapses and cognitive impairment; however, these mice also develop dyslipidemia and severe atherosclerosis. Here, we have shown that genetic restoration of plasma ApoE to wild-type levels normalizes plasma lipids in ApoE KO mice. While this does not rescue synaptic loss, it does completely restore learning and memory in the mice, suggesting that both CNS and plasma ApoE are independent parameters that affect brain health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 the authors 0270-6474/16/3610141-10$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane-Donovan</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Joachim.herz@utsouthwestern.edu Courtney.Lane@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Wen Mai</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durakoglugil</LastName><ForeName>Murat S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-4483-8166</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wasser</LastName><ForeName>Catherine R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0001-6396-0146</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xian</LastName><ForeName>Xunde</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-3059-1254</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390, Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, and Center for Neuroscience, Department of Neuroanatomy, Albert-Ludwigs-University, 79085 Freiburg, Germany Joachim.herz@utsouthwestern.edu Courtney.Lane@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS093382</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG047799</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T34 GM008073</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">ApoE4</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27683909</ArticleId><ArticleId IdType="pmc">PMC5039258</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1054-16.2016</ArticleId><ArticleId IdType="pii">36/39/10141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75:563&#x2013;573. doi: 10.1002/ana.24135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24135</ArticleId><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16:343&#x2013;354. doi: 10.1097/01.JGP.0000310778.20870.ae.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.JGP.0000310778.20870.ae</ArticleId><ArticleId IdType="pubmed">18448847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayata C, Shin HK, Dilek&#xf6;z E, Atochin DN, Kashiwagi S, Eikermann-Haerter K, Huang PL. Hyperlipidemia disrupts cerebrovascular reflexes and worsens ischemic perfusion defect. J Cereb Blood Flow Metab. 2013;33:954&#x2013;962. doi: 10.1038/jcbfm.2013.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2013.38</ArticleId><ArticleId IdType="pmc">PMC3677117</ArticleId><ArticleId IdType="pubmed">23486293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992;42:115&#x2013;119. doi: 10.1212/WNL.42.1.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.1.115</ArticleId><ArticleId IdType="pubmed">1734291</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999;843:87&#x2013;94. doi: 10.1016/S0006-8993(99)01894-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(99)01894-6</ArticleId><ArticleId IdType="pubmed">10528114</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5:279&#x2013;291. doi: 10.1016/j.cmet.2007.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2007.02.002</ArticleId><ArticleId IdType="pmc">PMC1913910</ArticleId><ArticleId IdType="pubmed">17403372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485:512&#x2013;516. doi: 10.1038/nature11087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11087</ArticleId><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkhem I, L&#xfc;tjohann D, Diczfalusy U, St&#xe5;hle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 1998;39:1594&#x2013;1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">9717719</ArticleId></ArticleIdList></Reference><Reference><Citation>Caligiuri G, Nicoletti A, Zhou X, T&#xf6;rnberg I, Hansson GK. Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis. 1999;145:301&#x2013;308. doi: 10.1016/S0021-9150(99)00081-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9150(99)00081-7</ArticleId><ArticleId IdType="pubmed">10488957</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011;3:89ra57. doi: 10.1126/scitranslmed.3002156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002156</ArticleId><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A. 2010;107:12011&#x2013;12016. doi: 10.1073/pnas.0914984107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0914984107</ArticleId><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, Banks WA, Morley JE. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology. 2008;149:2628&#x2013;2636. doi: 10.1210/en.2007-1722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2007-1722</ArticleId><ArticleId IdType="pmc">PMC2329289</ArticleId><ArticleId IdType="pubmed">18276751</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman LR, Haley-Zitlin V, Rosenberger DS, Granholm AC. Damaging effects of a high-fat diet to the brain and cognition: a review of proposed mechanisms. Nutr Neurosci. 2014;17:241&#x2013;251. doi: 10.1179/1476830513Y.0000000092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1476830513Y.0000000092</ArticleId><ArticleId IdType="pmc">PMC4074256</ArticleId><ArticleId IdType="pubmed">24192577</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol. 2001;169:13&#x2013;22. doi: 10.1006/exnr.2001.7631.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7631</ArticleId><ArticleId IdType="pubmed">11312553</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37:693&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">8732771</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett. 1995;199:1&#x2013;4. doi: 10.1016/0304-3940(95)12006-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(95)12006-P</ArticleId><ArticleId IdType="pubmed">8584214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon I, Genis I, Grauer E, Sehayek E, Michaelson DM. Biochemical and cognitive studies of apolipoprotein-E-deficient mice. Mol Chem Neuropathol. 1996;28:97&#x2013;103. doi: 10.1007/BF02815210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02815210</ArticleId><ArticleId IdType="pubmed">8871947</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezi-Moghadam A, Thomas KL, Wagner DD. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am J Physiol Cell Physiol. 2007;292:C1256&#x2013;C1262. doi: 10.1152/ajpcell.00563.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00563.2005</ArticleId><ArticleId IdType="pubmed">16870825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamanaka H, Katoh-Fukui Y, Suzuki K, Kobayashi M, Suzuki R, Motegi Y, Nakahara Y, Takeshita A, Kawai M, Ishiguro K, Yokoyama M, Fujita SC. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum Mol Genet. 2000;9:353&#x2013;361. doi: 10.1093/hmg/9.3.353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/9.3.353</ArticleId><ArticleId IdType="pubmed">10655544</ArticleId></ArticleIdList></Reference><Reference><Citation>Heverin M, Maioli S, Pham T, Mateos L, Camporesi E, Ali Z, Winblad B, Cedazo-Minguez A, Bj&#xf6;rkhem I. 27-hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice. Behav Brain Res. 2015;278:356&#x2013;359. doi: 10.1016/j.bbr.2014.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2014.10.018</ArticleId><ArticleId IdType="pubmed">25453744</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrich AJ, Jodelka FM, Chang JL, Brutman D, Bruno AM, Briggs CA, James BD, Stutzmann GE, Bennett DA, Miller SA, Rigo F, Marr RA, Hastings ML. Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides. EMBO Mol Med. 2016;8:328&#x2013;345. doi: 10.15252/emmm.201505846.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201505846</ArticleId><ArticleId IdType="pmc">PMC4818756</ArticleId><ArticleId IdType="pubmed">26902204</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;2897. doi: 10.1073/pnas.050004797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.050004797</ArticleId><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-&#x3b2; amyloidosis. J Neurosci. 2011;31:18007&#x2013;18012. doi: 10.1523/JNEUROSCI.3773-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3773-11.2011</ArticleId><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Herz J. Is apolipoprotein e required for cognitive function in humans? Implications for Alzheimer drug development. JAMA Neurol. 2014;71:1213&#x2013;1215. doi: 10.1001/jamaneurol.2014.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2013</ArticleId><ArticleId IdType="pmc">PMC4354854</ArticleId><ArticleId IdType="pubmed">25110920</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Philips GT, Herz J. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron. 2014;83:771&#x2013;787. doi: 10.1016/j.neuron.2014.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.08.005</ArticleId><ArticleId IdType="pmc">PMC4240629</ArticleId><ArticleId IdType="pubmed">25144875</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM. Anti-ApoE antibody given after plaque onset decreases A&#x3b2; accumulation and improves brain function in a mouse model of A&#x3b2; amyloidosis. J Neurosci. 2014;34:7281&#x2013;7292. doi: 10.1523/JNEUROSCI.0646-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0646-14.2014</ArticleId><ArticleId IdType="pmc">PMC4028501</ArticleId><ArticleId IdType="pubmed">24849360</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Kuhel DG, Shen L, Hui DY, Woods SC. Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol. 2012;303:R903&#x2013;R908. doi: 10.1152/ajpregu.00219.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00219.2012</ArticleId><ArticleId IdType="pmc">PMC3517701</ArticleId><ArticleId IdType="pubmed">22933021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak AC, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz JM, Gugliucci A, Movsesyan I, Ishida BY, Chu C, Poon A, Kim P, Stock EO, Schaefer EJ, Asztalos BF, Castellano JM, Wyss-Coray T, Duncan JL, Miller BL, Kane JP, et al. Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71:1228&#x2013;1236. doi: 10.1001/jamaneurol.2014.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.2011</ArticleId><ArticleId IdType="pmc">PMC4714860</ArticleId><ArticleId IdType="pubmed">25111166</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol. 1995;136:107&#x2013;122. doi: 10.1006/exnr.1995.1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1995.1088</ArticleId><ArticleId IdType="pubmed">7498401</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Samuel W, Veinbergs I, Mallory M, Mante M, Saitoh T. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 1997;751:307&#x2013;314. doi: 10.1016/S0006-8993(96)01420-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(96)01420-5</ArticleId><ArticleId IdType="pubmed">9099820</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357. doi: 10.1126/science.294.5545.1354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.294.5545.1354</ArticleId><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder M, Blokland A, van den Berg DJ, Schulten H, Bakker AH, Terwel D, Honig W, de Kloet ER, Havekes LM, Steinbusch HW, de Lange EC. Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest. 2001;81:953&#x2013;960. doi: 10.1038/labinvest.3780307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3780307</ArticleId><ArticleId IdType="pubmed">11454984</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917:148&#x2013;161. doi: 10.1016/0005-2760(87)90295-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0005-2760(87)90295-5</ArticleId><ArticleId IdType="pubmed">3539206</ArticleId></ArticleIdList></Reference><Reference><Citation>Plump AS, Smith JD, Hayek T, Aalto-Set&#xe4;l&#xe4; K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343&#x2013;353. doi: 10.1016/0092-8674(92)90362-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(92)90362-G</ArticleId><ArticleId IdType="pubmed">1423598</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci U S A. 1998;95:10914&#x2013;10919. doi: 10.1073/pnas.95.18.10914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.18.10914</ArticleId><ArticleId IdType="pmc">PMC27995</ArticleId><ArticleId IdType="pubmed">9724804</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB., Jr Familial apolipoprotein E deficiency. J Clin Invest. 1986;78:1206&#x2013;1219. doi: 10.1172/JCI112704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI112704</ArticleId><ArticleId IdType="pmc">PMC423806</ArticleId><ArticleId IdType="pubmed">3771793</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200&#x2013;1205. doi: 10.1001/archneur.61.8.1200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.8.1200</ArticleId><ArticleId IdType="pubmed">15313836</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea TB, Rogers E, Ashline D, Ortiz D, Sheu MS. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic Biol Med. 2002;33:1115&#x2013;1120. doi: 10.1016/S0891-5849(02)01001-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(02)01001-8</ArticleId><ArticleId IdType="pubmed">12374623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, Pearlstein RD, Roses AD, Warner DS. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab. 1998;18:361&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">9538900</ArticleId></ArticleIdList></Reference><Reference><Citation>Slooter AJ, de Knijff P, Hofman A, Cruts M, Breteler MM, Van Broeckhoven C, Havekes LM, van Duijn CM. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett. 1998;248:21&#x2013;24. doi: 10.1016/S0304-3940(98)00339-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(98)00339-5</ArticleId><ArticleId IdType="pubmed">9665654</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol. 1997;143:313&#x2013;318. doi: 10.1006/exnr.1996.6360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1996.6360</ArticleId><ArticleId IdType="pubmed">9056393</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukas S, Robert J, Lee M, Kulic I, Carr M, Tourigny K, Fan J, Namjoshi D, Lemke K, DeValle N, Chan J, Wilson T, Wilkinson A, Chapanian R, Kizhakkedathu JN, Cirrito JR, Oda MN, Wellington CL. Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J Am Heart Assoc. 2014;3:e001156. doi: 10.1161/JAHA.114.001156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.114.001156</ArticleId><ArticleId IdType="pmc">PMC4338702</ArticleId><ArticleId IdType="pubmed">25392541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972&#x2013;17980. doi: 10.1074/jbc.272.29.17972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.29.17972</ArticleId><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Veinbergs I, Masliah E. Synaptic alterations in apolipoprotein E knockout mice. Neuroscience. 1999;91:401&#x2013;403. doi: 10.1016/S0306-4522(98)00602-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(98)00602-2</ArticleId><ArticleId IdType="pubmed">10336088</ArticleId></ArticleIdList></Reference><Reference><Citation>Veinbergs I, Mallory M, Sagara Y, Masliah E. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. Eur J Neurosci. 2000;12:4541&#x2013;4546. doi: 10.1111/j.1460-9568.2000.01308.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2000.01308.x</ArticleId><ArticleId IdType="pubmed">11122365</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110:E1807&#x2013;E1816. doi: 10.1073/pnas.1220484110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1220484110</ArticleId><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar&#xf3; S, Camps L, Reina M, Perez-Clausell J, Llobera M, Olivecrona T. Localization of lipoprotein lipase to discrete areas of the guinea pig brain. Brain Res. 1990;506:249&#x2013;253. doi: 10.1016/0006-8993(90)91258-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(90)91258-I</ArticleId><ArticleId IdType="pubmed">2302565</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Eckel RH. Lipoprotein lipase in the brain and nervous system. Annu Rev Nutr. 2012;32:147&#x2013;160. doi: 10.1146/annurev-nutr-071811-150703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-nutr-071811-150703</ArticleId><ArticleId IdType="pmc">PMC4065112</ArticleId><ArticleId IdType="pubmed">22540257</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Walker D, Bernardo A, Brodbeck J, Balestra ME, Huang Y. Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J Neurosci. 2008;28:1452&#x2013;1459. doi: 10.1523/JNEUROSCI.3253-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3253-07.2008</ArticleId><ArticleId IdType="pmc">PMC6671590</ArticleId><ArticleId IdType="pubmed">18256266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbi V, Wiesmann M, Emmerzaal TL, Jansen D, Van Beek M, Mutsaers MP, Beckmann CF, Heerschap A, Kiliaan AJ. Resting-state functional connectivity changes in aging apoE4 and apoE-KO mice. J Neurosci. 2014;34:13963&#x2013;13975. doi: 10.1523/JNEUROSCI.0684-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0684-14.2014</ArticleId><ArticleId IdType="pmc">PMC6705289</ArticleId><ArticleId IdType="pubmed">25319693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468&#x2013;471. doi: 10.1126/science.1411543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1411543</ArticleId><ArticleId IdType="pubmed">1411543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27708076</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>353</Volume><Issue>6307</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Pathological &#x3b1;-synuclein transmission initiated by binding lymphocyte-activation gene 3.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">aah3374</ELocationID><Abstract><AbstractText>Emerging evidence indicates that the pathogenesis of Parkinson's disease (PD) may be due to cell-to-cell transmission of misfolded preformed fibrils (PFF) of &#x3b1;-synuclein (&#x3b1;-syn). The mechanism by which &#x3b1;-syn PFF spreads from neuron to neuron is not known. Here, we show that LAG3 (lymphocyte-activation gene 3) binds &#x3b1;-syn PFF with high affinity (dissociation constant = 77 nanomolar), whereas the &#x3b1;-syn monomer exhibited minimal binding. &#x3b1;-Syn-biotin PFF binding to LAG3 initiated &#x3b1;-syn PFF endocytosis, transmission, and toxicity. Lack of LAG3 substantially delayed &#x3b1;-syn PFF-induced loss of dopamine neurons, as well as biochemical and behavioral deficits in vivo. The identification of LAG3 as a receptor that binds &#x3b1;-syn PFF provides a target for developing therapeutics designed to slow the progression of PD and related &#x3b1;-synucleinopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xiaobo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Michael Tianhao</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karuppagounder</LastName><ForeName>Senthilkumar S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kam</LastName><ForeName>Tae-In</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Xiling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yulan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Preston</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umanah</LastName><ForeName>George Essien</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brahmachari</LastName><ForeName>Saurav</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Joo-Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Division of Pharmacology, Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute, Suwon 440-746, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ho Chul</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Physiology, Ajou University School of Medicine, Suwon 443-721, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jianmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jinchong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyejin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrabi</LastName><ForeName>Shaida A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Sung Ung</ForeName><Initials>SU</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gon&#xe7;alves</LastName><ForeName>Rafaella Ara&#xfa;jo</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Xin Hua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keiler</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyson</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Johns Hopkins Institute for NanoBio Technology, Johns Hopkins University, Baltimore, MD 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Donghoon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panicker</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Seung Pil</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Workman</LastName><ForeName>Creg J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vignali</LastName><ForeName>Dario A A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA. Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Valina L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA. Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. tdawson@jhmi.edu hko3@jhmi.edu vdawson1@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Han Seok</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA. tdawson@jhmi.edu hko3@jhmi.edu vdawson1@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Johns Hopkins Institute for NanoBio Technology, Johns Hopkins University, Baltimore, MD 21218, USA. Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. tdawson@jhmi.edu hko3@jhmi.edu vdawson1@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG046366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI108545</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082205</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000093322">Lymphocyte Activation Gene 3 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2016 Sep 30;353(6307):1498-1499. doi: 10.1126/science.aai9377.</RefSource><PMID Version="1">27708090</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093322" MajorTopicYN="N">Lymphocyte Activation Gene 3 Protein</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27708076</ArticleId><ArticleId IdType="mid">NIHMS874255</ArticleId><ArticleId IdType="pmc">PMC5510615</ArticleId><ArticleId IdType="doi">10.1126/science.aah3374</ArticleId><ArticleId IdType="pii">353/6307/aah3374</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goedert M. Alpha-synuclein and neurodegenerative diseases. Nature reviews. Neuroscience. 2001;2:492&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">11433374</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature reviews. Neurology. 2013;9:13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006;52:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, Vila M, Bezard E, Brundin P, Kordower JH. Alpha-synuclein propagation: New insights from animal models. Mov Disord. 2016;31:161&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">26347034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Desplats P, Lee HJ, Spencer B, Masliah E. Cell-to-cell transmission of alpha-synuclein aggregates. Methods Mol Biol. 2012;849:347&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940116</ArticleId><ArticleId IdType="pubmed">22528101</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson T, Steiner JA, Brundin P. Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. Journal of neurochemistry. 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958606</ArticleId><ArticleId IdType="pubmed">26617280</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging. 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Tredici K, Braak H. Review: Sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol. 2016;42:33&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26662475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine. 2008;14:504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine. 2008;14:501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci. 2015;38:87&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4803040</ArticleId><ArticleId IdType="pubmed">25840008</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Gedalya T, et al. Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic. 2009;10:218&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694501</ArticleId><ArticleId IdType="pubmed">18980610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, et al. alpha-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death. Journal of Neurochemistry. 2011;119:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">21883224</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SH, et al. Mesenchymal Stem Cells Inhibit Transmission of alpha-Synuclein by Modulating Clathrin-Mediated Endocytosis in a Parkinsonian Model. Cell Reports. 2016;14:835&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">26776513</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Lee VM. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nature Protocols. 2014;9:2135&#x2013;2146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372899</ArticleId><ArticleId IdType="pubmed">25122523</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HJ, Flanagan JG. Identification and cloning of ELF-1, a developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases. Cell. 1994;79:157&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HJ, Flanagan JG. Cloning and characterization of RTK ligands using receptor-alkaline phosphatase fusion proteins. Methods Mol Biol. 2001;124:313&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">11100484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MK, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --&gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences, U.S.A. 2002;99:8968&#x2013;8973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC124407</ArticleId><ArticleId IdType="pubmed">12084935</ArticleId></ArticleIdList></Reference><Reference><Citation>Huard B, et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proceedings of the National Academy of Sciences, U.S.A. 1997;94:5744&#x2013;5749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20850</ArticleId><ArticleId IdType="pubmed">9159144</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, Burgess K. Fluorescent indicators for intracellular pH. Chemical Reviews. 2010;110:2709&#x2013;2728.</Citation><ArticleIdList><ArticleId IdType="pubmed">19831417</ArticleId></ArticleIdList></Reference><Reference><Citation>Huotari J, Helenius A. Endosome maturation. The EMBO Journal. 2011;30:3481&#x2013;3500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181477</ArticleId><ArticleId IdType="pubmed">21878991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu FT, et al. EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. The Journal of Biological Chemistry. 1995;270:13503&#x2013;13511.</Citation><ArticleIdList><ArticleId IdType="pubmed">7768953</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha MS, et al. Subcellular fractionation and localization studies reveal a direct interaction of the fragile X mental retardation protein (FMRP) with nucleolin. PloS One. 2014;9:e91465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962360</ArticleId><ArticleId IdType="pubmed">24658146</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova PR, et al. Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity. Journal of Cell Science. 2016;129:1792&#x2013;1801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893653</ArticleId><ArticleId IdType="pubmed">26989132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hettiarachchi NT, et al. alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. Journal of Neurochemistry. 2009;111:1192&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">19860837</ArticleId></ArticleIdList></Reference><Reference><Citation>Melachroinou K, et al. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. Neurobiology of Aging. 2013;34:2853&#x2013;2865.</Citation><ArticleIdList><ArticleId IdType="pubmed">23891486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath S, Goodwin J, Engelborghs Y, Pountney DL. Raised calcium promotes alpha-synuclein aggregate formation. Molecular and Cellular Neurosciences. 2011;46:516&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">21145971</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava AN, et al. alpha-synuclein assemblies sequester neuronal alpha3-Na+/K+-ATPase and impair Na+ gradient. The EMBO Journal. 2015;34:2408&#x2013;2423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4601662</ArticleId><ArticleId IdType="pubmed">26323479</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3) European Journal of Immunology. 2002;32:2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209638</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo SR, et al. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. European Journal of Immunology. 2010;40:1768&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987677</ArticleId><ArticleId IdType="pubmed">20391435</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki T, Dierich A, Benoist C, Mathis D. Independent modes of natural killing distinguished in mice lacking Lag3. Science. 1996;272:405&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">8602528</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209:975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Karuppagounder SS, et al. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Scientific Reports. 2014;4:4874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4007078</ArticleId><ArticleId IdType="pubmed">24786396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nature Communications. 2013;4:1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proceedings of the National Academy of Sciences, U.S.A. 2013;110:E3138&#x2013;3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh GS, et al. Functional requirement for class I MHC in CNS development and plasticity. Science. 2000;290:2155&#x2013;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175035</ArticleId><ArticleId IdType="pubmed">11118151</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatz CJ. MHC class I: an unexpected role in neuronal plasticity. Neuron. 2009;64:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773547</ArticleId><ArticleId IdType="pubmed">19840547</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H. Control of glial immune function by neurons. Glia. 2001;36:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">11596127</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44:989&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4942846</ArticleId><ArticleId IdType="pubmed">27192565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JG, Takahama S, Zhang G, Tomarev SI, Ye Y. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nature Cell Biology. 2016;18:765&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10701763</ArticleId><ArticleId IdType="pubmed">27295555</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VMY. Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles. Journal of Biological Chemistry. 2011;286:15317&#x2013;15331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam TI, et al. FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer's disease. The Journal of Clinical Investigation. 2013;123:2791&#x2013;2802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696552</ArticleId><ArticleId IdType="pubmed">23921129</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker N, et al. Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease. The Journal of Neuroscience. 2015;35:10058&#x2013;10077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495236</ArticleId><ArticleId IdType="pubmed">26157004</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. European Journal of Immunology. 2003;33:970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672063</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrabi SA, et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nature Medicine. 2011;17:692&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709257</ArticleId><ArticleId IdType="pubmed">21602803</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HY, et al. Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease. The Journal of Neuroscience. 2014;34:11744&#x2013;11753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608409</ArticleId><ArticleId IdType="pubmed">25164669</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res. 2010;211:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862121</ArticleId><ArticleId IdType="pubmed">20211655</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27708338</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and Caenorhabditis elegans.</ArticleTitle><Pagination><StartPage>34477</StartPage><MedlinePgn>34477</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">34477</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep34477</ELocationID><Abstract><AbstractText>Misfolded alpha-synuclein (AS) and other neurodegenerative disorder proteins display prion-like transmission of protein aggregation. Factors responsible for the initiation of AS aggregation are unknown. To evaluate the role of amyloid proteins made by the microbiota we exposed aged rats and transgenic C. elegans to E. coli producing the extracellular bacterial amyloid protein curli. Rats exposed to curli-producing bacteria displayed increased neuronal AS deposition in both gut and brain and enhanced microgliosis and astrogliosis compared to rats exposed to either mutant bacteria unable to synthesize curli, or to vehicle alone. Animals exposed to curli producing bacteria also had more expression of TLR2, IL-6 and TNF in the brain than the other two groups. There were no differences among the rat groups in survival, body weight, inflammation in the mouth, retina, kidneys or gut epithelia, and circulating cytokine levels. AS-expressing C. elegans fed on curli-producing bacteria also had enhanced AS aggregation. These results suggest that bacterial amyloid functions as a trigger to initiate AS aggregation through cross-seeding and also primes responses of the innate immune system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shu G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Dept. of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stribinskis</LastName><ForeName>Vilius</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Brown Cancer Center, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rane</LastName><ForeName>Madhavi J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Dept. of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demuth</LastName><ForeName>Donald R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Dept. of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gozal</LastName><ForeName>Evelyne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Dept. of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Dept. of Physiology, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagadapillai</LastName><ForeName>Rekha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept. of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ruolan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept. of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Kyonghwan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dept. of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shivakumar</LastName><ForeName>Bhooma</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dept. of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Francheska</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dept. of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Shunying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept. of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerber</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept. of Epidemiology and Population Health, University of Louisville School of Public Health, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adame</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Experimental Neuropathology, University of California, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Experimental Neuropathology, University of California, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Dept. of Neurology, University of Louisville School of Medicine, Louisville, Kentucky, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029968">Escherichia coli Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497606">Snca protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>148349-72-8</RegistryNumber><NameOfSubstance UI="C077481">Crl protein, Bacteria</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="Y">Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029968" MajorTopicYN="N">Escherichia coli Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011916" MajorTopicYN="N">Rats, Inbred F344</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27708338</ArticleId><ArticleId IdType="pmc">PMC5052651</ArticleId><ArticleId IdType="doi">10.1038/srep34477</ArticleId><ArticleId IdType="pii">srep34477</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walker L. C. &amp; Jucker M. Amyloid by default. Nature neuroscience 14, 669&#x2013;670 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715806</ArticleId><ArticleId IdType="pubmed">21613991</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P. et al.. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 106, 13010&#x2013;13015 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner S. B. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511&#x2013;1513 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3942086</ArticleId><ArticleId IdType="pubmed">22723400</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland R. P. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. Journal of Alzheimer&#x2019;s disease: JAD 45, 349&#x2013;362 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25589730</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C. Transmissible proteins: expanding the prion heresy. Cell 149, 968&#x2013;977 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367461</ArticleId><ArticleId IdType="pubmed">22632966</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H. et al.. Staging of brain pathology related to sporadic Parkinson&#x2019;s disease. Neurobiology of aging 24, 197&#x2013;211 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>van Keulen L. J., Vromans M. E. &amp; van Zijderveld F. G. Early and late pathogenesis of natural scrapie infection in sheep. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica 110, 23&#x2013;32 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12064252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hufnagel D. A., Tukel C. &amp; Chapman M. R. Disease to dirt: the biology of microbial amyloids. PLoS pathogens 9, e1003740 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836715</ArticleId><ArticleId IdType="pubmed">24278013</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen P. et al.. Amyloid adhesins are abundant in natural biofilms. Environ Microbiol 9, 3077&#x2013;3090 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny I. et al.. The formation of Escherichia coli curli amyloid fibrils is mediated by prion-like peptide repeats. Journal of molecular biology 352, 245&#x2013;252 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16083908</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M. L. et al.. The bacterial curli system possesses a potent and selective inhibitor of amyloid formation. Mol Cell 57, 445&#x2013;455 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320674</ArticleId><ArticleId IdType="pubmed">25620560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundmark K., Westermark G. T., Olsen A. &amp; Westermark P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proceedings of the National Academy of Sciences of the United States of America 102, 6098&#x2013;6102 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087940</ArticleId><ArticleId IdType="pubmed">15829582</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A. et al.. Amyloidogenic potential of foie gras. Proceedings of the National Academy of Sciences of the United States of America 104, 10998&#x2013;11001 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1894569</ArticleId><ArticleId IdType="pubmed">17578924</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M. &amp; Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17, 201&#x2013;207 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E. et al.. Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nature medicine 21, 880&#x2013;886 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C. Review: systemic inflammation and Alzheimer&#x2019;s disease. Neuropathology and applied neurobiology 39, 51&#x2013;68 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23046210</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H. et al.. Inflammation and Alzheimer&#x2019;s disease. Neurobiology of aging 21, 383&#x2013;421 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lathrop S. K. et al.. Peripheral education of the immune system by colonic commensal microbiota. Nature 478, 250&#x2013;254 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192908</ArticleId><ArticleId IdType="pubmed">21937990</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukel C. et al.. Toll-like receptors 1 and 2 cooperatively mediate immune responses to curli, a common amyloid from enterobacterial biofilms. Cellular microbiology 12, 1495&#x2013;1505 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869100</ArticleId><ArticleId IdType="pubmed">20497180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C. et al.. Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Rep 13, 771&#x2013;782 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752835</ArticleId><ArticleId IdType="pubmed">26489461</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips R. J., Walter G. C., Ringer B. E., Higgs K. M. &amp; Powley T. L. Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. Experimental neurology 220, 109&#x2013;119 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761519</ArticleId><ArticleId IdType="pubmed">19664623</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker P. J., Dixon M. &amp; Roopenian D. C. Genetic control of susceptibility to Porphyromonas gingivalis-induced alveolar bone loss in mice. Infection and immunity 68, 5864&#x2013;5868 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC101548</ArticleId><ArticleId IdType="pubmed">10992496</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ham T. J. et al.. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS genetics 4, e1000027 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265412</ArticleId><ArticleId IdType="pubmed">18369446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman K. et al.. Bacterial curli protein promotes the conversion of PAP248-286 into the amyloid SEVI: cross-seeding of dissimilar amyloid sequences. PeerJ 1, e5 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629062</ArticleId><ArticleId IdType="pubmed">23638387</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J. L. &amp; Lee V. M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. The Journal of biological chemistry 286, 15317&#x2013;15331 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingelhoefer L. &amp; Reichmann H. Pathogenesis of Parkinson disease&#x2013;the gut-brain axis and environmental factors. Nature reviews. Neurology 11, 625&#x2013;636 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26503923</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum-Krammer C. I. &amp; Morimoto R. I. Caenorhabditis elegans as a model system for studying non-cell-autonomous mechanisms in protein-misfolding diseases. Dis Model Mech 7, 31&#x2013;39 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882046</ArticleId><ArticleId IdType="pubmed">24396152</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen Reish H. E. &amp; Standaert D. G. Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis 5, 1&#x2013;19 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405142</ArticleId><ArticleId IdType="pubmed">25588354</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A. et al.. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain: a journal of neurology 139, 891&#x2013;907 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed-Geaghan E. G., Savage J. C., Hise A. G. &amp; Landreth G. E. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. The Journal of neuroscience: the official journal of the Society for Neuroscience 29, 11982&#x2013;11992 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778845</ArticleId><ArticleId IdType="pubmed">19776284</ArticleId></ArticleIdList></Reference><Reference><Citation>Milatovic D., Zaja-Milatovic S., Montine K. S., Shie F. S. &amp; Montine T. J. Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo. Journal of neuroinflammation 1, 20 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC527876</ArticleId><ArticleId IdType="pubmed">15498098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo P. M. et al.. Amyloid-DNA Composites of Bacterial Biofilms Stimulate Autoimmunity. Immunity 42, 1171&#x2013;1184 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4500125</ArticleId><ArticleId IdType="pubmed">26084027</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J. &amp; Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Poehler A. M. et al.. Autophagy modulates SNCA/alpha-synuclein release, thereby generating a hostile microenvironment. Autophagy 10, 2171&#x2013;2192 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502760</ArticleId><ArticleId IdType="pubmed">25484190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chorell E. et al.. Bacterial Chaperones CsgE and CsgC Differentially Modulate Human alpha-Synuclein Amyloid Formation via Transient Contacts. PloS One 10, e0140194 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605646</ArticleId><ArticleId IdType="pubmed">26465894</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. &amp; Karran E. The Cellular Phase of Alzheimer&#x2019;s Disease. Cell 164, 603&#x2013;615 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Yuan P., Schain A. &amp; Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nature communications 6, 6176 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A. et al.. Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiology of aging 38, 56&#x2013;67 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759608</ArticleId><ArticleId IdType="pubmed">26827643</ArticleId></ArticleIdList></Reference><Reference><Citation>Raby A. C. et al.. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol 183, 506&#x2013;517 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19542461</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppong G. O. et al.. Biofilm-associated bacterial amyloids dampen inflammation in the gut: oral treatment with curli fibres reduces the severity of hapten-induced colitis in mice. NPJ Biofilms Microbiomes 1 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739805</ArticleId><ArticleId IdType="pubmed">26855788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilchrist K. B., Garcia M. C., Sobonya R., Lipke P. N. &amp; Klotz S. A. New features of invasive candidiasis in humans: amyloid formation by fungi and deposition of serum amyloid P component by the host. J Infect Dis 206, 1473&#x2013;1478 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570177</ArticleId><ArticleId IdType="pubmed">22802434</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz K. &amp; Boles B. R. Microbial amyloids&#x2013;functions and interactions within the host. Current opinion in microbiology 16, 93&#x2013;99 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622111</ArticleId><ArticleId IdType="pubmed">23313395</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A. Neurodegeneration: Alzheimer&#x2019;s disease under strain. Nature 512, 32&#x2013;34 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25100477</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W. et al.. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340&#x2013;344 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapsinski G. J. et al.. Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infect Immun 83, 693&#x2013;701 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294241</ArticleId><ArticleId IdType="pubmed">25422268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmes P., Heintz-Buschart A. &amp; Bond P. L. A decade of metaproteomics: where we stand and what the future holds. Proteomics 15, 3409&#x2013;3417 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5049639</ArticleId><ArticleId IdType="pubmed">26315987</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter M. R. et al.. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer&#x2019;s disease. Sci Rep. 21, 6:30028 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956742</ArticleId><ArticleId IdType="pubmed">27443609</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach T. et al.. Reduction of Alzheimer&#x2019;s disease beta-amyloid pathology in the absence of gut microbiota arXiv:1509.02273[q-bio.MN] (2015).</Citation></Reference><Reference><Citation>Baker P. J., DuFour L., Dixon M. &amp; Roopenian D. C. Adhesion molecule deficiencies increase Porphyromonas gingivalis-induced alveolar bone loss in mice. Infection and immunity 68, 3103&#x2013;3107 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC97538</ArticleId><ArticleId IdType="pubmed">10816450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu L. J. et al.. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 157, 401&#x2013;10 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850140</ArticleId><ArticleId IdType="pubmed">10934145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu L. J., Jan M. S. &amp; Lin Y. S. In vivo staphylococcal enterotoxin B (SEB)-primed murine splenocytes secrete mediators which suppress CD25(hi) expression and cell cycle progression of naive splenocytes in response to SEB in vitro. Cell Immunol 201, 50&#x2013;57 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10805973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y. et al.. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. The Journal of neuroscience: the official journal of the Society for Neuroscience 26, 13102&#x2013;13113 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674971</ArticleId><ArticleId IdType="pubmed">17167099</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullagh P. Regression Models for Ordinal Data. J. R. Statist. Soc. 42, 109&#x2013;142 (1980).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27720485</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.</ArticleTitle><Pagination><StartPage>407</StartPage><EndPage>418</EndPage><MedlinePgn>407-418</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2016.09.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(16)30581-5</ELocationID><Abstract><AbstractText>Many neurodegenerative proteinopathies share a common pathogenic mechanism: the abnormal accumulation of disease-related proteins. As growing evidence indicates that reducing the steady-state levels of disease-causing proteins mitigates neurodegeneration in animal models, we developed a strategy to screen for genes that decrease the levels of tau, whose accumulation contributes to the pathology of both Alzheimer disease (AD) and progressive supranuclear palsy (PSP). Integrating parallel cell-based and Drosophila genetic screens, we discovered that tau levels are regulated by Nuak1, an AMPK-related kinase. Nuak1 stabilizes tau by phosphorylation specifically at Ser356. Inhibition of Nuak1 in fruit flies suppressed neurodegeneration in tau-expressing Drosophila, and Nuak1 haploinsufficiency rescued the phenotypes of a tauopathy mouse model. These results demonstrate that decreasing total tau levels is a valid strategy for mitigating tau-related neurodegeneration and reveal Nuak1 to be a novel therapeutic entry point for tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lasagna-Reeves</LastName><ForeName>Cristian A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Haro</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeehye</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseaux</LastName><ForeName>Maxime W C</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ramahi</LastName><ForeName>Ismael</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar-Nejad</LastName><ForeName>Paymaan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilanova-Velez</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>See</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Maio</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitschke</LastName><ForeName>Larissa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Neuropathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westbrook</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX 77030, USA; Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jianrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botas</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoghbi</LastName><ForeName>Huda Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA; Program in Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, Houston, TX 77030, USA; Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: hzoghbi@bcm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K22 NS092688</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD083092</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS027699</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS096395</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C470845">NUAK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C571903">NUAK1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="Y">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003213" MajorTopicYN="N">Conditioning, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nuak1</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">tau levels</Keyword><Keyword MajorTopicYN="N">tau phosphorylation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27720485</ArticleId><ArticleId IdType="mid">NIHMS928472</ArticleId><ArticleId IdType="pmc">PMC5745060</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.09.022</ArticleId><ArticleId IdType="pii">S0896-6273(16)30581-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ando K, Maruko-Otake A, Ohtake Y, Hayashishita M, Sekiya M, Iijima KM. Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Abeta42-Induced Tau Toxicity. PLoS genetics. 2016;12:e1005917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4811436</ArticleId><ArticleId IdType="pubmed">27023670</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Buhrlage SJ, Huang HT, Deng X, Zhou W, Wang J, Traynor R, Prescott AR, Alessi DR, Gray NS. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. The Biochemical journal. 2014;457:215&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969223</ArticleId><ArticleId IdType="pubmed">24171924</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM. The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Molecular biology of the cell. 1999;10:727&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25198</ArticleId><ArticleId IdType="pubmed">10069814</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, Mandelkow EM. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Molecular biology of the cell. 2002;13:4013&#x2013;4028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC133611</ArticleId><ArticleId IdType="pubmed">12429843</ArticleId></ArticleIdList></Reference><Reference><Citation>Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain research Brain research reviews. 2000;33:95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C, Moore R, Calley J, Ramachandran D, Poidinger M, et al. An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. The Journal of biological chemistry. 2013;288:23331&#x2013;23347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743503</ArticleId><ArticleId IdType="pubmed">23798682</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annual review of biochemistry. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, Li D, Payami H, Awert F, Markopoulou K, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:13103&#x2013;13107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC23724</ArticleId><ArticleId IdType="pubmed">9789048</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Bliss TV, Dutrieux G, Laroche S, Errington ML. Induction and duration of long-term potentiation in the hippocampus of the freely moving mouse. Journal of neuroscience methods. 1997;75:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9262147</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. The Journal of clinical investigation. 2007;117:648&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1794119</ArticleId><ArticleId IdType="pubmed">17304350</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, et al. Akt and CHIP coregulate tau degradation through coordinated interactions. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:3622&#x2013;3627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265134</ArticleId><ArticleId IdType="pubmed">18292230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao S, Tang B, Wu Z, Ure K, Sun Y, Tao H, Gao Y, Patel AJ, Curry DJ, Samaco RC, et al. Forniceal deep brain stimulation rescues hippocampal memory in Rett syndrome mice. Nature. 2015;526:430&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828032</ArticleId><ArticleId IdType="pubmed">26469053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL. RNA interference improves motor and neuropathological abnormalities in a Huntington&#x2019;s disease mouse model. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:5820&#x2013;5825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556303</ArticleId><ArticleId IdType="pubmed">15811941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MW, Errington ML, French PJ, Fine A, Bliss TV, Garel S, Charnay P, Bozon B, Laroche S, Davis S. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nature neuroscience. 2001;4:289&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009;29:9078&#x2013;9089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849615</ArticleId><ArticleId IdType="pubmed">19605645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron. 2013;78:94&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784324</ArticleId><ArticleId IdType="pubmed">23583109</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450156</ArticleId></ArticleIdList></Reference><Reference><Citation>Malleret G, Haditsch U, Genoux D, Jones MW, Bliss TV, Vanhoose AM, Weitlauf C, Kandel ER, Winder DG, Mansuy IM. Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell. 2001;104:675&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">11257222</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Kaspar BK, Kops GJ, Yamanaka K, Christian LJ, Gage FH, Cleveland DW. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Annals of neurology. 2005;57:773&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1351126</ArticleId><ArticleId IdType="pubmed">15852369</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70:410&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004;116:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006350</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science. 2004;303:1800&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pubmed">15031492</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. Journal of neuroscience research. 1994;39:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Al-Ramahi I, Tan Q, Mollema N, Diaz-Garcia JR, Gallego-Flores T, Lu HC, Lagalwar S, Duvick L, Kang H, et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature. 2013;498:325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4020154</ArticleId><ArticleId IdType="pubmed">23719381</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press; 2001.</Citation></Reference><Reference><Citation>Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human molecular genetics. 2004;13:703&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickhardt M, von Bergen M, Gazova Z, Hascher A, Biernat J, Mandelkow EM, Mandelkow E. Screening for inhibitors of tau polymerization. Current Alzheimer research. 2005;2:219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">15974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative disorders. Human molecular genetics. 2006;15(Spec No 2):R188&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987883</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovelet-Lecrux A, Campion D. Copy number variations involving the microtubule-associated protein tau in human diseases. Biochemical Society transactions. 2012;40:672&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">22817714</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer&#x2019;s disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Gao L, Chien HY, Li WC, Zhao J. The regulation and function of the NUAK family. Journal of molecular endocrinology. 2013;51:R15&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23873311</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Miyamoto S, Ogura T, Ochiai A, Esumi H. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene. 2004;23:7067&#x2013;7075.</Citation><ArticleIdList><ArticleId IdType="pubmed">15273717</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki A, Ogura T, Esumi H. NDR2 acts as the upstream kinase of ARK5 during insulin-like growth factor-1 signaling. The Journal of biological chemistry. 2006;281:13915&#x2013;13921.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488889</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25&#x2013;35) enhances phosphorylation of tau in hippocampal neurons. Neuroscience research. 1998;31:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809590</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi H, Iba M, Inoue H, Higuchi M, Takao K, Tsukita K, Karatsu Y, Iwamoto Y, Miyakawa T, Suhara T, et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PloS one. 2011;6:e21050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115982</ArticleId><ArticleId IdType="pubmed">21698260</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J, Dani JA. Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine. Neuron. 2009;63:673&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746116</ArticleId><ArticleId IdType="pubmed">19755109</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer&#x2019;s disease and other tauopathies. Acta neuropathologica. 2011;121:337&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060560</ArticleId><ArticleId IdType="pubmed">20957377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mandelkow E. Tau in physiology and pathology. Nature reviews Neuroscience. 2016;17:22&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, Leng Y, Maehr R, Shi Y, Harper JW, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature. 2008;452:370&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688689</ArticleId><ArticleId IdType="pubmed">18354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science. 2006;313:1093&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends in neurosciences. 2008;31:521&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2580745</ArticleId><ArticleId IdType="pubmed">18778858</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nature medicine. 2004;10:816&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">15235598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H, Goedert M. Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. Journal of neurochemistry. 2012;120:165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">21985311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou F, Chai HS, Younkin CS, Allen M, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS genetics. 2012;8:e1002707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369937</ArticleId><ArticleId IdType="pubmed">22685416</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2004;24:8853&#x2013;8861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729947</ArticleId><ArticleId IdType="pubmed">15470152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27723745</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons.</ArticleTitle><Pagination><StartPage>1610</StartPage><EndPage>1618</EndPage><MedlinePgn>1610-1618</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4407</ELocationID><Abstract><AbstractText>Intronic hexanucleotide expansions in C9ORF72 are common in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, but it is unknown whether loss of function, toxicity by the expanded RNA or dipeptides from non-ATG-initiated translation are responsible for the pathophysiology. We determined the interactome of C9ORF72 in motor neurons and found that C9ORF72 was present in a complex with cofilin and other actin binding proteins. Phosphorylation of cofilin was enhanced in C9ORF72-depleted motor neurons, in patient-derived lymphoblastoid cells, induced pluripotent stem cell-derived motor neurons and post-mortem brain samples from ALS patients. C9ORF72 modulates the activity of the small GTPases Arf6 and Rac1, resulting in enhanced activity of LIM-kinases 1 and 2 (LIMK1/2). This results in reduced axonal actin dynamics in C9ORF72-depleted motor neurons. Dominant negative Arf6 rescues this defect, suggesting that C9ORF72 acts as a modulator of small GTPases in a pathway that regulates axonal actin dynamics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sivadasan</LastName><ForeName>Rajeeve</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital of Wuerzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornburg</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drepper</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7883-6479</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital of Wuerzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital of Wuerzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jablonka</LastName><ForeName>Sibylle</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital of Wuerzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansel</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital of Wuerzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lojewski</LastName><ForeName>Xenia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sterneckert</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Regenerative Therapies Dresden (CRTD), Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Regenerative Therapies Dresden (CRTD), Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ince</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Felix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1000-7989</Identifier><AffiliationInfo><Affiliation>Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sendtner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4737-2974</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, University Hospital of Wuerzburg, Wuerzburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/M010864/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051339">Actin Depolymerizing Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606498">C9orf72 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020662">Guanine Nucleotide Exchange Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051339" MajorTopicYN="N">Actin Depolymerizing Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020662" MajorTopicYN="N">Guanine Nucleotide Exchange Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008840" MajorTopicYN="N">Microfilament Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27723745</ArticleId><ArticleId IdType="doi">10.1038/nn.4407</ArticleId><ArticleId IdType="pii">nn.4407</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4530-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2013 Nov 27;33(48):18836-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24285890</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e59252</Citation><ArticleIdList><ArticleId IdType="pubmed">23533608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Signal. 2013 Sep;25(9):1813-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23707487</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2013 Mar 7;12 (3):354-67</Citation><ArticleIdList><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2014 Oct;128(4):485-503</Citation><ArticleIdList><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1999 Sep;23(1):99-103</Citation><ArticleIdList><ArticleId IdType="pubmed">10471508</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2016 Mar 18;351(6279):1324-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2007;2(8):1896-906</Citation><ArticleIdList><ArticleId IdType="pubmed">17703201</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2014 Dec;13(12):3410-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25193168</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Oct 16;80(2):415-28</Citation><ArticleIdList><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2016 Jul 13;8(347):347ra93</Citation><ArticleIdList><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2013 Mar 15;339(6125):1335-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2014 Mar 13;507(7491):195-200</Citation><ArticleIdList><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2016 Jul;132(1):145-7</Citation><ArticleIdList><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26174443</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Biochem Cell Biol. 2007;39(6):1071-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17188549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2014 Sep;13(9):2513-26</Citation><ArticleIdList><ArticleId IdType="pubmed">24942700</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Dec 20;76(6):1091-107</Citation><ArticleIdList><ArticleId IdType="pubmed">23259946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2000 Aug;20(16):5998-6007</Citation><ArticleIdList><ArticleId IdType="pubmed">10913182</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):245-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2012 Aug 15;21(16):3655-67</Citation><ArticleIdList><ArticleId IdType="pubmed">22641814</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Genet. 2012 Dec 13;3:283</Citation><ArticleIdList><ArticleId IdType="pubmed">23248642</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2010 Jan;5(1):31-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20057379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2012 Apr;11(4):323-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2001 Aug 6;154(3):599-610</Citation><ArticleIdList><ArticleId IdType="pubmed">11481345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2013 Feb 15;29(4):499-503</Citation><ArticleIdList><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 2013 Sep;126(3):401-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2015 May 27;35(21):8359-75</Citation><ArticleIdList><ArticleId IdType="pubmed">26019348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Proteome Res. 2011 Apr 1;10(4):1794-805</Citation><ArticleIdList><ArticleId IdType="pubmed">21254760</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2008 Dec;26(12):1367-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2013 Jul;14(7):405-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23778968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2015 Jan;14(1):120-35</Citation><ArticleIdList><ArticleId IdType="pubmed">25363814</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2002 Jan 7;156(1):125-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11777939</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1995 Jul 21;270(29):17582-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7615564</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1996 Aug;134(4):935-47</Citation><ArticleIdList><ArticleId IdType="pubmed">8769418</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2015 Oct;82:420-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26253605</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1998 May;20(5):847-54</Citation><ArticleIdList><ArticleId IdType="pubmed">9620690</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Proteomics. 2012 Mar;11(3):O111.013698</Citation><ArticleIdList><ArticleId IdType="pubmed">22159718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2015 Sep;78(3):426-38</Citation><ArticleIdList><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2005 Sep;8(9):1169-78</Citation><ArticleIdList><ArticleId IdType="pubmed">16116448</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4968-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 Jun 25;393(6687):809-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9655398</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2013 Aug 7;79(3):416-38</Citation><ArticleIdList><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2013 Apr;16(4):441-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23455608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2012 Jan;11(1):54-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2016 Sep;13(9):731-40</Citation><ArticleIdList><ArticleId IdType="pubmed">27348712</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2016 May 18;4(1):51</Citation><ArticleIdList><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Cells. 1996 Jan;1(1):73-86</Citation><ArticleIdList><ArticleId IdType="pubmed">9078368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2013 Aug;74(2):180-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2016 May 4;90(3):535-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 1995 Aug 17;11(4):701-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7651734</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2008 Nov;9(11):846-59</Citation><ArticleIdList><ArticleId IdType="pubmed">18946474</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Dec 12;8(12):e83450</Citation><ArticleIdList><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2003 Jan 6;160(1):17-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12515821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Biol Cell. 2004 Jan;15(1):111-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14565977</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2014 Apr 15;23(8):2005-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24271013</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Jan 29;11(1):e0148097</Citation><ArticleIdList><ArticleId IdType="pubmed">26824355</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2014 Dec 17;84(6):1213-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2006 Nov 15;158(1):109-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16828166</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2014 Jul 1;23 (13):3579-95</Citation><ArticleIdList><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2008 Jun 12;58(5):749-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18549786</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2007 Oct 8;179(1):139-49</Citation><ArticleIdList><ArticleId IdType="pubmed">17923533</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27723722</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Caspase-2 cleavage of tau reversibly impairs memory.</ArticleTitle><Pagination><StartPage>1268</StartPage><EndPage>1276</EndPage><MedlinePgn>1268-1276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.4199</ELocationID><Abstract><AbstractText>In Alzheimer's disease (AD) and other tauopathies, the tau protein forms fibrils, which are believed to be neurotoxic. However, fibrillar tau has been dissociated from neuron death and network dysfunction, suggesting the involvement of nonfibrillar species. Here we describe a novel pathological process in which caspase-2 cleavage of tau at Asp314 impairs cognitive and synaptic function in animal and cellular models of tauopathies by promoting the missorting of tau to dendritic spines. The truncation product, &#x394;tau314, resists fibrillation and is present at higher levels in brains from cognitively impaired mice and humans with AD. The expression of tau mutants that resisted caspase-2 cleavage prevented tau from infiltrating spines, dislocating glutamate receptors and impairing synaptic function in cultured neurons, and it prevented memory deficits and neurodegeneration in mice. Decreasing the levels of caspase-2 restored long-term memory in mice that had existing deficits. Our results suggest an overall treatment strategy for re-establishing synaptic function and restoring memory in patients with AD by preventing tau from accumulating in dendritic spines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotilinek</LastName><ForeName>Linda A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hlynialuk</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahs</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsden</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleary</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashe</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>N. Bud Grossman Center for Memory Research and Care, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS079374</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS063214</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060172">Morpholinos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017470">Receptors, Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C090208">Casp2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053143">Caspase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2016 Nov 8;22(11):1207-1208. doi: 10.1038/nm.4227.</RefSource><PMID Version="1">27824824</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053143" MajorTopicYN="N">Caspase 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060172" MajorTopicYN="N">Morpholinos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017470" MajorTopicYN="N">Receptors, Glutamate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27723722</ArticleId><ArticleId IdType="doi">10.1038/nm.4199</ArticleId><ArticleId IdType="pii">nm.4199</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Physiol Behav. 2001 Aug;73(5):745-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11566208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Jul 16;285(29):21978-87</Citation><ArticleIdList><ArticleId IdType="pubmed">20466727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Nov 15;22(22):9733-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12427828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1996 Jan;39(1):62-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8572669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Nov 16;25(46):10637-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Sci. 2000 Nov;113 Pt 21:3737-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11034902</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Dev. 1998 May 1;12(9):1304-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9573047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurodegener. 2011 Aug 19;6:59</Citation><ArticleIdList><ArticleId IdType="pubmed">21854568</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2015 Sep 17;34(38):4995-5002</Citation><ArticleIdList><ArticleId IdType="pubmed">25531319</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1995 Jun 1;375(6530):400-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7760933</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Res. 2014 Oct 1;272:181-95</Citation><ArticleIdList><ArticleId IdType="pubmed">25004446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2014 Mar 10;211(3):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24534188</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Feb 22;319(5866):1086-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18202255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Mar 1;22(5):1858-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2013 Apr;19(4):473-80</Citation><ArticleIdList><ArticleId IdType="pubmed">23524343</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2010 Jun;223(2):385-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19665462</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Med. 2000;32:361-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21318532</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2013 Apr 15;521(6):1334-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23047530</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Dev. 1994 Jul 15;8(14):1613-26</Citation><ArticleIdList><ArticleId IdType="pubmed">7958843</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10032-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12888622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2007 Sep;8(9):663-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2009 Mar;32(3):150-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19162340</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1995 Aug;15(2):427-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7646894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2005 Feb;64(2):104-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15751224</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Nov 9;338(6108):818-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23042294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2015 Apr;22(4):526-39</Citation><ArticleIdList><ArticleId IdType="pubmed">25526085</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Sep 8;30(36):11938-50</Citation><ArticleIdList><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Alzheimers Dis. 2012;2012:731063</Citation><ArticleIdList><ArticleId IdType="pubmed">22988541</ArticleId></ArticleIdList></Reference><Reference><Citation>Autophagy. 2014 Jun;10 (6):1054-70</Citation><ArticleIdList><ArticleId IdType="pubmed">24879153</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2014 Apr;39(7):1214-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24713000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2010 Aug 6;142(3):387-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Mar 16;440(7082):352-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Feb 1;53(3):337-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2000 Aug;75(2):624-33</Citation><ArticleIdList><ArticleId IdType="pubmed">10899937</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Jul 15;309(5733):476-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2013;4:1939</Citation><ArticleIdList><ArticleId IdType="pubmed">23748737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2013 Jun;12(6):609-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2014 Jan;42(Database issue):D503-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24157837</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Apr 22;464(7292):1201-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2015 Mar 4;85(5):959-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2010 Aug;38(4):955-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20658984</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2010 Dec 22;68(6):1067-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2014 Nov;20(11):1254-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25326800</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27643430</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Multimodal population brain imaging in the UK Biobank prospective epidemiological study.</ArticleTitle><Pagination><StartPage>1523</StartPage><EndPage>1536</EndPage><MedlinePgn>1523-1536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.4393</ELocationID><Abstract><AbstractText>Medical imaging has enormous potential for early disease prediction, but is impeded by the difficulty and expense of acquiring data sets before symptom onset. UK Biobank aims to address this problem directly by acquiring high-quality, consistently acquired imaging data from 100,000 predominantly healthy participants, with health outcomes being tracked over the coming decades. The brain imaging includes structural, diffusion and functional modalities. Along with body and cardiac imaging, genetics, lifestyle measures, biological phenotyping and health records, this imaging is expected to enable discovery of imaging markers of a broad range of diseases at their earliest stages, as well as provide unique insight into disease mechanisms. We describe UK Biobank brain imaging and present results derived from the first 5,000 participants' data release. Although this covers just 5% of the ultimate cohort, it has already yielded a rich range of associations between brain imaging and other measures collected by UK Biobank.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Karla L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaro-Almagro</LastName><ForeName>Fidel</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bangerter</LastName><ForeName>Neal K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Department of Electrical Engineering, Brigham Young University, Provo, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yacoub</LastName><ForeName>Essa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Junqian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8438-2066</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartsch</LastName><ForeName>Andreas J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neuroradiology, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jbabdi</LastName><ForeName>Saad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotiropoulos</LastName><ForeName>Stamatios N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Jesper L R</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffanti</LastName><ForeName>Ludovica</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douaud</LastName><ForeName>Gwena&#xeb;lle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okell</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><Identifier Source="ORCID">0000-0001-8258-0659</Identifier><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weale</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Siemens Healthcare UK, Frimley, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragonu</LastName><ForeName>Iulius</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Siemens Healthcare UK, Frimley, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garratt</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Biobank, Stockport, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UK Biobank, Stockport, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Rory</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>UK Biobank, Stockport, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkinson</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-8166-069X</Identifier><AffiliationInfo><Affiliation>Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_12027</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>202788/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M024903/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L009013/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K006673/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_15067</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="Y">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="Y">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="Y">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>PW and ID are employees of Siemens Healthcare UK, the vendor of MRI scanners for UK Biobank selected under a competitive bidding process. Other authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27643430</ArticleId><ArticleId IdType="mid">EMS69790</ArticleId><ArticleId IdType="pmc">PMC5086094</ArticleId><ArticleId IdType="doi">10.1038/nn.4393</ArticleId><ArticleId IdType="pii">nn.4393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Filippini N, et al. Distinct patterns of brain activity in young carriers of the APOE-e4 allele. Proc National Academy of Sciences USA. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, et al. Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer&#x2019;s Disease. Journal of Neuroscience. 2013;33:2147&#x2013;2155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6571077</ArticleId><ArticleId IdType="pubmed">23365250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Medicine. 2015;12:e1001779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen N, et al. UK Biobank: Current status and what it means for epidemiology. Health Policy and Technology. 2012;1:123&#x2013;126.</Citation></Reference><Reference><Citation>Wick J. Understanding frailty in the geriatric population. Consult Pharm. 2011;26:634&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">21896470</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanek K, et al. Obesity is associated with reduced white matter integrity in otherwise healthy adults. Obesity. 2011;19:500&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">21183934</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen S, et al. Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank - rationale, challenges and approaches. J Cardio Magn Reson. 2013;15:46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668194</ArticleId><ArticleId IdType="pubmed">23714095</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC, et al. The WU-Minn Human Connectome Project: An overview. NeuroImage. 2013;80:62&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3724347</ArticleId><ArticleId IdType="pubmed">23684880</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. NeuroImage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Karas G, et al. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. NeuroImage. 2003;18:895&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">12725765</ArticleId></ArticleIdList></Reference><Reference><Citation>Debette S, Markus H. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. British Medical Journal. 2010;341:c3666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910261</ArticleId><ArticleId IdType="pubmed">20660506</ArticleId></ArticleIdList></Reference><Reference><Citation>Haacke EM, Xu Y, Cheng Y-CN, Reichenbach J. Susceptibility weighted imaging (SWI) Magn Reson Med. 2004;52:612&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">15334582</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyn JH. MR susceptibility imaging. J Magn Reson. 2013;229:198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3602381</ArticleId><ArticleId IdType="pubmed">23273840</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu C. The basis of anisotropic water diffusion in the nervous system - a technical review. NMR Biomed. 2002;15:435&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489094</ArticleId></ArticleIdList></Reference><Reference><Citation>Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B. 1994;103:247&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8019776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Schneider T, Wheeler-Kingshott C, Alexander D. NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain. NeuroImage. 2012;61:1000&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">22484410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jbabdi S, Sotiropoulos S, Savio A, Grana M, Behrens T. Model-based analysis of multishell diffusion MR data for tractography: How to get over fitting problems. Magn Reson Med. 2012;68:1846&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3359399</ArticleId><ArticleId IdType="pubmed">22334356</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot M, et al. Improving alignment in Tract-based spatial statistics: Evaluation and optimization of image registration. NeuroImage. 2013;76:400&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588540</ArticleId><ArticleId IdType="pubmed">23523807</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakana S, et al. Reproducibility of quantitative tractography methods applied to cerebral white matter. NeuroImage. 2007;36:630&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2350213</ArticleId><ArticleId IdType="pubmed">17481925</ArticleId></ArticleIdList></Reference><Reference><Citation>Logothetis NK. What we can do and what we cannot do with fMRI. Nature. 2008;453:869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">18548064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri A, Tessitore A, Mattay V, Fera F, Weinberger D. The amygdala response to emotional stimuli: a comparison of faces and scenes. NeuroImage. 2002;17:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482086</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S, et al. Functional connectomics from resting-state fMRI. Trends in Cognitive Sciences. 2013;17:666&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004765</ArticleId><ArticleId IdType="pubmed">24238796</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, et al. DTI measures in crossing-fibre areas: Increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease. NeuroImage. 2011;55:880&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116583</ArticleId><ArticleId IdType="pubmed">21182970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennis D, Kindlmann G. Orthogonal tensor invariants and the analysis of diffusion tensor magnetic resonance images. Magn Reson Med. 2006;55:136&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16342267</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, et al. A default mode of brain function. Proc Natl Acad Sci. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterthwaite T, et al. An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. NeuroImage. 2013;64:240&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811142</ArticleId><ArticleId IdType="pubmed">22926292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznetsova K, et al. Brain white matter structure and information processing speed in healthy older age. Brain Structure and Function. 2015:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920858</ArticleId><ArticleId IdType="pubmed">26254904</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden DJ, et al. Diffusion Tensor Imaging of Cerebral White Matter Integrity in Cognitive Aging. Biochim Biophys Acta. 2012;1822:386&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241892</ArticleId><ArticleId IdType="pubmed">21871957</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Werf Y, et al. Thalamic volume predicts performance on tests of cognitive speed and decreases in healthy aging. A magnetic resonance imaging-based volumetric analysis. Cognitive Brain Research. 2001;11:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">11339987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell A, Walhovd KB. Structural Brain Changes in Aging: Courses, Causes and Cognitive Consequences. Reviews in the Neurosciences. 2010;21:187&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879692</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichle E, Carpenter P, Just M. The Neural Bases of Strategy and Skill in Sentence&#x2013;Picture Verification. Cognitive Psychology. 2000;40:261&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotelling H. Relations between two sets of variates. Biometrika. 1936;28:321&#x2013;377.</Citation></Reference><Reference><Citation>Hyv&#xe4;rinen A. Fast and robust fixed-point algorithms for independent component analysis. IEEE Transactions on Neural Networks. 1999;10:626&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">18252563</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S, et al. A positive-negative mode of population co-variation links brain connectivity, demographics and behavior. Nature Neuroscience. 2015;18:1565&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625579</ArticleId><ArticleId IdType="pubmed">26414616</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Correspondence of the brain's functional architecture during activation and rest. Proc Natl Acad Sci. 2009;106:13040&#x2013;13045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722273</ArticleId><ArticleId IdType="pubmed">19620724</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Browner W, Cauley J, Launer L, Harris T. Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc. 1999;47:1176&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pubmed">10522949</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A, et al. Bone mineral density and the risk of Alzheimer disease. Arch Neurol. 2005;62:107&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirpamer L, et al. Determinants of iron accumulation in the normal aging brain. Neurobiol Aging. 2016;43:149&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">27255824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biological Psychiatry. 2004;55:563&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013824</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Esposito M, Deouell LY, Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nature Reviews Neuroscience. 2003;4:863&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk R. Practical significance: A concept whose time has come. Educ Psychol Meas. 1996;56:746&#x2013;759.</Citation></Reference><Reference><Citation>Gage S, Smith G, Ware J, Flint J, Munafo M. G = E: What GWAS Can Tell Us about the Environment. PLoS Genetics. 2016;12:e1005765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750859</ArticleId><ArticleId IdType="pubmed">26866486</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson E. The Interpretation of Interaction in Contingency Tables. J Roy Stat Soc Ser B. 1951;13:238&#x2013;241.</Citation></Reference><Reference><Citation>Swanson J. The UK Biobank and selection bias. The Lancet. 2012;380:110.</Citation><ArticleIdList><ArticleId IdType="pubmed">22794246</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkson J. Limitations of the Application of Fourfold Table Analysis to Hospital Data. Biometrics Bulletin. 1946;2:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21001024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J. Causality: Models, Reasoning and Inference. Cambridge University Press; 2009.</Citation></Reference><Reference><Citation>Duff E, et al. Learning to identify CNS drug action and efficacy using multistudy fMRI data. Sci Transl Med. 2015;7:274ra216.</Citation><ArticleIdList><ArticleId IdType="pubmed">25673761</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel T, et al. Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders. Am J Psychiatry. 2010;167:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">20595427</ArticleId></ArticleIdList></Reference><Reference><Citation>Schram M, et al. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. Eur J Epidemiol. 2014;29:439&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">24756374</ArticleId></ArticleIdList></Reference><Reference><Citation>German National Cohort (GNC) Consortium. The German National Cohort: aims, study design and organization. Eur J Epidemiol. 2014;29:371&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050302</ArticleId><ArticleId IdType="pubmed">24840228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Beckmann CF, Behrens T, Woolrich M, Smith S. FSL. NeuroImage. 2012;62:782&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">21979382</ArticleId></ArticleIdList></Reference><Reference><Citation>Daducci A, et al. Accelerated microstructure imaging via convex optimization (AMICO) from diffusion MRI data. NeuroImage. 2015;105:32&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25462697</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser M, et al. The minimal preprocessing pipelines for the Human Connectome Project. NeuroImage. 2013;80:105&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720813</ArticleId><ArticleId IdType="pubmed">23668970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennes M, et al. Optimizing full-brain coverage in human brain MRI through population distributions of brain size. NeuroImage. 2014;98:513.</Citation><ArticleIdList><ArticleId IdType="pubmed">24747737</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson J, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. NeuroImage. 2003;20:870&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugurbil K, et al. Pushing spatial and temporal resolution for functional and diffusion MRI in the Human Connectome Project. NeuroImage. 2013;80:80&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740184</ArticleId><ArticleId IdType="pubmed">23702417</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkman DJ, et al. Use of multicoil arrays for separation of signal from multiple slices simultaneously excited. JMRI. 2001;13:313&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">11169840</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeller S, et al. Multiband multislice GE-EPI at 7 tesla, with 16-fold acceleration using partial parallel imaging with application to high spatial and temporal whole-brain fMRI. Magn Reson Med. 2010;63:1144&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906244</ArticleId><ArticleId IdType="pubmed">20432285</ArticleId></ArticleIdList></Reference><Reference><Citation>Setsompop K, et al. Blipped-controlled aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced g-factor penalty. Magn Reson Med. 2012;67:1210&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323676</ArticleId><ArticleId IdType="pubmed">21858868</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg D, et al. Multiplexed Echo Planar Imaging for Sub-Second Whole Brain FMRI and Fast Diffusion Imaging. 2010;5:e15710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004955</ArticleId><ArticleId IdType="pubmed">21187930</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson M, Bannister PR, Brady M, Smith S. Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain. NeuroImage. 2002</Citation><ArticleIdList><ArticleId IdType="pubmed">12377157</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson J, Jenkinson M, Smith S. Technical report: Non-linear registration aka spatial normalisation. FMRIB Centre, Oxford University; Oxford, UK: 2007.</Citation></Reference><Reference><Citation>Zhang Y, Brady M, Smith S. Segmentation of Brain MR Images through a Hidden Markov Random Field Model and the Expectation Maximization Algorithm. IEEE Trans on Medical Imaging. 2001;20:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293691</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Longitudinal and Cross-Sectional Analysis of Atrophy in Alzheimer's Disease: Cross-Validation of BSI, SIENA and SIENAX. NeuroImage. 2007;36:1200&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17537648</ArticleId></ArticleIdList></Reference><Reference><Citation>Patenaude B, Smith S, Kennedy D, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. NeuroImage. 2011;56:907&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mugler J. Optimized Three-Dimensional Fast-Spin-Echo MRI. J Magn Reson Imag. 2014;39:745&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">24399498</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson JL, Sotiropoulos SN. Non-parametric representation and prediction of single- and multi-shell diffusion-weighted MRI data using Gaussian processes. NeuroImage. 2016 In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627362</ArticleId><ArticleId IdType="pubmed">26236030</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson JL, Sotiropoulos SN. An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. NeuroImage. 2016;125:1063&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692656</ArticleId><ArticleId IdType="pubmed">26481672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez M, et al. Accelerating Fibre Orientation Estimation from Diffusion Weighted Magnetic Resonance Imaging Using GPUs. PLoS ONE. 2013;8:e61892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643787</ArticleId><ArticleId IdType="pubmed">23658616</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. NeuroImage. 2006;31:1487&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakana S, Jiang H, Nagae-Poetscher L, van Zijl PCM, Mori S. Fiber tract-based atlas of human white matter anatomy. Radiology. 2004;230:77&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannister PR, Brady JM, Jenkinson M. Integrating Temporal Information with a Non-rigid Method of Motion Correction for Functional Magnetic Resonance Images. Image and Vision Computing. 2007;25:311&#x2013;320.</Citation></Reference><Reference><Citation>Barch D, et al. Function in the Human Connectome: Task-fMRI and individual differences in behavior. NeuroImage. 2013;80:169&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011498</ArticleId><ArticleId IdType="pubmed">23684877</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolrich MW, Ripley BD, Brady JM, Smith SM. Temporal Autocorrelation in Univariate Linear Modelling of FMRI Data. NeuroImage. 2001;14:1370&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11707093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckmann CF, Smith SM. Probabilistic Independent Component Analysis for Functional Magnetic Resonance Imaging. IEEE Trans on Medical Imaging. 2004;23:137&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">14964560</ArticleId></ArticleIdList></Reference><Reference><Citation>Salimi-Khorshidi G, et al. Automatic denoising of functional MRI data: Combining independent component analysis and hierarchical fusion of classifiers. NeuroImage. 2014;90:449&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019210</ArticleId><ArticleId IdType="pubmed">24389422</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S, Hyvarinen A, Varoquaux G, Miller K, Beckmann C. Group-PCA for very large fMRI datasets. NeuroImage. 2014;101:738&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4289914</ArticleId><ArticleId IdType="pubmed">25094018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiviniemi V, Kantola J-H, Jauhiainen J, Hyv&#xe4;rinen A, Tervonen O. Independent Component Analysis of nondeterministic fMRI signal sources. NeuroImage. 2003;19:253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiviniemi V, et al. Functional segmentation of the brain cortex using high model order group PICA. Human Brain Mapping. 2009;30:3865&#x2013;3886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870574</ArticleId><ArticleId IdType="pubmed">19507160</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S. The future of FMRI connectivity. NeuroImage. 2012;62:1257&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pubmed">22248579</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, et al. Network modelling methods for FMRI. NeuroImage. 2011;54:875&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">20817103</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc Ser B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Genovese CR, Lazar N, Nichols T. Thresholding of Statistical Maps in Functional Neuroimaging Using the False Discovery Rate. NeuroImage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui J, et al. A CCA + ICA based model for multi-task brain imaging data fusion and its application to schizophrenia. NeuroImage. 2010;51:123&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847043</ArticleId><ArticleId IdType="pubmed">20114081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27732852</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer's Disease Mutations.</ArticleTitle><Pagination><StartPage>759</StartPage><EndPage>773</EndPage><MedlinePgn>759-773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.09.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)31256-6</ELocationID><Abstract><AbstractText>We investigated early phenotypes caused by familial Alzheimer's disease (fAD) mutations in isogenic human iPSC-derived neurons. Analysis of neurons carrying fAD PS1 or APP mutations introduced using genome editing technology at the endogenous loci revealed that fAD mutant neurons had previously unreported defects in the recycling state of endocytosis and soma-to-axon transcytosis of APP and lipoproteins. The endocytosis reduction could be rescued through treatment with a &#x3b2;-secretase inhibitor. Our data suggest that accumulation of &#x3b2;-CTFs of APP, but not A&#x3b2;, slow vesicle formation from an endocytic recycling compartment marked by the transcytotic GTPase Rab11. We confirm previous results that endocytosis is affected in AD and extend these to uncover a neuron-specific defect. Decreased lipoprotein endocytosis and transcytosis to the axon suggest that a neuron-specific impairment in endocytic axonal delivery of lipoproteins and other key materials might compromise synaptic maintenance in fAD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woodruff</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyna</LastName><ForeName>Sol M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlap</LastName><ForeName>Mariah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Der Kant</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callender</LastName><ForeName>Julia A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: lgoldstein@ucsd.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG048083</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475476">LRP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C088986">rab11 protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="Y">Transcytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">FAD</Keyword><Keyword MajorTopicYN="N">PS1</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">transcytosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27732852</ArticleId><ArticleId IdType="mid">NIHMS820307</ArticleId><ArticleId IdType="pmc">PMC5796664</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.09.034</ArticleId><ArticleId IdType="pii">S2211-1247(16)31256-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson E, Maday S, Sfakianos J, Hull M, Winckler B, Sheff D, F&#xf6;lsch H, Mellman I. Transcytosis of NgCAM in epithelial cells reflects differential signal recognition on the endocytic and secretory pathways. J Cell Biol. 2005;170:595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171499</ArticleId><ArticleId IdType="pubmed">16087710</ArticleId></ArticleIdList></Reference><Reference><Citation>Anthony SM, Granick S. Image analysis with rapid and accurate two-dimensional Gaussian fitting. Langmuir. 2009;25:8152&#x2013;8160.</Citation><ArticleIdList><ArticleId IdType="pubmed">19419178</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonell A, Llad&#xf3; A, Altirriba J, Botta-Orfila T, Balasa M, Fern&#xe1;ndez M, Ferrer I, S&#xe1;nchez-Valle R, Molinuevo JL. A preliminary study of the whole- genome expression profile of sporadic and monogenic early-onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2013;34:1772&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pubmed">23369545</ArticleId></ArticleIdList></Reference><Reference><Citation>Arold S, Sullivan P, Bilousova T, Teng E, Miller CA, Poon WW, Vinters HV, Cornwell LB, Saing T, Cole GM, et al. Apolipoprotein e level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer&#x2019;s disease and apoE TR mouse cortex. Acta Neuropathol. 2012;123:39&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404604</ArticleId><ArticleId IdType="pubmed">22020632</ArticleId></ArticleIdList></Reference><Reference><Citation>Asca&#xf1;o M, Richmond A, Borden P, Kuruvilla R. Axonal targeting of Trk receptors via transcytosis regulates sensitivity to neurotrophin responses. J Neurosci. 2009;29:11674&#x2013;11685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775807</ArticleId><ArticleId IdType="pubmed">19759314</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres Ba, Smith SJ. Cation Between Nerve Cells At Meet- Purified Neurons To Form Synaps- Science (80-) 2001;294:1296&#x2013;1297.</Citation></Reference><Reference><Citation>Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodbeck J, McGuire J, Liu Z, Meyer-Franke A, Balestra ME, Jeong DE, Pleiss M, McComas C, Hess F, Witter D, et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J Biol Chem. 2011;286:17217&#x2013;17226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3089564</ArticleId><ArticleId IdType="pubmed">21454574</ArticleId></ArticleIdList></Reference><Reference><Citation>Buggia-Pr&#xe9;vot V, Fernandez CG, Riordan S, Vetrivel KS, Roseman J, Waters J, Bindokas VP, Vassar R, Thinakaran G. Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase. Mol Neurodegener. 2014;9:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4031619</ArticleId><ArticleId IdType="pubmed">24386896</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci. 2003;23:5645&#x2013;5649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741250</ArticleId><ArticleId IdType="pubmed">12843267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, Lopes KO, Kim SH, Zheng H, Greengard P, et al. Presenilin-1 regulates intracellular trafficking and cell surface delivery of &#x3b2;-amyloid precursor protein. J Biol Chem. 2003;278:3446&#x2013;3454.</Citation><ArticleIdList><ArticleId IdType="pubmed">12435726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic Pathway Abnormalities Precede Amyloid &#x3b2; Deposition in Sporadic Alzheimer&#x2019;s Disease and Down Syndrome. Am J Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A, Rebeck G, Ghetti B, Hulette C, Lippa C, Van Brockhoven C, Van Duijn C, Cras P, Bogdanovic N, Bird T, et al. Endocytic disturbances distinguish among subtypes of Alzheimer&#x2019;s disease and related disorders. Ann Neurol. 2001;50:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KA, Suh YH. Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer&#x2019;s disease. J Pharmacol Sci. 2005;97:461&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">15821343</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A. 2010;107:12011&#x2013;12016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Coen K, Flannagan RS, Baron S, Carraro-Lacroix LR, Wang D, Vermeire W, Michiels C, Munck S, Baert V, Sugita S, et al. Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. Journal of Cell Biology. 2012;198:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392942</ArticleId><ArticleId IdType="pubmed">22753898</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform&#x2013;specific disruption of amyloid &#x3b2; peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>Diwu Z, Chen CS, Zhang C, Klaubert DH, Haugland RP. A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Chem Biol. 1999;6:411&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">10381401</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanchin C, Czech C, Campion D, Cuif MH, Poyot T, Martin C, Charbonnier F, Goud B, Pradier L, Frebourg T. Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport. Hum Mol Genet. 1999;8:1263&#x2013;1269.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369872</ArticleId></ArticleIdList></Reference><Reference><Citation>Encalada SE, Szpankowski L, Xia CH, Goldstein LSB. Stable kinesin and dynein assemblies drive the axonal transport of mammalian prion protein vesicles. Cell. 2011;144:551&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3576050</ArticleId><ArticleId IdType="pubmed">21335237</ArticleId></ArticleIdList></Reference><Reference><Citation>Fargo K, Bleiler L. Alzheimer&#x2019;s Association Report: 2014 Alzheimers disease facts and figures. Alzheimer&#x2019;s Dement. 2014;10:e47&#x2013;e92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24818261</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca ACRG, Resende R, Oliveira CR, Pereira CMF. Cholesterol and statins in Alzheimer&#x2019;s disease: current controversies. Exp Neurol. 2010;223:282&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Zhang YW, Ikin A, Schmidt SD, Levy E, Sheffield R, Nixon Ra, Liao FF, Mathews PM, Xu H, et al. Alzheimer&#x2019;s presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. J Neurochem. 2007;102:619&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">17630980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds Ca, Fratiglioni L, Johansson B, Mortimer Ja, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer&#x2019;s disease progression. Biol Psychiatry. 2010;68:885&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965820</ArticleId><ArticleId IdType="pubmed">20655510</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulian M, Simon SM. Tracking single proteins within cells. Biophysical journal. 2000;79:2188&#x2013;2198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301109</ArticleId><ArticleId IdType="pubmed">11023923</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Li H, Gaddam SSK, Justice NJ, Robertson CS, Zheng H. Amyloid precursor protein revisited: Neuron-specific expression and highly stable nature of soluble derivatives. J Biol Chem. 2012;287:2437&#x2013;2445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268404</ArticleId><ArticleId IdType="pubmed">22144675</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel Ma, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, et al. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaqaman K, Loerke D, Mettlen M, Kuwata H, Grinstein S, Schmid SL, Danuser G. Robust single-particle tracking in live-cell time-lapse sequences. Nature methods. 2008;5:695&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747604</ArticleId><ArticleId IdType="pubmed">18641657</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LW, Hua DH, Shie FS, Maezawa I, Sopher B, Martin GM. Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death. J Mol Neurosci. 2002;19:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">12212794</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Goate AM. Alzheimer&#x2019;s Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biol Psychiatry. 2014;77:43&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234692</ArticleId><ArticleId IdType="pubmed">24951455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini a, Rigoglioso a, Jiang Y, Nixon Ra. Evidence that the rab5 effector APPL1 mediates APP-&#x3b2;CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer&#x2019;s disease. Mol Psychiatry. 2015:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721948</ArticleId><ArticleId IdType="pubmed">26194181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted &#x3b2;-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Philips GT, Herz J. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron. 2014;83:771&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240629</ArticleId><ArticleId IdType="pubmed">25144875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazo OM, Gonzalez a, Ascano M, Kuruvilla R, Couve a, Bronfman FC. BDNF Regulates Rab11-Mediated Recycling Endosome Dynamics to Induce Dendritic Branching. J Neurosci. 2013;33:6112&#x2013;6122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684039</ArticleId><ArticleId IdType="pubmed">23554492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, et al. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, McBrayer M, Wolfe DM, Haslett LJ, Kumar A, Sato Y, Pearl PY, Mohan P, Coffey EE, Uday K, et al. Presenilin 1 maintains lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 2015;12:1430&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558203</ArticleId><ArticleId IdType="pubmed">26299959</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem JY, Saura CA, Pietrzik C, Christianson J, Wanamaker C, King LT, Veselits ML, Tomita T, Gasparini L, Iwatsubo T, et al. A Role for Presenilin 1 in Regulating the Delivery of Amyloid Precursor Protein to the Cell Surface. Neurobiol Dis. 2002;11:64&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">12460547</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G. Differential regulation of amyloid-&#x3b2; endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem. 2012;287:44593&#x2013;44601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531774</ArticleId><ArticleId IdType="pubmed">23132858</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Changes. 2012;29:997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS, Koo EH, Bredesen DE. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med. 2000;6:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10742146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A. 2006;103:5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauch DH, N&#xe4;gler K, Schumacher S, G&#xf6;ritz C, M&#xfc;ller EC, Otto a, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxfield FR. Role of endosomes and lysosomes in human disease. Cold Spring Harb Perspect Biol. 2014:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996470</ArticleId><ArticleId IdType="pubmed">24789821</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gler K, Mauch DH, Pfrieger FW. Glia-derived signals induce synapse formation in neurones of the rat central nervous system. J Physiol. 2001;533:665&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278670</ArticleId><ArticleId IdType="pubmed">11410625</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely KM, Green KN, LaFerla FM. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a &#x3b3;-secretase-independent manner. J Neurosci. 2011;31:2781&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064964</ArticleId><ArticleId IdType="pubmed">21414900</ArticleId></ArticleIdList></Reference><Reference><Citation>Niederst E, Reyna S, Goldstein LSB. Axonal Amyloid Precursor Protein and its Fragments Undergo Somatodendritic Endocytosis and Processing. Mol Biol Cell. 2015;26:205&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294669</ArticleId><ArticleId IdType="pubmed">25392299</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon Ra, Mcbrayer M. Lysosome and Calcium Dysregulation in Alzheimer&#x2019;s disease - Partners in Crime. Biochem Soc Trans. 2013;41:1495&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960943</ArticleId><ArticleId IdType="pubmed">24256243</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang DS. Autophagy failure in Alzheimer&#x2019;s disease--locating the primary defect. Neurobiol Dis. 2011;43:38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096679</ArticleId><ArticleId IdType="pubmed">21296668</ArticleId></ArticleIdList></Reference><Reference><Citation>Peric A, Annaert W. Early etiology of Alzheimer&#x2019;s disease: tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathol. 2015;129(3):363&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331606</ArticleId><ArticleId IdType="pubmed">25556159</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta - Biomembr. 2003;1610:271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">12648780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierrot N, Tyteca D, D&#x2019;auria L, Dewachter I, Gailly P, Hendrickx A, Tasiaux B, El Haylani L, Muls N, N&#x2019;Kuli F, et al. Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol Med. 2013;5:608&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628100</ArticleId><ArticleId IdType="pubmed">23554170</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002;21:5691&#x2013;5700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131065</ArticleId><ArticleId IdType="pubmed">12411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar SW, Nixon Ra, Robakis NK, Shen J, Tsai LH. Amyloid- independent mechanisms in Alzheimer&#x2019;s disease pathogenesis. J Neurosci. 2010;30:14946&#x2013; 14954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Polydoro M, Maury Ea, Nicholls SB, Reddy SM, Wegmann S, William C, Saqran L, Cagsal-Getkin O, Pitstick R, et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2015;3:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371800</ArticleId><ArticleId IdType="pubmed">25853174</ArticleId></ArticleIdList></Reference><Reference><Citation>Robakis NK. Mechanisms of AD neurodegeneration may be independent of A&#x3b2; and its derivatives. Neurobiol Aging. 2011;32:372&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385412</ArticleId><ArticleId IdType="pubmed">20594619</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakane H, Yamamoto H, Kikuchi A. LRP6 is internalized by Dkk1 to suppress its phosphorylation in the lipid raft and is recycled for reuse. J Cell Sci. 2010;123:360&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">20053636</ArticleId></ArticleIdList></Reference><Reference><Citation>Selfridge A, Hyun N, Chiang CC, Reyna SM, Weissmiller AM, Shi LZ, Preece D, Mobley WC, Berns MW. Rat embryonic hippocampus and induced pluripotent stem cell derived cultured neurons recover from laser-induced subaxotomy. Neurophotonics. 2015;2:015006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487718</ArticleId><ArticleId IdType="pubmed">26157985</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva Ea, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer&#x2019;s disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioi J, Georgakopoulos A, Mehta P, Kouchi Z, Litterst CM, Baki L, Robakis NK. FAD mutants unable to increase neurotoxic A&#x3b2; 42 suggest that mutation effects on eurodegeneration may be independent of effects on A&#x3b2;. J Neurochem. 2007;101:674&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">17254019</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci U S A. 1999;96:11049&#x2013;11053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34239</ArticleId><ArticleId IdType="pubmed">10500121</ArticleId></ArticleIdList></Reference><Reference><Citation>Soejitno A, Tjan A, Purwata T. Alzheimer&#x2019;s Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs. 2015;29:487&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">26187557</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82:756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer&#x2019;s disease. Science. 2005;307:1282&#x2013; 1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Almenar-Queralt A, Gunawardena S, Rodrigues EM, Falzone T, Kim J, Lillo C, Mount SL, Roberts Ea, McGowan E, et al. Amyloid precursor protein-induced axonopathies are independent of amyloid-&#x3b2; peptides. Hum Mol Genet. 2008;17:3474&#x2013;3486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722897</ArticleId><ArticleId IdType="pubmed">18694898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugino H, Watanabe A, Amada N, Yamamoto M, Ohgi Y, Kostic D, Sanchez R. Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. Clin Ther. 2015 Epub Ahead of Print.</Citation><ArticleIdList><ArticleId IdType="pubmed">26243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Svennerholm L, Gottfries CG. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II) J Neurochem. 1994;62:1039&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">8113790</ArticleId></ArticleIdList></Reference><Reference><Citation>Szpankowski L, Encalada SE, Goldstein LSB. Subpixel colocalization reveals amyloid precursor protein-dependent kinesin-1 and dynein association with axonal vesicles. Proc Natl Acad Sci. 2012;109:8582&#x2013;8587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365224</ArticleId><ArticleId IdType="pubmed">22582169</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Murate M, Fukuda M, Satoshi SB, Ohta A, Kobayashi T. Cholesterol Controls Lipid Endocytosis through Rab11. Mol Biol Cell. 2007;18:2667&#x2013; 2677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924824</ArticleId><ArticleId IdType="pubmed">17475773</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, et al. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci. 2008;28:12097&#x2013;12106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671640</ArticleId><ArticleId IdType="pubmed">19005074</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Blurton-jones M, Rhee SW, Cribbs DH, Carl W. A Microfluidic Culture Platform for CNS Axonal Injury, Regeneration, and Transport. Nat Methods. 2006;2:599&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1558906</ArticleId><ArticleId IdType="pubmed">16094385</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom V, Princen K, De Witte K, Griffioen G, Geenslaan G, Leuven B. Derailed intraneuronal signalling drives pathogenesis in sporadic and familial. Alzheimer&#x2019;s disease. 2014;2014:1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4160617</ArticleId><ArticleId IdType="pubmed">25243118</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyn JH, Ahlijanian MK. Interpreting Alzheimer&#x2019;s disease clinical trials in light of the effects on amyloid-&#x3b2;. Alzheimers Res Ther. 2014;6:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4014014</ArticleId><ArticleId IdType="pubmed">25031632</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, Shulman JM, Parrado A, Bevis BJ, Valastyan JS, et al. Functional Links Between A&#x3b2; Toxicity. 2011;334:1241&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference><Reference><Citation>Udayar V, Buggia-Pr&#xe9;vot V, Guerreiro RL, Siegel G, Rambabu N, Soohoo AL, Ponnusamy M, Siegenthaler B, Bali J, Simons M, et al. A Paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of &#x3b2;-amyloid production. Cell Rep. 2013;5:1536&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004174</ArticleId><ArticleId IdType="pubmed">24373285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich O, Reinsch S, Urb&#xe9; S, Zerial M, Parton RG. Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol. 1996;135:913&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2133374</ArticleId><ArticleId IdType="pubmed">8922376</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-&#x3b2; (A&#x3b2;) clearance despite minimal apoE/A&#x3b2; association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110:E1807&#x2013;E1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651443</ArticleId><ArticleId IdType="pubmed">23620513</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Bartheld CS. Axonal Transport and Neuronal Transcytosis of Trophic Factors, Tracers, and Pathogens. J Neurobiol. 2004;58:295&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">14704960</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L. Tau reduction prevents A&#x3b2;-induced axonal transport deficits by blocking activation of GSK3&#x3b2;. J Cell Biol. 2015;209:419&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427789</ArticleId><ArticleId IdType="pubmed">25963821</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J, van Echten-Deckert G. Cross-talk of membrane lipids and Alzheimer-related proteins. Mol Neurodegener. 2013;8:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016522</ArticleId><ArticleId IdType="pubmed">24148205</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmiller AM, Natera-Naranjo O, Reyna SM, Pearn ML, Zhao X, Nguyen P, Cheng S, Goldstein LSB, Tanzi RE, Wagner SL, et al. A &#x3b3;-Secretase Inhibitor, but Not a &#x3b3;-Secretase Modulator, Induced Defects in BDNF Axonal Trafficking and Signaling: Evidence for a Role for APP. PLoS One. 2015;10:e0118379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339551</ArticleId><ArticleId IdType="pubmed">25710492</ArticleId></ArticleIdList></Reference><Reference><Citation>Welz T, Wellbourne-Wood J, Kerkhoff E. Orchestration of cell surface proteins by Rab11. Trends Cell Biol. 2014;24:407&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">24675420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JM, de Hoop M, Zorzi N, Toh BH, Dotti CG, Parton RG. EEA1, a tethering protein of the early sorting endosome, shows a polarized distribution in hippocampal neurons, epithelial cells, and fibroblasts. Mol Biol Cell. 2000;11:2657&#x2013;2671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14947</ArticleId><ArticleId IdType="pubmed">10930461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B. Cholesterol and the Biology of Alzheimer&#x2019;s Disease. Neuron. 2004;41:7&#x2013; 10.</Citation><ArticleIdList><ArticleId IdType="pubmed">14715130</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff G, Young JE, Martinez FJ, Buen F, Gore A, Kinaga J, Li Z, Yuan SH, Zhang K, Goldstein LSB. The Presenilin-1 &#x3b4;E9 Mutation Results in Reduced &#x3b3;-Secretase Activity, but Not Total Loss of PS1 Function, in Isogenic Human Stem Cells. Cell Rep. 2013;5:974&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867011</ArticleId><ArticleId IdType="pubmed">24239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CC, Wisco D, Kujala P, Lasiecka ZM, Cannon JT, Chang MC, Hirling H, Klumperman J, Winckler B. The somatodendritic endosomal regulator NEEP21 facilitates axonal targeting of L1/NgCAM. J Cell Biol. 2008;180:827&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265569</ArticleId><ArticleId IdType="pubmed">18299352</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, Vidal JG, Mu Y, Killian RL, Israel Ma, et al. Cell-surface marker signatures for the Isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One. 2011:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Haapasalo A, Kim DY, Ingano LaM, Pettingell WH, Kovacs DM. Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment. FASEB J. 2006;20:1176&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">16645046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan Sa, Bennett ML, Scholze AR, Keeffe SO, Phatnani HP, Guarnieri XP, Caneda C, Ruderisch N, et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia. Neurons, and Vascular Cells of the Cerebral Cortex. 2014;34:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27733560</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>360</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.</ArticleTitle><Pagination><StartPage>360ra136</StartPage><MedlinePgn>360ra136</MedlinePgn></Pagination><Abstract><AbstractText>Inhaled drugs offer advantages, such as rapid onset of action, but require formulations and delivery systems that reproducibly and conveniently administer the drug. CVT-301 is a powder formulation of levodopa delivered by a breath-actuated inhaler that has been developed for treating OFF episodes (motor fluctuations between doses of standard oral levodopa) in patients with Parkinson's disease (PD). We present preclinical, phase 1, and phase 2 results for CVT-301. In dogs insufflated with a levodopa powder, plasma levodopa peaked in all animals 2.5 min after administration; in contrast, in dogs dosed orally with levodopa plus carbidopa, plasma levodopa was not detected until 30 min after administration. In 18 healthy persons, comparisons between inhaled CVT-301 and oral carbidopa/levodopa showed analogous differences in pharmacokinetics. Among 24 PD patients inhaling CVT-301 as a single 50-mg dose during an OFF episode, 77% showed an increase in plasma levodopa (&gt;400 ng/ml) within 10 min versus 27% for oral dosing with carbidopa/levodopa at a 25-mg/100-mg dose. Improvements in timed finger tapping and overall motor function (Part III of the Unified Parkinson's Disease Rating Scale) were seen 5 and 15 min after administration, the earliest assessment time points. For average and best change, the improvements were statistically significant compared to placebo. The most common adverse event was cough; all cough events were mild to moderate, occurred at the time of inhalation, resolved rapidly, and became less frequent after initial dosing. These results support further development of CVT-301 for better management of PD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipp</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Acorda Therapeutics, Chelsea, MA 02150, USA. mlipp@acorda.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batycky</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Acorda Therapeutics, Chelsea, MA 02150, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pacific BioDevelopment, LLC, Emeryville, CA 94608, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leinonen</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4Pharma AB, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freed</LastName><ForeName>Martin I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Acorda Therapeutics, Chelsea, MA 02150, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2012-000181-37</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011208">Powders</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="N">Translational Research, Biomedical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27733560</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aad8858</ArticleId><ArticleId IdType="pii">8/360/360ra136</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27629716</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>37</Issue><PubDate><Year>2016</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Youthful Brains in Older Adults: Preserved Neuroanatomy in the Default Mode and Salience Networks Contributes to Youthful Memory in Superaging.</ArticleTitle><Pagination><StartPage>9659</StartPage><EndPage>9668</EndPage><MedlinePgn>9659-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1492-16.2016</ELocationID><Abstract><AbstractText Label="UNLABELLED">Decline in cognitive skills, especially in memory, is often viewed as part of "normal" aging. Yet some individuals "age better" than others. Building on prior research showing that cortical thickness in one brain region, the anterior midcingulate cortex, is preserved in older adults with memory performance abilities equal to or better than those of people 20-30 years younger (i.e., "superagers"), we examined the structural integrity of two large-scale intrinsic brain networks in superaging: the default mode network, typically engaged during memory encoding and retrieval tasks, and the salience network, typically engaged during attention, motivation, and executive function tasks. We predicted that superagers would have preserved cortical thickness in critical nodes in these networks. We defined superagers (60-80 years old) based on their performance compared to young adults (18-32 years old) on the California Verbal Learning Test Long Delay Free Recall test. We found regions within the networks of interest where the cerebral cortex of superagers was thicker than that of typical older adults, and where superagers were anatomically indistinguishable from young adults; hippocampal volume was also preserved in superagers. Within the full group of older adults, thickness of a number of regions, including the anterior temporal cortex, rostral medial prefrontal cortex, and anterior midcingulate cortex, correlated with memory performance, as did the volume of the hippocampus. These results indicate older adults with youthful memory abilities have youthful brain regions in key paralimbic and limbic nodes of the default mode and salience networks that support attentional, executive, and mnemonic processes subserving memory function.</AbstractText><AbstractText Label="SIGNIFICANCE STATEMENT">Memory performance typically declines with age, as does cortical structural integrity, yet some older adults maintain youthful memory. We tested the hypothesis that superagers (older individuals with youthful memory performance) would exhibit preserved neuroanatomy in key brain networks subserving memory. We found that superagers not only perform similarly to young adults on memory testing, they also do not show the typical patterns of brain atrophy in certain regions. These regions are contained largely within two major intrinsic brain networks: the default mode network, implicated in memory encoding, storage, and retrieval, and the salience network, associated with attention and executive processes involved in encoding and retrieval. Preserved neuroanatomical integrity in these networks is associated with better memory performance among older adults.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Sun, Stepanovic et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Felicia W</ForeName><Initials>FW</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and Psychiatric Neuroimaging Division, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stepanovic</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreano</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and Psychiatric Neuroimaging Division, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and Department of Psychology, Northeastern University, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Lisa Feldman</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and Psychiatric Neuroimaging Division, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and Department of Psychology, Northeastern University, Boston, Massachusetts 02115 atouroutoglou@mgh.harvard.edu l.barrett@northeastern.edu brad.dickerson@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touroutoglou</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and atouroutoglou@mgh.harvard.edu l.barrett@northeastern.edu brad.dickerson@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Frontotemporal Disorders Unit, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02114, and atouroutoglou@mgh.harvard.edu l.barrett@northeastern.edu brad.dickerson@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG030311</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurosurgery. 2017 Mar 1;80(3):N11-N12. doi: 10.1093/neuros/nyx235.</RefSource><PMID Version="1">28426866</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">cerebral cortex</Keyword><Keyword MajorTopicYN="N">default mode network</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">salience network</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27629716</ArticleId><ArticleId IdType="pmc">PMC5039247</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1492-16.2016</ArticleId><ArticleId IdType="pii">36/37/9659</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews-Hanna JR, Reidler JS, Sepulcre J, Poulin R, Buckner RL. Functional-anatomic fractionation of the brain's default network. Neuron. 2010;65:550&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848443</ArticleId><ArticleId IdType="pubmed">20188659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour A, Morris JC, Wolk DA, Dickerson BC. The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage. 2013;76:332&#x2013;344. doi: 10.1016/j.neuroimage.2013.02.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2013.02.059</ArticleId><ArticleId IdType="pmc">PMC4098706</ArticleId><ArticleId IdType="pubmed">23507382</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes DE, Cauley JA, Lui LY, Fink HA, McCulloch C, Stone KL, Yaffe K. Women who maintain optimal cognitive function into old age. J Am Geriatr Soc. 2007;55:259&#x2013;264. doi: 10.1111/j.1532-5415.2007.01040.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2007.01040.x</ArticleId><ArticleId IdType="pubmed">17302664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole MW, Schneider W. The cognitive control network: Integrated cortical regions with dissociable functions. Neuroimage. 2007;37:343&#x2013;360. doi: 10.1016/j.neuroimage.2007.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.03.071</ArticleId><ArticleId IdType="pubmed">17553704</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbetta M, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci. 2002;3:201&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">11994752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. Neuroimage. 1999;9:179&#x2013;194. doi: 10.1006/nimg.1998.0395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.1998.0395</ArticleId><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test, Research Ed., manual. San Antonio, Texas: Harcourt Brace Jovanovich; 1987.</Citation></Reference><Reference><Citation>Depp CA, Jeste DV. Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies. Am J Geriatr Psychiatry. 2006;14:6&#x2013;20. doi: 10.1097/01.JGP.0000192501.03069.bc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.JGP.0000192501.03069.bc</ArticleId><ArticleId IdType="pubmed">16407577</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanjal NS, Wise RJ. Frontoparietal cognitive control of verbal memory recall in Alzheimer's disease. Ann Neurol. 2014;76:241&#x2013;251. doi: 10.1002/ana.24199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24199</ArticleId><ArticleId IdType="pubmed">24933580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Eichenbaum H. The episodic memory system: neurocircuitry and disorders. Neuropsychopharmacology. 2010;35:86&#x2013;104. doi: 10.1038/npp.2009.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2009.126</ArticleId><ArticleId IdType="pmc">PMC2882963</ArticleId><ArticleId IdType="pubmed">19776728</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Fenstermacher E, Salat DH, Wolk DA, Maguire RP, Desikan R, Pacheco J, Quinn BT, Van der Kouwe A, Greve DN, Blacker D, Albert MS, Killiany RJ, Fischl B. Detection of cortical thickness correlates of cognitive performance: reliability across MRI scan sessions, scanners, and field strengths. Neuroimage. 2008;39:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141650</ArticleId><ArticleId IdType="pubmed">17942325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, Visscher KM, Palmer ED, Miezin FM, Wenger KK, Kang HC, Burgund ED, Grimes AL, Schlaggar BL, Petersen SE. A core system for the implementation of task sets. Neuron. 2006;50:799&#x2013;812. doi: 10.1016/j.neuron.2006.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.04.031</ArticleId><ArticleId IdType="pmc">PMC3621133</ArticleId><ArticleId IdType="pubmed">16731517</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman JA, Klostermann EC, Marian DE, Verstaen A, Shimamura AP. Neural correlates of metacognitive monitoring during episodic and semantic retrieval. Cogn Affect Behav Neurosci. 2012;12:599&#x2013;609. doi: 10.3758/s13415-012-0096-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/s13415-012-0096-8</ArticleId><ArticleId IdType="pubmed">22562436</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97:11050&#x2013;11055. doi: 10.1073/pnas.200033797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.200033797</ArticleId><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20:70&#x2013;80. doi: 10.1109/42.906426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/42.906426</ArticleId><ArticleId IdType="pubmed">11293693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher PC, Shallice T, Dolan RJ. The functional roles of prefrontal cortex in episodic memory. I. Encoding. Brain. 1998;121:1239&#x2013;1248. doi: 10.1093/brain/121.7.1239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/121.7.1239</ArticleId><ArticleId IdType="pubmed">9679776</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gefen T, Shaw E, Whitney K, Martersteck A, Stratton J, Rademaker A, Weintraub S, Mesulam MM, Rogalski E. Longitudinal neuropsychological performance of cognitive SuperAgers. J Am Geriatr Soc. 2014;62:1598&#x2013;1600. doi: 10.1111/jgs.12967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12967</ArticleId><ArticleId IdType="pmc">PMC4135532</ArticleId><ArticleId IdType="pubmed">25116988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gefen T, Peterson M, Papastefan ST, Martersteck A, Whitney K, Rademaker A, Bigio EH, Weintraub S, Rogalski E, Mesulam MM, Geula C. Morphometric and histologic substrates of cingulate integrity in elders with exceptional memory capacity. J Neurosci. 2015;35:1781&#x2013;1791. doi: 10.1523/JNEUROSCI.2998-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2998-14.2015</ArticleId><ArticleId IdType="pmc">PMC4308613</ArticleId><ArticleId IdType="pubmed">25632151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber O, Goschke T. Executive control emerging from dynamic interactions between brain systems mediating language, working memory and attentional processes. Acta psychologica. 2004;115:105&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">14962396</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib R, Nyberg L, Nilsson LG. Cognitive and non-cognitive factors contributing to the longitudinal identification of successful older adults in the betula study. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14:257&#x2013;273. doi: 10.1080/13825580600582412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13825580600582412</ArticleId><ArticleId IdType="pubmed">17453560</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, Weintraub S, Mesulam MM, Rogalski E. Superior memory and higher cortical volumes in unusually successful cognitive aging. J Int Neuropsychol Soc. 2012;18:1081&#x2013;1085. doi: 10.1017/S1355617712000847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617712000847</ArticleId><ArticleId IdType="pmc">PMC3547607</ArticleId><ArticleId IdType="pubmed">23158231</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzlicht M, Bartholow BD, Hirsh JB. Emotional foundations of cognitive control. Trends Cogn Sci. 2015;19:126&#x2013;132. doi: 10.1016/j.tics.2015.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2015.01.004</ArticleId><ArticleId IdType="pmc">PMC4348332</ArticleId><ArticleId IdType="pubmed">25659515</ArticleId></ArticleIdList></Reference><Reference><Citation>Josefsson M, de Luna X, Pudas S, Nilsson LG, Nyberg L. Genetic and lifestyle predictors of 15-year longitudinal change in episodic memory. J Am Geriatr Soc. 2012;60:2308&#x2013;2312. doi: 10.1111/jgs.12000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12000</ArticleId><ArticleId IdType="pubmed">23110764</ArticleId></ArticleIdList></Reference><Reference><Citation>Koechlin E, Basso G, Pietrini P, Panzer S, Grafman J. The role of the anterior prefrontal cortex in human cognition. Nature. 1999;399:148&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">10335843</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi S, Wheeler ME, Donaldson DI, Buckner RL. Neural correlates of episodic retrieval success. Neuroimage. 2000;12:276&#x2013;286. doi: 10.1006/nimg.2000.0614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2000.0614</ArticleId><ArticleId IdType="pubmed">10944410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer AD, Guillory JE, Hancock JT. Experimental evidence of massive-scale emotional contagion through social networks. Proc Natl Acad Sci U S A. 2014;111:8788&#x2013;8790. doi: 10.1073/pnas.1320040111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320040111</ArticleId><ArticleId IdType="pmc">PMC4066473</ArticleId><ArticleId IdType="pubmed">24889601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist KA, Satpute AB, Wager TD, Weber J, Barrett LF. The brain basis of positive and negative affect: evidence from a meta-analysis of the human neuroimaging literature. Cereb Cortex. 2016;26:1910&#x2013;1922. doi: 10.1093/cercor/bhv001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhv001</ArticleId><ArticleId IdType="pmc">PMC4830281</ArticleId><ArticleId IdType="pubmed">25631056</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A, Chao LL. Semantic memory and the brain: structure and processes. Curr Opin Neurobiol. 2001;11:194&#x2013;201. doi: 10.1016/S0959-4388(00)00196-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(00)00196-3</ArticleId><ArticleId IdType="pubmed">11301239</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaniel MA, Einstein GO, Jacoby LL. New considerations in aging and memory: the glass may be half full. In: Craik FI, Salthouse T, editors. The handbook of aging and cognition. New York: Psychology; 2008. pp. 255&#x2013;310.</Citation></Reference><Reference><Citation>McGinnis SM, Brickhouse M, Pascual B, Dickerson BC. Age-related changes in the thickness of cortical zones in humans. Brain Topogr. 2011;24:279&#x2013;291. doi: 10.1007/s10548-011-0198-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10548-011-0198-6</ArticleId><ArticleId IdType="pmc">PMC3600370</ArticleId><ArticleId IdType="pubmed">21842406</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, Pihlajam&#xe4;ki M, Sperling RA. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A. 2008;105:2181&#x2013;2186. doi: 10.1073/pnas.0706818105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0706818105</ArticleId><ArticleId IdType="pmc">PMC2538895</ArticleId><ArticleId IdType="pubmed">18238903</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SM, Dosenbach NU, Cohen AL, Wheeler ME, Schlaggar BL, Petersen SE. Role of the anterior insula in task-level control and focal attention. Brain Struct Funct. 2010;214:669&#x2013;680. doi: 10.1007/s00429-010-0260-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-010-0260-2</ArticleId><ArticleId IdType="pmc">PMC2886908</ArticleId><ArticleId IdType="pubmed">20512372</ArticleId></ArticleIdList></Reference><Reference><Citation>Niendam TA, Laird AR, Ray KL, Dean YM, Glahn DC, Carter CS. Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. Cogn Affect Behav Neurosci. 2012;12:241&#x2013;268. doi: 10.3758/s13415-011-0083-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/s13415-011-0083-5</ArticleId><ArticleId IdType="pmc">PMC3660731</ArticleId><ArticleId IdType="pubmed">22282036</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Rangarajan V, Shirer WR, Desai N, Greicius MD. The will to persevere induced by electrical stimulation of the human cingulate gyrus. Neuron. 2013;80:1359&#x2013;1367. doi: 10.1016/j.neuron.2013.10.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.057</ArticleId><ArticleId IdType="pmc">PMC3877748</ArticleId><ArticleId IdType="pubmed">24316296</ArticleId></ArticleIdList></Reference><Reference><Citation>Power JD, Petersen SE. Control-related systems in the human brain. Curr Opin Neurobiol. 2013;23:223&#x2013;228. doi: 10.1016/j.conb.2012.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2012.12.009</ArticleId><ArticleId IdType="pmc">PMC3632325</ArticleId><ArticleId IdType="pubmed">23347645</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz G, Touroutoglou A, Wilson-Mendenhall C, Gilam G, Lin T, Gonen T, Jacob Y, Atzil S, Admon R, Bleich-Cohen M, Maron-Katz A, Hendler T, Barrett LF. Functional connectivity dynamics during film viewing reveal common networks for different emotional experiences. Cogn Affect Behav Neurosci. 2016;16:709&#x2013;723. doi: 10.3758/s13415-016-0425-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/s13415-016-0425-4</ArticleId><ArticleId IdType="pubmed">27142636</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Rogalski EJ, Gefen T, Shi J, Samimi M, Bigio E, Weintraub S, Geula C, Mesulam MM. Youthful memory capacity in old brains: anatomic and genetic clues from the Northwestern SuperAging Project. J Cogn Neurosci. 2013;25:29&#x2013;36. doi: 10.1162/jocn_a_00300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/jocn_a_00300</ArticleId><ArticleId IdType="pmc">PMC3541673</ArticleId><ArticleId IdType="pubmed">23198888</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnyer DM, Verfaellie M, Alexander MP, LaFleche G, Nicholls L, Kaszniak AW. A role for right medial prefontal cortex in accurate feeling-of-knowing judgements: evidence from patients with lesions to frontal cortex. Neuropsychologia. 2004;42:957&#x2013;966. doi: 10.1016/j.neuropsychologia.2003.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2003.11.020</ArticleId><ArticleId IdType="pubmed">14998710</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neuroscience. 2007;27:2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenhav A, Botvinick MM, Cohen JD. The expected value of control: an integrative theory of anterior cingulate cortex function. Neuron. 2013;79:217&#x2013;240. doi: 10.1016/j.neuron.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.007</ArticleId><ArticleId IdType="pmc">PMC3767969</ArticleId><ArticleId IdType="pubmed">23889930</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons JS, Spiers HJ. Prefrontal and medial temporal lobe interactions in long-term memory. Nat Rev Neurosci. 2003;4:637&#x2013;648. doi: 10.1038/nrn1178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1178</ArticleId><ArticleId IdType="pubmed">12894239</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR. Neuroscience. Rapid consolidation. Science. 2007;316:57&#x2013;58. doi: 10.1126/science.1141812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141812</ArticleId><ArticleId IdType="pmc">PMC2271071</ArticleId><ArticleId IdType="pubmed">17412942</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire LR, Stark CE, Clark RE. The medial temporal lobe. Annu Rev Neurosci. 2004;27:279&#x2013;306. doi: 10.1146/annurev.neuro.27.070203.144130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144130</ArticleId><ArticleId IdType="pubmed">15217334</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: Administration, norms, and commentary. 3rd ed. New York, NY: Oxford University Press; 2006.</Citation></Reference><Reference><Citation>Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203&#x2013;214. doi: 10.1016/S0887-6177(03)00039-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0887-6177(03)00039-8</ArticleId><ArticleId IdType="pubmed">15010086</ArticleId></ArticleIdList></Reference><Reference><Citation>Touroutoglou A, Hollenbeck M, Dickerson BC, Feldman Barrett L. Dissociable large-scale networks anchored in the right anterior insula subserve affective experience and attention. Neuroimage. 2012;60:1947&#x2013;1958. doi: 10.1016/j.neuroimage.2012.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.02.012</ArticleId><ArticleId IdType="pmc">PMC3345941</ArticleId><ArticleId IdType="pubmed">22361166</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dijk KR, Hedden T, Venkataraman A, Evans KC, Lazar SW, Buckner RL. Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization. J Neurophysiol. 2010;103:297&#x2013;321. doi: 10.1152/jn.00783.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00783.2009</ArticleId><ArticleId IdType="pmc">PMC2807224</ArticleId><ArticleId IdType="pubmed">19889849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD. Working memory contributions to human learning and remembering. Neuron. 1999;22:19&#x2013;22. doi: 10.1016/S0896-6273(00)80674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80674-1</ArticleId><ArticleId IdType="pubmed">10027285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Laviolette P, O'Keefe K, Putcha D, Bakkour A, Van Dijk KR, Pihlajam&#xe4;ki M, Dickerson BC, Sperling RA. Intrinsic connectivity between the hippocampus and posteromedial cortex predicts memory performance in cognitively intact older individuals. Neuroimage. 2010;51:910&#x2013;917. doi: 10.1016/j.neuroimage.2010.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.02.046</ArticleId><ArticleId IdType="pmc">PMC2856812</ArticleId><ArticleId IdType="pubmed">20188183</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Powell DH, Whitla DK. Successful cognitive aging: individual differences among physicians on a computerized test of mental state. J Geriatr Psychiatry. 1994;28:15&#x2013;34.</Citation></Reference><Reference><Citation>Wheeler MA, Stuss DT, Tulving E. Toward a theory of episodic memory: the frontal lobes and autonoetic consciousness. Psychol Bull. 1997;121:331&#x2013;354. doi: 10.1037/0033-2909.121.3.331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0033-2909.121.3.331</ArticleId><ArticleId IdType="pubmed">9136640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler ME, Buckner RL. Functional dissociation among components of remembering: control, perceived oldness, and content. J Neurosci. 2003;23:3869&#x2013;3880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742193</ArticleId><ArticleId IdType="pubmed">12736357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative Fractionating verbal episodic memory in Alzheimer's disease. Neuroimage. 2011;54:1530&#x2013;1539. doi: 10.1016/j.neuroimage.2010.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.09.005</ArticleId><ArticleId IdType="pmc">PMC2997155</ArticleId><ArticleId IdType="pubmed">20832485</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Fiocco AJ, Lindquist K, Vittinghoff E, Simonsick EM, Newman AB, Satterfield S, Rosano C, Rubin SM, Ayonayon HN, Harris TB. Predictors of maintaining cognitive function in older adults: the Health ABC Study. Neurology. 2009;72:2029&#x2013;2035. doi: 10.1212/WNL.0b013e3181a92c36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a92c36</ArticleId><ArticleId IdType="pmc">PMC2692177</ArticleId><ArticleId IdType="pubmed">19506226</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27760323</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Loss of Bin1 Promotes the Propagation of Tau Pathology.</ArticleTitle><Pagination><StartPage>931</StartPage><EndPage>940</EndPage><MedlinePgn>931-940</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2016.09.063</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(16)31319-5</ELocationID><Abstract><AbstractText>Tau pathology propagates within synaptically connected neuronal circuits, but the underlying mechanisms are unclear. BIN1-amphiphysin2 is the second most prevalent genetic risk factor for late-onset Alzheimer's disease. In diseased brains, the BIN1-amphiphysin2 neuronal isoform is downregulated. Here, we show that lowering BIN1-amphiphysin2 levels in neurons promotes Tau pathology propagation whereas overexpression of neuronal BIN1-amphiphysin2 inhibits the process in two in&#xa0;vitro models. Increased Tau propagation is caused by increased endocytosis, given our finding that BIN1-amphiphysin2 negatively regulates endocytic flux. Furthermore, blocking endocytosis by inhibiting dynamin also reduces Tau pathology propagation. Using a galectin-3-binding assay, we show that internalized Tau aggregates damage the endosomal membrane, allowing internalized aggregates to leak into the cytoplasm to propagate pathology. Our work indicates that lower BIN1 levels promote the propagation of Tau pathology by efficiently increasing aggregate internalization by endocytosis and endosomal trafficking.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calafate</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Discovery Neuroscience, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, 2340 Beerse, Belgium; VIB Center for Brain and Disease Research, 3000 Leuven, Belgium; KU Leuven Department for Human Genetics, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flavin</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Integrative Cell Biology Program, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 90270, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstreken</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, 3000 Leuven, Belgium; KU Leuven Department for Human Genetics, 3000 Leuven, Belgium. Electronic address: patrik.verstreken@cme.vib-kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moechars</LastName><ForeName>Diederik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Discovery Neuroscience, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, 2340 Beerse, Belgium. Electronic address: dmoechar@its.jnj.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C530914">Bin1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.5</RegistryNumber><NameOfSubstance UI="D034281">Dynamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034281" MajorTopicYN="N">Dynamins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer GWAS</Keyword><Keyword MajorTopicYN="N">BIN1</Keyword><Keyword MajorTopicYN="N">Rab5</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">endocytosis</Keyword><Keyword MajorTopicYN="N">galectin-3</Keyword><Keyword MajorTopicYN="N">in&#xa0;vitro model</Keyword><Keyword MajorTopicYN="N">spreading</Keyword><Keyword MajorTopicYN="N">synapse</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27760323</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2016.09.063</ArticleId><ArticleId IdType="pii">S2211-1247(16)31319-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27768896</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>C9orf72 Dipeptide Repeats Impair the Assembly, Dynamics, and Function of Membrane-Less Organelles.</ArticleTitle><Pagination><StartPage>774</StartPage><EndPage>788.e17</EndPage><MedlinePgn>774-788.e17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)31383-6</ELocationID><Abstract><AbstractText>Expansion of a hexanucleotide repeat GGGGCC (G<sub>4</sub>C<sub>2</sub>) in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Transcripts carrying (G<sub>4</sub>C<sub>2</sub>) expansions undergo unconventional, non-ATG-dependent translation, generating toxic dipeptide repeat (DPR) proteins thought to contribute to disease. Here, we identify the interactome of all DPRs and find that arginine-containing DPRs, polyGly-Arg (GR) and polyPro-Arg (PR), interact with RNA-binding proteins and proteins with low complexity sequence domains (LCDs) that often mediate the assembly of membrane-less organelles. Indeed, most GR/PR interactors are components of membrane-less organelles such as nucleoli, the nuclear pore complex and stress granules. Genetic analysis in Drosophila demonstrated the functional relevance of these interactions to DPR toxicity. Furthermore, we show that GR and PR altered phase separation of LCD-containing proteins, insinuating into their liquid assemblies and changing their material properties, resulting in perturbed dynamics and/or functions of multiple membrane-less organelles.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung-Ha</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Peipei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hong Joo</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitrea</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Mohona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freibaum</LastName><ForeName>Brian D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cika</LastName><ForeName>Jaclyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coughlin</LastName><ForeName>Maura</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messing</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molliex</LastName><ForeName>Amandine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nam Chul</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temirov</LastName><ForeName>Jamshid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolaitis</LastName><ForeName>Regina-Maria</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Timothy I</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Junmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; St. Jude Proteomics Facility, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kriwacki</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Sciences Center, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: jpaul.taylor@stjude.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R35NS097974</GrantID><Acronym>US</Acronym><Agency>United States</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047928</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>25191-13-3</RegistryNumber><NameOfSubstance UI="C011083">polyproline</NameOfSubstance></Chemical><Chemical><RegistryNumber>25212-18-4</RegistryNumber><NameOfSubstance UI="C015462">polyarginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>25718-94-9</RegistryNumber><NameOfSubstance UI="C011080">polyglycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002466" MajorTopicYN="N">Cell Nucleolus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003594" MajorTopicYN="N">Cytoplasmic Granules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007425" MajorTopicYN="N">Intracellular Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022022" MajorTopicYN="N">Nuclear Pore</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">dipeptide repeat</Keyword><Keyword MajorTopicYN="N">membrane-less organelle</Keyword><Keyword MajorTopicYN="N">nucleolus</Keyword><Keyword MajorTopicYN="N">phase separation</Keyword><Keyword MajorTopicYN="N">stress granule</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27768896</ArticleId><ArticleId IdType="mid">NIHMS821453</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pii">S0092-8674(16)31383-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SS, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Kedersha N. RNA granules: post-transcriptional and epigenetic modulators of gene expression. Nat Rev Mol Cell Biol. 2009;10:430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">19461665</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert FM, van Koningsbruggen S, Navascues J, Lamond AI. The multifunctional nucleolus. Nat Rev Mol Cell Biol. 2007;8:574&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">17519961</ArticleId></ArticleIdList></Reference><Reference><Citation>Brangwynne C, Tompa P, Pappu R. Polymer physics of intracellular phase transitions. NATURE PHYSICS. 2015;11:899&#x2013;904.</Citation></Reference><Reference><Citation>Brangwynne CP, Mitchison TJ, Hyman AA. Active liquid-like behavior of nucleoli determines their size and shape in Xenopus laevis oocytes. Proc Natl Acad Sci U S A. 2011;108:4334&#x2013;4339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060270</ArticleId><ArticleId IdType="pubmed">21368180</ArticleId></ArticleIdList></Reference><Reference><Citation>Caussinus E, Kanca O, Affolter M. Fluorescent fusion protein knockout mediated by anti-GFP nanobody. Nat Struct Mol Biol. 2012;19:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">22157958</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H, Larsen B, Lin ZY, Breitkreutz A, Mellacheruvu D, Fermin D, Qin ZS, Tyers M, Gingras AC, Nesvizhskii AI. SAINT: probabilistic scoring of affinity purification-mass spectrometry data. Nat Methods. 2011;8:70&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064265</ArticleId><ArticleId IdType="pubmed">21131968</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Feric M, Vaidya N, Harmon TS, Mitrea DM, Zhu L, Richardson TM, Kriwacki RW, Pappu RV, Brangwynne CP. Coexisting Liquid Phases Underlie Nucleolar Subcompartments. Cell 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127388</ArticleId><ArticleId IdType="pubmed">27212236</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 2013;126:829&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci. 1999;112(Pt 6):761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">10036227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackman P, Sarparanta J, Lehtinen S, Vihola A, Evila A, Jonson PH, Luque H, Kere J, Screen M, Chinnery PF, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol. 2013;73:500&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">23401021</ArticleId></ArticleIdList></Reference><Reference><Citation>Hormoz S. Amino acid composition of proteins reduces deleterious impact of mutations. Sci Rep. 2013;3:2919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794375</ArticleId><ArticleId IdType="pubmed">24108121</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, 3rd, Sun S, Herdy JR, Bieri G, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K, Yagi T, Cammack AJ, Mahadevan J, Kuroda M, Harms MB, Miller TM, Urano F. Poly-dipeptides encoded by the C9ORF72 repeats block global protein translation. Hum Mol Genet 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986334</ArticleId><ArticleId IdType="pubmed">26931465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Panas MD, Achorn CA, Lyons S, Tisdale S, Hickman T, Thomas M, Lieberman J, McInerney GM, Ivanov P, et al. G3BP-Caprin1-USP10 complexes mediate stress granule condensation and associate with 40S subunits. J Cell Biol. 2016;212:845&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810302</ArticleId><ArticleId IdType="pubmed">27022092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Klar J, Sobol M, Melberg A, Mabert K, Ameur A, Johansson AC, Feuk L, Entesarian M, Orlen H, Casar-Borota O, et al. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with perturbed splicing. Hum Mutat. 2013;34:572&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">23348830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroschwald S, Maharana S, Mateju D, Malinovska L, Nuske E, Poser I, Richter D, Alberti S. Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. Elife. 2015;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522596</ArticleId><ArticleId IdType="pubmed">26238190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Banjade S, Cheng HC, Kim S, Chen B, Guo L, Llaguno M, Hollingsworth JV, King DS, Banani SF, et al. Phase transitions in the assembly of multivalent signalling proteins. Nature. 2012;483:336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343696</ArticleId><ArticleId IdType="pubmed">22398450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK, Parker R. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Machyna M, Neugebauer KM, Stanek D. Coilin: The first 25 years. RNA Biol. 2015;12:590&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615369</ArticleId><ArticleId IdType="pubmed">25970135</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzahn MR, Marada S, Lee J, Nourse A, Kenrick S, Zhao H, Ben-Nissan G, Kolaitis RM, Peters JL, Pounds S, et al. Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles. EMBO J 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910529</ArticleId><ArticleId IdType="pubmed">27220849</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis NA, Li T, Miteva YV, Hauri S, Sardiu ME, Low TY, et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods. 2013;10:730&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773500</ArticleId><ArticleId IdType="pubmed">23921808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrea DM, Cika JA, Guy CS, Ban D, Banerjee PR, Stanley CB, Nourse A, Deniz AA, Kriwacki RW. Nucleophosmin integrates within the nucleolus via multi-modal interactions with proteins displaying R-rich linear motifs and rRNA. Elife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786410</ArticleId><ArticleId IdType="pubmed">26836305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Arzberger T, Grasser FA, Gijselinck I, May S, Rentzsch K, Weng SM, Schludi MH, van der Zee J, Cruts M, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126:881&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">24132570</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, Qamar S, Lin JQ, Schierle GS, Rees E, Miyashita A, Costa AR, Dodd RB, Chan FT, Michel CH, et al. ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron. 2015;88:678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie Z, Neale G, Taylor JP. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron. 2010;67:936&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield CJ, Dunker AK. Intrinsically disordered proteins and intrinsically disordered protein regions. Annu Rev Biochem. 2014;83:553&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">24606139</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, Stoynov S, Mahamid J, Saha S, Franzmann TM, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, Murray ME, Overstreet KK, Piazza-Johnston AE, Desaro P, et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;18:1175&#x2013;1182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, Greenberg SA. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40:19&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700211</ArticleId><ArticleId IdType="pubmed">19533646</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009;6:275&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">19305406</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweizer Burguete A, Almeida S, Gao FB, Kalb R, Akins MR, Bonini NM. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 2015;4:e08881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RJ, Cleveland DW. Decoding ALS from Genes to Mechanism. Nature. 2016 In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>UniProt C. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43:D204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384041</ArticleId><ArticleId IdType="pubmed">25348405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira NM, Naslavsky MS, Licinio L, Kok F, Schlesinger D, Vainzof M, Sanchez N, Kitajima JP, Gal L, Cavacana N, et al. A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G) Hum Mol Genet. 2014;23:4103&#x2013;4110.</Citation><ArticleIdList><ArticleId IdType="pubmed">24647604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wansink DG, Schul W, van der Kraan I, van Steensel B, van Driel R, de Jong L. Fluorescent labeling of nascent RNA reveals transcription by RNA polymerase II in domains scattered throughout the nucleus. J Cell Biol. 1993;122:283&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2119648</ArticleId><ArticleId IdType="pubmed">8320255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton JC, Federhen S. Analysis of compositionally biased regions in sequence databases. Methods Enzymol. 1996;266:554&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">8743706</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Poidevin M, Li X, Li Y, Shu L, Nelson DL, Li H, Hales CM, Gearing M, Wingo TS, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci U S A. 2013;110:7778&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Jansen-West K, Xu YF, Gendron TF, Bieniek KF, Lin WL, Sasaguri H, Caulfield T, Hubbard J, Daughrity L, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128:505&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159567</ArticleId><ArticleId IdType="pubmed">25173361</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011;108:260&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017129</ArticleId><ArticleId IdType="pubmed">21173221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27768897</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers.</ArticleTitle><Pagination><StartPage>789</StartPage><EndPage>802.e12</EndPage><MedlinePgn>789-802.e12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.10.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)31384-8</ELocationID><Abstract><AbstractText>Two complementary approaches were used in search of the intracellular targets of the toxic PR poly-dipeptide encoded by the repeat sequences expanded in the C9orf72 form of amyotrophic lateral sclerosis. The top categories of PR<sub>n</sub>-bound proteins include constituents of non-membrane invested cellular organelles and intermediate filaments. PR<sub>n</sub>&#xa0;targets are enriched for the inclusion of low complexity (LC) sequences. Evidence is presented indicating that LC sequences represent the direct target of PR<sub>n</sub> binding and that interaction between the PR<sub>n</sub> poly-dipeptide and LC domains is polymer-dependent. These studies indicate that PR<sub>n</sub>-mediated toxicity may result from broad impediments to the dynamics of cell structure and information flow from gene to message to protein.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Eiichiro</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Siheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Leeju</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Ilmin</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute, Suwon 16419, Korea. Electronic address: ilmin.kwon@skku.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>Steven L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9152, USA. Electronic address: steven.mcknight@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA142543</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 GM107623</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007381">Intermediate Filament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>25191-13-3</RegistryNumber><NameOfSubstance UI="C011083">polyproline</NameOfSubstance></Chemical><Chemical><RegistryNumber>25212-18-4</RegistryNumber><NameOfSubstance UI="C015462">polyarginine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007381" MajorTopicYN="N">Intermediate Filament Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">1,6-hexanediol</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">amyloid-like polymers</Keyword><Keyword MajorTopicYN="N">cellular puncta not invested by surrounding membranes</Keyword><Keyword MajorTopicYN="N">intermediate filaments</Keyword><Keyword MajorTopicYN="N">labile</Keyword><Keyword MajorTopicYN="N">low complexity sequence polymers</Keyword><Keyword MajorTopicYN="N">toxic PRn and GRn poly-dipeptides</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27768897</ArticleId><ArticleId IdType="mid">NIHMS824256</ArticleId><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.10.003</ArticleId><ArticleId IdType="pii">S0092-8674(16)31384-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ACD/Structure Elucidator. version 15.01. Toronto, ON, Canada: Advanced Chemistry Development, Inc.; 2015.   http://www.acdlabs.com/</Citation></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Astbury WT, Dickinson S, Bailey K. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem J. 1935;29:2351&#x2013;2360. 2351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1266766</ArticleId><ArticleId IdType="pubmed">16745914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergeron-Sandoval LP, Safaee N, Michnick SW. Mechanisms and Consequences of Macromolecular Phase Separation. Cell. 2016;165:1067&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">27203111</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlees J, Ackerley S, Grierson AJ, Jacobsen NJ, Shea K, Anderton BH, Leigh PN, Shaw CE, Miller CC. Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet. 2002;11:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393795</ArticleId></ArticleIdList></Reference><Reference><Citation>Castaing Y, Harf A. Evaluation of the distribution of pulmonary ventilation-perfusion ratios. Rev Mal Respir. 1986;3:399&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">3575859</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Goldman RD. Intermediate filaments mediate cytoskeletal crosstalk. Nat Rev Mol Cell Biol. 2004;5:601&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">15366704</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaxon. 2016 ( http://www.chemaxon.com/)</Citation></Reference><Reference><Citation>Cho A, Kato M, Whitwam T, Kim JH, Montell DJ. An Atypical Tropomyosin in Drosophila with Intermediate Filament-like Properties. Cell Rep. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971881</ArticleId><ArticleId IdType="pubmed">27396338</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol. 2005;6:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15738986</ArticleId></ArticleIdList></Reference><Reference><Citation>EPA, U. Estimation Programs Interface Suite&#x2122; for Microsoft&#xae; Windows. Washington, DC, USA: United States Environmental Protection Agency; 2016.</Citation></Reference><Reference><Citation>Eriksson JE, He T, Trejo-Skalli AV, Harmala-Brasken AS, Hellman J, Chou YH, Goldman RD. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci. 2004;117:919&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pubmed">14762106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrizi GM, Cavallaro T, Angiari C, Bertolasi L, Cabrini I, Ferrarini M, Rizzuto N. Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E. Neurology. 2004;62:1429&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">15111691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher DA, Mullins RD. Cell mechanics and the cytoskeleton. Nature. 2010;463:485&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851742</ArticleId><ArticleId IdType="pubmed">20110992</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar I, Sysoev V, Komissarov A, Ephrussi A. An RNA-binding tropomyosin recruits kinesin-1 dynamically to oskar mRNPs. BioRXiv. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5286366</ArticleId><ArticleId IdType="pubmed">28028052</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler N, Hatzfeld M, Weber K. Phosphorylation in vitro of vimentin by protein kinases A and C is restricted to the head domain. Identification of the phosphoserine sites and their influence on filament formation. Eur J Biochem. 1989;183:441&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">2503376</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiou DM, Zidar J, Korosec M, Middleton LT, Kyriakides T, Christodoulou K. A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics. 2002;4:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">12481988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwald J, Riek R. Biology of amyloid: structure, function, and regulation. Structure. 2010;18:1244&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pubmed">20947013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Shorter J. It's Raining Liquids: RNA Tunes Viscoelasticity and Dynamics of Membraneless Organelles. Mol Cell. 2015;60:189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653132</ArticleId><ArticleId IdType="pubmed">26474062</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, Simko EA, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Han TW, Kato M, Xie S, Wu LC, Mirzaei H, Pei J, Chen M, Xie Y, Allen J, Xiao G, et al. Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell. 2012;149:768&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">22579282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzfeld M, Burba M. Function of type I and type II keratin head domains: their role in dimer, tetramer and filament formation. J Cell Sci. 1994;107(Pt 7):1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">7527050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes MH, Weeks DL. Amyloids assemble as part of recognizable structures during oogenesis in Xenopus. Biol Open. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4920187</ArticleId><ArticleId IdType="pubmed">27215327</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann H, Bar H, Kreplak L, Strelkov SV, Aebi U. Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol Cell Biol. 2007;8:562&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551517</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann H, Haner M, Brettel M, Muller SA, Goldie KN, Fedtke B, Lustig A, Franke WW, Aebi U. Structure and assembly properties of the intermediate filament protein vimentin: the role of its head, rod and tail domains. J Mol Biol. 1996;264:933&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">9000622</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, 3rd, Sun S, Herdy JR, Bieri G, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Klymkowsky MW, Maynell LA, Polson AG. Polar asymmetry in the organization of the cortical cytokeratin system of Xenopus laevis oocytes and embryos. Development. 1987;100:543&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">2443336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroschwald S, Maharana S, Mateju D, Malinovska L, Nuske E, Poser I, Richter D, Alberti S. Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. Elife. 2015;4:e06807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522596</ArticleId><ArticleId IdType="pubmed">26238190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, Wu L, Theodoropoulos P, Wang T, Kim J, Yun J, Xie Y, McKnight SL. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110:E4530&#x2013;E4539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, Troakes C, Nishimura AL, Scotter EL, Vance C, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Protter DS, Rosen MK, Parker R. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins. Mol Cell. 2015;60:208&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609299</ArticleId><ArticleId IdType="pubmed">26412307</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh RE, Corey RB, Pauling L. An investigation of the structure of silk fibroin. Biochim Biophys Acta. 1955;16:1&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">14363226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 2013;126:845&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A, Temirov J, Lee J, Coughlin M, Kanagaraj AP, Kim HJ, Mittag T, Taylor JP. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke N, Wedig T, Burer A, Marekov LN, Steinert PM, Langowski J, Aebi U, Herrmann H. Molecular and biophysical characterization of assembly-starter units of human vimentin. J Mol Biol. 2004;340:97&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">15184025</ArticleId></ArticleIdList></Reference><Reference><Citation>Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">8602510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogrodnik M, Salmonowicz H, Brown R, Turkowska J, Sredniawa W, Pattabiraman S, Amen T, Abraham AC, Eichler N, Lyakhovetsky R, et al. Dynamic JUNQ inclusion bodies are asymmetrically inherited in mammalian cell lines through the asymmetric partitioning of vimentin. Proc Natl Acad Sci U S A. 2014;111:8049&#x2013;8054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050583</ArticleId><ArticleId IdType="pubmed">24843142</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, Stoynov S, Mahamid J, Saha S, Franzmann TM, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SS, Belmont BJ, Sante JM, Rexach MF. Natively unfolded nucleoporins gate protein diffusion across the nuclear pore complex. Cell. 2007;129:83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">17418788</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Olle R, Lopez-Toledano MA, Liem RK. The G336S variant in the human neurofilament-M gene does not affect its assembly or distribution: importance of the functional analysis of neurofilament variants. J Neuropathol Exp Neurol. 2004;63:759&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15290901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pondel MD, King ML. Localized maternal mRNA related to transforming growth factor beta mRNA is concentrated in a cytokeratin-enriched fraction from Xenopus oocytes. Proc Natl Acad Sci U S A. 1988;85:7612&#x2013;7616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC282242</ArticleId><ArticleId IdType="pubmed">2459710</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnapp BJ, Reese TS. Cytoplasmic structure in rapid-frozen axons. J Cell Biol. 1982;94:667&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112215</ArticleId><ArticleId IdType="pubmed">6182148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Pellarin R, Fridy PC, Fernandez-Martinez J, Thompson MK, Li Y, Wang QJ, Sali A, Rout MP, Chait BT. A strategy for dissecting the architectures of native macromolecular assemblies. Nat Methods. 2015;12:1135&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4803312</ArticleId><ArticleId IdType="pubmed">26436480</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JS, Chung KW, Cho SY, Yun J, Hwang SJ, Kang SH, Cho EM, Kim SM, Choi BO. NEFL Pro22Arg mutation in Charcot-Marie-Tooth disease type 1. J Hum Genet. 2008;53:936&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">18758688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolova AV, Kreplak L, Wedig T, Mucke N, Svergun DI, Herrmann H, Aebi U, Strelkov SV. Monitoring intermediate filament assembly by small-angle x-ray scattering reveals the molecular architecture of assembly intermediates. Proc Natl Acad Sci U S A. 2006;103:16206&#x2013;16211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1637561</ArticleId><ArticleId IdType="pubmed">17050693</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MS, LaCava J, Mita P, Molloy KR, Huang CR, Li D, Adney EM, Jiang H, Burns KH, Chait BT, et al. Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell. 2013;155:1034&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904357</ArticleId><ArticleId IdType="pubmed">24267889</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, Radchenko EV, Zefirov NS, Makarenko AS, et al. Virtual computational chemistry laboratory--design and description. J Comput Aided Mol Des. 2005;19:453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">16231203</ArticleId></ArticleIdList></Reference><Reference><Citation>Updike DL, Hachey SJ, Kreher J, Strome S. P granules extend the nuclear pore complex environment in the C. elegans germ line. J Cell Biol. 2011;192:939&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063144</ArticleId><ArticleId IdType="pubmed">21402789</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, Gendron TF, Baker MC, DeJesus-Hernandez M, Finch NA, Brown PH, Daughrity LM, Murray ME, Heckman MG, Jiang J, et al. Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathol. 2015;130:863&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655160</ArticleId><ArticleId IdType="pubmed">26437865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira NM, Naslavsky MS, Licinio L, Kok F, Schlesinger D, Vainzof M, Sanchez N, Kitajima JP, Gal L, Cavacana N, et al. A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G) Hum Mol Genet. 2014;23:4103&#x2013;4110.</Citation><ArticleIdList><ArticleId IdType="pubmed">24647604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y, Lin S, Shneider NA, Monaghan J, Pandey UB, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootton JC. Non-globular domains in protein sequences: automated segmentation using complexity measures. Comput Chem. 1994;18:269&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">7952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Fuxreiter M. The Structure and Dynamics of Higher-Order Assemblies: Amyloids, Signalosomes, and Granules. Cell. 2016;165:1055&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878688</ArticleId><ArticleId IdType="pubmed">27203110</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang S, Kato M, Wu LC, Lin Y, Ding M, Zhang Y, Yu Y, McKnight SL. The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei. Cell. 2015;163:829&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879888</ArticleId><ArticleId IdType="pubmed">26544936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, Miller TM, Harms MB, Falchook AE, Subramony SH, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;E4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27806159</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults.</ArticleTitle><Pagination><StartPage>1230</StartPage><EndPage>1237</EndPage><MedlinePgn>1230-1237</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2016.2657</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Emotional and behavioral symptoms in cognitively normal older people may be direct manifestations of Alzheimer disease (AD) pathophysiology at the preclinical stage, prior to the onset of mild cognitive impairment. Loneliness is a perceived state of social and emotional isolation that has been associated with cognitive and functional decline and an increased risk of incident AD dementia. We hypothesized that loneliness might occur in association with elevated cortical amyloid burden, an in vivo research biomarker of AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether cortical amyloid burden is associated with greater loneliness in cognitively normal older adults.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Cross-sectional analyses using data from the Harvard Aging Brain Study of 79 cognitively normal, community-dwelling participants. A continuous, aggregate measure of cortical amyloid burden, determined by Pittsburgh Compound B-positron emission tomography (PiB-PET), was examined in association with loneliness in linear regression models adjusting for age, sex, apolipoprotein E &#x3b5;4 (APOE&#x3b5;4), socioeconomic status, depression, anxiety, and social network (without and with the interaction of amyloid and APOE&#x3b5;4). We also quantified the association of high amyloid burden (amyloid-positive group) to loneliness (lonely group) using logistic regression, controlling for the same covariates, with the amyloid-positive group and the lonely group, each composing 32% of the sample (n&#x2009;=&#x2009;25).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Loneliness, as determined by the 3-item UCLA Loneliness Scale (possible range, 3-12, with higher score indicating greater loneliness).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 79 participants included 43 women and 36 men with a mean (SD) age of 76.4 (6.2) years. Mean (SD) cortical amyloid burden via PiB-PET was 1.230 (0.209), and the mean (SD) UCLA-3 loneliness score was 5.3 (1.8). Twenty-two (28%) had positive APOE&#x3b5;4 carrier status, and 25 (32%) were in the amyloid-positive group with cortical PiB distribution volume ratio greater than 1.2. Controlling for age, sex, APOE&#x3b5;4, socioeconomic status, depression, anxiety, and social network, we found that higher amyloid burden was significantly associated with greater loneliness: compared with individuals in the amyloid-negative group, those in the amyloid-positive group were 7.5-fold (95% CI, 1.7-fold to 34.0-fold) more likely to be classified as lonely than nonlonely (&#x3b2;&#x2009;=&#x2009;3.3, partial r&#x2009;=&#x2009;0.4, P&#x2009;=&#x2009;.002). Furthermore, the association of high amyloid burden and loneliness was stronger in APOE&#x3b5;4 carriers than in noncarriers.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">We report a novel association of loneliness with cortical amyloid burden in cognitively normal older adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD. This work will inform new research into the neural underpinnings and disease mechanisms involved in loneliness and may enhance early detection and intervention research in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donovan</LastName><ForeName>Nancy J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts4Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okereke</LastName><ForeName>Olivia I</ForeName><Initials>OI</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amariglio</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston6Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG048287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG045080</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Psychiatry. 2016 Dec 1;73(12):1237-1238. doi: 10.1001/jamapsychiatry.2016.2688.</RefSource><PMID Version="1">27806158</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008132" MajorTopicYN="N">Loneliness</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="Y">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures: Dr Donovan has received salary support from Eisai Inc and Eli Lilly and Company. Her spouse is employed by Alkermes PLC. Dr Rentz has served as a paid consultant for Eli Lilly, Janssen Alzheimer Immunotherapy, Biogen Idek, and Lundbeck Pharmaceuticals and sits on the Scientific Advisory Board for Neurotrack. Dr Marshall has received salary support from Eisai Inc and Eli Lilly and Company and consulting fees from Halloran and GliaCure Inc. Dr Johnson has served as paid consultant for Bayer, Biogen Idec, Bristol-Myers Squibb, GE Healthcare, Isis Pharmaceuticals Inc, Janssen Alzheimer&#x2019;s Immunotherapy, Piramal, Siemens Medical Solutions, Novartis, Roche, Lundbeck, and Genzyme. He is a site principal investigator or coinvestigator for Lilly/Avid, Biogen Idec, Bristol-Myers Squibb, Eisai, Pfizer, Janssen Alzheimer Immunotherapy, Merck, and Navidea clinical trials. He has spoken at symposia sponsored by Janssen Alzheimer&#x2019;s Immunotherapy, GEHC, Lundbeck, and Pfizer. Dr Sperling has served as a paid consultant for Abbvie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi. She has served as a coinvestigator for Avid, Eli Lilly, and Janssen Alzheimer Immunotherapy clinical trials. She has spoken at symposia sponsored by Eli Lilly, Biogen, and Janssen Alzheimer Immunotherapy. None of these relationships are related to the content of the article. No other disclosures are reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27806159</ArticleId><ArticleId IdType="mid">NIHMS842672</ArticleId><ArticleId IdType="pmc">PMC5257284</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2016.2657</ArticleId><ArticleId IdType="pii">2575729</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan NJ, Amariglio RE, Zoller AS, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014;22(12):1642&#x2013;1651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145054</ArticleId><ArticleId IdType="pubmed">24698445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Amariglio RE, Becker JA, et al. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49(9):2776&#x2013;2783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137730</ArticleId><ArticleId IdType="pubmed">21689670</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Roberts RO, Mielke MM, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry. 2014;171(5):572&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057095</ArticleId><ArticleId IdType="pubmed">24700290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Krueger KR, Arnold SE, et al. Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry. 2007;64(2):234&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17283291</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Gow AJ, Taylor MD, et al. The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. BMC Geriatr. 2007;7:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2222601</ArticleId><ArticleId IdType="pubmed">18053258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilvis RS, K&#xe4;h&#xf6;nen-V&#xe4;re MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci. 2004;59(3):268&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15031312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar A, Hamer M, McMunn A, Steptoe A. Social isolation and loneliness: relationships with cognitive function during 4 years of follow-up in the English Longitudinal Study of Ageing. Psychosom Med. 2013;75(2):161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">23362501</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan NJ, Wu Q, Rentz DM, Sperling RA, Marshall GA, Glymour MM. Loneliness, depression and cognitive function in older U.S. adults. [published online ahead of print May 9, 2016] Int J Geriatr Psychiatry. 2016 doi: 10.1002/gps.4495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4495</ArticleId><ArticleId IdType="pmc">PMC5102822</ArticleId><ArticleId IdType="pubmed">27162047</ArticleId></ArticleIdList></Reference><Reference><Citation>Perissinotto CM, Stijacic Cenzer I, Covinsky KE. Loneliness in older persons: a predictor of functional decline and death. Arch Intern Med. 2012;172(14):1078&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383762</ArticleId><ArticleId IdType="pubmed">22710744</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell DW. UCLA Loneliness Scale (Version 3): reliability, validity, and factor structure. J Pers Assess. 1996;66(1):20&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8576833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A short scale for measuring loneliness in large surveys: results from two population-based studies. Res Aging. 2004;26(6):655&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2394670</ArticleId><ArticleId IdType="pubmed">18504506</ArticleId></ArticleIdList></Reference><Reference><Citation>Theeke LA. Sociodemographic and health-related risks for loneliness and outcome differences by loneliness status in a sample of U.S. older adults. Res Gerontol Nurs. 2010;3(2):113&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">20415360</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried EI, Bockting C, Arjadi R, et al. From loss to loneliness: The relationship between bereavement and depressive symptoms. J Abnorm Psychol. 2015;124(2):256&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">25730514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacioppo JT, Hawkley LC, Thisted RA. Perceived social isolation makes me sad: 5-year cross-lagged analyses of loneliness and depressive symptomatology in the Chicago Health, Aging, and Social Relations Study. Psychol Aging. 2010;25(2):453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922929</ArticleId><ArticleId IdType="pubmed">20545429</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Betensky RA, Hedden T, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study. Amyloid and APOE &#x3b5;4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760&#x2013;1767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035706</ArticleId><ArticleId IdType="pubmed">24748674</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16(14):4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Knopman DS, Mrazek DA, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006;63(3):435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">16533972</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan NJ, Hsu DC, Dagley AS, et al. Depressive symptoms and biomarkers of Alzheimer&#x2019;s disease in cognitively normal older adults. J Alzheimers Dis. 2015;46(1):63&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544638</ArticleId><ArticleId IdType="pubmed">25697700</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Clinical core of the Alzheimer&#x2019;s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010;6(3):239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhmann M, Hawkley LC. Age differences in loneliness from late adolescence to oldest old age. Dev Psychol. 2016;52(6):943&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015413</ArticleId><ArticleId IdType="pubmed">27148782</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982&#x2013;1983;17(1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">7183759</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979;109(2):186&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">425958</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman TE, Kaplan GA, Knudsen L, Cohen R, Guralnik J. Social network ties and mortality among the elderly in the Alameda County Study. Am J Epidemiol. 1987;126(4):714&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">3631060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol. 2006;24(7):1105&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505430</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael YL, Colditz GA, Coakley E, Kawachi I. Health behaviors, social networks, and healthy aging: cross-sectional evidence from the Nurses&#x2019; Health Study. Qual Life Res. 1999;8(8):711&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">10855345</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Mendes de Leon CF, Wilson RS, Bienias JL, Evans DA. Social resources and cognitive decline in a population of older African Americans and whites. Neurology. 2004;63(12):2322&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623694</ArticleId></ArticleIdList></Reference><Reference><Citation>Juhn YJ, Beebe TJ, Finnie DM, et al. Development and initial testing of a new socioeconomic status measure based on housing data. J Urban Health. 2011;88(5):933&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191204</ArticleId><ArticleId IdType="pubmed">21499815</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Mormino EC, Amariglio RE, et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012;32(46):16233&#x2013;16242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523110</ArticleId><ArticleId IdType="pubmed">23152607</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62(3):229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer&#x2019;s disease with Pittsburgh Compound B. J Neurosci Methods. 2008;172(2):277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2501111</ArticleId><ArticleId IdType="pubmed">18582948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai R, Bahrami B, Duchaine B, Janik A, Banissy MJ, Rees G. Brain structure links loneliness to social perception. Curr Biol. 2012;22(20):1975&#x2013;1979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510434</ArticleId><ArticleId IdType="pubmed">23041193</ArticleId></ArticleIdList></Reference><Reference><Citation>Adolphs R. Cognitive neuroscience of human social behaviour. Nat Rev Neurosci. 2003;4(3):165&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612630</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris CJ, Chen EE, Zhu DC, Small SL, Cacioppo JT. The interaction of social and emotional processes in the brain. J Cogn Neurosci. 2004;16(10):1818&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701231</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor MF. Immunological and neuroimaging biomarkers of complicated grief. Dialogues Clin Neurosci. 2012;14(2):141&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384442</ArticleId><ArticleId IdType="pubmed">22754286</ArticleId></ArticleIdList></Reference><Reference><Citation>Freed PJ, Yanagihara TK, Hirsch J, Mann JJ. Neural mechanisms of grief regulation. Biol Psychiatry. 2009;66(1):33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782609</ArticleId><ArticleId IdType="pubmed">19249748</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ndel H, O&#x2019;Connor MF, Littrell L, Fort C, Lane RD. Functional neuroanatomy of grief: an FMRI study. Am J Psychiatry. 2003;160(11):1946&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="pubmed">14594740</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersting A, Ohrmann P, Pedersen A, et al. Neural activation underlying acute grief in women after the loss of an unborn child. Am J Psychiatry. 2009;166(12):1402&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">19884226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson JM, Heilbronner SR, Barack DL, Hayden BY, Platt ML. Posterior cingulate cortex: adapting behavior to a changing world. Trends Cogn Sci. 2011;15(4):143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070780</ArticleId><ArticleId IdType="pubmed">21420893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassuk SS, Glass TA, Berkman LF. Social disengagement and incident cognitive decline in community-dwelling elderly persons. Ann Intern Med. 1999;131(3):165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428732</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman TE, Lusignolo TM, Albert M, Berkman L. Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur studies of successful aging. Health Psychol. 2001;20(4):243&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">11515736</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo AR, Choi H, Andrea SB, et al. Does mode of contact with different types of social relationships predict depression in older adults? evidence from a nationally representative survey. J Am Geriatr Soc. 2015;63(10):2014&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5527991</ArticleId><ArticleId IdType="pubmed">26437566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, James BD, Leurgans SE, Buchman AS, Bennett DA. Negative social interactions and risk of mild cognitive impairment in old age. Neuropsychology. 2015;29(4):561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468039</ArticleId><ArticleId IdType="pubmed">25495828</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Mendes de Leon CF, et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology. 2002;59(3):364&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177369</ArticleId></ArticleIdList></Reference><Reference><Citation>Slavich GM, O&#x2019;Donovan A, Epel ES, Kemeny ME. Black sheep get the blues: a psychobiological model of social rejection and depression. Neurosci Biobehav Rev. 2010;35(1):39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2926175</ArticleId><ArticleId IdType="pubmed">20083138</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberger NI, Cole SW. Social neuroscience and health: neurophysiological mechanisms linking social ties with physical health. Nat Neurosci. 2012;15(5):669&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">22504347</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacioppo JT, Hawkley LC, Crawford LE, et al. Loneliness and health: potential mechanisms. Psychosom Med. 2002;64(3):407&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">12021415</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam EK, Hawkley LC, Kudielka BM, Cacioppo JT. Day-to-day dynamics of experience: cortisol associations in a population-based sample of older adults. Proc Natl Acad Sci U S A. 2006;103(45):17058&#x2013;17063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636578</ArticleId><ArticleId IdType="pubmed">17075058</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh JE, Lawlor BA. Perceived stress mediates the relationship between emotional loneliness and sleep quality over time in older adults. Br J Health Psychol. 2013;18(3):546&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">22988915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackett RA, Hamer M, Endrighi R, Brydon L, Steptoe A. Loneliness and stress-related inflammatory and neuroendocrine responses in older men and women. Psychoneuroendocrinology. 2012;37(11):1801&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">22503139</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaremka LM, Andridge RR, Fagundes CP, et al. Pain, depression, and fatigue: loneliness as a longitudinal risk factor. Health Psychol. 2014;33(9):948&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3992976</ArticleId><ArticleId IdType="pubmed">23957903</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai LM, Ghura S, Koster KP, et al. APOE-modulated A&#x3b2;-induced neuroinflammation in Alzheimer&#x2019;s disease: current landscape, novel data, and future perspective. J Neurochem. 2015;133(4):465&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4400246</ArticleId><ArticleId IdType="pubmed">25689586</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc Natl Acad Sci U S A. 2004;101(1):284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Valla J, Yaari R, Wolf AB, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE &#x3b5;4 allele, the major late-onset Alzheimer&#x2019;s susceptibility gene. J Alzheimers Dis. 2010;22(1):307&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124564</ArticleId><ArticleId IdType="pubmed">20847408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264(5160):850&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">8171342</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Wilson WA, Moore SD, et al. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis. 2005;18(2):390&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">15686968</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27810929</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.</ArticleTitle><Pagination><StartPage>2635</StartPage><EndPage>2654</EndPage><MedlinePgn>2635-2654</MedlinePgn></Pagination><Abstract><AbstractText>Filamentous tau aggregates are hallmark lesions in numerous neurodegenerative diseases, including Alzheimer's disease (AD). Cell culture and animal studies showed that tau fibrils can undergo cell-to-cell transmission and seed aggregation of soluble tau, but this phenomenon was only robustly demonstrated in models overexpressing tau. In this study, we found that intracerebral inoculation of tau fibrils purified from AD brains (AD-tau), but not synthetic tau fibrils, resulted in the formation of abundant tau inclusions in anatomically connected brain regions in nontransgenic mice. Recombinant human tau seeded by AD-tau revealed unique conformational features that are distinct from synthetic tau fibrils, which could underlie the differential potency in seeding physiological levels of tau to aggregate. Therefore, our study establishes a mouse model of sporadic tauopathies and points to important differences between tau fibrils that are generated artificially and authentic ones that develop in AD brains.</AbstractText><CopyrightInformation>&#xa9; 2016 Guo et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-8503-3746</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Sneha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1665-9681</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Changolkar</LastName><ForeName>Lakshmi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zhuohao</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-1505-8750</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stieber</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-1119-4886</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gathagan</LastName><ForeName>Ronald J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0001-5706-0803</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Michiyo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Jennifer D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0002-9239-8794</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0003-3536-6902</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 vmylee@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014020">Tissue Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014020" MajorTopicYN="N">Tissue Extracts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27810929</ArticleId><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="doi">10.1084/jem.20160833</ArticleId><ArticleId IdType="pii">jem.20160833</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams S.J., DeTure M.A., McBride M., Dickson D.W., and Petrucelli L.. 2010. Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One. 5:e10810 10.1371/journal.pone.0010810</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010810</ArticleId><ArticleId IdType="pmc">PMC2876030</ArticleId><ArticleId IdType="pubmed">20520830</ArticleId></ArticleIdList></Reference><Reference><Citation>Boluda S., Iba M., Zhang B., Raible K.M., Lee V.M., and Trojanowski J.Q.. 2015. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer&#x2019;s disease or corticobasal degeneration brains. Acta Neuropathol. 129:221&#x2013;237. 10.1007/s00401-014-1373-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1373-0</ArticleId><ArticleId IdType="pmc">PMC4305460</ArticleId><ArticleId IdType="pubmed">25534024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirita C.N., Necula M., and Kuret J.. 2003. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278:25644&#x2013;25650. 10.1074/jbc.M301663200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M301663200</ArticleId><ArticleId IdType="pubmed">12730214</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. . 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11:909&#x2013;913. 10.1038/ncb1901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Akatsu H., Fraser G., Crowther R.A., Frank S., Hench J., Probst A., Winkler D.T., Reichwald J., Staufenbiel M., et al. . 2013. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. USA. 110:9535&#x2013;9540. 10.1073/pnas.1301175110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301175110</ArticleId><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Hwo S.Y., and Kirschner M.W.. 1977a Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J. Mol. Biol. 116:227&#x2013;247. 10.1016/0022-2836(77)90214-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(77)90214-5</ArticleId><ArticleId IdType="pubmed">146092</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland D.W., Hwo S.Y., and Kirschner M.W.. 1977b Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116:207&#x2013;225. 10.1016/0022-2836(77)90213-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(77)90213-3</ArticleId><ArticleId IdType="pubmed">599557</ArticleId></ArticleIdList></Reference><Reference><Citation>Colby D.W., and Prusiner S.B.. 2011. De novo generation of prion strains. Nat. Rev. Microbiol. 9:771&#x2013;777. 10.1038/nrmicro2650</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2650</ArticleId><ArticleId IdType="pmc">PMC3924856</ArticleId><ArticleId IdType="pubmed">21947062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel P.D., Siddiqua A., Huynh H., Shah M., and Margittai M.. 2011. Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry. 50:4330&#x2013;4336. 10.1021/bi2004685</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi2004685</ArticleId><ArticleId IdType="pubmed">21510682</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinoza M., de Silva R., Dickson D.W., and Davies P.. 2008. Differential incorporation of tau isoforms in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 14:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882247</ArticleId><ArticleId IdType="pubmed">18525123</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B., Cavallini A., Angers R., Glover S., Murray T.K., Barnham L., Jackson S., O&#x2019;Neill M.J., Isaacs A.M., Hutton M.L., et al. . 2015. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J. Biol. Chem. 290:1049&#x2013;1065. 10.1074/jbc.M114.589309</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.589309</ArticleId><ArticleId IdType="pmc">PMC4294473</ArticleId><ArticleId IdType="pubmed">25406315</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff P., von Bergen M., Mandelkow E.M., Davies P., and Mandelkow E.. 1998. A nucleated assembly mechanism of Alzheimer paired helical filaments. Proc. Natl. Acad. Sci. USA. 95:15712&#x2013;15717. 10.1073/pnas.95.26.15712</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.26.15712</ArticleId><ArticleId IdType="pmc">PMC28109</ArticleId><ArticleId IdType="pubmed">9861035</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R.L., and Diamond M.I.. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284:12845&#x2013;12852. 10.1074/jbc.M808759200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Kaneko K., and Nukina N.. 2011. Tau protein assembles into isoform- and disulfide-dependent polymorphic fibrils with distinct structural properties. J. Biol. Chem. 286:27236&#x2013;27246. 10.1074/jbc.M111.248963</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.248963</ArticleId><ArticleId IdType="pmc">PMC3149317</ArticleId><ArticleId IdType="pubmed">21659525</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Spillantini M.G., Jakes R., Rutherford D., and Crowther R.A.. 1989. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 3:519&#x2013;526. 10.1016/0896-6273(89)90210-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(89)90210-9</ArticleId><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., Spillantini M.G., Hasegawa M., Smith M.J., and Crowther R.A.. 1996. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 383:550&#x2013;553. 10.1038/383550a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/383550a0</ArticleId><ArticleId IdType="pubmed">8849730</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J., Chen F., van Dorpe J., and Nitsch R.M.. 2001. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A&#x3b2;42 fibrils. Science. 293:1491&#x2013;1495. 10.1126/science.1062097</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062097</ArticleId><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., and Lee V.M.Y.. 2011. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286:15317&#x2013;15331. 10.1074/jbc.M110.209296</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.209296</ArticleId><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., and Lee V.M.Y.. 2013. Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett. 587:717&#x2013;723. 10.1016/j.febslet.2013.01.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.01.051</ArticleId><ArticleId IdType="pmc">PMC3678381</ArticleId><ArticleId IdType="pubmed">23395797</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., and Lee V.M.Y.. 2014. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20:130&#x2013;138. 10.1038/nm.3457</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3457</ArticleId><ArticleId IdType="pmc">PMC4011661</ArticleId><ArticleId IdType="pubmed">24504409</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., Covell D.J., Daniels J.P., Iba M., Stieber A., Zhang B., Riddle D.M., Kwong L.K., Xu Y., Trojanowski J.Q., and Lee V.M.. 2013. Distinct &#x3b1;-synuclein strains differentially promote tau inclusions in neurons. Cell. 154:103&#x2013;117. 10.1016/j.cell.2013.05.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.057</ArticleId><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes B.B., DeVos S.L., Kfoury N., Li M., Jacks R., Yanamandra K., Ouidja M.O., Brodsky F.M., Marasa J., Bagchi D.P., et al. . 2013. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. USA. 110:E3138&#x2013;E3147. 10.1073/pnas.1301440110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301440110</ArticleId><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., Guo J.L., McBride J.D., Zhang B., Trojanowski J.Q., and Lee V.M.. 2013. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J. Neurosci. 33:1024&#x2013;1037. 10.1523/JNEUROSCI.2642-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., McBride J.D., Guo J.L., Zhang B., Trojanowski J.Q., and Lee V.M.. 2015. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC&#x2019;s afferent and efferent connections. Acta Neuropathol. 130:349&#x2013;362. 10.1007/s00401-015-1458-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1458-4</ArticleId><ArticleId IdType="pmc">PMC4545685</ArticleId><ArticleId IdType="pubmed">26150341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T., Friedhoff P., Biernat J., Mandelkow E.M., and Mandelkow E.. 1996. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399:344&#x2013;349. 10.1016/S0014-5793(96)01386-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(96)01386-5</ArticleId><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N., Holmes B.B., Jiang H., Holtzman D.M., and Diamond M.I.. 2012. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287:19440&#x2013;19451. 10.1074/jbc.M112.346072</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.346072</ArticleId><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Guerrero-Munoz M.J., Kiritoshi T., Neugebauer V., Jackson G.R., and Kayed R.. 2012. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700 10.1038/srep00700</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00700</ArticleId><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.B., Skovronsky D.M., Abtahian F., Doms R.W., and Lee V.M.. 2003. Secretion and intracellular generation of truncated A&#x3b2; in &#x3b2;-site amyloid-&#x3b2; precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem. 278:4458&#x2013;4466. 10.1074/jbc.M210105200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210105200</ArticleId><ArticleId IdType="pubmed">12480937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V.M., Balin B.J., Otvos L. Jr., and Trojanowski J.Q.. 1991. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 251:675&#x2013;678. 10.1126/science.1899488</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1899488</ArticleId><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V.M., Wang J., and Trojanowski J.Q.. 1999. Purification of paired helical filament tau and normal tau from human brain tissue. Methods Enzymol. 309:81&#x2013;89. 10.1016/S0076-6879(99)09008-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(99)09008-4</ArticleId><ArticleId IdType="pubmed">10507018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V.M., Goedert M., and Trojanowski J.Q.. 2001. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121&#x2013;1159. 10.1146/annurev.neuro.24.1.1121</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.24.1.1121</ArticleId><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. . 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:1487&#x2013;1491. 10.1126/science.1058189</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1058189</ArticleId><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., and Lee V.M.. 2006. Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry. 45:15692&#x2013;15701. 10.1021/bi061422+</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi061422+</ArticleId><ArticleId IdType="pubmed">17176091</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk K.C., Kehm V., Carroll J., Zhang B., O&#x2019;Brien P., Trojanowski J.Q., and Lee V.M.. 2012a Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 338:949&#x2013;953. 10.1126/science.1227157</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk K.C., Kehm V.M., Zhang B., O&#x2019;Brien P., Trojanowski J.Q., and Lee V.M.. 2012b Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J. Exp. Med. 209:975&#x2013;986. 10.1084/jem.20112457</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112457</ArticleId><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E., von Bergen M., Biernat J., and Mandelkow E.M.. 2007. Structural principles of tau and the paired helical filaments of Alzheimer&#x2019;s disease. Brain Pathol. 17:83&#x2013;90. 10.1111/j.1750-3639.2007.00053.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2007.00053.x</ArticleId><ArticleId IdType="pmc">PMC8095506</ArticleId><ArticleId IdType="pubmed">17493042</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L., Latypova X., and Terro F.. 2011. Post-translational modifications of tau protein: implications for Alzheimer&#x2019;s disease. Neurochem. Int. 58:458&#x2013;471. 10.1016/j.neuint.2010.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2010.12.023</ArticleId><ArticleId IdType="pubmed">21215781</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D.M., and Hasegawa M.. 2013. Prion-like spreading of pathological &#x3b1;-synuclein in brain. Brain. 136:1128&#x2013;1138. 10.1093/brain/awt037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt037</ArticleId><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Morozova O.A., March Z.M., Robinson A.S., and Colby D.W.. 2013. Conformational features of tau fibrils from Alzheimer&#x2019;s disease brain are faithfully propagated by unmodified recombinant protein. Biochemistry. 52:6960&#x2013;6967. 10.1021/bi400866w</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi400866w</ArticleId><ArticleId IdType="pmc">PMC4142060</ArticleId><ArticleId IdType="pubmed">24033133</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T., Watanabe S.T., Iwatsubo T., and Hasegawa M.. 2010. Seeded aggregation and toxicity of &#x3b1;-synuclein and tau: cellular models of neurodegenerative diseases. J. Biol. Chem. 285:34885&#x2013;34898. 10.1074/jbc.M110.148460</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.148460</ArticleId><ArticleId IdType="pmc">PMC2966103</ArticleId><ArticleId IdType="pubmed">20805224</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S.W., Harris J.A., Ng L., Winslow B., Cain N., Mihalas S., Wang Q., Lau C., Kuan L., Henry A.M., et al. . 2014. A mesoscale connectome of the mouse brain. Nature. 508:207&#x2013;214. 10.1038/nature13186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13186</ArticleId><ArticleId IdType="pmc">PMC5102064</ArticleId><ArticleId IdType="pubmed">24695228</ArticleId></ArticleIdList></Reference><Reference><Citation>Paumier K.L., Luk K.C., Manfredsson F.P., Kanaan N.M., Lipton J.W., Collier T.J., Steece-Collier K., Kemp C.J., Celano S., Schulz E., et al. . 2015. Intrastriatal injection of pre-formed mouse &#x3b1;-synuclein fibrils into rats triggers &#x3b1;-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 82:185&#x2013;199. 10.1016/j.nbd.2015.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.06.003</ArticleId><ArticleId IdType="pmc">PMC4640952</ArticleId><ArticleId IdType="pubmed">26093169</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W., Bousset L., Van der Perren A., Moskalyuk A., Pulizzi R., Giugliano M., Van den Haute C., Melki R., and Baekelandt V.. 2015. &#x3b1;-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 522:340&#x2013;344. 10.1038/nature14547</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14547</ArticleId><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeraer E., Bottelbergs A., Van Kolen K., Stancu I.C., Vasconcelos B., Mahieu M., Duytschaever H., Ver Donck L., Torremans A., Sluydts E., et al. . 2015. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol. Dis. 73:83&#x2013;95. 10.1016/j.nbd.2014.08.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.08.032</ArticleId><ArticleId IdType="pmc">PMC4303592</ArticleId><ArticleId IdType="pubmed">25220759</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova A.T., Leapman R.D., Guo Z., Yau W.M., Mattson M.P., and Tycko R.. 2005. Self-propagating, molecular-level polymorphism in Alzheimer&#x2019;s &#x3b2;-amyloid fibrils. Science. 307:262&#x2013;265. 10.1126/science.1105850</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1105850</ArticleId><ArticleId IdType="pubmed">15653506</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler A.M., Polydoro M., Maury E.A., Nicholls S.B., Reddy S.M., Wegmann S., William C., Saqran L., Cagsal-Getkin O., Pitstick R., et al. . 2015. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 3:14 10.1186/s40478-015-0199-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0199-x</ArticleId><ArticleId IdType="pmc">PMC4371800</ArticleId><ArticleId IdType="pubmed">25853174</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D.W., Kaufman S.K., DeVos S.L., Sharma A.M., Mirbaha H., Li A., Barker S.J., Foley A.C., Thorpe J.R., Serpell L.C., et al. . 2014. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 82:1271&#x2013;1288. 10.1016/j.neuron.2014.04.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqua A., and Margittai M.. 2010. Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease. J. Biol. Chem. 285:37920&#x2013;37926. 10.1074/jbc.M110.185728</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.185728</ArticleId><ArticleId IdType="pmc">PMC2988394</ArticleId><ArticleId IdType="pubmed">20921227</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqua A., Luo Y., Meyer V., Swanson M.A., Yu X., Wei G., Zheng J., Eaton G.R., Ma B., Nussinov R., et al. . 2012. Conformational basis for asymmetric seeding barrier in filaments of three- and four-repeat tau. J. Am. Chem. Soc. 134:10271&#x2013;10278. 10.1021/ja303498q</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja303498q</ArticleId><ArticleId IdType="pmc">PMC3381011</ArticleId><ArticleId IdType="pubmed">22656332</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancu I.C., Vasconcelos B., Ris L., Wang P., Villers A., Peeraer E., Buist A., Terwel D., Baatsen P., Oyelami T., et al. . 2015. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Acta Neuropathol. 129:875&#x2013;894. 10.1007/s00401-015-1413-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1413-4</ArticleId><ArticleId IdType="pmc">PMC4436846</ArticleId><ArticleId IdType="pubmed">25862635</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;hr J., Watts J.C., Mensinger Z.L., Oehler A., Grillo S.K., DeArmond S.J., Prusiner S.B., and Giles K.. 2012. Purified and synthetic Alzheimer&#x2019;s amyloid beta (A&#x3b2;) prions. Proc. Natl. Acad. Sci. USA. 109:11025&#x2013;11030. 10.1073/pnas.1206555109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206555109</ArticleId><ArticleId IdType="pmc">PMC3390876</ArticleId><ArticleId IdType="pubmed">22711819</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S., Arai T., Kametani F., Nonaka T., Masuda-Suzukake M., Tarutani A., Murayama S., Saito Y., Arima K., Yoshida M., et al. . 2016. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131:267&#x2013;280. 10.1007/s00401-015-1503-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1503-3</ArticleId><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bergen M., Barghorn S., M&#xfc;ller S.A., Pickhardt M., Biernat J., Mandelkow E.M., Davies P., Aebi U., and Mandelkow E.. 2006. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry. 45:6446&#x2013;6457. 10.1021/bi052530j</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi052530j</ArticleId><ArticleId IdType="pubmed">16700555</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L.C., and Jucker M.. 2015. Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38:87&#x2013;103. 10.1146/annurev-neuro-071714-033828</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-071714-033828</ArticleId><ArticleId IdType="pmc">PMC4803040</ArticleId><ArticleId IdType="pubmed">25840008</ArticleId></ArticleIdList></Reference><Reference><Citation>Weingarten M.D., Lockwood A.H., Hwo S.Y., and Kirschner M.W.. 1975. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA. 72:1858&#x2013;1862. 10.1073/pnas.72.5.1858</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.72.5.1858</ArticleId><ArticleId IdType="pmc">PMC432646</ArticleId><ArticleId IdType="pubmed">1057175</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann C., Enari M., Kl&#xf6;hn P.C., Rossi D., and Flechsig E.. 2002. Transmission of prions. J. Infect. Dis. 186:S157&#x2013;S165. 10.1086/344575</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/344575</ArticleId><ArticleId IdType="pubmed">12424692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.W., Herman M., Liu L., Simoes S., Acker C.M., Figueroa H., Steinberg J.I., Margittai M., Kayed R., Zurzolo C., et al. . 2013. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J. Biol. Chem. 288:1856&#x2013;1870. 10.1074/jbc.M112.394528</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394528</ArticleId><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H.L., Fern&#xe1;ndez C., Fan J.B., Shewmaker F., Chen J., Minton A.P., and Liang Y.. 2010. Quantitative characterization of heparin binding to Tau protein: implication for inducer-mediated Tau filament formation. J. Biol. Chem. 285:3592&#x2013;3599. 10.1074/jbc.M109.035691</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.035691</ArticleId><ArticleId IdType="pmc">PMC2824206</ArticleId><ArticleId IdType="pubmed">19959468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27893874</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains.</ArticleTitle><Pagination><StartPage>91</StartPage><EndPage>99</EndPage><MedlinePgn>91-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.4370</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Cognitive impairment and dementia, including Alzheimer disease (AD), are common within the aging population, yet the factors that render the aging brain vulnerable to these processes are unknown. Perivascular localization of aquaporin-4 (AQP4) facilitates the clearance of interstitial solutes, including amyloid-&#x3b2;, through the brainwide network of perivascular pathways termed the glymphatic system, which may be compromised in the aging brain.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether alterations in AQP4 expression or loss of perivascular AQP4 localization are features of the aging human brain and to define their association with AD pathology.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Expression of AQP4 was analyzed in postmortem frontal cortex of cognitively healthy and histopathologically confirmed individuals with AD by Western blot or immunofluorescence for AQP4, amyloid-&#x3b2; 1-42, and glial fibrillary acidic protein. Postmortem tissue and clinical data were provided by the Oregon Health and Science University Layton Aging and Alzheimer Disease Center and Oregon Brain Bank. Postmortem tissue from 79 individuals was evaluated, including cognitively intact "young" individuals aged younger than 60 years (range, 33-57 years), cognitively intact "aged" individuals aged older than 60 years (range, 61-96 years) with no known neurological disease, and individuals older than 60 years (range, 61-105 years) of age with a clinical history of AD confirmed by histopathological evaluation. Forty-eight patient samples (10 young, 20 aged, and 18 with AD) underwent histological analysis. Sixty patient samples underwent Western blot analysis (15 young, 24 aged, and 21 with AD).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Expression of AQP4 protein, AQP4 immunoreactivity, and perivascular AQP4 localization in the frontal cortex were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Expression of AQP4 was associated with advancing age among all individuals (R2&#x2009;=&#x2009;0.17; P&#x2009;=&#x2009;.003). Perivascular AQP4 localization was significantly associated with AD status independent of age (OR, 11.7 per 10% increase in localization; z&#x2009;=&#x2009;-2.89; P&#x2009;=&#x2009;.004) and was preserved among eldest individuals older than 85 years of age who remained cognitively intact. When controlling for age, loss of perivascular AQP4 localization was associated with increased amyloid-&#x3b2; burden (R2&#x2009;=&#x2009;0.15; P&#x2009;=&#x2009;.003) and increasing Braak stage (R2&#x2009;=&#x2009;0.14; P&#x2009;=&#x2009;.006).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In this study, altered AQP4 expression was associated with aging brains. Loss of perivascular AQP4 localization may be a factor that renders the aging brain vulnerable to the misaggregation of proteins, such as amyloid-&#x3b2;, in neurodegenerative conditions such as AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeppenfeld</LastName><ForeName>Douglas M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haswell</LastName><ForeName>J Douglas</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Abreo</LastName><ForeName>Daryl</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murchison</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grafe</LastName><ForeName>Marjorie R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland3Department of Pathology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iliff</LastName><ForeName>Jeffrey J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland4Knight Cardiovascular Research Institute, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2016 Dec 7;8(368):368ec195. doi: 10.1126/scitranslmed.aal2804.</RefSource><PMID Version="1">27928021</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003933" MajorTopicYN="N">Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27893874</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.4370</ArticleId><ArticleId IdType="pii">2587489</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27893897</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>74</EndPage><MedlinePgn>67-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.3764</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Microglia, the resident immune cells of the central nervous system, play an important role in the brain's response to injury and neurodegenerative processes. It has been proposed that prolonged microglial activation occurs after single and repeated traumatic brain injury, possibly through sports-related concussive and subconcussive injuries. Limited in vivo brain imaging studies months to years after individuals experience a single moderate to severe traumatic brain injury suggest widespread persistent microglial activation, but there has been little study of persistent glial cell activity in brains of athletes with sports-related traumatic brain injury.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To measure translocator protein 18 kDa (TSPO), a marker of activated glial cell response, in a cohort of National Football League (NFL) players and control participants, and to report measures of white matter integrity.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This cross-sectional, case-control study included young active (n&#x2009;=&#x2009;4) or former (n&#x2009;=&#x2009;10) NFL players recruited from across the United States, and 16 age-, sex-, highest educational level-, and body mass index-matched control participants. This study was conducted at an academic research institution in Baltimore, Maryland, from January 29, 2015, to February 18, 2016.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Positron emission tomography-based regional measures of TSPO using [11C]DPA-713, diffusion tensor imaging measures of regional white matter integrity, regional volumes on structural magnetic resonance imaging, and neuropsychological performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean (SD) ages of the 14 NFL participants and 16 control participants were 31.3 (6.1) years and 27.6 (4.9) years, respectively. Players reported a mean (SD) of 7.0 (6.4) years (range, 1-21 years) since the last self-reported concussion. Using [11C]DPA-713 positron emission tomographic data from 12 active or former NFL players and 11 matched control participants, the NFL players showed higher total distribution volume in 8 of the 12 brain regions examined (P&#x2009;&lt;&#x2009;.004). We also observed limited change in white matter fractional anisotropy and mean diffusivity in 13 players compared with 15 control participants. In contrast, these young players did not differ from control participants in regional brain volumes or in neuropsychological performance.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The results suggest that localized brain injury and repair, indicated by higher TSPO signal and white matter changes, may be associated with NFL play. Further study is needed to confirm these findings and to determine whether TSPO signal and white matter changes in young NFL athletes are related to later onset of neuropsychiatric symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coughlin</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuchuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minn</LastName><ForeName>Il</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bienko</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambinder</LastName><ForeName>Emily B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dougherty</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vranesic</LastName><ForeName>Melin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Soo Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Hye-Hyun</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Merton</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cottrell</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sair</LastName><ForeName>Haris I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawa</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munro</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland3Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowinski</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Concussion Legacy Foundation, Waltham, Massachusetts5Alzheimer's Disease and CTE Center, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dannals</LastName><ForeName>Robert F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassiou</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Chemistry, University of Sydney, New South Wales, Australia7Discipline of Medical Radiation Sciences, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Gwenn</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caffo</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Susumu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilarte</LastName><ForeName>Tomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Health, Florida International University, Miami10Program in Cognitive Neuroscience and Imaging, Florida International University, Miami.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomper</LastName><ForeName>Martin G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland2Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES007062</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG027668</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007062</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002250">Carbon Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507091">N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018079">Receptors, GABA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C499229">TSPO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Jan 1;74(1):23-25. doi: 10.1001/jamaneurol.2016.4539.</RefSource><PMID Version="1">27893875</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol. 2017 Aug;264(8):1825-1827. doi: 10.1007/s00415-017-8565-1.</RefSource><PMID Version="1">28698896</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056352" MajorTopicYN="N">Athletes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002250" MajorTopicYN="N">Carbon Radioisotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005538" MajorTopicYN="N">Football</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018079" MajorTopicYN="N">Receptors, GABA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012179" MajorTopicYN="N">Retirement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27893897</ArticleId><ArticleId IdType="mid">NIHMS864678</ArticleId><ArticleId IdType="pmc">PMC5504689</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.3764</ArticleId><ArticleId IdType="pii">2587488</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkersma H, Boellaard R, Yaqub M, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med. 2011;52(8):1235&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">21764792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70(3):374&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">21710619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9(12):971&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">21119734</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol. 2009;219(1):53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728790</ArticleId><ArticleId IdType="pubmed">19409385</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarf AM, Kassiou M. The translocator protein. J Nucl Med. 2011;52(5):677&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">21498529</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin JM, Wang Y, Ma S, et al. Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV. J Neuroviroi. 2014;20(3):219&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078660</ArticleId><ArticleId IdType="pubmed">24567030</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323305</ArticleId><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin JM, Wang Y, Munro CA, et al. Neuroinflammation and brain atrophy in former NFL players: an in vivo multimodal imaging pilot study. Neurobiol Dis. 2015;74:58&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411636</ArticleId><ArticleId IdType="pubmed">25447235</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenton ME, Hamoda HM, Schneiderman JS, et al. A review of magnetic resonance imaging and diffusion tensor imaging findings in mild traumatic brain injury. Brain Imaging Behav. 2012;6(2):137&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3803157</ArticleId><ArticleId IdType="pubmed">22438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarian JJ, Zhu T, Blyth B, Borrino A, Zhong J. Subject-specific changes in brain white matter on diffusion tensor imaging after sports-related concussion. Magn Reson Imaging. 2012;30(2):171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254806</ArticleId><ArticleId IdType="pubmed">22079073</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajawelli N, Lao Y, Apuzzo ML, et al. Neuroimaging changes in the brain in contact versus noncontact sport athletes using diffusion tensor imaging. World Neurosurg. 2013;80(6):824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901423</ArticleId><ArticleId IdType="pubmed">24120614</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazarian JJ, Zhu T, Zhong J, et al. Persistent, long-term cerebral white matter changes after sports-related repetitive head impacts. PLoS One. 2014;9(4):e94734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989251</ArticleId><ArticleId IdType="pubmed">24740265</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry LC, Tremblay J, Tremblay S, et al. Acute and chronic changes in diffusivity measures after sports concussion. J Neurotrauma. 2011;28(10):2049&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pubmed">21864134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird JL, Izquierdo-Garcia D, Davies JR, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis. 2010;210(2):388&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884178</ArticleId><ArticleId IdType="pubmed">20056222</ArticleId></ArticleIdList></Reference><Reference><Citation>Subcommittee QS. Practice parameter: the management of concussion in sports (summary statement): report of the Quality Standards Subcommittee. Neurology. 1997;48(3):581&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin JM, Wang Y, Ambinder EB, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Transl Psychiatry. 2016;6:e777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872398</ArticleId><ArticleId IdType="pubmed">27070405</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, van Zijl PC, Kim J, Pearlson GD, Mori S. DtiStudio: resource program for diffusion tensor computation and fiber bundle tracking. Comput Methods Programs Biomed. 2006;81(2):106&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16413083</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson JL, Skare S. A model-based method for retrospective correction of geometric distortions in diffusion-weighted EPI. Neuroimage. 2002;16(1):177&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">11969328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LC, Jones DK, Pierpaoli C. RESTORE: robust estimation of tensors by outlier rejection. Magn Reson Med. 2005;53(5):1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">15844157</ArticleId></ArticleIdList></Reference><Reference><Citation>Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">17519979</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x2212;)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10(5):740&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi K, Faria A, Jiang H, et al. Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer&#x2019;s disease participants. Neuroimage. 2009;46(2):486&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885858</ArticleId><ArticleId IdType="pubmed">19385016</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria AV, Zhang J, Oishi K, et al. Atlas-based analysis of neurodevelopment from infancy to adulthood using diffusion tensor imaging and applications for automated abnormality detection. Neuroimage. 2010;52(2):415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886186</ArticleId><ArticleId IdType="pubmed">20420929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampert PW, Hardman JM. Morphological changes in brains of boxers. JAMA. 1984;251(20):2676&#x2013;2679.</Citation><ArticleIdList><ArticleId IdType="pubmed">6716598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner A, Kay-Lambkin F, Stanwell P, et al. A systematic review of diffusion tensor imaging findings in sports-related concussion. J Neurotrauma. 2012;29(16):2521&#x2013;2538.</Citation><ArticleIdList><ArticleId IdType="pubmed">22950876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright AD, Jarrett M, Vavasour I, et al. Myelin water fraction is transiently reduced after a single mild traumatic brain injury: a prospective cohort study in collegiate hockey players. PLoS One. 2016;11(2):e0150215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4767387</ArticleId><ArticleId IdType="pubmed">26913900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang J, Oishi K, et al. Atlas-guided tract reconstruction for automated and comprehensive examination of the white matter anatomy. Neuroimage. 2010;52(4):1289&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910162</ArticleId><ArticleId IdType="pubmed">20570617</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.</Citation></Reference><Reference><Citation>Green P, Astner K, editors. Manual for the Oral Word Memory Test: US Version. 1.1. Durham, NC: CogniSyst Inc; 1995.</Citation></Reference><Reference><Citation>Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington&#x2019;s disease gene carriers. Brain. 2007;130(pt 7):1759&#x2013;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">17400599</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6116):156&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron. 2013;77(1):10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23312512</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014;158(1):15&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24995975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Zhang J, Hu X, et al. Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J Cereb Blood Flow Metab. 2013;33(12):1864&#x2013;1874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3851898</ArticleId><ArticleId IdType="pubmed">23942366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Leak RK, Shi Y, et al. Microglial and macrophage polarization: new prospects for brain repair. Nat Rev Neurol. 2015;11(1):56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4395497</ArticleId><ArticleId IdType="pubmed">25385337</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2453598</ArticleId><ArticleId IdType="pubmed">18374421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ching AS, Kuhnast B, Damont A, Roeda D, Tavitian B, Doll&#xe9; F. Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases. Insights Imaging. 2012;3(1):111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292648</ArticleId><ArticleId IdType="pubmed">22696004</ArticleId></ArticleIdList></Reference><Reference><Citation>Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/macrophages in the brain. Glia. 2013;61(1):10&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580157</ArticleId><ArticleId IdType="pubmed">22615180</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, Matthews PM. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int Rev Neurobiol. 2011;101:19&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">22050847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauveau F, Boutin H, Van Camp N, Doll&#xe9; F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304&#x2013;2319.</Citation><ArticleIdList><ArticleId IdType="pubmed">18828015</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(pt 1):43&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Muccigrosso MM, Ford J, Benner B, et al. Cognitive deficits develop 1 month after diffuse brain injury and are exaggerated by microglia-associated reactivity to peripheral immune challenge. Brain Behav Immun. 2016;54:95&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828283</ArticleId><ArticleId IdType="pubmed">26774527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziebell JM, Rowe RK, Muccigrosso MM, et al. Aging with a traumatic brain injury: could behavioral morbidities and endocrine symptoms be influenced by microglial priming? Brain Behav Immun. doi: 10.1016/j.bbi.2016.03.008. [published online March 11, 2016]</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.03.008</ArticleId><ArticleId IdType="pubmed">26975888</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, et al. TBI/CTE group The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Shi Y, Jiang X, et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3&#x3b2;/PTEN/Akt axis. Proc Natl Acad Sci USA. 2015;112(9):2853&#x2013;2858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352818</ArticleId><ArticleId IdType="pubmed">25691750</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, Schetters ST, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139(pt 3):891&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27834383</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2016</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding A&#x3b2; plaques by iGluSnFR two-photon imaging.</ArticleTitle><Pagination><StartPage>13441</StartPage><MedlinePgn>13441</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13441</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms13441</ELocationID><Abstract><AbstractText>Amyloid-&#x3b2; (A&#x3b2;) plaques, a hallmark of Alzheimer's disease (AD), are surrounded by regions of neuronal and glial hyperactivity. We use in vivo two-photon and wide-field imaging of the glutamate sensor iGluSnFR to determine whether pathological changes in glutamate dynamics in the immediate vicinity of A&#x3b2; deposits in APPPS1 transgenic mice could alter neuronal activity in this microenvironment. In regions close to A&#x3b2; plaques chronic states of high spontaneous glutamate fluctuations are observed and the timing of glutamate responses evoked by sensory stimulation exhibit slower decay rates in two cortical brain areas. GLT-1 expression is reduced around A&#x3b2; plaques and upregulation of GLT-1 expression and activity by ceftriaxone partially restores glutamate dynamics to values in control regions. We conclude that the toxic microenvironment surrounding A&#x3b2; plaques results, at least partially, from enhanced glutamate levels and that pharmacologically increasing GLT-1 expression and activity may be a new target for early therapeutic intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hefendehl</LastName><ForeName>J K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LeDue</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>R W Y</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahler</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hertie-Institut f&#xfc;r klinische Hirnforschung, Otfried-M&#xfc;ller-Strasse 27, 72076 T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>T H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacVicar</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 1Z3.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027322">Amino Acid Transport System X-AG</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>75J73V1629</RegistryNumber><NameOfSubstance UI="D002443">Ceftriaxone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D027322" MajorTopicYN="N">Amino Acid Transport System X-AG</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002443" MajorTopicYN="N">Ceftriaxone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27834383</ArticleId><ArticleId IdType="pmc">PMC5114608</ArticleId><ArticleId IdType="doi">10.1038/ncomms13441</ArticleId><ArticleId IdType="pii">ncomms13441</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kosik K. S., Joachim C. L. &amp; Selkoe D. J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044&#x2013;4048 (1986).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer A. &#xdc;ber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift f&#xfc;r Psychiatrie und psychisch--gerichtliche Medizin 1&#x2013;2 (1907). Available at: (accessed 1 February 2016). English translation at: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.664.1065&amp;rep=rep1&amp;type=pdf.</Citation></Reference><Reference><Citation>Goedert M., Wischik C. M., Crowther R. A., Walker J. E. &amp; Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl Acad. Sci. USA 85, 4051&#x2013;4055 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280359</ArticleId><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>Graeber M. B. &amp; Mehraein P. Reanalysis of the first case of Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 249, (Suppl 3): 10&#x2013;13 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10654094</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J. C. et al.. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66, 1469&#x2013;1475 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner M. W. et al.. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 6, 202&#x2013;11.e7 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Grienberger C. et al.. Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease. Nat. Commun. 3, 774 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337977</ArticleId><ArticleId IdType="pubmed">22491322</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Schain A. &amp; Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci. Rep. 1, 19 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216507</ArticleId><ArticleId IdType="pubmed">22355538</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche M. A. et al.. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 321, 1686&#x2013;1689 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche M. A. et al.. Critical role of soluble amyloid-&#x3b2; for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 109, 8740&#x2013;8745 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Brawek B. &amp; Garaschuk O. Network-wide dysregulation of calcium homeostasis in Alzheimer's disease. Cell Tissue Res. 357, 427&#x2013;438 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24553999</ArticleId></ArticleIdList></Reference><Reference><Citation>Delekate A. et al.. Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model. Nat. Commun. 5, 5422&#x2013;14 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25406732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S. et al.. Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2; during age-related plaque formation. J. Neurosci. 31, 15861&#x2013;15869 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl J. K. et al.. Long-term in vivo imaging of &#x3b2;-amyloid plaque appearance and growth in a mouse model of cerebral &#x3b2;-amyloidosis. J. Neurosci. 31, 624&#x2013;629 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6623424</ArticleId><ArticleId IdType="pubmed">21228171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J., Grutzendler J., Duff K. &amp; Gan W.-B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7, 1181&#x2013;1183 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15475950</ArticleId></ArticleIdList></Reference><Reference><Citation>Grutzendler J., Helmin K., Tsai J. &amp; Gan W.-B. Various dendritic abnormalities are associated with fibrillar amyloid deposits in Alzheimer's disease. Ann. N. Y. Acad. Sci. 1097, 30&#x2013;39 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17413007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla K. V., Lattarulo C. R., Hyman B. T. &amp; Bacskai B. J. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323, 1211&#x2013;1215 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla K. V. et al.. A&#x3b2; plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59, 214&#x2013;225 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L. et al.. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050&#x2013;4058 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry M. C. et al.. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17, 7053&#x2013;7059 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573263</ArticleId><ArticleId IdType="pubmed">9278541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Dickson D. W., Trojanowski J. Q. &amp; Lee V. M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328&#x2013;337 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10415140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue L. F. et al.. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853&#x2013;862 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;slund J. et al.. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571&#x2013;1577 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvin J. S. et al.. An optimized fluorescent probe for visualizing glutamate neurotransmission. Nat. Methods 10, 162&#x2013;170 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469972</ArticleId><ArticleId IdType="pubmed">23314171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K. et al.. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell Physiol. 226, 2484&#x2013;2493 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130100</ArticleId><ArticleId IdType="pubmed">21792905</ArticleId></ArticleIdList></Reference><Reference><Citation>Talantova M. et al.. A&#x3b2; induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl Acad. Sci. USA 110, E2518&#x2013;E2527 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704025</ArticleId><ArticleId IdType="pubmed">23776240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynd M. R., Scott H. L. &amp; Dodd P. R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 45, 583&#x2013;595 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15234100</ArticleId></ArticleIdList></Reference><Reference><Citation>Schallier A. et al.. Region- and age-specific changes in glutamate transport in the A&#x3b2;PP23 mouse model for Alzheimer's disease. J. Alzheimer's Dis. 24, 287&#x2013;300 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21297271</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E., Alford M., DeTeresa R., Mallory M. &amp; Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40, 759&#x2013;766 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8957017</ArticleId></ArticleIdList></Reference><Reference><Citation>Woltjer R. L. et al.. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J. Neuropathol. Exp. Neurol. 69, 667&#x2013;676 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097122</ArticleId><ArticleId IdType="pubmed">20535038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mookherjee P. et al.. GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model. J. Alzheimer's Dis. 26, 447&#x2013;455 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256092</ArticleId><ArticleId IdType="pubmed">21677376</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumkehr J. et al.. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. Neurobiol. Aging 36, 2260&#x2013;2271 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25964214</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S. et al.. Evidence for age-dependent in vivo conformational rearrangement within A&#x3b2; amyloid deposits. ACS Chem. Biol. 8, 1128&#x2013;1133 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23521783</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J. D. et al.. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73&#x2013;77 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15635412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y.-Y. et al.. Ceftriaxone modulates uptake activity of glial glutamate transporter-1 against global brain ischemia in rats. J. Neurochem. 132, 194&#x2013;205 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25270764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu K. et al.. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 38, 177&#x2013;182 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17122424</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xf6;ne-Reineke C. et al.. The &#x3b2;-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J. Hypertens. 26, 2426&#x2013;2435 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19008722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang Y.-B., Voloboueva L. A., Xu L.-J. &amp; Giffard R. G. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J. Neurosci. 27, 4253&#x2013;4260 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140959</ArticleId><ArticleId IdType="pubmed">17442809</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma R., Mishra V., Sasmal D. &amp; Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur. J. Pharmacol. 638, 65&#x2013;71 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20423712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipski J. et al.. Neuroprotective potential of ceftriaxone in in vitro models of stroke. Neuroscience 146, 617&#x2013;629 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17363173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl J. K. et al.. Repeatable target localization for long-term in vivo imaging of mice with 2-photon microscopy. J. Neurosci. Methods 205, 357&#x2013;363 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22093765</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R. et al.. A&#x3b2;42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940&#x2013;946 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupp N. J., Wegenast-Braun B. M., Radde R., Calhoun M. E. &amp; Jucker M. Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol. Aging 32, 2324.e1&#x2013;2324.e6 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20970889</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S. et al.. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 6627&#x2013;6638 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.-G. et al.. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem. 283, 13116&#x2013;13123 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442320</ArticleId><ArticleId IdType="pubmed">18326497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K. J., Gilliland T. M. &amp; Winkelstein B. A. Upregulation of GLT-1 by treatment with ceftriaxone alleviates radicular pain by reducing spinal astrocyte activation and neuronal hyperexcitability. J. Neurosci. Res. 92, 116&#x2013;129 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24123246</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana H. et al.. Sensitive red protein calcium indicators for imaging neural activity. Elife 5, e12727 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846379</ArticleId><ArticleId IdType="pubmed">27011354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl J. K. et al.. Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell 13, 60&#x2013;69 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326865</ArticleId><ArticleId IdType="pubmed">23953759</ArticleId></ArticleIdList></Reference><Reference><Citation>Pologruto T. A., Sabatini B. L. &amp; Svoboda K. ScanImage: flexible software for operating laser scanning microscopes. Biomed. Eng. Online 2, 13 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC161784</ArticleId><ArticleId IdType="pubmed">12801419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim D. H., LeDue J. M., Mohajerani M. H. &amp; Murphy T. H. Optogenetic mapping after stroke reveals network-wide scaling of functional connections and heterogeneous recovery of the peri-infarct. J. Neurosci. 34, 16455&#x2013;16466 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608492</ArticleId><ArticleId IdType="pubmed">25471583</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27912057</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.</ArticleTitle><Pagination><StartPage>1469</StartPage><EndPage>1480.e12</EndPage><MedlinePgn>1469-1480.e12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2016.11.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(16)31590-2</ELocationID><Abstract><AbstractText>The intestinal microbiota influence neurodevelopment, modulate behavior, and contribute to neurological disorders. However, a functional link between gut bacteria and neurodegenerative diseases remains unexplored. Synucleinopathies are characterized by aggregation of the protein &#x3b1;-synuclein (&#x3b1;Syn), often resulting in motor dysfunction as exemplified by Parkinson's disease (PD). Using mice that overexpress &#x3b1;Syn, we report herein that gut microbiota are required for motor deficits, microglia activation, and &#x3b1;Syn pathology. Antibiotic treatment ameliorates, while microbial re-colonization promotes, pathophysiology in adult animals, suggesting that postnatal signaling between the gut and the brain modulates disease. Indeed, oral administration of specific microbial metabolites to germ-free mice promotes neuroinflammation and motor symptoms. Remarkably, colonization of &#x3b1;Syn-overexpressing mice with microbiota from PD-affected patients enhances physical impairments compared to microbiota transplants from healthy human donors. These findings reveal that gut bacteria regulate movement disorders in mice and suggest that alterations in the human microbiome represent a risk factor for PD.</AbstractText><CopyrightInformation>Copyright &#xc2;&#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA. Electronic address: trsamps@caltech.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debelius</LastName><ForeName>Justine W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thron</LastName><ForeName>Taren</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shastri</LastName><ForeName>Gauri G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ilhan</LastName><ForeName>Zehra Esra</ForeName><Initials>ZE</Initials><AffiliationInfo><Affiliation>Swette Center for Environmental Biotechnology, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Challis</LastName><ForeName>Collin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schretter</LastName><ForeName>Catherine E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biology and Biological Engineering Department, Chalmers University of Technology, Gothenburg 41296, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinaru</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chesselet</LastName><ForeName>Marie-Francoise</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshavarzian</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Section of Movement Disorders, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krajmalnik-Brown</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Swette Center for Environmental Biotechnology, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittung-Stafshede</LastName><ForeName>Pernilla</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biology and Biological Engineering Department, Chalmers University of Technology, Gothenburg 41296, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of California, San Diego, San Diego, CA 92110, USA; Department of Computer Science and Engineering, University of California, San Diego, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazmanian</LastName><ForeName>Sarkis K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Division of Biology &amp; Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA. Electronic address: sarkis@caltech.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS085910</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Dec 7;540(7632):172-173. doi: 10.1038/540172d.</RefSource><PMID Version="1">27929009</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2017 Feb;13(2):66-67. doi: 10.1038/nrneurol.2016.195.</RefSource><PMID Version="1">27982042</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2017 Mar;32(3):396. doi: 10.1002/mds.26933.</RefSource><PMID Version="1">28151555</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Apr 20;544(7650):304-305. doi: 10.1038/nature21910.</RefSource><PMID Version="1">28405021</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">gut-brain axis</Keyword><Keyword MajorTopicYN="N">microbiome</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">short chain fatty acids</Keyword><Keyword MajorTopicYN="N">synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27912057</ArticleId><ArticleId IdType="mid">NIHMS830352</ArticleId><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.11.018</ArticleId><ArticleId IdType="pii">S0092-8674(16)31590-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beilina A, Cookson MR. Genes associated with Parkinson's disease: regulation of autophagy and beyond. J Neurochem 2015</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834228</ArticleId><ArticleId IdType="pubmed">26223426</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141:599&#x2013;609. 609 e591&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">21683077</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of neural transmission. 2003;110:517&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12721813</ArticleId></ArticleIdList></Reference><Reference><Citation>Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, Korecka A, Bakocevic N, Ng LG, Kundu P, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6:263ra158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396848</ArticleId><ArticleId IdType="pubmed">25411471</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16:109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4312418</ArticleId><ArticleId IdType="pubmed">25588378</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Annals of neurology. 2008;64:485&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605160</ArticleId><ArticleId IdType="pubmed">19067353</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156573</ArticleId><ArticleId IdType="pubmed">20383131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of Parkinson's disease: the Thy1-aSyn (&#x201c;Line 61&#x201d;) mice. Neurotherapeutics. 2012;9:297&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337020</ArticleId><ArticleId IdType="pubmed">22350713</ArticleId></ArticleIdList></Reference><Reference><Citation>Chorell E, Andersson E, Evans ML, Jain N, Gotheson A, Aden J, Chapman MR, Almqvist F, Wittung-Stafshede P. Bacterial Chaperones CsgE and CsgC Differentially Modulate Human alpha-Synuclein Amyloid Formation via Transient Contacts. PLoS One. 2015;10:e0140194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605646</ArticleId><ArticleId IdType="pubmed">26465894</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18:666&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688187</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleynen I, Vazeille E, Artieda M, Verspaget HW, Szczypiorska M, Bringer MA, Lakatos PL, Seibold F, Parnell K, Weersma RK, et al. Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut. 2014;63:1265&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">24092863</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Tredici K, Braak H. A not entirely benign procedure: progression of Parkinson's disease. Acta neuropathologica. 2008;115:379&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">18320198</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E, Bruley des Varannes S, Naveilhan P, Nguyen JM, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis. 2013;50:42&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">23017648</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011;108:3047&#x2013;3052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041077</ArticleId><ArticleId IdType="pubmed">21282636</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan TG, Cryan JF. The impact of gut microbiota on brain and behaviour: implications for psychiatry. Curr Opin Clin Nutr Metab Care. 2015;18:552&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">26372511</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhofer G, Aneman A, Friberg P, Hooper D, Fandriks L, Lonroth H, Hunyady B, Mezey E. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab. 1997;82:3864&#x2013;3871.</Citation><ArticleIdList><ArticleId IdType="pubmed">9360553</ArticleId></ArticleIdList></Reference><Reference><Citation>Erny D, Hrabe de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5528863</ArticleId><ArticleId IdType="pubmed">26030851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci. 2004;24:9434&#x2013;9440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730110</ArticleId><ArticleId IdType="pubmed">15496679</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao B, Bian X, Mahbub R, Lu K. Gender-Specific Effects of Organophosphate Diazinon on the Gut Microbiome and Its Metabolic Functions. Environ Health Perspect 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289904</ArticleId><ArticleId IdType="pubmed">27203275</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect. 2011;119:807&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114815</ArticleId><ArticleId IdType="pubmed">21245015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert JA, Jansson JK, Knight R. The Earth Microbiome project: successes and aspirations. BMC Biol. 2014;12:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4141107</ArticleId><ArticleId IdType="pubmed">25184604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, Shibata A, Fujisawa Y, Minato T, Okamoto A, et al. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease. PLoS One. 2015;10:e0142164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4634857</ArticleId><ArticleId IdType="pubmed">26539989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoban AE, Stilling RM, Ryan FJ, Shanahan F, Dinan TG, Claesson MJ, Clarke G, Cryan JF. Regulation of prefrontal cortex myelination by the microbiota. Transl Psychiatry. 2016;6:e774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872400</ArticleId><ArticleId IdType="pubmed">27045844</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T, Wang ZY, Roybon L, Melki R, Li JY. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta neuropathologica. 2014;128:805&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">25296989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4420145</ArticleId><ArticleId IdType="pubmed">22674334</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9:665&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">18714325</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem. 2000;275:34328&#x2013;34334.</Citation><ArticleIdList><ArticleId IdType="pubmed">10915790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis. 2013;3:493&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102262</ArticleId><ArticleId IdType="pubmed">24275605</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015;30:1351&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pubmed">26179554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, Frosch M, Growdon J, McLean P, Hyman BT. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta neuropathologica. 2006;111:101&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16482476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohman RA, Bhattacharya TK, Kilby C, Bucko P, Rhodes JS. Effects of minocycline on spatial learning, hippocampal neurogenesis and microglia in aged and adult mice. Behav Brain Res. 2013;242:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725815</ArticleId><ArticleId IdType="pubmed">23274840</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopylova E, Noe L, Touzet H. SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data. Bioinformatics. 2012;28:3211&#x2013;3217.</Citation><ArticleIdList><ArticleId IdType="pubmed">23071270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci Transl Med. 2016;8:340ra372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505565</ArticleId><ArticleId IdType="pubmed">27225182</ArticleId></ArticleIdList></Reference><Reference><Citation>Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3819121</ArticleId><ArticleId IdType="pubmed">23975157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">16497592</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin R, Jiang Y, Zhao XY, Guan Y, Qian W, Fu XC, Ren HY, Hou XH. Four types of Bifidobacteria trigger autophagy response in intestinal epithelial cells. J Dig Dis. 2014;15:597&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">25123057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71:8228&#x2013;8235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317376</ArticleId><ArticleId IdType="pubmed">16332807</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Van Treuren W, White RA, Eggesbo M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis. 2015;26:27663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4450248</ArticleId><ArticleId IdType="pubmed">26028277</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016;353:aad8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer EA, Padua D, Tillisch K. Altered brain-gut axis in autism: comorbidity or causative mechanisms? Bioessays. 2014;36:933&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">25145752</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL, Knight R, Hugenholtz P. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6:610&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280142</ArticleId><ArticleId IdType="pubmed">22134646</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci Rep. 2016;6:30028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956742</ArticleId><ArticleId IdType="pubmed">27443609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RW, On NH, Del Bigio MR, Miller DW, Hatch GM. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem. 2011;117:735&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21395585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994a;180:147&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">7700568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994b;165:208&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">8015728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohle L, Mattei D, Heimesaat MM, Bereswill S, Fischer A, Alutis M, French T, Hambardzumyan D, Matzinger P, Dunay IR, et al. Ly6Chi Monocytes Provide a Link between Antibiotic-Induced Change in Gut Microbiota and Adult Hippocampal Neurogenesis. Cell Reports 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27210745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011;23:255&#x2013;264. e119.</Citation><ArticleIdList><ArticleId IdType="pubmed">21054680</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A. 2015;112:E5308&#x2013;5317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritz BR, Paul KC, Bronstein JM. Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease. Curr Environ Health Rep. 2016;3:40&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922777</ArticleId><ArticleId IdType="pubmed">26857251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68:568&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16:341&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541232</ArticleId><ArticleId IdType="pubmed">27231050</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov. 2002;1:267&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">12120278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 2013;5:113&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639751</ArticleId><ArticleId IdType="pubmed">23506036</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015;30:350&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22:1079&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pubmed">27711063</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkrig J, Wong P, Zhang X, Pettersson S. Metabolic tinkering by the gut microbiome: Implications for brain development and function. Gut Microbes. 2014;5:369&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4153776</ArticleId><ArticleId IdType="pubmed">24685620</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012;27:716&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">22550057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016;167:915&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127403</ArticleId><ArticleId IdType="pubmed">27814521</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807819</ArticleId><ArticleId IdType="pubmed">23828891</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, Goldmann J, Myers RH, Young RA, Jaenisch R. Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. Nature. 2016;533:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042324</ArticleId><ArticleId IdType="pubmed">27096366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. The Journal of physiology. 2004;558:263&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1664925</ArticleId><ArticleId IdType="pubmed">15133062</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson E, Horvath-Puho E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sorensen HT. Vagotomy and subsequent risk of Parkinson's disease. Annals of neurology. 2015;78:522&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">26031848</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Burmann J, Fassbender K, Schwiertz A, Schafer KH. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">27591074</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera E, Masliah E. Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord. 2016;31:225&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747680</ArticleId><ArticleId IdType="pubmed">26388203</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience. 2013;2:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076506</ArticleId><ArticleId IdType="pubmed">24280061</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007;69:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646625</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall R, Cryan JF, Ross RP, Fitzgerald GF, Dinan TG, Stanton C. Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol. 2014;817:221&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">24997036</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters W, Hyde ER, Berg-Lyons D, Ackermann G, Humphrey G, Parada A, Gilbert JA, Jansson JK, Caporaso JG, Fuhrman JA, et al. Improved Bacterial 16S rRNA Gene (V4 and V4-5) and Fungal Internal Transcribed Spacer Marker Gene Primers for Microbial Community Surveys. mSystems. 2016;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5069754</ArticleId><ArticleId IdType="pubmed">27822518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Magen I, Yuan PQ, Subramaniam SR, Richter F, Chesselet MF, Tache Y. Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. Neurogastroenterol Motil. 2012;24:e425&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712640</ArticleId><ArticleId IdType="pubmed">22779732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393509</ArticleId><ArticleId IdType="pubmed">25860609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Saur T, Duke AN, Grant SG, Platt DM, Rowlett JK, Isacson O, Yao WD. Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. J Neurogenet. 2014;28:98&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406490</ArticleId><ArticleId IdType="pubmed">24702501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27911827</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>50</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>13</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells.</ArticleTitle><Pagination><StartPage>E8187</StartPage><EndPage>E8196</EndPage><MedlinePgn>E8187-E8196</MedlinePgn></Pagination><Abstract><AbstractText>Tau prions are thought to aggregate in the central nervous system, resulting in neurodegeneration. Among the tauopathies, Alzheimer's disease (AD) is the most common, whereas argyrophilic grain disease (AGD), corticobasal degeneration (CBD), chronic traumatic encephalopathy (CTE), Pick's disease (PiD), and progressive supranuclear palsy (PSP) are less prevalent. Brain extracts from deceased individuals with PiD, a neurodegenerative disorder characterized by three-repeat (3R) tau prions, were used to infect HEK293T cells expressing 3R tau fused to yellow fluorescent protein (YFP). Extracts from AGD, CBD, and PSP patient samples, which contain four-repeat (4R) tau prions, were transmitted to HEK293 cells expressing 4R tau fused to YFP. These studies demonstrated that prion propagation in HEK cells requires isoform pairing between the infecting prion and the recipient substrate. Interestingly, tau aggregates in AD and CTE, containing both 3R and 4R isoforms, were unable to robustly infect either 3R- or 4R-expressing cells. However, AD and CTE prions were able to replicate in HEK293T cells expressing both 3R and 4R tau. Unexpectedly, increasing the level of 4R isoform expression alone supported the propagation of both AD and CTE prions. These results allowed us to determine the levels of tau prions in AD and CTE brain extracts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woerman</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoyagi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Daiichi Sankyo Co., Ltd., Tokyo 140-8710, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazmi</LastName><ForeName>Sabeen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobach</LastName><ForeName>Iryna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Chronic Traumatic Encephalopathy Program, Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA 02118.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA 02118.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Boston University School of Medicine, Boston, MA 02118.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs Boston Healthcare System, US Department of Veterans Affairs, Jamaica Plain, MA 02130.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>US Department of Veterans Affairs Medical Center, Bedford, MA 01730.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California, San Francisco, CA 94143; stanley.prusiner@ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG031220</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010770</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS086659</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054562">yellow fluorescent protein, Bacteria</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070627" MajorTopicYN="N">Chronic Traumatic Encephalopathy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020774" MajorTopicYN="N">Pick Disease of the Brain</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pick&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">argyrophilic grain disease</Keyword><Keyword MajorTopicYN="N">corticobasal degeneration</Keyword><Keyword MajorTopicYN="N">progressive supranuclear palsy</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword></KeywordList><CoiStatement>A provisional patent application has been submitted in connection with this work. Inventors include A.L.W., A.A., S.P., S.A.K., S.H.O., and S.B.P.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27911827</ArticleId><ArticleId IdType="pmc">PMC5167200</ArticleId><ArticleId IdType="doi">10.1073/pnas.1616344113</ArticleId><ArticleId IdType="pii">1616344113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iqbal K, et al. Defective brain microtubule assembly in Alzheimer&#x2019;s disease. Lancet. 1986;2(8504):421&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">2874414</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion J-P, Passareiro H, Nunez J, Flament-Durand J. Mise en &#xe9;vidence immunologique de la prot&#xe9;ine tau au niveau des l&#xe9;sions de d&#xe9;g&#xe9;n&#xe9;rescence neurofibrillaire de la maladie d&#x2019;Alzheimer. Arch Biol (Liege) 1985;95:229&#x2013;235. French.</Citation></Reference><Reference><Citation>Grundke-Iqbal I, et al. Abnormal phosphorylation of the microtubule-associated protein &#x3c4; (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83(13):4913&#x2013;4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (&#x3c4;) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA. 1986;83(11):4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (&#x3c4;) Proc Natl Acad Sci USA. 1986;83(11):4040&#x2013;4043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323661</ArticleId><ArticleId IdType="pubmed">2424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA. 1988;85(12):4506&#x2013;4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, et al. Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer&#x2019;s disease cases. Acta Neuropathol. 1992;85(1):23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1285493</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, et al. Amyloid Biomarker Study Group Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA. 2015;313(19):1924&#x2013;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, et al. Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum. J Neuropathol Exp Neurol. 2016;75(6):516&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250207</ArticleId><ArticleId IdType="pubmed">27105663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393(6686):702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43(6):815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford PM, et al. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol. 2004;251(9):1098&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15372253</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer&#x2019;s disease. Nature. 1991;349(6311):704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock NJ, Mirra SS, Binder LI, Hansen LA, Wood JG. Filamentous aggregates in Pick&#x2019;s disease, progressive supranuclear palsy, and Alzheimer&#x2019;s disease share antigenic determinants with microtubule-associated protein, tau. Lancet. 1986;2(8517):1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">2430155</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8(2):393&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400819</ArticleId><ArticleId IdType="pubmed">2498079</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8(1):159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human &#x3c4; gene. Biochemistry. 1992;31(43):10626&#x2013;10633.</Citation><ArticleIdList><ArticleId IdType="pubmed">1420178</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, et al. Specific pathological Tau protein variants characterize Pick&#x2019;s disease. J Neuropathol Exp Neurol. 1996;55(2):159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiezak-Reding H, et al. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol. 1994;145(6):1496&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887493</ArticleId><ArticleId IdType="pubmed">7992852</ArticleId></ArticleIdList></Reference><Reference><Citation>Flament S, Delacourte A, Verny M, Hauw J-J, Javoy-Agid F. Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol. 1991;81(6):591&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">1831952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM-Y, Trojanowski JQ. Neurodegenerative tauopathies: Human disease and transgenic mouse models. Neuron. 1999;24(3):507&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">10595503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282(5395):1914&#x2013;1917.</Citation><ArticleIdList><ArticleId IdType="pubmed">9836646</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza I, et al. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci USA. 1999;96(10):5598&#x2013;5603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21906</ArticleId><ArticleId IdType="pubmed">10318930</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ML, Zhukareva V, Newell KL, Lee VM, Trojanowski JQ. Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer&#x2019;s disease. Acta Neuropathol. 2001;101(5):518&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">11484824</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan K-M, et al. Conversion of &#x3b1;-helices into &#x3b2;-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA. 1993;90(23):10962&#x2013;10966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47901</ArticleId><ArticleId IdType="pubmed">7902575</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser H, Dickinson AG. Scrapie in mice. Agent-strain differences in the distribution and intensity of grey matter vacuolation. J Comp Pathol. 1973;83(1):29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">4199908</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretz D, et al. Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci. 2001;10(4):854&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2373967</ArticleId><ArticleId IdType="pubmed">11274476</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfarb LG, et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Disease phenotype determined by a DNA polymorphism. Science. 1992;258(5083):806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">1439789</ArticleId></ArticleIdList></Reference><Reference><Citation>Telling GC, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science. 1996;274(5295):2079&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953038</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet. 2013;47:601&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010318</ArticleId><ArticleId IdType="pubmed">24274755</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, et al. Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci USA. 2015;112(35):E4949&#x2013;E4958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568231</ArticleId><ArticleId IdType="pubmed">26286986</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med. 1998;4(10):1157&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771749</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Alvarez VE, McKee AC. Chronic traumatic encephalopathy: A spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther. 2014;6(1):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979082</ArticleId><ArticleId IdType="pubmed">24423082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhukareva V, et al. Sporadic Pick&#x2019;s disease: A tauopathy characterized by a spectrum of pathological &#x3c4; isoforms in gray and white matter. Ann Neurol. 2002;51(6):730&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112079</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, et al. TBI/CTE Group The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd M. Paired helical filaments in electron microscopy of Alzheimer&#x2019;s disease. Nature. 1963;197:192&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">14032480</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell. 1983;35(2 Pt 1):349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">6418385</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Evidence for &#x3b1;-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA. 2015;112(38):E5308&#x2013;E5317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586853</ArticleId><ArticleId IdType="pubmed">26324905</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci. 2013;33(3):1024&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, et al. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC&#x2019;s afferent and efferent connections. Acta Neuropathol. 2015;130(3):349&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545685</ArticleId><ArticleId IdType="pubmed">26150341</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014;127(2):299&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253855</ArticleId><ArticleId IdType="pubmed">24362441</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Alzheimer&#x2019;s and Parkinson&#x2019;s diseases: The prion concept in relation to assembled A&#x3b2;, tau, and &#x3b1;-synuclein. Science. 2015;349(6248):1255555.</Citation><ArticleIdList><ArticleId IdType="pubmed">26250687</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110(23):9535&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287(23):19440&#x2013;19451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Bussi&#xe8;re T, Bu&#xe9;e-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33(1):95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel PD, Siddiqua A, Huynh H, Shah M, Margittai M. Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry. 2011;50(20):4330&#x2013;4336.</Citation><ArticleIdList><ArticleId IdType="pubmed">21510682</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M. Seeded aggregation and toxicity of &#x3b1;-synuclein and tau: Cellular models of neurodegenerative diseases. J Biol Chem. 2010;285(45):34885&#x2013;34898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966103</ArticleId><ArticleId IdType="pubmed">20805224</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127(5):667&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell. 1990;63(4):673&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">1977523</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, Westaway D, DeArmond SJ, Peterson-Torchia M, Prusiner SB. Primary structure of prion protein may modify scrapie isolate properties. Proc Natl Acad Sci USA. 1989;86(19):7475&#x2013;7479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298087</ArticleId><ArticleId IdType="pubmed">2798418</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson GA, et al. Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc Natl Acad Sci USA. 1994;91(12):5690&#x2013;5694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44062</ArticleId><ArticleId IdType="pubmed">7911243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Q, Congdon EE, Nagaraja HN, Kuret J. Tau isoform composition influences rate and extent of filament formation. J Biol Chem. 2012;287(24):20711&#x2013;20719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370253</ArticleId><ArticleId IdType="pubmed">22539343</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R, et al. Characteristics of tau and its ligands in PET imaging. Biomolecules. 2016;6(1):7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808801</ArticleId><ArticleId IdType="pubmed">26751494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimers Dement. February 15, 2016 doi: 10.1016/j.jalz.2016.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.003</ArticleId><ArticleId IdType="pubmed">26892233</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SN, et al. Dual modification of Alzheimer&#x2019;s disease PHF-tau protein by lysine methylation and ubiquitylation: A mass spectrometry approach. Acta Neuropathol. 2012;123(1):105&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3249157</ArticleId><ArticleId IdType="pubmed">22033876</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci. 2015;18(8):1183&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049446</ArticleId><ArticleId IdType="pubmed">26192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mair W, et al. FLEXITau: Quantifying post-translational modifications of tau protein in vitro and in human disease. Anal Chem. 2016;88(7):3704&#x2013;3714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808556</ArticleId><ArticleId IdType="pubmed">26877193</ArticleId></ArticleIdList></Reference><Reference><Citation>Martland HS. Punch drunk. J Am Med Assoc. 1928;91:1103&#x2013;1107.</Citation></Reference><Reference><Citation>Owens BD, et al. Combat wounds in operation Iraqi Freedom and operation Enduring Freedom. J Trauma. 2008;64(2):295&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">18301189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoge CW, et al. Mild traumatic brain injury in U.S. soldiers returning from Iraq. N Engl J Med. 2008;358(5):453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">18234750</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrio H, et al. Traumatic brain injury screening: Preliminary findings in a US Army Brigade Combat Team. J Head Trauma Rehabil. 2009;24(1):14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19158592</ArticleId></ArticleIdList></Reference><Reference><Citation>Shively SB, et al. Characterisation of interface astroglial scarring in the human brain after blast exposure: A post-mortem case series. Lancet Neurol. 2016;15(9):944&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">27291520</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624697</ArticleId><ArticleId IdType="pubmed">23208308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol. 2010;119(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E-J, et al. Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. Cereb Cortex. 2012;22(2):251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256403</ArticleId><ArticleId IdType="pubmed">21653702</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonsattel JPG, et al. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol. 1995;54(1):42&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7815079</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27918765</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &#x3b1;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.</ArticleTitle><Pagination><StartPage>163</StartPage><EndPage>172</EndPage><MedlinePgn>163-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2016.4547</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Parkinson disease (PD) is a highly prevalent and incurable neurodegenerative disease associated with the accumulation of misfolded &#x3b1;-synuclein (&#x3b1;Syn) aggregates. An important problem in this disease is the lack of a sensitive, specific, and noninvasive biochemical diagnosis to help in clinical evaluation, monitoring of disease progression, and early differential diagnosis from related neurodegenerative diseases.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To develop a novel assay with high sensitivity and specificity to detect small quantities of &#x3b1;Syn aggregates circulating in cerebrospinal fluid (CSF) of patients affected by PD and related synucleinopathies.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The strategy evaluated in this proof-of-concept study uses the protein misfolding cyclic amplification (PMCA) technology that detects minute amounts of misfolded oligomers by taking advantage of their ability to nucleate further aggregation, enabling a very high amplification of the signal. The technology was first adapted with synthetic &#x3b1;Syn oligomers prepared in vitro and used to screen in 2 blinded cohorts of CSF samples from German and Japanese patients with PD (n&#x2009;=&#x2009;76) and individuals serving as controls affected by other neurologic disorders (n&#x2009;=&#x2009;65), neurodegenerative diseases (n&#x2009;=&#x2009;18), and Alzheimer disease (n&#x2009;=&#x2009;14). The kinetics of &#x3b1;Syn aggregation were measured by &#x3b1;Syn-PMCA in the presence of CSF samples from the participants to detect &#x3b1;Syn oligomeric seeds present in this biological fluid. The assays were conducted from November 15, 2013, to August 28, 2015.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Kinetic parameters correlated with disease severity at the time of sample collection, measured by the Hoehn and Yahr scale, with the lowest grade indicating unilateral involvement with minimal or no functional impairment, and the highest grade defining patients with complete confinement to wheelchair or bed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Studies with synthetic &#x3b1;Syn aggregates showed that &#x3b1;Syn-PMCA enabled to detect as little as 0.1 pg/mL of &#x3b1;Syn oligomers. The &#x3b1;Syn-PMCA signal was directly proportional to the amount of &#x3b1;Syn oligomers added to the reaction. A blinded study of CSF samples correctly identified patients affected by PD with an overall sensitivity of 88.5% (95% CI, 79.2%-94.6%) and specificity of 96.9% (95% CI, 89.3%-99.6%). The &#x3b1;Syn-PMCA results for different patients correlated with the severity of the clinical symptoms of PD (Japanese cohort: rs&#x2009;=&#x2009;-0.54, P&#x2009;=&#x2009;.006; German cohort: rs&#x2009;=&#x2009;-0.36, P&#x2009;=&#x2009;.02).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The findings suggest that detection of &#x3b1;Syn oligomers by &#x3b1;Syn-PMCA in the CSF of patients affected by PD may offer a good opportunity for a sensitive and specific biochemical diagnosis of the disease. Further studies are needed to investigate the usefulness of &#x3b1;Syn-PMCA to monitor disease progression and for preclinical identification of patients who may develop PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shahnawaz</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, The University of Texas School of Medicine at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan3Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan4Japan Agency for Medical Research and Development-Core Research for Evolutionary Medical Science and Technology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waragai</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Higashi Matsudo Municipal Hospital, Matsudo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, The University of Texas School of Medicine at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Ryotaro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan3Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trenkwalder</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Paracelsus-Elena-Klinik Kassel, Kassel, Germany7Institute of Neuropathology, University Medical Center Goettingen, Goettingen, Germany8Clinic for Neurosurgery, University Medical Center, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollenhauer</LastName><ForeName>Brit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Paracelsus-Elena-Klinik Kassel, Kassel, Germany7Institute of Neuropathology, University Medical Center Goettingen, Goettingen, Germany9Department of Neurosurgery, University Medical Center Goettingen, Goettingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, The University of Texas School of Medicine at Houston.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2017 Feb 1;74(2):146-147. doi: 10.1001/jamaneurol.2016.4813.</RefSource><PMID Version="1">27918751</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001669" MajorTopicYN="N">Biochemical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003955" MajorTopicYN="N">Diagnostic Tests, Routine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27918765</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2016.4547</ArticleId><ArticleId IdType="pii">2588684</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>